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Preface 
‘Glioma’ is the term that hits the human psyche with absolute despair. All our efforts 
to cease glioma limits it to an average of maximum 18 – 21 months of life after 
diagnosis and notably, this life expectancy altered marginally despite constant
research of last two decades. When I was working for my Ph.D thesis and allied
projects, I had to encounter a number of glioma patients and patient parties. Many of 
them I found first diagnosed, started treatment with surgery, radiation and 
chemotherapy in various combinations and after few months they disappeared. Some 
of them reappeared within a year with recurrence and others never turned. Rarely, a 
trivial number of patients were traced after 3 or 5 years. Many of those gloomy faces,
their eager questions, earnest appeals, anxiety are pertinent globally and the fate 
varies negligibly with economic or developmental status of the society. Such an issue 
always provoked me to know and contribute something which is larger than my 
focused thesis work. As a considerable section of my work was at the interface of
medical practitioners and basic scientists, I was lucky enough to observe the pattern of
proceedings and attitude of both the fields at least partially.  Strangely, I also sensed a
fissure between these two interdependent fields. Along with, the common question of
common mass that “What is medical science exactly doing against it?” is always
pertinent as the problem is still unmanageable.
To face these questions and find their suitable answers, at least on the basis of current 
knowledge, a multitude of information from different facets of glioma research is
needed to be analyzed. The fundamental biological nature of the problem, extent of its
graveness as a disease, diagnostic efforts and shortcomings, level of efficiency and
inefficiency of present medical interventions and therapeutics, current trends of 
medical research to combat glioma etc has to be scrutinized with extreme sincerity. 
This mammoth gathering of facts is possible if only the experts of different areas can 
share their expertise at the same platform. I also feel that, sometimes the gaps among 
medical scientists and doctors are due to the inability to build up an overview of this
vast expanse as well as shortfall of awareness about this rapidly developing arena by
either side. Therefore, a podium to cater the diverse problems and achievements in 
glioma is a much needed obligation. 
In this situation, I got the offer to be involved in the effort of the book project
“Glioma” by the present publisher. That was a simple but superb coincidence of my
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thoughts and their offer. As the subject editor of the project I had to evaluate near 
about 90 chapter proposals submitted from nearly every corners of the world. These 
worldwide contributions were then categorized and distributed into three volumes. 
The approach was initially to understand glioma and its biology with experimental 
approaches to explore the basics of the disease (vol. 1); next to share the knowledge 
about present diagnostic and prognostic approaches as well as current developments 
in modern therapeutics (vol. 2); and finally, to accustom the readers about the cutting 
edge basic to experimental developments and trends of biomedical research to restrict 
glioma (vol. 3). As the book editor I have chosen to edit the first volume, partially 
because of my personal background as a biomedical researcher from basic life-sciences 
and mostly the chapters arranged in this volume are aimed to find out the basic nature 
of the disease. Next two volumes are much oriented with facts that are directly 
relevant to medical practice to deal glioma.  
The name of the first volume “Glioma – Exploring Its Biology and Practical Relevance” is 
indicative of its content. This introducing first volume contains 21 chapters basically 
intended to explore glioma biology and discussing the experimental model systems for 
the purpose. Under the section “Introduction” first two chapters discuss general glioma 
epidemiology and etiology and the next two shows the relevance of biomarkers in 
glioma. Following six chapters under section “Gliomagenesis” deals with different 
genetic, molecular and cell biological aspects of origin and development of glioma. The 
next section “Glioma progression” contains three chapters which discusses about glioma 
invasiveness which is followed by the section “Glioma Immunology” that contains two 
chapters. A stretch of four chapters have been clustered next in the section “Glioma 
Model and Culture Systems” which are devoted to present different facets of 
experimental models and cell culture methods that are now utilized in glioma research. 
In the final section “Miscellaneous” the penultimate chapter deals with oxidative stress 
in glioma and the final chapter of this volume talks about a special experimental 
approach of glioma therapeutics. It is hoped that the present volume will provide 
supportive and relevant awareness and understanding on the fundamental advances of 
the subject to the professionals from any sphere interested about glioma and deliver the 
momentum to the audience for the following volumes of ‘Glioma’. 
In this enormous task I got support from many of which only few names can be 
mentioned here. First and foremost, I extend my thanks to the ‘InTech Open Access 
Publisher’ for offering me the exciting opportunity to act as the subject editor of the 
‘Glioma’ project, book editor of the present volume as well as chapter author. I 
enjoyed my involvement in a forum where participants are the biomedical researchers 
sharing their experiences and knowledge from every continents except Antarctica. To 
shape this gigantic effort Ms. Ana Panter and Ms. Petra Ninadic extended their 
continuous cooperation by building the liaison between editors, authors and the 
publisher. I express my heartiest thanks to them in spite of failing many ‘deadline’s set 
by them, and still getting their nonstop support to make this teamwork a success. I 
also express my gratitude to Prof. Swapna Chaudhuri, School of Tropical Medicine, 
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Kolkata, India; Prof. Ingo Bechmann, Institut für Anatomie der Universität Leipzig, 
Germany; Prof. Helmut Kettenmann, Max-Delbrück-Center for Molecular Medicine, 
Germany; Prof. Serge Rivest, Laval University, Québec, Canada and many others who 
helped or inspired me anyways in my recent research and activities. I am appreciative 
to my graduate students Nabanita Mukherjee and Payel Ghosh with other colleagues 
and students of my institute who cooperate me in this journey. The continuous 
support of the Principle of my institute Dr. Sanjoy K Ghosh and the authority made 
this process easier for me. Finally and most importantly, without the unparallel 
motivation and bearing of my wife Malabika and little son Upamanyu this effort 
would have never been achieved. I am dedicating this endeavor to them and all who 
are fighting to control glioma. 
 
Dr. Anirban Ghosh 
Assistant Professor and Head Department of Zoology 
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Epidemiology of Glioma 
Jimmy T. Efird 
Center for Health Disparities Research 
Department of Public Health 
Brody School of Medicine Greenville, North Carolina  
USA 
1. Introduction 
Giomas constitute a broad class of neuroectodermal tumours believed to originate from 
sustentacular neuroglial cells (Kleihues and Cavenee 2000). Astrocytomas form the largest 
group of gliomas (>75%) and glioblastoma multiforme (GBM) is the most common type of 
astrocytoma (CBTRUS 2011). Gliomas that share histologic characteristics with ependymal 
or oligodendrocyte cells are named ependymomas and oligodendrogliomas, but may not 
necessarily originate from the aforementioned cell types (Kleihues and Cavenee 2000). 
Mixed gliomas include those which consist of more than one glia cell type. For example, 
oligodendroglial glioblastoma multiforme (as defined by some neuropathologists) are GBM 
tumours with an oligodendroglioma component and generally have a significantly worse 
clinical outcome than GBM tumours overall (Louis et al 2007). Another mixed glioma is 
oligoastrocytoma, which contains both oligodendrocyte and astrocyte cells.  
The Third Edition of the International Classification of Diseases for oncology (ICD-O-3) is 
widely used to categorize gliomas by histology (e.g., malignant glioma=9380, ependymoma 
NOS=9391, astrocytoma=9430, glioblastoma NOS=9440, oligodendroglioma NOS=9450) 
(Fritz et al 2000). Furthermore, tumours are grouped by site in the ICD-O-3 system using C-
codes (e.g., cerebrum=C71.0, frontal lobal=C71.1, temporal lobe=C71.2, parietal lobe=C71.3, 
occipital lobe=C71.4, ventricle=C71.5, cerebellum=C71.6, spinal cord=C72.0). The World 
Health Organization (WHO) also has developed a classification index which grades gliomas 
by disease prognosis (I=best to IV=worst) (Kliehues et al 1993). Recent additions to the 
“WHO Classification of Tumours” include Grade I - angiocentric gliomas (predominantly 
occurring in children and young adults in the fronto-parietal cortex, temporal lobe, and 
hippocampal region), and Grade II – pilomyxoid astrocytoma (typically occurring in infants 
and children in the hypothalamic/chiasmatic region) (Louis et al 2007). Additionally, WHO 
has recognized a divergent pattern of gliomas named small cell glioblastoma characterized 
by EGFR amplification, p16INK4a homozygous deletion, PTEN mutations, and LOH 10q 
(Louis et al 2007). 
2. Incidence and death rates 
Gliomas comprise more than 80% of brain tumours (CBTRUS 2011), therefore, descriptive 
epidemiology about gliomas often is framed in the broader context of brain tumours as a whole.  
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Overall, brain tumors are relatively rare events. Only 1 in 165 men and women will be 
diagnosed with cancer of the brain and other nervous system tumours in their lifetime 
(Altekruse et al 2010). The incidence rate (IR) per 100,000 person-years (100KP-Y) for 
malignant adult brain tumours ranges from 5.4 (95%CI =4.7-6.1) for the state of Hawaii to 12 
(95%CI=12-13) for Wisconsin. IRs by state among children 0-19 years are less variable, 
ranging from 2 to 4. While geographic differences in IRs might suggest an environmental 
etiology for brain tumours, ecologic comparisons often do not account for variations in 
quality of reporting, diagnostic practices, and access/utilization to health care. States falling 
into the highest quantile for both age-adjusted incidence and death rates (DR) per 100KP-Y 
include Kentucky (IR=7.9, 95%CI=7.0-8.7; DR=4.9, 95%CI=4.3-5.6), Iowa (IR=7.6, 95%CI=6.7-
8.6; DR=5.4, 95%CI=4.6-6.2), and Oregon (IR=7.5, 95%CI=6.7-8.4; DR=5.2, 95%CI=4.5-5.9) 
(Figures 1 and 2) (NCI State Cancer Profiles 2011). A noticeable cluster of states (depicted in 
red) with the highest death rates is located along the northern portion of the U.S. from 
Oregon to Iowa (Figure 2). 
 
 
†Age-adjusted (2000 U.S. standard population) cases per 100,000 population per year. 
◊Data not available for Nevada. 
Fig. 1. Incidence rates (NCI State Cancer Profiles 2011). 
Gliomas IRs vary by histology, race, and sex. Histology. For example, the age-adjusted rate 
per 100KP-Y for glioblastoma is 3.19 (95% CI=3.16-3.23) compared with less than 0.2 for 
anaplastic oligodendroglioma (IR=0.12, 95%CI=0.11-0.13) and protoplasmic/fibrillary 
astrocytoma (IR=0.11, 95%CI=0.10-0.11) (CBTRUS 2011). Race. Whites consistently have 
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higher IR rates than blacks by histologic group (e.g., IR=3.55, 95%CI=3.52-3.59 vs. 1.64, 
95%CI=1.57-1.72 for glioblastoma; IR=0.47, 95%CI=0.45-0.48 vs. 0.19, 95%CI=0.17-0.22 for 
anaplastic astrocytoma; IR=0.29, 95%CI=0.27-0.30 vs. 0.17, 95%CI=0.15-0.19 for 
ependymoma/anaplastic ependymoma) (CBTRUS 2011). Sex. Similarly, men consistently 
have higher age-adjusted IRs than women by histology (e.g., IR=3.99, 95%CI=3.94-4.04 vs. 
IR=2.53, 95%CI=2.49-2.57 for glioblastoma; IR=0.48, 95%CI=0.46-0.50 vs. 0.35, 95%CI=0.33-
0.36 for anaplastic astrocytoma; and IR=0.27, 95%CI=0.26-0.29 vs. IR=0.25, 95%CI=0.24-0.27 
for ependymoma/anaplastic ependymoma), although the latter difference is not statistically 
significant (CBTRUS 2011). Interestingly, the female prevalence rate (PR) for primary brain 
tumours per 100KP-Y (PR=264.8) is higher than males (PR=158.7), perhaps attributable to 
survival bias among women (Porter et al 2010).  
 
 
*Counts suppressed since fewer than 16 cases reported in specific area-sex-race category. 
Fig. 2. Death rates (NCI State Cancer Profiles 2011). 
A higher male (IR=37) to female (IR=2.6) pattern also is observed internationally (Parkin et 
al 2005), although U.S. rates are higher in both men (IR=7.7, 95%CI=7.5-7.8) and women 
(IR=5.6., 95%CI=5.5-5.7) compared with international rates (NCI State Cancer Profiles 2011). 
Less developed countries tend to report lower rates (e.g., Africa, Pacific Islands; IR=3.0 per 
100KP-Y for males and 2.1 for females) than more developed countries (e.g., Australia, New 
Zealand, Europe, North America; IR=5.8 per 100KP-Y for men and 4.1 for females), possibly 
reflecting less access to modern medical facilities (Parkin et al 2005, CBTRUS 2011). In 
contrast, the standardized (age, sex, site, year at diagnosis) IR for brain tumours in Japan, a 
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country well known for accessible MR-imaging, is relatively low (2.5 per 100KP-Y person-
years) (Matsuda et al 2011). Similarly low rates have been observed in Korea (Lee et al 2010).  
2.2 Death rates and survival  
The annual number of brain tumour deaths at last count (2007) in the U.S. was n=7,315 for 
men and 5,919 for women. Age-adjusted rates steadily increased from 1975 to 1991, likely 
due to advances in neuroimaging, but have decreased linearly thereafter, with recent values 
on par with 1975 rates (Figure 3) (NCI State Cancer Profiles 2011). Overall DRs are higher 
among men (DR=5.1, 95%CI=5.0-5.2) than women (DR=3.5, 95%CI=3.4-3.6), however the 
difference is not statistically significant as was seen for IRs. The lowest DR for men and 
women combined was observed for the State of Hawaii (DR=2.1, 95%CI=1.4-3.0), which 
implemented almost complete universal health care coverage in 1994 under the Med-
QUEST programme (Hawaii Department of Human Services 2011). However, Hawaii also 
has the largest non Caucasian population of any state (i.e., 72.8% Asian/Pacific Islander), a 
factor associated with lower brain tumour incidence and death rates (NCI State Cancer 
Profiles 2011).  
 
 
Fig. 3. Mortality trends (NCI State Cancer Profiles 2011). 
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Survival rates for the majority of malignant gliomas remain disappointingly low, despite 
decades of advances in surgical, radiation, and chemical therapies, in contrast to 
improvements in many other cancers. GBMs, for example, typically present as highly 
aggressive, difficult to treat tumours without clinical, radiologic, or morphologic forewarning 
of a less virulent precursor tumour (Kanu et al 2009; Ostrom and Barnholtz-Sloan 2011). 
Secondary GBMs account for only about 10% of all GBMs, based on the presence of IDH1/2 
mutations (Ohgaki and Kleihues 2011). The infiltrating nature of these tumours makes 
treatment difficult. Other obstacles to effective treatment and improved survival include multi-
drug resistance, radioresistance, an impermeable blood-brain barrier, a lack of preclinical 
models, and a rudimentary understanding of neurooncogenetics (Kanu et al 2009).  
The relative survival percentages (RSP) for gliomas compared with the general U.S. 
population vary tremendously by histology and age at diagnosis. For example, the majority 
of patients diagnosed between age 0-14 years with pilocytic astrocytoma (RSP=97.3%), 
oligodendroglioma (RSP=95.3), protoplasmic & fibrillary astrocytoma (RSP=84.3%), and 
mixed glioma (RSP=75.6%) will live beyond 5 years, compared with anaplastic astrocytoma 
(RSP=32.0%) and glioblastoma (RSP=20.9%) (CBTRUS 2011). In contrast, 5-year relative 
RSPs are considerably lower across histologic types for those diagnosed between age 45-54 
(e.g., RSP=82.4% for pilocytic astrocytoma; RSP=76.8% for oligodendroglioma; RSP=51.1% 
for mixed glioma; RSP=39.5% for protoplasmic & fibrillary astrocytoma; RSP=28.6% for 
anaplastic astrocytoma; and RSP=5.6% for glioblastoma). Only 0.8% of patients diagnosed 
between age 55-64 will be alive after 10 years.  
 
5-Year Relative Survival (whites) by Year of Diagnosis 
 
Fig. 4. Survival percent (whites) for cancers of the brain and other nervous system tumours 
(NCI-SEER 2011). 
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RSPs also vary by race and sex. Black women (44%) have the highest 5-year RSPs for cancers 
of the brain and other nervous system tumours, when compared with white women (36.5%), 
black men (34.8%), and white men (32.6%) (Altekruse et al 2010). When examined by year of 
diagnosis from 1975 to 2002, whites (Figure 4) consistently have lower 5-year RSPs than 
blacks independent of sex (Figure 5) (NCI-SEER 2011).  
 
5-Year Relative Survival (blacks) by Year of Diagnosis 
 
 
Fig. 5. Survival percent (blacks) for cancers of the brain and other nervous system tumours 
(NCI-SEER 2011). 
Among adults, other factors associated with poorer survival include tumour site (frontal, 
cerebellum, multilobular), and socioeconomic status (less affluent individuals have lower 
survival rates) (Tseng et al 2006). The latter suggests that socioeconomic inequalities play an 
important role in glioma outcome, perhaps due to chronic comorbidities, inadequate access 
and utilization of health care, and longer wait times after surgery for adjuvant therapies 
(Tseng et al 2006). 
While population-based relative survival statistics paint a dismal prognostic picture for 
certain glioma types, conditional survival rates suggest a more favorable long term outcome 
for patients who have already survived for a specified amount of time after diagnosis (Table 
1) (Porter et al 2011). For Example, a GBM patient has a 70.4% (95%CI=55.6-81.2) relative 
probability of living 10 years beyond their diagnosis date if they have already survived 5 
years. In comparison, the 10-year unconditional probability for GBM is less than 3% (not 
shown in Table). 
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Table 1. Relative probability of a patient living 10 years beyond their diagnosis date if they 
have already survived 2 and 5 years. 
3. Risk factors 
The key epidemiologic determinants of glioma risk include advancing age, male sex, and 
Caucasian race (Bondy and Wrensch 1996). Few environmental or lifestyle exposures, except 
for ionising radiation, have been found to be consistently associated with glioma risk. 
Suspected risk factors include lifestyle behaviors (e.g., smoking, alcohol consumption, coffee 
drinking), infectious agents (e.g., polyomaviruses, cytomegaloviruses, influenza, varicella 
zoster, Toxoplasma gondii), diet/vitamins (e.g., nitrosamine compounds, vitamin C, vitamin 
D3), beauty products (e.g., hair dyes and lighteners, hair waving and straightening 
chemicals), industrial exposures (e.g., rubber manufacturing, petroleum products), mobile 
phones, electromagnetic fields, allergies/immunity, agricultural/farm animal exposures, 
handedness, birth weight/height, and various genetic polymorphisms. While the list is long, 
methodologic biases are believed to account for the bulk of observed associations. A 
comprehensive review of factors hypothesized to play a role in the etiology of brain tumors 
is beyond the intent of the current work and the reader is referred to several recent reviews 
on the topic (Ostrom and Barnholtz-Sloan 2011; Ohgaki 2009; Fisher et al 2007; 
Schwartzbaum et al 2006; Ohgaki and Kleihues 2005; Wrensch et al 2002). Rather, the aim of 
this section is to address the etiology of gliomas in the context of recent publications and 
current scientific debate on the topic.  
3.1 Mobile phones 
Mobile (cellular) phones initially appeared on the market in the late 1970’s in Japan and 
soon thereafter were sold in Europe and the U.S. (Bellis 2011). The first commercial wireless 
call originating in the U.S. occurred on 13 October 1983 (Green 2008). 
However, the widespread and frequent use of mobile phones on an affordable scale was not 
achieved until the earlier 2000’s when unlimited usage service contracts became a viable 
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option to “pay by the minute” billing plans. By the end of 2010 there were approximately 
303 million mobile phone subscribers in the U.S., representing 9 times the number in 1995 
(CTIA 2011). The World Health Organization estimates 4.6 billion subscribers globally in 
2010 (WHO 2011).  
The main challenge of epidemiologic studies on mobile phone risk has been the lack of long 
term, frequent use exposure data (NRPB 2003), especially among users who may be 
genetically predisposed to brain tumours (Wrensch et al 2009; Shete et al 2009 ). Population 
stratification and gene-environment interactions may mask the risk of mobile phone use in 
insufficiently powered studies. Compounding the situation, the average latency period for 
many cancers is measured in decades, sometimes as long as 50-60 years, and similarly long 
intervals may apply to brain tumours (Challis 2007). The flat or declining brain tumour 
incidence trends observed in the population during the same time period of increasing 
mobile phone use would seem incongruent if mobile phones are a significant cause of brain 
tumours (Inskip et al 2010). However, competing risks could explain the effect if brain 
tumours are caused by more than one factor.  
The majority of epidemiologic studies to date generally do not support a causative 
association between mobile phone use and brain tumours (Ahlbom et al 2009). However, 
methodologic concerns point to a cumulative underestimation of risk (Kundi 2010). 
Downward bias may have affected studies that excluded deceased and terminally ill 
patients, if mobile phone use presumably increases the case fatality rate vis-à-vis enhanced 
tumor progression. Pre-diagnostic effects of brain tumours may have reduced cell phone use 
and differentially resulted in lower risk estimates, since referents would not have been 
affected (NRPB 2003). The use of interviews rather than mailed questionnaire data collection 
(where it is possible to verify mobile phone use by checking billing records) may have 
decreased risk estimates due to non-differential exposure misclassification from relying on 
proxy information. Furthermore, participants tend to underestimate the prevalence of 
mobile phone use by up to 15% compared with non-participants, leading to a differential 
reduction in risk estimates for mobile phone use, since participation rates among cases 
typically are higher than referents by 10-15% (Vrijheid et al 2009; The INTERPHONE Study 
Group 2010). Risk estimates below unity for brain tumours have been reported in several 
analyses of mobile phone use (The INTERPHONE Study Group 2010; Inskip et al 2001; 
Johansen et al 2001; Muscat et al 2000; Hepworth et al 2006). A biologic basis for the results, 
particularly reports of deceased risk for contralateral use, is ambiguous. In many cases, the 
inverse associations likely are explained by the aforementioned factors that bias risk 
estimates in the downward direction. On the other hand, studies in which the participants’ 
status was blinded at interview tended to yield positive risk estimates compared with those 
who were not blinded (Myung et al 2008). 
Two large recent studies have reported increased risks for mobile phone use, especially 
among heavy users. A multicentric study (13 countries) with 2708 glioma cases and matched 
referents (age within 5 years, sex, and region of residence within each study centre) 
observed a 1.40 odds ratio (OR) [95% confidence interval (CI)=1.03-1.89] for glioma among 
those in the highest mobile phone exposure category (cumulative call time≥1640 hours) 
compared with the lowest category (never a regular user) (The INTERPHONE Study Group 
2010). A subset analysis of the concordance between tumour and preferred side of phone 
use similarly showed an increased estimated risk among those in the highest decile of 
cumulative call time (OR=1.55, 95%CI=1.24-1.99). Risk estimates were not reduced for the 
contralateral side, suggesting against potential reporting bias (Kundi et al 2009). A linear 
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dose response pattern (i.e., consistently increasing risk estimates with dose) is a feature of 
many but not all known carcinogens and conveys greater weight for a causative association. 
An upward trend across deciles of cumulative call time was not observed in the above 
study.  
However, in a second recently-conducted study of n=1251 maligant brain tumours (n=1148 
gliomas) and n=1267 referents (aged 20-80 years at diagnosis), adjusted estimated risk (age, 
sex, socioeconomic index, and year of diagnosis) increased with cumulative hours (h) of 
mobile phone use (none, OR=1.0; 1-100 h, OR=1.2, 95%CI=0.98-1.4; 1001-2000 h, OR=1.5, 
95%CI=11.1-2.1; >2000 h, OR=2.5, 95%CI=1.8-3.5) (Hardell et al 2011). Similarly, estimated 
risk (in the category with >74 hours cumulative use) increased with latency time [years (y) 
since first use of a cell phone until diagnosis] (none, OR=1.0; >1-5 y, OR=1.0, 95%CI=0.7-1.4; 
>5-10 y, OR=1.2, 95%CI=0.9-1.6; >10 y, OR=2.7, 95%CI=2.0-3.8), although the linear effect 
was less pronounce than for cumulative hours of exposure. A key advantage of this study 
was the use of a mailed questionnaire, which allowed participants to verify responses by 
checking telephone bills (Kundi 2010). Recall bias could have increased risk estimates in 
positive studies if more cases than referents believed mobile phone use to be the cause of 
their brain tumour (Sage and Carpenter 2009; Hepworth et al 2006). 
Studies of mobile phone use have been difficult to compare and interpret due to 
methodologic differences and the paucity of rigorous design. Background levels of 
electromagnetic radiation (e.g., power lines, fluorescent lights, computer monitors, 
televisions, and mobile phone base stations) may have confounded studies that did not 
account for such effects. A recent case-referent study conducted in Japan found a dose-
response pattern for increasing exposure to power-frequency magnetic fields (MF) 
measured in a child’s bedroom and brain tumours (<0.1µT, OR=1.0; 0.1 to <0.2 µT, OR=0.74, 
95%CI=0.17-3.18; 0.2 to <0.4 µT, OR=1.58, 95%CI=0.25-9.83; ≥0.4 µT, OR=10.9, 95%CI=1.05-
113). The OR reported for bedroom MF levels above 0.3 µT, as opposed to above 0.4 µT, was 
16 (95%CI=1.85-153). Mobile phones emit both radiofrequency and extremely-low frequency 
electromagnetic fields (Sage et al 2007). The level of near-field electromagnetic radiation 
typically emitted on a continuous basis by smart mobile phones ranges from 0.5-0.1 µT 
(spikes up to 93.5 µT have been recorded during send/receive mode operations), which is 
above the highest exposure category reported in the Japanese study (Sage et al 2007; 
Stevenson 2011). Measurements could have been influenced by near-field interference (Silva 
2007; Jaffa and Herz 2007), however readings were generally consistent with other 
independent sources (Sage and Johansson 2007). A large pooled analysis of low-frequency 
MFs and childhood brain tumors did not observe a dose-response relationship (Kheifets et 
al 2010). However, inconsistent/imprecise exposure measurements and low participation 
rates (40%-80%) across studies may have biased results. Furthermore, the actual exposure 
levels in brain tissue may not necessarily reflect the levels radiated by the mobile phone due 
to anatomic details and variations in tissue conductivity/permittivity (Kouveliotis et al 2006; 
Kuster and Balzano 1992).  
In March 2010, the Mobile Telecommunications and Health Research Programme (MTHR) 
initiated funding of a prospective cohort study that will follow approximately 250,000 
mobile phone users across 5 European countries for up to 30 years (MTHR 2011; Stewart 
2000). While MTHR concludes that short term (less than 10 years) exposure to mobile phone 
signals does not appear to be associated with an increase in brain and nervous system 
tumours, they emphasize that there remains “significant uncertainties that can only be 
resolved by monitoring the health of a large cohort of phone users over a long period of 
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dose response pattern (i.e., consistently increasing risk estimates with dose) is a feature of 
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2000). While MTHR concludes that short term (less than 10 years) exposure to mobile phone 
signals does not appear to be associated with an increase in brain and nervous system 
tumours, they emphasize that there remains “significant uncertainties that can only be 
resolved by monitoring the health of a large cohort of phone users over a long period of 
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time (MTHR 2011).” Furthermore, the reactions of children to mobile phone emissions may 
be different and/or stronger than those of adults (as is the case for other environmental 
exposures such as lead, tobacco smoke, ultraviolet radiation, and ionising radiation) and 
very little research has been conducted so far to determine whether this is the case (MTHR 
2011). No studies on mobile phone use and risk of brain tumours have been planned for the 
U.S. that are comparable in size and detail to the COSMOS.  
The thermal radiation emitted during average mobile phone use is low and generally is not 
believed to cause direct DNA damage or any other significant deleterious biologic effects on 
the brain (Wainwright 2000; Johansen et al 2001; Sage and Carpenter 2009; NRPB 2003). 
However, questions remain regarding the non-thermal effects of non-ionising radiation 
from mobile phones. Using positron emission tomography (PET), a National Institutes of 
Health study of 47 participants demonstrated a 7% increase in brain glucose uptake (a 
measure of metabolic activity) in response to mobile phone signals, supposedly independent 
of any thermal effects (Volkow et al 2011). The increases in regional glucose metabolism 
induced by the mobile phone signals were similar in magnitude to those reported after 
suprathrehold transcranial magnetic stimulation of the sensorimotor cortex. The authors 
hypothesize that the non-thermal effects on neuronal activity may be mediated by changes 
in cell membrane permeability, calcium efflux, cell excitability, and/or neurotransmitter 
release. A significant change in cell proliferation in response to radiofrequency MFs, 
independent of thermal activity, has been reported in a cell culture experiment involving 
transformed human epithelial amnion cells (Velizarov et al 1999). Effects demonstrated in 
other studies include up-regulation of apoptosis genes, induction of reactive oxygen species, 
changes in protein conformation, the creation of stress proteins, and immune system 
disturbances (Zhao et al 2007; Sage and Carpenter 2009; NRPB 2003; Valentini et al 2007; 
Ruediger 2009). Caution is advised when interpreting these effects since numerous 
contradictory results are present in the literature.  
The likelihood that mobile phone use has no impact on the brain is small. Yet, the exact 
biophysical/biologic mechanism(s), if any, underlying mobile phone effects on neuronal 
cells, especially in the context of cancer, remains to be confirmed. Additional research is 
needed to determine if mobile phone use specifically increases brain tumor risk, either 
independently or in combination with other potential risk factors. Until then, limiting 
exposure to potentially vulnerable populations (e.g., fetus, children) would seem to be 
prudent precautionary public health policy, especially given the unknown latency for the 
development of brain cancer (Kundi et al 2009; Sage and Carpenter 2009). Radiofrequency 
MF absorption rates are estimated to be two times higher in children than adults, due to the 
lower thickness of pinna, skin and skull of younger children (Wiart et al 2008). Accordingly, 
risk may be greater among individuals who use a mobile phone at younger ages, yet few 
studies have addressed this potential risk group as they age into adulthood. Based on an 
increased risk for glioma, the WHO/International Agency for Research on Cancer (IARC) 
has formally classified radiofrequency electromagnetic fields, such as those emitted by 
wireless communication devices, as “possibly carcinogic to humans (Group 2B) 
(WHO/IARC 2011).”  
3.2 Atopic diseases and farm exposures 
Several (Berg-Berkhoff et al 2009; Wigertz et al 2007; Schwartzbaum et al 2003; Hochberg et 
al 1990; Schlehofer et al 1992; Schlehofer et al 1999; Ryan et al 1992; Brenner et al 2002; Linos 
et al 2007; Wang and Diepgen 2005; Carrozzi and Viegi 2005) but not all (Hagströmer et al 
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2005; Turner et al 2005; Siegmund et al 2008; Eriksson et al 2005; Cicuttini et al 1997) 
epidemiologic studies of atopic diseases (e.g., asthma, allergies) have been negatively 
associated with glioma risk. The protective association has been suggested to reflect 
increased immune surveillance, although the exact biologic mechanism is unknown (Linos 
et al 2007; Carrozzi and Viegi 2005). Alterations of the immunological system can enhance 
the inflammatory response and promote tumor development (Carrozzi and Viegi 2005). The 
reduced association with allergies also may be due to reverse causality (i.e., 
immunosuppression induced by the tumor) (Wigertz et al 2007). Glioma patients are known 
to have an impaired immune system (Dix et al 1999). Interestingly, therapeutic immunity to 
intracranial tumors has been induced in the laboratory by peripheral immunization with 
interleukin-4 (IL-4) transduced glioma cells [Okada et al 2001; Benedetti et al 1998]. 
Farmers have been found to have an increased risk for brain cancer in some studies 
(Kristensen et al 1996; Reif et al 1989; Wingren et al 1992; Ahlbom et al 1986; Musicco et al 
1982; Musicco et al 1988; Brownson et al 1990; Heineman et al 1995), although they generally 
are healthier than the population-at-large (Kristensen et al 1996; Bråbäck 2002; Population 
and Public Health Branch (PPHB) 1995; Blair et al 2005; Ronco et al 1992), live longer 
(Alavanja 1996), and die less frequently from cancer overall (Blair et al 1993). Being raised on 
a farm (Alfven et al 2006; Ege et al 2007; Riedler et al 2001; Braun-Fahrländer et al 1999; 
Riedler et al 2000; von Ehrenstein et al 2000; Kilpelainen et al 2000; Klintberg et al 2001; Ernst 
and Cormier 2000; Remes et al 2003; Leynaert et al 2001; Gassner-Bachmann and Wüthrich 
2000; Vercelli 2008) or in a rural area (Godfrey 1975) has been shown to protect against 
asthma, hay fever, and atopic sensitization. Farm children are exposed to higher 
concentrations of airborne allergens, but paradoxically become sensitized less frequently 
and manifest a weaker sensitization response than non-farm controls (Gassner-Bachmann 
and Wüthrich 2000). The protective effect may be due to a form of “tolerance” that 
conceivably develops early in life, following repeated exposure to high levels of allergens 
(e.g., organic dusts, fungi, and endotoxins). Component lipopolysaccharides have been 
shown to excite Th1 responses and suppress the development of immunoglobulin-E (IgE)-
antibodies (Klintberg et al 2001; Bråbäck 2002).  
Specific determinants of asthma and atopy in the farm setting remain largely unknown. Any 
relationship with glioma risk likely is complex and must be interpreted in light of 
substantial heterogeneity in the protective ability of farming environments and differences 
in farming practices, especially with respect to microbial exposures (Alfven et al 2006; Ege et 
al 2007; Vercelli 2008). By self-selection, those who manifest allergies may choose a career 
path other than farming (i.e., healthy worker effect) (Bråbäck 2002). Farmers represent a 
diverse group (e.g., dairy, field crop, hog, beef cattle, poultry, fish, marijuana, cotton, and 
organic), and brain cancer risk, or lack thereof, for farmers could reflect differences in 
activities and the type, magnitude, and seasonality of exposures. In one report, marijuana 
smoking was associated with glioma risk, but the study did not specifically examine 
marijuana farming (Efird et al 2004). Farmers and their families have greater contact with 
seasonal elements. Season of birth has been associated with adult (Brenner et al 2004; Koch 
et al 2006; Mainio et al 2006; Efird 2009) and childhood brain tumours (Makino et al 2011; 
McNally et al 2002; Heuch et al 1998; Yamakawa et al 1979; Hoffman et al 2007; Halperin et 
al 2004), but the period of greatest risk has varied between studies.  
Differences in the definition and the lack of objective measures of atopy should be 
considered when interpreting the above studies (Wang and Diepgen 2005; Schoemaker et al 
2006). Furthermore, there is no definitive trend toward a decreasing risk for glioma with 
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younger ages at onset of the allergic condition, arguing against an immunologic cause for 
glioma (Schoemaker et al 2006). Paradoxically, increased risk for glioma has been observed 
in patients with AIDS-related immuno-suppression (Goedert et al 1998; Frisch et al 2001; 
Grulich et al 1999), but not in those with iatrogenic immuno-suppression (Schiff 2004). Many 
farm chemicals are classified as probable or likely human carcinogens by the US 
Environmental Protection Agency (EPA) (e.g., acephate, dichlorvos, dimethoate, lindane, 
parathion, phosmet, and tetrachlorvinphos) and these agents acting alone or in parallel with 
decreased atopic sensitization conceivably may increase glioma risk (US Environmental 
Protection Agency 2003).  
3.3 Infectious agents  
Polyomaviruses have been detected in the cancerous brain tissue of some patients 
diagnosed with gliomas (Rollison et al 2003). Polyomaviruses manifest a strong tropism for 
glial cells in vivo, possibly due to the interaction of glial transcription factors such as Tst-
1/Ict6/SCIP with viral promoter sequences (Vasilyera et al 2004). The inoculation of 
immunologic immature neonate mice with human polyomavirus has been shown to readily 
cause tumor formation at multiple sites including the brain; older mice do not develop 
tumors in response to polyoma virus either in the laboratory or by natural infection 
(Nagashima et al 1984; Zu Rhein and Varakis 1979; London et al 1978; London et al 1983, 
Sanders 1977; Nagashima et al 1984; Zu Rhein and Varakis, 1979). Similarly, owl and 
squirrel monkeys injected (intracerebral, subcutaneous, or intravenous) with human JC 
polyomavirus have developed astrocytomas and glioblastomas (London et al 1978; London 
et al 1983). Recently, two new members of the Polyomaviridae family,Karolinska Institutet Virus 
(KIPyV) and Washington Univerisity virus (WUPyV), have been detected in samples from 
children with lower respiratory tract disease (Foulongne et al 2008). 
Paradoxically, animals are not a permissive host for human JC virus replication, even 
though integrated JC viral DNA has been identified in the tumors of animals induced with 
the virus (White et al. 2005; Miller et al, 1984). Though monkeys themselves are not affected, 
simian virus (SV)-40 (extracted from monkey kidneys) gives cancer to hamsters (Rosenfeld 
1962). Human adenovirus type 12 and Rous sarcoma virus are examples of other neuro-
oncogenic viruses capable of causing gliomas under laboratory conditions (Zimmerman 
1975). Yet, adenovirus in the worst case only causes respiratory disease in humans 
(Rosenfeld 1962). Some tumor viruses must be injected in animals on the first day of life to 
be effective, although they may not cause cancer until years later (Bailar and Gurian 1964).  
Analogous to human and simian polyomaviruses causing brain tumours in non-permissive 
rodents, animal polyomaviruses conceivably may cause brain tumours in humans, yet little 
is understood about the latter topic. Polyomavirus are ubiquous among animals (e.g., cattle, 
birds, rodents,) (Ashok and Atwood 2006). For example, mouse polyomaviruses (Mus 
musculus) are capable of inducing a wide array of mesenchymal and epithelial cell type 
cancers in mice (Dawe et al 1987). Exposure to farm animals has been associated in some 
studies with childhood brain tumours (Efird et al 2003; Bunin et al 1994) but not adult brain 
tumors (Ménégoz et al 2002).  
Epidemiologic evidence in support of a viral/pathogenic etiology for brain tumors remains 
controversial. In adults, Toxoplasma gondii infection has been associated with an increased 
prevalence of astrocytomas (Schuman et al 1967), while decreased glioma risk has been 
associated with a history of infections/colds (Schlehofer et al 1999), and chicken pox 
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(Wrensch et al 2005; Wrensch et al 2001). On the other hand, increased risk for childhood 
brain tumors has been associated with a history of chicken pox (Bithell et al 1973), influenza 
(Dickinson et al 2002; Linos et al 1998), measles (Dickinson et al 2002), general viral 
infections (Fear et al 2001; Linet et al 1996), and neonatal urinary tract infections (Linet et al 
1996). A 7.5-fold OR (95% CI=1.3-44.9) for low grade astrocytoma has been observed for 
neonatal urinary tract infections (Linet et al 1996). 
A recent cohort study of 20,132 workers in poultry slaughtering and processing plants, a 
group with high potential exposures to avian leukosis/sarcoma, reticuloendothesliosis, and 
Marek’s disease viruses, were observed to have a significant excess of brain cancer, 
compared with the U.S. population (standardized mortality ratio=1.7, 95% CI=1.1-2.4). 
Although the aforementioned poultry viruses are well established carcinogens in their 
natural species, it is not known if they cause cancer in humans (Johnson et al 2000). 
An infectious etiology for brain tumors is complicated by many factors (Naumova 2006). 
The same infectious agent may present a different pattern of incidence depending on the 
host location. A peak evident in the general population may not behave uniformly within 
certain subpopulations. Temperature, humidity, precipitation, and indoor air quality are 
among the mitigating factors that may affect the survival and transmissibility of a pathogen. 
Other factors include poor nutrition, population density, travel, hygiene practices, cultural 
practices in food consumption/preparation, changes in herd immunity, or evolution of the 
infectious agent over time. Furthermore, seasonal variation in immune function may 
increase host susceptibility to infections at certain times of the year (Melnikov et al 1987; 
Carandente et al 1988).  
4. Discussion 
The vast majority of glioma cases are idiopathic in origin. Demographic differences in 
incidence by race, sex, and country suggests that genetics, hormones, and environmental 
risk factors may play a role in some gliomas. However, study bias (e.g., participation, 
information, survival), variations in health care access/utilization, residual confounding, 
and other yet-to-be realized influences may explain the differences in glioma incidence. 
Complicating matters, the etiology of glioma may be multifactor in nature. That is, several 
factors operating in unison may cumulatively increase/decrease risk or mask the effect of 
individual factors when examined in isolation. Additionally, gene-environment and gene-
gene interactions may modify underlying risk. Future epidemiologic studies will benefit by 
improved measures of environmental exposures, more precise statistical methods for 
detecting interaction effects, and larger multicentre collaborations aimed at better 
understanding the impact of population stratification.  
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the virus (White et al. 2005; Miller et al, 1984). Though monkeys themselves are not affected, 
simian virus (SV)-40 (extracted from monkey kidneys) gives cancer to hamsters (Rosenfeld 
1962). Human adenovirus type 12 and Rous sarcoma virus are examples of other neuro-
oncogenic viruses capable of causing gliomas under laboratory conditions (Zimmerman 
1975). Yet, adenovirus in the worst case only causes respiratory disease in humans 
(Rosenfeld 1962). Some tumor viruses must be injected in animals on the first day of life to 
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1. Introduction 
In the landmark review by Hanahan and Weinberg1, the authors distilled the essence of 
cancer into six distinct phenotypes, including evasion of apoptosis, self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless 
replicative potentials, and sustained angiogenesis. The widely accepted paradigm suggests 
that cancer arises as a result of mutations or epigenetic events, which alter function of genes 
critical for attaining these phenotypes. These gene functions are intimately linked to the 
regulation of developmental processes2, their aberrant function in tumor inevitably lead to 
cell states that resemble stages during normal development. These cell states can be 
captured using genomic technologies to define distinct molecular subtypes. With the advent 
of The Genome Cancer Atlas project for glioblastoma3,4, we now have a glimpse of the 
genetic events underlying glioblastoma pathogenesis as well as distinct molecular subtypes. 
In this review, the genomic profiles of glioblastoma will be reviewed in the context of the 
properties described by Hanahan and Weinberg. Molecular subtypes of glioblastoma will be 
discussed in the context of developmental biology and the cell of origin. 
2. Glioblastoma 
Glioblastoma is the most common form of primary brain tumor, with dismal prognosis. The 
incidence of this tumor is fairly low, with 2-3 cases per 100,000 people in Europe and North 
America. Despite its rarity, overall mortality related to glioblastoma is comparable to the 
more prevalent tumors5. This is, in large part, due to the near uniform fatality of the afflicted 
patients. Indeed, glioblastoma is one of the most aggressive of the malignant tumors. 
Without treatment, the median survival is approximately 3 months6. The current standard of 
treatment involves maximal surgical resection followed by concurrent radiation therapy and 
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1. Introduction 
In the landmark review by Hanahan and Weinberg1, the authors distilled the essence of 
cancer into six distinct phenotypes, including evasion of apoptosis, self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless 
replicative potentials, and sustained angiogenesis. The widely accepted paradigm suggests 
that cancer arises as a result of mutations or epigenetic events, which alter function of genes 
critical for attaining these phenotypes. These gene functions are intimately linked to the 
regulation of developmental processes2, their aberrant function in tumor inevitably lead to 
cell states that resemble stages during normal development. These cell states can be 
captured using genomic technologies to define distinct molecular subtypes. With the advent 
of The Genome Cancer Atlas project for glioblastoma3,4, we now have a glimpse of the 
genetic events underlying glioblastoma pathogenesis as well as distinct molecular subtypes. 
In this review, the genomic profiles of glioblastoma will be reviewed in the context of the 
properties described by Hanahan and Weinberg. Molecular subtypes of glioblastoma will be 
discussed in the context of developmental biology and the cell of origin. 
2. Glioblastoma 
Glioblastoma is the most common form of primary brain tumor, with dismal prognosis. The 
incidence of this tumor is fairly low, with 2-3 cases per 100,000 people in Europe and North 
America. Despite its rarity, overall mortality related to glioblastoma is comparable to the 
more prevalent tumors5. This is, in large part, due to the near uniform fatality of the afflicted 
patients. Indeed, glioblastoma is one of the most aggressive of the malignant tumors. 
Without treatment, the median survival is approximately 3 months6. The current standard of 
treatment involves maximal surgical resection followed by concurrent radiation therapy and 
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chemotherapy with the DNA alkylating agent, temozolomide7. With this regimen, the 
median survival is approximately 14 months. For nearly all affected, the treatments 
available remain palliative. 
Studies carried out over the past three decades suggest that glioblastomas, like other 
cancers, arise secondary to the accumulation of genetic alterations. These alterations can 
take the form of epigenetic modifications, point mutations, translocations, amplifications, or 
deletions, and modify gene function in ways that deregulate cellular signaling pathways 
leading to the cancer phenotype1. The exact number and nature of genetic alterations and 
deregulated signaling pathways required for tumorogenesis remains an issue of debate8, 
although it is now clear that CNS carcinogenesis requires multiple disruptions to the normal 
cellular circuitry3, 4.  
3. The Cancer Genome Atlas (TCGA) project 
The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to catalogue 
the genetic and epigenetic changes in the cancer genome, with goals of identifying those 
responsible for carcinogenesis. The project constitutes a joint effort of the National Human 
Genome Research Institute (NHGRI), National Cancer Institute (NCI), and the U.S. 
Department of Health and Human Services, and collects tumor specimen from major cancer 
centers spanning across the continental U.S. The project aims to provide the genomic profile 
of 500 specimens of various cancer types using state-of-the-art platforms for sequencing, 
microRNA, mRNA, single-nucleotide polymorphisms, and methylation profiling. 
TCGA started as a pilot project in 2006 with focus on glioblastoma as the first cancer type for 
study. With the success of the pilot project, TCGA plans to expand its efforts to aggressively 
pursue 20 or more additional cancers. This article will review the major insights derived 
from the TCGA in the context of the cancer phenotypes proposed by Hanahan and 
Weinberg1. 
4. The cancer phenotype 
The aggregate of cancer research investigation spanning the past three decades suggest that 
cancer is a genetic disease characterized by mutations or epigenetic events that abrogate or 
compromise regulatory circuitry governing cell proliferation and homeostasis8. In the 
landmark review by Hanahan and Weinberg1, the authors distilled the essence of these 
regulatory circuits into six distinct phenotypes, including evading apoptosis, self-sufficiency 
in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potentials, and sustained angiogenesis. The following section will 
review the TCGA findings pertinent to these phenotypes. 
4.1 Self-sufficiency in growth signals – The Receptor Tyrosine Kinase 
(RTK)/PhosphoInosital 3 Kinase (PI3K) signaling cascade 
Active cellular proliferation in normal cells requires signals from its environment. These 
signals typically involve the binding of a transmembrane receptor to growth factors, 
extracellular matrix components, or cell surface components. This mitogenic signaling process 
is under stringent regulation in normal cells. Typically, multiple ligand-receptor interactions in 
a permissive cellular state are required before cellular proliferation can take place. This 
regulation minimizes the probability of dysregulated, autonomous cell growth1,9. The 
Molecular Etiology of Glioblastomas: 
Implication of Genomic Profiling From the Cancer Genome Atlas Project 
 
27 
importance of growth factors in biology was recognized by a Nobel Prize in Physiology or 
Medicine to Stanley Cohen and Rita Levi-Montalcini in 1986. Subsequent identification that 
many oncogenes participate in cellular signaling related to growth factor function was also 
awarded a Nobel Prize in Physiology or Medicine (to Michael Bishop and Harold Varmus in 
1989). 
To abridge this stringent growth regulation, tumors often mutate the transmembrane 
receptors or their downstream effectors in ways that constitutively activate the pathway. 
The pathway most commonly mutated to achieve this end in glioblastoma involves the 
RTK-PI3K pathway9,10. RTKs are cell surface receptors that are normally activated only in 
response to growth factor binding9. Results from the TCGA revealed that nearly all 
glioblastomas harbor activating mutations or amplifications in genes required for this 
signaling cascade3,4,11,12. Epidermal Growth Factor Receptor (EGFR) and Platelet Derived 
Growth Factor Receptor (PDGFR) are two prototypical members of RTK3, 4, 12.  
For EGFR and PDGFR, binding of the growth factor to the ligand leads to homo- or hetero- 
dimerization of the receptor. This dimerization facilitates autophosphorylation of the 
cytoplasmic domains of the dimerized receptor at select tyrosine residues9. The 
phosphorylated tyrosine residue, in turn, recruits and binds to other signaling proteins to 
the cell membrane. In some cases, the phospho-tyrosine bound proteins serve as a platform 
for the recruitment of other effector proteins. In other cases, the bound protein undergoes a 
conformational change upon binding to the RTK and becomes activated in the process9.  
One of the critical cellular kinases that become activated upon binding to RTK is PI3K13. 
PI3Ks catalyze the phosphorylation of a critical component of the cell surface, 
phosphatidylinositol-4,5-isphosphate (PI(4,5)P2). This phosphorylation generates 
phosphatidylinositol-1,4,5-isphosphate (PI(1,4,5)P3), which in turn serves as a docking site 
for pro-proliferative down-stream effector proteins 10. Thus, RTK activation transforms the 
cell membrane into a catalytic surface populated with a high density of pro-mitotic signaling 
molecules, ultimately leading to cell proliferation. 
Expectedly, gene functions that inhibit the generation of this pro-proliferative “catalytic 
surface” function as tumor suppressors. For instance, the hydrolysis of (PI(1,4,5)P3) into 
(PI(4,5)P2) is catalyzed by a phosphatase termed Phosphatase and Tensin Homology 
(PTEN). PTEN inactivating mutations have been identified in up to 50% of tumor specimens 
14. Similarly, one of the effector proteins recruited to a phosphorylated RTK is Ras. Ras 
encodes a monomeric G-protein that cycles between an active form bound to GTP and an 
inactive form that binds to GDP15. It functions as a critical component of the pro-
proliferative “catalytic surface”. Through a series of protein-protein interactions, RTK 
activation catalyzes the exchange of GDP for GTP in Ras, initiating signals required for 
cellular proliferation. The protein encoded by neurofibromatosis 1 (NF1) functions to 
catalyze the exchange of GTP for GDP in Ras, consequently preventing cell proliferation. In 
this context, it is not surprising that NF1 patients are predisposed to gliomagenesis 16. The 
TCGA results showed that approximately 20% of glioblastomas harbor loss of function 
mutations in NF13,4. TCGA additionally revealed gain of function mutations in K-ras have 
also been identified in glioblastoma specimens 3. 
4.2 Insensitivity to anti-growth signals – The RB axis 
In addition to receiving pro-growth signals from their environment, cells also receive 
multiple anti-proliferative signals to prevent cell growth. These anti-growth signals, like 
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chemotherapy with the DNA alkylating agent, temozolomide7. With this regimen, the 
median survival is approximately 14 months. For nearly all affected, the treatments 
available remain palliative. 
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take the form of epigenetic modifications, point mutations, translocations, amplifications, or 
deletions, and modify gene function in ways that deregulate cellular signaling pathways 
leading to the cancer phenotype1. The exact number and nature of genetic alterations and 
deregulated signaling pathways required for tumorogenesis remains an issue of debate8, 
although it is now clear that CNS carcinogenesis requires multiple disruptions to the normal 
cellular circuitry3, 4.  
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The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to catalogue 
the genetic and epigenetic changes in the cancer genome, with goals of identifying those 
responsible for carcinogenesis. The project constitutes a joint effort of the National Human 
Genome Research Institute (NHGRI), National Cancer Institute (NCI), and the U.S. 
Department of Health and Human Services, and collects tumor specimen from major cancer 
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of 500 specimens of various cancer types using state-of-the-art platforms for sequencing, 
microRNA, mRNA, single-nucleotide polymorphisms, and methylation profiling. 
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in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potentials, and sustained angiogenesis. The following section will 
review the TCGA findings pertinent to these phenotypes. 
4.1 Self-sufficiency in growth signals – The Receptor Tyrosine Kinase 
(RTK)/PhosphoInosital 3 Kinase (PI3K) signaling cascade 
Active cellular proliferation in normal cells requires signals from its environment. These 
signals typically involve the binding of a transmembrane receptor to growth factors, 
extracellular matrix components, or cell surface components. This mitogenic signaling process 
is under stringent regulation in normal cells. Typically, multiple ligand-receptor interactions in 
a permissive cellular state are required before cellular proliferation can take place. This 
regulation minimizes the probability of dysregulated, autonomous cell growth1,9. The 
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importance of growth factors in biology was recognized by a Nobel Prize in Physiology or 
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many oncogenes participate in cellular signaling related to growth factor function was also 
awarded a Nobel Prize in Physiology or Medicine (to Michael Bishop and Harold Varmus in 
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To abridge this stringent growth regulation, tumors often mutate the transmembrane 
receptors or their downstream effectors in ways that constitutively activate the pathway. 
The pathway most commonly mutated to achieve this end in glioblastoma involves the 
RTK-PI3K pathway9,10. RTKs are cell surface receptors that are normally activated only in 
response to growth factor binding9. Results from the TCGA revealed that nearly all 
glioblastomas harbor activating mutations or amplifications in genes required for this 
signaling cascade3,4,11,12. Epidermal Growth Factor Receptor (EGFR) and Platelet Derived 
Growth Factor Receptor (PDGFR) are two prototypical members of RTK3, 4, 12.  
For EGFR and PDGFR, binding of the growth factor to the ligand leads to homo- or hetero- 
dimerization of the receptor. This dimerization facilitates autophosphorylation of the 
cytoplasmic domains of the dimerized receptor at select tyrosine residues9. The 
phosphorylated tyrosine residue, in turn, recruits and binds to other signaling proteins to 
the cell membrane. In some cases, the phospho-tyrosine bound proteins serve as a platform 
for the recruitment of other effector proteins. In other cases, the bound protein undergoes a 
conformational change upon binding to the RTK and becomes activated in the process9.  
One of the critical cellular kinases that become activated upon binding to RTK is PI3K13. 
PI3Ks catalyze the phosphorylation of a critical component of the cell surface, 
phosphatidylinositol-4,5-isphosphate (PI(4,5)P2). This phosphorylation generates 
phosphatidylinositol-1,4,5-isphosphate (PI(1,4,5)P3), which in turn serves as a docking site 
for pro-proliferative down-stream effector proteins 10. Thus, RTK activation transforms the 
cell membrane into a catalytic surface populated with a high density of pro-mitotic signaling 
molecules, ultimately leading to cell proliferation. 
Expectedly, gene functions that inhibit the generation of this pro-proliferative “catalytic 
surface” function as tumor suppressors. For instance, the hydrolysis of (PI(1,4,5)P3) into 
(PI(4,5)P2) is catalyzed by a phosphatase termed Phosphatase and Tensin Homology 
(PTEN). PTEN inactivating mutations have been identified in up to 50% of tumor specimens 
14. Similarly, one of the effector proteins recruited to a phosphorylated RTK is Ras. Ras 
encodes a monomeric G-protein that cycles between an active form bound to GTP and an 
inactive form that binds to GDP15. It functions as a critical component of the pro-
proliferative “catalytic surface”. Through a series of protein-protein interactions, RTK 
activation catalyzes the exchange of GDP for GTP in Ras, initiating signals required for 
cellular proliferation. The protein encoded by neurofibromatosis 1 (NF1) functions to 
catalyze the exchange of GTP for GDP in Ras, consequently preventing cell proliferation. In 
this context, it is not surprising that NF1 patients are predisposed to gliomagenesis 16. The 
TCGA results showed that approximately 20% of glioblastomas harbor loss of function 
mutations in NF13,4. TCGA additionally revealed gain of function mutations in K-ras have 
also been identified in glioblastoma specimens 3. 
4.2 Insensitivity to anti-growth signals – The RB axis 
In addition to receiving pro-growth signals from their environment, cells also receive 
multiple anti-proliferative signals to prevent cell growth. These anti-growth signals, like 
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their pro-mitotic counterparts, are sensed by the binding of transmembrane receptors to 
soluble factors, extracellular matrix components, or cell surface components. 
Most of these anti-proliferative signals operate at the G1 phase of the cell cycle to trigger 
either 1) entry into a transient quiescent (G0) state or 2) entry into a post-mitotic, 
differentiated state. The importance of cell cycle regulation in biology was recognized by a 
Nobel Prize in Physiology or Medicine to Leland Hartwell, Tim Hunt, and Sir Paul Nurse in 
2001. 
At the molecular level, nearly all of these signals converge at the retinoblastoma protein 
(RB) 1. In quiescent cells, the RB protein is hyper-phosphorylated. This form of RB binds and 
sequesters the E2F family of transcription factors17. The genes transcribed by these 
transcription factors are essential for the G1-S transition of the cell cycle18. Phosphorylation 
of RB releases the sequestered E2F transcription factors and allows for cell growth. During 
normal cell cycle progression, induction of cyclin D1 and its associated cyclin-dependent 
kinases, CDK4 and CDK6, at the G1-S transition is responsible for the phosphorylation of 
RB. The kinase activity of the CDK4/6-cyclin D complex is under complex regulation, 
including the critical negative regulators CDKN2A (p16Ink4a), CDKN2B, and CDKN2C. 
TCGA results showed that mutations and gene amplifications disrupting RB function are 
found in approximately 80% of glioblastomas, suggesting the critical importance of escaping 
anti-growth signals3,4. Additionally, single nucleotide polymorphisms in the CDKN2A and 
CDKN2B have been identified as risk factors for glioma development19,20. 
4.3 Evading apoptosis – The p53 axis  
Apoptotic programs are inherent in all normal cells. These programs are activated by a 
number of physiologic signals during development and/or in response to cellular stress. 
Since the tumor state is associated with cellular stress capable of activating apoptosis (e.g. 
increased oxidative stress, increased DNA damage accumulation), inactivation of these 
programs constitute a critical step during carcinogenesis. The importance of apoptosis as a 
fundamental biologic process was recognized by a Nobel Prize in Physiology or Medicine 
awarded to Sydney Brenner, Robert Horvitz, and John Sulston in 2002. 
The regulation of apoptotic pathways is highly complex21. Broadly speaking, there are two 
pathways of apoptosis that converge on the activation of effector proteases (termed 
caspases), which ultimately trigger the pathognomonic DNA fragmentation, cell shrinkage, 
and membrane blebbing. The intrinsic cell death pathway (often termed the mitochondrial 
apoptotic pathway) involves the release of cytochrome c from the mitochondrial membrane 
space22. Binding of cytochrome c to a protein termed apoptosis protease-activating factor 1 
(APAF-1), in turn, initiates the caspase cascade. In contrast, the extrinsic apoptotic pathway 
operates independently of mitochondria and is activated by direct signaling from cell 
surface receptors to the effector caspase23.  
Both intrinsic and extrinsic apoptotic programs are profoundly influenced by the p53 tumor 
suppressor protein24. TP53 encodes a transcription factor that regulates gene sets critical for 
cell cycle progression and apoptosis. Under normal conditions, p53 is a short-lived protein25. 
In response to cellular stress (for instance, DNA damage or oncogene expression), p53 
undergoes post-translational modifications and protein-protein interactions that enhance its 
stability and transcriptional activity25. Key among the transcripts regulated by p53 are pro-
apoptotic genes (including BAX and Puma) that facilitate both the intrinsic and extrinsic 
pathway24. Additionally, p53 interact with a number of anti-apoptotic proteins to inhibit 
their function24.  
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There are several lines of evidence that point to the importance of the p53 axis in 
glioblastoma pathogenesis. In the TCGA database, mutations that inactivate this axis are 
found in greater than 70% of glioblastoma specimens3,4. Patients harboring germ-line 
mutations in TP53 are afflicted with cancer predisposition including increased risk for 
glioblastoma26. Finally, inactivation of p53 is required for glioma formation in genetically 
defined murine models27. 
4.4 Replicative potential 
The definition of cancer as a continuous growing entity implies that normal cells exhibit a 
limited capacity for proliferation. Indeed, estimates based on tissue culture work suggest 
that most normal cells have the capacity for 50 doublings 28. Studies over the past three 
decades suggest that the main reason for this limited life span involve progressive 
shortening of chromosomes due to loss of telomeres. Telomeres consist of thousands of six 
base pair sequence element of repeats that are located at the ends of every chromosome. 
Because of the inability of DNA polymerases to replicate the 3’ ends of chromosomal DNA, 
approximately 60 base pairs of the telomeric sequence is lost with each replicative cycle29. 
With progressive erosion of the telomeric sequence, the unprotected chromosomal ends 
participate in aberrant fusion events that inevitably result in cell death30. 
To overcome this inherent limitation, most cancer cells activate an enzyme called 
telomerase. Telomerase is a reverse transcriptase capable of elongating telomeres31. Various 
mechanisms are employed by tumors to activate telomerase in order to sustain continued 
cell growth. Elizabeth Balckburn, Carol Greider, and Jack Szostak were awarded the Nobel 
Prize in Physiology or Medicine in 2009 for their discovery of telomerase.  
With regards to glioblastomas, single nucleotide polymorphisms in two genes encoding 
components of the telomerase (RTEL1 and TERT) have been identified as risk factors for 
glioma development19, 20. Additionally, elevated expression level of TERT in glioblastoma is 
associated with decreased patient survival 32. These studies suggest a critical importance of 
telomeric biology in glioblastoma growth and survival.  
Angiogenesis. The intense proliferation of cancer cells require continued supply of oxygen 
and nutrients. Due to inherent limitations on the distance that oxygen and macromolecules 
can travel, virtually all cells in a tissue reside with 100 um of a capillary. In xenograft model 
systems, solid tumors can only proliferate up to a size of 1-2 mm without development of 
new blood supply33. Thus, angiogenesis necessarily constitutes a pre-requisite during solid 
tumor progression.  
One way by which cancer cells signal angiogenesis is by secretion of soluble factors that 
bind to receptors present on the surface endothelial cells. A key soluble factor that functions 
in such capacity is the Vascular Endothelial Growth Factor (VEGF). VEGF binds to RTKs on 
the surface of endothelial cells to facilitate their proliferation – leading to angiogenesis34. In 
normal cells, transcription of VEGF and other pro-angiogenic signaling factors are under 
strict regulation. The induction of Hypoxia Inducible Factor I (HIF1) is a pivotal element in 
this regulatory network35. HIF1 encodes a dimeric transcription factor consisting of two 
subunits: HIF1 and HIF1. HIF1 is constitutively expressed irrespective of oxygen 
concentration, whereas HIF1 levels increase dramatically in response to hypoxia. The 
underlying mechanism for this regulation is that HIF1is hydroxylated by HIF Prolyl-4-
Hydroxylase (HPH) in the presence of di-oxygen (O2), iron, and -ketoglutarate. The 
hydroxylated HIF1is targeted for proteasome degradation. Without molecular oxygen, 
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normal cell cycle progression, induction of cyclin D1 and its associated cyclin-dependent 
kinases, CDK4 and CDK6, at the G1-S transition is responsible for the phosphorylation of 
RB. The kinase activity of the CDK4/6-cyclin D complex is under complex regulation, 
including the critical negative regulators CDKN2A (p16Ink4a), CDKN2B, and CDKN2C. 
TCGA results showed that mutations and gene amplifications disrupting RB function are 
found in approximately 80% of glioblastomas, suggesting the critical importance of escaping 
anti-growth signals3,4. Additionally, single nucleotide polymorphisms in the CDKN2A and 
CDKN2B have been identified as risk factors for glioma development19,20. 
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Apoptotic programs are inherent in all normal cells. These programs are activated by a 
number of physiologic signals during development and/or in response to cellular stress. 
Since the tumor state is associated with cellular stress capable of activating apoptosis (e.g. 
increased oxidative stress, increased DNA damage accumulation), inactivation of these 
programs constitute a critical step during carcinogenesis. The importance of apoptosis as a 
fundamental biologic process was recognized by a Nobel Prize in Physiology or Medicine 
awarded to Sydney Brenner, Robert Horvitz, and John Sulston in 2002. 
The regulation of apoptotic pathways is highly complex21. Broadly speaking, there are two 
pathways of apoptosis that converge on the activation of effector proteases (termed 
caspases), which ultimately trigger the pathognomonic DNA fragmentation, cell shrinkage, 
and membrane blebbing. The intrinsic cell death pathway (often termed the mitochondrial 
apoptotic pathway) involves the release of cytochrome c from the mitochondrial membrane 
space22. Binding of cytochrome c to a protein termed apoptosis protease-activating factor 1 
(APAF-1), in turn, initiates the caspase cascade. In contrast, the extrinsic apoptotic pathway 
operates independently of mitochondria and is activated by direct signaling from cell 
surface receptors to the effector caspase23.  
Both intrinsic and extrinsic apoptotic programs are profoundly influenced by the p53 tumor 
suppressor protein24. TP53 encodes a transcription factor that regulates gene sets critical for 
cell cycle progression and apoptosis. Under normal conditions, p53 is a short-lived protein25. 
In response to cellular stress (for instance, DNA damage or oncogene expression), p53 
undergoes post-translational modifications and protein-protein interactions that enhance its 
stability and transcriptional activity25. Key among the transcripts regulated by p53 are pro-
apoptotic genes (including BAX and Puma) that facilitate both the intrinsic and extrinsic 
pathway24. Additionally, p53 interact with a number of anti-apoptotic proteins to inhibit 
their function24.  
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There are several lines of evidence that point to the importance of the p53 axis in 
glioblastoma pathogenesis. In the TCGA database, mutations that inactivate this axis are 
found in greater than 70% of glioblastoma specimens3,4. Patients harboring germ-line 
mutations in TP53 are afflicted with cancer predisposition including increased risk for 
glioblastoma26. Finally, inactivation of p53 is required for glioma formation in genetically 
defined murine models27. 
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Because of the inability of DNA polymerases to replicate the 3’ ends of chromosomal DNA, 
approximately 60 base pairs of the telomeric sequence is lost with each replicative cycle29. 
With progressive erosion of the telomeric sequence, the unprotected chromosomal ends 
participate in aberrant fusion events that inevitably result in cell death30. 
To overcome this inherent limitation, most cancer cells activate an enzyme called 
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mechanisms are employed by tumors to activate telomerase in order to sustain continued 
cell growth. Elizabeth Balckburn, Carol Greider, and Jack Szostak were awarded the Nobel 
Prize in Physiology or Medicine in 2009 for their discovery of telomerase.  
With regards to glioblastomas, single nucleotide polymorphisms in two genes encoding 
components of the telomerase (RTEL1 and TERT) have been identified as risk factors for 
glioma development19, 20. Additionally, elevated expression level of TERT in glioblastoma is 
associated with decreased patient survival 32. These studies suggest a critical importance of 
telomeric biology in glioblastoma growth and survival.  
Angiogenesis. The intense proliferation of cancer cells require continued supply of oxygen 
and nutrients. Due to inherent limitations on the distance that oxygen and macromolecules 
can travel, virtually all cells in a tissue reside with 100 um of a capillary. In xenograft model 
systems, solid tumors can only proliferate up to a size of 1-2 mm without development of 
new blood supply33. Thus, angiogenesis necessarily constitutes a pre-requisite during solid 
tumor progression.  
One way by which cancer cells signal angiogenesis is by secretion of soluble factors that 
bind to receptors present on the surface endothelial cells. A key soluble factor that functions 
in such capacity is the Vascular Endothelial Growth Factor (VEGF). VEGF binds to RTKs on 
the surface of endothelial cells to facilitate their proliferation – leading to angiogenesis34. In 
normal cells, transcription of VEGF and other pro-angiogenic signaling factors are under 
strict regulation. The induction of Hypoxia Inducible Factor I (HIF1) is a pivotal element in 
this regulatory network35. HIF1 encodes a dimeric transcription factor consisting of two 
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HIF1is not hydroxylated and is free to dimerize with HIF1to activate the transcription of 
downstream pro-angiogenetic factors. 
Integrated analysis of genomic data in glioblastoma revealed recurrent mutations in the 
R132 residue of isocitrate dehydrogenase 1 (IDH1)4, a gene largely responsible for the 
production of -ketoglutarate. The TCGA data revealed that the IDH1 mutation is 
predominantly found in one particular molecular subtype of glioblastoma12, 36 (see following 
section on molecular subtypes). The wildtype IDH1 normally functions as a homodimer 
that converts isocitrate to -ketoglutarate37. Biochemical characterization of the R132 
mutated IDH1 revealed that it functions in a dominantly negative fashion to inhibit the 
process. Expectedly, glioblastoma harboring the R132 IDH1 mutation harbor decreased 
levels of  -ketoglutarate. Given the importance of  -ketoglutarate in HIF1degradation, 
one would anticipate increased HIF1 accumulation and increased VEGF secretion in 
glioblastoma harboring the IDH1 mutation. These observations were confirmed in a panel of 
primary glioblastoma specimens38. Thus, the IDH1 mutation constitutes an example of how 
glioblastoma subverts the endogenous molecular circuit to facilitate angiogenesis. It should 
be noted that the effect of the IDH1 mutation appears pleiotropic. Another study revealed 
that the R132 mutant IDH1 proteins exhibits a gain-of-function phenotype by generating  
R(-)-2-hydroxyglutarate, a carcinogenic metabolite39.  
In glioblastomas without IDH1 mutation, alternate mechanisms are utilized to facilitate 
angiogenesis. It is somewhat intuitive that during normal development, periods of cellular 
proliferation must be coordinated with angioogenesis. Indeed, a large body of work 
suggests that gene functions that facilitate cell-autonomous growth or insensitivity to 
growth inhibition and apoptosis also tend to facilitate angiogenesis40, 41. It is likely that most 
glioblastoma cells attain angiogenesis by aberrant activation of such coordinated 
developmental programs. For instance, EGFR activation has been shown to up-regulate 
VEGF in both HIF dependent and independent manner42. Inactivation of Rb increases VEGF 
expression and angiogenesis in vivo40. Similarly, p53 normally up-regulates thrombospondin 
1, an inhibitor of angiogenesis43; inactivation of p53 can facilitate angiogenesis by ablation of 
this up-regulation. 
4.5 Invasion and metastasis  
The ability to invade and metastasize constitutes the fundamental distinction between 
benign and malignant tumors. It is important to note that invasion refers not just to 
distortion of normal tissue secondary to tumor growth. Instead, it refers to a coordinated set 
of cellular activities to destroy and migrate into the surrounding normal tissue. Metastasis 
refers to the capacity to travel via circulation to a distant tissue site33. Glioblastoma is unique 
in that while it is one of the most invasive of cancers, it rarely metastasizes outside of the 
central nervous system.  
It is a truism that cancer cells generally retain some general properties of the cell of origin. 
Since glioblastoma originates from astrocytes, which normally possess significant migratory 
capacity, the invasive nature of glioblastoma would be anticipated. During normal 
development, astrocytes migrate in a centripetal manner to establish a scaffold for 
neuroblasts44. Additionally, in response to injury, astrocytes migrate to the affected region to 
form a gliotic scar45. This migratory capacity is the phenotypic expression of carefully 
orchestrated interactions between cellular cytoskeletal proteins, cell adhesion molecules, 
and extracellular matrix33.  
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To date, the TCGA has not uncovered gain of function mutations in these proteins. 
However, enhanced invasive properties have been associated with mutations establishing 
autonomous growth or suppressing apoptosis. For instance, aberrant EGFR activation 
results in increased expression and phosphorylation of cell adhesion molecules that 
ultimately lead to increased invasiveness46. Similarly, the p53 mutation drives cancer 
invasiveness by facilitating the recycling of integrin, a class of cell surface receptor that 
interacts with extracellular matrix during cell migration47.  
The aggregate of the data suggest that both angiogenesis and cell migratory properties are 
intimately integrated into a master circuitry controlled by critical proteins that dictate 
cellular response to growth or apoptotic signals. In this context, mutations facilitating self-
autonomous growth or suppression of apoptosis also contribute to angiogenesis and cell 
invasion. 
4.6 Cross-talk between canonical pathways 
The conceptualization of distinct pathways contributing to the various critical phenotypes 
constitutes a simplification aimed to consolidate distinct biological concepts. The reality is 
that pathways mediating the cancer phenotype exhibit high degrees of cross-talk and 
functional redundancy. For instance, EGFR hyperactivation is associated with increased 
tumor growth (replicative potential), angiogenesis, and increased tumor motility 48. 
Similarly, many genes mediating cell motility, telomere function, and angiogenesis are 
under transcriptional regulation by p53 and RB associated E2Fs49. 
5. Pathway of glioblastoma progression 
It was previously thought that glioblastoma arises from the acquisition of a defined set of 
mutations that occur in a particular temporal order. This model is largely grounded on the 
framework established in colon cancer, where a series of genetic alterations characterizes 
different phases of neoplastic progression50. The framework is supported by the observation 
that Grade II astrocytomas typically harbor mutations in p53; Grade III astrocytomas harbor 
activating mutations/amplifications of CDKN2A (p16Ink4a); and Grade IV astrocytomas 
harbor mutations in PTEN and EGFR51. This data was interpreted to mean that glioblastoma 
results from sequential inactivation of the p53, RB, and RTK/PI3K axes. 
While such a paradigm may hold true for a subset of the secondary glioblastomas, the 
picture emerging from the genomic characterization of primary glioblastomas reveals a 
much more dynamic process3,4. The profile of somatic mutations in different glioblastomas 
is highly variable. These results suggest that most glioblastomas evolve along a multitude of 
pathways in response to differing selective pressures to achieve the phenotypes described 
by Hanahan and Weinberg52. This somewhat stochastic model of cancer progression further 
implies that mutations critical at one juncture in the neoplastic process may lose relevance as 
additional mutations are acquired. Thus, while a mutational profile constitutes an 
archeological profile of the history of the neoplasm, extrapolating therapeutic targets from 
such a profile may be challenging. 
6. Molecular subtypes  
Genome-scale gene expression profiling using microarray technology have revealed distinct 
molecular subtypes within tumors previously classified as glioblastomas 12, 53-55. The number 
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HIF1is not hydroxylated and is free to dimerize with HIF1to activate the transcription of 
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process. Expectedly, glioblastoma harboring the R132 IDH1 mutation harbor decreased 
levels of  -ketoglutarate. Given the importance of  -ketoglutarate in HIF1degradation, 
one would anticipate increased HIF1 accumulation and increased VEGF secretion in 
glioblastoma harboring the IDH1 mutation. These observations were confirmed in a panel of 
primary glioblastoma specimens38. Thus, the IDH1 mutation constitutes an example of how 
glioblastoma subverts the endogenous molecular circuit to facilitate angiogenesis. It should 
be noted that the effect of the IDH1 mutation appears pleiotropic. Another study revealed 
that the R132 mutant IDH1 proteins exhibits a gain-of-function phenotype by generating  
R(-)-2-hydroxyglutarate, a carcinogenic metabolite39.  
In glioblastomas without IDH1 mutation, alternate mechanisms are utilized to facilitate 
angiogenesis. It is somewhat intuitive that during normal development, periods of cellular 
proliferation must be coordinated with angioogenesis. Indeed, a large body of work 
suggests that gene functions that facilitate cell-autonomous growth or insensitivity to 
growth inhibition and apoptosis also tend to facilitate angiogenesis40, 41. It is likely that most 
glioblastoma cells attain angiogenesis by aberrant activation of such coordinated 
developmental programs. For instance, EGFR activation has been shown to up-regulate 
VEGF in both HIF dependent and independent manner42. Inactivation of Rb increases VEGF 
expression and angiogenesis in vivo40. Similarly, p53 normally up-regulates thrombospondin 
1, an inhibitor of angiogenesis43; inactivation of p53 can facilitate angiogenesis by ablation of 
this up-regulation. 
4.5 Invasion and metastasis  
The ability to invade and metastasize constitutes the fundamental distinction between 
benign and malignant tumors. It is important to note that invasion refers not just to 
distortion of normal tissue secondary to tumor growth. Instead, it refers to a coordinated set 
of cellular activities to destroy and migrate into the surrounding normal tissue. Metastasis 
refers to the capacity to travel via circulation to a distant tissue site33. Glioblastoma is unique 
in that while it is one of the most invasive of cancers, it rarely metastasizes outside of the 
central nervous system.  
It is a truism that cancer cells generally retain some general properties of the cell of origin. 
Since glioblastoma originates from astrocytes, which normally possess significant migratory 
capacity, the invasive nature of glioblastoma would be anticipated. During normal 
development, astrocytes migrate in a centripetal manner to establish a scaffold for 
neuroblasts44. Additionally, in response to injury, astrocytes migrate to the affected region to 
form a gliotic scar45. This migratory capacity is the phenotypic expression of carefully 
orchestrated interactions between cellular cytoskeletal proteins, cell adhesion molecules, 
and extracellular matrix33.  
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To date, the TCGA has not uncovered gain of function mutations in these proteins. 
However, enhanced invasive properties have been associated with mutations establishing 
autonomous growth or suppressing apoptosis. For instance, aberrant EGFR activation 
results in increased expression and phosphorylation of cell adhesion molecules that 
ultimately lead to increased invasiveness46. Similarly, the p53 mutation drives cancer 
invasiveness by facilitating the recycling of integrin, a class of cell surface receptor that 
interacts with extracellular matrix during cell migration47.  
The aggregate of the data suggest that both angiogenesis and cell migratory properties are 
intimately integrated into a master circuitry controlled by critical proteins that dictate 
cellular response to growth or apoptotic signals. In this context, mutations facilitating self-
autonomous growth or suppression of apoptosis also contribute to angiogenesis and cell 
invasion. 
4.6 Cross-talk between canonical pathways 
The conceptualization of distinct pathways contributing to the various critical phenotypes 
constitutes a simplification aimed to consolidate distinct biological concepts. The reality is 
that pathways mediating the cancer phenotype exhibit high degrees of cross-talk and 
functional redundancy. For instance, EGFR hyperactivation is associated with increased 
tumor growth (replicative potential), angiogenesis, and increased tumor motility 48. 
Similarly, many genes mediating cell motility, telomere function, and angiogenesis are 
under transcriptional regulation by p53 and RB associated E2Fs49. 
5. Pathway of glioblastoma progression 
It was previously thought that glioblastoma arises from the acquisition of a defined set of 
mutations that occur in a particular temporal order. This model is largely grounded on the 
framework established in colon cancer, where a series of genetic alterations characterizes 
different phases of neoplastic progression50. The framework is supported by the observation 
that Grade II astrocytomas typically harbor mutations in p53; Grade III astrocytomas harbor 
activating mutations/amplifications of CDKN2A (p16Ink4a); and Grade IV astrocytomas 
harbor mutations in PTEN and EGFR51. This data was interpreted to mean that glioblastoma 
results from sequential inactivation of the p53, RB, and RTK/PI3K axes. 
While such a paradigm may hold true for a subset of the secondary glioblastomas, the 
picture emerging from the genomic characterization of primary glioblastomas reveals a 
much more dynamic process3,4. The profile of somatic mutations in different glioblastomas 
is highly variable. These results suggest that most glioblastomas evolve along a multitude of 
pathways in response to differing selective pressures to achieve the phenotypes described 
by Hanahan and Weinberg52. This somewhat stochastic model of cancer progression further 
implies that mutations critical at one juncture in the neoplastic process may lose relevance as 
additional mutations are acquired. Thus, while a mutational profile constitutes an 
archeological profile of the history of the neoplasm, extrapolating therapeutic targets from 
such a profile may be challenging. 
6. Molecular subtypes  
Genome-scale gene expression profiling using microarray technology have revealed distinct 
molecular subtypes within tumors previously classified as glioblastomas 12, 53-55. The number 
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of subtypes varies depending on the study, however, three subtypes consistently appear 
across independent studies and reflect distinct biologic and clinical behaviors 12, 55, 56. 
Importantly, the transcript signature parallels those obtained during distinct stages in 
neural development, suggesting the tumor may have arisen from different stages of 
neurogenesis55.  
The first subtype is termed pro-neural. The transcript signature resembles those of neuro-
blasts and oligodendrocytes derived from fetal and adult brain55. This subtype harbors 
molecular and clinical features that closely mirror those previously classified as secondary 
glioblastomas. Molecularly, pro-neural glioblastomas harbor mutations classically 
associated with the secondary subtype, including p53 and PDGFR12. Accordingly, grade II 
and III gliomas harbor molecular signatures most reminiscent of the pro-neural subtype55. 
Clinically, this subtype typically affects younger patients, is associated with improved 
overall survival55, and responds poorly to concurrent radiation/temozolomide treatment 
upon disease progression12. Interestingly, mutations in the isocitrate dehydrogenase 1 gene 
(IDH1), a metabolic protein required for conversion of isocitrate to a-ketoglutamate during 
the citric acid cycle, is frequently observed in pro-neural glioblastomas (see section on 
glioblastoma predisposition syndromes). The molecular basis of how this mutation 
contributes to the cancer phenotype remains an active area of investigation. 
Classical (also termed proliferative by some authors) constitutes the second molecular 
subtype. Transcript signature in the classical subtype resembles those observed in transit 
amplifying neural progenitor cells55 and murine astrocytes12. This subtype is exclusively 
found in WHO grade IV tumors and constitutes a form of primary glioblastoma57. 
Molecularly, this subtype is characterized by amplification of (or activating mutations in) 
EGFR and CDKN2A (p16Ink4a). Genes involved in pathways highly active in neural stem and 
progenitor cells (including the Notch and Sonic hedgehog pathway) are highly expressed in 
the classical subtype).58 The patients afflicted are typically older than those with the pro-
neural subtype. Relative to the other subtype, patients afflicted with the classical subtype 
exhibit the worst prognosis, but the best therapeutic response to concurrent 
radiation/temozolomide treatment.  
The mesenchymal subtype makes up the final category. The transcript signature in the 
mesenchymal subtype mirrors those observed in the neural stem cells of the forebrain55 and 
cultured astroglial cells59. Most cultured glioblastoma cell lines exhibit transcript signatures 
that fall into this subtype. Molecularly, the subtype is characterized by inactivating NF1 and 
PTEN mutations12. This subgroup also has the highest expression of angiogenesis markers 
including VEGF (Vascular Epithelial Growth Factor) transcripts and highest density of 
microvascular proliferation12. The patients afflicted are typically older than those with the 
pro-neural subtype. Relative to the other subtypes, mesenchymal glioblastomas exhibit 
clinical response similar to the classical subtype, and a trend toward slightly improved 
prognosis and response to radiation/temozolomide therapy12. 
There is significant debate with regards to the origin of the distinct molecular subtypes. On 
one extreme is the thought that the subtypes originate from the same cell type with 
differences driven by distinct signaling pathways. The other extreme suggests that subtypes 
are determined by the same signaling pathways activated in a different cell of origin. The 
observation that the same canonical pathways are altered irrespective of subtype would 
tend to support the latter hypothesis. However, it is conceivable that different genes thought 
to participate in the same canonical pathway may modulate processes distinct of that 
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pathway. Such functions may contribute to the distinct molecular subtypes. Still, it is 
conceivable that differences in signaling and cell of origin both contribute to subtype 
formation. This critical debate awaits experimental resolution. 
7. Summary 
The past three decades of work in cancer research has generated a sophisticated conceptual 
framework for the process of neoplastic transformation. The framework suggests that 
genetic and epigenetic events inactivating critical pathways that regulate several key aspects 
of cellular function are an etiology. These cellular functions can be categorized as self-
sufficiency in growth signaling, evasion of apoptosis, insensitivity to anti-growth signals, 
tissue invasion, and limitless replicative potential and angiogenesis. This framework has 
largely been validated by a large scale, high-throughput characterization of the genomic and 
epigenomic landscape in glioblastomas. The picture emerging from these analyses suggests 
that most glioblastomas evolve along a multitude of pathways in response to differing 
selective pressures to achieve the cancer phenotypes. Transcript based analysis revealed 
distinct subtypes with potential implications with regards to the cell of origin. The dynamic 
interplay of growth dysregulation and the cell of origin during the neoplastic 
transformation process harbors vital implications with regards to therapeutic development.  
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of subtypes varies depending on the study, however, three subtypes consistently appear 
across independent studies and reflect distinct biologic and clinical behaviors 12, 55, 56. 
Importantly, the transcript signature parallels those obtained during distinct stages in 
neural development, suggesting the tumor may have arisen from different stages of 
neurogenesis55.  
The first subtype is termed pro-neural. The transcript signature resembles those of neuro-
blasts and oligodendrocytes derived from fetal and adult brain55. This subtype harbors 
molecular and clinical features that closely mirror those previously classified as secondary 
glioblastomas. Molecularly, pro-neural glioblastomas harbor mutations classically 
associated with the secondary subtype, including p53 and PDGFR12. Accordingly, grade II 
and III gliomas harbor molecular signatures most reminiscent of the pro-neural subtype55. 
Clinically, this subtype typically affects younger patients, is associated with improved 
overall survival55, and responds poorly to concurrent radiation/temozolomide treatment 
upon disease progression12. Interestingly, mutations in the isocitrate dehydrogenase 1 gene 
(IDH1), a metabolic protein required for conversion of isocitrate to a-ketoglutamate during 
the citric acid cycle, is frequently observed in pro-neural glioblastomas (see section on 
glioblastoma predisposition syndromes). The molecular basis of how this mutation 
contributes to the cancer phenotype remains an active area of investigation. 
Classical (also termed proliferative by some authors) constitutes the second molecular 
subtype. Transcript signature in the classical subtype resembles those observed in transit 
amplifying neural progenitor cells55 and murine astrocytes12. This subtype is exclusively 
found in WHO grade IV tumors and constitutes a form of primary glioblastoma57. 
Molecularly, this subtype is characterized by amplification of (or activating mutations in) 
EGFR and CDKN2A (p16Ink4a). Genes involved in pathways highly active in neural stem and 
progenitor cells (including the Notch and Sonic hedgehog pathway) are highly expressed in 
the classical subtype).58 The patients afflicted are typically older than those with the pro-
neural subtype. Relative to the other subtype, patients afflicted with the classical subtype 
exhibit the worst prognosis, but the best therapeutic response to concurrent 
radiation/temozolomide treatment.  
The mesenchymal subtype makes up the final category. The transcript signature in the 
mesenchymal subtype mirrors those observed in the neural stem cells of the forebrain55 and 
cultured astroglial cells59. Most cultured glioblastoma cell lines exhibit transcript signatures 
that fall into this subtype. Molecularly, the subtype is characterized by inactivating NF1 and 
PTEN mutations12. This subgroup also has the highest expression of angiogenesis markers 
including VEGF (Vascular Epithelial Growth Factor) transcripts and highest density of 
microvascular proliferation12. The patients afflicted are typically older than those with the 
pro-neural subtype. Relative to the other subtypes, mesenchymal glioblastomas exhibit 
clinical response similar to the classical subtype, and a trend toward slightly improved 
prognosis and response to radiation/temozolomide therapy12. 
There is significant debate with regards to the origin of the distinct molecular subtypes. On 
one extreme is the thought that the subtypes originate from the same cell type with 
differences driven by distinct signaling pathways. The other extreme suggests that subtypes 
are determined by the same signaling pathways activated in a different cell of origin. The 
observation that the same canonical pathways are altered irrespective of subtype would 
tend to support the latter hypothesis. However, it is conceivable that different genes thought 
to participate in the same canonical pathway may modulate processes distinct of that 
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pathway. Such functions may contribute to the distinct molecular subtypes. Still, it is 
conceivable that differences in signaling and cell of origin both contribute to subtype 
formation. This critical debate awaits experimental resolution. 
7. Summary 
The past three decades of work in cancer research has generated a sophisticated conceptual 
framework for the process of neoplastic transformation. The framework suggests that 
genetic and epigenetic events inactivating critical pathways that regulate several key aspects 
of cellular function are an etiology. These cellular functions can be categorized as self-
sufficiency in growth signaling, evasion of apoptosis, insensitivity to anti-growth signals, 
tissue invasion, and limitless replicative potential and angiogenesis. This framework has 
largely been validated by a large scale, high-throughput characterization of the genomic and 
epigenomic landscape in glioblastomas. The picture emerging from these analyses suggests 
that most glioblastomas evolve along a multitude of pathways in response to differing 
selective pressures to achieve the cancer phenotypes. Transcript based analysis revealed 
distinct subtypes with potential implications with regards to the cell of origin. The dynamic 
interplay of growth dysregulation and the cell of origin during the neoplastic 
transformation process harbors vital implications with regards to therapeutic development.  
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1. Introduction 
Malignant gliomas – the most frequent glial tumor of Central Nervous System (CNS) 
anaplasic astrocytoma and glioblastoma multiforme, are regarded by the World Health 
Organization as the form of cancer with the worst prognosis in humans. Its biological 
behavior and severity are associated with increased concentrations of various growth 
factors, like fibroblastic growth factor (FGF), vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF) and hepatocyte growth factor (HGF). 
Hepatocyte growth factor (HGF) is a pleomorphic protein with several properties. It was 
described in 1996 as a protein related to cell proliferation and motility in the rat liver. It has 
also been associated with morphogenesis of the central nervous system in mammals. HGF 
has been associated with proliferation of several cell lines, for example carcinoma of colon, 
stomach, gallbladder, pancreas, and breast. In human gliomas high intratumoral 
concentrations of HGF and its receptor c-met are associated with poor prognosis; it has also 
been associated with long-time recurrence of meningioma. In vitro, transfer of the HGF gene 
increases tumorigenicity, growth, and angiogenesis; interestingly, inhibition of this gene 
reduces growth rate and malignancy in experimentally induced-glioma in rats. 
Human studies have shown that HGF contents in blood (Wen et al. 2011) are closely related 
with malignancy of glioma; low-grade glioma shows a lower intratumoral concentration of 
HGF than high-grade glioma.  
Recently, we have found HGF directly related in human gliomas to increased angiogenesis, 
cellular proliferation, resistance to apoptosis induced by gamma radiation, and invasion of 
healthy tissue along white matter tracts. All of these features are characteristic of 
malignancy. 
In the clinical setting, high HGF levels in cerebrospinal fluid predict mortality and a short 
disease-free time in patients with malignant glioma, and helps to explain the great variance 
observed on survival of patients with malignant glioma, suggesting that HGF inhibition 
strategies could be a useful means of improving survival and disease-free time among 
glioma patients. 
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observed on survival of patients with malignant glioma, suggesting that HGF inhibition 
strategies could be a useful means of improving survival and disease-free time among 
glioma patients. 
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Thus, experimental and clinical findings suggest that HGF is a good target for therapeutic 
strategies with pharmacogenomic methods and could be useful as a biological marker for 
monitoring malignant gliomas activity. 
2. Malignant glioma 
Intracranial neoplasms include a great diversity of tumors with different histopathologic 
origins, prognoses and treatments: Malignant gliomas such as anaplasic astrocytoma (AA) 
and glioblastoma multiforme (GM) are the most frequent glial tumors: their incidence is 
4/100,000, and they account for 2% of all malignant tumors in adults. Malignant gliomas are 
associated with poor prognosis; the mean survival time of patients with GM is one year, this 
gloomy picture has not changed significantly for the last three decades. Similarly, the 
survival for patients with AA is minor than three years. Therefore, it is of paramount 
importance to understand the pathophysiology of malignant glial tumors and identify 
prognostic factors. Both GM and AA have high proliferation and intense vascularity, 
features closely related with malignant cell growth.  
Malignant conditions are related to ability of malignant cells to produce growth factors such 
as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and 
fibroblastic growth factor (FGF) (Arrieta et al., 2002). 
Due to their invasive nature, glioblastomas cannot be resected completely by surgery and, 
despite the progress of neurosurgical techniques and radio/chemotherapy, less than a half 
of patients survive more than a year, aged subjects have the most significant adverse 
prognostic factor.  
Glioblastoma is the most frequent malignant tumor of the brain, it account for 
approximately 12–15% of all intracranial neoplasms and 60-75% of astrocytic tumors (Lantos 
et al., 2002; Lois et al., 2007). In most European and North American countries, the yearly 
incidence is in the range of 3-4 new cases per 100 000 population (Lois et al., 2007).  
2.1 Prognostic factors  
Despite progress in surgery, radiotherapy and chemotherapy of brain tumors, the overall 
survival of patients with glioblastoma remains dismal. Population-based studies from 
Switzerland and Canada have shown that less than 20% of patients survive more than one 
year after diagnosis and less than 3% lived longer than 3 years (Lantos et al., 2002; Ohgaki et 
al., 2007). Clinical trials show a slightly better prognosis, with median survival rates of 
approximately 12 month; however, they have strong bias toward the recruitment of younger 
patients and those with higher preoperative Karnofsky performance scores, both are strong 
predictors of a more favorable clinical outcome. 
Virtually all therapy trials have shown that younger glioblastoma patients (<50 years at 
diagnosis) have a significantly better prognosis (Lois et al., 2007). In a large population-
based study, age was the most significant prognostic factor; persisting through all age 
groups in a linear manner (Ohgaki et al., 2007). Patients with secondary glioblastoma 
survived significantly longer than those with primary glioblastoma, but this is likely due to 
their age rather than a reflection of a different biological behavior. 
The prognostic value of TP53 mutations in glioblastomas is controversial, it either shows no 
association or the presence of TP53 mutations was a favorable prognostic factor. In a large 
population-based study, the presence of TP53 mutations was predictive of longer survival 
but this was not significant when adjusted for younger age.  
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There is no consistent correlation of epidermal growth factor receptor (EGFR) amplification 
with survival largely irrespective of the age at first clinical manifestation. LOH 10 (Lois et 
al., 2007) is the most frequent genetic alteration in glioblastoma and is associated with 
reduced survival. The presence of PTEN mutations is not associated with prognosis of 
glioblastoma patients (Lois et al., 2007). 
Since the initial histological description of astrocytic neoplasms, several efforts have been 
made to identify biomarkers that could predict the biological behavior of the tumor. 
However, to date only few peptides been identified substances that show a weak association 
with prognosis. 
3. Biological markers of glioblastoma activity  
The following paragraphs describe some substances that have been reported as candidates 
for surveillances of tumor activity by measuring their contents in serum. 
A molecular event determining the development of malignancy is the activation of b-
catenin, a protein necessary for the alignment and maintenance of epithelial cells by 
regulating cell growth and cell adhesion. The coexpression of -catenin reduces the cellular 
growth and migration induced by EGF on human glioma cells (Ji et al., 2010). 
A secreted protein of unknown function, YKL-40 (chitinase-3-like-1), is overexpressed in 
glioblastoma [4], its presence is associated with LOH 10q (Lois et al., 2007), poorer radiation 
response, shorter time to tumor progression and reduced overall survival (Ohgaki et al., 
2004). It is typically coexpressed with matrix metalloproteinase-9 (MMP-9), and its detection 
in serum has been used to monitor patients with recurrent tumor growth (Pelloski et al., 
2005). One report showed that increased expression of GD3 synthase mRNA, in combination 
with decreased GalNAcT, correlate with an increased survival of patients with glioblastoma 
(Hormingo et al. 2006).  
3.1 Growth factors 
The expression of growth factors and their receptors are associated with glioma malignancy. 
Thus, their potential therapeutic importance has been demonstrated using specific inhibitors 
of growth factors in experimental and clinical studies. However, recent results have shown 
that glioma cells are resistant to this treatment and illustrate the therapeutic difficulties in 
malignant gliomas. 
3.2 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a signal protein that stimulates vasculogenesis 
and angiogenesis; VEGF's normal function is to induce growth of vessels during early 
developmental stages, after injury, at muscle following exercise, and to generate new vessels 
to bypass blocked arteries. When VEGF is overexpressed, it can contribute to malignant 
glioma progression. Cancers that express VEGF grow and metastasize, VEGF belongs to 
platelet-derived growth factor family. They are involved in both, vasculogenesis, the novo, 
and angiogenesis (Mentlein et al., 2004; Reux et al., 2006).  
Within the major growth factors related to angiogenesis, VEGF is one of the most important. 
In several tumors, VEGF plays a pivotal role for vascularization necessary to supply the 
malignant tissue with oxygen and nutrients. Human glioma cells are characterized by high 
production of VEGF, however, functional and autocrine growth stimulatory effects on 
glioma cells are minor (Reux et al., 2006). 
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In recurrent GBM trials with temozolomide shown a poor therapeutic response where as 
VEGF inhibitors as bevacizumab, improve the response rate by 25% to 74%, and the period-
free of symptoms increases by 32% to 64%, which is superior to the rate reported for 
temozolomide alone (Pope et al., 2006; Guiu et al., 2008; Narayana et al., 2009; Nghiemphu 
et al., 2009; Poulsen et al., 2009; Zuniga et al., 2009). The main effect of VEGF inhibitors is 
centered on rapid reduction in peritumoral edema, improving corticosteroid use. These 
studies also indicated that bevacizumab treatment is well tolerated and the risk of 
intratumoral hemorrhage is low. Toxicity related to bevacizumab therapy in patients with 
malignant glioma includes hypertension, proteinuria, fatigue, thromboembolic events, and 
wound-healing delay.  
3.2.1 Epidermal growth factor 
Epidermal growth factor (EGF), is a prototype member of the EGF-family of peptides which 
have highly similar structural and functional characteristics. Other peptides include: 
Transforming Growth Factor- (TGF-), amphiregulin, epiregulin, and neuregulin 1-4, all of 
them related to tyrosine kinase activity which initiates a signal transduction cascade that 
result in several changes: rise in intracellular calcium contents, increased glycolysis, protein 
synthesis, DNA synthesis and cell proliferation (Fallon et al., 1984).  
EGF is overexpressed in various cancers; malignant glioma, breast, pancreas and liver 
carcinoma, indicating its main role in malignant cell transformation, tumor occurrence and 
growth by promoting cell division (Xian et al., 2001). Recent reports show that +61G 
polymorphism of EGF gene increase the risk for glioma development in European subjects 
but are a protective factor in Chinese subjects (Tan et al., 2010). 
The Epidermal growth factor receptor (EGFR) gene is amplified and overexpressed in 
approximately 40% of patients with primary GBMs. Increased EGFR signaling drives tumor 
cell proliferation, invasiveness, motility, angiogenesis, and inhibition of apoptosis. Attempts 
to identify biomarkers to help predict response to EGFR inhibitors have yielded conflicting 
results. Currently, there is no convincing evidence of a correlation between EGFR expression 
in tumoral tissue and prognosis (Van Meir et al., 2010).  
3.2.2 Hepatocyte growth factor 
Hepatocyte growth factor (HGF), also called scatter factor, is a multifunction protein with 
strong mitogenic effect on hepatocytes. It was initially isolated as a peptide related to 
hepatic regeneration. It is considered a reliable indicator of hepatic function alter 
hepatectomy. This protein is constituted by a heavy chain (60 kD) with four domains and a 
Light chain (32 kD); it binds through its tirosine-kinase receptor, a product of the proto-
oncogene c-Met. Hepatocyte growth factor, secreted by mesenchymal cells, acts as a 
paracrine effector on different epithelial cells inducing mitogenesis and stimulating cellular 
motility. It is also a powerful angiogenic factor for endothelial cells in vitro and in vivo. In 
the liver and kidney, it may have a role as antiapoptotic (Xiao et al., 2001). It is also 
necessary for embriogenesis as regulator of cell migration and growth. Hepatocyte growth 
factor is also produced by other cells, such as osteoclasts, participating in the regulation of 
bone remodeling; its production by monocytes has a role in the regulation of hematopoyesis 
by stimulation of growth and differentiation of erythroid precursors (Arrieta et al., 2002). 
Knockout mice for the HGF gene develop severe abnormalities in the liver, placenta, and 
nervous system causing fetal death. A direct genetic relation between HGF and cancer has 
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also been recently proposed due to mutations in the catalytic domain of c-Met from patients 
with renal carcinoma. Overexpression of HGF is present in various cells lines of leukemia 
and lymphoma and in solid tumors of the breast, prostate, colon, liver, kidney, uterine 
cervix, endometrium, and bladder (Arrieta et al., 2002). Hepatocyte growth factor also 
promotes adhesion and migration of cancer cells, due to the high affinity of integrins to their 
ligands, a phenomenon related to the metastatic tendency of carcinomas (Trussolino et al., 
2000; Arrieta et al., 2002). 
Normal human astrocytes express HGF and its receptor c-Met (Yamada et al, 1994). Met is a 
proto-oncogene that when mutated can transform a variety of cell types; the Met receptor is 
a heterodimer consisting of an extracellular alpha chain and a trans-membrane beta chain, 
which is a tyrosine kinase, it is widely expressed by epithelial and endothelial cells as well 
as melanocytes, chondrocytes, skeletal muscle, hematopoietic, lymphoid, and neural cells. 
The activation of Met by HGF binding is linked to cell growth and survival, including the 
avoidance of anoikis which is apoptosis induced by insufficient association with cell-matrix, 
through activation of both the PI3-kinase/PDK/Akt and the Ras/Raf/MEK/ERK pathways 
and to cell mobility and cytoskeletal organization via activation of the Rho-GTPases, Rho, 
Rac and CDC (Arrieta et al., 2002).  
Activation of Met tyrosine kinase also activates phospholipase C, resulting in the elevation 
of intracellular calcium and activation of conventional and novel protein kinase C pathways. 
HGF and Met have been associated with progression, invasiveness and metastasis in a 
number of neoplasms. Met is expressed in a wide variety of carcinomas, musculoskeletal 
tumors, soft tissue sarcomas, glioblastoma, astrosarcoma, and several hematopoietic 
malignancies. HGF Met signaling is a major potential target for the development of cancer 
therapeutics. 
3.2.2.1 Hepatocyte growth factor and malignant gliomas 
As HGF, its receptor c-met has been implicated in the genesis, malignant progression, and 
chemo/radioresistance of multiple human malignancies, including gliomas (Peruzzi et al, 
2006; Carapancea et al, 2009; Hadjipanayis et al, 2009a, 2009b). Experimental studies using 
transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes suppress 
SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and 
anchorage-independent colony formation in vitro. The delivery of U1snRNA/ribozymes to 
established subcutaneous glioma xenografts via liposome-DNA complexes significantly 
inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histological 
analysis of tumors treated showed a significant decrease in blood vessel density, increase in 
activation of the pro-apoptotic enzyme caspase-3, and increase in tumor cell apoptosis. 
Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-
met U1snRNA/ribozymes substantially inhibited tumor growth and promoted animal 
survival (Abounander et al, 1999, 2002; Kim et al, 2006).  
The use of monoclonal antibodies against the NK23 and NK422 domains of the HGF reduce 
tumor growth and mitotic rate (Bhargava et al., 1992; Boros et al., 1995; Kimura et al., 1995; 
Miwa et al., 1997; Neaud et al., 1997; Takeuchi et al 1997; Stella et al., 1999; Grierson et al., 
2000; Cao et al, 2001; Brockmann et al, 2003; Burgess et al, 2006); Also, viral transgenes 
against HGF-RNA reduce invasion of white matter tracts, improving response to 
radiotherapy (Lal et al, 2005; Chu et al, 2006). 
The therapeutic efficacy of SGX523 has recently been proven in human brain tumors. It 
seems that SGX523 inhibits c-Met, AKT and MAPK phosphorylation, cell proliferation, cell 
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In recurrent GBM trials with temozolomide shown a poor therapeutic response where as 
VEGF inhibitors as bevacizumab, improve the response rate by 25% to 74%, and the period-
free of symptoms increases by 32% to 64%, which is superior to the rate reported for 
temozolomide alone (Pope et al., 2006; Guiu et al., 2008; Narayana et al., 2009; Nghiemphu 
et al., 2009; Poulsen et al., 2009; Zuniga et al., 2009). The main effect of VEGF inhibitors is 
centered on rapid reduction in peritumoral edema, improving corticosteroid use. These 
studies also indicated that bevacizumab treatment is well tolerated and the risk of 
intratumoral hemorrhage is low. Toxicity related to bevacizumab therapy in patients with 
malignant glioma includes hypertension, proteinuria, fatigue, thromboembolic events, and 
wound-healing delay.  
3.2.1 Epidermal growth factor 
Epidermal growth factor (EGF), is a prototype member of the EGF-family of peptides which 
have highly similar structural and functional characteristics. Other peptides include: 
Transforming Growth Factor- (TGF-), amphiregulin, epiregulin, and neuregulin 1-4, all of 
them related to tyrosine kinase activity which initiates a signal transduction cascade that 
result in several changes: rise in intracellular calcium contents, increased glycolysis, protein 
synthesis, DNA synthesis and cell proliferation (Fallon et al., 1984).  
EGF is overexpressed in various cancers; malignant glioma, breast, pancreas and liver 
carcinoma, indicating its main role in malignant cell transformation, tumor occurrence and 
growth by promoting cell division (Xian et al., 2001). Recent reports show that +61G 
polymorphism of EGF gene increase the risk for glioma development in European subjects 
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The Epidermal growth factor receptor (EGFR) gene is amplified and overexpressed in 
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cell proliferation, invasiveness, motility, angiogenesis, and inhibition of apoptosis. Attempts 
to identify biomarkers to help predict response to EGFR inhibitors have yielded conflicting 
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3.2.2 Hepatocyte growth factor 
Hepatocyte growth factor (HGF), also called scatter factor, is a multifunction protein with 
strong mitogenic effect on hepatocytes. It was initially isolated as a peptide related to 
hepatic regeneration. It is considered a reliable indicator of hepatic function alter 
hepatectomy. This protein is constituted by a heavy chain (60 kD) with four domains and a 
Light chain (32 kD); it binds through its tirosine-kinase receptor, a product of the proto-
oncogene c-Met. Hepatocyte growth factor, secreted by mesenchymal cells, acts as a 
paracrine effector on different epithelial cells inducing mitogenesis and stimulating cellular 
motility. It is also a powerful angiogenic factor for endothelial cells in vitro and in vivo. In 
the liver and kidney, it may have a role as antiapoptotic (Xiao et al., 2001). It is also 
necessary for embriogenesis as regulator of cell migration and growth. Hepatocyte growth 
factor is also produced by other cells, such as osteoclasts, participating in the regulation of 
bone remodeling; its production by monocytes has a role in the regulation of hematopoyesis 
by stimulation of growth and differentiation of erythroid precursors (Arrieta et al., 2002). 
Knockout mice for the HGF gene develop severe abnormalities in the liver, placenta, and 
nervous system causing fetal death. A direct genetic relation between HGF and cancer has 
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also been recently proposed due to mutations in the catalytic domain of c-Met from patients 
with renal carcinoma. Overexpression of HGF is present in various cells lines of leukemia 
and lymphoma and in solid tumors of the breast, prostate, colon, liver, kidney, uterine 
cervix, endometrium, and bladder (Arrieta et al., 2002). Hepatocyte growth factor also 
promotes adhesion and migration of cancer cells, due to the high affinity of integrins to their 
ligands, a phenomenon related to the metastatic tendency of carcinomas (Trussolino et al., 
2000; Arrieta et al., 2002). 
Normal human astrocytes express HGF and its receptor c-Met (Yamada et al, 1994). Met is a 
proto-oncogene that when mutated can transform a variety of cell types; the Met receptor is 
a heterodimer consisting of an extracellular alpha chain and a trans-membrane beta chain, 
which is a tyrosine kinase, it is widely expressed by epithelial and endothelial cells as well 
as melanocytes, chondrocytes, skeletal muscle, hematopoietic, lymphoid, and neural cells. 
The activation of Met by HGF binding is linked to cell growth and survival, including the 
avoidance of anoikis which is apoptosis induced by insufficient association with cell-matrix, 
through activation of both the PI3-kinase/PDK/Akt and the Ras/Raf/MEK/ERK pathways 
and to cell mobility and cytoskeletal organization via activation of the Rho-GTPases, Rho, 
Rac and CDC (Arrieta et al., 2002).  
Activation of Met tyrosine kinase also activates phospholipase C, resulting in the elevation 
of intracellular calcium and activation of conventional and novel protein kinase C pathways. 
HGF and Met have been associated with progression, invasiveness and metastasis in a 
number of neoplasms. Met is expressed in a wide variety of carcinomas, musculoskeletal 
tumors, soft tissue sarcomas, glioblastoma, astrosarcoma, and several hematopoietic 
malignancies. HGF Met signaling is a major potential target for the development of cancer 
therapeutics. 
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2006; Carapancea et al, 2009; Hadjipanayis et al, 2009a, 2009b). Experimental studies using 
transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes suppress 
SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and 
anchorage-independent colony formation in vitro. The delivery of U1snRNA/ribozymes to 
established subcutaneous glioma xenografts via liposome-DNA complexes significantly 
inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histological 
analysis of tumors treated showed a significant decrease in blood vessel density, increase in 
activation of the pro-apoptotic enzyme caspase-3, and increase in tumor cell apoptosis. 
Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-
met U1snRNA/ribozymes substantially inhibited tumor growth and promoted animal 
survival (Abounander et al, 1999, 2002; Kim et al, 2006).  
The use of monoclonal antibodies against the NK23 and NK422 domains of the HGF reduce 
tumor growth and mitotic rate (Bhargava et al., 1992; Boros et al., 1995; Kimura et al., 1995; 
Miwa et al., 1997; Neaud et al., 1997; Takeuchi et al 1997; Stella et al., 1999; Grierson et al., 
2000; Cao et al, 2001; Brockmann et al, 2003; Burgess et al, 2006); Also, viral transgenes 
against HGF-RNA reduce invasion of white matter tracts, improving response to 
radiotherapy (Lal et al, 2005; Chu et al, 2006). 
The therapeutic efficacy of SGX523 has recently been proven in human brain tumors. It 
seems that SGX523 inhibits c-Met, AKT and MAPK phosphorylation, cell proliferation, cell 
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cycle progression, migration and invasion in different human glioblastoma cell lines, 
glioblastoma primary cells, glioblastoma stem cells and medulloblastoma cell lines. 
Importantly, oral administration of SGX523 to mice bearing intracranial human glioma 
xenografts led to inhibition of tumor growth in vivo. This experimental data suggests that c-
Met kinase inhibition is a feasible and promising approach for brain tumor therapy 
(Guessous et al., 2010).  
4. HGF and gliomas on clinical setting 
Hepatocyte growth factor and its receptor (c-Met) have been detected in normal astrocytes 
as well as in human gliomas, and other malignant tumors (Koochekpour et al., 1995; 
Nabeshima et al., 1997; Hirose et al., 1998). In human cultured glioma cells, HGF and c-Met 
are simultaneously expressed, with an autocrinous effect inducing cell proliferation and 
migration. 
Recent findings suggest that HGF contributes to glioma progression, inducing angiogenesis 
and expression of additional angiogenic autocrine factors such as VEGF (Laterra et al., 1997; 
Lamszus et al., 1999; Moriyama et al., 1999; Schmidt et al., 1999). The overexpression of HGF 
and its receptor c-Met increases cell motility and proliferation of human glioma cells in vitro 
(Koochekpour et al., 1995). 
Intratumoral concentration of HGF in malignant gliomas is greatly increased in comparison 
with other intracranial tumors and nontumoral brain tissue (Arrieta et al., 2002); it is also 
related to cell proliferation and peritumoral edema, showing its participation in the 
pathogenesis of these tumors.  
A common cause of failure of treatment of malignant gliomas is resistance to radiotherapy 
and chemotherapy; the mechanism by which the cell survives to therapeutic attempts 
involves the production of growth factors that regulate DNA repair and apoptosis. In vitro 
and in vivo, HGF inhibits drug-induced cytotoxicity and apoptosis in experimental 
neoplasms treated by radiation, cisplatin, and camptothencin (Bowers et al., 2000); this effect 
might decrease the therapeutic response of patients with high intratumoral contents of HGF. 
There is intense infiltration by microglia in gliomas, which may enhance malignancy by 
secretion of epidermal growth factor and by inhibition of cytotoxic lymphocytes (Wood et 
al., 1983); in vitro HGF stimulates the microglial infiltration of gliomas, favoring their 
growth (Badie et al., 1999). 
The direct correlation of cell proliferation with the presence of HGF supports its 
participation in the promotion of tumoral growth of glioma, as has been shown for other 
tumors such as breast carcinoma (Lamszus et al., 1997). 
The mechanism by which HGF stimulates cell proliferation seems to be related to the 
tirosine kinase activity of its receptor, which involves Ras and mitosis activation proteins 
(Arrieta et al., 2002). Such effects can be antagonized by tirosine kinase inhibitors. However, 
not all HGF effects require phosphorylation of its receptor; for instance, its antiapoptotic 
effect is independent, suggesting that it could also participate in the genesis of the tumor. 
The insertion of the HGF gene in human glioma cells increases proliferation of independent 
colonies in vitro and tumorigenesis in vivo (Laterra et al., 1997). 
There are some histological features of malignant glioma associated with prognosis, such as 
the extent of necrosis or vascular density (Barker et al., 1996). Hepatocyte growth factor is a 
strong inductor of angiogenesis; its effects are synergistic with other growth factors such as 
VEGF and bFGF. Intratumoral concentration of HGF shows a direct relation with 
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peritumoral edema, independent of vascular density. Previous studies have shown that 
HGF increases the permeability of the hematoencephalic barrier, independently of VEGF 
expression, possibly by the induction of endothelial fenestrations and by the tumoral 
expression of proteases such as urokinase and extracellular matrix metalloproteinases (Book 
et al., 1999).  
A paracrine loop for HGF effects related with migration of tumor cells along white matter 
has been described. The increase of HGF in CSF observed may therefore reflect either the 
transport of HGF from brain parenchyma to the ventricular system or the diffusion of HGF 
along the subarachnoid space (Garcia-Navarrete et al., 2010).  
HGF concentration is closely related with malignancy of glioma; low-grade glioma shows a 
lower intratumoral concentration of HGF than high-grade glioma. CSF concentrations of 
HGF greater than 850 pg/ml prior to surgery was predictive of a shorter disease-free time 
among malignant glioma patients than was observed for patients with a lower concentration 
(6 ± 0.6 months (95% [CI], 5–7) vs. 9 ± 0.5 months (95% [CI], 8–10), respectively, p< 0.001), 
besides total-gross resection surgery (Garcia-Navarrete et al., 2010). CSF concentration of 
HGF shows a negative correlation with survival of patients with malignant glioma and 
explains with high certainty the variance for survival. This suggests that HGF could be a 
good target candidate for molecular therapy such as RNA interference, by silencing the 
specific gene for HGF. 
Although HGF seems a good target for therapeutic attempts, a phase II study reported the 
use of a monoclonal antibody against HGF (AMD 102). This study was conducted in 
patients with histopathologically confirmed diagnosis of GBM, gliosarcoma and history of 
more than 3 relapses; increases up to 10 times the basal levels of HGF in patients during 
treatment with AMD did not induce changes in survival time or clinical status as compared 
with controls (Wen et al., 2011) 
5.Conclusions 
To date, there is no biological marker that can accurately discern the activity of malignant 
gliomas. The scientific evidence obtained from experimental studies suggests that 
Hepatocyte Growth Factor plays a crucial role in the pathophysiology of high-grade 
gliomas. Findings from clinical studies suggest that HGF may be considered a 
distinguishing marker of biological activity of malignant gliomas, as it has been consistently 
demonstrated that the intratumoral, cerebrospinal fluid and serum concentrations are 
directly associated with prognosis and survival. The results of clinical trials aimed to 
evaluate the role of inhibitors of HGF or its receptor c-Met have shown disappointing 
therapeutic results. However, scientific advances in molecular biology could improve the 
response to treatment with specific inhibitors of HGF metabolism through ingenious 
genomic manipulations in patients with malignant gliomas. 
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cycle progression, migration and invasion in different human glioblastoma cell lines, 
glioblastoma primary cells, glioblastoma stem cells and medulloblastoma cell lines. 
Importantly, oral administration of SGX523 to mice bearing intracranial human glioma 
xenografts led to inhibition of tumor growth in vivo. This experimental data suggests that c-
Met kinase inhibition is a feasible and promising approach for brain tumor therapy 
(Guessous et al., 2010).  
4. HGF and gliomas on clinical setting 
Hepatocyte growth factor and its receptor (c-Met) have been detected in normal astrocytes 
as well as in human gliomas, and other malignant tumors (Koochekpour et al., 1995; 
Nabeshima et al., 1997; Hirose et al., 1998). In human cultured glioma cells, HGF and c-Met 
are simultaneously expressed, with an autocrinous effect inducing cell proliferation and 
migration. 
Recent findings suggest that HGF contributes to glioma progression, inducing angiogenesis 
and expression of additional angiogenic autocrine factors such as VEGF (Laterra et al., 1997; 
Lamszus et al., 1999; Moriyama et al., 1999; Schmidt et al., 1999). The overexpression of HGF 
and its receptor c-Met increases cell motility and proliferation of human glioma cells in vitro 
(Koochekpour et al., 1995). 
Intratumoral concentration of HGF in malignant gliomas is greatly increased in comparison 
with other intracranial tumors and nontumoral brain tissue (Arrieta et al., 2002); it is also 
related to cell proliferation and peritumoral edema, showing its participation in the 
pathogenesis of these tumors.  
A common cause of failure of treatment of malignant gliomas is resistance to radiotherapy 
and chemotherapy; the mechanism by which the cell survives to therapeutic attempts 
involves the production of growth factors that regulate DNA repair and apoptosis. In vitro 
and in vivo, HGF inhibits drug-induced cytotoxicity and apoptosis in experimental 
neoplasms treated by radiation, cisplatin, and camptothencin (Bowers et al., 2000); this effect 
might decrease the therapeutic response of patients with high intratumoral contents of HGF. 
There is intense infiltration by microglia in gliomas, which may enhance malignancy by 
secretion of epidermal growth factor and by inhibition of cytotoxic lymphocytes (Wood et 
al., 1983); in vitro HGF stimulates the microglial infiltration of gliomas, favoring their 
growth (Badie et al., 1999). 
The direct correlation of cell proliferation with the presence of HGF supports its 
participation in the promotion of tumoral growth of glioma, as has been shown for other 
tumors such as breast carcinoma (Lamszus et al., 1997). 
The mechanism by which HGF stimulates cell proliferation seems to be related to the 
tirosine kinase activity of its receptor, which involves Ras and mitosis activation proteins 
(Arrieta et al., 2002). Such effects can be antagonized by tirosine kinase inhibitors. However, 
not all HGF effects require phosphorylation of its receptor; for instance, its antiapoptotic 
effect is independent, suggesting that it could also participate in the genesis of the tumor. 
The insertion of the HGF gene in human glioma cells increases proliferation of independent 
colonies in vitro and tumorigenesis in vivo (Laterra et al., 1997). 
There are some histological features of malignant glioma associated with prognosis, such as 
the extent of necrosis or vascular density (Barker et al., 1996). Hepatocyte growth factor is a 
strong inductor of angiogenesis; its effects are synergistic with other growth factors such as 
VEGF and bFGF. Intratumoral concentration of HGF shows a direct relation with 
Biological Markers of Recurrence and 
Survival of High-Grade Gliomas: The Role of Hepatocyte Growth Factor 
 
43 
peritumoral edema, independent of vascular density. Previous studies have shown that 
HGF increases the permeability of the hematoencephalic barrier, independently of VEGF 
expression, possibly by the induction of endothelial fenestrations and by the tumoral 
expression of proteases such as urokinase and extracellular matrix metalloproteinases (Book 
et al., 1999).  
A paracrine loop for HGF effects related with migration of tumor cells along white matter 
has been described. The increase of HGF in CSF observed may therefore reflect either the 
transport of HGF from brain parenchyma to the ventricular system or the diffusion of HGF 
along the subarachnoid space (Garcia-Navarrete et al., 2010).  
HGF concentration is closely related with malignancy of glioma; low-grade glioma shows a 
lower intratumoral concentration of HGF than high-grade glioma. CSF concentrations of 
HGF greater than 850 pg/ml prior to surgery was predictive of a shorter disease-free time 
among malignant glioma patients than was observed for patients with a lower concentration 
(6 ± 0.6 months (95% [CI], 5–7) vs. 9 ± 0.5 months (95% [CI], 8–10), respectively, p< 0.001), 
besides total-gross resection surgery (Garcia-Navarrete et al., 2010). CSF concentration of 
HGF shows a negative correlation with survival of patients with malignant glioma and 
explains with high certainty the variance for survival. This suggests that HGF could be a 
good target candidate for molecular therapy such as RNA interference, by silencing the 
specific gene for HGF. 
Although HGF seems a good target for therapeutic attempts, a phase II study reported the 
use of a monoclonal antibody against HGF (AMD 102). This study was conducted in 
patients with histopathologically confirmed diagnosis of GBM, gliosarcoma and history of 
more than 3 relapses; increases up to 10 times the basal levels of HGF in patients during 
treatment with AMD did not induce changes in survival time or clinical status as compared 
with controls (Wen et al., 2011) 
5.Conclusions 
To date, there is no biological marker that can accurately discern the activity of malignant 
gliomas. The scientific evidence obtained from experimental studies suggests that 
Hepatocyte Growth Factor plays a crucial role in the pathophysiology of high-grade 
gliomas. Findings from clinical studies suggest that HGF may be considered a 
distinguishing marker of biological activity of malignant gliomas, as it has been consistently 
demonstrated that the intratumoral, cerebrospinal fluid and serum concentrations are 
directly associated with prognosis and survival. The results of clinical trials aimed to 
evaluate the role of inhibitors of HGF or its receptor c-Met have shown disappointing 
therapeutic results. However, scientific advances in molecular biology could improve the 
response to treatment with specific inhibitors of HGF metabolism through ingenious 
genomic manipulations in patients with malignant gliomas. 
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Australia 
1. Introduction 
Combined radiotherapy and chemotherapy with the alkylating agent, temozolomide plus an 
additional six cycles of temozolomide has been the mainstay of treatment for patients 
diagnosed with glioblastoma for the past 6 years. Clinically, high variability in the response 
to this treatment is typically observed, with some patients enjoying progression free survival 
for longer than others. However, tumour relapse is inevitable in the majority of patients. 
Local tumour recurrence, occurring within 2-3cm of the original resection cavity (the area 
exposed to radiation treatment) is most frequently observed. Relapsed glioblastomas are 
typically unmanageable with median survival after recurrence of only a few months (Brandes et al. 
2001). Numerous chemotherapeutic agents have been trialled in patients with recurrent 
glioblastomas and include enzastaurin (Wick et al. 2010), immunotherapeutic targeting of 
EGFRvIII (Sampson et al. 2011), cilengitide (trial ongoing) (Reardon et al. 2011), NovoTTF-
100A (trial ongoing), gefitinib (Uhm et al. 2010), imatinib (Dresemann et al. 2010), 
bevacizumab plus irinotecan (Vredenburgh et al. 2007). Only bevacizumab has shown 
promise for the treatment of recurrent glioblastoma, although the benefits of such a drug are 
still debatable. The Food and Drug Administration (FDA) in the USA approved 
bevacizumab for GBM under its accelerated approval process. However in Europe, the 
Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion. 
As new therapeutic regimes are developed, it is paramount that we develop a strategy for 
identifying the patients that will show a positive response to treatment. The recognition and 
validation of biomarkers of clinical response is important for several reasons: to avoid 
unnecessary toxicity in patients that fail to respond to the particular treatment; to reduce the 
colossal cost to healthcare which is typically associated with targeted therapy and most 
importantly, to better understand drug resistance. This improved knowledge could lead to 
new strategies to overcome the initial resistance and identify synergistic drug combinations.  
1.1 Prognostic and predictive biomarkers 
Hopes for progressing curative treatment programs for cancer patients centre on the 
development and successful implementation of personalised medicine. Personalised 
medicine hinges on biomarkers which are highly sensitive and highly specific in revealling 
information that is relevant for diagnosis, prognosis and therapy. The most sought after 
biomarkers are the ones that can identify which patients are at high risk of tumour relapse 
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1. Introduction 
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1.1 Prognostic and predictive biomarkers 
Hopes for progressing curative treatment programs for cancer patients centre on the 
development and successful implementation of personalised medicine. Personalised 
medicine hinges on biomarkers which are highly sensitive and highly specific in revealling 
information that is relevant for diagnosis, prognosis and therapy. The most sought after 
biomarkers are the ones that can identify which patients are at high risk of tumour relapse 
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and developing cytotoxicity to specific chemotherapeutic agents. The use of biomarkers to 
identify patients who don’t respond to treatment early could confer enormous benefits for 
patients diagnosed with glioblastoma, especially considering the short survival time. Many 
biomarkers have shown excellent utility in survival prognostication but not necessarily at 
the level of influencing an oncologist’s decision to administer a specific drug or alter the 
treatment schedule (Figure 1). In addition, another challenge in oncology is the translation 




capacity to estimate survival outcome in 
patients, independent of treatment
identify groups of patients who are most 
likely to respond to a given treatment
The key difference between a prognostic and a predictive biomarker is that the predictive 
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Fig. 1. Schematic overview of the key difference between biomarkers with prognostic and 
predictive qualities. Prognostic markers are more common in glioblastoma. 
Most biomarkers often have both prognostic and predictive value. There is no strict rule 
when it comes to what constitutes a biomarker. A marker can consist of genomic and 
proteomic patterns, single genes or proteins, chromosomal abnormalities, epigenetic 
signatures, aberrant microRNA as well as imaging changes observed on a MRI or PET scan. 
A prognostic marker has the capacity to estimate survival outcome in patients, 
independent of treatment. The genetic profiling of large tumour cohorts with 
comprehensive clinical and survival data have promoted the discovery of novel molecular 
biomarkers associated with survival, in addition to traditional clinical and morphological 
features. Examples of biomarkers with prognostic significance include amplification of 
Epithelial Growth Factor Receptor (EGFR) (Shinojima et al. 2003; Layfield et al. 2006; Kaloshi 
et al. 2007; Gan et al. 2009; Inda et al. 2010), over-expression of chitinase-3-like-1 (CH3L1 or 
YKL-40) (Hormigo et al. 2006; Pelloski et al. 2007), osteopontin (Sreekanthreddy et al. 2010), 
loss of phosphatase and tensin homolog (PTEN) (Hill et al. 2003; Parsa et al. 2007) and 
mutations in the tumour suppressor protein, p53 (Shiraishi et al. 2002; Ruano et al. 2009). 
Prognostic biomarkers have great utility in the clinic. Not only do these markers present as 
potential therapeutic targets but they can be used to pool groups of glioma with similar 
genetic profile. This enrichment of the test population leads to increased homogeneity and a 
much more uniform response to treatment (Figure 2).  
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Fig. 2. Molecular diagnostics allows for the identification of GBM subgroups with similar 
genetic profile. This enrichment allows for a more uniform tumour response. 
Much more difficult to identify are biomarkers with predictive power in the context of a 
specific therapy. Predictive biomarkers are markers which can be used to identify groups of 
patients who are most likely to respond to a given treatment. The key difference between a 
prognostic and a predictive biomarker is that the predictive biomarker should instigate a 
change in the treatment provided to the patient (Figure 1). Estrogen Receptor (ER) status in 
patients with breast cancer strongly predicts treatment response to tamoxifen (Kurokawa et 
al. 2000; Hu&Mokbel 2001). Additionally, patients with variant forms of the gene CYP2D6 
(also called simply 2D6) may not receive full benefit from tamoxifen because of the slow 
metabolism of the tamoxifen prodrug into its active metabolite 4-hydroxytamoxifen (Goetz 
2010; Stingl et al. 2010; de Souza&Olopade 2011). Approximately 60% of malignant 
melanomas harbour the BRAF mutation. Although patients with the damaged BRAF are 
non-responsive to the KRAS/BRAF inhibitor, sorafenib, response to the second-generation 
drug called PLX4720 is favourable (Whittaker et al. 2010). Improved outcomes have also 
been reported in patients with non-small cell lung cancer (NSCLC) harbouring EGFR 
mutations treated with the tyrosine kinase inhibitors (TKI) erlotinib and gefitinib (Kim et al. 
2008; Paz-Ares et al. 2010). 
In a highly heterogeneous tumour such as glioblastoma, the search for predictive markers to treatment 
for use in clinical trials and in every day clinic has been disappointing. 
1.2 Molecular subtypes of glioblastoma 
Most centres around the world use the World Health Organisation (WHO) grading of 
tumours of the central nervous system (Fuller&Scheithauer 2007). Glioma grade is defined 
by the presence or absence of histopathological features, namely: nuclear pleomorphism, 
mitoses, proliferative index and necrosis and/or microvascular proliferation. A significant 
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limitation to this histopathology-based analysis is its inability to detect functional 
differences occurring on the subcellular level. This is evidenced by the high variability 
observed in the clinical outcomes in patients with the same diagnosis and differences in 
response to therapy. To advance survival times and clinical treatment of these patients with 
an, on average, dismal prognosis molecular markers with capacity to take into consideration 
the high molecular heterogeneity are needed in the clinic. 
The wide spectrum of molecular difference in glioblastoma is evident from global 
expression studies, in particular, the molecular cataloguing project: The Cancer Genome 
Atlas (TCGA) (2008). Surveying the mutational environment of glioblastoma revealed that 
aberrations occur most commonly in genes whose protein products regulate the core cell 
growth signalling pathways that are already known to be important such as EGFR, PTEN, 
p53 and CDKN2A. What this survey did reveal was the extent of genomic complexity. Each 
tumour harbours different mutations. In addition, we are beginning to appreciate that the 
core pathways of cancer are not linear, rather complex and interacting. Given this 
complexity, it is very unlikely that a single genetic change will predict treatment response. 
Gene expression profiling has provided an opportunity to further define prognostic and 
predictive factors (Settle&Sulman 2011). Gene signatures have successfully categorised 
glioblastomas that histologically appear indistinguishable, into molecular subgroups which 
often have very different clinical outcomes (Colman et al. 2010; Verhaak et al. 2010). Based 
on survival associated genes, 76 high grade gliomas were classified into the broad 
genotology groups; proneural, mesenchymal and proliferative (Phillips et al. 2006). The use 
of larger and multiple datasets have refined these subtypes into two broad groups, 
proneural and mesenchymal angiogenic (Colman et al. 2010). Overexpression of a 
mesenchymal gene expression signature and loss of a proneural signature are associated 
with a poor prognosis group. By subtyping glioblastoma into mesenchymal and proneural 
subtypes, the sameness of patient populations is improved. In addition, the genes belonging 
to each group provides biologists hints for therapeutic targeting. For example, the 
mesenchymal subtype of glioblastoma is over-represented by genes involved in 
angiogenesis and invasion (Colman et al. 2010). This subgroup of patients is more 
responsive to bevacizumab. Mutation in the isocitrate dehydrogenase 1 (IDH1) gene is 
strongly associated with the proneural subtype of glioblastoma and a much better prognosis 
(Noushmehr et al. 2010). Increasing evidence suggests that proneural glioblastomas have a 
different histogenic origin which is further supported by the recent discovery of a glioma-
CpG island methylator phenotype (G-CIMP) (Noushmehr et al. 2010). Both IDH1mt and the 
G-CIMP have a higher incidence in secondary GBMs which arise from a prior, lower grade 
lesion. MGMT promoter methylation, G-CIMP and mutations in IDH1 are all prognostic. 
Although a correlation between proneural GBM subtypes and specific treatment has not 
been determined, it has been suggested by a few studies that chemotherapy agents such as 
temozolomide and others targeted at cell growth may not be as effective for this group as 
previously thought (Verhaak&Valk 2010). 
2. Prognostic biomarkers in glioma 
Molecular markers identified to hold prognostic significance in glioma include loss of 
heterozygosity of the chromosomal arms 1p and 19q (LOH 1p/19q), methylguanine 
methyltransferase (MGMT) promoter methylation, mutations in the isocitrate 
dehydrogenase 1 (IDH1) gene, mutations in TP53, loss of PTEN activity, amplification of 
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EGFR, presence of the EGFR delta variant (EGFRvIII) and overexpression of chitinase 3-like 
1 (YKL40). Gene profiling and cross validation in multiple independent datasets has 
resulted in the separation of glioblastoma into two major subgroupings: proneural and 
mesenchymal. The proneural tumours have a much better survival outlook and can be 
further characterised by the presence of a glioma CpG island methylation phenotype 
(gCIMP).  
Extensive reviews of EGFR, PTEN and TP53 are covered elsewhere. This discussion will 
focus on LOH 1p/19q, MGMT promoter methylation and mutations in IDH. 
2.1. Loss of heterozygosity 1p and 19q 
A hallmark of oligodendroglial tumours is the co-deletion of the chromosomal arms 1p and 
19q corresponding to an unbalanced translocation t(1;19) (q10;p10). This can be readily 
detected using Fluorescence In situ hybridisation (FISH) (Figure 3). LOH at 1p19q is 
observed in up to 69% of grade II and grade III (anaplastic) oligodendrogliomas and is far 
more common in ‘pure’ oligodendroglioma than astrocytoma and mixed oligoastrocytoma 
(Barbashina et al. 2005). LOH of 1p19q confers a clear survival advantage in anaplastic 
oligodendroglioma and mixed oligoastrocytoma however the survival advantage conferred 
for grade II lesions is less clear (Laigle-Donadey et al. 2005; Jenkins et al. 2006; Walker et al. 
2006) . Whether the co-deletion mediates a prognostic advantage or results in a heightened 
sensitivity to radiation and chemotherapy is unknown. In general, oligodendrogliomas with 
LOH at 1p19q represent a group of highly chemosensitive gliomas, especially to the 





Fig. 3. Representative photomicrographs of loss of 1p (A) and loss of 19q (B) chromosomal 
arms detected using FISH. Arrow indicates only one chromosome copy instead of the 
expected two. Photomicrographs were kindly donated by Dr Michael Buckland, Department 
of Neuropathology, University of Sydney. 
The standard treatment for anaplastic oligodendrogliomas consists of complete surgical 
removal where possible followed by radiation therapy and chemotherapy, typically with 
temozolomide because it is well tolerated. It is generally accepted that chemotherapy is of 
value in the treatment of patients with anaplastic oligodendrogliomas (Mokhtari et al. 2011). 
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Because of the potential toxicity to the CNS, many clinicians have suggested that 
radiotherapy treatment may be better reserved for progressive disease. Treatment with 
temozolomide is now favoured over PVC treatment because of its low toxicity. Studies 
treating anaplastic oligodendroglioma patients with temozolomide have also found that the 
presence of LOH at 1p/19q is a favourable predictive marker (Brandes et al. 2006; Mikkelsen 
et al. 2009; Ramirez et al. 2010). This could also be because the majority of 
oligodendrogliomas harbouring LOH at 1p/19q also show methylation in the promoter 
region of MGMT. Clinical studies have been designed to establish whether combining or 
adding chemotherapy to radiotherapy is of benefit to oligodendroglioma patients or 
whether these patients could benefit from upfront chemotherapy (without radiotherapy).  
Two large prospective trials have shown little benefit for adding adjuvant PVC before 
radiotherapy (Cairncross et al. 2006) or after radiotherapy (van den Bent et al. 2006). To 
address whether treatment of oligodendrogliomas with chemotherapy alone is feasible and 
safe, the NOA-04 Phase III trial compared radiotherapy versus chemotherapy with either 
PCV or temozolomide as initial therapy in 318 patients with anaplastic gliomas (WHO grade 
3) (randomly assigned 2:1:1 to receive radiotherapy (arm A) or chemotherapy with either 
PCV (arm B1) or temozolomide (arm B2)) (Wick et al. 2009). The clinical relevance of 1p/19q 
codeletion, O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation, and 
IDH1 mutations in codon 132 in these tumours were also measured and analysed. This 
important trial confirmed that there was no survival difference in administering initial 
radiotherapy or initial chemotherapy (Wick et al. 2009). One very important finding to 
emerge from the study was the presence of mutations in IDH1 provided the best prognostic 
model. An ongoing EORCT 26081 Phase III trial of radiotherapy, temozolomide and 
concomitant and adjuvant temozolomide in patients with anaplastic oligodendrogliomas 
with 1p/19q codeletions will further confirm what the optimal treatment for these tumours 
is (more information below). 
The gene products that are affected as a result of LOH remain under investigation and may 
include mediators of cytotoxic resistance or may represent an early oncogenic lesion still 
retaining sensitivity to genotoxic agents or insults. Microarray technology has been used to 
profile gene expression in oligodendrogliomas to look for putative tumour suppressor gene 
candidates and genes which could mediate the observed chemosensitivity using a variety of 
microarray platforms (Mukasa et al. 2002; Nutt et al. 2003; Mukasa et al. 2004; Tews et al. 
2006; Tews et al. 2007; Ducray et al. 2008). These studies have identified some interesting 
gene candidates located on the 1p and 19q chromosomal arms however none have gone on 
to be validated prospectively. Interestingly, these profiling experiments identified a 
proneural signature associated with 1p19q codeleted oligodendrogliomas and a better 
survival outcome (Phillips et al. 2006). In contrast, the mesenchymal signature is more 
commonly associated with glioblastoma (discussed in more detail below). Noteworthy is the 
absence of EGFR amplifications in the proneural group. Ducray and colleagues compared 
1p19q codeleted gliomas to EGFR-amplified gliomas and found that the proneural gene 
internexin (INA) which encodes neurofilament-interacting protein was significantly 
differentially expressed (Ducray et al. 2009). The prognostic significance of INA was further 
assessed and confirmed in the prospective, randomized EORTC 26951 trial of adjuvant PVC 
(Mokhtari et al. 2011). INA strongly correlated with 1p19q codeletion, mutated IDH1 and 
MGMT promoter methylation.  
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The O6-methylguanine-DNA methyltransferase gene, MGMT, located on chromosome 
10q26.1 encodes a DNA repair protein that restores mutagenic O6-alkylguanine to normal 
guanine within genomic DNA. O6-alkylguanines can pair erroneously with thymine during 
DNA replication, resulting in G:C>A:T transitions, as well as causing cross-links between 
adjacent strands of DNA, both of which can lead to neoplastic transformation (Gerson 2004). 
MGMT thus protects cells from the toxic and carcinogenic effects of alkylating agents and is 
absent in many types of human malignancy. Loss of MGMT protein expression is frequently 
associated with transcriptional silencing of the MGMT gene by methylation of its CpG 
island promoter in various neoplasia, (Esteller et al. 1999) as exemplified by 35-55% of 
gliomas (Silber et al. 1998; Esteller et al. 2000; Nakamura et al. 2001; Kamiryo et al. 2004; Paz 
et al. 2004; Brell et al. 2005; Hegi et al. 2005). However, several large studies of glioma have 
shown the correlation between immunohistochemical loss of MGMT and promoter 
methylation is not always correlative (Preusser et al. 2008; Cao et al. 2009; Hawkins et al. 
2009; Mellai et al. 2009). 
Alkylating drugs such as temozolomide are used in chemotherapy for the targeted cell 
death of rapidly-replicating neoplastic cells and MGMT expression is a key factor in 
conferring resistance to these agents. In 2005, a new treatment regime was developed and 
tested in a randomised, phase III clinical trial whereby the alkylating agent, temozolomide 
was combined with radiotherapy (RT) in concurrent treatment followed by an additional 6 
cycles of Temozolomide for newly diagnosed glioblastoma (Stupp et al. 2005). This was the 
first trial to achieve a clinically meaningful and statistically significant overall median 
survival benefit of 2.5 months when compared to radiotherapy alone. More compelling were 
the two-year survival rates with 26% of patients treated with concurrent treatment still alive 
after two years compared with just 10.4% for patients treated with radiotherapy alone. 
These survival benefits were still apparent after 5 years of follow-up (Stupp et al. 2009).  
The molecular basis for the differential response of glioblastoma patients to temozolomide 
has been recognized. Temozolomide is an oral alkylating chemotherapy which is 
spontaneously converted into its active metabolite and readily crosses the blood-brain 
barrier. The primary mode of action of temozolomide is to damage the DNA by introducing 
alkyl adducts. These cause genetic mutations as well as cross-links between DNA strands 
that inhibit DNA replication and thereby trigger cell death. Thus alkylating agents target 
rapidly replicating neoplastic cells. However, while temozolomide introduces alkyl adducts 
into DNA, MGMT reverses them. Thus tumour cells expressing MGMT are chemoresistant 
to this class of drugs (Pegg 1990). In a companion laboratory study to the phase III trial 
combining radiotherapy with temozolomide, Hegi et al. demonstrated a pronounced 
positive survival response in patients whose tumours had lost MGMT by promoter 
methylation. Strikingly, patients whose tumours were MGMT-methylated demonstrated 
extended overall and progression-free survival compared to those whose tumours were 
unmethylated, and therefore MGMT methylation was postulated to be a positive predictor 
of patient response to alkylating agents (Esteller et al. 2000; Hegi et al. 2005). Since these 
seminal reports in 2005, the standard of care for patients diagnosed with glioblastoma has 
comprised surgery with maximal feasible resection and radiotherapy with concurrent and 
adjuvant temozolomide. Yet widespread adoption of MGMT methylation as a marker of 
response to temozolomide in clinical practice has not transpired.  
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Because of the potential toxicity to the CNS, many clinicians have suggested that 
radiotherapy treatment may be better reserved for progressive disease. Treatment with 
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oligodendrogliomas harbouring LOH at 1p/19q also show methylation in the promoter 
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important trial confirmed that there was no survival difference in administering initial 
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with 1p/19q codeletions will further confirm what the optimal treatment for these tumours 
is (more information below). 
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2006; Tews et al. 2007; Ducray et al. 2008). These studies have identified some interesting 
gene candidates located on the 1p and 19q chromosomal arms however none have gone on 
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(Mokhtari et al. 2011). INA strongly correlated with 1p19q codeletion, mutated IDH1 and 
MGMT promoter methylation.  
Biomarker Discovery, Validation and Clinical 




The O6-methylguanine-DNA methyltransferase gene, MGMT, located on chromosome 
10q26.1 encodes a DNA repair protein that restores mutagenic O6-alkylguanine to normal 
guanine within genomic DNA. O6-alkylguanines can pair erroneously with thymine during 
DNA replication, resulting in G:C>A:T transitions, as well as causing cross-links between 
adjacent strands of DNA, both of which can lead to neoplastic transformation (Gerson 2004). 
MGMT thus protects cells from the toxic and carcinogenic effects of alkylating agents and is 
absent in many types of human malignancy. Loss of MGMT protein expression is frequently 
associated with transcriptional silencing of the MGMT gene by methylation of its CpG 
island promoter in various neoplasia, (Esteller et al. 1999) as exemplified by 35-55% of 
gliomas (Silber et al. 1998; Esteller et al. 2000; Nakamura et al. 2001; Kamiryo et al. 2004; Paz 
et al. 2004; Brell et al. 2005; Hegi et al. 2005). However, several large studies of glioma have 
shown the correlation between immunohistochemical loss of MGMT and promoter 
methylation is not always correlative (Preusser et al. 2008; Cao et al. 2009; Hawkins et al. 
2009; Mellai et al. 2009). 
Alkylating drugs such as temozolomide are used in chemotherapy for the targeted cell 
death of rapidly-replicating neoplastic cells and MGMT expression is a key factor in 
conferring resistance to these agents. In 2005, a new treatment regime was developed and 
tested in a randomised, phase III clinical trial whereby the alkylating agent, temozolomide 
was combined with radiotherapy (RT) in concurrent treatment followed by an additional 6 
cycles of Temozolomide for newly diagnosed glioblastoma (Stupp et al. 2005). This was the 
first trial to achieve a clinically meaningful and statistically significant overall median 
survival benefit of 2.5 months when compared to radiotherapy alone. More compelling were 
the two-year survival rates with 26% of patients treated with concurrent treatment still alive 
after two years compared with just 10.4% for patients treated with radiotherapy alone. 
These survival benefits were still apparent after 5 years of follow-up (Stupp et al. 2009).  
The molecular basis for the differential response of glioblastoma patients to temozolomide 
has been recognized. Temozolomide is an oral alkylating chemotherapy which is 
spontaneously converted into its active metabolite and readily crosses the blood-brain 
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rapidly replicating neoplastic cells. However, while temozolomide introduces alkyl adducts 
into DNA, MGMT reverses them. Thus tumour cells expressing MGMT are chemoresistant 
to this class of drugs (Pegg 1990). In a companion laboratory study to the phase III trial 
combining radiotherapy with temozolomide, Hegi et al. demonstrated a pronounced 
positive survival response in patients whose tumours had lost MGMT by promoter 
methylation. Strikingly, patients whose tumours were MGMT-methylated demonstrated 
extended overall and progression-free survival compared to those whose tumours were 
unmethylated, and therefore MGMT methylation was postulated to be a positive predictor 
of patient response to alkylating agents (Esteller et al. 2000; Hegi et al. 2005). Since these 
seminal reports in 2005, the standard of care for patients diagnosed with glioblastoma has 
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2.2.1 Routine testing for MGMT methylation 
While MGMT methylation could be routinely used as a prognostic/predictive marker in 
glioblastoma, there is so far no consensus on the method to be applied. Assessment of 
MGMT promoter methylation is difficult due to the complex nature of the techniques 
involved. To detect methylation, bisulfite treatment of the DNA is required, a process that 
may result in degradation of DNA and subsequent low success rates in PCR. This is further 
compounded by the fact that the most commonly available tissue for assessment is formalin 
fixed paraffin embedded (FFPE), and the DNA subsequently extracted from this tissue is 
usually fragmented, again making PCR more difficult.  
Promoter methylation analysis by qualitative methyl-specific polymerase chain reaction 
(MSP) or semi-quantitative methyl-specific polymerase chain reaction (SQ-MSP), especially 
from FPPE tissue is technically demanding. MSP is the more limited because the 
methylation status of only a few CpG sites (i.e., those interfering with the PCR primer 
binding) can be interrogated at once. The technique also has the drawback of providing only 
a qualitative indication of the methylation status of the sites. Karayan-Tapon (Karayan-
Tapon et al. 2010) evaluated MGMT promoter methylation using MSP, SQ-MSP and 
pyrosequencing. The best predictive value for overall survival was obtained by 
pyrosequencing. Pyrosequencing technology is a technique that generates a quantitative 
measure of methylation and automatically calculates and reports percent methylation for 
each CpG site in the studied sequence, thus allowing detection of partially methylated CpG 
sites. 
There are other methodologies for assessing the promoter methylation of MGMT. The 
testing needs to be resolved for MGMT to be used routinely in the clinic and perhaps a 
surrogate marker of MGMT such as another protein product readily visualised by 
immunohistochemistry or a polymorphism detected in blood may be the way forward.  
2.2.2 Strategies to overcome MGMT activity  
With the recognition that an unmethylated MGMT promoter is associated with a poorer 
response to temozolomide, strategies have evolved to circumvent the resistance that MGMT 
confers. Combination therapy with multiple chemotherapeutic drugs known to deplete 
MGMT (specifically procarbazine and temozolomide) has been successfully assessed in a 
Phase I trial (Newlands et al. 2003) but as yet has not been shown to confer a benefit in 
survival. O6 benzylguanine (O6BG), a substrate for MGMT, has also been used to decrease 
MGMT levels. However, systemic administration of O6BG has been associated with 
significant toxicity, thereby necessitating a reduction in chemotherapy dose (Quinn et al. 
2002; Quinn et al. 2005). A recent case report of local administration of O6BG, allowing the 
systemic effects to be avoided, shows some promise (Koch et al. 2007).  
Alteration of temozolomide dosing regimens from the usual method of 5 days of treatment 
every 28 days to more frequent, lower-dose treatment has been evaluated. Protracted 
temozolomide exposure may reduce MGMT activity. Brock and colleagues demonstrated 
safety of a low dose of temozolomide for up to 49 consecutive days, however the efficacy of 
this lower dose is unclear (Brock et al. 1998). Depletion of peripheral mononuclear MGMT 
has been demonstrated with more prolonged dosing regimens and unfortunately this has 
been associated with profound lymphocytopaenia and opportunistic infections (Tolcher et 
al. 2003; Wick et al. 2004; Wick&Weller 2005). More recent evidence suggest that daily 
dosing may be associated with improved outcome (Buttolo et al. 2006). Additionally, a 
dosing regimen of 14 days of treatment out of every 28 days has not only been shown to 
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lead to a progression free survival benefit, outcome with this treatment regimen was not 
significantly associated with MGMT promoter methylation (Wick et al. 2007).  
Treating patients with continuous 50mg/m2 at relapse after a standard temozolomide 
schedule of 150-200mg/m2 resulted in a PFS6 of 47-57% (Perry et al. 2008). The efficacy and 
safety of this continuous dose-intense temozolomide schedule for recurrent GBM was tested 
in a multicenter, phase II study, RESCUE. Overall, PFS6 in 116 patients with recurrent GBM 
was 24% (Perry et al. 2010). Not surprisingly, the best responding patients were those who 
were treated with conventional chemoradiotherapy. However, what was interesting was the 
similar benefit to treatment recorded in the patients who experienced early progression on 
standard therapy (Perry et al. 2010).  
2.3 IDH mutations 
The Cancer Genome Atlas (TCGA) efforts made the initial breakthrough discovery that 11% 
of glioblastomas harbour point mutations in cytoplasmic and mitochondrial NADP+-
dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) (Balss et al. 2008; Parsons et 
al. 2008; Dang et al. 2009). The normal function of the IDH enzymes is to convert isocitrate 
into α-ketoglutarate. Mutations, specifically at the arginine 132 (R132) codon, are more 
frequently observed in low grade and anaplastic gliomas and secondary glioblastomas (50-
93%) than mutations found in IDH2 [arginine 172 (R172) codon] (3-5%). No gliomas have 




Fig. 4. Representative photomicrographs of IDH1 mutations detected with the Anti-Human 
IDH1 R132H Mouse Monoclonal Antibody (DIA-H09M) at x20 magnification (A) and x40 
(B) Photomicrographs were kindly donated by Dr Michael Buckland, Department of 
Neuropathology, University of Sydney. 
Hartmann and colleagues used an antibody which specifically detected the R132 mutation 
in IDH1 allowing assessment with simple immunohistochemistry (Hartmann et al. 2010). 
(Figure 4). The mutation was detected in 72% low grade astrocytomas (AII; n=227); 64% 
anaplastic astrocytomas (AA; n=228); 82% low grade oligodendroglioma (OII; n=128); 70% 
anaplastic oligodendroglioma (AO; n=174); 82% low grade oligoastrocytomas (OAII; n=76); 
66% anaplastic oligoastrocytoma (AOA; n=177) and 9% glioblastoma (GBM; n=521). What 
was most significant about this study was the progression free and overall survival curves. 
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safety of a low dose of temozolomide for up to 49 consecutive days, however the efficacy of 
this lower dose is unclear (Brock et al. 1998). Depletion of peripheral mononuclear MGMT 
has been demonstrated with more prolonged dosing regimens and unfortunately this has 
been associated with profound lymphocytopaenia and opportunistic infections (Tolcher et 
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lead to a progression free survival benefit, outcome with this treatment regimen was not 
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similar benefit to treatment recorded in the patients who experienced early progression on 
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into α-ketoglutarate. Mutations, specifically at the arginine 132 (R132) codon, are more 
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Fig. 4. Representative photomicrographs of IDH1 mutations detected with the Anti-Human 
IDH1 R132H Mouse Monoclonal Antibody (DIA-H09M) at x20 magnification (A) and x40 
(B) Photomicrographs were kindly donated by Dr Michael Buckland, Department of 
Neuropathology, University of Sydney. 
Hartmann and colleagues used an antibody which specifically detected the R132 mutation 
in IDH1 allowing assessment with simple immunohistochemistry (Hartmann et al. 2010). 
(Figure 4). The mutation was detected in 72% low grade astrocytomas (AII; n=227); 64% 
anaplastic astrocytomas (AA; n=228); 82% low grade oligodendroglioma (OII; n=128); 70% 
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In order of most favourable to poor survival: (1) AA with IDH1 mutation, (2) GBM with 
IDH1 mutation, (3) AA with IDH1 wild type and (4) GBM with IDH1 wild type. Routine 
testing for IDH1 mutations will have clinical ramifications regarding histological diagnosis 
and treatment schemes. The IDH1 mutation is of greater prognostic relevance than 
histopathological diagnosis according to the World Health Organisation (WHO) 
classification system (Hartmann et al. 2010). Subsidised treatment schemes approved for 
glioblastoma such as concomitant radiotherapy and temozolomide and bevacizumab (USA 
only) may need to be revised to allow anaplastic gliomas with IDH1 wild type status to be 
treated. 
Mutations of the codons in IDH1 and 2 lead to a loss in the production of α-ketoglutarate 
and a gain of the catalytic activity to produce 2-hydroxyglutarate (2-HG) (Xu et al. 2011). 2-
HG levels are highly elevated in IDH-mutated cancers and lead to genome wide histone and 
DNA methylation alterations (Xu et al., 2011; Dang et al., 2009). Hypermethylation at a large 
number of loci have been associated with IDH-mutated glioma suggesting that IDH 
mutation is associated with a distinct DNA methylation phenotype (Noushmehr et al. 2010; 
Christensen et al. 2011). GoldenGate array methylation data was obtained from 131 glioma 
patients (all types and histological grades) to interrogate methylation patterns associated 
with IDH mutation and survival. IDH1 mutations were present in 60% of tumours. Distinct 
differences between the numbers of significantly differentially hypermethylated loci were 
noted in IDH mutant tumours compared to IDH wild type tumours. Specific to IDH mutant 
tumours, cellular signalling pathways were hypermethylated whilst metabolism and 
biosynthesis pathways were hypermethylated (Christensen et al. 2011). This might be 
compensatory for the metabolic stress related to the mutation.  
In a series of elegant in vitro-based experiments, Yan’s group transformed human 
oligodendroglial (HOG) cells with IDH1-R132 or treated cells with 2-HG (Yan et al. 2009). 
They noted changes in gene expression common to both IDH1-R132 cells and 2-HG-treated 
cells when compared to IDH1-wildtype and untreated cells, implying that these changes 
were the result of increased 2HG (Reitman et al. 2010; Reitman&Yan 2010). However, 
reductions in glutamate and several glutamate-related metabolites were observed 
exclusively in the IDH1-R132 cells. Particular attention was paid to reduced levels of a 
common dipeptide in the brain, N-acetyl-aspartyl-glutamate (NAAG), however its 
contribution to pathogenesis remains unclear (Reitman et al. 2011).  
Recently, IDH mutations have been shown to be tightly associated with the presence of a 
glioma CpG island methylator phenotype (gCIMP) (Noushmehr et al. 2010). CIMPs are 
characterised by highly concordant DNA methylation of a subset of loci. Improved survival 
was observed in gliomas with IDH1 mutation and positive for gCIMP suggesting that there 
are molecular features within gCIMP gliomas that encourage a less aggressive phenotype. 
CIMP positive colon cancers also have a better prognosis. It is not known whether glioma 
cells acquire the mutation in IDH1 which then leads to genome histone and DNA 
methylation patterns, reflected by the presence of a gCIMP or that transcriptional silencing 
of gCIMP targets may provide the optimal environment for gliomas to acquire the mutation 
(genomic instability) (Noushmehr et al. 2010).  
Gliomas with IDH1 mutations as well as the presence of gCIMP displayed significantly 
better overall survival (median survival: 2.9 years) compared to all other patients (median 
survival: 1.04 years). The favourable survival observed in IDH1 mutation-gCIMP positive 
gliomas may be because these tumours are highly represented in the proneural subset of 
gliomas. Clinically, the prognostic utility of IDH1 mutations emerged in the NOA-04 trial. 
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IDH1 mutations conferred a significantly longer time to treatment failure (TTF) which was 
independent of histology, treatment, codeletion of 1p and 19q and MGMT promoter 
methylation status (Wick et al. 2009). IDH1 mutations as well as the gCIMP represent a 
significant breakthrough in how we diagnose patients. Testing for IDH1 mutations has 
quickly translated into routine diagnostic use. No doubt, IDH1 mutations and perhaps the 
gCIMP will be used to stratify patients for future clinical trials. Attention has shifted to 
examining therapeutic targets for IDH1 as well as the possibility of inducing mutations in 
IDH1 in GBMs that don’t possess the mutation.  
3. Use as predictive biomarkers 
Biomarkers which can foretell whether patients are resistant to a certain treatment and 
predict drug sensitivity are urgently needed. The success rate of matching biomarkers with 
treatments has been less than satisfactory. Fewer than 100 biomarkers have been validated 
for routine clinical practice, despite the publication of more than 150,000 claimed 
biomarkers. Impeding the successful translation of biomarkers into the clinical setting is 
non-standardised biological specimen and clinical data collection, particularly clinical 
information pertaining to drug sensitivity and progression free survival. In addition, far 
greater numbers of tumour specimens from patients treated uniformly may be needed to be 
analysed than what we previously assumed. 
The only biomarker with reported predictive value is MGMT promoter methylation. As 
discussed earlier in the MGMT section, the role of MGMT is to protect cells from alkylating 
damage specifically by removing the alkyl adducts from the O6 position of guanine and the 
O4 position of thymine and effectively restoring the DNA bases and prevent TMZ-induced 
cell death. However, the present NOA-04 trial does not support the suggestion that MGMT 
promoter methylation is simply predictive for response to alkylating chemotherapy (Wick et 
al. 2009). NOA-04 showed a striking difference in PFS between patients with versus without 
MGMT promoter methylation who were treated with radiotherapy alone. Thus MGMT 
promoter hypermethylation in anaplastic gliomas may be regarded as (1) a prognostic 
marker for good outcome in patients treated with radiotherapy or (2) predictive for response 
to radiotherapy itself.  
The most significant issue with implementing MGMT promoter methylation as a predictive 
test for TMZ therapy is that there is currently no alternative treatment strategy available for 
those patients with unmethylated MGMT tumours. Until alternative treatments are 
available and the MGMT test is more reliable and robust, will clinicians consider MGMT 
promoter methylation as a predictive test. 
4. Use of biomarkers in clinical trials 
Co-deletion of the chromosomal arms 1p and 19q is a requirement for entry of anaplastic 
gliomas into the CODEL study which is assessing the role of concomitant and adjuvant 
temozolomide added to standard radiotherapy and has temozolomide monotherapy in an 
observation arm. A phase III randomized sister study to CODEL, CATNON, examines 
radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-
1p/19q deleted anaplastic gliomas (Figure 5). This type of dual study design allows for the 
patient populations to be enriched in a specific marker, yet it doesn’t exclude either tumour 
types (codeleted and nondeleted 1p/19q). All specimens will also be tested for MGMT 
promoter methylation. 
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IDH1 mutations conferred a significantly longer time to treatment failure (TTF) which was 
independent of histology, treatment, codeletion of 1p and 19q and MGMT promoter 
methylation status (Wick et al. 2009). IDH1 mutations as well as the gCIMP represent a 
significant breakthrough in how we diagnose patients. Testing for IDH1 mutations has 
quickly translated into routine diagnostic use. No doubt, IDH1 mutations and perhaps the 
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temozolomide added to standard radiotherapy and has temozolomide monotherapy in an 
observation arm. A phase III randomized sister study to CODEL, CATNON, examines 
radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-
1p/19q deleted anaplastic gliomas (Figure 5). This type of dual study design allows for the 
patient populations to be enriched in a specific marker, yet it doesn’t exclude either tumour 
types (codeleted and nondeleted 1p/19q). All specimens will also be tested for MGMT 
promoter methylation. 
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Fig. 5. Overview of the CATNON and CODEL trials 
A phase I/IIa trial examined the effectiveness of adding cilengitide to concurrent 
chemoradiotherapy (Stupp et al. 2010). This study demonstrated the effectiveness of 
cilengitide but also showed that there was a clear survival benefit in the patients with 
MGMT promoter methylation (Stupp et al. 2010). The phase III CENTRIC trial 
(recruitment closed in Feb, 2011) restricted recruitment to newly diagnosed GBM patients 
with confirmed MGMT methylation. An additional two phase II trials sponsored by the 
pharmaceutical company, EMD Serono, are designed to treat patients with unmethylated 
MGMT: CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients 
with Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status) and 
ExCentric. CORE (trial still open; May 2011) examines the efficacy of increasing the dose 
schedule of cilengitide (2000mg twice weekly and 2000mg five times per week) versus 
standard concurrent chemoradiotherapy (without cilengitide). The ExCentric trial 
(recruitment open, May 2011) has taken a much different approach. In this trial, 
procarbazine is added to the concurrent schedule of radiotherapy, TMZ, cilengitide and 
patients will be treated adjuvantly for an additional 6 cycles with the triple cocktail of 
cilengitide, TMZ and procarbazine. The patients have so far shown excellent toleration of 
this combination. 
The RTOG-0825 examines the effect of bevacizumab administered with radiotherapy 
compared to conventional concurrent chemoradiotherapy (TMZ) in primary GBM. All 
patients enrolled in this study will be tested for MGMT promoter methylation. Unique to 
this study, however, all samples will be prospectively tested with the nine-gene profile 
which separates the proneural GBM from the mesenchymal-angiogenic GBM (Colman et al. 
2010). It is becoming mandatory for future trial design to incorporate molecular inclusion 
criteria to identify the poorly responding patients from the patients who benefit.  
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5. Targeted therapies for glioblastoma 
Molecular targeted therapies specifically inhibit amplified or aberrant proteins that drive 
tumour cell growth. The key to targeted therapy is identifying a target whose inhibition will 
stop the growth of the tumour cell. Whilst this field has rapidly developed, our understanding 
at the molecular level of the precise role that potential targets have in tumorigenesis and the 
survival dependence that tumours have on these components has not progressed at the 
same rate. Unlike melanoma, lung and breast cancer, glioblastoma lacks significant driver 
mutations which are present in ample abundance and in all tumours. The TCGA analysis 
revealed a wide spectrum of molecular variation in glioblastoma. TCGA used global gene 
expression analysis to show aberrations occurred more commonly in genes whose protein 
products regulated the core cell growth signalling pathways that were already known to be 
important such as EGFR, PTEN, p53 and CDKN2A. One pathway which is frequently 
dysregulated is the receptor tyrosine kinase (RTK)/phosphatidylinositol 3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) cascade. Approximately 86% of 
clinical samples analysed by the TCGA with both copy number and sequencing data had a 
genetic alteration in the RTK/PI3K pathway (Parsons et al. 2008). In addition, genetic 
alterations in two other core pathways; RB (87%) and TP53 (78%) were documented. At the 
time (3 years ago now) it was reasonable to suggest that all tumours be sequenced and the 
genetic aberrations be documented before selecting the targeted therapy. For example, for 
tumours with alterations in CDKN2A or CDKN2C or amplifications in CDK4 or CDK6, a 
CDK inhibitor should be recommended. Unfortunately, we underestimated the extent of 
genomic complexity and it is very doubtful that therapies targeted to a single genetic change 
will ever be effective. A range of molecular targeted drugs applied in combination or in 
addition to each other is needed (Jansen et al. 2010). In clinical practice, the multi-drug 
approach is currently limited by intellectual property. Most likely the efficacy of two drugs 
may require two competing pharmaceutical companies to work together.  
To understand why our current single targeted therapies are ineffective, it is useful to 
examine the earlier clinical studies with EGFR- and VEGF-targeted drugs. We can also glean 
value from trials using targeted therapy in other cancers. Even when the target of interest is 
much more prominent such as KRAS or BRAF, valuable lessons can still be learnt.  
5.1 Targeting the RTK/PI3K pathway  
In a study of 49 patients with recurrent glioblastoma, tumour shrinkage was evident in 9 
patients (25%) (Mellinghoff et al. 2005). Logically, it was of great interest to better 
understand the underlying molecular biology of these 9 responders. Pre-treatment tissue 
was only available for 7 of the responding patients and 19 patients who did not respond. 
The authors found coexpression of EGFRvIII and PTEN sensitised glioblastoma to erlotinib 
and correctly validated this finding in tissue samples from different institutions undergoing 
similar treatment (n=33) (Mellinghoff et al. 2005). Unfortunately, the relationship between 
EGFRvIII and intact PTEN co-expression did not translate to the subsequent prospective 
phase I/II trials (Brown et al. 2008; van den Bent et al. 2009). No relationship between 
aberrations in the RTK core and the EGFR inhibitor, lapatinib (Thiessen et al. 2010) or 
addition of erlotinib with the mTOR inhibitor, sirolimus (Reardon et al. 2010) were linked 
with response.  
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5.2 Targeting angiogenesis 
The development of anti-angiogenic agents for glioblastoma have been promising and 
include bevacizumab (Vascular endothelial growth factor [VEGF] antibody), cediranib 
(VEGF receptor antagonist), cilengitide (mentioned previously; integrin antagonist) and 
Enzastaurin (Protein Kinase-C-β-antagonist).  
The preclinical and clinical data for cediranib treatment in glioblastoma looked very 
promising (Dietrich et al. 2009; Gerstner et al. 2011). Unfortunately, the International 
Multicentre Phase III trial, REGAL was negative. The REGAL study compared the use of 
cediranib alone, cediranib in combination with lomustine and lomustine plus placebo. In the 
325 patients with recurrent GBM studied, only 16% treated with cediranib monotherapy 
were alive and progression free at 6 months (APF6) compared to 34.5% in the combination 
group and 24.5% in the lomustine plus placebo group (results reported by T. Batchelor at the 
Society of Neuro-oncology Annual Meeting, 2010; (Ahluwalia 2011)). Akin to cediranib, 
preclinical and studies of enzastaurin showed good anti-glioma activity but failed to show 
any significant benefits when trialled in a phase III study comparing enzastaurin to 
lomustine. Although less toxicity was observed with enzastaurin, no significant differences 
in median progression free survival and overall survival were observed (Wick et al. 2011). 
The humanized antibody, Bevacizumab (Avastin), has received the most attention, with 
Food and Drug Administration (FDA) approval for use in recurrent GBM in the USA. No 
such approvals have been obtained in Europe and Australia. This is predominantly because 
there is only a modest overall survival benefit of 7.8-9.2 months suggesting a further 
improvement of efficacy is needed. Numerous phase II studies have shown modest survival 
benefits with bevacizumab either as a monotherapy or in combination with irinotecan 
(Chinot et al. 2011; Jakobsen et al. 2011; Lai et al. 2011; Prados et al. 2011; Reardon et al. 
2011). Consistent to all trials examining bevacizumab efficacy is the reduction of steroids for 
patients and valuable palliation with preservation of key performance status (KPS), 
supporting a role for bevacizumab as a therapy in late stage disease (Hofer et al. 2011). 
Whether bevacizumab results in true glioma cell destruction or is it merely its ability to 
control the perivascular leak, resulting in better symptom control (associated with 
improvement of gadolinium MRI) needs to be elucidated. 
An issue consistent with all trials of cediranib, enzastaurin and bevacizumab is their testing 
on recurrent glioblastoma as opposed to primary glioblastoma. Recurrent glioblastoma are 
already highly refractory to treatment and the potential benefits of these drugs may be 
missed. New studies are investigating bevacizumab up front with standard radiation 
therapy and temozolomide. This has shown to be well tolerated (Vredenburgh et al. 2011) 
and it is a strategy that the RTOG-0825 trial has incorporated (discussed previously).  
With all of these targeted therapies, it would seem obvious that the more target present, the 
more efficacious the drug. Unfortunately, this has not been the case. For example, why 
patients with high expression of VEGF have not shown strong response to bevacizumab? 
These issues pertaining to biomarkers in targeted therapy trials will be discussed in turn 
below:  
5.3 Many retrospective analyses of single arm investigations are performed in small 
and often heterogeneous cohorts of patients 
The co-expression of EGFRvIII and PTEN was first discovered in an initial test set consisting 
of 49 recurrent GBM treated with either gefitinib (n=37) or erlotinib (n=12). 26 patients with 
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clear-cut evidence of a response or tumour progression had sufficient tissue for molecular 
analysis. Hence, just over half of the originally small cohort was analysed for molecular 
biomarkers. The validation study used a different tissue type entirely as only paraffin-
embedded slides were available. Again, this material was untreated tumour tissue, not the 
recurrent lesion. The validation set was extremely underpowered (n=33) with only 8 
responders identified in this dataset. It is imperative that collaborations between different 
institutes and countries work together to increase the power of these biomarker studies.  
5.3.1 A lack of standardisation in the methods used for marker measurement 
Assays for biomarkers need to be reliable. The assay needs to give identical results if 
repeated in the same or in another laboratory. The result needs to be the same, even when 
different methodologies are used. And finally, we need to ask whether the test provides 
added value to clinical practice. This has often been a strong criticism of studies 
incorporating MGMT promoter methylation (as discussed previously) and unfortunately 
the same issues surround biomarkers for targeted therapies. The original study by 
Mellinghoff and colleagues used immunohistochemistry (IHC) to assess PTEN expression 
(Mellinghoff et al. 2005). The problem with this approach is the antibody used does not 
detect the full length PTEN protein. Should mutations arise in the C-terminal end of the 
protein, these would go undiscovered using IHC assay. IHC for EGFR is also contentious. 
EGFR overexpression in GBM is generally driven by EGFR amplification. The scoring of 
EGFR IHC can be variable and different antibodies have different specificities to the EGFR 
protein. Amplification of EGFR or more specifically gain of copy number is most commonly 
detected by fluorescence in situ hybridization (FISH) and can be routinely performed in 
most histopathological laboratories. What is puzzling is the lack of sequencing of both EGFR 
and PTEN genes in the subsequent phase I/II clinical trials assessing TKIs. The most 
frequent mutant form of EGFR is EGFR Variant III (EGFRvIII or EGFR delta) which is 
missing the ligand –binding domain resulting in the constitutive activation of the EGFR-
phosphoinositide 3-kinase pathway. IHC specific to the EGFRvIII mutant form is highly 
specific as too is the commonly used RT-PCR method. However, there are additional 
missense mutations encoding extracellular EGFR that have been shown to drive oncogenesis 
in vitro and can be inhibited by small-molecular tyrosine kinase inhibitors. 
The original pre-clinical/clinical study sequenced all exons and flanking intronic sequences 
for EGFR (kinase domain), the HER2/neu (kinase domain) and all exons of PTEN. FISH was 
also performed to detect EGFR amplification and RT-PCR was used to amplify EGFR (1044-
bp product) and EGFRvIII (243-bp product). In addition, EGFR and PTEN were examined 
with IHC (Mellinghoff et al. 2005). 26 of the 49 patients underwent sequencing, which 
included 6 patients who showed a response to erlotinib. No mutations were found. Van den 
Bent and colleagues assessed the benefits of erlotinib compared to temozolomide or 
cumustine in recurrent GBM in a randomized phase II study (van den Bent et al. 2009). 
Obtaining full data for all patients in this study was problematic. From 100 patients, PTEN 
expression could be determined in 82 patient cases and pAKT in 64 patients. Like the 
Mellinghoff study, no mutations in EGFR were detected, however only exons 19 to 21 were 
assessed. Although an association between EGFRvIII and EGFR amplification with poor 
overall survival was shown, no correlation between response and the co-expression of PTEN 
and EGFR was measured (van den Bent et al. 2009). In fact, no significant activity of 
erlotinib was observed. In another study of 65 patients, erlotinib efficacy was assessed in 
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combination with temozolomide (Prados et al. 2009). Again no association with EGFRvIII 
and PTEN and response was measured, however in this study, MGMT promoter 
methylation was associated with better response. EGFR was measured with FISH and IHC, 
PTEN and EGFRvIII were analysed by IHC. No mutational analysis of EGFR was 
undertaken. Reardon and colleagues assessed the combination of erlotinib with a mTOR 
inhibitor, sirolimus in recurrent GBM (Reardon et al. 2010). Again, EGFR, EGFRvIII, PTEN, 
PI3K and pS6 were assessed by IHC and no association for these markers with clinical 
response was found. Mutational analysis was not conducted. Moreover, the general 
methodologies did not differ in the studies addressing erlotinib and response and the Phase 
II studies could not validate the findings of Mellinghoff et al.  
Elegant biomarker studies have been associated with the anti-angiogenic drugs. Attention 
has focused predominantly on secreted factors and imaging modalities. Interleukin 6 (IL-6) 
is over-expressed in the majority of gliomas and functions as an immune regulator and an 
autocrine growth factor (Saidi et al. 2009). High starting levels of IL-6 may influence the 
efficacy of bevacizumab as it provides redundancy for the VEGF/VEGFR pathway and 
promotes an immune response that stimulates angiogenesis by non-VEGF mechanisms. 
Sorenson et al. reported the combination of MRI imaging (measured changes in vascular 
permeability/flow [Ktrans] and changes in microvessel volume) and circulating collagen IV 
levels in plasma to be predictive of outcome in glioblastoma patients treated with cediranib 
(Sorensen et al. 2009). The level of circulating endothelial progenitor cells (cEPCs) and viable 
circulating endothelial cells (cECs) has also been shown to correlate with response (Sorensen 
et al. 2009). The ability to identify changes in a tumour’s perfusion offers the potential to 
predict growth or regression. Dynamic susceptibility-weighted contrast-enhanced (DSC) 
MR imaging can be used to measure relative cerebral blood volume (rCBV) as a surrogate 
marker of perfusion. A pilot study of 16 patients with recurrent glioblastoma and treatment 
with bevacizumab found that MR perfusion imaging showed a significantly improved 
correlation with time to progression (Sawlani et al. 2011). Studies from Tsien (Tsien et al. 
2011) and Server (Server et al. 2011)- both show positive results for this scan in patients with 
PsPD. Only changes in the hypoxia inducing factor (HIF) 2 alpha [HIF2] have been shown 
to be promising surrogates of response to anti-angiogenic therapies (Mao et al. 2011). 
5.3.2 Methodologies chosen in the study may not represent a comprehensive analysis 
of multiple components of a specific pathway  
None of the studies examining erlotinib have comprehensively analysed the downstream 
components involved in EGFR signalling. Additional testing of PI3K and PS6 were added in 
some studies. It is very common for glioblastomas to have dysregulated signalling cascades 
downstream of EGFR, particular the negative feedback loops. Several growth factor 
pathways are also triggered. It’s not economically feasible in most instances to assess all 
aspects of the RTK/PI3K/AKT/mTOR signalling cascade. However, a new system of 
testing drugs and identifying which subtypes of glioblastoma are susceptible to the drug 
could be to use human glioblastoma xenograft panels serially passaged in nude mice. This 
model allows tumour burden to be monitored non-invasively and rapid assessment of 
biological pathways (Prasad et al. 2011).  
Feedback mechanisms also pose an issue with targeted therapies blocking angiogenesis. 
Tumours frequently recur after treatment with cediranib and bevacizumab and are 
refractory to further treatments. There have been different theories postulated as to why this 
“rebound” effect occurs. Tumours may switch to VEGF-independent angiogenic pathways 
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or vessel co-option. A commonly held theory is that recurrent glioblastomas switch their 
growth pattern after anti-VEGF treatment (di Tomaso et al. 2011). The tumour cells are 
exposed to an increased hypoxic environment leading to increased migration, invasion, 
heightened glycolysis and increased PI3K pathway activation. Combining bevacizumab 
with anti-glycolytic agents or PI3K inhibitors might be more effective. Tumour-initiating 
CD133+ve cells are radio-resistant and can self renew to reform tumours, suggesting that 
these cells are responsible for tumour relapse (Liu et al. 2009). More significantly, exposure 
to bevacizumab inhibited the maturation of tumour endothelial progenitors into the 
endothelium but not the differentiation of CD133+ cells into progenitor cells (Wang et al. 
2011). This fundamental study showed that there is a dynamic balance between the CD133+ 
cell population and tumour cells and we need to target the endothelial transition as well as 
VEGF.  
5.3.3 Not all mutations within a given gene are screened 
In simplistic terms, the plethora of TKIs are designed to be effective on patients harbouring 
EGFR mutations. However, in the majority of studies exploring gefitinib and erlotinib, the 
EGFR gene is not fully sequenced to identify variants and mutations. TCGA analyses have 
identified a high diversity of genes mutated within glioblastoma. As prices drop with Next 
Generation sequencing, capabilities to better define precise genetic aberrations associated 
with response to a specific treatment will improve. Copy number aberrations (amplifications 
and deletions) and structural aberrations (intra-chromosomal rearrangements- inversions, 
inverted/tandem duplications) are not detected using traditional Sanger sequencing in the 
lab. Our ability to assess these aberrations must improve at the rate that new targeted 
therapies are flooding the market. BRAF is a commonly deleted gene in approximately 8% 
of solid tumours, however over 30 different mutations in the BRAF gene have been 
implicated in cancer (Dienstmann&Tabernero 2011; Puzanov et al. 2011).  
5.3.4 A pathway-centric approach is needed 
As eluded to in our discussion of multiple pathways and feedback loops in any given target, 
we need to develop ways to target multiple points of a pathway akin to attacking the 
Achilles heel of the tumour. Recent data suggest that miRNA expression is tightly 
coordinated, and that each miRNA may target numerous messages. Thus, a specific miRNA 
has the potential to regulate several members of an entire signalling pathway. miRNAs 
negatively regulate their targets by one of two mechanisms: either by near perfect binding to 
the mRNA target and induction of miRNA-associated, multiprotein RNA-induced-silencing 
complex (miRISC), which results in accelerated mRNA decay (Yekta 2004; Wu 2006) or by 
less perfect binding to the target mRNA 3’-UTR and inhibition of translation through a RISC 
complex similar to, or identical with, the complex recruited in RNA interference (RNAi) 
(Humphreys et al. 2005; Pillai et al. 2005; Esquela-Kerscher&Slack 2006). 
miR-7 directly regulates the expression of EGFR in glioblastoma and has also been shown to 
directly attenuate the activation of AKT and ERK1/2 (extracellular signal-regulated kinase) 
indicating its ability to co-ordinately regulate EGFR signalling (Webster et al. 2009). We also 
showed that miR-124a attenuated glioblastoma migration and invasion at multiple points of 
the pathway (Fowler et al. 2011). New technologies are currently being developed to 
facilitate the use of miRNAs as a realistic therapeutic option. Until then, combination 
treatments and developing inhibitors which can affect a multiplicity of targets are critical. 
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5.3.5 Differing response criterion 
The inability to accurately define endpoints from clinical trials makes the evaluation of new 
therapies subjective and significantly delays treatment development. At present overall 
survival (OS) and 6 month progression free survival (PFS6) are two defined end points 
accepted in most clinical trials testing for new GBM therapies. PFS6 relies on a combination 
of gadolinium enhanced MRI imaging and potentially subjective clinical evaluation. 
Seizures, depression and steroid induced myopathy can all influence clinical signs and 
symptoms. Since 1990, the MacDonald criterion has been used as an objective radiologic 
assessment of response in GBM. This two dimensional measurement has been mainstay for 
evaluating tumour response and is based upon measurements of the enhancing tumour area 
(the product of the maximal cross-sectional enhancing diameters) (Macdonald et al. 1990). 
With the advance of treatments administered to patients with GBM, the MacDonald Criteria 
has a number of important limitations. The MacDonald criteria does not discriminate 
measurable disease from non-measureable disease, cannot identify non-tumour related 
increases in enhancement and provides no use for the evaluation of anti-angiogenic drugs. 
Bevacizumab can cause accelerated regression of VEGF driven angiogenesis and rapid 
resolution of gadolinium MRI changes in responding patients. There is concern however as 
to whether anti-VEGF therapy results in true glioma cell destruction or their ability to 
control the perivascular leak, resulting in better symptom control (associated with 
improvement of gadolinium MRI). 
An international working group was formed to review and improve the response 
assessment criteria for high grade gliomas, coined Response Assessment in Neuro-Oncology 
(RANO) (Wen et al. 2010). The guidelines have devised a better standardisation of how 
clinicians measure response, which will ultimately result in a more uniform assessment of 
disease status across different centres. Unfortunately, the new RANO guidelines do not 
address the persistent problem of the irregularity of gliomas and the difficulty of measuring 
tumours treated with anti-angiogenic drugs, suggesting that volumetric measurements that 
count all enhancing and non-enhancing voxels may prove more accurate in the future.The 
RANO working party acknowledges that an important area of future research is the need to 
develop advanced novel MRI techniques.  
5.3.6 Inadequate tissue 
Biobanks or biorepositories play a critical role in the evolution of biomarkers, targets and 
targeted therapies. Five years ago, the NCI announced their plans to enlist dozens of bio-
repositories in the USA to provide large tumour numbers and use high-throughput DNA 
sequencing and computational biology to produce with new methods of detecting and 
treating cancers. Unfortunately sub-standard tissue and data collection provided a 
significant road block to the Cancer Genome Atlas effort. Biorepositories remain 
underfunded and unappreciated. Despite billions of dollars poured into cancer research, 
innovation in the field of biobanking is sadly lacking. Standard operating procedures (SOPs) 
are not consistent between sites, and sometimes differ within single institutes. 
Methodologies for preserving tissue vary and times between tumour removal and time of 
processing fluctuate. Significant genetic changes can occur between the time of tissue 
removal from the body and time of processing. The collection of tissue has to be taken 
seriously and investments need to be urgently made to promote basic, translational and 
clinical research as well as social gain in terms of improved cancer care and economic 
development. 
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Collection and storage of frozen tissue is critical for biomarker development. Many of our 
current biomarker assays are performed on Formalin Fixed Paraffin Embedded (FFPE) 
tissue. This type of tissue, whilst preserving morphology for diagnosis, induces problems 
for downstream molecular applications. High quality RNA is difficult to obtain from FFPE 
tissue and PCR amplification from FFPE DNA is limited to products of less than 200 base 
pairs. It is also difficult to control the processes leading up to tissue fixation. In a first class 
Neuro-oncology centre in Australia, FFPE blocks were being sent to Central Headquarters 
for MGMT methylation detection. Unfortunately, a sizeable batch of tissues were non-
determinative (could not be amplified). Tissue from surgeries performed on a Friday were 
fixed in formalin, however the laboratory was unattended over the weekend, resulting in 
the tissue submerged in formalin for up to 72 hours (routinely, formalin should be removed 
after 24 hours). 
Another issue that we are not taking into careful consideration are the molecular changes 
acquired in the tumour after treatment. Many biomarker studies are performed on tumour 
obtained at initial surgery event. This tissue has not been exposed to treatment. However, 
the majority of novel treatments are tested at the time of recurrence. Changes in 
chromosome aberrations and mismatch repair proteins have been detected in paired tumour 
specimens (primary and relapsed). Careful consideration of the tissue and its relevance to 
the clinical circumstance of the patient is required.  
6. Future directions for biomarker development 
To advance personalised medicine, a co-operative effort between cancer researchers and 
clinicians is urgently needed. There is very little collaboration between scientists working on 
targeted therapies such as the TKIs and anti-angiogenics...what worked, what didn’t? 
Specific consideration needs to be paid to increasing sample sizes, sequencing entire genes, 
implementing robust methodologies and taking a holistic approach to understanding 
pathways. Cancer is multifaceted and we urgently need to unravel these complexities. Two 
prospective biomarker trials have been encouraging: the I-SPY 2 (investigation of serial 
studies to predict your therapeutic response with imaging and molecular analysis 2) for 
women with locally advanced breast cancer (Barker et al. 2009) and BATTLE (Biomarker 
Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) for pre-treated 
patients with non-small cell lung cancer (NSLC) (Kim 2011). Both trials employ an adaptive 
phase II/III clinical trial design. The I-SPY 2 is performed as a neo-adjuvant trial. A core 
biopsy is provided and tested for Estrogen Receptor (ER), Progesterone Receptor (PR), 
Human Epidermal Growth Factor Receptor 2 (HER2) and MammaPrint status (a gene 
signature known to be predictive of outcome). Based upon the marker outcomes, the 
patients will be stratified into two arms of a standard neoadjuvant regime: paclitaxel (plus 
trastuzumab [Herceptin] for HER2+ patients followed by doxorubicin (Adriamycin) and 
cyclophosphamide (Cytoxan). Five new drugs will be trialled in the other arms (each being 
added to the standard therapy). Patients are currently being recruited. The BATTLE trial 
takes on a very similar adaptive design but differs in its examination of samples from post-
treated NSLC. Key drugs and associated biomarkers (Erlotinib/EGFR; Vandetanib/VEGFR; 
Erlotinib + bexarotene/ Retinoid + EGFR and Sorafenib/ KRAS/BRAF) were tested both as 
an equal randomisation design and an adaptive randomisation design. This trial confirmed 
that tumours harbouring mutations in KRAS/BRAF showed a disease control of 79% when 
treated with sorafenib but only 14% of the patients responded to erlotinib. Conversely, 
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sorafenib, although active against wild type or mutated KRAS, had worse disease control in 
patients with EGFR mutations. A limitation in applying these adaptive trial designs to 
glioblastoma will be adequate numbers. Additionally, the BATTLE trial identified that 
grouping mutations together were less predictive than individual markers. This may also 
impact on a highly heterogenous cancer such as glioblastoma. Nevertheless, these trials 
show that, with a highly integrated team of multidisciplinary investigators, better overall 
survival in glioblastoma is achievable. 
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sorafenib, although active against wild type or mutated KRAS, had worse disease control in 
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show that, with a highly integrated team of multidisciplinary investigators, better overall 
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7. Acknowledgements 
I would like to acknowledge the support and financial assistance from the Cure For Life 
Foundation and the Cancer Institute NSW. 
8. References 
(2008). Comprehensive genomic characterization defines human glioblastoma genes and 
core pathways. Nature, Vol. 455, No. 7216, (Oct 23) pp. 1061-1068. 
Ahluwalia, M. S. (2011). 2010 Society for Neuro-Oncology Annual Meeting: a report of 
selected studies. Expert Rev Anticancer Ther, Vol. 11, No. 2, (Feb) pp. 161-163. 
Balss, J., et al. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta 
Neuropathol, Vol. 116, No. 6, (Dec) pp. 597-602. 
Barbashina, V., et al. (2005). Allelic losses at 1p36 and 19q13 in gliomas: correlation with 
histologic classification, definition of a 150-kb minimal deleted region on 1p36, and 
evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res, Vol. 
11, No. 3, (Feb 1) pp. 1119-1128. 
Barker, A. D., et al. (2009). I-SPY 2: an adaptive breast cancer trial design in the setting of 
neoadjuvant chemotherapy. Clin Pharmacol Ther, Vol. 86, No. 1, (Jul) pp. 97-100. 
Brandes, A. A., et al. (2001). Changing boundaries in the treatment of malignant gliomas. 
Expert Rev Anticancer Ther, Vol. 1, No. 3, (Oct) pp. 357-370. 
Brandes, A. A., et al. (2006). Temozolomide 3 weeks on and 1 week off as first-line therapy 
for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di 
neuro-oncologia (GICNO). Br J Cancer, Vol. 95, No. 9, (Nov 6) pp. 1155-1160. 
Brell, M., et al. (2005). Prognostic significance of O6-methylguanine-DNA methyltransferase 
determined by promoter hypermethylation and immunohistochemical expression 
in anaplastic gliomas. Clin Cancer Res, Vol. 11, No. 14, (Jul 15) pp. 5167-5174. 
Brock, C. S., et al. (1998). Phase I trial of temozolomide using an extended continuous oral 
schedule. Cancer Research, Vol. 58, No. 19, (Oct 1) pp. 4363-4367. 
Brown, P. D., et al. (2008). Phase I/II trial of erlotinib and temozolomide with radiation 
therapy in the treatment of newly diagnosed glioblastoma multiforme: North 
Central Cancer Treatment Group Study N0177. J Clin Oncol, Vol. 26, No. 34, (Dec 1) 
pp. 5603-5609. 
Buttolo, L., et al. (2006). Alternative schedules of adjuvant temozolomide in glioblastoma 
multiforme: A 6-year experience. Journal Of Clinical Oncology, Vol. 24, No. 18, (Jun 
20) pp. 60S-60S. 
Cairncross, G., et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared 
with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
69 
Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol, Vol. 24, No. 
18, (Jun 20) pp. 2707-2714. 
Calin, G. A., et al. (2002). Frequent deletions and down-regulation of micro- RNA genes 
miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S 
A, Vol. 99, No. 24, (Nov 26) pp. 15524-15529. 
Cao, V. T., et al. (2009). The correlation and prognostic significance of MGMT promoter 
methylation and MGMT protein in glioblastomas. Neurosurgery, Vol. 65, No. 5, 
(Nov) pp. 866-875; discussion 875. 
Chinot, O. L., et al. (2011). AVAglio: Phase 3 trial of bevacizumab plus temozolomide and 
radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther, Vol. 28, No. 4, 
(Apr) pp. 334-340. 
Christensen, B. C., et al. (2011). DNA methylation, isocitrate dehydrogenase mutation, and 
survival in glioma. J Natl Cancer Inst, Vol. 103, No. 2, (Jan 19) pp. 143-153. 
Colman, H., et al. (2010). A multigene predictor of outcome in glioblastoma. Neuro Oncol, 
Vol. 12, No. 1, (Jan) pp. 49-57. 
Conti, A., et al. (2009). miR-21 and 221 upregulation and miR-181b downregulation in 
human grade II-IV astrocytic tumors. J Neurooncol, Vol. 93, No. 3, (Jul) pp. 325-332. 
Dang, L., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. 
Nature, Vol. 462, No. 7274, (Dec 10) pp. 739-744. 
de Souza, J. A. and O. I. Olopade (2011). CYP2D6 genotyping and tamoxifen: an unfinished 
story in the quest for personalized medicine. Semin Oncol, Vol. 38, No. 2, (Apr) pp. 
263-273. 
di Tomaso, E., et al. (2011). Glioblastoma recurrence after cediranib therapy in patients: lack 
of "rebound" revascularization as mode of escape. Cancer Res, Vol. 71, No. 1, (Jan 1) 
pp. 19-28. 
Dienstmann, R. and J. Tabernero (2011). BRAF as a Target for Cancer Therapy. Anticancer 
Agents Med Chem, Vol. 11, No. 3, (Mar 1) pp. 285-295. 
Dietrich, J., et al. (2009). Cediranib: profile of a novel anti-angiogenic agent in patients with 
glioblastoma. Expert Opin Investig Drugs, Vol. 18, No. 10, (Oct) pp. 1549-1557. 
Dresemann, G., et al. (2010). Imatinib in combination with hydroxyurea versus hydroxyurea 
alone as oral therapy in patients with progressive pretreated glioblastoma resistant 
to standard dose temozolomide. J Neurooncol, Vol. 96, No. 3, (Feb) pp. 393-402. 
Ducray, F., et al. (2009). alpha-Internexin expression identifies 1p19q codeleted gliomas. 
Neurology, Vol. 72, No. 2, (Jan 13) pp. 156-161. 
Ducray, F., et al. (2008). Anaplastic oligodendrogliomas with 1p19q codeletion have a 
proneural gene expression profile. Mol Cancer, Vol. 7, No., pp. 41. 
Esquela-Kerscher, A. and F. J. Slack (2006). Oncomirs - microRNAs with a role in cancer. Nat 
Rev Cancer, Vol. 6, No. 4, (Apr) pp. 259-269. 
Esteller, M., et al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical 
response of gliomas to alkylating agents. N Engl J Med, Vol. 343, No. 19, (Nov 9) pp. 
1350-1354. 
Esteller, M., et al. (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA 
methyltransferase by promoter hypermethylation is a common event in primary 
human neoplasia. Cancer Res, Vol. 59, No. 4, (Feb 15) pp. 793-797. 
Fowler, A., et al. (2011). miR-124a is frequently down-regulated in glioblastoma and is 
involved in migration and invasion. Eur J Cancer, Vol. 47, No. 6, (Apr) pp. 953-963. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
70
Fuller, G. N. and B. W. Scheithauer (2007). The 2007 Revised World Health Organization 
(WHO) Classification of Tumours of the Central Nervous System: newly codified 
entities. Brain Pathol, Vol. 17, No. 3, (Jul) pp. 304-307. 
Gan, H. K., et al. (2009). The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci, 
Vol. 16, No. 6, (Jun) pp. 748-754. 
Gerson, S. L. (2004). MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev 
Cancer, Vol. 4, No. 4, (Apr) pp. 296-307. 
Gerstner, E. R., et al. (2011). Infiltrative patterns of glioblastoma spread detected via 
diffusion MRI after treatment with cediranib. Neuro Oncol, Vol. 12, No. 5, (May) pp. 
466-472. 
Goetz, M. P. (2010). Update on CYP2D6 and its impact on tamoxifen therapy. Clin Adv 
Hematol Oncol, Vol. 8, No. 8, (Aug) pp. 536-538. 
Hartmann, C., et al. (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit 
worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status 
accounts for the unfavorable prognostic effect of higher age: implications for 
classification of gliomas. Acta Neuropathol, Vol. 120, No. 6, (Dec) pp. 707-718. 
Hawkins, N. J., et al. (2009). MGMT methylation is associated primarily with the germline 
C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol, 
Vol. 22, No. 12, (Dec) pp. 1588-1599. 
Hegi, M. E., et al. (2005). MGMT gene silencing and benefit from temozolomide in 
glioblastoma. N Engl J Med, Vol. 352, No. 10, (Mar 10) pp. 997-1003. 
Hill, C., et al. (2003). Genetic markers in glioblastoma: prognostic significance and future 
therapeutic implications. Adv Anat Pathol, Vol. 10, No. 4, (Jul) pp. 212-217. 
Hofer, S., et al. (2011). Clinical outcome with bevacizumab in patients with recurrent high-
grade glioma treated outside clinical trials. Acta Oncol, Vol. 50, No. 5, (Jun) pp. 630-
635. 
Hormigo, A., et al. (2006). YKL-40 and matrix metalloproteinase-9 as potential serum 
biomarkers for patients with high-grade gliomas. Clin Cancer Res, Vol. 12, No. 19, 
(Oct 1) pp. 5698-5704. 
Hu, J. C. and K. Mokbel (2001). Does c-erbB2/HER2 overexpression predict adjuvant 
tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol, Vol. 27, No. 
4, (Jun) pp. 335-337. 
Humphreys, D. T., et al. (2005). MicroRNAs control translation initiation by inhibiting 
eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S 
A, Vol. 102, No. 47, (Nov 22) pp. 16961-16966. 
Inda, M. M., et al. (2010). Tumor heterogeneity is an active process maintained by a mutant 
EGFR-induced cytokine circuit in glioblastoma. Genes Dev, Vol. 24, No. 16, (Aug 15) 
pp. 1731-1745. 
Jakobsen, J. N., et al. (2011). Irinotecan and bevacizumab in recurrent glioblastoma 
multiforme. Expert Opin Pharmacother, Vol. 12, No. 5, (Apr) pp. 825-833. 
Jansen, M., et al. (2010). Molecular pathology in adult gliomas: diagnostic, prognostic, and 
predictive markers. Lancet Neurol, Vol. 9, No. 7, (Jul) pp. 717-726. 
Jenkins, R. B., et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q 
and predicts a better prognosis of patients with oligodendroglioma. Cancer Res, Vol. 
66, No. 20, (Oct 15) pp. 9852-9861. 
Ji, J., et al. (2009). MicroRNA expression, survival, and response to interferon in liver cancer. 
N Engl J Med, Vol. 361, No. 15, (Oct 8) pp. 1437-1447. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
71 
Kaloshi, G., et al. (2007). FABP7 expression in glioblastomas: relation to prognosis, invasion 
and EGFR status. J Neurooncol, Vol. 84, No. 3, (Sep) pp. 245-248. 
Kamiryo, T., et al. (2004). Correlation between promoter hypermethylation of the O6-
methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in 
patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 
1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-b ased 
chemotherapy. Neurosurgery, Vol. 54, No. 2, (Feb) pp. 349-357; discussion 357. 
Karayan-Tapon, L., et al. (2010). Prognostic value of O6-methylguanine-DNA 
methyltransferase status in glioblastoma patients, assessed by five different 
methods. Journal of neuro-oncology, Vol. 97, No. 3, pp. 311-322. 
Kefas, B., et al. (2009). The neuronal microRNA miR-326 acts in a feedback loop with notch 
and has therapeutic potential against brain tumors. J Neurosci, Vol. 29, No. 48, (Dec 
2) pp. 15161-15168. 
Kim, E., Herbst RS, Wistuba II, Lee IJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, 
Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, 
Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou, David SE, 
Lippman SM, Hong WK (2011). The BATTLE Trial: Personalizing Therapy for Lung 
Cancer. Cancer Discovery, Vol. 1, No. 1, pp. 43. 
Kim, H., et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating 
glioblastoma survivorship. Proc Natl Acad Sci U S A, Vol. 107, No. 5, (Feb 2) pp. 
2183-2188. 
Kim, H. P., et al. (2008). Combined lapatinib and cetuximab enhance cytotoxicity against 
gefitinib-resistant lung cancer cells. Mol Cancer Ther, Vol. 7, No. 3, (Mar) pp. 607-
615. 
Koch, D., et al. (2007). Local intracerebral administration of O(6)-benzylguanine combined 
with systemic chemotherapy with temozolomide of a patient suffering from a 
recurrent glioblastoma. J Neurooncol, Vol. 82, No. 1, (Mar) pp. 85-89. 
Kurokawa, H., et al. (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein 
kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-
resistant breast cancer cells. Cancer Res, Vol. 60, No. 20, (Oct 15) pp. 5887-5894. 
Lai, A., et al. (2011). Phase II study of bevacizumab plus temozolomide during and after 
radiation therapy for patients with newly diagnosed glioblastoma multiforme. J 
Clin Oncol, Vol. 29, No. 2, (Jan 10) pp. 142-148. 
Laigle-Donadey, F., et al. (2005). [Molecular biology of oligodendroglial tumors]. 
Neurochirurgie, Vol. 51, No. 3-4 Pt 2, (Sep) pp. 260-268. 
Layfield, L. J., et al. (2006). Epidermal growth factor receptor gene amplification and protein 
expression in glioblastoma multiforme: prognostic significance and relationship to 
other prognostic factors. Appl Immunohistochem Mol Morphol, Vol. 14, No. 1, (Mar) 
pp. 91-96. 
Li, Y., et al. (2009). MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in 
glioblastoma multiforme. Brain Res, Vol. 1286, No., (Aug 25) pp. 13-18. 
Liu, Q., et al. (2009). Molecular properties of CD133+ glioblastoma stem cells derived from 
treatment-refractory recurrent brain tumors. J Neurooncol, Vol. 94, No. 1, (Aug) pp. 
1-19. 
Macdonald, D. R., et al. (1990). Response criteria for phase II studies of supratentorial 
malignant glioma. J Clin Oncol, Vol. 8, No. 7, (Jul) pp. 1277-1280. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
70
Fuller, G. N. and B. W. Scheithauer (2007). The 2007 Revised World Health Organization 
(WHO) Classification of Tumours of the Central Nervous System: newly codified 
entities. Brain Pathol, Vol. 17, No. 3, (Jul) pp. 304-307. 
Gan, H. K., et al. (2009). The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci, 
Vol. 16, No. 6, (Jun) pp. 748-754. 
Gerson, S. L. (2004). MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev 
Cancer, Vol. 4, No. 4, (Apr) pp. 296-307. 
Gerstner, E. R., et al. (2011). Infiltrative patterns of glioblastoma spread detected via 
diffusion MRI after treatment with cediranib. Neuro Oncol, Vol. 12, No. 5, (May) pp. 
466-472. 
Goetz, M. P. (2010). Update on CYP2D6 and its impact on tamoxifen therapy. Clin Adv 
Hematol Oncol, Vol. 8, No. 8, (Aug) pp. 536-538. 
Hartmann, C., et al. (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit 
worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status 
accounts for the unfavorable prognostic effect of higher age: implications for 
classification of gliomas. Acta Neuropathol, Vol. 120, No. 6, (Dec) pp. 707-718. 
Hawkins, N. J., et al. (2009). MGMT methylation is associated primarily with the germline 
C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol, 
Vol. 22, No. 12, (Dec) pp. 1588-1599. 
Hegi, M. E., et al. (2005). MGMT gene silencing and benefit from temozolomide in 
glioblastoma. N Engl J Med, Vol. 352, No. 10, (Mar 10) pp. 997-1003. 
Hill, C., et al. (2003). Genetic markers in glioblastoma: prognostic significance and future 
therapeutic implications. Adv Anat Pathol, Vol. 10, No. 4, (Jul) pp. 212-217. 
Hofer, S., et al. (2011). Clinical outcome with bevacizumab in patients with recurrent high-
grade glioma treated outside clinical trials. Acta Oncol, Vol. 50, No. 5, (Jun) pp. 630-
635. 
Hormigo, A., et al. (2006). YKL-40 and matrix metalloproteinase-9 as potential serum 
biomarkers for patients with high-grade gliomas. Clin Cancer Res, Vol. 12, No. 19, 
(Oct 1) pp. 5698-5704. 
Hu, J. C. and K. Mokbel (2001). Does c-erbB2/HER2 overexpression predict adjuvant 
tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol, Vol. 27, No. 
4, (Jun) pp. 335-337. 
Humphreys, D. T., et al. (2005). MicroRNAs control translation initiation by inhibiting 
eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S 
A, Vol. 102, No. 47, (Nov 22) pp. 16961-16966. 
Inda, M. M., et al. (2010). Tumor heterogeneity is an active process maintained by a mutant 
EGFR-induced cytokine circuit in glioblastoma. Genes Dev, Vol. 24, No. 16, (Aug 15) 
pp. 1731-1745. 
Jakobsen, J. N., et al. (2011). Irinotecan and bevacizumab in recurrent glioblastoma 
multiforme. Expert Opin Pharmacother, Vol. 12, No. 5, (Apr) pp. 825-833. 
Jansen, M., et al. (2010). Molecular pathology in adult gliomas: diagnostic, prognostic, and 
predictive markers. Lancet Neurol, Vol. 9, No. 7, (Jul) pp. 717-726. 
Jenkins, R. B., et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q 
and predicts a better prognosis of patients with oligodendroglioma. Cancer Res, Vol. 
66, No. 20, (Oct 15) pp. 9852-9861. 
Ji, J., et al. (2009). MicroRNA expression, survival, and response to interferon in liver cancer. 
N Engl J Med, Vol. 361, No. 15, (Oct 8) pp. 1437-1447. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
71 
Kaloshi, G., et al. (2007). FABP7 expression in glioblastomas: relation to prognosis, invasion 
and EGFR status. J Neurooncol, Vol. 84, No. 3, (Sep) pp. 245-248. 
Kamiryo, T., et al. (2004). Correlation between promoter hypermethylation of the O6-
methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in 
patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 
1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-b ased 
chemotherapy. Neurosurgery, Vol. 54, No. 2, (Feb) pp. 349-357; discussion 357. 
Karayan-Tapon, L., et al. (2010). Prognostic value of O6-methylguanine-DNA 
methyltransferase status in glioblastoma patients, assessed by five different 
methods. Journal of neuro-oncology, Vol. 97, No. 3, pp. 311-322. 
Kefas, B., et al. (2009). The neuronal microRNA miR-326 acts in a feedback loop with notch 
and has therapeutic potential against brain tumors. J Neurosci, Vol. 29, No. 48, (Dec 
2) pp. 15161-15168. 
Kim, E., Herbst RS, Wistuba II, Lee IJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, 
Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, 
Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou, David SE, 
Lippman SM, Hong WK (2011). The BATTLE Trial: Personalizing Therapy for Lung 
Cancer. Cancer Discovery, Vol. 1, No. 1, pp. 43. 
Kim, H., et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating 
glioblastoma survivorship. Proc Natl Acad Sci U S A, Vol. 107, No. 5, (Feb 2) pp. 
2183-2188. 
Kim, H. P., et al. (2008). Combined lapatinib and cetuximab enhance cytotoxicity against 
gefitinib-resistant lung cancer cells. Mol Cancer Ther, Vol. 7, No. 3, (Mar) pp. 607-
615. 
Koch, D., et al. (2007). Local intracerebral administration of O(6)-benzylguanine combined 
with systemic chemotherapy with temozolomide of a patient suffering from a 
recurrent glioblastoma. J Neurooncol, Vol. 82, No. 1, (Mar) pp. 85-89. 
Kurokawa, H., et al. (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein 
kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-
resistant breast cancer cells. Cancer Res, Vol. 60, No. 20, (Oct 15) pp. 5887-5894. 
Lai, A., et al. (2011). Phase II study of bevacizumab plus temozolomide during and after 
radiation therapy for patients with newly diagnosed glioblastoma multiforme. J 
Clin Oncol, Vol. 29, No. 2, (Jan 10) pp. 142-148. 
Laigle-Donadey, F., et al. (2005). [Molecular biology of oligodendroglial tumors]. 
Neurochirurgie, Vol. 51, No. 3-4 Pt 2, (Sep) pp. 260-268. 
Layfield, L. J., et al. (2006). Epidermal growth factor receptor gene amplification and protein 
expression in glioblastoma multiforme: prognostic significance and relationship to 
other prognostic factors. Appl Immunohistochem Mol Morphol, Vol. 14, No. 1, (Mar) 
pp. 91-96. 
Li, Y., et al. (2009). MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in 
glioblastoma multiforme. Brain Res, Vol. 1286, No., (Aug 25) pp. 13-18. 
Liu, Q., et al. (2009). Molecular properties of CD133+ glioblastoma stem cells derived from 
treatment-refractory recurrent brain tumors. J Neurooncol, Vol. 94, No. 1, (Aug) pp. 
1-19. 
Macdonald, D. R., et al. (1990). Response criteria for phase II studies of supratentorial 
malignant glioma. J Clin Oncol, Vol. 8, No. 7, (Jul) pp. 1277-1280. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
72
Mao, X. G., et al. (2011). Overexpression of ZNF217 in glioblastoma contributes to the 
maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest, 
Vol., No., (Apr 11). 
Mellai, M., et al. (2009). MGMT promoter hypermethylation in a series of 104 glioblastomas. 
Cancer Genomics Proteomics, Vol. 6, No. 4, (Jul-Aug) pp. 219-227. 
Mellinghoff, I. K., et al. (2005). Molecular determinants of the response of glioblastomas to 
EGFR kinase inhibitors. N Engl J Med, Vol. 353, No. 19, (Nov 10) pp. 2012-2024. 
Mikkelsen, T., et al. (2009). Temozolomide single-agent chemotherapy for newly diagnosed 
anaplastic oligodendroglioma. Journal of neuro-oncology, Vol. 92, No. 1, pp. 57-63. 
Mokhtari, K., et al. (2011). Alpha-internexin expression predicts outcome in anaplastic 
oligodendroglial tumors and may positively impact the efficacy of chemotherapy: 
European organization for research and treatment of cancer trial 26951. Cancer, 
Vol., No., (Jan 18). 
Mukasa, A., et al. (2004). Selective expression of a subset of neuronal genes in 
oligodendroglioma with chromosome 1p loss. Brain Pathol, Vol. 14, No. 1, (Jan) pp. 
34-42. 
Mukasa, A., et al. (2002). Distinction in gene expression profiles of oligodendrogliomas with 
and without allelic loss of 1p. Oncogene, Vol. 21, No. 25, (Jun 6) pp. 3961-3968. 
Nakamura, M., et al. (2001). Promoter methylation of the DNA repair gene MGMT in 
astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 
tumor suppressor gene. Carcinogenesis, Vol. 22, No. 10, (Oct) pp. 1715-1719. 
Newlands, E. S., et al. (2003). Phase I study of temozolamide (TMZ) combined with 
procarbazine (PCB) in patients with gliomas. Br J Cancer, Vol. 89, No. 2, (Jul 21) pp. 
248-251. 
Noushmehr, H., et al. (2010). Identification of a CpG island methylator phenotype that 
defines a distinct subgroup of glioma. Cancer Cell, Vol. 17, No. 5, (May 18) pp. 510-
522. 
Nutt, C. L., et al. (2003). Gene expression-based classification of malignant gliomas 
correlates better with survival than histological classification. Cancer Res, Vol. 63, 
No. 7, (Apr 1) pp. 1602-1607. 
Parsa, A. T., et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 
expression and immunoresistance in glioma. Nat Med, Vol. 13, No. 1, (Jan) pp. 84-
88. 
Parsons, D. W., et al. (2008). An integrated genomic analysis of human glioblastoma 
multiforme. Science, Vol. 321, No. 5897, (Sep 26) pp. 1807-1812. 
Paz-Ares, L., et al. (2010). Clinical outcomes in non-small-cell lung cancer patients with 
EGFR mutations: pooled analysis. J Cell Mol Med, Vol. 14, No. 1-2, (Jan) pp. 51-69. 
Paz, M. F., et al. (2004). CpG island hypermethylation of the DNA repair enzyme 
methyltransferase predicts response to temozolomide in primary gliomas. Clin 
Cancer Res, Vol. 10, No. 15, (Aug 1) pp. 4933-4938. 
Pegg, A. E. (1990). Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and 
importance in response to alkylating carcinogenic and therapeutic agents. Cancer 
Res, Vol. 50, No. 19, (Oct 1) pp. 6119-6129. 
Pelloski, C. E., et al. (2007). Epidermal growth factor receptor variant III status defines 
clinically distinct subtypes of glioblastoma. J Clin Oncol, Vol. 25, No. 16, (Jun 1) pp. 
2288-2294. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
73 
Perry, J. R., et al. (2010). Phase II trial of continuous dose-intense temozolomide in recurrent 
malignant glioma: RESCUE study. J Clin Oncol, Vol. 28, No. 12, (Apr 20) pp. 2051-
2057. 
Perry, J. R., et al. (2008). Temozolomide rechallenge in recurrent malignant glioma by using 
a continuous temozolomide schedule: the "rescue" approach. Cancer, Vol. 113, No. 
8, (Oct 15) pp. 2152-2157. 
Phillips, H. S., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, 
delineate a pattern of disease progression, and resemble stages in neurogenesis. 
Cancer Cell, Vol. 9, No. 3, (Mar) pp. 157-173. 
Pierson, J., et al. (2008). Regulation of cyclin dependent kinase 6 by microRNA 124 in 
medulloblastoma. J Neurooncol, Vol. 90, No. 1, (Oct) pp. 1-7. 
Pillai, R. S., et al. (2005). Inhibition of translational initiation by Let-7 MicroRNA in human 
cells. Science, Vol. 309, No. 5740, (Sep 2) pp. 1573-1576. 
Prados, M., et al. (2011). Response as a predictor of survival in patients with recurrent 
glioblastoma treated with bevacizumab. Neuro Oncol, Vol. 13, No. 1, (Jan) pp. 143-
151. 
Prados, M. D., et al. (2009). Phase II study of erlotinib plus temozolomide during and after 
radiation therapy in patients with newly diagnosed glioblastoma multiforme or 
gliosarcoma. J Clin Oncol, Vol. 27, No. 4, (Feb 1) pp. 579-584. 
Prasad, G., et al. (2011). Inhibition of PI3K/mTOR pathways in glioblastoma and 
implications for combination therapy with temozolomide. Neuro Oncol, Vol. 13, No. 
4, (Apr) pp. 384-392. 
Preusser, M., et al. (2008). Anti-O6-methylguanine-methyltransferase (MGMT) 
immunohistochemistry in glioblastoma multiforme: observer variability and lack of 
association with patient survival impede its use as clinical biomarker. Brain Pathol, 
Vol. 18, No. 4, (Oct) pp. 520-532. 
Puzanov, I., et al. (2011). Biological challenges of BRAF inhibitor therapy. Mol Oncol, Vol. 5, 
No. 2, (Apr) pp. 116-123. 
Quinn, J. A., et al. (2005). Phase I trial of temozolomide plus O6-benzylguanine for patients 
with recurrent or progressive malignant glioma. J Clin Oncol, Vol. 23, No. 28, (Oct 1) 
pp. 7178-7187. 
Quinn, J. A., et al. (2002). Phase II trial of carmustine plus O(6)-benzylguanine for patients 
with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol, 
Vol. 20, No. 9, (May 1) pp. 2277-2283. 
Ramirez, C., et al. (2010). Loss of 1p, 19q, and 10q heterozygosity prospectively predicts 
prognosis of oligodendroglial tumors--towards individualized tumor treatment? 
Neuro-oncology, Vol. 12, No. 5, pp. 490-499. 
Reardon, D. A., et al. (2010). Phase 2 trial of erlotinib plus sirolimus in adults with recurrent 
glioblastoma. J Neurooncol, Vol. 96, No. 2, (Jan) pp. 219-230. 
Reardon, D. A., et al. (2011). Cilengitide: an RGD pentapeptide alphanubeta3 and 
alphanubeta5 integrin inhibitor in development for glioblastoma and other 
malignancies. Future Oncol, Vol. 7, No. 3, (Mar) pp. 339-354. 
Reitman, Z. J., et al. (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 
mutations on the cellular metabolome. Proc Natl Acad Sci U S A, Vol. 108, No. 8, 
(Feb 22) pp. 3270-3275. 
Reitman, Z. J., et al. (2010). IDH1 and IDH2: not your typical oncogenes. Cancer Cell, Vol. 17, 
No. 3, (Mar 16) pp. 215-216. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
72
Mao, X. G., et al. (2011). Overexpression of ZNF217 in glioblastoma contributes to the 
maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest, 
Vol., No., (Apr 11). 
Mellai, M., et al. (2009). MGMT promoter hypermethylation in a series of 104 glioblastomas. 
Cancer Genomics Proteomics, Vol. 6, No. 4, (Jul-Aug) pp. 219-227. 
Mellinghoff, I. K., et al. (2005). Molecular determinants of the response of glioblastomas to 
EGFR kinase inhibitors. N Engl J Med, Vol. 353, No. 19, (Nov 10) pp. 2012-2024. 
Mikkelsen, T., et al. (2009). Temozolomide single-agent chemotherapy for newly diagnosed 
anaplastic oligodendroglioma. Journal of neuro-oncology, Vol. 92, No. 1, pp. 57-63. 
Mokhtari, K., et al. (2011). Alpha-internexin expression predicts outcome in anaplastic 
oligodendroglial tumors and may positively impact the efficacy of chemotherapy: 
European organization for research and treatment of cancer trial 26951. Cancer, 
Vol., No., (Jan 18). 
Mukasa, A., et al. (2004). Selective expression of a subset of neuronal genes in 
oligodendroglioma with chromosome 1p loss. Brain Pathol, Vol. 14, No. 1, (Jan) pp. 
34-42. 
Mukasa, A., et al. (2002). Distinction in gene expression profiles of oligodendrogliomas with 
and without allelic loss of 1p. Oncogene, Vol. 21, No. 25, (Jun 6) pp. 3961-3968. 
Nakamura, M., et al. (2001). Promoter methylation of the DNA repair gene MGMT in 
astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 
tumor suppressor gene. Carcinogenesis, Vol. 22, No. 10, (Oct) pp. 1715-1719. 
Newlands, E. S., et al. (2003). Phase I study of temozolamide (TMZ) combined with 
procarbazine (PCB) in patients with gliomas. Br J Cancer, Vol. 89, No. 2, (Jul 21) pp. 
248-251. 
Noushmehr, H., et al. (2010). Identification of a CpG island methylator phenotype that 
defines a distinct subgroup of glioma. Cancer Cell, Vol. 17, No. 5, (May 18) pp. 510-
522. 
Nutt, C. L., et al. (2003). Gene expression-based classification of malignant gliomas 
correlates better with survival than histological classification. Cancer Res, Vol. 63, 
No. 7, (Apr 1) pp. 1602-1607. 
Parsa, A. T., et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 
expression and immunoresistance in glioma. Nat Med, Vol. 13, No. 1, (Jan) pp. 84-
88. 
Parsons, D. W., et al. (2008). An integrated genomic analysis of human glioblastoma 
multiforme. Science, Vol. 321, No. 5897, (Sep 26) pp. 1807-1812. 
Paz-Ares, L., et al. (2010). Clinical outcomes in non-small-cell lung cancer patients with 
EGFR mutations: pooled analysis. J Cell Mol Med, Vol. 14, No. 1-2, (Jan) pp. 51-69. 
Paz, M. F., et al. (2004). CpG island hypermethylation of the DNA repair enzyme 
methyltransferase predicts response to temozolomide in primary gliomas. Clin 
Cancer Res, Vol. 10, No. 15, (Aug 1) pp. 4933-4938. 
Pegg, A. E. (1990). Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and 
importance in response to alkylating carcinogenic and therapeutic agents. Cancer 
Res, Vol. 50, No. 19, (Oct 1) pp. 6119-6129. 
Pelloski, C. E., et al. (2007). Epidermal growth factor receptor variant III status defines 
clinically distinct subtypes of glioblastoma. J Clin Oncol, Vol. 25, No. 16, (Jun 1) pp. 
2288-2294. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
73 
Perry, J. R., et al. (2010). Phase II trial of continuous dose-intense temozolomide in recurrent 
malignant glioma: RESCUE study. J Clin Oncol, Vol. 28, No. 12, (Apr 20) pp. 2051-
2057. 
Perry, J. R., et al. (2008). Temozolomide rechallenge in recurrent malignant glioma by using 
a continuous temozolomide schedule: the "rescue" approach. Cancer, Vol. 113, No. 
8, (Oct 15) pp. 2152-2157. 
Phillips, H. S., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, 
delineate a pattern of disease progression, and resemble stages in neurogenesis. 
Cancer Cell, Vol. 9, No. 3, (Mar) pp. 157-173. 
Pierson, J., et al. (2008). Regulation of cyclin dependent kinase 6 by microRNA 124 in 
medulloblastoma. J Neurooncol, Vol. 90, No. 1, (Oct) pp. 1-7. 
Pillai, R. S., et al. (2005). Inhibition of translational initiation by Let-7 MicroRNA in human 
cells. Science, Vol. 309, No. 5740, (Sep 2) pp. 1573-1576. 
Prados, M., et al. (2011). Response as a predictor of survival in patients with recurrent 
glioblastoma treated with bevacizumab. Neuro Oncol, Vol. 13, No. 1, (Jan) pp. 143-
151. 
Prados, M. D., et al. (2009). Phase II study of erlotinib plus temozolomide during and after 
radiation therapy in patients with newly diagnosed glioblastoma multiforme or 
gliosarcoma. J Clin Oncol, Vol. 27, No. 4, (Feb 1) pp. 579-584. 
Prasad, G., et al. (2011). Inhibition of PI3K/mTOR pathways in glioblastoma and 
implications for combination therapy with temozolomide. Neuro Oncol, Vol. 13, No. 
4, (Apr) pp. 384-392. 
Preusser, M., et al. (2008). Anti-O6-methylguanine-methyltransferase (MGMT) 
immunohistochemistry in glioblastoma multiforme: observer variability and lack of 
association with patient survival impede its use as clinical biomarker. Brain Pathol, 
Vol. 18, No. 4, (Oct) pp. 520-532. 
Puzanov, I., et al. (2011). Biological challenges of BRAF inhibitor therapy. Mol Oncol, Vol. 5, 
No. 2, (Apr) pp. 116-123. 
Quinn, J. A., et al. (2005). Phase I trial of temozolomide plus O6-benzylguanine for patients 
with recurrent or progressive malignant glioma. J Clin Oncol, Vol. 23, No. 28, (Oct 1) 
pp. 7178-7187. 
Quinn, J. A., et al. (2002). Phase II trial of carmustine plus O(6)-benzylguanine for patients 
with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol, 
Vol. 20, No. 9, (May 1) pp. 2277-2283. 
Ramirez, C., et al. (2010). Loss of 1p, 19q, and 10q heterozygosity prospectively predicts 
prognosis of oligodendroglial tumors--towards individualized tumor treatment? 
Neuro-oncology, Vol. 12, No. 5, pp. 490-499. 
Reardon, D. A., et al. (2010). Phase 2 trial of erlotinib plus sirolimus in adults with recurrent 
glioblastoma. J Neurooncol, Vol. 96, No. 2, (Jan) pp. 219-230. 
Reardon, D. A., et al. (2011). Cilengitide: an RGD pentapeptide alphanubeta3 and 
alphanubeta5 integrin inhibitor in development for glioblastoma and other 
malignancies. Future Oncol, Vol. 7, No. 3, (Mar) pp. 339-354. 
Reitman, Z. J., et al. (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 
mutations on the cellular metabolome. Proc Natl Acad Sci U S A, Vol. 108, No. 8, 
(Feb 22) pp. 3270-3275. 
Reitman, Z. J., et al. (2010). IDH1 and IDH2: not your typical oncogenes. Cancer Cell, Vol. 17, 
No. 3, (Mar 16) pp. 215-216. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
74
Reitman, Z. J. and H. Yan (2010). Isocitrate dehydrogenase 1 and 2 mutations in cancer: 
alterations at a crossroads of cellular metabolism. J Natl Cancer Inst, Vol. 102, No. 
13, (Jul 7) pp. 932-941. 
Ruano, Y., et al. (2009). Worse outcome in primary glioblastoma multiforme with concurrent 
epidermal growth factor receptor and p53 alteration. Am J Clin Pathol, Vol. 131, No. 
2, (Feb) pp. 257-263. 
Saidi, A., et al. (2009). Combined targeting of interleukin-6 and vascular endothelial growth 
factor potently inhibits glioma growth and invasiveness. Int J Cancer, Vol. 125, No. 
5, (Sep 1) pp. 1054-1064. 
Salter, K. H., et al. (2008). An integrated approach to the prediction of chemotherapeutic 
response in patients with breast cancer. PLoS One, Vol. 3, No. 4, pp. e1908. 
Sampson, J. H., et al. (2011). Greater chemotherapy-induced lymphopenia enhances tumor-
specific immune responses that eliminate EGFRvIII-expressing tumor cells in 
patients with glioblastoma. Neuro Oncol, Vol. 13, No. 3, (Mar) pp. 324-333. 
Sasayama, T., et al. (2009). MicroRNA-10b is overexpressed in malignant glioma and 
associated with tumor invasive factors, uPAR and RhoC. Int J Cancer, Vol. 125, No. 
6, (Sep 15) pp. 1407-1413. 
Sawlani, R. N., et al. (2011). Glioblastoma: a method for predicting response to 
antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. 
Radiology, Vol. 255, No. 2, (May) pp. 622-628. 
Server, A., et al. (2011). Diagnostic examination performance by using microvascular 
leakage, cerebral blood volume, and blood flow derived from 3-T dynamic 
susceptibility-weighted contrast-enhanced perfusion MR imaging in the 
differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology, 
Vol. 53, No. 5, (May) pp. 319-330. 
Settle, S. H. and E. P. Sulman (2011). Tumor profiling: development of prognostic and 
predictive factors to guide brain tumor treatment. Curr Oncol Rep, Vol. 13, No. 1, 
(Feb) pp. 26-36. 
Shi, L., et al. (2008). hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human 
glioma cells. Brain Res, Vol. 1236, No., (Oct 21) pp. 185-193. 
Shinojima, N., et al. (2003). Prognostic value of epidermal growth factor receptor in patients 
with glioblastoma multiforme. Cancer Res, Vol. 63, No. 20, (Oct 15) pp. 6962-6970. 
Shiraishi, S., et al. (2002). Influence of p53 mutations on prognosis of patients with 
glioblastoma. Cancer, Vol. 95, No. 2, (Jul 15) pp. 249-257. 
Silber, J., et al. (2008). miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme 
cells and induce differentiation of brain tumor stem cells. BMC Med, Vol. 6, No., pp. 
14. 
Silber, J. R., et al. (1998). O6-methylguanine-DNA methyltransferase activity in adult 
gliomas: relation to patient and tumor characteristics. Cancer Res, Vol. 58, No. 5, 
(Mar 1) pp. 1068-1073. 
Sorensen, A. G., et al. (2009). A "vascular normalization index" as potential mechanistic 
biomarker to predict survival after a single dose of cediranib in recurrent 
glioblastoma patients. Cancer Res, Vol. 69, No. 13, (Jul 1) pp. 5296-5300. 
Sreekanthreddy, P., et al. (2010). Identification of potential serum biomarkers of 
glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer 
Epidemiol Biomarkers Prev, Vol. 19, No. 6, (Jun) pp. 1409-1422. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
75 
Stingl, J. C., et al. (2010). Impact of CYP2D6*4 genotype on progression free survival in 
tamoxifen breast cancer treatment. Curr Med Res Opin, Vol. 26, No. 11, (Nov) pp. 
2535-2542. 
Stupp, R., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised phase III 
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, Vol. 10, No. 5, (May) 
pp. 459-466. 
Stupp, R., et al. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant 
radiotherapy followed by cilengitide and temozolomide maintenance therapy in 
patients with newly diagnosed glioblastoma. J Clin Oncol, Vol. 28, No. 16, (Jun 1) 
pp. 2712-2718. 
Stupp, R., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med, Vol. 352, No. 10, (Mar 10) pp. 987-996. 
Tews, B., et al. (2006). Identification of novel oligodendroglioma-associated candidate tumor 
suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. 
Int J Cancer, Vol. 119, No. 4, (Aug 15) pp. 792-800. 
Tews, B., et al. (2007). Hypermethylation and transcriptional downregulation of the CITED4 
gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. 
Oncogene, Vol. 26, No. 34, (Jul 26) pp. 5010-5016. 
Thiessen, B., et al. (2010). A phase I/II trial of GW572016 (lapatinib) in recurrent 
glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular 
correlation. Cancer Chemother Pharmacol, Vol. 65, No. 2, (Jan) pp. 353-361. 
Tolcher, A. W., et al. (2003). Marked inactivation of O-6-alkylguanine-DNA alkyltransferase 
activity with protracted temozolomide schedules. British Journal Of Cancer, Vol. 88, 
No. 7, (Apr 7) pp. 1004-1011. 
Tsien, C., et al. (2011). Parametric response map as an imaging biomarker to distinguish 
progression from pseudoprogression in high-grade glioma. J Clin Oncol, Vol. 28, 
No. 13, (May 1) pp. 2293-2299. 
Uhm, J. H., et al. (2010). Phase II Evaluation of Gefitinib in Patients with Newly Diagnosed 
Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. 
Int J Radiat Oncol Biol Phys, Vol., No., (May 24). 
van den Bent, M. J., et al. (2009). Randomized phase II trial of erlotinib versus temozolomide 
or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J 
Clin Oncol, Vol. 27, No. 8, (Mar 10) pp. 1268-1274. 
van den Bent, M. J., et al. (2006). Adjuvant procarbazine, lomustine, and vincristine 
improves progression-free survival but not overall survival in newly diagnosed 
anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European 
Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol, Vol. 
24, No. 18, (Jun 20) pp. 2715-2722. 
Verhaak, R. G., et al. (2010). Integrated genomic analysis identifies clinically relevant 
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, 
and NF1. Cancer Cell, Vol. 17, No. 1, (Jan 19) pp. 98-110. 
Verhaak, R. G. and P. J. Valk (2010). Genes predictive of outcome and novel molecular 
classification schemes in adult acute myeloid leukemia. Cancer Treat Res, Vol. 145, 
No., pp. 67-83. 
Vredenburgh, J. J., et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma 
multiforme. J Clin Oncol, Vol. 25, No. 30, (Oct 20) pp. 4722-4729. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
74
Reitman, Z. J. and H. Yan (2010). Isocitrate dehydrogenase 1 and 2 mutations in cancer: 
alterations at a crossroads of cellular metabolism. J Natl Cancer Inst, Vol. 102, No. 
13, (Jul 7) pp. 932-941. 
Ruano, Y., et al. (2009). Worse outcome in primary glioblastoma multiforme with concurrent 
epidermal growth factor receptor and p53 alteration. Am J Clin Pathol, Vol. 131, No. 
2, (Feb) pp. 257-263. 
Saidi, A., et al. (2009). Combined targeting of interleukin-6 and vascular endothelial growth 
factor potently inhibits glioma growth and invasiveness. Int J Cancer, Vol. 125, No. 
5, (Sep 1) pp. 1054-1064. 
Salter, K. H., et al. (2008). An integrated approach to the prediction of chemotherapeutic 
response in patients with breast cancer. PLoS One, Vol. 3, No. 4, pp. e1908. 
Sampson, J. H., et al. (2011). Greater chemotherapy-induced lymphopenia enhances tumor-
specific immune responses that eliminate EGFRvIII-expressing tumor cells in 
patients with glioblastoma. Neuro Oncol, Vol. 13, No. 3, (Mar) pp. 324-333. 
Sasayama, T., et al. (2009). MicroRNA-10b is overexpressed in malignant glioma and 
associated with tumor invasive factors, uPAR and RhoC. Int J Cancer, Vol. 125, No. 
6, (Sep 15) pp. 1407-1413. 
Sawlani, R. N., et al. (2011). Glioblastoma: a method for predicting response to 
antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. 
Radiology, Vol. 255, No. 2, (May) pp. 622-628. 
Server, A., et al. (2011). Diagnostic examination performance by using microvascular 
leakage, cerebral blood volume, and blood flow derived from 3-T dynamic 
susceptibility-weighted contrast-enhanced perfusion MR imaging in the 
differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology, 
Vol. 53, No. 5, (May) pp. 319-330. 
Settle, S. H. and E. P. Sulman (2011). Tumor profiling: development of prognostic and 
predictive factors to guide brain tumor treatment. Curr Oncol Rep, Vol. 13, No. 1, 
(Feb) pp. 26-36. 
Shi, L., et al. (2008). hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human 
glioma cells. Brain Res, Vol. 1236, No., (Oct 21) pp. 185-193. 
Shinojima, N., et al. (2003). Prognostic value of epidermal growth factor receptor in patients 
with glioblastoma multiforme. Cancer Res, Vol. 63, No. 20, (Oct 15) pp. 6962-6970. 
Shiraishi, S., et al. (2002). Influence of p53 mutations on prognosis of patients with 
glioblastoma. Cancer, Vol. 95, No. 2, (Jul 15) pp. 249-257. 
Silber, J., et al. (2008). miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme 
cells and induce differentiation of brain tumor stem cells. BMC Med, Vol. 6, No., pp. 
14. 
Silber, J. R., et al. (1998). O6-methylguanine-DNA methyltransferase activity in adult 
gliomas: relation to patient and tumor characteristics. Cancer Res, Vol. 58, No. 5, 
(Mar 1) pp. 1068-1073. 
Sorensen, A. G., et al. (2009). A "vascular normalization index" as potential mechanistic 
biomarker to predict survival after a single dose of cediranib in recurrent 
glioblastoma patients. Cancer Res, Vol. 69, No. 13, (Jul 1) pp. 5296-5300. 
Sreekanthreddy, P., et al. (2010). Identification of potential serum biomarkers of 
glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer 
Epidemiol Biomarkers Prev, Vol. 19, No. 6, (Jun) pp. 1409-1422. 
Biomarker Discovery, Validation and Clinical 
Application for Patients Diagnosed with Glioma 
 
75 
Stingl, J. C., et al. (2010). Impact of CYP2D6*4 genotype on progression free survival in 
tamoxifen breast cancer treatment. Curr Med Res Opin, Vol. 26, No. 11, (Nov) pp. 
2535-2542. 
Stupp, R., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised phase III 
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, Vol. 10, No. 5, (May) 
pp. 459-466. 
Stupp, R., et al. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant 
radiotherapy followed by cilengitide and temozolomide maintenance therapy in 
patients with newly diagnosed glioblastoma. J Clin Oncol, Vol. 28, No. 16, (Jun 1) 
pp. 2712-2718. 
Stupp, R., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med, Vol. 352, No. 10, (Mar 10) pp. 987-996. 
Tews, B., et al. (2006). Identification of novel oligodendroglioma-associated candidate tumor 
suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. 
Int J Cancer, Vol. 119, No. 4, (Aug 15) pp. 792-800. 
Tews, B., et al. (2007). Hypermethylation and transcriptional downregulation of the CITED4 
gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. 
Oncogene, Vol. 26, No. 34, (Jul 26) pp. 5010-5016. 
Thiessen, B., et al. (2010). A phase I/II trial of GW572016 (lapatinib) in recurrent 
glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular 
correlation. Cancer Chemother Pharmacol, Vol. 65, No. 2, (Jan) pp. 353-361. 
Tolcher, A. W., et al. (2003). Marked inactivation of O-6-alkylguanine-DNA alkyltransferase 
activity with protracted temozolomide schedules. British Journal Of Cancer, Vol. 88, 
No. 7, (Apr 7) pp. 1004-1011. 
Tsien, C., et al. (2011). Parametric response map as an imaging biomarker to distinguish 
progression from pseudoprogression in high-grade glioma. J Clin Oncol, Vol. 28, 
No. 13, (May 1) pp. 2293-2299. 
Uhm, J. H., et al. (2010). Phase II Evaluation of Gefitinib in Patients with Newly Diagnosed 
Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. 
Int J Radiat Oncol Biol Phys, Vol., No., (May 24). 
van den Bent, M. J., et al. (2009). Randomized phase II trial of erlotinib versus temozolomide 
or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J 
Clin Oncol, Vol. 27, No. 8, (Mar 10) pp. 1268-1274. 
van den Bent, M. J., et al. (2006). Adjuvant procarbazine, lomustine, and vincristine 
improves progression-free survival but not overall survival in newly diagnosed 
anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European 
Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol, Vol. 
24, No. 18, (Jun 20) pp. 2715-2722. 
Verhaak, R. G., et al. (2010). Integrated genomic analysis identifies clinically relevant 
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, 
and NF1. Cancer Cell, Vol. 17, No. 1, (Jan 19) pp. 98-110. 
Verhaak, R. G. and P. J. Valk (2010). Genes predictive of outcome and novel molecular 
classification schemes in adult acute myeloid leukemia. Cancer Treat Res, Vol. 145, 
No., pp. 67-83. 
Vredenburgh, J. J., et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma 
multiforme. J Clin Oncol, Vol. 25, No. 30, (Oct 20) pp. 4722-4729. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
76
Vredenburgh, J. J., et al. (2011). The Addition of Bevacizumab to Standard Radiation 
Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and 
Irinotecan for Newly Diagnosed Glioblastoma. Clin Cancer Res, Vol., No., (Apr 29). 
Walker, C., et al. (2006). Clinical use of genotype to predict chemosensitivity in 
oligodendroglial tumors. Neurology, Vol. 66, No. 11, (Jun 13) pp. 1661-1667. 
Wang, R., et al. (2011). Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 
Vol. 468, No. 7325, (Dec 9) pp. 829-833. 
Wang, S. and E. N. Olson (2009). AngiomiRs--key regulators of angiogenesis. Curr Opin 
Genet Dev, Vol. 19, No. 3, (Jun) pp. 205-211. 
Webster, R. J., et al. (2009). Regulation of epidermal growth factor receptor signaling in human 
cancer cells by microRNA-7. J Biol Chem, Vol. 284, No. 9, (Feb 27) pp. 5731-5741. 
Wen, P. Y., et al. (2010). Updated response assessment criteria for high-grade gliomas: 
response assessment in neuro-oncology working group. J Clin Oncol, Vol. 28, No. 
11, (Apr 10) pp. 1963-1972. 
Whittaker, S., et al. (2010). Gatekeeper mutations mediate resistance to BRAF-targeted 
therapies. Sci Transl Med, Vol. 2, No. 35, (Jun 9) pp. 35ra41. 
Wick, A., et al. (2007). Efficacy and tolerability of temozolomide in an alternating weekly 
regimen in patients with recurrent glioma. J Clin Oncol, Vol. 25, No. 22, (Aug 1) pp. 
3357-3361. 
Wick, W., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy 
of anaplastic glioma with procarbazine, lomustine, and vincristine or 
temozolomide. J Clin Oncol, Vol. 27, No. 35, (Dec 10) pp. 5874-5880. 
Wick, W., et al. (2010). Phase III study of enzastaurin compared with lomustine in the 
treatment of recurrent intracranial glioblastoma. J Clin Oncol, Vol. 28, No. 7, (Mar 1) 
pp. 1168-1174. 
Wick, W., et al. (2011). Phase III study of enzastaurin compared with lomustine in the 
treatment of recurrent intracranial glioblastoma. J Clin Oncol, Vol. 28, No. 7, (Mar 1) 
pp. 1168-1174. 
Wick, W., et al. (2004). One week on/one week off regimen of temozolomide for recurrent 
glioblastoma: A phase III study. Journal Of Clinical Oncology, Vol. 22, No. 14, (Jul 15) 
pp. 116S-116S. 
Wick, W. and M. Weller (2005). How lymphotoxic is dose-intensified temozolomide? The 
glioblastoma experience. Journal Of Clinical Oncology, Vol. 23, No. 18, (Jun 20) pp. 
4235-4236. 
Wu, L. e. a. (2006). MicroRNA direct rapid demethylation of mRNA. PNAS, Vol. 103, No., 
pp. 4034-4039. 
Xu, W., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer Cell, Vol. 19, No. 1, (Jan 18) pp. 17-30. 
Yan, H., et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, Vol. 360, No. 8, 
(Feb 19) pp. 765-773. 
Yekta, S. e. a. (2004). MicroRNA-directed cleavage of HOXB8 mRNA. Science, Vol. 304, No., 
pp. 594-596. 
Zhang, Y., et al. (2009). MicroRNA-128 inhibits glioma cells proliferation by targeting 




Glioma – Exploring Its Biology and Practical Relevance 
 
76
Vredenburgh, J. J., et al. (2011). The Addition of Bevacizumab to Standard Radiation 
Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and 
Irinotecan for Newly Diagnosed Glioblastoma. Clin Cancer Res, Vol., No., (Apr 29). 
Walker, C., et al. (2006). Clinical use of genotype to predict chemosensitivity in 
oligodendroglial tumors. Neurology, Vol. 66, No. 11, (Jun 13) pp. 1661-1667. 
Wang, R., et al. (2011). Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 
Vol. 468, No. 7325, (Dec 9) pp. 829-833. 
Wang, S. and E. N. Olson (2009). AngiomiRs--key regulators of angiogenesis. Curr Opin 
Genet Dev, Vol. 19, No. 3, (Jun) pp. 205-211. 
Webster, R. J., et al. (2009). Regulation of epidermal growth factor receptor signaling in human 
cancer cells by microRNA-7. J Biol Chem, Vol. 284, No. 9, (Feb 27) pp. 5731-5741. 
Wen, P. Y., et al. (2010). Updated response assessment criteria for high-grade gliomas: 
response assessment in neuro-oncology working group. J Clin Oncol, Vol. 28, No. 
11, (Apr 10) pp. 1963-1972. 
Whittaker, S., et al. (2010). Gatekeeper mutations mediate resistance to BRAF-targeted 
therapies. Sci Transl Med, Vol. 2, No. 35, (Jun 9) pp. 35ra41. 
Wick, A., et al. (2007). Efficacy and tolerability of temozolomide in an alternating weekly 
regimen in patients with recurrent glioma. J Clin Oncol, Vol. 25, No. 22, (Aug 1) pp. 
3357-3361. 
Wick, W., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy 
of anaplastic glioma with procarbazine, lomustine, and vincristine or 
temozolomide. J Clin Oncol, Vol. 27, No. 35, (Dec 10) pp. 5874-5880. 
Wick, W., et al. (2010). Phase III study of enzastaurin compared with lomustine in the 
treatment of recurrent intracranial glioblastoma. J Clin Oncol, Vol. 28, No. 7, (Mar 1) 
pp. 1168-1174. 
Wick, W., et al. (2011). Phase III study of enzastaurin compared with lomustine in the 
treatment of recurrent intracranial glioblastoma. J Clin Oncol, Vol. 28, No. 7, (Mar 1) 
pp. 1168-1174. 
Wick, W., et al. (2004). One week on/one week off regimen of temozolomide for recurrent 
glioblastoma: A phase III study. Journal Of Clinical Oncology, Vol. 22, No. 14, (Jul 15) 
pp. 116S-116S. 
Wick, W. and M. Weller (2005). How lymphotoxic is dose-intensified temozolomide? The 
glioblastoma experience. Journal Of Clinical Oncology, Vol. 23, No. 18, (Jun 20) pp. 
4235-4236. 
Wu, L. e. a. (2006). MicroRNA direct rapid demethylation of mRNA. PNAS, Vol. 103, No., 
pp. 4034-4039. 
Xu, W., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer Cell, Vol. 19, No. 1, (Jan 18) pp. 17-30. 
Yan, H., et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, Vol. 360, No. 8, 
(Feb 19) pp. 765-773. 
Yekta, S. e. a. (2004). MicroRNA-directed cleavage of HOXB8 mRNA. Science, Vol. 304, No., 
pp. 594-596. 
Zhang, Y., et al. (2009). MicroRNA-128 inhibits glioma cells proliferation by targeting 




Genomic Abnormalities in Gliomas 
Giovanny Pinto et al.* 
Federal University of Piauí, Parnaíba, 
Brazil 
1. Introduction 
In general, studies reveal that cancer arises through genetic and epigenetic alterations that 
affect specific genes within a given cell type. These changes involve a gain of function when 
the alterations involve oncogenes, a loss of function when the target genes are tumor 
suppressor genes. Thus, both genetic and epigenetic changes promote the instability of 
cellular homeostasis (Bello & Rey, 2006; Richardson, 2003; Sugimura & Ushijima, 2000). This 
lack of stability reflects the complexity of cancer because the loss of controlled cell growth 
occurs due to changes in one or more genes. These genetic and epigenetic events are 
followed by the growing accumulation of changes in hundreds, if not thousands, of genes. 
Over time, this accumulation causes the tumor to reach its highest degree of malignancy, 
which usually culminates in metastasis (Bartek & Lukas, 2001). However, in recent years, a 
subpopulation of tumor cells has been found to display a slow rate of cell division, high 
tumorigenic potential and characteristics similar to those of normal stem cells. This 
discovery has changed the concept of metastasis to one associated with strictly terminal 
states (Stiles & Rowitch, 2008). 
Hanahan & Weinberg (2000) proposed that all tumor cells must acquire six essential 
alterations in cell physiology that collectively dictate malignant growth: (1) loss of normal 
signaling for cell proliferation arrest, (2) loss of signaling for cell differentiation, (3) 
autocrine signaling for cell division, (4) reduction in apoptosis, (5) ability to enter the 
basement membrane and other tissues and organs, and (6) induction of angiogenesis. All of 
these processes involve biochemical pathways that form a complex network of cell 
signaling. These processes are usually altered in tumors because the genes that compose 
them are changed, resulting in cell cycle dysregulation. Therefore, the identification and 
determination of oncogenes and tumor suppressor genes is essential for understanding both 
cancer biology and clinical applications, such as the identification of therapeutic targets, 
early detection, and prediction of the disease course. Studies concerning cell cycle control 
genes have served as a starting point for identifying genes related to tumorigenesis and 
their biochemical role in various pathways (Paige, 2003). 
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Changes in oncogenes can lead to constitutive activation, which involves activation under 
conditions in which an oncogene would normally be inactive. For this process to occur, a 
cell needs only one allele of an oncogene to be altered, resulting in a selective growth 
advantage. In contrast, changes in tumor suppressor genes often reduce the gene product 
and consequently its activity. For this reason, cells that develop a selective advantage with 
changes in tumor suppressor genes usually require inactivation of both alleles of the target 
gene. Conceptually, tumor suppressor genes can be subdivided into two categories: 
"gatekeepers" that directly inhibit tumor growth and thereby suppress tumor formation and 
"caretakers" that ensure DNA integrity by repairing damage or preventing genomic 
instability (Vogelstein & Kinzler, 2004). 
Studies of hereditary and sporadic forms of tumors, particularly retinoblastoma, culminated 
in the formulation of Knudson’s “two events” model in 1971. In hereditary tumors, the first 
mutation occurs in one allele in the germline and results in a predisposition to develop 
tumors. Throughout development, a second change (mutation or loss of heterozygosity) 
inactivates the other allele and silences the altered gene. In contrast, sporadic tumors acquire 
the two allelic alterations that lead to gene silencing throughout the organism's 
development (Knudson, 1971). Over time, the neoplastic transformation and metabolic-
phenotype of the cell can evolve. Ultimately, these changes result in a cancer in which clonal 
expansion of modified somatic cells destroys the adjacent normal tissue (Bartek & Lukas, 
2001). 
For many years, research in cancer genetics has prioritized understanding the role of genetic 
alterations in carcinogenesis. Studies revealed that base deletions, insertions, recombination 
and amplification in oncogenes and tumor suppressor genes were related to metastasis and 
invasion. These changes were also closely related to tumorigenesis and tumor progression. 
For this reason, the scientific community accepted that genetic changes almost exclusively 
explained the process of carcinogenesis (Sugimura & Ushijima, 2000). However, studies also 
indicated that embryogenesis and differentiation, which are characterized by specific 
patterns of gene expression in tissues and organs, can occur without changes in the DNA 
sequence. This notion has interested the scientific community in potential epigenetic 
mechanisms of carcinogenesis (Jones & Buckley, 1990; Rush & Plass, 2002).  
An epigenetic phenomenon is defined as a change in gene function that is heritable through 
mitosis or meiosis but cannot be explained by changes in the DNA sequence. Aberrant 
epigenetic mechanisms, such as promoter hypermethylation, histone modifications, or non-
coding RNA expression, are known to be important for tumor formation and comprise the 
“third pathway” in Knudson’s model. These mechanisms result in transcriptional repression 
equivalent to that observed with the mutations and deletions proposed in Knudson’s model 
(Jones & Baylin, 2007).  
DNA methylation, the main epigenetic modification studied, occurs at cytosine residues in 
the cytosine-guanine sequences (CpG) of DNA through the action of an enzyme family 
called DNA methyltransferases (DNMT). In humans, approximately 70% of CpG sites, 
which are generally located in repetitive DNA sequences, are methylated. Clusters of 
unmethylated CpG sites are present in the genome as well, and these clusters are referred to 
as CpG islands. Approximately 60% of genes have CpG islands in the promoter regions and 
in the first exon. CpG islands are often dimethylated when associated with housekeeping 
genes. Moreover, CpG islands are tissue specific and are generally methylated except in 
those tissues where the associated gene is expressed (Cross & Bird, 1995; Gonzalez-Gomez 
et al., 2003). A recent genome-wide analysis revealed that CpG islands are also found in 
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non-promoter regions. In addition, epigenetic abnormalities causing loss of gene function 
are more frequent than genetic abnormalities in cancer cells (Schuebel et al., 2007). Thus, 
cellular epigenetic inheritance mediated by aberrant DNA methylation resulting in gene 
silencing, gene imprinting, andor activation of cancer-associated genes is now accepted as 
an important factor defining the transformed phenotype (Natsume et al., 2010) 
2. Tumors of the central nervous system 
Tumors of the central nervous system (CNS) are relatively rare and represent approximately 
5-9% of all cancers, with an estimated incidence of 4.2 to 5.4 per 100,000 people/year. 
Moreover, tumors of the CNS carry a very poor prognosis and are associated with 
considerable morbidity and mortality. They are a leading cause of childhood cancer deaths, 
the second leading cause of cancer-related death in men aged 20–39, and the fifth leading 
cause of cancer-related death in women aged 20–39 (Ohgaki & Kleihues, 2005). 
Although the incidence of CNS tumors is small compared with the incidence of other 
cancers, CNS tumors are among the most serious human malignancies because they affect 
the organ responsible for the coordination and integration of all biological activities. 
Moreover, as each region of the brain has a vital function, therapies used to treat other 
cancers (e.g., total surgical removal of an organ or tumor with a generous margin of normal 
tissue) cannot be applied to brain tumors. The inability to use these therapies hinders 
quality of life and patient survival (Louis et al., 2002). 
In CNS tumors, the histopathological classifications are extensive and based primarily on 
descriptive morphology. Because the histogenesis of these tumors is unique and 
heterogeneous, it is difficult to characterize several of the tumor subtypes, which is reflected 
in the difficulties encountered in tumor diagnosis (Gilbertson, 2002). 
In contrast with the first World Health Organization (WHO) classifications for CNS tumors 
(Kleihues et al., 1993; Zülch, 1979), the third edition by Kleihues & Cavenee (2000) 
incorporated genetic profiles as additional aids in defining brain tumors. The fourth edition 
of the WHO classifications for CNS tumors, which was published in 2007, lists several new 
characteristics. The fourth edition is based on consensus from an international working 
group of 25 pathologists and geneticists, as well as contributions from more than 70 
international experts. Currently, this edition is the standard for defining brain tumors for 
clinical oncology and cancer research communities world-wide (Louis et al., 2007). 
3. Gliomas 
Gliomas are the most common tumors of the CNS. However, in spite of marked progress in 
characterizing the molecular pathogenesis of gliomas, these tumors remain incurable. In 
most cases, gliomas are also refractory to treatment because of their molecular 
heterogeneity. Gliomas rarely metastasize outside of the brain but instead infiltrate 
extensively into the surrounding normal brain. Therefore, surgery is not curative but can 
establish the diagnosis and relieve symptoms by decompressing the brain, which is located 
in the rigid intracranial cavity. Radiation therapy and chemotherapy increase survival; 
however, disease recurrence is frequently inevitable (Park & Rich, 2009). 
The following four degrees of malignancy are recognized by the WHO: grades I and II (low-
grade), which are biologically less aggressive and grades III and IV (high-grade), which are 
the most aggressive. The histological criteria for grading malignancies are not uniform for 
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all subtypes of gliomas. Thus, all tumors should be classified before the degree of 
malignancy is determined. This classification is made according to the cell type thought to 
be responsible for the tumor and based on the characteristics exhibited by astrocytes, 
oligodendrocytes, ependymal cells, or their neuronal progenitors (Louis et al., 2007). Table 1 
shows the heterogeneous WHO classification for gliomas according to the degree of 
malignancy. 
 
 WHO Grade   WHO Grade 
Astrocytic tumors I II III IV  Ependymal tumors I II III IV 
Subependymal giant 
cell astrocytoma ●    
 Subependymoma ●    
Pilocytic astrocytoma ●     Myxopapillary ependymoma ●    
Pilomyxoid 
astrocytoma  ●   
 Ependymoma  ●   
Diffuse astrocytoma  ●    Anaplastic ependymoma   ●  
Pleomorphic 
xanthoastrocytoma  ●   
      
Anaplastic astrocytoma   ●   Choroid plexus tumors     
Glioblastoma    ●  Choroid plexus papilloma ●    
Giant cell glioblastoma    ●  Atypical choroid plexus papilloma  ●   
Gliosarcoma    ●  Choroid plexus carcinoma   ●  
           
Oligodendroglial 




    
Oligodendroglioma  ●    Angiocentric glioma ●    
Anaplastic 
oligodendroglioma   ●  
 Chordoid glioma of 
the third ventricle  ●   
           
Oligoastrocytic tumors           
Oligoastrocytoma  ●         
Anaplastic 
oligoastrocytoma   ●  
      
Table 1. WHO grading of gliomas (Louis et al., 2007). 
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Gliomas of astrocytic, oligodendroglial, and ependymal origin account for 80% of CNS 
tumors. For this reason, some morphological and genetic characteristics of these tumors are 
discussed below. 
3.1 Astrocytomas 
Astrocytomas represent the vast majority of gliomas and account for 70% of the total 
gliomas seen in patients. Astrocytomas can be further characterized as pilocytic 
astrocytomas (WHO grade I) or diffuse astrocytomas, including low-grade astrocytomas 
(WHO grade II), anaplastic astrocytomas (WHO grade III) and glioblastomas (WHO grade 
IV) (Kleihues et al., 2002). 
Pilocytic astrocytomas are more commonly seen in children and carry a good prognosis 
because of their biology. Patients with neurofibromatosis type 1, a familial syndrome caused 
by germline mutations in the gene NF1 (neurofibromin 1), have an increased incidence of 
pilocytic astrocytomas. These tumors are usually not aggressive and stand out among 
astrocytomas because they have maintained their WHO grade I status for years and even 
decades, in contrast to diffuse astrocytic tumors (WHO grades II-IV). However, some cases 
can progress to a higher degree of malignancy, though such a progression is rare (Listernick 
et al., 1999). 
More than 100 cases of pilocytic astrocytomas were analyzed by cytogenetics and many 
others were used for comparative genomic hybridization (CGH); however, the vast majority 
of the results indicated normal patterns (Bigner et al., 1997; Sanoudou et al., 2000; Zattara-
Cannoni et al., 1998). In adults, genetic changes were more frequent but were still rare. The 
few molecular genetics studies on these tumors indicated allelic loss of both gene loci TP53 
(tumor protein p53) and NF1 in regions 17p and 17q, respectively. In sporadic tumors, few 
mutations were reported in the TP53 locus and none in NF1 (Gutmann et al., 2000; Kluwe et 
al., 2001). 
The relevance of a malignancy-grading scheme based on histopathology is indicated by the 
correlation with patient survival. Patients with low-grade astrocytomas (WHO grade II) 
have a median survival of approximately seven years, whereas patients with anaplastic 
astrocytomas (WHO grade III) have a mean survival of half that time (McCormack et al., 
1992). Patients with glioblastomas have a median survival time of 9 to 11 months (Simpson 
et al., 1993).  
Unlike pilocytic astrocytomas, diffuse astrocytic tumors are often seen in adults. Low-grade 
astrocytomas have a peak incidence between 25 and 50 years of age, whereas glioblastomas 
have a peak incidence between 45 and 50 years (Colins, 2004). 
Ng & Lam (1998) suggested dividing glioblastomas into two distinct molecular and clinical 
entities: primary or de novo glioblastomas, which occur in elderly patients and are clinically 
very aggressive and secondary glioblastomas, which develop from low-grade astrocytomas 
and have a more prolonged clinical course. 
Many mechanisms are involved in the initiation and progression of secondary 
glioblastomas, including the loss of NF1 and TP53 genes and the activation of signal 
transduction pathways, such as PDGF (platelet-derived growth factor) and its receptor 
PDGFR (PDGF receptor). These pathways are involved in the induction of low-grade 
tumors (e.g., pilocytic astrocytomas), which can progress to high-grade tumors (e.g., 
anaplastic astrocytomas and secondary glioblastoma). This progression is associated with 
the lack of a functional RB1 (retinoblastoma 1) because of the loss of RB1 or gene 
amplification/overexpression of CDK4 (cyclin-dependent kinase 4) (Fig. 1a). In primary 
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all subtypes of gliomas. Thus, all tumors should be classified before the degree of 
malignancy is determined. This classification is made according to the cell type thought to 
be responsible for the tumor and based on the characteristics exhibited by astrocytes, 
oligodendrocytes, ependymal cells, or their neuronal progenitors (Louis et al., 2007). Table 1 
shows the heterogeneous WHO classification for gliomas according to the degree of 
malignancy. 
 
 WHO Grade   WHO Grade 
Astrocytic tumors I II III IV  Ependymal tumors I II III IV 
Subependymal giant 
cell astrocytoma ●    
 Subependymoma ●    
Pilocytic astrocytoma ●     Myxopapillary ependymoma ●    
Pilomyxoid 
astrocytoma  ●   
 Ependymoma  ●   
Diffuse astrocytoma  ●    Anaplastic ependymoma   ●  
Pleomorphic 
xanthoastrocytoma  ●   
      
Anaplastic astrocytoma   ●   Choroid plexus tumors     
Glioblastoma    ●  Choroid plexus papilloma ●    
Giant cell glioblastoma    ●  Atypical choroid plexus papilloma  ●   
Gliosarcoma    ●  Choroid plexus carcinoma   ●  
           
Oligodendroglial 




    
Oligodendroglioma  ●    Angiocentric glioma ●    
Anaplastic 
oligodendroglioma   ●  
 Chordoid glioma of 
the third ventricle  ●   
           
Oligoastrocytic tumors           
Oligoastrocytoma  ●         
Anaplastic 
oligoastrocytoma   ●  
      
Table 1. WHO grading of gliomas (Louis et al., 2007). 
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Gliomas of astrocytic, oligodendroglial, and ependymal origin account for 80% of CNS 
tumors. For this reason, some morphological and genetic characteristics of these tumors are 
discussed below. 
3.1 Astrocytomas 
Astrocytomas represent the vast majority of gliomas and account for 70% of the total 
gliomas seen in patients. Astrocytomas can be further characterized as pilocytic 
astrocytomas (WHO grade I) or diffuse astrocytomas, including low-grade astrocytomas 
(WHO grade II), anaplastic astrocytomas (WHO grade III) and glioblastomas (WHO grade 
IV) (Kleihues et al., 2002). 
Pilocytic astrocytomas are more commonly seen in children and carry a good prognosis 
because of their biology. Patients with neurofibromatosis type 1, a familial syndrome caused 
by germline mutations in the gene NF1 (neurofibromin 1), have an increased incidence of 
pilocytic astrocytomas. These tumors are usually not aggressive and stand out among 
astrocytomas because they have maintained their WHO grade I status for years and even 
decades, in contrast to diffuse astrocytic tumors (WHO grades II-IV). However, some cases 
can progress to a higher degree of malignancy, though such a progression is rare (Listernick 
et al., 1999). 
More than 100 cases of pilocytic astrocytomas were analyzed by cytogenetics and many 
others were used for comparative genomic hybridization (CGH); however, the vast majority 
of the results indicated normal patterns (Bigner et al., 1997; Sanoudou et al., 2000; Zattara-
Cannoni et al., 1998). In adults, genetic changes were more frequent but were still rare. The 
few molecular genetics studies on these tumors indicated allelic loss of both gene loci TP53 
(tumor protein p53) and NF1 in regions 17p and 17q, respectively. In sporadic tumors, few 
mutations were reported in the TP53 locus and none in NF1 (Gutmann et al., 2000; Kluwe et 
al., 2001). 
The relevance of a malignancy-grading scheme based on histopathology is indicated by the 
correlation with patient survival. Patients with low-grade astrocytomas (WHO grade II) 
have a median survival of approximately seven years, whereas patients with anaplastic 
astrocytomas (WHO grade III) have a mean survival of half that time (McCormack et al., 
1992). Patients with glioblastomas have a median survival time of 9 to 11 months (Simpson 
et al., 1993).  
Unlike pilocytic astrocytomas, diffuse astrocytic tumors are often seen in adults. Low-grade 
astrocytomas have a peak incidence between 25 and 50 years of age, whereas glioblastomas 
have a peak incidence between 45 and 50 years (Colins, 2004). 
Ng & Lam (1998) suggested dividing glioblastomas into two distinct molecular and clinical 
entities: primary or de novo glioblastomas, which occur in elderly patients and are clinically 
very aggressive and secondary glioblastomas, which develop from low-grade astrocytomas 
and have a more prolonged clinical course. 
Many mechanisms are involved in the initiation and progression of secondary 
glioblastomas, including the loss of NF1 and TP53 genes and the activation of signal 
transduction pathways, such as PDGF (platelet-derived growth factor) and its receptor 
PDGFR (PDGF receptor). These pathways are involved in the induction of low-grade 
tumors (e.g., pilocytic astrocytomas), which can progress to high-grade tumors (e.g., 
anaplastic astrocytomas and secondary glioblastoma). This progression is associated with 
the lack of a functional RB1 (retinoblastoma 1) because of the loss of RB1 or gene 
amplification/overexpression of CDK4 (cyclin-dependent kinase 4) (Fig. 1a). In primary 
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glioblastomas, the same genetic pathways are disrupted but by different mechanisms. For 
example, reduction of the TP53 pathway generally occurs through the loss of the gene ARF4 
(ADP-ribosylation factor 4) or less frequently through amplification of the gene MDM2 
(transformed 3T3 cell double minute 2). The lack of RB1 also occurs via a loss of the gene 
CDKN2A (cyclin-dependent kinase inhibitor 2A). In primary glioblastomas, amplification 
and/or mutation of EGFR (epidermal growth factor receptor) and loss of PTEN 
(phosphatase and tensin homolog) are the most frequently observed genetic defects (Fig. 1b) 
(Zu & Parada, 2002). 
 
 
Fig. 1. Genetic pathways involved in the development of (a) primary and (b) secondary 
glioblastomas (Zhu & Parada, 2000). 
Sequencing of the genome recently identified mutations in the IDH1/IDH2 genes (isocitrate 
dehydrogenase 1 and 2 genes) that occur in the majority of WHO grade II–III gliomas and 
secondary glioblastomas (Hartmann et al., 2009; Yan et al., 2009), all of which harbor a better 
prognosis compared with the wild-type cases (Sanson et al., 2009). However, pilocytic 
astrocytomas (WHO grade I) that are potentially curable by complete resection rarely harbor 
IDH mutations. IDH appears to function as a tumor suppressor when inactivated through 
mutation, rendering the IDH enzyme unable to catalyze conversion of isocitrate to 
alphaketoglutarate. This process also induces HIF1-alpha (hypoxia-inducible factor), which 
triggers the angiogenic process. However, the precise mechanism of its effect on tumor 
biology remains unclear (Dang et al., 2009). 
Aberrant activation of the BRAF proto-oncogene (v-raf murine sarcoma viral oncogene 
homolog B1) at 7q34, which is most commonly caused by gene duplication and fusion or 
less frequently by point mutation, has only recently been identified as the characteristic 
genetic aberration in pilocytic astrocytomas. BRAF abnormalities occur in 60–80% of 
pilocytic astrocytomas but almost never in diffuse, infiltrating astrocytomas (Jones et al., 
2009). Thus, testing for BRAF gene alterations might be helpful for differentiating during 
diagnosis between pilocytic astrocytomas and low-grade, diffuse astrocytomas (Korshunov 
et al., 2009). 
The importance of silencing DNA repair pathways, especially the DNA-repair enzyme 
AGAT (O6-alkylguanine DNA alkyltransferase), which is encoded by the gene MGMT (O6-
methylguanine-DNA-methyltransferase), has been the subject of substantial debate in recent 
years (Hofer & Lassman, 2010). The MGMT gene is frequently silenced by promoter 
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hypermethylation in diffuse gliomas, and this hypermethylation has been pinpointed as an 
epigenetic mechanism that reduces MGMT expression levels. There are 97 CpG islands in 
the MGMT promoter, and these CpG islands are further divided into two hypermethylated 
regions (Nakagawachi et al., 2003). Because of its critical role in DNA repair, the epigenetic 
silencing of MGMT is associated with an increased number of mutations and with a poorer 
outcome in glioblastomas. Thus, MGMT silencing is considered to be a biomarker for poor 
prognosis (Komine et al., 2003). However, an association between MGMT promoter 
methylation and the response of malignant gliomas to alkylating chemotherapy using 
nitrosourea compounds, temozolomide, or a combination of both has been observed 
(Esteller et al., 2000; Herrlinger et al., 2006). Furthermore, Hegi et al. (2005) reported that 
patients treated with radiotherapy and temozolomide, and whose tumors had a methylated 
MGMT promoter (which is seen in approximately 40% of primary glioblastomas), survived 
significantly longer than did patients whose tumors lacked MGMT promoter methylation. 
Rivera et al. (2010) recently reported that MGMT promoter methylation in anaplastic 
gliomas (WHO grade III) is also predictive of the response to radiotherapy and linked to 
longer survival in the absence of adjuvant chemotherapy. The use of temozolomide based 
on MGMT methylation status highlights the importance of understanding epigenetic 
changes in glioblastomas for the discovery of novel therapies and prognostic factors for the 
treatment of this deadly cancer (Komine et al., 2003; Nakagawachi et al., 2003) 
3.2 Oligodendrogliomas 
Oligodendrogliomas represent approximately 10-15% of gliomas, are more common in 
adults, and can be divided into two histological subtypes: low-grade (WHO grade II) and 
anaplastic (WHO grade III) (Kleihues et al., 2002). 
Low-grade oligodendrogliomas are less biologically aggressive than are astrocytic tumors. 
Therefore, the prognosis is quite favorable and survival beyond 15 years is achieved in up to 
90% of cases that receive a complete surgical resection. There is potential for malignancy, 
but even the aggressive tumors respond well to additional treatments (e.g., radiation and 
chemotherapy). Anaplastic oligodendrogliomas have a more aggressive course; however, 
survival is still five to eight years longer than that observed with anaplastic astrocytomas 
(Reifenberger & Louis, 2003). 
In 1990, the PCV chemotherapy regimen (procarbazine, carmustine, and vincristine) was 
shown to result in a dramatic tumor response in oligodendrogliomas. Since that time, the 
identification of all forms of gliomas with oligodendroglial components became crucial 
(Macdonald et al., 1990). Importantly, these studies indicated that the prognostic power of 
oligodendroglial components was independent of whether radiotherapy, chemotherapy or 
combined radio-chemotherapy was used (Wick et al., 2009). This phenomenon is likely due 
to oligodendrogliomas exhibiting specific genetic abnormalities that distinguish them from 
other gliomas. Reifenberger et al. (1994), after a thorough analysis of the genome, reported a 
loss of genetic information in the 1p and 19q loci in oligodendrogliomas, the so-called 
chromosome 1p/19q co-deletion. This loss was later linked with a good response to PCV 
and provided the first molecular indicator of treatment response in brain tumors (Cairncross 
et al., 1998; Reifenberger et al., 2003). Further studies corroborated these findings, and it is 
now known that the chromosomal loss results from an unbalanced translocation (Franco-
Hernandez et al., 2009; Jenkins et al., 2006). Approximately 85% of low-grade 
oligodendrogliomas and 65% of anaplastic oligodendrogliomas present with 1p/19q co-
deletions (Smith et al., 2000). 
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glioblastomas, the same genetic pathways are disrupted but by different mechanisms. For 
example, reduction of the TP53 pathway generally occurs through the loss of the gene ARF4 
(ADP-ribosylation factor 4) or less frequently through amplification of the gene MDM2 
(transformed 3T3 cell double minute 2). The lack of RB1 also occurs via a loss of the gene 
CDKN2A (cyclin-dependent kinase inhibitor 2A). In primary glioblastomas, amplification 
and/or mutation of EGFR (epidermal growth factor receptor) and loss of PTEN 
(phosphatase and tensin homolog) are the most frequently observed genetic defects (Fig. 1b) 
(Zu & Parada, 2002). 
 
 
Fig. 1. Genetic pathways involved in the development of (a) primary and (b) secondary 
glioblastomas (Zhu & Parada, 2000). 
Sequencing of the genome recently identified mutations in the IDH1/IDH2 genes (isocitrate 
dehydrogenase 1 and 2 genes) that occur in the majority of WHO grade II–III gliomas and 
secondary glioblastomas (Hartmann et al., 2009; Yan et al., 2009), all of which harbor a better 
prognosis compared with the wild-type cases (Sanson et al., 2009). However, pilocytic 
astrocytomas (WHO grade I) that are potentially curable by complete resection rarely harbor 
IDH mutations. IDH appears to function as a tumor suppressor when inactivated through 
mutation, rendering the IDH enzyme unable to catalyze conversion of isocitrate to 
alphaketoglutarate. This process also induces HIF1-alpha (hypoxia-inducible factor), which 
triggers the angiogenic process. However, the precise mechanism of its effect on tumor 
biology remains unclear (Dang et al., 2009). 
Aberrant activation of the BRAF proto-oncogene (v-raf murine sarcoma viral oncogene 
homolog B1) at 7q34, which is most commonly caused by gene duplication and fusion or 
less frequently by point mutation, has only recently been identified as the characteristic 
genetic aberration in pilocytic astrocytomas. BRAF abnormalities occur in 60–80% of 
pilocytic astrocytomas but almost never in diffuse, infiltrating astrocytomas (Jones et al., 
2009). Thus, testing for BRAF gene alterations might be helpful for differentiating during 
diagnosis between pilocytic astrocytomas and low-grade, diffuse astrocytomas (Korshunov 
et al., 2009). 
The importance of silencing DNA repair pathways, especially the DNA-repair enzyme 
AGAT (O6-alkylguanine DNA alkyltransferase), which is encoded by the gene MGMT (O6-
methylguanine-DNA-methyltransferase), has been the subject of substantial debate in recent 
years (Hofer & Lassman, 2010). The MGMT gene is frequently silenced by promoter 
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hypermethylation in diffuse gliomas, and this hypermethylation has been pinpointed as an 
epigenetic mechanism that reduces MGMT expression levels. There are 97 CpG islands in 
the MGMT promoter, and these CpG islands are further divided into two hypermethylated 
regions (Nakagawachi et al., 2003). Because of its critical role in DNA repair, the epigenetic 
silencing of MGMT is associated with an increased number of mutations and with a poorer 
outcome in glioblastomas. Thus, MGMT silencing is considered to be a biomarker for poor 
prognosis (Komine et al., 2003). However, an association between MGMT promoter 
methylation and the response of malignant gliomas to alkylating chemotherapy using 
nitrosourea compounds, temozolomide, or a combination of both has been observed 
(Esteller et al., 2000; Herrlinger et al., 2006). Furthermore, Hegi et al. (2005) reported that 
patients treated with radiotherapy and temozolomide, and whose tumors had a methylated 
MGMT promoter (which is seen in approximately 40% of primary glioblastomas), survived 
significantly longer than did patients whose tumors lacked MGMT promoter methylation. 
Rivera et al. (2010) recently reported that MGMT promoter methylation in anaplastic 
gliomas (WHO grade III) is also predictive of the response to radiotherapy and linked to 
longer survival in the absence of adjuvant chemotherapy. The use of temozolomide based 
on MGMT methylation status highlights the importance of understanding epigenetic 
changes in glioblastomas for the discovery of novel therapies and prognostic factors for the 
treatment of this deadly cancer (Komine et al., 2003; Nakagawachi et al., 2003) 
3.2 Oligodendrogliomas 
Oligodendrogliomas represent approximately 10-15% of gliomas, are more common in 
adults, and can be divided into two histological subtypes: low-grade (WHO grade II) and 
anaplastic (WHO grade III) (Kleihues et al., 2002). 
Low-grade oligodendrogliomas are less biologically aggressive than are astrocytic tumors. 
Therefore, the prognosis is quite favorable and survival beyond 15 years is achieved in up to 
90% of cases that receive a complete surgical resection. There is potential for malignancy, 
but even the aggressive tumors respond well to additional treatments (e.g., radiation and 
chemotherapy). Anaplastic oligodendrogliomas have a more aggressive course; however, 
survival is still five to eight years longer than that observed with anaplastic astrocytomas 
(Reifenberger & Louis, 2003). 
In 1990, the PCV chemotherapy regimen (procarbazine, carmustine, and vincristine) was 
shown to result in a dramatic tumor response in oligodendrogliomas. Since that time, the 
identification of all forms of gliomas with oligodendroglial components became crucial 
(Macdonald et al., 1990). Importantly, these studies indicated that the prognostic power of 
oligodendroglial components was independent of whether radiotherapy, chemotherapy or 
combined radio-chemotherapy was used (Wick et al., 2009). This phenomenon is likely due 
to oligodendrogliomas exhibiting specific genetic abnormalities that distinguish them from 
other gliomas. Reifenberger et al. (1994), after a thorough analysis of the genome, reported a 
loss of genetic information in the 1p and 19q loci in oligodendrogliomas, the so-called 
chromosome 1p/19q co-deletion. This loss was later linked with a good response to PCV 
and provided the first molecular indicator of treatment response in brain tumors (Cairncross 
et al., 1998; Reifenberger et al., 2003). Further studies corroborated these findings, and it is 
now known that the chromosomal loss results from an unbalanced translocation (Franco-
Hernandez et al., 2009; Jenkins et al., 2006). Approximately 85% of low-grade 
oligodendrogliomas and 65% of anaplastic oligodendrogliomas present with 1p/19q co-
deletions (Smith et al., 2000). 
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Low-grade oligodendrogliomas and astrocytomas present a loss of ARF4 expression and 
overexpression of EGFR and PDGF signaling. Malignant progression is associated with 
additional genetic abnormalities that are similar to those described above for astrocytomas, 
including a lack of the RB1 pathway, loss of RB1, or gene amplification/overexpression of 
the CDK4 gene (Franco-Hernandez et al., 2007; Reifenberger & Louis, 2003). 
3.3 Ependymomas 
Ependymomas arise in or near the ependymal surface, and these tumors can occur 
anywhere in the ventricular system, spinal cord and even occasionally at extraneural sites. 
The most common location is in the fourth ventricle, followed by the spinal cord, the lateral 
ventricles and the third ventricle. These tumors are more common in children but can also 
occur in adults (Ebert et al., 1999). 
WHO classification identifies four major subtypes of ependymomas: subependymomas 
(WHO grade I), myxopapillary ependymomas (WHO grade I), low-grade ependymomas 
(WHO grade II) and anaplastic ependymomas (WHO grade III). Subependymomas are 
intraventricular in location, while myxopapillary ependymomas are commonly found in the 
cauda equina. The low-grade ependymomas can be differentiated from their anaplastic 
counterparts based on the low rate of mitosis and the low level of nuclear polymorphism; 
however, the distinction between the two tumors remains poorly defined (Kleihues et al., 
2002). 
In ependymomas, chromosomal abnormalities detected by classic cytogenetics and CGH 
involve chromosomes 1, 6, 7, 9, 10, 13, 17, 19 and 22. Deletions are the most commonly 
observed changes, and chromosome 22 losses are common in adults (50%) but rare in 
pediatric ependymomas (Kraus et al., 2001; Lamszus et al., 2001; von Haken et al., 1996). The 
target genes, located in regions of chromosomal gain or loss, are unknown, with the 
exception of cases in which both copies of the wild-type NF2 gene (neurofibromin 2) are lost 
in intramedullary ependymomas (Alonso et al., 2002). Isolated cases of MEN1 gene 
(multiple endocrine neoplasia I) loss have also been reported (Urioste et al., 2002). Germline 
mutations in TP53 are uncommon, in contrast with those seen in diffuse astrocytomas 
(Nozaki et al., 1998). 
When reviewed together, the data on genetic and epigenetic abnormalities presented above 
allow us to define four molecular biomarkers: MGMT hypermethylation in glioblastomas 
and anaplastic gliomas, IDH1 and IDH2 mutations in diffuse gliomas, BRAF aberrations in 
pilocytic astrocytomas, and combined deletions of chromosome arms 1p and 19q in 
oligodendroglial tumors. These biomarkers and their clinical significance are summarized in 
Table 2. 
4. Single nucleotide polymorphisms and gliomas 
A single nucleotide polymorphism (SNP) is generally defined as a stable replacement of 
only one DNA base, with a frequency greater than 1% in at least one population (Taylor et 
al., 2001). In human genetics studies, SNPs are simply referred to as bi-allelic markers 
because tri-and tetra-allelic markers are rare (Brookes, 1999). 
Initially, only a few thousand SNPs were thought to exist in the entire genome. However, 
since 2000, that number has increased about one thousand-fold. In 2001, an international 
consortium on mapping SNPs described 1.42 million polymorphic loci. More important than 
this large number is the precision of their placement in the genome; there is approximately 
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one polymorphism every 1.91 Kb. Therefore, 90% of sequences greater than 20 Kb in length 
have at least one SNP, and this density can be higher in genic regions. Of the known genes, 
93% contain SNPs and 98% are at least 5 Kb away from a SNP. Soon, almost all genes or 
gene regions will be marked by one of these variable sequences (Sachidanandam et al., 
2001). 
 
Molecular marker Clinical significance 
IDH1/IDH2 mutation 
 Diagnostic marker for diffuse WHO grade II and III gliomas, 
as well as secondary glioblastomas, and associated with a 
better prognosis in these tumors 
 Rare in primary glioblastomas, but when present, it is 
associated with a more favorable outcome 
 Not predictive for response to a particular type of therapy 
BRAF duplication/fusion
 Diagnostic marker for pilocytic astrocytomas and helpful in 
distinguishing these tumors from diffuse astrocytomas 
 Prognostic significance within the group of pilocytic 
astrocytoma patients is unknown 
MGMT promoter 
methylation 
 Predictive for response of glioblastomas to alkylating 
chemotherapy 
 Associated with longer survival in glioblastoma patients 
treated with radiotherapy combined with concurrent and 
adjuvant temozolomide 
 Prognostic in anaplastic glioma patients treated with 
radiotherapy and/or alkylating chemotherapy 
1p/19q co-deletion 
 Associated with improved prognosis in oligodendroglial 
tumor patients receiving adjuvant radiotherapy and/or 
chemotherapy 
 Not predictive for response to a particular type of therapy 
Table 2. The four most relevant markers for the molecular diagnosis of gliomas (Hofer & 
Lassman, 2010; Riemenschneider et al., 2010). 
Because they are found throughout the genome, some alleles containing SNPs produce 
functional or physiologically relevant gene products. For example, SNPs in a coding region 
can affect the coded protein. When located in an intron, SNPs can influence the splicing 
mechanism, and when located in the promoter, SNPs can alter gene transcription (Krawczak 
et al., 1992). For this reason, SNPs are recognized as important tools in human genetics and 
medicine and have been widely used in genetic association studies of various complex 
diseases, including cancer. In humans, several reviews of SNPs have been carried out in an 
attempt to determine the patterns of SNP haplotypes in different populations (Conrad et al., 
2006; Gonzalez-Neira et al., 2006; Jakobsson et al., 2008; Nothnagel & Rohde, 2005; Salisbury 
et al., 2003). Data from these tests are extremely useful for studying the genetic basis of 
cancer. For this reason, several research groups have focused on elucidating the role of SNPs 
in different genes related to the initiation and progression of gliomas in different 
populations. We performed association studies between SNPs, the risk of developing 
gliomas, and the prognosis for gliomas in a Brazilian population. Brazilians form one of the 
most heterogeneous populations in the world, which is the result of five centuries of 
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Low-grade oligodendrogliomas and astrocytomas present a loss of ARF4 expression and 
overexpression of EGFR and PDGF signaling. Malignant progression is associated with 
additional genetic abnormalities that are similar to those described above for astrocytomas, 
including a lack of the RB1 pathway, loss of RB1, or gene amplification/overexpression of 
the CDK4 gene (Franco-Hernandez et al., 2007; Reifenberger & Louis, 2003). 
3.3 Ependymomas 
Ependymomas arise in or near the ependymal surface, and these tumors can occur 
anywhere in the ventricular system, spinal cord and even occasionally at extraneural sites. 
The most common location is in the fourth ventricle, followed by the spinal cord, the lateral 
ventricles and the third ventricle. These tumors are more common in children but can also 
occur in adults (Ebert et al., 1999). 
WHO classification identifies four major subtypes of ependymomas: subependymomas 
(WHO grade I), myxopapillary ependymomas (WHO grade I), low-grade ependymomas 
(WHO grade II) and anaplastic ependymomas (WHO grade III). Subependymomas are 
intraventricular in location, while myxopapillary ependymomas are commonly found in the 
cauda equina. The low-grade ependymomas can be differentiated from their anaplastic 
counterparts based on the low rate of mitosis and the low level of nuclear polymorphism; 
however, the distinction between the two tumors remains poorly defined (Kleihues et al., 
2002). 
In ependymomas, chromosomal abnormalities detected by classic cytogenetics and CGH 
involve chromosomes 1, 6, 7, 9, 10, 13, 17, 19 and 22. Deletions are the most commonly 
observed changes, and chromosome 22 losses are common in adults (50%) but rare in 
pediatric ependymomas (Kraus et al., 2001; Lamszus et al., 2001; von Haken et al., 1996). The 
target genes, located in regions of chromosomal gain or loss, are unknown, with the 
exception of cases in which both copies of the wild-type NF2 gene (neurofibromin 2) are lost 
in intramedullary ependymomas (Alonso et al., 2002). Isolated cases of MEN1 gene 
(multiple endocrine neoplasia I) loss have also been reported (Urioste et al., 2002). Germline 
mutations in TP53 are uncommon, in contrast with those seen in diffuse astrocytomas 
(Nozaki et al., 1998). 
When reviewed together, the data on genetic and epigenetic abnormalities presented above 
allow us to define four molecular biomarkers: MGMT hypermethylation in glioblastomas 
and anaplastic gliomas, IDH1 and IDH2 mutations in diffuse gliomas, BRAF aberrations in 
pilocytic astrocytomas, and combined deletions of chromosome arms 1p and 19q in 
oligodendroglial tumors. These biomarkers and their clinical significance are summarized in 
Table 2. 
4. Single nucleotide polymorphisms and gliomas 
A single nucleotide polymorphism (SNP) is generally defined as a stable replacement of 
only one DNA base, with a frequency greater than 1% in at least one population (Taylor et 
al., 2001). In human genetics studies, SNPs are simply referred to as bi-allelic markers 
because tri-and tetra-allelic markers are rare (Brookes, 1999). 
Initially, only a few thousand SNPs were thought to exist in the entire genome. However, 
since 2000, that number has increased about one thousand-fold. In 2001, an international 
consortium on mapping SNPs described 1.42 million polymorphic loci. More important than 
this large number is the precision of their placement in the genome; there is approximately 
 
Genomic Abnormalities in Gliomas 
 
87 
one polymorphism every 1.91 Kb. Therefore, 90% of sequences greater than 20 Kb in length 
have at least one SNP, and this density can be higher in genic regions. Of the known genes, 
93% contain SNPs and 98% are at least 5 Kb away from a SNP. Soon, almost all genes or 
gene regions will be marked by one of these variable sequences (Sachidanandam et al., 
2001). 
 
Molecular marker Clinical significance 
IDH1/IDH2 mutation 
 Diagnostic marker for diffuse WHO grade II and III gliomas, 
as well as secondary glioblastomas, and associated with a 
better prognosis in these tumors 
 Rare in primary glioblastomas, but when present, it is 
associated with a more favorable outcome 
 Not predictive for response to a particular type of therapy 
BRAF duplication/fusion
 Diagnostic marker for pilocytic astrocytomas and helpful in 
distinguishing these tumors from diffuse astrocytomas 
 Prognostic significance within the group of pilocytic 
astrocytoma patients is unknown 
MGMT promoter 
methylation 
 Predictive for response of glioblastomas to alkylating 
chemotherapy 
 Associated with longer survival in glioblastoma patients 
treated with radiotherapy combined with concurrent and 
adjuvant temozolomide 
 Prognostic in anaplastic glioma patients treated with 
radiotherapy and/or alkylating chemotherapy 
1p/19q co-deletion 
 Associated with improved prognosis in oligodendroglial 
tumor patients receiving adjuvant radiotherapy and/or 
chemotherapy 
 Not predictive for response to a particular type of therapy 
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Lassman, 2010; Riemenschneider et al., 2010). 
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interethnic crosses of peoples from three continents: the European colonizers who are 
mainly represented by the Portuguese, the African slaves, and the autochthonous 
Amerindians (Parra et al., 2003). 
Until recently, we were the only laboratory investigating the association between WRN 
Cys1367Arg, the risk for brain tumor development, and the prognosis of brain tumors, 
especially with regard to gliomas (Pinto et al., 2008a). Werner syndrome (WS) is a premature 
aging disorder characterized by early onset of symptoms related to normal aging and is 
caused by inherited, recessive mutations in the WRN gene. The WRN gene encodes a 
member of the RecQ family of helicases involved in DNA replication and in maintaining the 
integrity of the genome (Harrigan et al., 2006). The cells of WS patients exhibit a high level 
of chromosomal translocations and deletions, and these patients present an increased 
predisposition to various types of cancer, including CNS tumors (Kobayashi et al., 1980). 
However, despite its putative tumor suppressor function, little is known about the 
contribution of the WRN protein to sporadic human malignancies. Taking into account that 
almost all cancers occur in the elderly and that mutations in the WRN gene lead to 
accelerated aging, it has been suggested that polymorphisms of the WRN gene, similar to 
Cys1367Arg, might be associated with age-related pathologies and cancer predisposition. 
However, our data indicate that neither glioma risk (OR = 1.38; 95% CI, 0.78-2.43; P = 0.334) 
nor patient survival (overall and disease-free survival, P = 0.396 and P = 0.843, respectively) 
was associated with variant alleles. 
Similar results were found when we evaluated the genotype distribution of TP53 Pro47Ser 
and Arg72Pro SNPs for their involvement in susceptibility to gliomas and in determining 
the oncologic prognosis of patients (Pinto et al., 2008b). A critical site in the TP53 protein for 
apoptosis signaling is a proline-rich region located between codons 64 and 92. Dumont et al. 
(2003) reported that the homozygous Arg72 allele induces apoptosis at a rate that is 15-fold 
higher than the Pro72 allele. According to Leu et al. (2004), the apoptosis-inducing ability of 
the Arg72 allele is in part due to its mitochondrial location, which makes it possible for TP53 
to directly interact with the pro-apoptotic protein, BAK. However, the TP53 Pro47Ser SNP 
resulted in a significantly decreased ability of the TP53 protein to induce apoptosis. A 
critical event in TP53-induced apoptosis is phosphorylation of the serine residue at codon 
46. This region is where allele Pro47 acts as a substrate for proline-directed kinases such as 
the MAPK1 protein. Li et al. (2005) reported that the Ser47 allele, which is a poor substrate 
for MAPK1, has an apoptosis-inducing ability that is 5-fold lower than that of the wild-type 
Pro47 allele. However, our data again indicated that neither glioma susceptibility nor 
patient survival was associated with the TP53 Arg72Pro or Pro47Ser alleles in the Brazilian 
population. 
In 2009, we investigated the role of EGF +61 A>G as a potential risk factor and/or 
prognostic marker for gliomas in the Brazilian population. The EGF  gene encodes a ligand 
for EGFR that activates a cascade of events responsible for promoting cell proliferation, 
inhibition of apoptosis, and differentiation. Alterations in the EGF/EGFR signaling pathway 
are associated with tumor progression in a variety of human cancers. Therefore, high 
expression of EGF may play a key role in glioma development and progression (Salomon et 
al., 1995). Shahbazi et al. (2002) first reported that the +61 A>G SNP in the 5’-UTR region of 
EGF is associated with increased EGF production and risk of malignant melanoma. Since 
that discovery, other research groups have obtained conflicting findings regarding the 
relationship of this functional SNP with different human cancers, including gliomas (Bao et 
al., 2010; Bhowmick et al., 2004; Costa et al., 2007; Liu et al., 2009; Vauleon et al., 2007; Wang 
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et al., 2010). In our results, the genotype and allele frequencies between cases and controls 
were similar, indicating no significant association with glioma risk (P = 0.94 and P = 0.887, 
respectively) and suggesting that EGF +61 A>G may not significantly contribute to the 
susceptibility to gliomas in the Brazilian population. This result is consistent with that of 
Vauleon et al. (2007) and Liu et al. (2009) in French and Chinese populations, respectively. 
However, we found that the major +61G allele (frequency among controls, 0.51) was 
associated with a shorter overall survival in patients (P = 0.023). Thus, with regard to patient 
survival, our results corroborate those of Bhowmick et al. (2004) in a population of North 
American patients. 
We have also studied the GSTP1 gene, which encodes a protein accounting for 
approximately 90% of the enzymatic activity of the glutathione S-transferase (GST) family 
(Custodio et al., 2010). GSTs constitute a superfamily of ubiquitous, multifunctional 
enzymes that are involved in cellular detoxification of a large number of endogenous and 
exogenous chemical agents that possess electrophilic functional groups (Ryberg et al., 1997). 
The GSTP1 protein is a pi-class enzyme and GSTP1 structure has been extensively examined 
in association with the risk of cancer (White et al., 2008). The influence of the GSTP1 
Ile105Val SNP on cancer has been reported with inconsistent results from different parts of 
the world (Syamala et al., 2008). Our results demonstrate that the Val105 allele was more 
frequent in a population of cancer patients than in a healthy population (0.29 and 0.06, 
respectively; P < 0.001) and that the presence of this genotype may increase the risk of 
developing astrocytomas and glioblastomas (OR = 8.60; 95% CI, 4.14-17.87; P < 0.001). 
However, we did not find an association between the GSTP1 Ile105Val SNP and patient 
survival. 
Recently, we began studying SNPs in DNA repair genes and we performed association 
analysis of SNPs in genes for the XRCC (X-ray cross-complementing) family, XRCC1 and 
XRCC3, in a series of gliomas (unpublished data). Human tumors may develop through 
alterations to the DNA repair system, which is crucially important for cellular life 
(Kawabata et al., 2005). To ensure the integrity of the genome, a complex system of DNA 
repair was developed. Base excision repair is the first defense mechanism of cells against 
DNA damage and a major means for preventing mutagenesis (Hu et al., 2005). Repair genes 
may play an important role in maintaining genomic stability through different pathways 
mediating base excision repair (Sreeja et al., 2008). For this reason, much attention has been 
given to the study of SNPs in XRCCs and their involvement in different types of cancer, 
including gliomas. We performed analysis of the Arg194Trp and Arg399Gln SNPs in XRCC1 
and the Thr241Met SNP in XRCC3 to assess their roles in the risk and prognosis for gliomas 
in Brazilians. Our results provide evidence that the XRCC1 Arg194Trp SNP may contribute 
to the etiology of human gliomas because the Trp194 allele was strongly associated with risk 
and the Gln399 allele revealed a small, increased risk for tumor development. In regard to 
the XRCC3 Thr241Met SNP, we also found evidence that XRRC3 Thr241Met may contribute 
to the etiology of human gliomas. However, when the Arg194Trp and Arg399Gln SNPs in 
XRCC1 and the Thr241Met SNP in XRCC3 were considered together, we did not find 
statistical difference between genotypes and patient survival.  
Around the globe, other groups have analyzed the association between SNPs found in 
XRCCs genes and the risk of developing gliomas. Kiuru et al. (2003) evaluated the 
association between the XRCC1 Arg194Trp, Arg280His, and Arg399Gln SNPS, the XRCC3 
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Thr241Met SNP, and glioma risk in a prospective, population-based, case-control study 
conducted in Denmark, Finland, Sweden, and the UK. They found no significant association 
with gliomas for any of the SNPs when examined individually. However, the results 
indicated possible associations between combinations of XRCC1 and XRCC3 SNPs and the 
risk of glioma development, as carriers of both homozygous variant genotypes, i.e., XRCC1 
Gln399Gln and XRCC3 Met241Met were associated with a three-fold increased risk of 
glioma (OR = 3.18; 95% CI, 1.26-8.04). In a haplotype-based approach in a Chinese 
population, Liu et al. (2007) investigated the role of 22 tagging SNPs (tSNPs) of XRCC5, 
XRCC6 and XRCC7. They found that glioma risk was significantly associated with three of 
the XRCC5 tSNPs (rs828704, rs3770502 and rs9288516, P = 0.005, 0.042 and 0.003, 
respectively), one XRCC6 tSNP (rs6519265, P = 0.044), and none of the XPCC7 tSNPs in a 
single-locus analysis. Haplotype-based association analysis revealed that glioma risk was 
significantly associated with one protective XRCC5 haplotype "CAGTT," which accounted 
for a 40% reduction (OR = 0.60, 95% CI, 0.43-0.85) in glioma risk. In a study of North 
Americans, Wang et al. (2004) found that the variant XRCC7T allele of the XRCC7 G6721T 
SNP was significantly more common in the glioma cases than in the controls (P = 0.045). The 
XRCC7 genotype frequency was also significant when comparing the cases and controls (P = 
0.040). Likewise, the difference in distribution of the combined T-variant genotype (GT + 
TT) between the cases and controls was also statistically significant (P = 0.012), suggesting 
that the T allele may be a risk factor for glioma. 
In addition to the studies mentioned above, several others were published indicating the 
results of associations, positive or negative, of genomic variations with the risk of 
developing gliomas. However, the ethnic variations, methodological variations, and the 
presence of responsible, functionally unknown SNPs in linkage disequilibrium with those 
SNPs analyzed have contributed to the dissemination of conflicting results in different parts 
of the world. Gu et al. (2009) presented a review including a list of eight literature-defined, 
putative, functional, SNPs associated with gliomas in at least two populations from case-
control studies. A summary of this list is presented in Table 3. 
Gene selection for association studies has previously been based on studies reporting the 
role of genes and their SNPs in the regulation of cellular functions. However, after the 
completion of the human genome project and the development of analytical platforms 
capable of parallel genotype processing, which resulted in new selection strategies for 
identifying susceptibility genes in many complex genetic disorders, gene selection is 
currently based on genome-wide association (GWA) studies. 
The two glioma GWA studies performed so far were published in 2010 in the same issue of 
Nature Genetics. In the first pages, Shete et al. (2009) presented the results of a meta-analysis 
of two GWA studies that involved the genotyping of 454,576 tSNPs in a total of 1,878 glioma 
cases and 3,670 controls, with posterior validation in three additional independent series 
totaling 2,545 cases and 2,953 controls. The authors identified five risk loci for glioma at 
5p15.33 (TERT rs2736100), 8q24.21 (CCDC26 rs4295627), 9p21.3 (CDKN2A-CDKN2B 
rs4977756), 11q23.3 (PHLDB1 rs498872), and 20q13.33 (RTEL1 rs6010620). In the second 
study, Wrensch et al. (2009) analyzed 275,895 SNPs in 692 adult patients with high-grade 
glioma and 3,992 controls, with a replication series of 176 high-grade glioma cases and 174 
controls. That analysis provided further evidence to implicate 9p21 (CDKN2B rs1412829) 
and 20q13.3 (RTEL1 rs6010620) in glioma risk. 
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Main paths, genes Associated SNPs Effect OR (95% CI) 
DNA repair    
XRCC7 G6721T Risk GG vs. TT, 1.82 (1.13–2.93)1 
   GG vs. TT, 1.44 (1.13–1.84)2 
    
XRCC1 Arg399Gln Risk AA vs. GG, 1.23 (0.96–1.57)2 
   AA vs. GG, 1.32 (0.97–1.81)3 
   GA/AA vs. GG, 1.44 (1.05–1.92)4 
    
PARP1 Val762ala Protective CT/CC vs. TT, 0.80 (0.67–0.95)2 
   CT/CC vs. TT, 0.71 (0.52–0.97)4 
    
ERCC1 A8092C Risk AA/AC vs. CC, 4.41 (1.6–12.2)5 
   AA/AC vs. CC, 1.67 (0.93–3.02)6 
    
ERCC2 Gln751Lys Risk CC vs. AA, 1.19 (0.93–1.52)2 
   AA vs. AC/CC, 1.66 (1.01–2.72)6 
    
MGMT Phe84Leu Protective or risk? CT/TT vs. CC, 0.66 (0.45–0.94)4 
   CT/TT vs. CC, 1.26 (0.90–1.75)7 
    
Cell cycle, EGF +61 A>G Risk P = 0.0328 
   AG/GG vs. AA, 1.52 (1.03–2.23)9 
    
Inflammation: IL13 Arg130Gln Protective AG vs. GG, 0.75 (0.48–1.17)10 
   TT vs. CC/CT, 0.39 (0.16–0.93)11 
Table 3. Selected glioma susceptibility genes and SNPs observed in at least two studies. 
1Wang et al. (2004); 2McKean-Cowdin et al. (2009); 3Kiuru et al. (2008); 4Liu et al. (2009); 
5Chen et al. (2000); 6Wrensch et al. (2005); 7Felini et al. (2007); 8Bhowmick et al. (2004); 9Costa 
et al. (2007); 10Schwartzbaum et al. (2005); 11Amirian et al. (2010). 
5. Cancer stem cells 
Both the invasive nature of the tumor and its heterogeneity probably contribute to the poor 
response to the treatment regimens available today. Tumor heterogeneity is traditionally 
attributed to the accumulation of regional variations in the tumor microenvironment and 
the diversity of subpopulations of cancer cells, which result from random genetic changes 
(Reya et al., 2001). 
The majority tumors consist of a heterogeneous population of cells with different 
proliferative potential, as well as the ability to re-form the tumor upon transplantation into 
immunodeficient mice (Visvader & Lindeman, 2008). Recently, evidence has accumulated 
that tumors contain a population with characteristics similar to normal stem cells called 
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cancer stem cells, which are also multipotent cells. This subpopulation has the ability to 
repair itself and is believed to control tumor initiation, a process that is responsible for 
tumor recurrence and the resistance to therapy observed in different tumor types, including 
gliomas (Bao et al., 2006). The observation that normal stem cells and cancer stem cells share 
common features (e.g., undifferentiated state and unlimited capacity for self-regeneration) 
led to the hypothesis of cancer stem cells (Park & Rich, 2009). 
A practical component of the cancer stem cell hypothesis is directed to the matter of intrinsic 
resistance to radiation and chemotherapy. Cancer stem cells are predicted to be difficult 
targets for tumor therapy because they exhibit a slowed cell cycle and high levels of drug 
export. Furthermore, these cells may not express or may not be dependent on the 
oncoproteins that are targeted by the most recent generation of cancer drugs (Cheng et al., 
2010). 
Cancer stem cells, similar to normal stem cells, are dependent on the microenvironment in 
which they are located. This microenvironment, formed by cells and extracellular matrix, 
controls the maintenance of organ functions. Therefore, disturbance of the local 
microenvironment in neoplastic processes can trigger tumor development (Barcellos-Hoff et 
al., 2009). In glioma, for example, studies have shown that the microenvironment is 
surrounded by blood vessels, which provide access to signaling molecules, nutrition, and 
possibly to the use of the nascent vasculature for migration, which provides direct cell 
contact and secreted factors that are responsible for maintaining the state of quiescence of 
cancer stem cells, regulating their self-renewal and multipotency (Gilbertson & Rich, 2007; 
Jandial et al., 2008). Thus, one can say that cancer stem cells and the microenvironment are 
parts of the tumor. Therefore, knowledge of the associated characteristics will lead to a new 
understanding of tumor biology and the development of new therapeutic strategies against 
these cells. For this reason, it is extremely important to characterize the different 
subpopulations of cancer stem cells that contribute to tumor formation (Denysenko et al., 
2010). 
6. Conclusion 
The development and progression of gliomas may likely be due to a multistep process that 
involves the functional inactivation of tumor suppressor genes and DNA repair genes, as 
well as the activation of oncogenes. Given the limitations of current therapies, 
understanding the pathways that lead to tumor progression should remain a high priority 
in cancer research. If the mechanisms that culminate in metastasis are fully understood, the 
development of new diagnostic and therapeutic methods may allow for a substantial 
improvement in the quality of life of affected patients and a better means of predicting 
patient prognosis. Genetic and epigenetic studies involving large cohorts of glioma patients 
in different populations have provided important information for understanding the role of 
key genes in the development and risk of gliomas. Because it is considered a work in 
progress, the WHO classification for brain tumors may soon incorporate molecular data to 
refine the classification of these diseases, which are complex from a therapeutic standpoint. 
SNPs have become increasingly popular in the genetic study of gliomas because of the 
quick, inexpensive and accurate analysis of SNPs. The identification of SNPs as risk factors 
for different glioma subtypes can be important for prevention, diagnosis and prognosis. 
Variations in the genomic sequence contribute to phenotypic diversity and susceptibility to 
or protection against many complex diseases. Thus, it is estimated that the risk of gliomas 
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may be strongly influenced by the patterns of SNPs in certain key susceptibility genes; these 
SNPs are still being identified. The same reasoning can be applied to inter-individual 
variations in genetic responses to medications, which is a field of great interest to the 
pharmaceutical industry. The benefit of having a SNP map of different populations is that it 
allows for coverage of the entire genome so that researchers can compare the patterns and 
frequencies of SNPs in their patients and associate these patterns with the disease 
concerned. The GWA studies with significant numbers and carefully matched controls have 
become a powerful tool in identifying genes involved in common genetic diseases, including 
gliomas. The identification of susceptibility alleles provides a greater understanding of 
gliomagenesis and provides target genes for potential therapeutic intervention. Unlike 
environmental exposure, SNPs do not change during the process of tumorigenesis. 
Therefore, SNPs may be useful as indicators of risk. 
The main features of normal stem cells are the capacity for self-regeneration and 
differentiation to different cell types. These characteristics are heavily regulated by the local 
microenvironment. Because studies have shown that cancer stem cells behave like normal 
stem cells, understanding the regulatory mechanisms of cancer stem cells and their 
microenvironment has changed our understanding of the biology of gliomas and has 
precipitated a reassessment of current therapies. The cure of glioma will require the 
elimination of all tumor cells, including cancer stem cells. Therefore, further studies to 
provide a better understanding of the origin of cancer stem cells and their interactions with 
the microenvironment are needed. These findings hold great promise for the development 
of new therapies that can help us improve the results achieved with current therapies and 
thereby prolong patient survival. 
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1. Introduction 
Glioblastoma multiforme (GBM; WHO grade IV) is the most malignant type of glioma and 
in addition the most abundant malignant cancer of the adult human brain. Despite progress 
in diagnosis, surgery and chemotherapy, the median survival time of patients suffering 
from GBM is approximately 15 months (Stupp et al., 2005). The five years survival time is 
less than 5% (CBTRUS, 2010). Because glioblastoma cells show a highly infiltrating growth 
into the brain tissue, a total resection is not possible. In addition, glioblastoma cells are 
remarkably resistant to chemotherapy and ionizing radiation. In addition, the association of 
a portion of these cells with hypoxic and necrotic areas within the tumor increases their 
resistance.  
Gliobastoma multiforme tumors can be classified: 
1. by histopathology (WHO) in conventional glioblastomas (93%), giant cell glioblastoma 
(5%) and gliosarcoma (2%);  
2. by pathogenesis in primary GBM (90%) and secondary GBM (10%); 
3. by gene expression analysis in (I) classical, (II) mesenchymal, (III) proneural or (IV) 
neural type of GBM; 
4. by genomic analysis in subgroups harboring specific mutations and/or altered gene 
dosage/chromosome number. 
Conventional glioblastomas constitute approximately 93% of all glioblastomas and can be 
divided into primary or secondary tumors: primary glioblastomas represent approximately 
90% and develop de novo, whereas the incidence of secondary glioblastomas that arise from 
astroyctomas WHO grade II and III is in the range of 5 to 10%. Primary and secondary 
glioblastomas differ in their genetic defects: for example 39% of primary glioblastomas 
harbor an amplification of the EGF receptor (EGFR) locus, whereas in secondary 
glioblastomas no amplification was detected. Mutations within the p53 gene are more 
abundant in secondary glioblastomas. Unconventional glioblastomas include giant cell 
glioblastomas, gliosarcomas and other rare types (for details see section 4). 
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 Conventional Glioblastoma 
Giant cell 








 de novo secondary de novo de novo 
Preoperative history 
(mo) 1,7 >25 1,6 2 
Age at diagnosis (yr) 
 55 39 42 56 
Table 1. Clinical profile of the common histopathological glioblastoma subtypes according 
to WHO. Modified from Kleihues et al., 2007; Peraud et al., 1997; Peraud et al., 1999 and Reis 
et al., 2000. 
2. Genetics of glioblastoma multiforme 
2.1 Genetic defects in human cancer 
For an introduction into the history of this field the reader is referred to the review of 
Bignold et al. (2006). Abnormalities of mitoses and chromosomes in cancer cells were 
described in late 1880s and Hansemann (1890) suggested that cancer cells develop from 
normal cells due to a tendency to maldistribute chromosomes during mitosis. The term 
somatic mutation was introduced into tumor biology by Tyzzer (1916). To explain the 
complexity of cancer phenomena “multi-hit” models (Knudson, 1971) increased in 
popularity over “single-hit” models of somatic mutation. In the multistep progression 
model of sporadic colorectal carcinoma five to ten genetic alterations seemed to be necessary 
for generation of the malignant phenotype  (for review see: Fearon and Vogelstein, 1990). 
The onset and extent of genetic alterations in progression of sporadic colorectal tumors was 
studied in detail by Stoler et al. (1999). Their observation of about 10,000 genomic alterations 
occurring per cancer cell has brought into attention the issue of genetic instability in human 
cancer. Genetic and phenotypic instability are hallmarks of cancer cells and appear early in 
tumor progression; most cancers are of clonal origin, but individual cancer cells are highly 
heterogenous. There are three major forms of genetic instability in cancer: (1) aneuploidy, in 
which entire chromosomes are lost or gained; (2) intrachromosomal instability, 
distinguished by insertions, deletions, translocations or amplifications and (3) point 
mutations, which accumulate in certain forms of hereditary cancer as well as in a small 
portion of sporadic cancers. Stanbridge et al. (1981) reported that specific chromosome loss 
is associated with the expression of tumorigenicity in human cell hybrids. It was published 
by Duesberg et al. (1998) that genetic instability of cancer cells is proportional to their degree 
of aneuploidy. Aneuploidy, an abnormal number of chromosomes, is the result of 
asymmetrical segregation of chromosomes to daughter cells during mitosis. Once 
aneuploid, cells will continue to segregate chromosomes asymmetrically during subsequent 
rounds of mitosis, a process that has been termed “chromosome error propagation” (for 
review see: Holliday, 1989).  
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Unlike oncogenes, tumor suppressor genes generally follow the “two hit” model, which 
implies that both alleles of a particular tumor suppressor gene have to be inactivated before 
an effect is manifested. If only one allele is inactivated, the second correct allele can still 
produce the correct protein. Whereas mutant oncogene alleles are typically dominant, 
mutant tumor suppressor genes are usually recessive.  
The mutational activation of oncogenes induces loss of heterozygosity and genomic 
instability in mammalian cells. These results have used to formulate the oncogene-induced 
replication stress model (for review see: Halazonetis et al., 2008). In precancerous lesions 
with intact p53 gene, the oncogene-induced DNA damage leads to p53-dependent apoptosis 
and/or senescence. After the function of p53 is lost, cells are able to escape its apoptotic 
and/or senescence effects, and the precancerous lesion is predestinated to become cancerous 
(Gorgoulis et al., 2005; Bartkova et al., 2005; Bartkova et al., 2006; Di Micco et al., 2006). DNA 
damage has an important role in promoting polyploidization. If cells with altered DNA 
enter mitosis, defects in chromosomal segregation and cytokinesis occur (for review see: 
Chow and Poon, 2010). 
The gene for the tumor suppressor protein p53 is mutated in about half of human cancers. It 
was shown recently by several groups, that eliminating p53 function by mutation leads to 
dramatically increased reprogramming efficiency of differentiated cells into induced 
pluripotent stem cells. Important for the field of cancer biology is the report of Mizuno et al. 
(2010), demonstrating that breast and lung cancers harboring TP53 mutations exhibit stem 
cell-like transcriptional signatures. These data suggest a role for active p53 in preventing the 
emergence of cancerous stem-like cells during tumor progression. Since TP53 mutations 
often arise in a late stage of tumor progression, when many cancer cells with different 
genetic alterations coexist, some cancer cells may be susceptible to reprogramming to 
generate stem-like cancer cells, leading to further tumor progression and cellular 
heterogeneity. 
2.2 Genetic diversity of glioblastoma multiforme 
DNA sequencing and gene dosage analysis of GBM revealed a high number of shared as 
well as individual-specific mutations, deletions and amplifications of DNA sequences. A 
hallmark of many primary GBMs is the loss of one copy of chromosome 10 harboring the 
locus for the PTEN tumor suppressor gene and/or amplification of the EGF receptor locus 
at chromosome 7. As a consequence, the Akt signalling pathway is often overactivated in 
GBM. Array comparative genomic hybridization (CGH) analyses revealed, that primary 
glioblastomas can be divided into three major genetic subgroups, i.e. tumors with 
chromosome 7 gain and chromosome 10 loss, tumors with chromosome 10 loss and tumors 
without copy number changes in chromosomes 7 or 10 (Misra et al., 2005). 
Parsons et al. (2008) sequenced 20661 genes coding for proteins in 22 GBM samples and 1 
normal sample. They observed that 685 genes contained at least 1 non-silent somatic 
mutation. 94% of these alterations were single base substitutions that were uniformly 
distributed among the 21 GBM samples, resulting in an average of 47 mutations per GBM.  
About 15% of the missense mutations were predicted to have a significant effect on protein 
function. The same 22 GBM samples were analysed for copy number alterations through 
hybridization of DNA samples to single nucleotide polymorphism (SNP) arrays, leading to 
the identification of 147 amplifications and 134 homozygous deletions.   
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Parsons et al. (2008) next studied the probabilities that the mutations were either “driver” or 
“passenger”. Driver mutations may provide a selective advantage to the cancer cell, whereas 
passenger mutations arise by the instability of the tumor genome and have no effect on 
tumor growth. Analysis of all data was used to identify GBM candidate cancer genes that 
were likely drivers, pointing to alterations in several signaling pathways: CDKN2A (altered 
in 50% of GBMs); TP53, EGFR, and PTEN (altered in 30 to 40%); NF1, CDK4, and RB1 
(altered in 12 to 15%); and PIK3CA and PIK3R1 (altered in 8 to 10%). By analysing 
additional gene members within signaling pathways affected by these genes, the authors 
identified alterations of critical genes in the RB1 pathway (RB1, CDK4, and CDKN2A; 
altered in 68% of GBMs), TP53 pathway (TP53, MDM2, and MDM4; altered in 64%), and the 
PI3K/PTEN pathway (PIK3CA, PIK3R1, PTEN, and IRS1; altered in 50%). Mutations in the 
NF1 gene (coding for neurofibromatosis-related protein NF-1 or neurofibromin 1, a 
stimulator of GTPase activity of ras proteins) were observed in 16 of 105 GBMs (15%). 
Mutations in the IDH1 gene (coding for the citric acid cycle enzyme isocitrate dehydro-
genase 1) were reported in 18 of 149 GBMs (12%).   
The Cancer Genome Atlas Research Network (2008) study analysed 91 GBM samples and 
found 453 non-silent somatic mutations in 223 genes. Affected signaling pathways include 
TP53, PTEN, NF1, EGFR, ERBB2, RB1, NF1, PIK3R1, and PIK3CA. High-level amplifications 
were observed frequently for EGFR, CDK4, PDGFR, MDM2, and MDM4 genes, whereas 
homozygous deletion events were often associated with CDKN2A/B and PTEN genes. In 
this study, GBMs from patients treated with temozolomide and/or lomustine were analysed 
for mutations. Treatment with alkylating agents resulted in more than tenfold increase in 
the number of mutations, that was dependent on the methylation status of the gene for the 
DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). 
Bredel et al. (2009) published “A Network Model of a Cooperative Genetic Landscape in 
Brain Tumors”. The authors demonstrate that a multigene risk scoring model based on gene 
dosis and expression of 7 landscape genes (POLD2, CYCS, MYC, AKR1C3, YME1L1, 
ANXA7, and PDCD4) is associated with the overall length of survival in 189 glioblastoma 
samples. Yadav et al. (2009) reported that loss of function of ANXA7 (annexin 7) stabilizes 
the EGFR protein and increases EGFR signaling in glioblastoma cells. ANXA7 
haploinsuffiency doubles the tumorigenic potential of glioblastoma cells. The heterozygous 
loss of ANXA7 in about 75% of GBM in the Cancer Genome Atlas Research Network study 
(2008) plus the observed infrequent ANXA7 mutation in about 6% of GBM is indicative for 
its role as a haploinsuffiency gene. A multigene predictor model of outcome in GBM based 
on expression analysis of 9 genes was published by Colman et al. (2009). 
Verhaak et al. (2010) used gene expression analysis to divide GBM into 4 subtypes: I. 
Classical, II. Mesenchymal, III. Proneural, and IV. Neural. The reproducibility of this 
classification was demonstrated in an independent validation set. To get insight into the 
genomic events, the authors used copy number and sequence data from the Cancer Genome 
Atlas Research Network (2008).  
I. Classical subtype of GBM  (21% of core samples): 
Neural precursor and stem cell markers NES, as well as Notch and Sonic hedgehog 
signaling pathways were highly expressed in the Classical subtype. Chromosome 7 
amplification paired with chromosome 10 loss was seen in 100% of the Classical subtype. 
High level EGF receptor (EGFR) gene amplification was observed in 97% of the Classical 
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subtype and infrequently in other subtypes. Even though TP53 is the most frequently 
mutated gene in GBM (Cancer Genome Atlas Research Network, 2008), there was a distinct 
lack of TP53 mutations in the Classical subtype samples sequenced. Deletion events at 10q23 
harboring the PTEN locus were observed in 100% of the Classical subtype. Focal 9p21.3 
homozygous deletion targeting CDKN2A (encoding for both p16INK4A and p14 ARF) was 
frequent and co-occurred with EGFR amplification in 94% of the Classical subtype. 
II. Mesenchymal subtype of GBM (32% of core samples): 
The Mesenchymal subtype displayed expression of mesenchymal markers as described 
earlier (Phillips et al. 2006). Genes in the tumor necrosis super family pathway are highly 
expressed in this subtype. Focal hemizygous deletion of a region at 17q11.2, containing the 
gene NF1 (coding for neurofibromatosis-related protein NF-1 or neurofibromin 1, a 
stimulator of GTPase activity of ras proteins) occurred predominantly in the Mesenchymal 
subtype. NF1 mutations were found in 20 samples, 14 of which were classified as 















TP53 0% 32% 54% 21% 23% 
PTEN 23% 32% 16% 21% 17% 
NF1 5% 37% 5% 16% 13% 
EGFR 32% 5% 16% 26% 13% 
IDH1 0% 0% 30% 5% 8% 
PIK3R 5% 0% 19% 11% 6% 
RB1 0% 13% 3% 5% 5% 
ERBB2 5% 3% 5% 16% 5% 
EGFRvIII 23% 3% 3% 0% 5% 
PIK3CA 5% 3% 8% 5% 4% 
PDGFRA 0% 0% 11% 0% 3% 
Table 2. Frequently mutated genes in Glioblastoma multiforme and their distribution among 
GBM subtypes according to Verhaak et al (2010). Outstanding frequencies are grayed out for 
comparison between subtypes. Modified from Verhaak et al. (2010). 
III. Proneural subtype of GBM  (31% of core samples): 
The Proneural group showed high expression of oligodendrocytic genes, underlining its 
status as an atypical GBM subtype. The majority of TP53 mutations and TP53 loss of 
heterozygosity were found in Proneural samples.  The classic GBM signature, chromosome 
7 amplification associated with chromosome 10 loss was less prevalent and occurred in only 
54% of the Proneural subtype. Focal amplifications of the locus at 4q12 harboring the PDGF 
Receptor A (PDGFRA) gene were seen in all subtypes of GBM but at a much higher rate 
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TP53 0% 32% 54% 21% 23% 
PTEN 23% 32% 16% 21% 17% 
NF1 5% 37% 5% 16% 13% 
EGFR 32% 5% 16% 26% 13% 
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Table 2. Frequently mutated genes in Glioblastoma multiforme and their distribution among 
GBM subtypes according to Verhaak et al (2010). Outstanding frequencies are grayed out for 
comparison between subtypes. Modified from Verhaak et al. (2010). 
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status as an atypical GBM subtype. The majority of TP53 mutations and TP53 loss of 
heterozygosity were found in Proneural samples.  The classic GBM signature, chromosome 
7 amplification associated with chromosome 10 loss was less prevalent and occurred in only 
54% of the Proneural subtype. Focal amplifications of the locus at 4q12 harboring the PDGF 
Receptor A (PDGFRA) gene were seen in all subtypes of GBM but at a much higher rate 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
108 
(35%) in Proneural samples. 11 of the 12 observed mutations in the isocitrate dehydrogenase 
1 gene (IDH1) were found in this class. 
IV. Neural subtype of GBM (16% of core samples): 
The Neural subtype was typified by the expression of neuron markers. The two normal 
brain tissues samples examined in this data set were both classified as Neural subtype. 

























7p11.2 EGFR 100% 95% 54% 96% 
7q21.2 CDK6 92% 89% 46% 96% 
7q31.2 MET 86% 91% 54% 92% 
7q34  86% 91% 52% 92% 






















17q11.2 NF1 5% 38% 6% 17% 
10q23 PTEN 100% 87% 69% 96% 
9p21.3 CDKN2A/CDKN2B 95% 67% 56% 71% 
13q14 RB1 16% 53% 52% 46% 
Table 3. Frequency of copy number alterations in Glioblastoma subtypes according to gene 
expression. Modified from Verhaak et al. (2010). 
2.2.1 Subtypes and clinical correlations 
Three of four tumors classified as secondary GBMs were found in the Proneural group. The 
Proneural subtype was associated with younger age, PDGFRA abnormalities, IDH1 and 
TP53 mutations, all of which have been associated with secondary GBM in earlier studies 
(Arjona et al., 2006; Furnari et al., 2007; Kleihues and Ohgaki, 1999; Watanabe et al., 1996; 
Yan et al., 2009). Verhaak et al. (2010) concluded that tumors did not change class at 
recurrence, because recurrent tumors were found in all subtypes (Murat et al., 2008). 
Although statistically not significant, there was a trend towards longer survival for patients 
with a Proneural signature. Aggressive treatment significantly reduced mortality in Classi-
cal and Mesenchymal subtypes, had a less pronounced effect in the Neural subtype and did 
not alter survival in the Proneural subtype. There was no association of GBM subtype with 
methylation status of the DNA repair gene MGMT, which has been positively linked to 
therapy response (all data and conclusions from Verhaak et al., 2010).  
Bredel et al. (2010) reported that NFKBIA (nuclear factor of κ-light polypeptide gene 
enhancer in B-cells inhibitor-α), an inhibitor of EGFR signaling pathway, is often deleted in 
GBM (Table 4). Most deletions occur in non-classical subtypes of GBM. Deletion and low 
expression of NFKBIA were reported to be associated with unfavorable outcomes. The 
authors present a two-gene model based on the expression of NFKBIA and MGMT that is 
strongly associated with the clinical course of GBM (Table 5). 
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NFKBIA deletion 6% 30% 39% 22% 
EGFR amplification 80% 20% 11% 46% 
Table 4. Relationship of four molecular subtypes of glioblastoma to gene-dosage profiles for 
NFKBIA and EGFR across 188 glioblastomas. NFKBIA deletions are rare in classical (6%) and 
more common in non-classical (32%) glioblastomas.  
Irrespective of subtype a degree of mutual exclusivity between NFKBIA deletion and EGFR 
amplification was suggested: NFKBIA deletion or  EGFR amplification were observed in 
53%, whereas concomitant occurrence (NFKBIA deletion together with EGFR amplification) 
was observed only in 5%. All data and conclusions are from Bredel et al. (2010). 





















































High-risk Low NFKBIA, 
High MGMT 
44 Low NFKBIA, 
Unmeth. MGMT 
























92 High NFKBIA, 
Meth. MGMT 
91 High NFKBIA, 
Meth. MGMT 
122 
Table 5. The strong association of the clinical course of GBM with expression of NFKBIA 
and expression/methylation status of the promoter of O6-methylguanine-DNA methyltrans-
ferase (MGMT). All data and conclusions are from Bredel et al. (2010). 
To add an additional level of complexity, gene dosage analysis of separate tumor areas 
derived from one GBM revealed area-specific genomic imbalances (see chapter 5). 
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2.3 Correlation between genetic and histopathologic diversity in GBM 
Glioblastomas are morphologically highly heterogeneous and in addition the histological 
features often vary in different areas of one tumor. Currently three distinct common 
histopathological variants of GBM are recognized by the actual World Health Organization 
classification scheme, including conventional glioblastoma, giant cell glioblastoma, and 
gliosarcoma.  
Despite of lack of any histopathological difference, primary (de novo) and secondary (with an 
evidence of a lower-grade precursor) conventional glioblastomas harbor distinct molecular 
genetic abnormalities: Primary glioblastomas are characterized by relatively high 
frequencies of EGFR amplification, PTEN deletion, and CDKN2A (p16) loss, whereas secon-
dary glioblastomas often contain TP53 mutations, especially those involving codons 248 and 
273 or G:C->A:T mutations at CpG sites (Ohgaki et al., 2004). 
Even within the conventional glioblastoma category, the cellular composition is 
heterogeneous and may include small or fibrillary, gemistocytic, granular, lipidized and 
occasional giant cells or oligodendroglial components. According to the predomination of 
one of these cell types indicating patterns of differentiation, the WHO distinguishes 
respective subtypes of glioblastoma such as small cell glioblastoma, glioblastoma with 
granular cell astrocytoma features, glioblastoma with lipidized cells; whereas giant cell 
glioblastoma is recognized as a distinct clinicopathologic entity (Kleihues et al., 2007; Miller 
and Perry, 2007). 
Small cell astrocytoma is an aggressive histologic variant being often misdiagnosed as 
anaplastic oligodendroglioma because of considerable morphologic similarities. Despite of 
histological overlap clinicopathologic and genetic features are distinct: there are no small 
cell astrocytomas harboring 1p/19q codeletions, whereas vIII mutant form of EGFR, EGFR 
amplification and 10q deletions are present in 50%, 69% and 97% of small cell astrocytomas, 
respectively (Perry et al., 2004). 
Once thought to represent a reactive component, gemistocytes have been found to harbor 
TP53 mutations and cytogenetic abnormalities (chromosome 7p gains and 10q losses); 
therefore, they are now thought to represent a true neoplastic component (Kros et al., 2000). 
In rare cases granular cells may predominate and create the impression of a granular cell 
tumor. Similar to astrocytomas with non-granular cytology, these tumors may also harbor 
TP53 mutations, high-frequency loss of heterozygosity at 9p, 10q, and 17p, and less frequent 
loss of heterozygosity at 1p and 19q (Castellano-Sanchez et al., 2003). Brat et al. (2002) 
reported the largest series of such tumors to date (22 cases, including 4 grade II, 7 grade III, 
and 11 grade IV tumors) and found that these tumors were more aggressive than non-
granular cell astrocytomas of the same grade. 
Glioblastoma with oligodendroglioma component is an astrocytoma WHO-grade IV containing 
oligodendroglial areas varying in size and frequency (Kleihues et al., 2007). Despite of 
oligodendroglial component and in contrast to rather frequent codeletions in WHO grade III 
anaplastic oligodendroglioma (approximately 85%), deletion of either 1p (24%), 19q (43%), 
or combined 1p/19q (22%) is relatively infrequent in glioblastoma with oligodendroglioma 
component (Miller and Perry, 2007). 
Giant cell glioblastoma is a rare variant that constitutes up to 5% of glioblastoma and is 
recognized as a distinct clinicopathologic entity in the WHO 2007 classification. Although 
occasional giant cells may be found in conventional glioblastoma, these cells are a 
predominating cytologic component in giant cell glioblastoma. As the name implies, the 
tumor cells are markedly enlarged and bizarre, often appear often multi-nucleated and 
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tumor masses are typically well-circumscribed. It occurs in younger patients (fifth decade) 
(Kleihues et al., 2007). 
The molecular genetic features include relatively high frequencies of TP53 mutations (59% 
to 90%) and PTEN deletion (up to 33%), whereas EGFR amplification/overexpression and 
homozygous p16 deletion (p16INK4a gene at the CDKN2A locus, 9p21) are lacking in 
comparison to conventional glioblastoma (Meyer-Puttlitz et al., 1997; Peraud et al., 1997; 
Peraud et al. 1999; Temme et al. 2010). Therefore, giant cell glioblastomas contain clinical 
and molecular genetic features of both primary and secondary glioblastomas. Giant cell 
glioblastomas have an increased expression of Aurora Kinase B; combined with TP53 
mutations this may be responsible in induce cytokinesis defects and the development of 
multinucleated cells (Temme et al., 2010).  
 





PTEN mutation 38% 32% 33% 4% 
EGFR amplification 0% 39% 5% 0% 
TP53 mutation 23% 11% 84% 67% 
p16INK4a deletion 37% 36% 0% 4% 
MDM2 amplification
5% 8% 0% 0% 
Table 6. Genetic profile of the common histopathological glioblastoma subtypes. Similar 
tendencies are indicated by grayscale. Modified from Kleihues et al., 2007; Peraud et al., 
1997; Peraud et al., 1999 and Reis et al., 2000. 
Despite showing a very poor prognosis giant cell glioblastoma appears to carry a slightly 
better prognosis than conventional glioblastoma (Burger and Vollmer, 1980; Margetts and 
Kalyan-Raman, 1989; Shinojima et al., 2004), perhaps because of a less infiltrative behaviour. 
Gliosarcoma constitutes roughly 2% of GBMs and is also recognized as a distinct clinico-
pathologic entity in the WHO 2007 classification. These tumors are characterized by their 
well-circumscribed, biphasic tissue pattern with clearly distinguishable areas of glial and 
mesenchymal differentiation. The glial component of gliosarcoma may display any of the 
aforementioned cytologic attributes and is typically immunoreactive for GFAP. The 
mesenchymal component is GFAP-negative and may also carry a wide variety of 
morphologic appearances, with evidence of differentiation along fibroblastic, cartilaginous, 
osseous, smooth and striated muscle, and adipose lines (Kleihues et al., 2007). There is a 
cytogenetic and molecular evidence for a monoclonal origin of both components (Actor et 
al., 2002; Paulus et al., 1994; Reis et al., 2000).  
Exept for the infrequent EGFR amplification, gliosarcomas are genetically similar to primary 
glioblastomas: they harbor likewise low frequency of TP53 mutations (up to 24%) and 
similar rates of PTEN deletions (38%) as well as deletions of p16INK4a gene (at the CDKN2A 
locus, 9p21) in roughly 37% (Actor et al., 2002; Reis et al., 2000). 
Comparative genomic hybridization analysis in 20 gliosarcomas by Actor et al. (2002) 
revealed such common chromosomal imbalances as gains on chromosomes 7 (75%), X 
(20%), 9q and 20q (15% each) as well as losses on chromosomes 13q (15%), 10 and 9p (35% 
each). 
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2.4 Area-specific genomic Imbalances in glioblastoma multiforme 
Using flow cytometry data analysis Hoshino et al. (1978) reported that different tumor 
regions of one glioblastoma showed a highly variable distribution of ploidy. By use of a 
DNA fingerprinting technique Misra et al. (2000) analysed genetic alterations within two or 
three tumor areas from seven glioblastomas. In all cases except one, different areas of one 
tumor displayed different fingerprints, indicating a striking extent of intratumoral genetic 
heterogeneity. Conventional comparative genomic hybridization (CGH) was used to study 
the intratumoral patterns of genomic imbalance in Glioblastoma multiforme (Harada et al., 
1998; Jung et al., 1999). Array comparative genomic hybridization was utilized by 
Nobusawa et al. (2010) to study in detail tumor area-specific genomic imbalances. Genetic 
alterations common to all the areas analyzed within a single tumor included gains at 
chromosomes 1q32.1 (PIK3C2B, MDM4), 4q11-q12 (KIT, PDGFRA), 7p12.1-11.2 (EGFR), 
12q13.3-12q14.1 (GLI1, CDK4), and 12q15 (MDM2), and loss of chromosomes at 9p21.1-24.3 
(p16INK4a/p14ARF = CDKN2a), 10p15.3-q26.3 (PTEN, etc.), and 13q12.11-q34 (SPRY2, RB1). 
These alterations are likely to be causative in the pathogenesis of glioblastomas (driver 
mutations). Additionally, the authors reported numerous tumor area-specific genomic 
imbalances, which may be either nonfunctional (passenger mutations) or functional, but 
constitute secondary events reflecting clonal selection and/or progressive genomic 
instability, a hallmark of glioblastomas. Area specific-evolution of genomic imbalances in 
GBM may be comparable to the genetic evolution and genomic instability of metastatic 
pancreas cancer that has been studied in detail recently (Campbell et al., 2010; Yachida et al., 
2010). 
Loeper et al. (2001) reported that frequent mitotic errors occur in genetically micro-
heterogenous glioblastomas. The authors used fluorescent in situ hybridization (FISH) to 
study chromosome numbers in a series of 24 glioblastomas. All examined chromosomes 
showed mitotic instability indicated by numerical aberrations within significant amounts of 
tumor cells.  For chromosomes 10 and 17 only monosomy was observed, whereas 
chromosome 7 showed trisomy/polysomy. In contrast to other chromosomes displaying 
monosomy as well as trisomy, copy number changes of chromosomes 7, 10 and 17 seem to 
be the result of selection in favor of the respective aberration (Loeper et al., 2001). In this 
context it is interesting to note that neural stem and progenitor cells in the subventricular 
zone of mouse postnatal brain are frequently aneuploid (Kaushal et al., 2003) and that 
chromosome segregation defects contribute to aneuploidy in normal neural progenitor cells 
of the mouse cerebral cortex (Yang et al., 2003). Studies in mice and human demonstrate that 
chromosomal mosaicism is a prominent feature of neural stem cells, whereas 
interchromosomal translocations or partial chromosomal deletions or insertions are 
extremely rare (for review see: Peterson et al., 2008). Glioblastoma stem cells share several 
properties with neural stem cells, i.e. the growth in floating spheres under serum-free 
conditions, the expression of the stem cell marker nestin and the differentiation into neural 
cells like astrocytes or neurons. This similarity in marker expression and behaviour has led 
to the hypothesis that glioblastoma stem cells may be derived from NSCs (Berger et al., 2004; 
Sanai et al., 2005).  
Recent research makes clear that GBMs do not behave as a whole; local heterogeneity may 
arise because the tumor regionally adapts to the microenvironment. The influence of 
microenvironment-induced stimuli may be the force behind clonal selection and acquisition 
of area specific genomic imbalances in GBM. In addition, regional genomic alterations may 
be associated with the development of resistance to irradiation and/or chemotherapy, 
resulting in tumor recurrence and/or progression. 
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2.5 Mechanisms leading to genetic alterations in glioblastoma multiforme 
Analysis of copy number alterations showed an average of 7 amplifications and 6 
homozygous deletions per GBM. In addition, an average of 47 mutations was reported 
(Parsons et al., 2008). 
A characteristic feature of GBM is a chromosomal instability (CIN) phenotype distinguished 
by the loss or gain of complete chromosomes, for example by the gain of chromosome 7 
and/or loss of chromosome 10. These chromosome copy number changes can be explained 
by merotelic spindle attachment that is associated with bipolar but more often with 
multipolar mitosis. Multipolar spindle pole coalescence in cells with supernumerary 
centrosomes has been reported as a major source of chromosomal misattachment and 
chromosome missegregation in colorectal cancer cell lines (Silkworth et al., 2009). 
Obviously, specific chromosome aberrations may be associated with growth advantage for 
clonal populations of cancer cells (for example by the loss of tumor suppressor genes).  
In addition to its well-defined role in signal transduction at the plasma membrane, recent 
results have identified PTEN as a new guardian of the genome (for review see: Yin and 
Shen, 2008). Pten-deficient mouse embryo fibroblasts revealed an increased frequency of 
mitotic centromere-associated chromosomal instability as well as spontaneous DNA double-
strand  breaks (Shen et al., 2007). Li Li et al. (2008) developed a mouse model by infecting 
PTEN-/- neural precursor cells with an EGFRvIII expressing retrovirus and found that 
EGFRvIII expression and PTEN loss synergistically induced chromosomal instability and 
glial tumors. 
Interestingly, polyploidization of mammalian hepatocytes occurs through failed cytokinesis 
and is followed by a process that was called reductive mitoses (Duncan et al. 2010). The 
authors postulate a dynamic model of hepatocyte polyploidization, ploidy reversal and 
aneuploidy (ploidy conveyor) and propose that this mechanism evolved to generate genetic 
diversity and permits adaptation of hepatocytes to xenobiotic and nutritional injury.  
Several studies point to a link between centrosome amplification, chromosomal  instability 
and the development of cancer (for review see: D´Assoro et al., 2002). Cells in resected high 
grade gliomas and cultured glioblastoma cells have been reported to exhibit often 
centrosome amplifications (Loh et al., 2010) and the centrosomal protein γ-tubulin is over-
expressed and shows altered subcellular localization in GBM (Katsetos et al., 2006; Loh et al., 
2010). Multipolar mitoses were occasionally observed in time lapse recordings of cultured 
glioblastoma cells (Hegedüs et al., 2000). Our laboratory used long term life cell imaging to 
study mitoses in a newly established glioblastoma cell line and found that cytokinesis 
defects followed by multipolar mitosis may be an important mechanism that is used by 
glioblastoma cells to reduce ploidy and generate viable daughter cells (our unpublished 
results). 
2.6 Epigenetics in glioblastoma multiforme 
To add another level of complexity, many types of cancer cells carry aberrant epigenetic 
modifications. Changes in epigenetic marks (caused or not caused by genetic alterations) 
may have an fundamental impact on tumor development and/or tumor progression. 
Epigenetic markers in human gliomas have been reviewed by Hesson et al. (2008). Two 
groups have studied in detail DNA methylation profiles in GBM (Etcheverry et al. 2010; 
Nousmehr et al., 2010).  Hypermethylation at a large number of genetic loci occurred in a 
subgroup (proneural group) of glioblastoma patients and was associated with improved 
outcome (Nousmehr et al., 2010).  
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Genetic Diversity of Glioblastoma Multiforme: Impact on Future Therapies 
 
113 
2.5 Mechanisms leading to genetic alterations in glioblastoma multiforme 
Analysis of copy number alterations showed an average of 7 amplifications and 6 
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(Parsons et al., 2008). 
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by merotelic spindle attachment that is associated with bipolar but more often with 
multipolar mitosis. Multipolar spindle pole coalescence in cells with supernumerary 
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groups have studied in detail DNA methylation profiles in GBM (Etcheverry et al. 2010; 
Nousmehr et al., 2010).  Hypermethylation at a large number of genetic loci occurred in a 
subgroup (proneural group) of glioblastoma patients and was associated with improved 
outcome (Nousmehr et al., 2010).  
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Epigenetic mechanisms like methylation of DNA have already an impact on chemotheraypy 
of GBM. Temozolomide (TMZ, Temodal®) is an orally administered alkylating drug that is 
often used for chemotherapy of GBM. O6-Methylguanine-DNA methyltransferase (MGMT) 
is a DNA repair enzyme that specifically removes promutagenic alkyl DNA adducts from 
the O6 position of guanine residues in DNA which are induced by alkylating agents like 
temozolomide (Goth and Rajewsky, 1974; Margison and Kleihues, 1975). Loss of MGMT 
expression may be caused by transcriptional silencing through hypermethylation of its CpG 
islands (Esteller et al., 1999; Qian & Brent, 1997), is frequently (45% to 75%) present in 
glioblastomas (Bello et al., 2004; Kamiryo et al., 2004; Nakamura et al., 2001) and results in 
improved survival of glioblastoma patients treated with the alkylating agent temozolomide 
(Fukushima et al., 2009; Hegi et al, 2005; Hegi et al., 2008). On the other hand not all 
glioblastoma patients with MGMT promoter methylation respond to alkylating agents and 
in addition responding GBMs cannot avoid eventual recurrence (Fukushima et al., 2009; 
Hegi et al., 2008). MGMT promoter methylation appears to occur with a higher frequency in 
secondary than in primary glioblastoma (Bello et al., 2004; Nakamura et al., 2001) but there 
is no evidence about its correlation with other histopathologic subtypes.  
However, prospective randomized studies of EORTC (European Organisation for Research 
and Treatment of Cancer) and NCIC (National Cancer Institute of Canada) trial have 
revealed a significant prolongation of progression free and overall survival for patients with 
newly diagnosed glioblastoma treated by the concomitant and adjuvant temozolomide and 
irradiation. By this means median survival has been increased over one year (Stupp et al., 
2005, 2009).  
The methylation status of the MGMT gene promoter is being used as a biomarker for the 
potential benefit of the addition of temozolomide to the therapy because its epigenetic 
silencing has been identified as a strong and independent predictive factor of treatment 
response for anaplastic glioma patients undergoing chemotherapy with alkylating agents 
(Hegi et al., 2005; Wick et al., 2009). 3 to 5% of the GBM patients survive for more than 3 
years. MGMT hypermethylation was reported to be significantly more frequent in the long-
term survivor group (Krex et al., 2007).  
The assumption that DNA methylation of CpG island on the MGMT promoter represses 
consecutively transcriptional activity of the MGMT gene and expression of MGMT protein 
has been used to explain the correlation between the positive promoter methylation status 
and favorable treatment response after chemotherapy with temozolomide (Kaina et al., 
2007).  
However, studies that were performed to validate a relationship between MGMT promoter 
methylation and protein expression have yielded contradictory results in brain tumors as 
well as in other neoplasms (Brell et al., 2011). While some studies report a significant 
correlation between MGMT protein expression analyzed by immunohistochemistry (IHC) 
and MGMT promoter status measured by methylation-specific polymerase chain reaction 
(MSP) in glioblastoma and brain metastases of various origin (Ingold et al., 2009; Spiegl-
Kreinecker et al., 2009; Tang et al., 2011), other studies failed to detect correlations between 
both parameters (Brell et al., 2005, 2011; Christmann et al., 2010; Preusser et al., 2008).  
In addition, there is increasing evidence that MGMT mRNA expression, unlike MGMT protein 
expression, could be a better predictor for tumor sensitivity to alkylating agents than MGMT 
methylation status (Everhard et al., 2009; Kreth et al., 2011). Kreth et al. (2011) provide not only 
evidence that the degree of MGMT mRNA expression is highly correlated with the MGMT 
promoter methylation status, but also that low MGMT mRNA expression is strongly 
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predictive for prolonged time to progression, treatment response, and length of survival. 
Furthermore, the authors found that in case of discordance the patients with methylated 
tumors combined with high MGMT mRNA expression did significantly worse than those with 
low transcriptional activity or unmethylated tumors with low MGMT mRNA expression. 
Finally Kreth et al. (2011) assume  methylation-independent pathways of MGMT expression 
regulation; however, the exact role of DNA-methyltransferases DNMT1 and DNMT3b that are 
likely to be involved in methylation of CpG islands of MGMT gene promoter remains unclear. 
In the Cancer Genome Atlas Research Network (2008) study, GBMs from patients treated 
with temozolomide and/or lomustine were analysed for mutations. Treatment with 
alkylating agents resulted in a more than tenfold increase in the number of mutations that 
was dependent on the methylation status of the MGMT gene. This phenotype seems to be 
caused by mutations in the MSH6 gene (Cahill et al., 2007; Hunter et al., 2006; Yip et al., 
2009) and other genes of the DNA mismatch repair pathway (Cancer Genome Atlas 
Research Network, 2008). The loss of the mismatch repair protein MSH6 in GBM is 
associated with tumor progression during temozolomide treatment (Cahill et al., 2007; 
Hunter et al., 2006; Yip et al., 2009). 
2.7 Stem cells in glioblastoma multiforme 
The cancer stem cell concept that is of importance for the genesis of many types of cancer 
receives increasing credit also in the field of GBM. A minor population of GBM cancer stem 
cells, which may be derived from genetically altered neural stem cells, is presumed to 
generate transit amplifying cells with high mitotic activity. Because these stem cells appear 
to have a low mitotic activity, they are difficult to target by radiotherapy and conventional 
chemotherapy. 
For recent reviews on glioblastoma stem cells the reader is referred to Huang et al. (2010) 
and McLendon and Rich (2010). Ignatova et al. (2002) firstly described cells with stem-like 
properties in human cortical glial tumors. Singh et al. (2003) used the cell surface marker 
CD133 to isolate a clonogenic population of cells showing stem-like features in medullo-
blastomas and pilocytic astrocytomas. These cells were declared as tumor stem cells based 
on their capabilities of self-renewal and multilineage differentiation. Galli et al. (2004) and 
Yuan et al. (2004) confirmed these findings for glioblastomas. Bao et al. (2006a) selected 
CD133+ cells from glioblastoma biopsies that were capable of forming tumorspheres in 
vitro, demonstrated self-renewal and multilineage differentiation and resulted in tumours 
after transplantation into nude mice. In contrast, CD133- cells did not form tumorspheres in 
vitro und were not tumorigenic in nude mice. CD133+ cells proved to be a minor population 
of cells in GBM biopsies. Clinical studies suggested that the percentage of CD133+ cells 
(Zhang et al., 2008; Zeppernick et al., 2008) or the rate of tumorsphere formation in vitro 
(Laks et al., 2009; Panosyan et al., 2010) can be used to predict overall survival time of 
patients. However, it should be noted, that contrary results also exist (Phi et al., 2009; Kim et 
al., 2011). In recurrent glioblastomas the percentage of CD133+ cells is increased strongly 
when compared with primary glioblastomas (Pallini et al., 2010). Surprisingly, the increase 
in expression of CD133 after tumor recurrence was associated significantly with longer 
survival.  Thon et al. (2008) described a correlation between the amount of CD133+ cells 
within the tumor mass and the WHO grade of glioma (WHO grade II, III and IV). Bao et al. 
(2006a) demonstrated that CD133+ cells constitutively expressed DNA repair genes at much 
higher levels that CD133- cells, mediating resistance to X-irradiation in CD133+ cells.  
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Brain tumor stem cells seem to be localized in a perivascular niche (Bao et al., 2006b; 
Calabrese et al., 2007; Shen et al., 2008) and low oxygen tension (hypoxia) is associated with 
its undifferentiated state. In glioblastomas, cancer stem cells express much higher levels of 
VEGF than non-stem cancer cells and show increased angiogenic potential in vivo (Bao et 
al., 2006b; Li et al., 2009). Because VEGF expression is under control of transcription factors 
of the hypoxia inducible factor (HIF) family, one should note that expression of HIF2α is 
unique to glioma stem cells and correlated with poor patient survival, whereas HIF1α is 
found in all malignant cells (Li et al., 2009).  It has been reported that different human 
cancers (GBM, colorectal carcinoma, and NSCL carcinoma) converge at the HIF2α oncogenic 
axis (Franovic et al., 2009). The authors propose that inhibition of HIF2α may be of broad 
clinical interest in the treatment of cancers with different genetic signatures. Hjelmeland et 
al. (2010) published recently that acidic stress promotes a glioma stem cell phenotype by 
induction of HIF2α and other glioma stem cell markers. The authors suggest that an increase 
in intratumoral pH may be of benefit for targeting the stem cell phenotype.   
Three recent papers demonstrate that stem-like cells in GBM are able to differentiate into 
endothelial cells and may give rise to tumor endothelium (Ricci-Vitiani et al., 2010; Thon et 
al., 2008; Wang et al., 2010). These results define a novel mechanism for cancer 
vasculogenesis and may help to explain the failure of currently used inhibitors of 
angiogenesis. Glioma stem cells as targets for novel strategies of treatment have been 
recently reviewed (Dietrich et al., 2010; Gilbert & Ross, 2011). 
2.8 Promising targets for chemotherapy of glioblastoma multiforme 
GBMs are highly infiltrative tumors that show resistance to conventional chemotherapy. 
Many chemotherapeutic agents are not able to reach the tumor in sufficient doses, because 
the blood brain barrier is at least partially intact in these tumors. 
Most mitotic inhibitors used in clinic impair the function of mitotic spindles by targeting 
tubulins that are basic components of microtubules. Because microtubules in non-mitotic 
cells are also affected, these compounds often exhibit significant side effects (for example 
neurotoxicity). Future therapies of GBM may involve small molecules that inhibit the 
activity of aurora kinases A or B, polo kinases or the mitotic kinesin Eg5, all proteins that 
have specific functions in different phases of mitosis (for review see: Kaestner and Bastians, 
2010; Sudakin and Yen, 2007). Pharmaceutical companies are on the way to develop 
selective inhibitors that target these proteins. Phase I and II studies on different forms of 
solid cancers are currently underway to study newly developed mitosis inhibitors and may 
also open the way for a more efficient therapy of GBM. Interestingly, it has been reported 
that in glioblastoma expression of aurora kinases A (Barton et al., 2010) and B (Zeng et al., 
2007) were both associated with poor prognosis and may be targets for therapy. Among 
several other proteins also histone deacetylases (HDACs) may be promising targets for 
future therapy of GBM (Argyriou and Kalofonos, 2009). ABC transporters play an important 
role in the development of multidrug resistance. The role of ABC transporters in the 
resistance network of glioblastoma was reviewed by Bleau et al. (2009). 
The humanized monoclonal antibody against vascular endothelial growth factor 
(Bevacizumab, Avastin®) has been approved by the FDA for treatment of GBM. Although 
targeting the tumor vasculature with Bevacizumab reduced the number of cancer-like stem 
cells in orthotopic brain tumor xenografts (Calabrese et al., 2007), a recent phase II study 
indicates that bevacizumab does not affect median survival of patients with recurrent GBM 
(Pope et al, 2011). 
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Potential targets for directed therapy of GBM may include extracellular matrix proteins of 
the perivascular niche that influence proliferation and/or migration of cancer stem cells. 
Targeting integrin α6 has recently been shown to inhibit self-renewal, proliferation, and 
tumor formation capacity of glioblastoma stem cells (Lathia et al., 2010). Cilengitide 
(Impetreve®) is a cyclic pentapeptide harboring a RGD sequence. RGD sequences present 
on extracellular matrix proteins mediate the binding to integrins, a class of cell surface 
receptors. Cilengitide is a selective inhibitor of ανβ3/5 integrins and currently under study 
as an inhibitor of angiogenesis in several types of solid cancer. Cilengitide monotherapy was 
well tolerated and exhibited modest antitumor activity among patients with recurrent GBM 
in a randomized phase II study (Reardon et al., 2008). Also targeting glioma stem cells 
through the neural cell adhesion molecule L1CAM has been reported to suppress glioma 
growth (Bao et al., 2008). Glioblastoma cells display complex surface structures with 
numerous microvilli and filopodia that resist the actions of cytolytic effector lymphocytes 
(Hoa et al., 2010). It should also be noted that gliomas are accompanied by numerous 
microglia/macrophages. As was recently reported, inhibition of microglia/macrophage 
activation may represent a new and effective strategy to suppress proliferation of glioma 
cells (Zhai et al., 2011). 
Subtypes of breast cancer or leukemia can be efficiently treated by inhibiting the one 
excessively activated signal transduction pathway that is linked to malignancy. For GBM a 
monocausal therapy by inhibition of a single overactivated signaling pathway seems to be 
less promising, because cells or even regions with different genetic defects coexist in one 
tumor. A personalized therapy based on analysis of the individual genetic defects is not yet 
in sight for GBM. 
3. Summary and perspective 
Many types of cancer cells evolve through a multistep process in which genetic aberrations 
accumulate and finally lead to cells exhibiting aberrant gene expression programs. GBM has 
been considered as a system/network disease (Fathallah-Shaykh, 2010), because its 
phenotypes appear to be generated by several interconnected aberrant signal transduction 
pathways as well as numerous molecular abnormalities, thereby resulting in uncontrolled 
mitosis and migration of GBM cancer cells. In GBM local heterogeneity arises as the tumor 
regionally adapts to microenvironmental cues. Future molecular therapies of GBM should 
target its Achilles' heels: the elimination of the small intratumoral subpopulation of cells that 
exert stem cell properties and the inhibition of mitosis within the population of transit 
amplifying cells, which is responsible for forming the tumor mass. 
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cells are also affected, these compounds often exhibit significant side effects (for example 
neurotoxicity). Future therapies of GBM may involve small molecules that inhibit the 
activity of aurora kinases A or B, polo kinases or the mitotic kinesin Eg5, all proteins that 
have specific functions in different phases of mitosis (for review see: Kaestner and Bastians, 
2010; Sudakin and Yen, 2007). Pharmaceutical companies are on the way to develop 
selective inhibitors that target these proteins. Phase I and II studies on different forms of 
solid cancers are currently underway to study newly developed mitosis inhibitors and may 
also open the way for a more efficient therapy of GBM. Interestingly, it has been reported 
that in glioblastoma expression of aurora kinases A (Barton et al., 2010) and B (Zeng et al., 
2007) were both associated with poor prognosis and may be targets for therapy. Among 
several other proteins also histone deacetylases (HDACs) may be promising targets for 
future therapy of GBM (Argyriou and Kalofonos, 2009). ABC transporters play an important 
role in the development of multidrug resistance. The role of ABC transporters in the 
resistance network of glioblastoma was reviewed by Bleau et al. (2009). 
The humanized monoclonal antibody against vascular endothelial growth factor 
(Bevacizumab, Avastin®) has been approved by the FDA for treatment of GBM. Although 
targeting the tumor vasculature with Bevacizumab reduced the number of cancer-like stem 
cells in orthotopic brain tumor xenografts (Calabrese et al., 2007), a recent phase II study 
indicates that bevacizumab does not affect median survival of patients with recurrent GBM 
(Pope et al, 2011). 
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Potential targets for directed therapy of GBM may include extracellular matrix proteins of 
the perivascular niche that influence proliferation and/or migration of cancer stem cells. 
Targeting integrin α6 has recently been shown to inhibit self-renewal, proliferation, and 
tumor formation capacity of glioblastoma stem cells (Lathia et al., 2010). Cilengitide 
(Impetreve®) is a cyclic pentapeptide harboring a RGD sequence. RGD sequences present 
on extracellular matrix proteins mediate the binding to integrins, a class of cell surface 
receptors. Cilengitide is a selective inhibitor of ανβ3/5 integrins and currently under study 
as an inhibitor of angiogenesis in several types of solid cancer. Cilengitide monotherapy was 
well tolerated and exhibited modest antitumor activity among patients with recurrent GBM 
in a randomized phase II study (Reardon et al., 2008). Also targeting glioma stem cells 
through the neural cell adhesion molecule L1CAM has been reported to suppress glioma 
growth (Bao et al., 2008). Glioblastoma cells display complex surface structures with 
numerous microvilli and filopodia that resist the actions of cytolytic effector lymphocytes 
(Hoa et al., 2010). It should also be noted that gliomas are accompanied by numerous 
microglia/macrophages. As was recently reported, inhibition of microglia/macrophage 
activation may represent a new and effective strategy to suppress proliferation of glioma 
cells (Zhai et al., 2011). 
Subtypes of breast cancer or leukemia can be efficiently treated by inhibiting the one 
excessively activated signal transduction pathway that is linked to malignancy. For GBM a 
monocausal therapy by inhibition of a single overactivated signaling pathway seems to be 
less promising, because cells or even regions with different genetic defects coexist in one 
tumor. A personalized therapy based on analysis of the individual genetic defects is not yet 
in sight for GBM. 
3. Summary and perspective 
Many types of cancer cells evolve through a multistep process in which genetic aberrations 
accumulate and finally lead to cells exhibiting aberrant gene expression programs. GBM has 
been considered as a system/network disease (Fathallah-Shaykh, 2010), because its 
phenotypes appear to be generated by several interconnected aberrant signal transduction 
pathways as well as numerous molecular abnormalities, thereby resulting in uncontrolled 
mitosis and migration of GBM cancer cells. In GBM local heterogeneity arises as the tumor 
regionally adapts to microenvironmental cues. Future molecular therapies of GBM should 
target its Achilles' heels: the elimination of the small intratumoral subpopulation of cells that 
exert stem cell properties and the inhibition of mitosis within the population of transit 
amplifying cells, which is responsible for forming the tumor mass. 
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1. Introduction 
Human gliomas are the most frequent tumours of the central nervous system (Kleihues & 
Cavenee, 2000). They are of neuroectodermal origin and present as different histological 
types and malignancy grades (Louis et al., 2007).  
According to the WHO (world health organization) system, astrocytoma, 
oligodendroglioma and mixed oligoastrocytoma are classified as differentiated gliomas, 
while anaplastic glioma and glioblastoma show increasing grades of malignancy (Box 1).  
 
 
Box 1.  
Gliomas are composed of different cell types displaying, even within low-grade tumours, a 
wide spectrum of heterogeneity regarding morphology, genotype, invasive potentiality, and 
treatment sensitivity (Noble & Dietrich, 2004). The development and progression of glioma 
malignancies is driven by accumulation of genomic alterations, including both mutations 
and chromosomal instability (CIN). 
2. Chromosomal instability (CIN) in glioma 
CIN refers to the rate of lost or gained chromosomes and/or structural chromosome 
anomalies and ploidy changes during cell divisions (Geigl et al., 2008; Lengauer et al., 1998). 
Structural chromosome anomalies (translocations, deletions, insertions, inversion and 
additions) may be balanced or unbalanced and involve one or more chromosomes (Bayani 
et al., 2007). Chromosomal instability in glioma is mainly characterized by aneuploidy 
(Bigner et al., 1988; Hecht et al., 1995; Jenkins et al., 1989; Lindstrom et al., 1991; Magnani et 
al., 1994; Park et al., 1995; Thiel et al., 1992) affecting in particular glioblastoma, the most 
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malignant glioma. Gliomas frequently display near-diploid (2n+/-) and/or near-tri-
tetraploid (3n+/-)/(4n+/-) karyotypes, implicating aberrant mitotic divisions, in addition to 
chromosomal rearrangements. Highly polyploid subpopulations and the presence of 
apoptotic nuclei are also reported (Figures 1a-d).  
 
 
Fig. 1. (a) The G-banded, near diploid karyotype of MI-4 GBM (glioblastoma multiforme) 
cell line (Magnani et al., 1994), showing trisomy of chromosome 7, monosomy of 
chromosome 10 and a complex rearrangement involving chromosomes 1, 9 and 19. (b) The 
G-banded, near tetraploid karyotype of MI-4 cell line, displaying several chromosome losses 
and structural rearrangements including marker chromosomes. (c) Representative polyploid 
metaphase from MI-60 GBM cell line, characterized by a high frequency of hyperdiploid 
cells. (d) Apoptotic and large nuclei of MI-60 cell line. 
Low-grade astrocytomas and oligodendrogliomas (WHO grades I-II) show a number of 
chromosome aberrations quite low. When present, they involve the gain of chromosome 7, 
the loss of chromosomes 10, 22 and one sex chromosome (see Figures 1a, b), while structural 
changes affect in particular 1p (Figure 2a) and 9p (Figure 2b) chromosome arms. 
These chromosome abnormalities are qualitatively similar to those found in anaplastic 
astrocytoma (WHO grade III) and glioblastoma (WHO grade IV), but their frequency is 
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increased in the latter and multiple chromosomal rearrangements are also present. The 
finding of common abnormalities associated to both low- and high-grade glioma has 
suggested a progressive chromosomal evolution during tumour growth (Bigner et al., 1988; 
Jenkins et al., 1989; Magnani et al., 1994; Thiel et al., 1992) even though it has been 
demonstrated that a subset of glioblastomas arises clonally de novo, further emphasizing the 
genetic heterogeneity of glioma (Kleihues & Ohgaki, 2000; von Deimling et al., 1993). Given 
that numerical CIN features many cancer cells, it has been hypothesized that it may have a 
primary role in tumorigenesis (Duesberg et al., 2006; Weaver et al., 2007). Recently it has 
been shown that the main pathway to aneuploidy in cancer cells is triggered by extra 
centrosomes that, increasing improper merotelic attachments of kinetochores to spindle 
microtubules, cause chromosome mis-segregation (Meraldi et al., 2002) (Figure 3) (see Box 3 
for centrosomes and Box 4 for mitotic spindle). 
 
 
Fig. 2. (a) Chromosome 1 rearrangements of both p and q arms observed in different glioma 
cell lines by G-banding. (b) Rearrangements of chromosome 9p, sharing the loss of p21 
band, observed in different glioblastoma cell lines by G-banding. 
At early mitosis, the merotelic orientation escapes the spindle mitotic checkpoint thus 
representing the major mechanism of chromosome mis-segregation in non-cancer cells. 
Usually these errors are corrected before cells enter anaphase, to preserve genome stability 
(Cimini et al., 2004). 
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Fig. 3. Proposed events of lagging chromosomes in cancer cells with extra centrosomes 
through merotelic kinetochore orientation. (top) In the presence of extra centrosomes (three 
instead of two, as example), merotelic kinetochore orientation may occur: one kinetochore is 
bound by spindle microtubules from two centrosomes (right) instead of just one (left). 
(bottom) As cells move to mitosis and cluster extra centrosomes in a bipolar spindle, many 
attachment errors persist into anaphase, leading to lagging chromosomes. 
3. Tetraploidy, centrosome amplification and spontaneous chromosomal 
instability in glioma 
A relationship between extra centrosomes and the formation of multipolar spindles in 
cancer cells has been proposed by different authors (Basto et al., 2008; Cimini et al., 2004; 
Saunders, 2005; Sluder & Nordberg, 2004). Multipolarity in cancer cells is considered an 
essential transient stage prior to clustering extra centrosomes in a bipolar fashion (Brinkley, 
2001). Multiple centrosomes have been detected in many types of cancer cells including 
glioma (Figure 4) and strongly linked to aneuploidy in a variety of studies (D'Assoro et al., 
2002; Ganem et al., 2009; Ghadimi et al., 2000; Katsetos et al., 2006; Lingle et al., 2002; 
Magnani et al., 2009; Pihan et al., 1998).  
A positive linear correlation between the percentage of cells with supernumerary 
centrosomes and the extent of aneuploidy within a panel of glioblastoma cell lines is shown 
in Figure 5. 
In tumour development, aneuploidy is frequently preceded by tetraploidy, often with 
prolonged tetraploid precancerous status, a feature that makes it of central importance to 
cancer research (Margolis et al., 2003). It has been proposed that failure of cytokinesis is a 
key step in the formation of tetraploid karyotypes and in tumour initiation (Fujiwara et al., 
2005). A tetraploid cell inherits twice the normal complement of centrosomes, a condition 
assessed to generate chromosomes mis-segregation in subsequent cell divisions (Ganem et 
al., 2007). However, tetraploid cells are observed in some normal tissues including liver and 
heart, indicating that cytokinesis is physiologically regulated. The possible fate of a 
tetraploid progeny is shown in Figure 6.  
 




Fig. 4. Immunofluorescence with anti-tubulin antibody (red) of representative glioblastoma 
cell lines, showing (a) multiple centrosomes; (b) multipolar spindles; (c) a mitotic bipolar 
spindle in which centrosomes are larger than the normal one (likely extra centrosomes 
clustered into two spindle poles), a condition that favours mitotic stability and neoplastic 
growth; (d) normal centrosomes and a mitotic bipolar spindle configuration. The nuclei are 
counterstained with DAPI (4’,6-di amidino-2-phenyl indole) (blue). 
 
 
Fig. 5. Regression analysis between aneuploidies and centrosome aberrations in glioma cell 
lines, showing a statistically significant positive correlation. OA: oligoastrocytomas; A: 
astrocytomas; GBM: glioblastoma multiforme; GC-GBM: giant cell-GBM. 
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Fig. 6. Fate of a tetraploid cell: if extra centrosomes coalesce, a bipolar spindle assures the 
progeny maintains a tetraploid set, while lack of this escamotage gives rise to aneuploid 
progeny through a multipolar mitosis.  
Binucleated tetraploid cells with multiple centrosomes are frequently observed in glioma 
cell lines, as illustrated by a representative image in Figure 7.  
 
 
Fig. 7. Immunofluorescence with anti-tubulin antibody (red) of a binucleated, tetraploid-
derived glioblastoma cell line, showing coalesced centrosomes in one (left) of the two nuclei. 
Nuclei are counterstained with DAPI (blue). 
To measure the occurrence of DNA damage in once-divided binucleated (BN) cells, the 
cytokinesis-block micronucleus cytome (CBMN Cyt) assay, an established biomarker to 
detect spontaneous genomic instability (Fenech, 2007), can be used. Application of CBMN 
Cyt to a series of glioma cell lines evidenced a high rate of micronuclei (MNi), a biomarker 
of chromosome breakage and/or whole chromosome loss, and chromosome aberrations 
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such as nucleoplasmic bridges (NPBs), a biomarker of DNA misrepair and/or telomere end-
fusions determining the furrow regression, and nuclear buds (NBUDSs), a biomarker of 
elimination of amplified DNA and/or DNA repair complexes (Figure 8a, b).  
 
 
Fig. 8. Photomicrographs of glioma cell lines showing (a) typical binucleated cells with 
nucleoplasmic bridges and (b) binucleated cells with micronuclei and nuclear buds. 
Thus, binucleated tetraploid cells may be transmitted to the progeny and enhance 
subsequent rounds of aberrant mitosis. 
4. Cytogenomics of gliomas 
Chromosomal instability can be detected by different techniques, including conventional 
karyotyping, fluorescence in situ hybridization (FISH), spectral karyotyping (SKY) and 
array-based comparative genomic hybridization (aCGH) analyses. 
The classic assay to monitor and quantify chromosome aberrations is karyotyping (see 
Figure 2).  
The in situ hybridization technique with fluorescently labelled probes targeting specific 
chromosomes is commonly applied on fixed glioma cells, allowing the analysis of 
chromosomes of interest cell by cell. Examples of FISH analysis in glioma cell lines are 
shown in Figure 9. 
Aneuploidies are rapidly detectable by interphase FISH as well as by quantification of 
micronuclei formed by chromosomes that lagged behind during a previous mitosis (Figure 
10). 
The technique of array-CGH is considered the most powerful tool for identifying copy 
number changes of genetic material, since it combines high resolution and large scale 
genomic analysis, characteristics that are not combined by conventional approaches. Since it 
allows a quantification of amplifications and deletions, pointing through human genome 
databases directly to the affected genes, aCGH technology is more and more used in the 
study of tumours for the identification of potentially causative cancer genes. 
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Fig. 9. Partial karyotype of MI-4 GBM cell line displaying chromosome 1 alterations by (a) 
whole chromosome 1 painting probe and (b) dual colour FISH of YACs 745h6, spanning the 
1p36.3 breakpoint (green), and 957f12, mapping to 1p36.1 (red), showing a transposition of 
1p36.1 material to der (1)(p22). DNA is counterstained with DAPI (blue). Interphase dual 
colour FISH of RP11-111p21, mapping to 3p21 control clone (red), and RP11-172g5, mapping 
to 3q26.3 (green), (c) in a normal diploid cell and (d) in MI-60 GBM cell line showing 
amplification of the region targeted by RP22-172g5 (green). 
 
 
Fig. 10. (a) Interphase FISH with centromeric probes of chromosomes 7 and 10 showing 
trisomy of chromosome 7 and monosomy of chromosome 10 in MI-4 GBM cell line. (b) 
Interphase FISH with whole chromosome 19 painting probe showing a micronucleus 
labelled by chromosome 19 material. DNA is counterstained with DAPI (blue). 
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aCGH studies have been applied to gliomas and have successfully complemented 
previously published metaphase-CGH, SKY and LOH (loss of heterozigosity) analyses 
(Bredel et al, 2005; Cowell et al., 2004a, 2004b; Kitange et al., 2005; Nigro et al., 2005). 
Integration of the results has demonstrated an excellent correlation between the findings 
obtained through this genomic approach and those obtained by alternative techniques, 
stressing the usefulness and overall accuracy of aCGH as compared to classic previously 
widely employed analyses (Cowell et al., 2004a, 2004b). Comparative analysis of elaborated 
aCGH data led to identify copy number changes shared by various glioma grades as well as 
aberrations apparently related to progression to glioblastoma (GBM) (Roversi et al., 2006).  
5. Non-random chromosomal aberrations in gliomas: The 19q13 abnormalities 
Over the last decade, molecular approaches including mutation screening, LOH and aCGH 
analyses have led to identify the most frequently recurring genomic imbalances associated 
with each WHO glioma subtype (Kitange et al., 2005; Koschny et al., 2002; Shapiro, 2002) 
and hence the driver genes acting in pathways involved in glioma development, either in 
the initiation stages (Tp53 and Ras by PDGF-NF1) or in malignant progression (Rb-CDKN2-
CDK4) (Collins, 2004; Zhu & Parada, 2002). Comprehensive genomic characterization by 
integrative analysis of DNA copy number, gene expression and DNA methylation 
aberrations in >200 glioblastomas has then refined the definition of human glioblastoma 
genes and core pathways (The Cancer Genome Atlas [TGCA] Research Network, 2008). 
Deletion of chromosome 19q is nevertheless of particular interest, as it is shared by all three 
glioma subtypes, occurring in approximately 75% of oligodendrogliomas, 45% of mixed 
oligoastrocytomas and 40% of astrocytomas (von Deimling et al., 1992, 1994), where it is 
associated with the transition from low-grade to anaplastic tumours (Ohgaki et al., 1995; 
Ritland et al., 1995; Smith et al., 1999) (Box 2). 
 
 
Box 2. TSGs: tumour suppressor genes. 
At the cytogenetic level, chromosome 19q abnormalities are more frequently detectable in 
GBM than in low grade glioma, with 19q13 as the most affected region, as shown in Table1.  
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Table 1. Cytogenetic alterations of chromosome 19 in gliomas; 19q13 alterations are marked 
by red stars. GBM: glioblastoma multiforme; AMG: anaplastic mixed glioma; PA: pilocytic 
astrocytoma; O: oligodendroglioma; AA: anaplastic astrocytoma; AO: anaplastic 
oligodendroglioma; PXA: pleomorphic xanthoastrocytoma; nr: not reported. 
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Furthermore, similarly to oligodendroglioma, combined LOH of 1p and 19q was found to 
define a small subset of GBM patients with a significantly better survival, even if their 
tumours were not morphologically distinguishable from the bulk of GBMs (Schmidt et al., 
2002). This finding has been translated into significant advance in the prognosis and 
treatment of oligodendrogliomas (van den Bent, 2004). A candidate tumour suppressor 
region has been assigned by LOH to 19q13.3 (Hartmann et al., 2002), but no positional or 
functional candidate gene in this band has yet been appointed. 
Only recently an integrated analysis of human glioblastoma multiforme with the application 
of next generation sequencing technology disclosed a new marker associated with an 
increase in overall survival, represented by recurrent mutations in the active site of isocitrate 
dehydrogenase 1 (IDH1) in a large fraction of young patients with secondary GBM (Parsons 
et al., 2008).  
6. Identification of MARK4 gene through refined FISH mapping of 19q13 
breakpoints 
FISH studies of structural 19q chromosomal rearrangements in glioma (Magnani et al., 1999) 
and a detailed analysis of the breakpoints underlying the 19q13 alterations in the MI-4 
glioblastoma cell line, led to identify a 19q13.2 intrachromosomal duplication of the 
MAP/microtubule affinity-regulating kinase 4 (MARK4) gene (Beghini et al., 2003) (Figure 11).  
Genomic profiling by means of array-CGH interrogation of 25 primary glioma cell lines 
including the MI-4 GBM cell line (Roversi et al., 2006) revealed that the BAC clone 
encompassing MARK4 at 19q13.2 (Figure 12) is included in a “gain” region in a few of  




Fig. 11. 19q13.2 intrachromosomal duplication of MARK4 in the MI-4 GBM cell line detected 
by G-banding and FISH analysis using a whole chromosome painting 19 probe and a 
MARK4-specific cosmid clone. 
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Fig. 12. MARK4 genomic region (http://genome.ucsc.edu/). Clones of chromosome 19q full 
coverage (blue) overlapping MARK4 gene are circled in red: the gene is entirely 
encompassed by BAC clones RP11-746H08, RP11-568L16, RP11-202G02, RP11-752G09 RP11-
584B04, RP13-647G21 and partially encompassed by RP11-577I16.  
 
 
Fig. 13. (left) Chromosome 19q array-CGH of MI-4 GBM cell line, showing duplicated 
MARK4 gene (red star) and the common LOH region in glioma. (right) Schematic 
representation of MARK4 position on chromosome 19, at the boundary of 19q13.3 LOH 
region. 
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The combined FISH and array-CGH results provided the rationale for investigating a 
possible role of the serine-threonine kinase MARK4 in glioma. It’s worth of note that this 
gene, belonging to the so called “kinome”, maps at the centromeric boundary of the 19q13.3 
LOH region in glioma.  
7. The family of MARK kinases 
MARK4 (MAP/microtubule affinity-regulating kinase 4) is a member of the MARKs family, 
constituted in mammals by four serine-threonine kinases (MARK1-4) which are able to 
phosphorylate the microtubule-associated proteins (MAPs, including Tau, MAP2, MAP4 
and doublecortin) (Drewes et al., 1997). Microtubules (MTs) are cytoskeleton cylindrical 
structures formed by α and β tubulin dimers; dimers can quickly assemble or disassemble, 
causing the microtubules to grow or shorten and making them very dynamic. MAPs 
association stabilizes the MTs; when MARK kinases link a phosphate group to MAPs 
(phosphorylation), MAPs cannot associate to MTs any longer, thus microtubules become 
more instable and disassemble (Figure 14). 
 
 
Fig. 14. Schematic representation of microtubules. Assembled α and β tubulin dimers form 
the microtubules, stabilized by MAP association. When MAPs are phosphorylated, they are 
no more able to bind microtubules, which disassemble. 
7.1 MARKs protein structure  
All MARK proteins have a very conserved structure, consisting of six sequence segments 
(Marx et al., 2010) (Figure 15): 
 the N-terminal header, whose role is unknown; 
 the catalytic or kinase domain, containing both the activation/inactivation loop (MARK 
kinases are in turn activated/inactivated by phosphorylation/dephosphorylation) and 
the catalytic loop, by which MARKs transfer a phosphate group to substrate proteins; 
 a linker, that is a highly and negatively charged motif resembling the common docking 
(CD) site in MAP kinases; it may bind interactors; 
 the UBA domain, a small globular domain with sequence homology to ubiquitin-
associated proteins; it may exert an autoregulatory function through interaction with 
the catalytic domain; 
 a spacer, the most variable region among MARK members; it is probably important for 
regulating MARK activity since it holds phosphorylation sites; 
 the C-terminal tail, consisting of the kinase-associated (KA1) domain, whose function is 
still uncertain. It is characterized by a hydrophobic portion surrounded by positively 
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charged residues, which may interact with negatively charged regions of cytoskeletal 
proteins, MARK catalytic domain or MARK CD domain (Tochio et al., 2006) with an 
inhibitory effect. It has been proposed it could be involved in protein localization to the 
membrane, being identified as a domain that binds membrane anionic phospholipids, 
in particular phosphatidylserine (Moravcevic et al., 2010). 
 
 
Fig. 15. Schematic representation of MARK protein structure. Boxes are not drawn to scale. 
7.2 MARKs regulation  
Being composed of several domains, MARK proteins are regulated by multiple mechanisms. 
All MARKs are activated by liver kinase B (LKB1) and MARK kinase (MARKK) by 
phosphorylation on the threonine residue in the activation loop (Timm et al., 2008); in 
addition, phosphorylation by CaMKI (calcium/calmodulin-dependent protein kinase I) 
activates MARK2 (Matenia & Mandelkow, 2009). On the contrary, phosphorylation by the 
glycogen synthase kinase 3β (GSK3β) on the serine residue in the activation loop, by aPKC 
(atypical protein kinase C) in the spacer region or by Pim1 kinase, down-regulates MARK 
activity (Matenia & Mandelkow, 2009; Timm et al., 2008). Finally, interaction between 
MARK catalytic domain and other proteins/MARK domains (such as 14-3-3 proteins, PAK5, 
MARK UBA and KA1 domains) inhibits MARK activity (Marx et al., 2010). 
7.3 MARKs functions  
Since MARK kinases regulate the affinity between MAPs and MTs, they are implicated in 
several cellular processes involving the microtubules, such as cytoskeleton dynamics, 
neuron motility (Schaar et al., 2004), and microtubule-dependent transport of proteins, 
vesicles and organelles (Mandelkow et al., 2004). Microtubules also play an important role 
in centrosome formation (Box 3) and in the correct distribution of the chromosomes in the 
two daughter cells during cell division (mitosis and cytokinesis; Box 4).  
Tau is a microtubule-associated protein particularly expressed in the central nervous system. 
The aggregation of hyperphosphorylated Tau has been demonstrated to form insoluble 
neurofibrillary tangles (Chin et al., 2000; Gamblin et al., 2003) which are characteristic of 
Alzheimer’s disease. MARKs role in this pathology has been evaluated in many studies, 
demonstrating, as an example, MARK co-localization with neurofibrillary tangles (Chin et 
al., 2000). 
MARK2 is involved in establishing cell polarity, cooperating in the organization of the 
epithelial structure of liver, kidney and stomach (Cohen et al., 2004; Matenia & Mandelkow, 
2009), and regulating axon formation in neuronal cells (Chen et al., 2006). Experiments in 
mice demonstrated that MARK2 is also implicated in many physiological functions, such as 
fertility, homeostasis of the immune system, memory, growth and metabolism (Bessone et 
al., 1999; Hurov et al., 2001; Hurov & Piwnica-Worms, 2007; Segu et al., 2008). MARK3 plays 
an important role in cell signaling and cell cycle control: phosphorylation of some proteins 
by MARK3 induces their binding to 14-3-3 proteins thus regulating many cellular pathways 
(Bachmann et al., 2004; Müller et al., 2001). 
 




MARK4 is the less characterized member among MARK proteins. It has been discovered by 
Kato and colleagues in 2001 among a few genes whose expression resulted significantly 
increased in hepatocarcinoma cells with elevated β-catenin levels in their nucleus (Kato et 
al., 2001).  
MARK4 gene is located on chromosome 19q13.2, consists of 18 exons and encodes at least 
two isoforms, namely MARK4S and MARK4L, originated by alternative splicing (Kato et al., 
2001) (Figure 16). mRNA splicing is a complex process consisting in the removal of introns, 
which are non-coding sequences, and in the joining of exons, the coding sequences, to 
generate the “edited” mRNA ready to be translated into a protein.  
 MARK4S (“short”) protein is the native isoform, consisting of all the 18 exons, and is 
688 aminoacid-long with predicted molecular weight of 75.3 kilo Daltons (kDa);  
 MARK4L protein derives from skipping of exon 16, which causes a shift of the reading 
frame1 with a downstream stop codon, originating a longer protein (752 aminoacids; 
predicted molecular weight: 82.5 kDa).  
 
 
Fig. 16. Alternative splicing of exon 16 gives origin to MARK4 isoforms. When exon 16 is 
included in the mRNA, the stop codon is inside exon 18 and the encoded protein, MARK4S, 
lacks the KA1 domain at the C-terminal tail (left); when exon 16 is skipped, a shift of the 
reading frame occurs, changing the stop codon and generating a longer MARK4L protein, 
which has the classical KA1 domain (right). 
Both MARK4L and S share the same protein structure of MARKs, with 90% sequence 
homology in the kinase domain. The two isoforms differ in the C-terminal tail, since 
MARK4L includes the kinase-associated 1 domain as the other MARK proteins, whereas 
MARK4S contains a domain with no homology to any known structure (Kato et al., 2001; 
Moroni et al., 2006) (Figure 16). Actually, MARK4 has less sequence homology in the C-
terminus compared to the other MARKs; nevertheless MARK4L tail seems to fold in a 
similar shape, suggesting that the role of the C-terminal region may apply also to MARK4L 
(Marx et al., 2010).  
                                                 
1 The mRNA sequence is “read” by an enzyme which matches a determinate “codon”, made by three 
nucleotides, with its respective aminoacid. There are two particular codons, namely the start and the 
stop codon, which mark the beginning and the end of the protein. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
144 
charged residues, which may interact with negatively charged regions of cytoskeletal 
proteins, MARK catalytic domain or MARK CD domain (Tochio et al., 2006) with an 
inhibitory effect. It has been proposed it could be involved in protein localization to the 
membrane, being identified as a domain that binds membrane anionic phospholipids, 
in particular phosphatidylserine (Moravcevic et al., 2010). 
 
 
Fig. 15. Schematic representation of MARK protein structure. Boxes are not drawn to scale. 
7.2 MARKs regulation  
Being composed of several domains, MARK proteins are regulated by multiple mechanisms. 
All MARKs are activated by liver kinase B (LKB1) and MARK kinase (MARKK) by 
phosphorylation on the threonine residue in the activation loop (Timm et al., 2008); in 
addition, phosphorylation by CaMKI (calcium/calmodulin-dependent protein kinase I) 
activates MARK2 (Matenia & Mandelkow, 2009). On the contrary, phosphorylation by the 
glycogen synthase kinase 3β (GSK3β) on the serine residue in the activation loop, by aPKC 
(atypical protein kinase C) in the spacer region or by Pim1 kinase, down-regulates MARK 
activity (Matenia & Mandelkow, 2009; Timm et al., 2008). Finally, interaction between 
MARK catalytic domain and other proteins/MARK domains (such as 14-3-3 proteins, PAK5, 
MARK UBA and KA1 domains) inhibits MARK activity (Marx et al., 2010). 
7.3 MARKs functions  
Since MARK kinases regulate the affinity between MAPs and MTs, they are implicated in 
several cellular processes involving the microtubules, such as cytoskeleton dynamics, 
neuron motility (Schaar et al., 2004), and microtubule-dependent transport of proteins, 
vesicles and organelles (Mandelkow et al., 2004). Microtubules also play an important role 
in centrosome formation (Box 3) and in the correct distribution of the chromosomes in the 
two daughter cells during cell division (mitosis and cytokinesis; Box 4).  
Tau is a microtubule-associated protein particularly expressed in the central nervous system. 
The aggregation of hyperphosphorylated Tau has been demonstrated to form insoluble 
neurofibrillary tangles (Chin et al., 2000; Gamblin et al., 2003) which are characteristic of 
Alzheimer’s disease. MARKs role in this pathology has been evaluated in many studies, 
demonstrating, as an example, MARK co-localization with neurofibrillary tangles (Chin et 
al., 2000). 
MARK2 is involved in establishing cell polarity, cooperating in the organization of the 
epithelial structure of liver, kidney and stomach (Cohen et al., 2004; Matenia & Mandelkow, 
2009), and regulating axon formation in neuronal cells (Chen et al., 2006). Experiments in 
mice demonstrated that MARK2 is also implicated in many physiological functions, such as 
fertility, homeostasis of the immune system, memory, growth and metabolism (Bessone et 
al., 1999; Hurov et al., 2001; Hurov & Piwnica-Worms, 2007; Segu et al., 2008). MARK3 plays 
an important role in cell signaling and cell cycle control: phosphorylation of some proteins 
by MARK3 induces their binding to 14-3-3 proteins thus regulating many cellular pathways 
(Bachmann et al., 2004; Müller et al., 2001). 
 




MARK4 is the less characterized member among MARK proteins. It has been discovered by 
Kato and colleagues in 2001 among a few genes whose expression resulted significantly 
increased in hepatocarcinoma cells with elevated β-catenin levels in their nucleus (Kato et 
al., 2001).  
MARK4 gene is located on chromosome 19q13.2, consists of 18 exons and encodes at least 
two isoforms, namely MARK4S and MARK4L, originated by alternative splicing (Kato et al., 
2001) (Figure 16). mRNA splicing is a complex process consisting in the removal of introns, 
which are non-coding sequences, and in the joining of exons, the coding sequences, to 
generate the “edited” mRNA ready to be translated into a protein.  
 MARK4S (“short”) protein is the native isoform, consisting of all the 18 exons, and is 
688 aminoacid-long with predicted molecular weight of 75.3 kilo Daltons (kDa);  
 MARK4L protein derives from skipping of exon 16, which causes a shift of the reading 
frame1 with a downstream stop codon, originating a longer protein (752 aminoacids; 
predicted molecular weight: 82.5 kDa).  
 
 
Fig. 16. Alternative splicing of exon 16 gives origin to MARK4 isoforms. When exon 16 is 
included in the mRNA, the stop codon is inside exon 18 and the encoded protein, MARK4S, 
lacks the KA1 domain at the C-terminal tail (left); when exon 16 is skipped, a shift of the 
reading frame occurs, changing the stop codon and generating a longer MARK4L protein, 
which has the classical KA1 domain (right). 
Both MARK4L and S share the same protein structure of MARKs, with 90% sequence 
homology in the kinase domain. The two isoforms differ in the C-terminal tail, since 
MARK4L includes the kinase-associated 1 domain as the other MARK proteins, whereas 
MARK4S contains a domain with no homology to any known structure (Kato et al., 2001; 
Moroni et al., 2006) (Figure 16). Actually, MARK4 has less sequence homology in the C-
terminus compared to the other MARKs; nevertheless MARK4L tail seems to fold in a 
similar shape, suggesting that the role of the C-terminal region may apply also to MARK4L 
(Marx et al., 2010).  
                                                 
1 The mRNA sequence is “read” by an enzyme which matches a determinate “codon”, made by three 
nucleotides, with its respective aminoacid. There are two particular codons, namely the start and the 
stop codon, which mark the beginning and the end of the protein. 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
146 
8.1 MARK4 regulation  
Phosphorylation by LKB1, in the activation loop, activates MARK4, while 
polyubiquitination of MARK4 inhibits the kinase activation (Al-Hakim et al., 2008). 
Furthermore, as MARK4 interacts with aPKC (Brajenovic et al., 2008), it could be 
phosphorylated and inactivated by this kinase as reported for MARK2 and MARK3.  
8.2 MARK4 interactors and hypothetical functions  
By tandem affinity purification and immunoprecipitation experiments, near twenty proteins 
have been identified as putative MARK4 interactors (Brajenovic et al., 2008). Among them, 
PKCλ and Cdc42 are implicated in cell polarity control and TGFβIAF (transforming growth 
factor β-inducing anti-apoptotic factor) is thought to be a hortologue of Miranda, a protein 
involved in the asymmetric division of neuroblasts in Drosophila. MARK4 interacts with the 
14-3-3η isoform (Angrand et al., 2006; Brajenovic et al., 2008) of 14-3-3 proteins, which 
control multiple cellular processes by binding phosphorylated proteins and could directly 
regulate MARK4 or act as bridges among different pathways. Other MARK4 interactors are 
ARHGEF2, a cytoskeleton binding protein, and Phosphatase 2A, which is associated to 
microtubules and regulates Tau (Brajenovic et al., 2008). MARK4 protein has been also 
found to co-localize and co-precipitate in complex with α, β, and γ tubulin, myosin and actin 
(Brajenovic et al., 2008; Trinczek et al., 2004). 
As the other MARK members, MARK4 phosphorylates MAPs, increasing microtubule 
dynamics; therefore, as also suggested by the interactions above reported, MARK4 may be 
involved in many processes involving microtubules, such as cytoskeleton dynamics.  
9. Up-regulation of MARK4L in glioma 
MARK4 gene is expressed ubiquitously in human tissues, with particularly elevated levels 
in brain and testis (Kato et al., 2001).  
Few MARK4 expression studies are reported in literature; they were performed with non-
quantitative methods, such as northern blot (Kato et al., 2001; Schneider et al., 2004; Trinczek 
et al., 2004) and semi-quantitative competitive PCR (polymerase chain reaction) (Moroni et 
al., 2006), on different organisms (human, rat and mouse tissues) not always allowing to 
discern between the two MARK4 isoforms. MARK4 transcriptional variants are 
differentially regulated in human tissues, especially in the central nervous system: MARK4S 
is the predominant isoform in mouse and human brain, while MARK4L has been found 
highly expressed in neural progenitors and in gliomas (Beghini et al., 2003; Moroni et al., 
2006). 
By a semi-quantitative approach MARK4L has been found up-regulated in glioma tissue 
samples (fragments of glial tumours excised from patients) and glioma cell lines, of different 
malignancy grades, including the MI-4 GBM cell line carrying the MARK4 duplicated gene 
as detected by FISH and aCGH analysis. MARK4L has been also found highly expressed in 
neural progenitors and down-regulated during their glial differentiation into astrocytes, 
suggesting that it might be necessary for proliferation, being thus highly enriched in 
proliferating or undifferentiated cells (Beghini et al., 2003) (Figure 17).  
Protein kinase activation, often caused by gene amplification and/or mutation, is frequently 
associated to cancer initiation and progression, as most kinases are involved in cell 
proliferation. Although array-CGH analyses on glioma cell lines showed that the BAC clone 
encompassing MARK4 at 19q13.2 is included in a “gain” region in a few of the tested cell 
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lines, it did not evidence MARK4 copy number variations, except for the MI-4 GBM cell line 
(Roversi et al., 2006). Only a few MARK4 alterations are reported in the literature, namely 
two missense mutations (aminoacidic substitution) in exon 12 (R377Q and R418C in the 
spacer region), two silent mutations (no aminoacidic substitution) in exons 5 (Y137Y) and 9 
(I286I) (kinase domain), while one intronic mutation (exon 8 +5 C>T; kinase domain) has 
been found in a few tumour samples (Greenman et al., 2007). In addition, only a splice-site 
mutation (exon 13 +1 G>A; spacer region) has been identified in one among 91 glioblastoma 
samples (TGCA Research Network, 2008). However, CpG methylation and/or promoter 
amplification have not yet been investigated. Based on this evidence, neither amplification 
nor mutations of MARK4 gene seem to be the cause of its reported sustained expression in 
glioma samples.  
 
 
Fig. 17. (a) Semi-quantitative Reverse Transcription-PCR of MARK4S and MARK4L 
isoforms in whole normal brain (WNB) and in 32 glioma cell lines, subdivided according to 
WHO grade (A: astrocytoma; AA: anaplastic astrocytoma; OA: oligoastroctytoma; AOA: 
anaplastic oligoastrocytoma; O: oligodendroglioma; GBM: glioblastoma multiforme). (b) 
Downregulation of MARK4L expression during glial differentiation of human neural 
progenitors: semi-quantitative RT-PCR (top) and graph representation (bottom) of MARK4L 
expression in neural progenitors at times 0, 10 and 28 days of induced differentiation.  
10. MARK4 sub-cellular localization in glioma cell lines 
Recently, immunofluorescence analyses with a specific anti-MARK4L antibody highlighted 
multiple sub-cellular localizations for the endogenous MARK4L protein in glioma cell lines 
(Magnani et al., 2009).  
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multiple sub-cellular localizations for the endogenous MARK4L protein in glioma cell lines 
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10.1 Centrosome localization 
It has been assessed that, under microtubule-stabilizing conditions, MARK4L localizes in the 
perinuclear region of glioma cell lines. By co-localization experiments with both anti-MARK4L 
and anti-γtubulin (the main centrosomal protein) antibodies, this perinuclear localization has 
been demonstrated to correspond to the centrosome (Magnani et al., 2009), as shown in Figure 
18 (Box 3). This result confirms previous data referring to exogenous MARK4 protein 
conjugated to GFP (green fluorescent protein), which has been shown to co-localize with 
microtubules and centrosomes of CHO (Chinese hamster ovary) and neuroblastoma cell lines 
(Trinczek et al., 2004), in contrast to MARK1, MARK2 and MARK3 that exhibit uniform 
cytoplasmic localization. Furthermore, it has been demonstrated that the association with the 
centrosome is independent from microtubules, since it is not abolished when microtubules are 
depolimerized by nocodazole treatment (Magnani et al., 2009). 
 
 
Fig. 18. Anti-MARK4L (green; left) and anti-γtubulin (red; right) antibodies showing co-
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The endogenous MARK4L localizes both at normal interphase centrosomes (Figure 18) as 
well as at the aberrant centrosomes frequently observed in glioma cell lines (see Figure 4), 
suggesting a possible link between the alternatively spliced kinase and the mitotic instability 
frequently observed in human glioma. Two abnormal centrosome configurations are 
reported: a random one (multiple centrosomes randomly distributed) and a clustered one 
(multiple centrosomes collected in a single large aggregate) (Magnani et al., 2009), as 
depicted in Figure 19. 
 
 
Fig. 19. Anti-MARK4L (green; left) and anti-γtubulin (red; middle) antibodies showing co-
localization signals in abnormal centrosomes of glioma cell lines. Both the abnormal 
centrosome configurations are reported: the random one (top) and the clustered one 
(bottom). The nuclei are counterstained with DAPI (blue, right). 
10.2 Midbody localization 
The centrosome association is maintained during the entire course of mitosis, as MARK4L 
co-localizes with γtubulin in all the cell cycle phases. The anti-MARK4L antibody is also 
detected in the midbody, a microtubule structure forming at the contact point between the 
two daughter cells at the end of the cell division. These data demonstrate that the kinase is 
endogenously associated with the centrosomes during the whole cell cycle and concentrates 
thereafter into the midbody during cytokinesis (Magnani et al., 2009) (Figure 20) (Box 4). 
 
 
Fig. 20. Co-localization of MARK4L (green) and γtubulin (red) proteins at the midbody 
(arrow) during the cytokinesis of a glioma cell. The nuclei are counterstained with DAPI 
(blue). 
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10.3 Nucleolar localization 
Under standard immunofluorescence conditions, anti-MARK4L antibody is also detected in 
the nucleoli (Box 5). 
Silver-colloid method, which allows visualizing the nucleolar organizing regions (NORs), 
and co-localization experiments with anti-nucleolin (a nucleolar protein) antibody allowed 
to assess that the nuclear structures bound by MARK4L antibody are indeed the nucleoli 
(Magnani et al., 2009) (Figure 21) (Box 5).  
 
 
Fig. 21. Co-localization of MARK4L (green) and nucleolin (red) proteins in the nucleoli of 
glioma cells. The nuclei are counterstained with DAPI (blue). 
 





The overall immunofluorescence data on endogenous MARK4L protein confirm the 
previous evidence on its centrosome association and highlight two novel localization sites of 
MARK4L: the nucleolus and the midbody (Magnani et al., 2009). 
Immunoblotting with anti-MARK4L antibody on centrosomes, midbody and nucleoli 
isolated by biochemical fractionation from glioblastoma cell lines confirmed the presence of 
MARK4L protein in each fraction, validated by antibodies specific for each cell structure: 
anti-γtubulin antibody for centrosomes, anti-βtubulin for the midbody (βtubulin, together 
with αtubulin, accounts for 30% of midbody proteins) and anti-nucleolin for the nucleolus 
(Magnani et al., 2009).  
The localization pattern of MARK4L delineated by the above studies suggests that the 
kinase may take part in cell cycle progression and influence the microtubules, particularly 
those affecting the centrosome and midbody. 
MARK4L association with the nucleolus in glial tumours is very interesting, since MARK4L 
could have a functional impact on this organelle, being requested for its building and 
maintenance like other protein kinases, as well as it could be spatially regulated by alternate 
translocation in and out the nucleolus. Many proteins are indeed sequestered in the 
nucleolus and then released according to a temporally regulated activity, since they must 
exert their function in certain phases of the cell cycle (Visintin & Amon, 2000). Last, the 
nucleolar localization of a protein may also influence its stability, protecting the protein 
from proteasomal degradation, since proteasomes are present in the nucleoplasm but not in 
nucleoli (Wojcik & DeMartino, 2003). 
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A few remarks can be drawn from the above synthesis on cytogenomics of human gliomas 
and the MARK4 cell cycle gene as a likely “player” in gliomagenesis. 
Gliomas are one of the most intractable tumours due to their “complex identity”: as it has 
been beautifully underlined, the generation - since the earliest glioma stages - of multiple 
cell populations with different genotypic and phenotypic features makes unlikely to succeed 
therapeutic strategies targeting only clones with “dominant” or “average” characteristics of 
the cell population (Noble & Dietrich, 2004). The intrinsic genomic heterogeneity of human 
glioma has first been disclosed cytogenetically, as documented by a huge number of studies 
which across two decades have used the cytogenetic tools suitable to monitor the 
intratumour cell heterogeneity and to discern “recurrent” and potentially causative 
chromosomal rearrangements. A few of these rearrangements entered the diagnostic and 
prognostic flow chart of gliomas, others allowed to identify crucial genes which mutations 
or imbalance are the signature of a specific glioma type or glioma malignancy stage. In line 
with a research pathway that has been reiterated for several genes of relevance in cancer, 
focus on MARK4 has been pinpointed by cytogenetics and deepened by multiple tools 
ranging from gene-targeted molecular to genomic and cytogenomic analyses. Despite its 
nature of serine-threonine kinase gene, MARK4 has not be found mutated or affected by 
copy number alterations in glioma, while its encoded proteins represented by two different 
isoforms, MARK4S and MARK4L, could be featured as a potential target of dysregulation in 
tumours due to its dual nature. The latter isoform, produced by alternative splicing, has 
been found up-regulated in glioma and shown to display sub-cellular localizations, namely 
the centrosome, the midbody and the nucleolus, which strictly associate it with the process 
of cell division. Interestingly, alternative mRNA splicing has been considered a mechanism 
not only increasing proteomic complexity but also involved in cancer, through mechanisms 
of oncogenes/tumour suppressors activation/inactivation or through the generation of CIN 
(López-Saavedra & Herrera, 2010). CIN is a general property of aneuploid cancer cells and is 
generated by defects in different processes, among which the regulation of the number of 
centrosomes, the dynamics of microtubules attachment to the kinetochores and the overall 
control of cell cycle. Defects in centrosomal number and structure have been well 
documented in gliomas (D'Assoro et al., 2002; Katsetos et al., 2006; Magnani et al., 2009) 
raising the issue whether the increased MARK4L isoform, a gene involved in microtubule 
dynamics, may concur to errors in chromosomal segregation driving gliomagenesis. 
Recent application of multidimensional technological approaches has comprehensively 
highlighted the scenario of glioma genes and core pathways. However, despite the 
impressive advances, the links between genes alteration and cellular behavior are yet 
hampered by the multiplicity of the genetic lesions and the interconnections among the 
different affected pathways. Hopefully ongoing and next years research will compose 
the puzzle promising to translate into the clinical set the unraveled glioma 
pathomechanisms.  
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13.1 Cell cultures and preparation of human metaphase chromosomes 
Glioma cell lines were derived from primary tumour post-surgery specimens and 
subsequently maintained by serial passages in RPMI 1640 medium containing 5% Fetal Calf 
Serum at 37°C in a 5% CO2 atmosphere. Most of the cell lines were used within the first 30 
passages.  
Metaphase spreads were obtained on both fresh tumours and cultured cell lines, harvested 
when “peak” mitotic activity was observed; usually, a 16-hour treatment with Colcemid at a 
final concentration of 0.01-0.02 mg/ml is employed (Magnani et al., 1994). 
13.2 Fluorescence in situ hybridization (FISH) analysis 
Fluorescence hybridization with genomic DNA has proven to be a powerful tool for 
identification of chromosome rearrangements in cancer cells. Potential applications include 
detection of chromosome-specific aneuploidy in metaphase and interphase cells, 
quantification of the frequency of chromosome translocations and/or aneuploidy as a 
measure of genetic damage, and detection of diagnostically and prognostically relevant 
chromosomal lesions. Detection of translocations between human metaphase chromosomes 
is possible by using cocktails of chromosome-specific sequences that hybridize more or less 
uniformly along the chromosome. Depending on the aberration, its detection may be by 
visual fluorescence microscopy (see Figures 9, 10). In brief: slides carrying interphase or 
metaphase spreads are washed in 2x SSC (1 x SSC is 0.15 M NaCl/0.015 M sodium citrate), 
dehydrated in an ethanol series and denatured [70% (vol/vol) formamide/2x SSC (final 
concentration), pH 7, at 70°C for 2 min]. The hybridization mix consists of (final 
concentrations) 50% formamide, 2x SSC, 20% dextran sulfate, carrier DNA (sonicated 
herring sperm DNA), and biotin-labeled human genomic DNA. The mixture is applied to 
the slides under a glass coverslip. After overnight incubation at 37°C, the slides are washed 
at 45°C (50% formamide/2x SSC, pH 7), and immersed in BN buffer (0.1 M sodium 
bicarbonate, 0.05% Nonidet P-40, pH 8). The slides are never allowed to dry after this step. 
The coverslips are then removed and fluorescein-avidin DCS is applied. The coverslips are 
put back in their original places and the slides incubated 20 min at 37°C. They are then 
washed in BN buffer at 45°C. The intensity of biotin fluorescence is amplified by adding a 
layer of biotinylated goat anti-avidin antibody followed, after washing as above, by another 
layer of fluorescein-avidin DCS. After washing in BN buffer a fluorescence anti-fade 
solution is added. The DNA counterstain [4,6-diamidino-2-phenylindole (DAPI) or 
propidium iodide] is included in the anti-fade solution (Magnani et al., 1999; Pinkel et al., 
1986). 
13.3 Immunofluorescence 
Immunofluorescence analyses enable to visualize, by fluorescence microscopy, the sub-
cellular localization of a specific protein in cultured cells. The target protein is recognized by 
an antibody, which in turn is conjugated to a fluorochrome emitting fluorescent light. 
Briefly, cells are grown on glass chamber slides, then permeabilized (with solvents that 
extract lipids from the membranes allowing antibodies to reach a sub-cellular structure) and 
fixed (in order to protect the cell structure from eventual damages and to “freeze” cells in 
their current state). Afterwards, cells are incubated with bovine serum albumin (BSA) to 
block non-specific binding of antibodies. Glass slides are then incubated with a primary 
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an antibody, which in turn is conjugated to a fluorochrome emitting fluorescent light. 
Briefly, cells are grown on glass chamber slides, then permeabilized (with solvents that 
extract lipids from the membranes allowing antibodies to reach a sub-cellular structure) and 
fixed (in order to protect the cell structure from eventual damages and to “freeze” cells in 
their current state). Afterwards, cells are incubated with bovine serum albumin (BSA) to 
block non-specific binding of antibodies. Glass slides are then incubated with a primary 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
154 
antibody specific to the target protein, then with a secondary antibody conjugated to the 
fluorochrome and finally observed under the microscope (Magnani et al., 2009).  
13.4 Biochemical fractionation and immunoblotting 
By biochemical fractionation we mean the whole techniques that allow to separate and 
isolate intact cellular components. It usually consists in carefully breaking the cell 
membrane with homogenizers and isotonic/hypotonic solutions, so that intact organelles 
can come out, and in separating cellular components by centrifugation, on the basis of 
differences in their mass and specific weight. Centrosome, midbody and nucleoli isolation 
protocols are described in Magnani et al., 2009 and based on methods respectively by 
Moudjou & Bornens, 1994; Chu & Sisken, 1977; Muramatsu et al., 1963. In particular, for 
midbody isolation cells are synchronized in mitosis by nocodazole treatment and then 
released from mitotic arrest in nocodazole-free medium, so that after 30 minutes near 90% of 
cells had formed the midbody.  
After membrane breaking, all the passages are done at 4°C and with protease inhibitors, in 
order to prevent protein degradation, possibly exerted by released proteases. Proteins 
extracted from centrosome, midbody and nucleolus fractions are then analyzed by 
immunoblotting. Proteins are first separated, according to their molecular weight, by SDS-
PAGE (Sodium Dodecyl Sulphate – PolyAcrilamide Gel Electrophoresis): this technique 
allows proteins to migrate, driven by electric current, in a porous gel, with speed depending 
exclusively on their size. Afterwards, separated proteins are transferred onto a membrane, 
incubated with a blocking solution (BSA or milk) to prevent non-specific binding of 
antibodies and then incubated with appropriate antibodies (immunoblotting). The primary 
antibody is specific to the target protein and is recognized by the secondary antibody 
conjugated to HRP (horse radish peroxidase). Antibodies are detected by covering the 
membrane with a peroxide/enhancer solution, which is oxidized by HRP and emits light 
signals.  
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fluorochrome and finally observed under the microscope (Magnani et al., 2009).  
13.4 Biochemical fractionation and immunoblotting 
By biochemical fractionation we mean the whole techniques that allow to separate and 
isolate intact cellular components. It usually consists in carefully breaking the cell 
membrane with homogenizers and isotonic/hypotonic solutions, so that intact organelles 
can come out, and in separating cellular components by centrifugation, on the basis of 
differences in their mass and specific weight. Centrosome, midbody and nucleoli isolation 
protocols are described in Magnani et al., 2009 and based on methods respectively by 
Moudjou & Bornens, 1994; Chu & Sisken, 1977; Muramatsu et al., 1963. In particular, for 
midbody isolation cells are synchronized in mitosis by nocodazole treatment and then 
released from mitotic arrest in nocodazole-free medium, so that after 30 minutes near 90% of 
cells had formed the midbody.  
After membrane breaking, all the passages are done at 4°C and with protease inhibitors, in 
order to prevent protein degradation, possibly exerted by released proteases. Proteins 
extracted from centrosome, midbody and nucleolus fractions are then analyzed by 
immunoblotting. Proteins are first separated, according to their molecular weight, by SDS-
PAGE (Sodium Dodecyl Sulphate – PolyAcrilamide Gel Electrophoresis): this technique 
allows proteins to migrate, driven by electric current, in a porous gel, with speed depending 
exclusively on their size. Afterwards, separated proteins are transferred onto a membrane, 
incubated with a blocking solution (BSA or milk) to prevent non-specific binding of 
antibodies and then incubated with appropriate antibodies (immunoblotting). The primary 
antibody is specific to the target protein and is recognized by the secondary antibody 
conjugated to HRP (horse radish peroxidase). Antibodies are detected by covering the 
membrane with a peroxide/enhancer solution, which is oxidized by HRP and emits light 
signals.  
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1. Role of TRP channels in glioma growth and progression 
Gliomas are primary brain tumours believed to arise from glial cells or their progenitors. 
They account for 78% of malignant brain tumours (Shwartzbaum et al., 2006). The vast 
majority of gliomas is high-grade glioblastoma multiforme (GBM), and is characterized by 
almost unrestrained growth. Consequently, the median survival of patients with GBM was 
approximately 12 months (Huncharek & Muscat, 1998). While research has generated 
abundant information regarding the growth characteristics of these cancers, clinical care 
remains palliative and the prognosis dismal (Butowski et al., 2006). Gliomagenesis and 
progression are complex processes only partly understood. At molecular level, tumor 
progression and the associated heterogeneity is likely the result of multiple mutations in 
certain key signaling proteins (Furnari et al., 2007). Among these proteins, the Transient 
Receptor Potential (TRP) channel family has been identified to profoundly affect a variety of 
physiological and pathological processes (Kiselyov et al., 2007; Nilius et al., 2007). Members 
of TRP channels control cellular homeostasis by regulating calcium flux, cell proliferation, 
differentiation and apoptosis; moreover, in the last years an additional role for TRP ion 
channel family in malignant cancer growth and progression  has been recognized (Xu et al., 
2001; Wisnoskey et al., 2003; Xin et al., 2005; Bidaux et al., 2007; Prevarskaya et al., 2007; 
Gkika & Prevarskaya, 2009). Approximately thirty TRPs have been identified to date, and 
are classified in seven different families: TRPC (Canonical), TRPV (Vanilloid), TRPM 
(Melastatin), TRPML (Mucolipin), TRPP (Polycystin), and TRPA (Ankyrin transmembrane 
protein) and TRPN (NomPC-like) (Montell, 2003) (Fig.1).  
The expression levels and activity of members of the TRPC, TRPM, and TRPV families 
have been correlated with malignant growth and progression (Duncan et al., 1998; 
Tsavaler et al., 2001; Wissenbach et al., 2001; Thebault et al., 2006; Amantini et al., 2007; 
Caprodossi et al., 2008; Nabissi et al., 2010). TRP channels may regulate glioma growth 
and progression at different levels by controlling cell proliferation, inhibiting apoptosis, 
stimulating angiogenesis and triggering the migration and the invasion during tumor 
progression (Table 1).  
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Fig. 1. TRP superfamily. TRP subgroups are represented in square, the members are 
indicated for each subfamily.  
2. Role of TRPC and TRPV channels in cell cycle arrest and cytokinesis in 
malignant glioma 
Growth control of cancer cell populations has been studied extensively over the past 
decades and research has identified a multitude of transmembrane TRP channels involved 
in this process (Schönherr, 2005; Santoni et al., 2011) (Fig.2). While our understanding of 
their exact role in the physiology of cell proliferation remains tentative, many TRP channel 
agonists or antagonists also stimulate or retard cell population growth, which support the 
notion that TRP channels are intrinsic component of the cell cycle. In particular, calcium 
Ca(2+) signaling plays an important role in normal and aberrant cell proliferation, and some 
members of the Ca(2+)-permeable TRPC family have demonstrated a role in the 
proliferation of many types of cancer cells (Malarkey et al., 2008). Using a combination of 
molecular, biochemical and biophysical approaches, it was demonstrated the expression of 
five TRPC channel proteins (TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6) in patient biopsies 
and cell lines derived from glioma patients (Tables 1). Activation of TRPC channels typically 
occurs through the triggering of phospholipase C and this signaling cascade is the target of a 
number of G-protein-coupled receptors and receptor tyrosine kinases. An important form of 
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TRPV1 Ca(2+) influx, p38MAPK-dependent 
apoptosis 
Amantini et al., 2007 
 
TRPV2 
Inhibition of cell survival and 
proliferation, increase sensitivity to Fas-
induced apoptosis in an ERK-dependent 
manner 
Nabissi et al., 2010 
TRPM2 ROS-induced cell death Ishii et al., 2007 
TRPM8 Increases intracellular Ca(2+), BK channel 
activity, cell migration 
Wondergem et al., 2008 
Wondergem & Bartley, 2009 
Table 1. Expression and function of TRP channels in human gliomas 
TRPC activation has been shown downstream of the epidermal growth factor receptor 
(EGFR) (Odell et al.,2005) that is the major growth factor receptor activated in malignant 
gliomas. Indeed, mutated or amplified EGFR is often observed in malignant gliomas and 
has been associated with the increased cell proliferation seen in them (Bryant et al., 2004). In 
Cos-7 cells, EGFR activation causes phosphorylation of TRPC4 and results in channel 
insertion into the plasma membrane (Odell et al., 2005). Additionally, knockdown of TRPC4 
in human corneal epithelial cells suppresses epidermal growth factor (EGF)-induced cell 
proliferation, again linking proliferation to TRPC channels (Yang et al., 2005). Among TRPC 
channels, TRPC6 and TRPC1 seem to play a major role in the control of cell cycle and glioma 
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cell proliferation. Functional TRPC6 channels were overexpressed in human U251, U87, and 
T98G glioma cell lines. Moreover, increased TRPC6 expression was found in GBM biopsies 
compared with normal brain tissue, suggesting a role for TRPC6 in malignant growth of 
gliomas in vitro and in vivo (Ding et al., 2010). TRPC6 channels have been implicated in cell 
proliferation and hypertrophic gene expression through the activation of the calcineurin-
nuclear factor of activated T-cell (NFAT) pathway in normal (K. Kuwahara et al., 2006; 
Onohara et al., 2006) and malignant cells (Bomben & Sontheimer, 2008). Because glioma cells 
lack the expression of voltage-gated calcium channels (Kunzelmann, 2005) and Ca(2+) 
signaling promotes G1/S phase transition and cell cycle progression in a variety of cell types 
(Lipskaia & Lopré, 2004; M. Kuwahara et al., 2006), the TRPC6-mediated sustained elevation 
of [Ca(2+)]i and calcineurin-NFAT pathway activation is vital for the proliferation and 
malignant growth of gliomas under hypoxia. Consistently, inhibition of hypoxia-induced 
TRPC6 expression causes a dramatic decrease in NFAT activation (Bucholz & Ellenrieder, 
2007). In glioma cells, inhibition of TRPC6 activity or expression by using a dominant-
negative mutant TRPC6 (DNC6) or RNA interference, respectively, attenuated the increase 
in intracellular Ca(2+) induced by platelet-derived growth factor (PDGF), suppressed cell 
growth and clonogenic ability, induced cell cycle arrest at the G2/M phase, and enhanced 
the antiproliferative effect of ionizing radiation. Cyclin-dependent kinase 1 (CdK1) 
activation and cell division cycle 25 homolog C (Cdc25) expression regulated the DNC6-
induced cell cycle arrest. Inhibition of TRPC6 activity also significantly reduced tumor 
volume in a subcutaneous mouse model of xenografted human tumors and increased mean 
survival in mice in an intracranial model (Ding et al., 2010). In addition to TRPC6 a role for 
TRPC3 in glioma cell proliferation has been suggested. The TRPC3 channel has been found 
to cause intracytoplasmic calcium oscillations in rat glial cells (Grimaldi et al., 2003). In rat 
cortical astrocytes, thrombin via Ca(2+) signal, induces TRPC3 upregulation and enhanced 
proliferation, and these effects were inhibited by TRPC3 blockers and siTRPC3 RNA 
(Shirakawa et al., 2010). Ca(2+) mobilization mediated by TRPC3 is associated with 
thrombin-induced morphological changes in human astrocytoma cells (Nakao et al., 2008).  
Glioblastoma multiforme proliferates extensively and cells often undergo incomplete cell 
divisions, resulting in multinucleated cells. Cytokinesis, which begins at the onset of 
anaphase, is the division of remaining cytoplasmic substances in the cell, aside from the 
nuclear events of mitosis (Glotzer, 2005; Eggert et al., 2006). Recent evidence (Bomben & 
Sontheimer, 2010) indicated that the functional loss of TRPC1 channels involved in agonist-
induced calcium entry and reloading of intracellular Ca(2+) stores disrupts glioma 
cytokinesis leading to bizarre and greatly enlarged multinucleated glioma cells (GMGCs) 
showing slow growth (Palma et al., 1989). Pharmacological inhibition of TRPC1 expression 
using the continuously administration for up to 4 days of the chronic inhibitor of TRPC 
channels, SKF96365, or TRPC1 suppression using a doxycycline inducible shRNA 
knockdown approach, causes loss of functional channels and store-operated calcium entry 
in glioma cells, and a significant decrease of tumor size, respectively. This effect is 
associated with reduced cell proliferation and, frequently, with incomplete cell division due 
to arrest at the G2/M phase of the cell cycle (Stark & Taylor, 2006).  Cytokinesis is typically 
described with two key components being the central spindle and the contractile ring. RhoA 
guanosine triphosphatase GTPase is one key player in contractile ring formation, which is 
important for actin nucleation and myosin activation (Bement et al., 2006). Recently reports 
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have indicated an association between TRPC1 and RhoA (Mehta et al., 2003) and  
independently of TRPC6 and RhoA in certain cell types (Singh et al., 2007). Finally, receptors 
belonging to the TRPV channel family have been found to inhibit in vitro glioma cell 
proliferation. In this regard, we have recently reported that TRPV2 mRNA was expressed in 
benign astrocyte tissues, and its expression progressively declined in high-grade glioma 
tissues as histological grade increased. TRPV2  negatively controls glioblastoma survival 
and proliferation. In U87 glioma cells, silencing of TRPV2 by RNA interference (siRNA) 
affects several genes controlling cell cycle and proliferation (Nabissi et al., 2010). Down-
regulation of CD95/Fas and parallel up-regulation of CCNE1, CDK2, E2F1, Raf-1 gene 
expression was observed in siTRPV2-U87 glioma cells as respect to controls. Moreover, 
TRPV2 knock-out increased glioblastoma proliferation and survival in an ERK-dependent 
manner. Inhibition of ERK activation by treatment of siRNA-TRPV2 U87 glioma cells with 
the specific MEK-1 inhibitor PD98059, promoted Fas expression and restored Akt/PKB 
pathway activation leading to reduced cell survival and proliferation (Nabissi et al., 2010). 
Conversely, TRPV2 transfection of primary MZC glioblastoma cells also reduced glioma 
viability and proliferation  (Nabissi et al., 2010). 
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GBM microvasculature provides little support in oxygen/nutrient delivery, paradoxically 
contributing to exacerbate a metabolic mismatch between supply and demand leading to 
progressive hypoxia and eventually necrosis. In addition with the poor vascular architecture, 
endothelial cells associated with tumor vasculature fail to form tight junctions and have few 
associated pericytes or astrocytic foot processes leaving the integrity of the brain blood 
barrier compromised. This process requires that endothelial cells respond to a variety of 
extracellular signals that activate receptors responsible for growth and differentiation. VEGF 
(Vascular Endothelial Growth Factor), and Angiopoietin are key molecules in the promotion 
of angiogenesis via activation of the VEGFR (VEGF Receptor), and Tyrosine kinase with 
immunoglobulin-like and EGF-like domains 1 (TIE) expressed on vascular endothelial cells 
(Lutsenko et al., 2003). The Ca(2+) is another important second messenger and its entry 
through plasma membrane affects the angiogenesis. VEGF causes an increase in intracellular 
Ca(2+) concentration in cultured endothelial cells (Criscuolo et al., 1989) through both 
intracellular Ca(2+) release and extracellular Ca(2+) entry (Brock et al., 1991; Faehling et al., 
2001; Wu et al., 1999; Cheng et al., 2006) and up-regulates vascular permeability (Criscuolo 
et al., 1988). Many of its physiological functions are dependent on Ca(2+) influx (Kawasaki 
et al., 2000; Faehling et al., 2002) through a store-independent mechanism (Pocock et al., 
2000). Vascular permeability has been shown to be dependent on calcium influx, possibly 
through a TRPC-mediated channels. In particular, recent data indicate that TRPC6 represent 
an obligatory component of cation channels required for the VEGF-mediated increase in 
cytosolic calcium and subsequent downstream signaling that leads to processes associated 
with angiogenesis. The TRPC6 channel can be activated by VEGF. Overexpression of a 
dominant negative TRPC6 construct in human microvascular endothelial cells (HMVECs) 
inhibited the VEGF-mediated increase in cytosolic calcium, migration, sprouting, and 
proliferation. In contrast, overexpression of a wild-type TRPC6 construct increased the 
proliferation and migration of HMVECs (Hamdollah Zadeh et al., 2008). Inhibition of 
TRPC6 in HUVECs by pharmacological or genetic approaches arrested HUVECs at G2/M 
phase and suppressed VEGF-induced HUVEC proliferation and tube formation. 
Furthermore, inhibition of TRPC6 abolished VEGF-, but not FGF-induced angiogenesis in 
the chick embryo chorioallantoic membrane (Ge et al., 2009). Reduced oxygen availability 
(hypoxia) in the surrounding brain tissue is a major driving force behind GBM angiogenesis, 
and the low oxygen environment in the brain is positively related to GBM aggressiveness 
and poor prognosis (Hockel & Vaupel, 2001). The role of Hif-1α in tumor growth and 
invasion is well established (Semenza, 2003). Hif-1α protein was undetectable or low in 
glioma cells under normoxic conditions but increased markedly under hypoxia. Similarly, 
Notch1 activity was low in glioma cells but was elevated after the hypoxic switch. In 
addition to Notch1, other components of the Notch pathway were increased in glioma cells 
after the hypoxic switch. Specifically, the levels of Jagged-1 protein were increased under 
hypoxia. The molecular signals that link tissue hypoxia, Hif-1α activation to tumor 
angiogenesis are poorly understood. In glioma cells, the expression of TRPC6 is low or 
undetectable. Hypoxia by inducing Notch1 activation, increases TRPC6 expression in 
primary GBM and cell lines derived from GBM. Knockdown of TRPC6 expression inhibits 
glioma angiogenesis. Moreover, pharmacologic inhibition of Notch blocked the hypoxia-
induced upregulation of TRPC6. The induction of TRPC6 expression in gliomas was TRPC 
subtype specific because other members of TRPC subfamily were unaffected. Although  
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Notch signaling is critical for TRPC6 upregulation, it remains to be determined whether the 
Notch pathway directly or indirectly, through cross-talk with other transcription factors 
(Gustafsson et al., 2005; Song et al., 2008), regulates TRPC6 transcription. TRPC6 activity is 
increased with EGFR activation (Odell et al., 2005), suggesting a link between growth factor 
response to tumor growth, and angiogenesis. Functionally, TRPC6 causes a sustained 
elevation of intracellular calcium that is coupled to the activation of the calcineurin-nuclear 
factor of activated T-cell (NFAT) pathway. Pharmacologic inhibition of the calcineurin-
NFAT pathway substantially reduces hypoxia-induced glioma progression (Mosieniak et al., 
1998; Chigurupati et al., 2010). The activation of TRPC6 by Galphaq induces RhoA activation 
and increased [Ca(2+)]i that stimulate thrombin-induced increase of actinomyosin-mediated 
endothelial cell contraction, cell shape change and consequently increased endothelial 
permeability. Inhibitor of Galphaq or phospholipase C and the Ca(2+) chelator, BAPTA-AM, 
abrogated thrombin-induced RhoA activation. By contrast, activation of TRPC6 by oleoyl-2-
acetyl-sn-glycerol (OAG), the membrane permeable analogue of the Galphaq-phospholipase 
C product, diacylglycerol, induced RhoA activity. Receptor-operated Ca(2+) activation was 
mediated by TRPC6. Thus, TRPC6 knockdown significantly reduced Ca(2+) entry and 
prevented RhoA activation, myosin light chain phosphorylation, and actin stress fiber 
formation as well as inter-endothelial junctional gap formation in response to either OAG or 
thrombin (Singh et al., 2007). Lysophosphatidylcholine (lysoPC) has been also found to 
induce a rapid translocation of TRPC6 in endothelial cells, that triggeres calcium influx 
resulting in externalization of TRPC5. Activation of this novel TRPC6-TRPC5 channel 
cascade by lysoPC, inhibits endothelial cell migration. TRPC5 siRNA down-regulates the 
lysoPC-induced rise in [Ca(2+)]i and reverts the inhibition of EC migration (Chaudhuri et al., 
2008), suggesting a negative role played by this channel in the regulation of EC migration. 
Finally, the phosphatase and tensin homologue (PTEN), has been found to serves as a 
scaffold for TRPC6 channel by enabling cell surface expression of the channel. Ca(2+) entry 
through TRPC6 induces an increase in endothelial permeability and directly promotes 
angiogenesis (Kini et al., 2010) (Fig 3). PTEN is a dual lipid-protein phosphatase that 
catalyzes the conversion of phosphoinositol 3,4,5-triphosphate to phosphoinositol 4,5-
bisphosphate and thereby inhibits PI3K-Akt-dependent cell proliferation, migration, and 
tumor vascularization. Recently, a PTEN phosphatase-independent mechanism in 
regulating Ca(2+) entry through TRPC6 has been reported. PTEN tail-domain residues 394-
403 permit PTEN to associate with TRPC6, and thrombin promotes this association. Deletion 
of PTEN residues 394-403 prevents TRPC6 cell surface expression and Ca(2+) entry (Kini et 
al., 2010). Other TRPC channels have been found to be involved in glioma angiogenesis. 
Studies in zebrafish, have demonstrated that the involvement of TRPCs channels in 
angiogenesis represents a reminiscent of the role of TRPC channels in axon guidance (Yu et 
al., 2010). Activation of TRPC1 seems to be essential for the angiogenesis in vivo. 
Knockdown of TRPC1 by antisense oligonucleotides severely disrupted angiogenic 
sprouting of intersegmental vessels (ISVs). In vivo time-lapse imaging revealed that the 
angiogenic defect was attributable to impairment of filopodia extension, migration, and 
proliferation of ISV tip cells. TRPC1 acts synergistically with VEGFA in controlling ISV 
growth, and appeared to be downstream to VEGFA in controlling angiogenesis (Yu et al., 
2010). Recently a role for TRPC1 in hypoxia-induced VEGF expression in U87 glioma cells 
has been reported. TRPC1 siRNA markedly inhibits hypoxia-induced up-regulation of  
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VEGF mRNA and protein levels (Wang  et al., 2009). TRPC1-dependent Ca(2+) influx 
induced by VEGF also increases endothelial permeability. Angiopoietin-1 (Ang1) that exerts 
a vascular endothelial barrier protective effect by blocking the action of permeability-
increasing mediators such as VEGF, inhibited the VEGF-induced Ca(2+) influx and 
increased the endothelial permeability in a concentration-dependent manner. Ang1 
interfered with downstream IP3-dependent plasmalemmal Ca(2+) entry. Anti-TRPC1 
antibody (Ab) inhibited the VEGF-induced Ca(2+) entry and the increased endothelial 
permeability. TRPC1 overexpression in endothelial cells augmented the VEGF-induced 
Ca(2+) entry, and application of Ang1 opposed this effect. Consistent with the coupling 
hypothesis of Ca(2+) entry, Ang1 by inhibiting the association of IP3 receptor (IP3R) and 
TRPC1, abrogates the increase in endothelial permeability (Jho et al., 2005). Although the 
previously reported study has been focused on Ang1 regulation of TRPC1 activation, we 
cannot rule out the involvement of other relevant TRPC channels. TRPC4 acts as a functional 
homologue in mouse endothelia to TRPC1 in humans (Nilius et al., 2003; Tiruppathi et al., 
2002). For agonist-induced Ca(2+) entry in mouse aortic endothelial cells, TRPC4 was essential 
as either a channel-forming subunit or a constituent required for channel activation  (Freichel 
et al., 2001). Because TRPC1 and TRPC4 can oligomerize (Hofmann et al., 2002), it is possible 
that both may be needed for the VEGF-induced Ca(2+) entry. The importance of TRPC4 in 
regulation of endothelial permeability in mice has been reinforced by the observations that the 
effects of Ang1 on VEGF-induced Ca(2+) entry and permeability were mimicked by deletion of 
the TRPC4 gene in mice (Tiruppathi et al., 2002). Finally, VEGF-induced activation of Ca(2+) 
entry can also occur via TRPC6 which is activated by PLC-generated DAG (Pocock et al., 2001, 
2004). TRPC4 has been also found to control thrombospondin-1 (TSP-1) secretion and 
angiogenesis in renal cell carcinoma (RCC) (Veliceasa et al., 2007). TRPC4 loss has been lead to 
impaired Ca(2+) intake, misfolding, retrograde transport and diminished secretion of 
antiangiogenic TSP-1, thus enabling angiogenic switch during RCC progression.  TRPC4 has 
been recently reported to be expressed in glioma cells (Wang et al., 2009), however at present 
no data on the role of this channel in the inhibition of glioma angiogenesis has been provided 
so far. Membrane-stretch activated TRPV calcium channels have been known to mediate the 
orientation of endothelial cells lining blood vessels thus influencing the angiogenesis. So, 
TRPV4 channels expressed in the plasma membrane of capillary endothelial cells is required 
for mechanical-induced changes in focal adhesion assembly, cell orientation and directional 
migration. Recent reports indicate that activation of the mechanosensitive TRPV4 in capillary 
endothelial cells, stimulates phosphatidylinositol 3-kinase-dependent activation and binding 
of additional 1 integrin receptors, which promotes cytoskeletal remodeling and cell 
reorientation. Inhibition of integrin activation using blocking Abs and knock-down of TRPV4 
using siRNA, suppress capillary cell reorientation. Activation of TRPV4 channels by force 
transfer from integrins and CD98 may enable compartmentalization of calcium signaling 
within focal adhesions. This early-immediate calcium signaling response required the distal 
region of the 1 integrin cytoplasmic tail that contains a binding site for the integrin-associated 
transmembrane CD98 protein, and application of external force to CD98 within focal 
adhesions activated the same ultra-rapid calcium signaling response (Matthews et al., 2010). 
Thus, mechanical forces that physically deform extracellular matrix (ECM) guide capillary cell 
reorientation through an "integrin-to-integrin" signaling mechanism mediated by activation of 
mechanically gated TRPV4 channels on the cell surface (Thodeti et al., 2009). We have recently 
reported the expression of TRPV4 channels in glioma cell lines (Santoni et al., 2011), however 
the potential role of TRPV4 in the migration of endothelial cells during glioma angionenesis is 
at present unknown.  
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Fig. 3. Different modes of TRPC6 activation and cellular response, in glioma cells A) Spike in 
[Ca2+]i entry  induces endothelial cell (EC) contraction, cell shape and permeability; B) while 
prolonged [Ca2+]i entry by LysoPC-induced TRPC6 activation inhibits EC migration.   
4. TRPC and TRPM channels stimulate glioma cell migration and invasion 
Glioblastoma multiforme is extremely invasive and consequently the clinical prognosis for 
patients is dismal. Invasion by glioma cells into regions of normal brain is driven by a 
multifactorial process involving cell interactions with ECM and with adjacent cells, as well 
as accompanying biochemical processes supportive of proteolytic degradation of ECM, and 
active cell movements (Bomben et al., 2010). These processes bear a striking resemblance to 
the robust inherent migration potential of glial cells during embryogenesis. Invasion and 
migration of glial tumors differ from other tumors where local spread is very limited and 
dissemination occurs hematogenously or via the lymphatic system. As they spread and form 
metastasis, glioma cells migrate through the narrow extracellular brain spaces often 
following the path of nerve fiber or blood vessels. Invading glioma cells commonly assume 
an elongated spindle-shaped morphology, suggesting that the cells have shrunk to fit into 
the narrow space into the brain (Sontheimer, 2008). Several studies have focused on the 
understanding of different molecular mechanisms expressed by invading tumor cells. 
Gliomas utilize a number of proteins and pathways to infiltrate the brain parenchyma 
including ion channels and calcium signaling pathways. Ion channels have recently 
involved in glioma invasion as a means to control cell volume or regulating Ca(2+) signaling 
pathways in invasive cells. Calcium signaling has been shown to play important roles in 
glioma cell invasion (Komuro & Kumada, 2005).  Cell shrinkage by adaptation of cell size 
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Fig. 3. Different modes of TRPC6 activation and cellular response, in glioma cells A) Spike in 
[Ca2+]i entry  induces endothelial cell (EC) contraction, cell shape and permeability; B) while 
prolonged [Ca2+]i entry by LysoPC-induced TRPC6 activation inhibits EC migration.   
4. TRPC and TRPM channels stimulate glioma cell migration and invasion 
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as accompanying biochemical processes supportive of proteolytic degradation of ECM, and 
active cell movements (Bomben et al., 2010). These processes bear a striking resemblance to 
the robust inherent migration potential of glial cells during embryogenesis. Invasion and 
migration of glial tumors differ from other tumors where local spread is very limited and 
dissemination occurs hematogenously or via the lymphatic system. As they spread and form 
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following the path of nerve fiber or blood vessels. Invading glioma cells commonly assume 
an elongated spindle-shaped morphology, suggesting that the cells have shrunk to fit into 
the narrow space into the brain (Sontheimer, 2008). Several studies have focused on the 
understanding of different molecular mechanisms expressed by invading tumor cells. 
Gliomas utilize a number of proteins and pathways to infiltrate the brain parenchyma 
including ion channels and calcium signaling pathways. Ion channels have recently 
involved in glioma invasion as a means to control cell volume or regulating Ca(2+) signaling 
pathways in invasive cells. Calcium signaling has been shown to play important roles in 
glioma cell invasion (Komuro & Kumada, 2005).  Cell shrinkage by adaptation of cell size 
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and volume to fit into narrow spaces is a prerequisite for cell movement and migration. 
Most immature cells that can migrate are well equipped to accumulate and release 
intracellular ions to shrink. How cell movement and invasion are coupled to the controlled 
activation of Ca(2+) channels is only partially understood (Mcferrin & Sontheimer, 2006). In 
glioma cells, invasion appears to involve a coordinated reduction in cell volume, which is 
mediated by the efflux of Cl− and K+ through ion channels. The Cl− efflux is accompanied by 
the movement of K+ ions. The principal pathway for K+ efflux from glioma cells appears to 
be via Ca(2+)-activated bradykinin (BK) channels, which have the unique ability to couple 
changes in intracellular Ca(2+) to changes in membrane K+ conductance and are expressed 
highly in glioma cells (Ransom & Sontheimer, 2001). In glioma cells, migration is 
accompanied by oscillatory changes in intracellular Ca(2+)  in response to different stimuli 
(Grimaldi et al., 2003), which activate BK K+ channels, and the velocity of cell migration of 
glioma cells correlates with oscillatory changes in intracellular Ca(2+) concentration (Bordey 
et al., 2000). Among ion channels contributing to Ca(2+) signaling, cytoskeleton changes, 
movement and migration, the TRPM and TRPC channel families seem to play an important 
role. Thus, triggering of TRPM8 by the specific agonist, menthol (Wondergem & Bartley, 
2009), as TRPC3 and TRPC6 (Kim et al., 2009) increases glioma cell [Ca(2+)]i that in turn 
activates BK channels. Thus. TRP-mediated activation of Ca(2+) influx appears to be the 
prerequisite for cell migration and this Ca(2+) signal is instructive with regards to cell 
volume changes that occur down-stream. Cell shape, adhesion and migration have been 
regulated by actomyosin contractility. TRPM7-like transcripts current has been identified in 
rat microglia (Jiang et al., 2003). TRPM7 plays a role in linking receptor-mediated signals to 
actomyosin remodelling and cell adhesion. Activation of TRPM7 by BK, leads to a Ca(2+) 
and kinase-dependent interaction with the actomyosin cytoskeleton. Overexpression of 
TRPM7, by increasing the intracellular Ca(2+) levels resulted in cell spreading, adhesion and 
formation of focal adhesions (Clark et al., 2006). The effects of TRPM7 on cell morphology is 
directly dependent on integrin activation or is associated to increase in cytosolic Ca(2+) 
concentrations that affect the actomyosin cytoskeleton. The integrin activation can lead to 
the remodeling of the actomyosin cytoskeleton that promotes cell spreading via outside-in 
signaling pathways. Alternatively, Ca(2+) is an important second messenger in actin 
remodeling including polymerization, severing of filaments and F-actin–membrane 
interactions. The TRPC channels play a role in store-operated calcium entry (SOCE), and in 
particular TRPC1 is involved in SOCE in glioma cells  (Bomben & Sontheimer, 2010). 
TRPC1-dependent migration and chemotaxis have been reported in different cell types such 
as myoblasts (Louis et al., 2008), renal epithelial (Fabian et al., 2008) and nervous cells 
(Wang & Poo, 2005) (Fig.2). Recently, (Bomben & Sontheimer, 2010) showed that TRPC1 
channel association with lipid rafts is essential for glioma chemotaxis in response to stimuli, 
such as EGF, but not chemokinesis. EGF stimulation affects both TRPC trafficking 
(Bezzerides et al., 2004) and activation (Beech, 2005; Liu et al., 2009), and TRPC1 channel 
localization to the leading edge of migrating glioma cells. TRPC1 channels co-localize with 
the lipid raft proteins, caveolin-1. Chemotaxis toward EGF was lost when TRPC channels 
were pharmacologically inhibited or by shRNA knock-down of TRPC1 channels, yet 
without affecting unstimulated cell motility. Lipid raft integrity was required for gliomas 
chemotaxis; thus disruption of lipid rafts not only impaired chemotaxis but also impaired 
TRPC currents and decreased store-operated calcium entry. TRPC6 is markedly up-
regulated under hypoxia in a manner dependent on Notch activation. The Notch-regulated 
transcriptional targets that are responsible for the development of the aggressive and 
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malignant phenotypes in GBM remain poorly characterized. Notch signaling mediates 
hypoxia-induced tumor migration and invasion under hypoxic environment (Sahlgren et al., 
2008). TRPC6 has been found to markedly inhibited glioma cell migration and invasion in 
response to hypoxia by regulating actin cytoskeleton assembling and disassembling which 
control cell shape, allowing the cell to move along the surface. The last step of invasion 
requires cytoskeletal rearrangements and formation of lamillipodia and fillopodia for which 
the family of Rho GTPases plays an important role. Most Rho proteins, cycle between GTP-
bound active and GDP-bound inactive state. From the family members, Rho stimulates 
formation of stress fibres and focal adhesion, Rac is required for the formation of 
lamellipodia and Cdc42 regulates cell polarity and fillopodia formation (Teodorczyk & 
Martin-Villalba, 2009). A role for TRPC6 in Rho activation and actin cytoskeleton 
rearrangements has been suggested (Albert & Large, 2003). The TRPC6-mediated Ca(2+) 
entry may contribute to invasion by promoting actin-myosin interactions and the formation 
and disassembly of cell-substratum adhesions that are important for glioma migration (Kim 
& Saffen, 2005). Moreover, a role for TRPC3 activation has been also proposed. Thus, Ca(2+) 
entry in type I astrocytes and rat C6 glioma cells induced by OAG was InsP3-independent 
and inhibited by a TRPC3 antisense (Grimaldi et al., 2003). In addition, TRPC3 is 
functionally involved in Ca(2+) entry and thrombin stimulated morphological changes (cell 
rounding) induced by PAR-1 activation in 1321N1 human astrocytoma cells (Nakao et al., 
2008). Finally, GBM cells express TRPM8 mRNA and protein, and its involvement in 
menthol and hepatocyte growth factor/scatter factor  (HGF/SF) increase of [Ca(2+)]i and 
glioma cell migration has been reported (Wondergem et al., 2008). Menthol a TRPM8 
agonist, stimulated influx of Ca(2+), membrane current, and migration of human 
glioblastoma DBTRG cells. The effects on Ca(2+) and migration were enhanced by pre-
treatment with HGF/SF. The effects on Ca(2+) also were greater in migrating cells 
compared with non-migrating cells. 2-Aminoethoxydiphenyl borate inhibited all menthol 
stimulations. In addition, menthol, by increasing [Ca(2+)]i, in human glioblastoma cells, 
resulted in activation of the large-conductance Ca(2+)-activated K+ membrane ion channels 
(BK channels). Kinetic analysis showed that menthol increased channel open probability 
and mean open frequency after 5 min, and this increase was abolished either by added 
paxilline, tetraethylammonium ion or by Ca(2+)-free external solution. In addition, 
inhibition of BK channels by paxillin reverses menthol-stimulated increase of [Ca(2+)]i 
and cell migration. Finally, menthol stimulated the rate of DBTRG cell migration into 
scratch wounds made in confluent cells, and this also was inhibited by paxilline or 
tetraethylammonium ion (Wondergem & Bartley, 2009). Invasion and metastasis are 
biologic hallmarks of malignant tumour. The invasion of ECM requires active degradation 
of ECM components. Tumour cells themselves secrete proteolytic enzymes 
(metalloproteinases, MMPs) or induce host cells to elaborate proteases (Pluda, 1997; Price 
et al., 1997; Liotta & Kohn, 1997). Glioma cells secrete MMPs to degradate the ECM 
surrounding invading cells (Levicar et al., 2003). In this regard, cannabidiol (CBD) has 
been found to impair the migration of U87 glioma cells in a cannabinoid receptor-
independent manner (Vaccani et al., 2005), by increasing the tissue inhibitor of MMP1, 
(TIMP-1) (Ramer et al., 2010) and down-regulating the MMP-2 expression (Blazquez et al., 
2008). Since CBD represents a specific ligand for TRPV2 (Qin et al., 2008), and being 
TRPV2 downregulated in the more invasive malignat gliomas (Nabissi et al., 2010), 
activation of this channel may represent an important  target in anti-invasive 
chemotherapeutic strategy in GBM patients.  
 
Glioma – Exploring Its Biology and Practical Relevance 
 
172 
and volume to fit into narrow spaces is a prerequisite for cell movement and migration. 
Most immature cells that can migrate are well equipped to accumulate and release 
intracellular ions to shrink. How cell movement and invasion are coupled to the controlled 
activation of Ca(2+) channels is only partially understood (Mcferrin & Sontheimer, 2006). In 
glioma cells, invasion appears to involve a coordinated reduction in cell volume, which is 
mediated by the efflux of Cl− and K+ through ion channels. The Cl− efflux is accompanied by 
the movement of K+ ions. The principal pathway for K+ efflux from glioma cells appears to 
be via Ca(2+)-activated bradykinin (BK) channels, which have the unique ability to couple 
changes in intracellular Ca(2+) to changes in membrane K+ conductance and are expressed 
highly in glioma cells (Ransom & Sontheimer, 2001). In glioma cells, migration is 
accompanied by oscillatory changes in intracellular Ca(2+)  in response to different stimuli 
(Grimaldi et al., 2003), which activate BK K+ channels, and the velocity of cell migration of 
glioma cells correlates with oscillatory changes in intracellular Ca(2+) concentration (Bordey 
et al., 2000). Among ion channels contributing to Ca(2+) signaling, cytoskeleton changes, 
movement and migration, the TRPM and TRPC channel families seem to play an important 
role. Thus, triggering of TRPM8 by the specific agonist, menthol (Wondergem & Bartley, 
2009), as TRPC3 and TRPC6 (Kim et al., 2009) increases glioma cell [Ca(2+)]i that in turn 
activates BK channels. Thus. TRP-mediated activation of Ca(2+) influx appears to be the 
prerequisite for cell migration and this Ca(2+) signal is instructive with regards to cell 
volume changes that occur down-stream. Cell shape, adhesion and migration have been 
regulated by actomyosin contractility. TRPM7-like transcripts current has been identified in 
rat microglia (Jiang et al., 2003). TRPM7 plays a role in linking receptor-mediated signals to 
actomyosin remodelling and cell adhesion. Activation of TRPM7 by BK, leads to a Ca(2+) 
and kinase-dependent interaction with the actomyosin cytoskeleton. Overexpression of 
TRPM7, by increasing the intracellular Ca(2+) levels resulted in cell spreading, adhesion and 
formation of focal adhesions (Clark et al., 2006). The effects of TRPM7 on cell morphology is 
directly dependent on integrin activation or is associated to increase in cytosolic Ca(2+) 
concentrations that affect the actomyosin cytoskeleton. The integrin activation can lead to 
the remodeling of the actomyosin cytoskeleton that promotes cell spreading via outside-in 
signaling pathways. Alternatively, Ca(2+) is an important second messenger in actin 
remodeling including polymerization, severing of filaments and F-actin–membrane 
interactions. The TRPC channels play a role in store-operated calcium entry (SOCE), and in 
particular TRPC1 is involved in SOCE in glioma cells  (Bomben & Sontheimer, 2010). 
TRPC1-dependent migration and chemotaxis have been reported in different cell types such 
as myoblasts (Louis et al., 2008), renal epithelial (Fabian et al., 2008) and nervous cells 
(Wang & Poo, 2005) (Fig.2). Recently, (Bomben & Sontheimer, 2010) showed that TRPC1 
channel association with lipid rafts is essential for glioma chemotaxis in response to stimuli, 
such as EGF, but not chemokinesis. EGF stimulation affects both TRPC trafficking 
(Bezzerides et al., 2004) and activation (Beech, 2005; Liu et al., 2009), and TRPC1 channel 
localization to the leading edge of migrating glioma cells. TRPC1 channels co-localize with 
the lipid raft proteins, caveolin-1. Chemotaxis toward EGF was lost when TRPC channels 
were pharmacologically inhibited or by shRNA knock-down of TRPC1 channels, yet 
without affecting unstimulated cell motility. Lipid raft integrity was required for gliomas 
chemotaxis; thus disruption of lipid rafts not only impaired chemotaxis but also impaired 
TRPC currents and decreased store-operated calcium entry. TRPC6 is markedly up-
regulated under hypoxia in a manner dependent on Notch activation. The Notch-regulated 
transcriptional targets that are responsible for the development of the aggressive and 
New Insight on the Role of Transient 
Receptor Potential (TRP) Channels in Driven Gliomagenesis Pathways 
 
173 
malignant phenotypes in GBM remain poorly characterized. Notch signaling mediates 
hypoxia-induced tumor migration and invasion under hypoxic environment (Sahlgren et al., 
2008). TRPC6 has been found to markedly inhibited glioma cell migration and invasion in 
response to hypoxia by regulating actin cytoskeleton assembling and disassembling which 
control cell shape, allowing the cell to move along the surface. The last step of invasion 
requires cytoskeletal rearrangements and formation of lamillipodia and fillopodia for which 
the family of Rho GTPases plays an important role. Most Rho proteins, cycle between GTP-
bound active and GDP-bound inactive state. From the family members, Rho stimulates 
formation of stress fibres and focal adhesion, Rac is required for the formation of 
lamellipodia and Cdc42 regulates cell polarity and fillopodia formation (Teodorczyk & 
Martin-Villalba, 2009). A role for TRPC6 in Rho activation and actin cytoskeleton 
rearrangements has been suggested (Albert & Large, 2003). The TRPC6-mediated Ca(2+) 
entry may contribute to invasion by promoting actin-myosin interactions and the formation 
and disassembly of cell-substratum adhesions that are important for glioma migration (Kim 
& Saffen, 2005). Moreover, a role for TRPC3 activation has been also proposed. Thus, Ca(2+) 
entry in type I astrocytes and rat C6 glioma cells induced by OAG was InsP3-independent 
and inhibited by a TRPC3 antisense (Grimaldi et al., 2003). In addition, TRPC3 is 
functionally involved in Ca(2+) entry and thrombin stimulated morphological changes (cell 
rounding) induced by PAR-1 activation in 1321N1 human astrocytoma cells (Nakao et al., 
2008). Finally, GBM cells express TRPM8 mRNA and protein, and its involvement in 
menthol and hepatocyte growth factor/scatter factor  (HGF/SF) increase of [Ca(2+)]i and 
glioma cell migration has been reported (Wondergem et al., 2008). Menthol a TRPM8 
agonist, stimulated influx of Ca(2+), membrane current, and migration of human 
glioblastoma DBTRG cells. The effects on Ca(2+) and migration were enhanced by pre-
treatment with HGF/SF. The effects on Ca(2+) also were greater in migrating cells 
compared with non-migrating cells. 2-Aminoethoxydiphenyl borate inhibited all menthol 
stimulations. In addition, menthol, by increasing [Ca(2+)]i, in human glioblastoma cells, 
resulted in activation of the large-conductance Ca(2+)-activated K+ membrane ion channels 
(BK channels). Kinetic analysis showed that menthol increased channel open probability 
and mean open frequency after 5 min, and this increase was abolished either by added 
paxilline, tetraethylammonium ion or by Ca(2+)-free external solution. In addition, 
inhibition of BK channels by paxillin reverses menthol-stimulated increase of [Ca(2+)]i 
and cell migration. Finally, menthol stimulated the rate of DBTRG cell migration into 
scratch wounds made in confluent cells, and this also was inhibited by paxilline or 
tetraethylammonium ion (Wondergem & Bartley, 2009). Invasion and metastasis are 
biologic hallmarks of malignant tumour. The invasion of ECM requires active degradation 
of ECM components. Tumour cells themselves secrete proteolytic enzymes 
(metalloproteinases, MMPs) or induce host cells to elaborate proteases (Pluda, 1997; Price 
et al., 1997; Liotta & Kohn, 1997). Glioma cells secrete MMPs to degradate the ECM 
surrounding invading cells (Levicar et al., 2003). In this regard, cannabidiol (CBD) has 
been found to impair the migration of U87 glioma cells in a cannabinoid receptor-
independent manner (Vaccani et al., 2005), by increasing the tissue inhibitor of MMP1, 
(TIMP-1) (Ramer et al., 2010) and down-regulating the MMP-2 expression (Blazquez et al., 
2008). Since CBD represents a specific ligand for TRPV2 (Qin et al., 2008), and being 
TRPV2 downregulated in the more invasive malignat gliomas (Nabissi et al., 2010), 
activation of this channel may represent an important  target in anti-invasive 
chemotherapeutic strategy in GBM patients.  
 
Glioma – Exploring Its Biology and Practical Relevance 
 
174 
5. TRPV and TRPM channels trigger cell death in human glioma cells 
Members of the TRPV and TRPM channels have been found to regulate apoptotic and 
necrotic cell death processes, respectively, as well as resistance to apoptotic stimuli in 
glioblastoma cells. In this regard, a role for TRPV1 in the apoptosis of glioma cells has been 
reported (Amantini et al., 2007). Thus, TRPV1 mRNA and protein expression was evidenced 
in normal astrocytes and glioma cells and tissues (Contassot et al., 2004; Amantini et al., 
2007). TRPV1 expression inversely correlated with glioma grading, with a marked loss of 
TRPV1 expression in the majority of grade IV glioblastoma tissues. In addition, TRPV1 
activation by the synthetic ligand, capsaicin (CPS) induced apoptosis of U373 glioma cells, 
and involved rise of Ca(2+) influx, p38MAPK activation, mitochondrial permeability 
transmembrane pore opening and transmembrane potential dissipation and caspase-3 
activation (Amantini et al., 2007). Similarly, an other TRPV1 agonist, 
arachidonylethanolamide (AEA) induces apoptosis of human glioma cells in a TRPV1-
dependent-manner (Contassot et al., 2004). Resistance of cancer cells to chemotherapeutic-
induced cytotoxicity during tumor progression partially depends by a decrease sensitivity 
to CD95/Fas-induced apoptosis (Amantini et al., 2009). Induction of cell death by some 
cytotoxic drugs seems to depend to an intact Fas/FasL system. Tumour progression by 
exerting selective pressure alters Fas status and subsequently affects the sensitivity of cancer 
cells to chemotherapy (Sindhwani et al., 2001). Glioblastoma cells are resistant to Fas-
induced cell death. We have recently reported that TRPV2 negatively controls glioblastoma 
survival as well as resistance to Fas/CD95-induced apoptosis in an ERK-dependent manner. 
Silencing of TRPV2 by RNA interference (siRNA) in U87 glioma cells down-regulated 
Fas/CD95 and procaspase-8 expression, and up-regulated Bcl-XL mRNA expression. 
Moreover, TRPV2 siRNA increased glioblastoma survival to Fas/CD95-induced apoptosis 
in an ERK-dependent manner (Nabissi et al., 2010). Inhibition of ERK activation by 
treatment of the siRNA-TRPV2 U87 glioma cells with the specific MEK-1 inhibitor PD98059, 
reduced Bcl-XL protein levels, promoted Fas/CD95 expression and restored Akt/PKB 
pathway activation leading to reduced cell survival and increased sensitivity to Fas/CD95-
induced apoptosis (Nabissi et al., 2010). These events are consistent with previous evidence 
showing that PI3K pharmacological inhibitors inhibited calcium overload and cell death in 
TRPV2-transfected mouse cells (Penna et al., 2006). Consistently, TRPV2 transfection of the 
primary MZC glioblastoma cells also reduced glioma viability and increased spontaneous 
and Fas/CD95-induced apoptosis, by inducing Fas/CD95 expression (Nabissi et al., 2010). 
Among TRPM channels, a role for the Ca(2+) permeable TRPM2 channel in glioma cell 
death has been reported. Thus, insertion of TRPM2 in human A172 glioma cells enhanced 
cell death induced by H2O2  (Ishi et al., 2007).  
6. TRP channels as cross-road of deregulated transcriptional activity in 
glioma stem like-cells 
Evidence that malignant gliomas may arise from and contain a minority tumour cells with 
stem cell-like (GSCs) properties has been increased by the demonstration that GSCs 
maintain the potential for self-renewal and multi-lineage differentiation that recap the 
phenotype of the original glioma (Galli et al., 2004; Singh et al., 2003; Yuan et al., 2004), Since 
GSCs has been suggested to play an important role in glioma initiation, growth, and 
recurrence, it is extremely important to understand the signal pathways that contribute to 
their formation and maintenance, with the future aims to eliminate GSCs from the bulk 
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tumor mass as a therapeutic strategy (Reya et al., 2001). Recent evidences adscript an 
emergent role of TRP channels in  regulating neurogenesis (Tai et al., 2009) as well as neural 
differentiation (Shin et al., 2010), suggesting that deregulation of specific TRP target genes 
may be involved in gliomagenesis (Van Meir et al., 2010; Liu et al., 2010). In this regard, the 
expression of TRPV2 in normal neural stem/progenitor cells (NS/PC) from olfactory bulb 
and GSC lines derived from GBM patients, and a role of this TRP channel in the regulation 
of cellular proliferation and differentiation, have been observed (Nabissi et al., personal 
communication). Stem cells proliferation is maintained by a balance between proliferative 
and antiproliferative signals and any genetic or biochemical modifications that lead stem 
cells to become independent of growth signals, could induce an  uncontrolled proliferation 
and possible tumorogenesis (Li & Neaves, 2006). GSCs divide core regulatory pathways 
with normal neural stem cells (NPSs), sharing developmental programs that lead NSCs to 
differentiate into astrocytes, oligodendrocytes and neurons (Galli et al., 2004; Singh et al., 
2003), but induce in GSCs an aberrant differentiation (Cheng et al., 2010). GSCs are reported 
to express CD133 and nestin and to differentiate into cells expressing neuronal or glial cell 
markers upon growth factor depletion (Gunther et al., 2008). In addition to these NSC 
characteristics, glioma-derived neurospheres or CD133+ cells are tumorigenic and when 
transplanted into SCID mice formed secondary tumors with phenotypic and cytogenetic 
similarities to the patient tumor from which they were originally derived (Singh et al., 2003; 
Lee et al., 2006). Recent findings in GSCs demonstrated that the upregulation of classical 
pathways associated with neural development, as Notch, WNT, Hedgehog and TGF/BMT 
pathways (Clark et al., 2007; Silver & Steindler, 2009), induce in GSC-derived GBMs an 
invasive, angiogenetic, proliferative and chemoresistant phenotype (Sanai et al., 2005). So, 
modulation of these pathways may represent novel therapeutic approach for GBM. Notch is 
a family of hetero-dimeric transmembrane receptors composed of an extracellular domain 
responsible for ligand recognition, a transmembrane domain, and an intracellular domain 
involved in transcriptional regulation (Stockhausen et al., 2010). Notch proteins (and 
ligands)contain extracellular EGF-like repeats, which interact with the DSL domain of 
ligands. Activation of Notch upon ligand binding is accompanied by proteolytic processing 
that releases an intracellular domain of Notch (NICD) from the membrane tether. The NICD 
contains the RAM23 domain (RAM), which enhances interaction with the CSL protein, NLS 
(Nuclear Localization Signals), a CDC10/Ankyrin repeat domain ANK, which mediates 
interactions with CSL and other proteins, and a PEST domain rich in proline, glutamate, 
serine and threonine residues (Kopan, 2002). When Notch receptor is triggered by the 
ligands on the neighboring cells, the intracellular domain of the Notch receptor (NICD) is 
released from the membrane, after successive proteolytic cleavages by the -secretase 
complex. NICD then translocates into the nucleus and associates with the transcription 
factor RBP-J. This complex by secruiting other co-activators, stimulates the expression of 
downstream genes as Cyclin-D1, EGFR, and MAPK (Mitogen-Activated Protein Kinase) 
inducing cell proliferation, angiogenesis and chemoresistance, in GSCs (Stockhausen et al., 
2010). Regarding the role of Notch signaling in GBM, gene microarray analysis have 
demonstrated that its expression in brain tumors correlated with good versus poor 
prognosis (Phillips et al., 2006). Moreover, in GBM tissue samples, high expression of Notch 
signal has been associated with high nestin levels, suggesting a correlation between GSCs 
and Notch expression (Purow et al., 2005; Lino et al.,2010; Boulay et al., 2007; Shih & 
Holland, 2006). Infact, Notch signaling plays a pivotal role in the maintenance of NSCs  
and leads to GSC-driven brain tumor development ( Lino et al., 2010; Louvi & Artavanis-
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tumor mass as a therapeutic strategy (Reya et al., 2001). Recent evidences adscript an 
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pathways associated with neural development, as Notch, WNT, Hedgehog and TGF/BMT 
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ligands. Activation of Notch upon ligand binding is accompanied by proteolytic processing 
that releases an intracellular domain of Notch (NICD) from the membrane tether. The NICD 
contains the RAM23 domain (RAM), which enhances interaction with the CSL protein, NLS 
(Nuclear Localization Signals), a CDC10/Ankyrin repeat domain ANK, which mediates 
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inducing cell proliferation, angiogenesis and chemoresistance, in GSCs (Stockhausen et al., 
2010). Regarding the role of Notch signaling in GBM, gene microarray analysis have 
demonstrated that its expression in brain tumors correlated with good versus poor 
prognosis (Phillips et al., 2006). Moreover, in GBM tissue samples, high expression of Notch 
signal has been associated with high nestin levels, suggesting a correlation between GSCs 
and Notch expression (Purow et al., 2005; Lino et al.,2010; Boulay et al., 2007; Shih & 
Holland, 2006). Infact, Notch signaling plays a pivotal role in the maintenance of NSCs  
and leads to GSC-driven brain tumor development ( Lino et al., 2010; Louvi & Artavanis-
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Tsakonas, 2006). Recently, has been demonstrated that Notch activation is increased 
during hypoxia and hypoxia direct GBM to the development of an aggressive phenotype 
and resistance to radiation and chemotherapy (Flynn et al., 2008). Regarding the 
relationship between Notch signaling and TRP channels, a direct correlation has been 
demonstrated in human glioma cell lines where TRPC6 transcripts have been found to be 
increased under hypoxic condition and the involvement of Notch in hypoxia-induced 
TRPC6 expression in glioma has been demonstrated. Silencing of Notch1 gene inhibits 
TRPC6 expression suggesting that Notch1 is required for hypoxia-induced TRPC6 over-
expression (Chigurupati et al., 2010). In response to hypoxia, the hypoxia inducing factors 
(HIF1- and HIF-2) are stabilized and as a consequence VEGF and TGF are up-
regulated (Birlik et al., 2006). Moreover, hypoxia-induced endothelial cell proliferation is 
associated with an increase of AP-1 expression, elevated store-operated calcium entry, 
and enhanced TRPC4 expression (Fantozzi et al., 2003), suggesting that additional TRP 
channels may regulate angiogenic signals (Fig.4). The interplay between GSCs and the 
endothelial compartement seems to be critical in gliomagenesis. Thus, GSCs closely 
interacting with the endothelial cells in vascular niche, promote angiogenesis through 
VEGF release (Bao et al., 2006a; Folkins et al., 2009). GSCs are reported to express CD133 
 
 
Fig. 4. The putative role of TRP channels in neural and glioma stem cell-like  differentiation 
and angiogenesis. A schematic representation of different TRP members involved in the 
regulation of neuro- and glioma-genesis 
and nestin (Yuan et al., 2004; Gunther et al., 2008) and have been demonstrated to have 
multipotent differentiative potential (Galli et al., 2004; Singh et al., 2003). Several authors 
have hypothesized that CD133+ tumor stem cells are the source of the recurrent tumors after 
treatment (Chua et al., 2008; Bleau et al., 2009) and the CD133+ cell population was enriched 
after radiation or chemotherapy and exhibited an increase in DNA repair capacity (Bao et 
New Insight on the Role of Transient 
Receptor Potential (TRP) Channels in Driven Gliomagenesis Pathways 
 
177 
al., 2006b). A series of pathways, including the Sonic hedgehog (Shh) and Notch, have been 
shown to be implicated in glioma’s resistance to alkylating agents and/or the maintenance 
of brain tumor stem cells (Ulasov et al., 2011; Clement et al., 2007). Moreover, 
overexpression of Dkk-1, a gene encoding for a Wnt antagonist protein, has been shown to 
sensitize the U87 glioma cells to the cytotoxic effects of bis-chloronitrosourea (BCNU) and 
cisplatin (Shou et al., 2002). In this regard, an inverse correlation between TRPV2 and SHH 
and Notch pathways (Phillips et al., 2006; Nabissi et al., 2010) in regulating chemoresistance 
to the alkylating agent bis-chloronitrosourea (BCNU), can be supposed. TRPV2 expression 
progressively declined in high-grade glioma tissues as histological grade increased, while 
Notch and SHH signaling was activated in GBM. Knockdown of TRPV2 gene in gliomas 
increased the resistance to BCNU cytotoxicity which was associated with Ras/MEK/Erk 
and Akt overexpression in chemosensitive glioma cells, while TRPV2 overexpression 
augmented the chemosensitivity of resistant glioma cells to BCNU. In addition, down-
regulation of TRPV2 reduced Fas expression and Fas-mediated apoptosis (Nabissi et al., 
2010). Parallelely, upregulation of Notch 1, increased the resistance of glioma cell to 
apoptosis (Purow et al., 2005). Finally, forced Notch 1 overexpression in glioma cells 
increased the proliferation and the formation of nestin-positive, neurosphere-forming stem 
cells (Zhang et al., 2008). Overall, these data suggest that in gliomas, TRPV2 could be a 
downstream gene target of Notch signaling rescuing glioma cells to apoptosis and 
promoting cell proliferation.  
 
7. Conclusions and prospectives 
In this chapter, we have summarized current basic and translational changes and highlight 
the striking scientific advances regarding the expression and the function of the TRP 
channel family in glioma growth and progression, that promise to improve the clinical 
course of this lethal disease. These include a more comprensive view of the interplay 
between changes in TRP channel expression and functions (e.g., TRPC, TRPM and TRPV 
family) and alterations in transcriptional and growth factor pathways (e.g., Notch, PTEN, 
HIF-α, EGFR) driving the uncontrolled cellular proliferation, aberrant angiogenesis, intense 
migration and invasion, increased resistance to apoptosis. Clearly, the identification of 
cluster of TRP ion channels altered during glioma progression presents an opportunity for 
improving the understanding of this cancer. The progress and depth of understanding of 
the role of ion channels, including the TRP family in glioma, together with truly 
manipulable experimental models, now offer a real opportunities for the development of 
effective target therapy (Santoni & Farfariello, 2011). Despite significant gaps in our 
understanding, a wealth of information now exists about clinical and biological behaviour of 
these tumours, the genetic pathways involved in gliomagenesis and the nature and the role 
of their alterations. The challenge is now to integrate all of this knowledge in an 
interdisciplinary way to full understand this disease and how its heterogenicity contributes 
to the relatively poor therapeutic responses of GBM patients. In regard to stem cell issue, the 
fact that the glioma-like stem cells (GSCs) that play an important role in the development 
and recurrence of malignat glioma, not only express TRP channels, but also show functional 
alterations in their expression and transcriptional regulation, combined with the evidence 
that they displayed nearly identical Ca(2+) transients and pharmacological sensitivities to 
TRP channel antagonists (Nabissi et al., personal communication; Weick et al., 2009), may 
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offer a new target for regulating GSC proliferation and developing novel therapeutic 
strategies. We are only at the begin of a new story; further studies on the expression and 
function of TRP channels in gliomas and GSCs must to be required to understand their 
contribute to malignant transformation and tumour progression, to delivery a specific target 
therapy in this devastating disease. 
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1. Introduction 
Malignant glioma is the most common type of primary brain tumor and represents one of 
the most lethal cancers. In contrast to the long-standing and well-defined histopathology, 
the underlying molecular and genetic bases for gliomas are less known. (Collins, 2004; Dai & 
Holland, 2001).  
As some other human cancers, particularly central nervous tumors are highly 
heterogeneous. Primarily because of its diffuse nature, relatively little is known about the 
processes by which they develop (Hulleman & Helin, 2005). Thus, the traditional evolution 
concept of tumors arising from a single mutated cell has limitations in explaining the 
heterogeneity observed in a single tumor nest. 
Recent decades have seen only limited progress in treatment trials and basic research on 
human glioma, the most common central nervous malignancy (Huang et al., 2008). 
Unfortunately, for such gliomas, tumor recurrence after treatment is the rule due to the 
infiltrative nature of these tumors and the presence of cellular populations with ability to 
escape therapies and drive tumor recurrence and progression. At least in some cases, these 
resistant cells exhibit stem cell properties (Frosina, 2011). For these reasons the 
comprehension of the current knowledge of cancer stem cells (CSC) in relation to gliomas 
origin, growth and treatment is crucial. As the stem cells (for glioma, neuronal stem cells) 
are more susceptible to mutation, they become altered easily for their genetic composition 
and therefore act as the source of cancer/glioma cells. They are not actually a separate cell 
type and in most cases they are misinterpreted as cancer stem cells (in brain, they are glioma 
stem cells). 
2. Glioma and the concept of cancer stem cells 
For a long time it has been known that there are subpopulations of cells within solid tumors 
that contain different biological behaviors. Among these subpopulations, accumulating 
evidence supports the existence of the so-called cancer stem cells (CSCs), because these 
tumor cells possess stem cell properties, possibly being responsible for the initiation, growth 
and recurrence of tumors. Apparent similarities with non-transformed stem cells, including 
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1. Introduction 
Malignant glioma is the most common type of primary brain tumor and represents one of 
the most lethal cancers. In contrast to the long-standing and well-defined histopathology, 
the underlying molecular and genetic bases for gliomas are less known. (Collins, 2004; Dai & 
Holland, 2001).  
As some other human cancers, particularly central nervous tumors are highly 
heterogeneous. Primarily because of its diffuse nature, relatively little is known about the 
processes by which they develop (Hulleman & Helin, 2005). Thus, the traditional evolution 
concept of tumors arising from a single mutated cell has limitations in explaining the 
heterogeneity observed in a single tumor nest. 
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2. Glioma and the concept of cancer stem cells 
For a long time it has been known that there are subpopulations of cells within solid tumors 
that contain different biological behaviors. Among these subpopulations, accumulating 
evidence supports the existence of the so-called cancer stem cells (CSCs), because these 
tumor cells possess stem cell properties, possibly being responsible for the initiation, growth 
and recurrence of tumors. Apparent similarities with non-transformed stem cells, including 
high self-renewal capacity and the ability to generate differentiated progeny of several 
cellular lineages, have led to the proposal that stem cell-like cancer cells may either originate 
from adult undifferentiated stem and progenitor cells or that these properties are being 
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expressed as an effect of the genetic alterations which drive tumorigenicity (Reya et al., 2001; 
Gilbertson, 2006; Das et al., 2008). Basically, the CSCs, which have also been described as 
tumor initiating cells or tumor propagating cells, are tumor cells that self-renew and 
propagate tumors phenotypically similar to the parental tumor (Li et al., 2009). Furthermore, 
recent studies have suggested that CSC cause tumor recurrence based on their resistance to 
radiotherapy and chemotherapy (Inoue et al, 2010).  
Although considerable controversy still surrounds the existence, behaviors and even the 
nomenclature of CSCs, there is no doubt that populations of cells with stem-like properties 
do exist inside several solid and non-solid tumors, including brain cancers. So, despite the 
fact that CSCs in solid tumors have not yet been precisely identified, the “CSC hypothesis” 
opens a new paradigm in understanding the biology of cancers. For this reason, the search 
for the tumor stem cells that may originate and perpetuate the tumor growth has been 
receiving great attention in the literature (Sanchez-Martin, 2008), but the available 
knowledge on this issue with regards to the gliomas is scant. Particularly, the exact identity 
and cell(s) of origin of the so-called glioma stem cell remains elusive (Park & Rich, 2009). 
Vescovi (2006) offered a functional definition of brain tumor stem cells, namely: brain tumor 
cells should qualify as stem cells if they show cancer-initiating ability upon orthotopic 
implantation, extensive self-renewal ability demonstrated either ex vivo or in vivo, 
karyotypic or genetic alterations, aberrant differentiation properties, capacity to generate 
non-tumorigenic end cells, and multilineage differentiation capacity. Furthermore, parallels 
between normal neurogenesis and brain tumorigenesis have been proposed (Singh et al., 
2004). It has been more recently confirmed that cancer stem cells from glioblastomas share 
some characteristics with normal neural stem cells including the expression of neural stem 
cell markers, the capacity for self-renewal and long term proliferation, the formation of 
neurospheres, and the ability to differentiate into multiple nervous system lineages 
(astrocytic, oligodendrocytic and/or neuronal differentiation) (Li et al., 2009). 
Among the so far evaluated stem cell markers, the transmembrane protein CD133 has been 
widely used to isolate putative CSC populations in several cancer types. In fact, CD133 is 
currently one of the best markers to characterize CSCs (Singh et al., 2004). In both human 
glioblastomas (GBMs) and medulloblastomas, the expression of the neural stem cell marker 
CD133 (also known as prominin 1) has been associated with both tumor initiation capacity 
and radioresistance (Pérez Castillo et al., 2008). Extensive computational comparisons with a 
compendium of published gene expression profiles revealed that the CD133 gene signature 
transcriptionally resembles human embryonic stem cells and in vitro cultured GBMs stem 
cells (GSC), and this signature successfully distinguishes GBMs from lower-grade gliomas. 
Moreover, the CD133 gene signature identifies an aggressive subtype of GBMs seen in 
younger patients with a shorter survival (Yan et al., 2011), confirming previous observations 
that Glioma stem cells are more aggressive in recurrent tumors (Huang et al., 2008). 
Nevertheless, it must be pointed out that the use of CD133 as a unique glioma stem cell 
marker is probably not sufficient to tag the whole self-renewing tumor cell reservoir 
(Clément et al., 2009). 
Holmberg et al (2011) have recently characterized human gliomas in various malignancy 
grades according to the expression of stem cell regulatory proteins. These authors have 
shown that cells in high grade glioma co-express an array of markers defining neural stem 
cells (NSCs) and that these proteins can fulfill similar functions in tumor cells as in NSCs. In 
contrast to NSCs, the glioma cells co-express neural proteins together with pluripotent stem 
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cell markers, including the transcription factors as Oct4, Sox2, Nanog and Klf4. In line with 
these findings, in high grade gliomas,  mesodermal- and endodermal-specific transcription 
factors were detected together with neural proteins, a combination of lineage markers not 
normally present in the central nervous system. These findings demonstrate a general 
deregulated expression of neural and pluripotent stem cell traits in malignant human 
gliomas. 
3. Stem cells and the origin of gliomas 
Primarily because of the diffuse nature of gliomas, relatively little is known about the 
processes by which they develop (Hulleman & Helin, 2005). The concept of stem cells 
originating gliomas is gaining increased recognition in neuro-oncology (Richj & Eyler, 2008). 
Until recently, the paradigm of a tumor-initiating stem cell was confined to hematopoietic 
malignancies where the hierarchical lineages of stem progenitor cells are well established. 
Nevertheless, the demonstration of persistent stem cells and cycling progenitors in the adult 
brain is coupled with the expansion of the cancer stem cell concept to solid tumors, leading 
to the exploration of “stemness” within gliomas. Emerging data are highly suggestive of the 
subsistence of transformed multipotential cells within a glioma, with a subfraction of cells 
exhibiting increased efficiency at tumor initiation stage. However, data in support of the 
true glioma stem cells are inconclusive to date, particularly in respect to the functional 
characterization of these cells. (Panagiotakos & Tabar, 2007). 
Thus, it may be considered that currently it is conceivable thought that malignant gliomas 
may arise from neural stem cells and appear to contain tumor stem cells. It is thought that 
normal stem cells live in protected pockets of the body called niches, where they divide 
infrequently to avoid accumulating damaging mutations. Upon injury or in response to 
normal stimuli, stem cells are mobilized to divide (Gilbertson, 2006). Hence, parallel to the 
role that normal stem cells play in organogenesis, stem cells are thought to be crucial for 
tumorigenesis. 
The normal adult neural stem cells (NSCs) arise from radial glia (RG) within the central 
nervous system (Weiner, 2008). The RG progeny includes all the main lineages of the CNS: 
neurons, astrocytes, oligodendrocytes, ependymocytes and adult neural stem cells 
(Malatesta et al. 2003). By comparing the gene expression profiles of ependymomas with 
those of cells in the normal developing nervous system, it was possible to identify the RG as 
candidate stem cells of this brain tumor (Gilbertson, 2006). Furthermore, RG cells produce 
neurons in addition to glia during central nervous system development in all vertebrates 
and are also involved in reparative process (Weiner, 2008). 
Until recently, it was thought that ependymomas originated from neuroepithelial cells, 
glioblastomas from abnormal astrocytes, and medulloblastomas from primitive cells in the 
external granular layer, but there is now evidence that all tumors can originate from a 
special type of stem cell called “radial glial cell” (RGC). It is interesting to note that in the 
human brain, most of stem cells are located in the subventricular zones (SVZ). Both supra- 
and infratentorially and when stimulated with carcinogens, cells in the SVZ become 
tumorigenic faster than those located elsewhere. In the SVZ, stem cells exist in the form of 
RGCs, which remain quiescent until they receive transformational signals. It is not clear 
whether RGCs, after receiving transformation signals, return to their initial stem cell 
configuration and then become tumorigenic or they transform to tumor progenitor cells 
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directly. In the cerebellum, depending upon the signals received, RGCs and stem cells may 
give origin to either ependymoma or medulloblastoma. 
Tumours with the highest incidence in humans— medulloblastomas and glioblastomas — 
both originate from abnormal brain stem cells. . Not surprising, both of these tumors are 
CD133-positive, containing great neuronal differentiation, which makes them prone to be 
diffuse and resistant to treatment (Castilo, 2010). 
4. Gliomas and the field cancerization concept 
It is universally accepted that tumors growth as a clonal evolution from a single cell  
(Nowell, 1976). The “field cancerization theory” was introduced more than fifty years ago 
by Slaugher et al (1953), when studying the presence of histologically abnormal tissue 
surrounding carcinomas. In a classic report on oral cancer, Slaughter called “field 
cancerization” – a process of repeated exposure of a region’s entire tissue area to 
carcinogenic insult (e.g., tobacco and alcohol), which increases the tissue’s risk for 
developing multiple independent premalignant and malignant foci. The field cancerization 
hypothesis states that multiple cells form independent tumors on one given tissue, since 
carcinogenic exposure affects multiple cells in the field (Slaughter et al., 1953), and predicts 
that second primary or synchronous tumours arise from independent genetic events (Garcia 
et al., 1999). The field cancerization theory may be explained by the concept that a given 
stem cell that acquires genetic alterations may form a “patch”, a clonal unit of altered 
daughter cells. The proliferation of these patch cells forms expanding fields which gradually 
displace the normal tissue and, by clonal divergence, ultimately leads to the development of 
one or more tumors within a contiguous field of preneoplastic cells (Garcia et al., 1999). An 
important clinical implication is that fields often remain after surgery of the primary tumor 
and may lead to new cancers, designated presently by clinicians as "a second primary 
tumor" or "local recurrence," depending on the exact site and time interval (Braakhuis et al., 
2003; Ryan, 2007). We had previously discussed how mutated clones from mutated stem 
cells may spread on tissues and that the field cancerization theory implies that the mutated 
genotype and molecular changes occur before the appearance of histopathological evidence 
of malignant cells (Garcia et al., 1999). Therefore, this "anomaly" might be due to changes 
that occur in a "premalignant" neoplastic condition that was histologically identified as 
"normal". In the clinical aspect, the field cancerization may have an etiologic role in a 
substantial number of recurrences. For example, a surgical resection margin that includes a 
genetically altered field can explain the occurrence of scar recurrence. This explanation 
suggests that molecular profiling of surgical margins will help reduce scar recurrences. 
Since multiple independent patches of cancer fields may be present in the same organ 
exposed to the same insults, clean molecular margins may not necessarily prevent 
recurrences in the residual organ (Dakubo et al., 2007). Similarly to gliomas, tumor 
recurrence is a major clinical concern for patients with urothelial carcinoma of the urinary 
bladder. Traditional morphological analysis is of limited utility for identifying cases in 
which recurrence will occur. However, recent studies have suggested that urothelial 
carcinogenesis occurs as a ‘field effect’ that can involve any number of sites in the bladder 
mucosa. Accumulating evidence supports the notion that resident urothelial stem cells in 
the affected field are transformed into cancer stem cells by acquiring genetic alterations that 
lead to tumor formation through clonal expansion (Cheng et al., 2009). 
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The available information in regards to the existence of a field phenomenon in gliomas is 
scant. In malignant gliomas, the high recurrence rates, the characteristically heterogeneous 
features and frequent diffuse spread within the brain have raised the question of whether 
malignant gliomas arise monoclonally from a single precursor cell or polyclonally from 
multiple transformed cells forming confluent clones (Inoue et al., 2008). To address this 
issue, Kattar et al (1997) have evaluated the clonality of low-grade and malignant gliomas by 
using polymerase chain reaction (PCR)-based assay for nonrandom X chromosome 
inactivation using surgical and autopsy material. The same pattern of nonrandom X 
chromosome inactivation was present in all areas of fifteen of 19 tumors, which were 
considered as monoclonal, suggesting that low-grade and malignant gliomas are, at least, 
usually monoclonal tumors, and extensively infiltrating tumors must result from migration 
of tumor cells. 
Gliomatosis cerebri may shed some light in this issue. It is a rare condition in which the brain 
is infiltrated by an exceptionally diffusely growing of malignant glial cell population 
involving at least 2 lobes, though often more extensive, sometimes even affecting 
infratentorial regions. Kross et al (2002) have evaluated the existence of field cancerization in 
this affection, since gliomatosis cerebri may initiate as an oligoclonal process or result from 
collision of different gliomas. It was hypothesized that the presence of an identical set of 
genetic aberrations throughout the lesion would point to monoclonality of the process. In 
contrast, the finding of non-identical genetic changes in widely separated regions within the 
neoplasm would support the concept of collision of different mutated clones. For such, the 
authors used one autopsy case of gliomatosis cerebri, from which tissue samples were 
randomly taken from 24 locations throughout the brain and used for genetic investigation. 
With this aim, genome-wide screening for chromosomal aberrations was accomplished by 
comparative genomic hybridization (CGH). The authors found a wide distribution of 
particular sets of genetic aberrations, supporting the concept of monoclonal tumor 
proliferation (Kross et al., 2002). Nevertheless, it has been observed and well documented in 
one clinical case that on the long term, after initial treatment for gliomatosis cerebri, one 
glioblastoma multiforme has developed, and in a location separate from the initial lesion, 
suggesting that different clonal origin may had occurred (Inoue et al., 2008). More recently, 
Chen et al (2010) showed that the capacities for self-renewal and tumour initiation in GBM 
need not be restricted to a uniform population of stemlike cells.  
5. The contribution of studies in animal models: Unifying the cancer stem 
cells and field cancerization concepts 
Many genetic alterations have been identified in human gliomas, however, establishing 
unequivocal correlation between these genetic alterations and gliomagenesis requires 
accurate animal models for these cancers (Dai & Holland, 2001). Indeed, it is useful and 
necessary to have animal models for CNS tumors studies allowing to be carried out in 
different stages of  tumor growth, especially in  early stages, rare to be detected and 
observed in clinical practice (Bulnes-Sesma, 2006). 
Experimental models of gliomagenesis most commonly used alkylating agents such as N-
ethyl N-nitrosourea (ENU), which has been considered as a suitable model to study 
malignant changes. These changes were reported to appear firstly as early neoplastic 
proliferation (ENP) center, which continues in following stages subsequently progressing to 
‘‘microtumors’’ until a tumor in itself. (Koestner et al., 1971; Naito et al., 1984).  
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By using the experimental model of gliomagenesis induced by the N-ethyl N-nitrosourea, 
we were able to detect putative tumor stem cells in early oncogenesis, yielding to analyze a 
field cancerization process and observe a close morphological relationship between 
metallothionein (MT) positive cells and blood vessels. With this aim, we have developed an 
experimental model to track putative mutated stem cells, using the ENU experimental 
model and metallothioneins (MT) immunostaining. MTs are metal binding proteins that 
take part in the homeostasis of the ions of the metals which are necessary for the proper 
metabolism of the organism (zinc, copper), disintoxication of metals and protect the tissues 
from the effects of free radicals, radiation and from mutagens (Thirumoorthy et al., 2007). 
MT expression is present in a significant portion of especially malignant brain tumors. In 
astrocytic tumors an acquired enhanced ability to produce MT has been observed as the 
malignant potential of a tumor increases (Hiura et al., 1998), and MT might be involved in 
poor response to antineoplastic drugs (Maier et al., 1997). In the murine colonic mucosa, the 
crypt restricted immunopositivity for MT has been shown to be reliable marker of stem cell 
mutation that may be induced early after mutagen treatment and that can be assayed in 
paraffin-fixed tissue sections (Cook et al., 2000). We have observed that 30 days after the 
treatment of rats with ENU, the main location of the MT positive cells have striking 
similarity to that of the RG cells and that the frequency of these cells (a) is strongly 
correlated with the increased appearing of ENP centers and new blood vessels, (b) is 
augmented at higher levels in long-term observation, i.e., 180 days after the carcinogen 
administration, (c) is related to a high staining intensity in both nucleus and cytoplasm, and 
(d) is very similar to the pattern of immunostaining that was observed in the nervous tissue 
surrounding gliomas, which were originated at an average of 321 days after the ENU 
administration (Fernandes-da-Silva et al., 2009). The mechanisms and reasons why MT is 
expressed in the preneoplastic and neoplastic lesions remain to be fully elucidated. It has 
been hypothesized that mutation-induced MT overexpression may interfere with the 
function of zinc finger DNA binding transcription factors (Zeng et al., 1991), which have 
been implicated in transcriptional control of various genes, including TP53, involved in cell 
proliferation and apoptosis. These MT-mediated effects on gene transcription are thought to 
confer a selective growth or survival advantage (or both) on the mutated cells (Bruewer, 
2002). 
6. Glioma, stem cells niche and angiogenesis 
Recently in a review article, Gilbertson & Rich JN (2007) address a number of key questions 
which remain to be answered: do all cancer stem cells require the support of aberrant 
niches? Are cancer stem cell niches the primary drivers of tumor development, or are they 
recruited by pre-formed cancer stem cells? How do cancer stem cells and their niches 
subvert the tight regulatory conditions that characterize normal stem cell niches?  
The stem cells of glioblastoma seem to be dependent on signals from aberrant vascular 
niches that mimic the normal neural stem cell niche (Gilbertson & Rich, 2007). Stem cells of 
various tissues are tightly regulated by the immediate microenvironment or stem cell niche 
(Moore & Lemischka, 2006), which is provided by capillaries in specific locations (Riquelme 
et al., 2008). This organization places the stem cells in close proximity to endothelial and 
other vascular cells, facilitating cross-talking among these cell types and affecting stem cell 
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fate choices (Gilbertson, 2006). It is well-known that stem cells and their microenvironments 
may influence each other (Scadden, 2006). In fact, Cues within the niche, from cell–cell 
interactions to diffusible factors, are spatially and temporally coordinated to regulate 
proliferation and neurogenesis, ultimately (Riquelme et al., 2008). 
In ENU treated rats, we have observed the existence of a close morphological relationship 
between MT positive cells and blood vessels. What is the relationship between them? It is 
known that MT is involved in the regulation of the functions of endothelial cells as well as in 
their protection against cytotoxic agents (Kaji et al., 1993). MT knock-out (MT-KO) mice 
presented dramatically decreased IL-6-induced angiogenesis caused by cortical freeze 
injury, suggesting that the MT have major regulatory functions in the angiogenesis process 
(Penkowa et al., 2000). In fact, human CD133+ Glioma CSCs are capable of producing 
vascular endothelial growth factor (VEGF) and thus may play an important role in glioma 
angiogenesis (Yao et al.,2008). 
7. The concept of stemness, modulation of csc and glioma treatment 
Understanding the characteristics and function of CSCs has shed light on their roles in glioma 
progression, including the implications for prognosis and treatment resistance. The original 
use of the term stemness was derived from a number of articles aimed to look for genes that 
could be expressed in general stem cell populations. The stemness hypothesis states that all stem 
cells use common mechanisms to regulate self-renewal and multi-lineage potential. This 
hypothesis has been debated and so far no conclusive evidence for a set of genes expressed in 
all stem cells. Certainly, identifying genes regulating stem cell properties will greatly improve 
our understanding of the molecular mechanisms regulating stem cell functions, our ability to 
manipulate stem cell fate, and the roles of stem cells in cancer (Koeva et al., 2011). 
Interestingly, overexpression of the transcription factor NANOG in gliomas and its close 
relationship with the undifferentiated state of glioma cells in vivo and in vitro indicated that 
NANOG may contribute to the existence of brains CSCs and may be related to tumorigenesis 
of the cerebrum by maintaining the undifferentiated state of glioma cells (Niu et al., 2011). 
The new concept stemness is closely related to the observation that there are tissue 
environment factors that are able to influence or modulate CSCs. The main one is hypoxia, 
which activates the Hypoxia Induced Factor alpha number 1 (HIFα-1) alpha to enhance the 
self-renewal activity of CD133-positive cells and to inhibit their differentiation (Soeda et al., 
2009). This and other signaling systems drive the transformation of normal stem cells, and 
perhaps of the bulk of tumor cells to cancer stem cells or to maintain the CSC phenotype 
(Katoh, 2011). For instance, the oxygen level of 7% has been observed to enhance the stem 
cell–like phenotype of CD133+ in GBM cells (McCord et al., 2009). Furthermore, it has been 
observed that human glioblastoma cells from tumor biopsies, which were engrafted 
intracerebrally into nude rats, that CD133 negative glioma cells were tumorgenic in nude 
rats, and that CD133 positive cells can be obtained from these tumors. Upon the passing of 
the cell tumors in vivo, CD133 expression is upregulated, coinciding with the onset of 
angiogenesis and a shorter patient survival (Wang et al., 2008). Furthermore, the bone 
morphogenic protein BMP4 effectively reduces proliferation of CD133 positive cells in vitro 
and the tumor growth in vivo. BMP4 may act as a key inhibitory regulator of cancer 
initiation and therefore may be used in combined stem cell-based therapy as a non-cytotoxic 
therapeutic agent (Altaner, 2008). 
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If one accepts that there is a subpopulation of cancer cells with stem cell properties, which is 
responsible for tumor maintenance and progression, and may contribute to the resistance to 
anticancer treatments, it is very reasonable to deduce that compounds that target cancer 
stem-like cells could be effective to impair or even to destroy a neoplasm and nas important 
therapeutic implications. Various compounds have been investigated as putative influencers 
of stemness and malignancies in glioma stem-like cells, leading the proposal that stem cell 
regulatory factors may provide significant targets for therapeutic strategies (Holmberg et al., 
2011). Ongoing work aims the identification of unique pathways governing self-renewal of 
these putative stem cells and their validation as ultimate therapeutic targets (Panagiotakos 
& Tabar, 2007). Additionally, it is possible to conceive that epigenetic-based drugs that 
modulate gene expression in CSC possibly constitute a promising alternative resource for 
target therapy in the treatment of these, thus far, incurable malignancy. 
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1. Introduction 
Gliomas, the most common primary brain tumors, exist as a continuum between low-grade 
and high-grade states. Low grade gliomas are generally found in children and young adults. 
These tumors are characterized by well-differentiated cellularity which is mildly 
pleomorphic. These tumors lack mitotic figures and neovascularization and do not enhance 
on MRI. The average survival of patients after diagnosis is 7-10 years; the morbidity 
associated with these lesions is largely dependent on progression of these lesions to a higher 
grade state. High-grade gliomas, conversely, which exist on the other end of the glial 
neoplasm spectrum, are extremely malignant with poorly differentiated cells that are highly 
pleomorphic and display numerous mitotic figures. These tumors contain significant 
vascular proliferation, hemorrhage and necrosis. High grade gliomas enhance brightly on 
contrast MRI and often exhibit widespread invasion throughout the brain. Prognosis is poor 
for high grade gliomas, with a median survival of 18 months even with aggressive therapies. 
One of the key events in the transition from the low-grade to high-grade state has been 
referred to as the angiogenic switch. This is defined as the period during which the tumor 
undergoes a transition to an environment capable of rapid blood vessel formation 
supporting subsequent exponential tumor growth. It is theorized that in the low-grade state, 
tumor growth may be limited, at least in part, by a lack of blood supply limiting the tumor 
to linear growth. Once the tumor acquires the ability to recruit or form new blood vessels 
through this angiogenic switch, exponential growth may occur, which results in rapid 
clinical progression. It has been well-described in the literature that bone marrow-derived 
cells (BMDC) participate in the progression of cancer. BMDCs in the local tumor 
microenvironment have been proposed to be capable of breaking down normal structures 
thereby promoting vasculogenesis and invasiveness. This, in turn,  provides an environment 
capable of sustaining and promoting tumor growth. The role of BMDC in metastatic disease 
has been well-documented and recent data suggests that BMDC participate in the growth 
and progression of brain tumors as well. This chapter will explore the role of BMDC in the 
transition from low-grade to high-grade gliomas particularly with respect to the angiogenic 
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switch. The possibility of this pathway as a potential therapeutic target will also be 
reviewed. 
2. Low-grade glioma transformation in adults 
Low-grade gliomas (LGG) are a heterogeneously diverse group of tumors with a generally 
benign histology and an associated variable outcome. This unpredictable course relies, in 
part, on the potential for malignant transformation to a higher grade. These tumors present 
a unique therapeutic challenge as they are typically associated with minimal symptoms and 
benign radiographic appearance. Initially, the majority of LGGs run an indolent clinical 
course but often ultimately progress into aggressive tumors with a poor prognosis. As a 
result, significant controversy exists as to appropriate treatment protocols for this disease. 
The natural history of LGG, and the risk factors for progression, have been one focus of 
glioma research due to the potential impact on treatment strategy. Many recent studies have 
helped clarify treatment recommendations including extent of resection, timing and efficacy 
of radiation therapy, and response to chemotherapy. Significant debate remains, however, 
regarding standardization of treatment for low-grade glioma given the tremendous 
diversity in tumor histology, biology, and outcome. While observation of low-grade gliomas 
was previously considered a valid treatment option to avoid the morbidity of surgery, 
chemotherapy, and radiation, early intervention has gradually become standard of care as 
the impact and incidence of malignant progression has become fully realized. Subjecting 
patients to the morbidity of aggressive treatment in an unpredictable tumor with variable 
outcome remains controversial, however. Currently, significant effort is focused on 
identification of risk factors and tumor characteristics that lead to progression. Better 
appreciation for the molecular and cellular mechanisms of malignant transformation carries 
the potential to create novel treatment regimens with less morbidity, thereby alleviating the 
use of radiation and chemotherapy which present significant toxicity to both children and 
adults. A review of the characteristics of low-grade gliomas, current treatment strategies, 
their transformation potential, and current efforts to define novel pathways involved in 
malignant transformation follows.  
The term LGG includes World Health Organization Grade I and Grade II tumors, which are 
typically associated with indolent tumor growth and significantly better prognosis 
compared to high grade gliomas. Grade I gliomas include pilocytic astrocytoma, 
desmoplastic neuroectodermal tumors, subependymoma, ganglioglioma, myxopapillary 
ependymoma, and desmoplastic infantile tumors, which represent a spectrum of typically 
benign lesions. Within this class, pilocytic histology is the most common (Stieber, 2001). 
These pilocytic tumors are well-circumscribed, non-infiltrative, and do not generally 
transform to more malignant, higher grade lesions. While malignant transformation has 
been reported in WHOI tumors, the primary risk for malignant degeneration exists in Grade 
II tumors including low-grade or fibrillary astrocytoma, oligodendroglioma, or mixed oligo-
astrocytoma. Ependymoma, ganglioglioma, pleomorphic xanthoastrocytoma, and choroid 
gliomas of the third ventricle are also considered grade II. Fibrillary astrocytomas, which 
comprise the majority of grade II lesions (Stieber, 2001), have garnered significant attention 
due to the significant morbidity and mortality of patients with this diagnosis.  
While WHO I gliomas are typically well-circumscribed tumors with benign histology, WHO 
II gliomas are diffuse, infiltrative and have malignant potential (Stieber, 2001). Both classes, 
however, are associated with slow tumor growth. The incidence of LGG is reported to be 
 
Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma 
 
203 
between 2,700 and 4,700 cases per year, comprising approximately 30% of all malignant 
gliomas (Schiff et al., 2007, Wessels et al., 2003). These tumors are most common in 
Caucasian males, and typically present in the second to fourth decades (Schomas et al., 2009, 
Wessels et al., 2003). Patients greater than 60 years of age carry a poorer prognosis with 
generally lower Karnofsky scores and larger tumor burden at diagnosis.  In adults, the most 
common presenting symptom is seizure followed by incidental findings on imaging. Less 
common presentations include trauma trauma, sinus pathology, and pituitary disorder 
(Wessels et al., 2003). Thirty percent of patients present with neurological deficit, and only 
10% present with symptoms of raised intracranial pressure ICP. Speech and language 
deficits have been reported in 10% of patients (Prabhu et al., 2010), however, focal deficits 
are less common (Schomas et al., 2009, Wessels et al., 2003). 
In adults, LGGs are generally hemispheric, supratentorial, and typically occur in the frontal 
and temporal lobes. They may involve eloquent cortex, which limits the capacity for gross 
total resection due to significant risk of morbidity (Prabhu et al., 2010, Stieber, 2001). LGG 
are hypointense on T1 weighted magnetic resonance imaging (MRI), hyperintense on FLAIR 
and T2 sequences, and enhance in 30% of cases. There is often associated vasogenic edema 
(Prabhu et al., 2010, Wessels et al., 2003). 
LGG are typically sporadic tumors, although they can occur in association with Li 
Fraumeni syndrome and Neurofibromatosis Types 1 and 2 (Prabhu et al., 2010, Wessels et 
al., 2003). Additional risk factors include previous irradiation and exposure to industrial 
chemicals (Prabhu et al., 2010, Wessels et al., 2003). Allergy has been reported to lower the 
risk for LGG, suggesting a possible role for immune surveillance in tumor pathogenesis 
(Prabhu et al., 2010). Survival is highly variable for LGG as median overall survival (OS) 
is reported to range from 3 to 40 years. Median progression free survival (PFS) is only 50% 
at 5 years and 17% at 15 years (Bauman et al., 1999, Berger et al., 1994, Jaeckle et al., 
Stieber, 2001). Median time to progression is 7.2 years (Schomas et al., 2009). In adults, the 
overall malignant transformation rate ranges from 35-89% with 74% in primary 
astrocytoma, 70% with mixed tumors, and 45% with primarily oligodendroglial histology 
(Jaeckle et al., 2010).  Importantly, 50% of low risk adults, defined as patients less than 40 
years of age with gross total resection (GTR), underwent transformation within 5 years 
(Jaeckle et al., 2010, Schiff et al., 2007).  
Multiple studies have found that age greater than 40 years, extent of resection, tumor 
diameter greater than 6cm, tumor crossing midline, neurological deficit at diagnosis, and 
astrocytic histology are risk factors for poor prognosis in LGG (Bauman et al., 1999, E. G. 
Shaw et al., 2008, Stieber, 2001, Jaeckle et al., 2010, Schiff et al., 2007, E. G. Shaw & Wisoff, 
2003). The NCCTG found that astrocytomas carry a worse prognosis than 
oligodendroglioma. Other retrospective reports corroborate these finding and further 
specify gemistocytic astrocytoma as carrying a worse prognosis (Jaeckle et al., 2010, 
Schomas et al., 2009, Stieber, 2001, Wessels et al., 2003, E. G. Shaw et al., 2008). Contrast 
enhancement, Karnofsky score, mitotic activity, and genetics have also been identified as 
risk factors for progression (Schiff et al., 2007, Schomas et al., 2009, E. G. Shaw & Wisoff, 
2003, Stieber, 2001). Additionally, a Ki67-MIB1 index greater than 4% is associated with a 
more rapid rate of transformation.  
3. Malignant transformation of pediatric low-grade glioma 
The presentation and prognosis of LGG in children differs significantly from that in adults. 
Overall survival and rate of malignant transformation is significantly different in the 
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switch. The possibility of this pathway as a potential therapeutic target will also be 
reviewed. 
2. Low-grade glioma transformation in adults 
Low-grade gliomas (LGG) are a heterogeneously diverse group of tumors with a generally 
benign histology and an associated variable outcome. This unpredictable course relies, in 
part, on the potential for malignant transformation to a higher grade. These tumors present 
a unique therapeutic challenge as they are typically associated with minimal symptoms and 
benign radiographic appearance. Initially, the majority of LGGs run an indolent clinical 
course but often ultimately progress into aggressive tumors with a poor prognosis. As a 
result, significant controversy exists as to appropriate treatment protocols for this disease. 
The natural history of LGG, and the risk factors for progression, have been one focus of 
glioma research due to the potential impact on treatment strategy. Many recent studies have 
helped clarify treatment recommendations including extent of resection, timing and efficacy 
of radiation therapy, and response to chemotherapy. Significant debate remains, however, 
regarding standardization of treatment for low-grade glioma given the tremendous 
diversity in tumor histology, biology, and outcome. While observation of low-grade gliomas 
was previously considered a valid treatment option to avoid the morbidity of surgery, 
chemotherapy, and radiation, early intervention has gradually become standard of care as 
the impact and incidence of malignant progression has become fully realized. Subjecting 
patients to the morbidity of aggressive treatment in an unpredictable tumor with variable 
outcome remains controversial, however. Currently, significant effort is focused on 
identification of risk factors and tumor characteristics that lead to progression. Better 
appreciation for the molecular and cellular mechanisms of malignant transformation carries 
the potential to create novel treatment regimens with less morbidity, thereby alleviating the 
use of radiation and chemotherapy which present significant toxicity to both children and 
adults. A review of the characteristics of low-grade gliomas, current treatment strategies, 
their transformation potential, and current efforts to define novel pathways involved in 
malignant transformation follows.  
The term LGG includes World Health Organization Grade I and Grade II tumors, which are 
typically associated with indolent tumor growth and significantly better prognosis 
compared to high grade gliomas. Grade I gliomas include pilocytic astrocytoma, 
desmoplastic neuroectodermal tumors, subependymoma, ganglioglioma, myxopapillary 
ependymoma, and desmoplastic infantile tumors, which represent a spectrum of typically 
benign lesions. Within this class, pilocytic histology is the most common (Stieber, 2001). 
These pilocytic tumors are well-circumscribed, non-infiltrative, and do not generally 
transform to more malignant, higher grade lesions. While malignant transformation has 
been reported in WHOI tumors, the primary risk for malignant degeneration exists in Grade 
II tumors including low-grade or fibrillary astrocytoma, oligodendroglioma, or mixed oligo-
astrocytoma. Ependymoma, ganglioglioma, pleomorphic xanthoastrocytoma, and choroid 
gliomas of the third ventricle are also considered grade II. Fibrillary astrocytomas, which 
comprise the majority of grade II lesions (Stieber, 2001), have garnered significant attention 
due to the significant morbidity and mortality of patients with this diagnosis.  
While WHO I gliomas are typically well-circumscribed tumors with benign histology, WHO 
II gliomas are diffuse, infiltrative and have malignant potential (Stieber, 2001). Both classes, 
however, are associated with slow tumor growth. The incidence of LGG is reported to be 
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between 2,700 and 4,700 cases per year, comprising approximately 30% of all malignant 
gliomas (Schiff et al., 2007, Wessels et al., 2003). These tumors are most common in 
Caucasian males, and typically present in the second to fourth decades (Schomas et al., 2009, 
Wessels et al., 2003). Patients greater than 60 years of age carry a poorer prognosis with 
generally lower Karnofsky scores and larger tumor burden at diagnosis.  In adults, the most 
common presenting symptom is seizure followed by incidental findings on imaging. Less 
common presentations include trauma trauma, sinus pathology, and pituitary disorder 
(Wessels et al., 2003). Thirty percent of patients present with neurological deficit, and only 
10% present with symptoms of raised intracranial pressure ICP. Speech and language 
deficits have been reported in 10% of patients (Prabhu et al., 2010), however, focal deficits 
are less common (Schomas et al., 2009, Wessels et al., 2003). 
In adults, LGGs are generally hemispheric, supratentorial, and typically occur in the frontal 
and temporal lobes. They may involve eloquent cortex, which limits the capacity for gross 
total resection due to significant risk of morbidity (Prabhu et al., 2010, Stieber, 2001). LGG 
are hypointense on T1 weighted magnetic resonance imaging (MRI), hyperintense on FLAIR 
and T2 sequences, and enhance in 30% of cases. There is often associated vasogenic edema 
(Prabhu et al., 2010, Wessels et al., 2003). 
LGG are typically sporadic tumors, although they can occur in association with Li 
Fraumeni syndrome and Neurofibromatosis Types 1 and 2 (Prabhu et al., 2010, Wessels et 
al., 2003). Additional risk factors include previous irradiation and exposure to industrial 
chemicals (Prabhu et al., 2010, Wessels et al., 2003). Allergy has been reported to lower the 
risk for LGG, suggesting a possible role for immune surveillance in tumor pathogenesis 
(Prabhu et al., 2010). Survival is highly variable for LGG as median overall survival (OS) 
is reported to range from 3 to 40 years. Median progression free survival (PFS) is only 50% 
at 5 years and 17% at 15 years (Bauman et al., 1999, Berger et al., 1994, Jaeckle et al., 
Stieber, 2001). Median time to progression is 7.2 years (Schomas et al., 2009). In adults, the 
overall malignant transformation rate ranges from 35-89% with 74% in primary 
astrocytoma, 70% with mixed tumors, and 45% with primarily oligodendroglial histology 
(Jaeckle et al., 2010).  Importantly, 50% of low risk adults, defined as patients less than 40 
years of age with gross total resection (GTR), underwent transformation within 5 years 
(Jaeckle et al., 2010, Schiff et al., 2007).  
Multiple studies have found that age greater than 40 years, extent of resection, tumor 
diameter greater than 6cm, tumor crossing midline, neurological deficit at diagnosis, and 
astrocytic histology are risk factors for poor prognosis in LGG (Bauman et al., 1999, E. G. 
Shaw et al., 2008, Stieber, 2001, Jaeckle et al., 2010, Schiff et al., 2007, E. G. Shaw & Wisoff, 
2003). The NCCTG found that astrocytomas carry a worse prognosis than 
oligodendroglioma. Other retrospective reports corroborate these finding and further 
specify gemistocytic astrocytoma as carrying a worse prognosis (Jaeckle et al., 2010, 
Schomas et al., 2009, Stieber, 2001, Wessels et al., 2003, E. G. Shaw et al., 2008). Contrast 
enhancement, Karnofsky score, mitotic activity, and genetics have also been identified as 
risk factors for progression (Schiff et al., 2007, Schomas et al., 2009, E. G. Shaw & Wisoff, 
2003, Stieber, 2001). Additionally, a Ki67-MIB1 index greater than 4% is associated with a 
more rapid rate of transformation.  
3. Malignant transformation of pediatric low-grade glioma 
The presentation and prognosis of LGG in children differs significantly from that in adults. 
Overall survival and rate of malignant transformation is significantly different in the 
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pediatric population, leading to the hypothesis that tumor biology in children is inherently 
different from that in adults. For LGG in children, the overall rate of malignant 
transformation ranges from 4.3%-38%, which is much lower than in adults (Armstrong et al., 
2011, Pollack et al., 1995). This difference may be accounted for in part by the higher rate of 
pilocytic astrocytomas that comprise the vast majority of pediatric LGG, a histological 
subset that rarely transforms (Tihan et al., 1999). While no prospective studies have been 
performed to identify reliable risk factors for transformation in children, radiation therapy is 
reported to be a possible causative agent (Dirks et al., 1994). Mean time to transformation is 
relatively short at approximately 6.4 years (Dirks et al., 1994).  While the overall rate of 
progression is certainly lower in children, the risk of transformation in this population is still 
significant and warrants active and expectant observation.  
Despite this risk for malignant degeneration, overall prognosis for children with LGG is 
significantly better than that for adults. Overall survival in children with LGG 65-90%, 
however, OS is 51% when pilocytic pathology is excluded (Armstrong et al., 2011, Fisher et 
al., 2008, Pollack et al., 1995). Following gross total resection, survival is 90-100% with 0% 
progression, in comparison to the adult transformation rate of 50% even in low risk, young 
patients with complete resection (Pollack et al., 1995). Progression free survival is between 
approximately 50% at 10 years, and 53% at 15 years (Armstrong et al., 2011). Gross total 
resection has been the only factor currently identified to have an impact on progression free 
survival in children with 0% progression with GTR and 17% progression with near total 
resection (Pollack et al., 1995). Due to the infiltrative nature of non-pilocytic grade II 
astrocytomas, this histology in children is more comparable to the adult population and is 
associated with poorer prognosis (Pollack et al., 1995). 
4. Effect of resection and adjuvant therapy on malignant transformation 
Currently, initial treatment consists of pharmacologic seizure control if patients present with 
seizures and steroids for vasogenic edema (Prabhu et al., 2010, Stieber, 2001). For patients 
with lesions amenable to surgery, the goal is gross total resection as many studies have 
found overall survival to correlate with extent of initial resection irrespective of adjuvant 
therapy. At 5 years, OS was 63% with GTR versus 27% OS with STR (Prabhu et al., 2010). 
Recurrence is also higher with STR (Prabhu et al., 2010). Berger et al. (1994) reported no 
recurrences within 54 months with GTR, 14.8% recurrence with residual tumor less than 
10cm3, and 46.2% recurrence with residual greater than 10cm3 (Berger et al., 1994, Stieber, 
2001). In some cases, tumor location within or near eloquent cortex limits the extent of 
resection, therefore, newer methods including functional MRI, fiber tracking with diffuser 
tensor imaging (DTI), intra-operative stimulation and mapping, or intra-operative MRI have 
helped reduce morbidity and allow more aggressive surgery. As survival decreases with 
lower Karnofsky score, while the surgical goal remains complete resection, equally 
important is the avoidance of new neurological deficit (Gil-Robles & Duffau, 2010, Schomas 
et al., 2009). 
The role of adjuvant therapy following surgical resection remains controversial. Although 
LGG are fairly slow growing tumors with low or absent mitotic activity, their infiltrative 
behavior and high rate of recurrence and malignant transformation has caused most centers 
to institute adjuvant therapy regardless of the extent of resection. Recent prospective trials 
have addressed the role of radiation therapy (E. Shaw et al., 2002). RT was found to improve 
PFS but not OS (Stieber, 2001). As a result, early RT is administered to patients at high risk 
 
Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma 
 
205 
for malignant transformation (defined as age > 40yrs, astrocytic histology, crossing midline, 
diameter > 6cm, or intractable seizures) or for control of disease at the time of progression 
(Prabhu et al., 2010). The study also recommended RT to all patients greater than 40 years of 
age irrespective of resection, as age was the most consistent prognostic factor for malignant 
transformation (Stieber, 2001). For patients aged 18 to 40, RT was recommended only for 
patients with incomplete resection. Regardless of these data, treatment protocols vary 
widely and are often practitioner dependant.  
Chemotherapy has also been used as an initial treatment in LGG, most commonly in the 
setting of unresectable disease, or in patients less than 3 years of age in which RT should be 
deferred (Prabhu et al., 2010). The response rates to available agents are highly variable, 
with favorable responses reported between 10 and 60%. Poor response is often associated 
with low grade tumors as they tend to have lower sensitivity to chemotherapeutic agents 
due their inherently slow growth and minimal mitosis (Prabhu et al., 2010). The Southwest 
Oncology Group (SWOG) investigated the use of CCNU in addition to RT following GTR 
and found no added benefit of CCNU (E. G. Shaw & Wisoff, 2003). The NCCTG found a 
favorable response using PCV in the treatment of primary disease. Currently, the RTOG is 
investigating the safety and efficacy of PCV in unfavorable patients following resection and 
RT. Temozolamide is also under investigation for use in LGG patients at high risk for 
transformation (Schomas et al., 2009). Clearly, the use of adjuvant therapy requires more 
investigation before formal recommendations can be defined. Until then, adjuvant therapies 
will remain controversial and site dependant.  
Treatment of pediatric gliomas is subject to a different set of considerations and standards as 
toxicity of therapy has a greater impact on the developing nervous and skeletal system. 
Surgery with GTR is the primary mode of therapy as this has been shown to be the most 
effective method for cure (Fisher et al., 2008, Unal et al., 2008). While rare, malignant 
transformation does occur so observation is not recommended with lesions that are 
amenable to surgery. As an exception, optic and hypothalamic gliomas are treated initially 
with observation and chemotherapy. Due to their slow growth and associated morbidity 
with surgery or radiotherapy in these locations, conservative management is standard. 
Ultimately, these tumors are associated with a worse prognosis due to their location and 
difficulty of surgical intervention in the event of progression. Similarly, first line of therapy 
for brainstem lesions is observation and potential biopsy only for progression of symptoms 
or radiographic appearance (Fisher et al., 2008). Based on the 0% progression in the setting 
of GTR, RT has no role following complete resection in children, as compared to adults 
(Pollack et al., 1995). 
Although standard dose RT (50.4-54 Gy) has been shown to be effective in the pediatric 
population, RT is deferred in children irrespective of residual tumor burden, recurrence or 
progression due to the risk of toxicity including endocrine dysfunction, cognitive 
impairment with decreased memory, lower IQ, attention deficit, cerebrovascular disease, 
and secondary neoplasms (Fisher et al., 2008, Pollack et al., 1995). Standard dose RT is 
associated with 34% cognitive dysfunction compared to 8.6% without RT, and 17% 
endocrine dysfunction compared to 2.9% without RT (Pollack et al., 1995). Overall, the rate 
of endocrine dysfunction was 10% and cognitive dysfunction was 21%. These findings 
support the use of repeat surgery and chemotherapy prior to the use of RT for recurrence in 
children. Chemotherapeutic agents possess significant toxicity as well. While carboplatin 
and vincristine showed good response rates with 68% 3 year PFS, 40% of patients 
demonstrated hypersensitivity reactions. CCNU, vincristine, and dibromodulcitol have all 
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pediatric population, leading to the hypothesis that tumor biology in children is inherently 
different from that in adults. For LGG in children, the overall rate of malignant 
transformation ranges from 4.3%-38%, which is much lower than in adults (Armstrong et al., 
2011, Pollack et al., 1995). This difference may be accounted for in part by the higher rate of 
pilocytic astrocytomas that comprise the vast majority of pediatric LGG, a histological 
subset that rarely transforms (Tihan et al., 1999). While no prospective studies have been 
performed to identify reliable risk factors for transformation in children, radiation therapy is 
reported to be a possible causative agent (Dirks et al., 1994). Mean time to transformation is 
relatively short at approximately 6.4 years (Dirks et al., 1994).  While the overall rate of 
progression is certainly lower in children, the risk of transformation in this population is still 
significant and warrants active and expectant observation.  
Despite this risk for malignant degeneration, overall prognosis for children with LGG is 
significantly better than that for adults. Overall survival in children with LGG 65-90%, 
however, OS is 51% when pilocytic pathology is excluded (Armstrong et al., 2011, Fisher et 
al., 2008, Pollack et al., 1995). Following gross total resection, survival is 90-100% with 0% 
progression, in comparison to the adult transformation rate of 50% even in low risk, young 
patients with complete resection (Pollack et al., 1995). Progression free survival is between 
approximately 50% at 10 years, and 53% at 15 years (Armstrong et al., 2011). Gross total 
resection has been the only factor currently identified to have an impact on progression free 
survival in children with 0% progression with GTR and 17% progression with near total 
resection (Pollack et al., 1995). Due to the infiltrative nature of non-pilocytic grade II 
astrocytomas, this histology in children is more comparable to the adult population and is 
associated with poorer prognosis (Pollack et al., 1995). 
4. Effect of resection and adjuvant therapy on malignant transformation 
Currently, initial treatment consists of pharmacologic seizure control if patients present with 
seizures and steroids for vasogenic edema (Prabhu et al., 2010, Stieber, 2001). For patients 
with lesions amenable to surgery, the goal is gross total resection as many studies have 
found overall survival to correlate with extent of initial resection irrespective of adjuvant 
therapy. At 5 years, OS was 63% with GTR versus 27% OS with STR (Prabhu et al., 2010). 
Recurrence is also higher with STR (Prabhu et al., 2010). Berger et al. (1994) reported no 
recurrences within 54 months with GTR, 14.8% recurrence with residual tumor less than 
10cm3, and 46.2% recurrence with residual greater than 10cm3 (Berger et al., 1994, Stieber, 
2001). In some cases, tumor location within or near eloquent cortex limits the extent of 
resection, therefore, newer methods including functional MRI, fiber tracking with diffuser 
tensor imaging (DTI), intra-operative stimulation and mapping, or intra-operative MRI have 
helped reduce morbidity and allow more aggressive surgery. As survival decreases with 
lower Karnofsky score, while the surgical goal remains complete resection, equally 
important is the avoidance of new neurological deficit (Gil-Robles & Duffau, 2010, Schomas 
et al., 2009). 
The role of adjuvant therapy following surgical resection remains controversial. Although 
LGG are fairly slow growing tumors with low or absent mitotic activity, their infiltrative 
behavior and high rate of recurrence and malignant transformation has caused most centers 
to institute adjuvant therapy regardless of the extent of resection. Recent prospective trials 
have addressed the role of radiation therapy (E. Shaw et al., 2002). RT was found to improve 
PFS but not OS (Stieber, 2001). As a result, early RT is administered to patients at high risk 
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for malignant transformation (defined as age > 40yrs, astrocytic histology, crossing midline, 
diameter > 6cm, or intractable seizures) or for control of disease at the time of progression 
(Prabhu et al., 2010). The study also recommended RT to all patients greater than 40 years of 
age irrespective of resection, as age was the most consistent prognostic factor for malignant 
transformation (Stieber, 2001). For patients aged 18 to 40, RT was recommended only for 
patients with incomplete resection. Regardless of these data, treatment protocols vary 
widely and are often practitioner dependant.  
Chemotherapy has also been used as an initial treatment in LGG, most commonly in the 
setting of unresectable disease, or in patients less than 3 years of age in which RT should be 
deferred (Prabhu et al., 2010). The response rates to available agents are highly variable, 
with favorable responses reported between 10 and 60%. Poor response is often associated 
with low grade tumors as they tend to have lower sensitivity to chemotherapeutic agents 
due their inherently slow growth and minimal mitosis (Prabhu et al., 2010). The Southwest 
Oncology Group (SWOG) investigated the use of CCNU in addition to RT following GTR 
and found no added benefit of CCNU (E. G. Shaw & Wisoff, 2003). The NCCTG found a 
favorable response using PCV in the treatment of primary disease. Currently, the RTOG is 
investigating the safety and efficacy of PCV in unfavorable patients following resection and 
RT. Temozolamide is also under investigation for use in LGG patients at high risk for 
transformation (Schomas et al., 2009). Clearly, the use of adjuvant therapy requires more 
investigation before formal recommendations can be defined. Until then, adjuvant therapies 
will remain controversial and site dependant.  
Treatment of pediatric gliomas is subject to a different set of considerations and standards as 
toxicity of therapy has a greater impact on the developing nervous and skeletal system. 
Surgery with GTR is the primary mode of therapy as this has been shown to be the most 
effective method for cure (Fisher et al., 2008, Unal et al., 2008). While rare, malignant 
transformation does occur so observation is not recommended with lesions that are 
amenable to surgery. As an exception, optic and hypothalamic gliomas are treated initially 
with observation and chemotherapy. Due to their slow growth and associated morbidity 
with surgery or radiotherapy in these locations, conservative management is standard. 
Ultimately, these tumors are associated with a worse prognosis due to their location and 
difficulty of surgical intervention in the event of progression. Similarly, first line of therapy 
for brainstem lesions is observation and potential biopsy only for progression of symptoms 
or radiographic appearance (Fisher et al., 2008). Based on the 0% progression in the setting 
of GTR, RT has no role following complete resection in children, as compared to adults 
(Pollack et al., 1995). 
Although standard dose RT (50.4-54 Gy) has been shown to be effective in the pediatric 
population, RT is deferred in children irrespective of residual tumor burden, recurrence or 
progression due to the risk of toxicity including endocrine dysfunction, cognitive 
impairment with decreased memory, lower IQ, attention deficit, cerebrovascular disease, 
and secondary neoplasms (Fisher et al., 2008, Pollack et al., 1995). Standard dose RT is 
associated with 34% cognitive dysfunction compared to 8.6% without RT, and 17% 
endocrine dysfunction compared to 2.9% without RT (Pollack et al., 1995). Overall, the rate 
of endocrine dysfunction was 10% and cognitive dysfunction was 21%. These findings 
support the use of repeat surgery and chemotherapy prior to the use of RT for recurrence in 
children. Chemotherapeutic agents possess significant toxicity as well. While carboplatin 
and vincristine showed good response rates with 68% 3 year PFS, 40% of patients 
demonstrated hypersensitivity reactions. CCNU, vincristine, and dibromodulcitol have all 
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been associated with significant hypersensitivity reactions (Fisher et al., 2008). As a result, 
TPCV is now being tested for efficacy and safety in a prospective pediatric trial (Fisher et al., 
2008). 
5. Histology of malignant transformation 
As mentioned previously, low grade gliomas comprise a histologically diverse group of 
tumors. The current WHO classification describes four categories for astrocytomas (Kleihues 
et al., 1995, Louis et al., 2007). While it is theorized that the majority of grade IV 
glioblastomas (GBM) occur de novo (primary GBM), a significant number of lesions result 
from progression of a low-grade tumor (secondary GBM). Excluding Grade I pilocytic 
astrocytomas as they rarely progress, low grade (II) and high grade (III and IV) 
astrocytomas can be viewed to exist along a continuum based on the histological analysis of 
tumor tissue. Grade II lesions are defined by low or absent mitotic activity and, unlike 
Grade I gliomas, are infiltrative and invasive and should not be considered benign. Cellular 
density is low to moderate, and well-differentiated, mildly pleomorphic tumor cells are 
present. One important feature of low grade astrocytomas is the absence of 
neovascularization. 
This is in distinct comparison to high grade gliomas, grade III anaplastic tumors  and grade 
IV GBMs, which are poorly differentiated, widely infiltrative and display prominent mitotic 
activity and neovascularization. Both confer a poor prognosis. High-grade lesions display 
increased cellularity, marked pleomorphism and nuclear atypia and may include 
multinucleated giant cells. Necrosis is the defining feature of GBM and these areas are 
typically surrounded by pseudopalisading cells. Most importantly, extensive irregular 
vascular proliferation is present in GBM as these tumors have adopted the capability of 
undergoing the angiogenic switch to produce their own vasculature, allowing for 
exponential tumor growth.  
While morbidity is associated with low-grade astrocytomas themselves, it is hypothesized 
that the majority of morbidity is caused by progression to high-grade tumor.  One of the key 
factors in this progression is the angiogenic switch whereby the tumor adopts the ability to 
acquire its own vascular supply. This enables explosive growth and precipitates rapid 
clinical deterioration. While an increased understanding of LGG biology and behavior has 
led to a more aggressive approach to these tumors, clinical outcome measures still remain 
poor. This is due mostly in part to our inability to prevent or detect malignant degeneration. 
A significant amount of research is now focused on understanding the factors involved in 
the angiogenic switch, which is likely to lead to additional treatment targets and potentially 
better outcomes. This will be further discussed in the sections to follow. 
6. Molecular biology of malignant transformation 
While histological characteristics currently determine tumor grade in astrocytoma, 
important molecular differences also exist between low grade and high-grade gliomas 
(Table 1) (Godard et al., 2003). These molecular differences are likely to be an important 
factor in initiating or promoting the angiogenic switch (Wen & Kesari, 2008). Both primary 
and secondary GBM exhibit elevated VEGF expression and loss of heterozygosity at 10q. 
The majority of primary GBM show overexpression of EGFR and PTEN mutations. In 
particular, glioblastomas that express the EGFRvIII genetic variant have a worse prognosis 
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and show resistance to current therapeutic regimens (Furnari et al., 2007, Hatanpaa et al., 
Johns et al., 2007, Pelloski et al., 2007). While PTEN mutations occur more frequently in 
primary glioblastoma in adults, PTEN mutations exist in high frequency in pediatric 









p53 (TP53) ↑↑↑ ↑ 
EGFR ↑ ↑↑↑ 
PTEN ↑↑ ↑↑↑ 
IDH  1&2 ↑↑↑ ↑↑ 
PDGF ↑↑↑ ↑↑ 
BRAF ↑ -- 
Table 1. Various genetic mutations associated with gliomas. EGFR - epidermal growth factor 
receptor, PTEN - phosphatase and tensin homolog, IDH - isocitrate deyhdrogenase, PDGFR 
– platelet derived growth factor receptor. 
In contrast, secondary GBMs often have p53 mutations and overexpress PDGF. Mutations of 
p53 frequently are associated with low-grade gliomas occurring in 53% of astrocytoma, 44% 
of oligoastrocytoma, and 13% of oligodendroglioma (Okamoto et al., 2004). Therefore, p53 
may be an important molecular event involved in the malignant progression of low-grade 
gliomas (Louis et al., 2007).  Interestingly, in children, the rate of p53 mutations is reported 
as only 10% in progressive pediatric LGG. While this alteration may seem to possibly 
explain the improved survival in pediatric gliomas, the 1p19q deletion, an indicator of a 
favorable response to specific chemotherapies in adults, is not found in pediatric gliomas 
(Fisher et al., 2008).  
Other molecular changes have also been identified (Ichimura et al., 2009, Watanabe et al., 
2009). IDH1 abnormalities exist in 59-88% of diffuse astrocytomas, 68-82% of 
oligodendrogliomas, 50-78% of anaplastic astrocytomas, 49-75% of anaplastic 
oligodendrogliomas, and 50-88% of secondary glioblastomas and often co-exist with p53 
mutated lesions or 1p19q co-deleted tumors (Hartmann et al., 2009, Ichimura et al., 2009, 
Parsons et al., 2008, Sanson et al., 2009, Watanabe et al., 2009, Yan et al., 2009). While the 
presence of IDH mutations in low-grade tumors and secondary GBMs suggests a role for 
IDH in malignant progression , the literature suggests that the presence of IDH1 or IDH2 
mutations correlates with better outcomes in patients (De Carli et al., 2009, Yan et al., 2009). 
PDGFR and the p16ink4a /RB1 pathway have also been implicated in gliomagenesis as 
hypermethylation of the RB1 gene may result in uncontrolled cell cycle progression, which 
may then drive tumor formation (Sathornsumetee et al., 2007). Both primary and secondary 
GBMs express PDGF, but increased RB1 gene promoter methylation appears to occur more 
frequently in secondary GBMs (43%) than primary GBMs (14%) (Nakamura et al., 2001).   
The expression of MGMT, a DNA repair enzyme, has also been implicated in glioblastoma 
and low-grade gliomas (Bourne & Schiff, 2010). Of particular interest is the methylation 
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been associated with significant hypersensitivity reactions (Fisher et al., 2008). As a result, 
TPCV is now being tested for efficacy and safety in a prospective pediatric trial (Fisher et al., 
2008). 
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astrocytomas as they rarely progress, low grade (II) and high grade (III and IV) 
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IV GBMs, which are poorly differentiated, widely infiltrative and display prominent mitotic 
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While morbidity is associated with low-grade astrocytomas themselves, it is hypothesized 
that the majority of morbidity is caused by progression to high-grade tumor.  One of the key 
factors in this progression is the angiogenic switch whereby the tumor adopts the ability to 
acquire its own vascular supply. This enables explosive growth and precipitates rapid 
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6. Molecular biology of malignant transformation 
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factor in initiating or promoting the angiogenic switch (Wen & Kesari, 2008). Both primary 
and secondary GBM exhibit elevated VEGF expression and loss of heterozygosity at 10q. 
The majority of primary GBM show overexpression of EGFR and PTEN mutations. In 
particular, glioblastomas that express the EGFRvIII genetic variant have a worse prognosis 
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and show resistance to current therapeutic regimens (Furnari et al., 2007, Hatanpaa et al., 
Johns et al., 2007, Pelloski et al., 2007). While PTEN mutations occur more frequently in 
primary glioblastoma in adults, PTEN mutations exist in high frequency in pediatric 









p53 (TP53) ↑↑↑ ↑ 
EGFR ↑ ↑↑↑ 
PTEN ↑↑ ↑↑↑ 
IDH  1&2 ↑↑↑ ↑↑ 
PDGF ↑↑↑ ↑↑ 
BRAF ↑ -- 
Table 1. Various genetic mutations associated with gliomas. EGFR - epidermal growth factor 
receptor, PTEN - phosphatase and tensin homolog, IDH - isocitrate deyhdrogenase, PDGFR 
– platelet derived growth factor receptor. 
In contrast, secondary GBMs often have p53 mutations and overexpress PDGF. Mutations of 
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mutations correlates with better outcomes in patients (De Carli et al., 2009, Yan et al., 2009). 
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may then drive tumor formation (Sathornsumetee et al., 2007). Both primary and secondary 
GBMs express PDGF, but increased RB1 gene promoter methylation appears to occur more 
frequently in secondary GBMs (43%) than primary GBMs (14%) (Nakamura et al., 2001).   
The expression of MGMT, a DNA repair enzyme, has also been implicated in glioblastoma 
and low-grade gliomas (Bourne & Schiff, 2010). Of particular interest is the methylation 
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status of MGMT as it may correlate to resistance to alkylating therapy in some patients 
(Hegi et al., 2005).  
Finally, chromosomal e 7 (7q34) gene BRAF mutations and overexpression of B-raf, which 
stimulates the mitogen-activated protein kinase (MAPK) pathway, is a major factor in 
tumorigenesis of pilocytic astrocytomas (Pfister et al., 2008). This mutation is also present in 
23-38% of adult grade II astrocytomas.  The role of BRAF mutation in progression to high-
grade tumors, however, has yet to be elucidated. 
Defining molecular differences amongst glioma subpopulations offers an exciting new 
dynamic in understanding the behaviors of this highly diverse tumor although much work 
is required before the variability observed is completely delineated. Already, studies are 
underway to target tumors at the molecular level in hopes of providing better treatment 
options (Johns et al., 2007). As it is apparent that the angiogenic switch is important in the 
progression of low-grade to high-grade glioma, defining the molecular changes that 
promote this event may offer additional treatment benefits. Animal studies have already 
shown that preventing the angiogenic switch in other solid tumors reduces tumor growth 
(Lyden et al., 2001). Therefore, further understanding of how specific molecular changes in 
tumor cells promote angiogenesis may offer promising new treatment options in gliomas.  
7. Advancing imaging of low-grade gliomas  
MRI is the initial imaging modality of choice in brain tumors. Low-grade gliomas usually 
appear as well defined lesions with little mass effect. They have low-signal on T1- and high-
signal on T2-weighted imaging - particularly on fluid attenuated inversion recovery (FLAIR) 
sequences where low-grade gliomas are very hyperintense (Kates et al., 1996). Currently, the 
absence of gadolinium enhancement is used to differentiate low grade versus high grade 
glioma (Fig. 2) (Castillo, 1994), however, a significant portion of the low-grade gliomas 
defined by MRI were found to be high-grade after biopsy (Kondziolka et al., 1993). As a 
result, MRI is not sensitive enough to definitively diagnose low-grade gliomas as there are 
frequently small areas within the tumor that have already undergone malignant 
progression. Therefore, advanced imaging technologies, such as perfusion imaging, 
diffusion-weighted and diffusion tensor imaging, MR spectroscopy, and position emission 
tomography (PET), are currently being employed to more accurately identify low-grade 
versus high-grade gliomas. These modalities provide exciting insight into tumor vascularity, 
cellularity, metabolism, and proliferation and may prove more effective in differentiating 
low-grade from high-grade glioma particularly in regions within a given tumor.  
Since the degree of vascularity correlates with tumor grade in gliomas, (Daumas-Duport et 
al., 1997) perfusion MRI and MRI with gradient echo differentiates low-grade versus high-
grade gliomas based on relative cerebral blood volume (rCBV) (Boxerman et al., 2006, Law 
et al., 2003, Law et al., 2004, Shin et al., 2002, Sugahara et al., 1998, Sugahara et al., 2001). 
While promising, it has been difficult to establish a reliable threshold based on rCBV for 
low- versus high-grade state. Diffusion-weighted MRI has also been utilized based on the 
apparent diffusion coefficient, which inversely correlates with tumor cellularity (Gauvain et 
al., 2001, Kono et al., 2001, Sugahara et al., 1999). Again, it has been difficult to reliably 
predict tumor grade using diffusion MRI (Bulakbasi et al., 2003, Stieber, 2001).  Diffusion 
tensor imaging (DTI) is a modification of diffusion-weighted imaging and measures 
fractional anisotropy (FA), which correlated with tumor cellularity and vascularity (Price, 
2010). DTI is a promising new modality as one study reports the ability to distinguish 
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Fig. 1. Serial imaging of malignant progression of glioma. A, T1-weighted MRI with 
contrast. Patient presented with headache. MRI revealed hypointense lesion in right 
hemisphere. Note edema and mass effect but lack of contrast enhancement. Pt underwent 
gross total surgical resection and pathology revealed grade II astrocytoma. B, T1-weighted 
MRI with contrast. Subsequent imaging revealed recurrent tumor seen as a contrast 
enhancing lesion in the previous resection cavity. Pathology revealed progression to grade 
IV astrocytoma (GBM). 
MR spectroscopy (MRS) also can potentially differentiate low-grade versus high-grade 
gliomas in the brain. All gliomas have an increased choline peak and a reduced N-acetyl 
aspartate peak (NAA) which are markers of membrane turnover and neuronal cell death 
respectively. Levels of lipid and lactate are markers of necrosis and hypoxia respectively 
and are decidedly elevated in high-grade compared to low-grade gliomas (McBride et al., 
1995, Nafe et al., 2003, Negendank et al., 1996). Creatine (Cr), which serves as a marker of 
energy metabolism, is decreased in brain tumors (Meyerand et al., 1999, Moller-Hartmann et 
al., 2002), however, this reduction does not appear to correlate with tumor grade by itself 
(Moller-Hartmann et al., 2002). Using the choline/Cr ratio may be more effective, however, 
as low-grade gliomas tend to have a lower ratio of choline/Cr (McBride et al., 1995, Murphy 
et al., 2002, Sijens & Oudkerk, 2002), as well as an increase in NAA/Cr ratio (Law et al., 
2003, McKnight et al., 2002, Murphy et al., 2002, Nafe et al., 2003, Negendank et al., 1996). 
MRS is a promising technique in differentiating low- from high-grade gliomas with 
sensitivity between 73% and 92% and specificity between 63% and 100% (Astrakas et al., 
2004, Fayed & Modrego, 2005, Law et al., 2003, Nafe et al., 2003, Setzer et al., 2007). MRS 
may also be capable of identifying regions that have undergone malignant transformation 
within a given tumor that may not be identifiable by other imaging techniques although one 
such study attempting to detect malignant transformation within low-grade glioma yielded 
a specificity of only 57.1% (Alimenti et al., 2007).  
Positron emission tomography (PET) imaging has been employed to examine gliomas in the 
brain by measuring the metabolic activity of tissue. Fluorinated glucose analogue 2-[18F]-
fluoro-2-deoxy-D-glucose (FDG), which is administered to patients intravascularly, has high 
sensitivity for identifying areas of increased tumor metabolism and has been used as an 
index to predict tumor aggressiveness. While low-grade gliomas tend to have the same or 
even lower uptake of FDG than normal brain matter, high-grade gliomas demonstrate 
increased uptake of FDG on PET imaging (Derlon et al., 1997, Tamura et al., 1998), Studies 
have shown that it is possible to differentiate low- from high-grade gliomas with a 
sensitivity of 94% and specificity of 77% using a tumor-to-white-matter ratio of  greater than 
1.5 and tumor-to-grey-matter ratio of greater than 0.6 (Delbeke et al., 1995).  
 
Glioma – Exploring Its Biology and Practical Relevance 
 
208 
status of MGMT as it may correlate to resistance to alkylating therapy in some patients 
(Hegi et al., 2005).  
Finally, chromosomal e 7 (7q34) gene BRAF mutations and overexpression of B-raf, which 
stimulates the mitogen-activated protein kinase (MAPK) pathway, is a major factor in 
tumorigenesis of pilocytic astrocytomas (Pfister et al., 2008). This mutation is also present in 
23-38% of adult grade II astrocytomas.  The role of BRAF mutation in progression to high-
grade tumors, however, has yet to be elucidated. 
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versus high-grade gliomas. These modalities provide exciting insight into tumor vascularity, 
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low-grade from high-grade glioma particularly in regions within a given tumor.  
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apparent diffusion coefficient, which inversely correlates with tumor cellularity (Gauvain et 
al., 2001, Kono et al., 2001, Sugahara et al., 1999). Again, it has been difficult to reliably 
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Fig. 1. Serial imaging of malignant progression of glioma. A, T1-weighted MRI with 
contrast. Patient presented with headache. MRI revealed hypointense lesion in right 
hemisphere. Note edema and mass effect but lack of contrast enhancement. Pt underwent 
gross total surgical resection and pathology revealed grade II astrocytoma. B, T1-weighted 
MRI with contrast. Subsequent imaging revealed recurrent tumor seen as a contrast 
enhancing lesion in the previous resection cavity. Pathology revealed progression to grade 
IV astrocytoma (GBM). 
MR spectroscopy (MRS) also can potentially differentiate low-grade versus high-grade 
gliomas in the brain. All gliomas have an increased choline peak and a reduced N-acetyl 
aspartate peak (NAA) which are markers of membrane turnover and neuronal cell death 
respectively. Levels of lipid and lactate are markers of necrosis and hypoxia respectively 
and are decidedly elevated in high-grade compared to low-grade gliomas (McBride et al., 
1995, Nafe et al., 2003, Negendank et al., 1996). Creatine (Cr), which serves as a marker of 
energy metabolism, is decreased in brain tumors (Meyerand et al., 1999, Moller-Hartmann et 
al., 2002), however, this reduction does not appear to correlate with tumor grade by itself 
(Moller-Hartmann et al., 2002). Using the choline/Cr ratio may be more effective, however, 
as low-grade gliomas tend to have a lower ratio of choline/Cr (McBride et al., 1995, Murphy 
et al., 2002, Sijens & Oudkerk, 2002), as well as an increase in NAA/Cr ratio (Law et al., 
2003, McKnight et al., 2002, Murphy et al., 2002, Nafe et al., 2003, Negendank et al., 1996). 
MRS is a promising technique in differentiating low- from high-grade gliomas with 
sensitivity between 73% and 92% and specificity between 63% and 100% (Astrakas et al., 
2004, Fayed & Modrego, 2005, Law et al., 2003, Nafe et al., 2003, Setzer et al., 2007). MRS 
may also be capable of identifying regions that have undergone malignant transformation 
within a given tumor that may not be identifiable by other imaging techniques although one 
such study attempting to detect malignant transformation within low-grade glioma yielded 
a specificity of only 57.1% (Alimenti et al., 2007).  
Positron emission tomography (PET) imaging has been employed to examine gliomas in the 
brain by measuring the metabolic activity of tissue. Fluorinated glucose analogue 2-[18F]-
fluoro-2-deoxy-D-glucose (FDG), which is administered to patients intravascularly, has high 
sensitivity for identifying areas of increased tumor metabolism and has been used as an 
index to predict tumor aggressiveness. While low-grade gliomas tend to have the same or 
even lower uptake of FDG than normal brain matter, high-grade gliomas demonstrate 
increased uptake of FDG on PET imaging (Derlon et al., 1997, Tamura et al., 1998), Studies 
have shown that it is possible to differentiate low- from high-grade gliomas with a 
sensitivity of 94% and specificity of 77% using a tumor-to-white-matter ratio of  greater than 
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In addition to FDG, other tracers have been utilized in attempts to further characterize these 
tumors such as carbon 11 and fluorine 18 (18F)-labeled amino acid (Isselbacher, 1972).  
Methionine PET appears to have a higher sensitivity than FDG PET in detecting low-grade 
versus high-grade gliomas  (Derlon et al., 1997, Giammarile et al., 2004, Ogawa et al., 1993). 
In particular, methionine PET exhibits a heightened sensitivity in detecting radiation 
necrosis from recurrent tumors, as inflammatory cells in radiation necrosis have little uptake 
of methionine (Thiel et al., 2000). Perhaps the most promising technique for diagnosing low-
grade gliomas is 18F-FDOPA PET imaging. 18F-FDOPA PET is more accurate that FDG PET 
and has been shown to be highly predictive in determining tumor grade on initial diagnosis 
and may help differentiate tumor necrosis from recurrence (Chen et al., 2006, Fueger et al., 
Tripathi et al., 2009). 
While there currently is no one imaging modality capable of definitively determining low-
grade from high-grade tumors on its own, advanced imaging technology continues to 
develop and complement standard MRI.  As we come to understand the behavior and 
variability of these tumors, advance imaging techniques provide exciting new possibilities 
for more precise treatments. Given the variability within a given tumor, advanced imaging 
techniques may allow for more precise targets for biopsy, vigilant monitoring of malignant 
transformation, and improved prognostic power in the management of low- and high-grade 
gliomas.  
8. The Role of bone-marrow derived cells in malignant transformation 
The vast majority of brain tumor research, molecular profiling, histological characteristics, 
diagnostic imaging modalities and treatment targets have focused on the actual tumor cells 
themselves. As mentioned earlier, one of the key events in the transition from the low-grade 
to the high-grade state is the angiogenic switch. It is theorized that in the low-grade state, 
tumor growth may be limited, at least in part, by a lack of blood supply. In this state, the 
tumor is only capable of a steady-state or linear growth (Mandonnet et al., 2003). Once the 
tumor acquires the ability to recruit or form new blood vessels, exponential growth occurs 
(Rees et al., 2009) resulting in rapid clinical decline. While there is considerable evidence 
that tumor cells undergo continued molecular changes that increase their malignant 
potential, these changes also allow these cells to initiate the angiogenic switch. It must also 
be noted that while recent evidence suggests that tumor cells may be capable of directly 
forming new blood vessels (Ricci-Vitiani et al., Wang et al.), a considerable body of evidence 
suggests that tumor cells do not do this completely on their own. While the exact details of 
this process still remain to be fully elucidated, tumor cells acquire the ability to transition 
the local tumor niche to an environment capable of rapid blood vessel formation. A variety 
of growth factors, signaling pathways, and indigenous populations of cells is hypothesized 
to participate in this process. If this theory proves to be correct, this population of cells 
forms an additional therapeutic target that may be as important as the tumor cells 
themselves. As current therapies directed at neoplastic cells are limited in part to their 
toxicity, elucidating other potential treatment pathways may further benefit patient 
outcome. 
Neovascularization is a normal process in tissues and the brain during ischemia. In low 
oxygen states, cells release signals such as VEGF, PDGF, PlGF and HIF-1 that recruit from 
local existing vessels within the tissue itself (angiogenesis.)  In addition, this can activate 
distant processes that facilitate neovascularization and may even form de novo blood vessels 
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(vasculogenesis). These factors mobilize bone marrow precursor cells which then travel to 
the site of ischemia via the bloodstream. It is theorized that these cells facilitate 
vasculogenesis by breaking down existing structures and creating an environment that 
promotes new blood vessel growth. 
Tumors are capable of adopting this machinery to increase growth and invasiveness by 
activating the angiogenic switch (Bergers & Benjamin, 2003, Rafii & Lyden, 2008). During 
early tumor development, neoplastic cells rely on existing blood flow and grow in a slow 
linear fashion (Mandonnet et al., 2003). Once the switch is initiated and neovascularization 
brings more oxygen and nutrients, tumor cells grow at a much faster rate and tumor size 
increases significantly (Rees et al., 2009). This initial process is thought to occur mostly by 
angiogenesis (Kioi, 2010). The release of proteases and proangiogenic factors causes 
pericytes to detach from existing vessels creating a defect in the extracellular matrix in the 
environment surrounding the vessel wall (Bergers & Benjamin, 2003). Endothelial cells 
proliferate locally and sprout outward into the tumor bed creating newly formed blood 
vessels feeding the tumor. While angiogenesis is an important factor in the angiogenic 
switch, vasculogenesis and the contribution of BMDC play a critical role as well. For 
example, when recruitment of BMDC is impaired in an animal model of lymphoma and 
lung carcinoma, tumor angiogenesis and growth is significantly decreased (Lyden et al., 
2001) suggesting that BMDCs contribute significantly to neovascularization and growth in 
solid tumors. 
In metastatic disease, the contribution of BMDC has been well described (Wels et al., 2008).  
Endothelial (EPCs) and hematopoietic precursor cells (HPC), mesenchymal stem cells 
(MSC), myeloid-derived suppressor cells (MDSCs), Tie-2 expressing monocytes (TEM) and 
tumor associated macrophages (TAM) all are mobilized from the bone marrow to future 
metastatic sites prior to tumor formation. It should be noted that these primitive cells are 
prominent during embryology and that a significant population of these cells is not present 
under normal conditions. While the exact role of each cell type has yet to be fully elucidated, 
their basic function is to break down normal structures and promote vasculogenesis and 
tumor invasiveness. The net result is a tumor friendly environment capable of sustaining 
tumor growth. This has been demonstrated experimentally in a murine model of metastatic 
disease by implanting m-cherry labeled melanoma cells into the flank of mice with GFP-
labeled bone marrow and examining the lungs of these animals over time (Kaplan et al., 
2005). It was observed that the first cells to arrive in future metastases were not tumor cells, 
but actual BMDC. This suggested, at least in metastatic disease, that the environment in 
future metastatic sites is primed by cells from the bone marrow before tumors can begin to 
grow in these distant areas (Rafii & Lyden, 2008). This also supports the hypothesis by 
Stephen Paget over 100 years ago that the tumor microenvironment may play as important a 
role as the tumor cells themselves.  
In the brain, the role of BMDC has only recently garnered attention. One of the basic 
histological differences between low-grade and high-grade gliomas is a lack of 
neovascularization. Thus, activation of the angiogenic switch is a key element in the 
transformation of low-grade to high-grade glioma. Two elements are likely to contribute to 
this process. Genetic changes in tumor cells that occur during progression of disease activate 
pro-angiogenic factors. This has been observed in human tumor samples whereby genes 
involved in angiogenesis are upregulated in glioblastoma as compared to low grade 
astrocytoma (Godard et al., 2003). Kioi et al. also showed in their animal model that release 
of soluble factors by tumor cells or cells within the tumor microenvironment including 
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this process still remain to be fully elucidated, tumor cells acquire the ability to transition 
the local tumor niche to an environment capable of rapid blood vessel formation. A variety 
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forms an additional therapeutic target that may be as important as the tumor cells 
themselves. As current therapies directed at neoplastic cells are limited in part to their 
toxicity, elucidating other potential treatment pathways may further benefit patient 
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(vasculogenesis). These factors mobilize bone marrow precursor cells which then travel to 
the site of ischemia via the bloodstream. It is theorized that these cells facilitate 
vasculogenesis by breaking down existing structures and creating an environment that 
promotes new blood vessel growth. 
Tumors are capable of adopting this machinery to increase growth and invasiveness by 
activating the angiogenic switch (Bergers & Benjamin, 2003, Rafii & Lyden, 2008). During 
early tumor development, neoplastic cells rely on existing blood flow and grow in a slow 
linear fashion (Mandonnet et al., 2003). Once the switch is initiated and neovascularization 
brings more oxygen and nutrients, tumor cells grow at a much faster rate and tumor size 
increases significantly (Rees et al., 2009). This initial process is thought to occur mostly by 
angiogenesis (Kioi, 2010). The release of proteases and proangiogenic factors causes 
pericytes to detach from existing vessels creating a defect in the extracellular matrix in the 
environment surrounding the vessel wall (Bergers & Benjamin, 2003). Endothelial cells 
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their basic function is to break down normal structures and promote vasculogenesis and 
tumor invasiveness. The net result is a tumor friendly environment capable of sustaining 
tumor growth. This has been demonstrated experimentally in a murine model of metastatic 
disease by implanting m-cherry labeled melanoma cells into the flank of mice with GFP-
labeled bone marrow and examining the lungs of these animals over time (Kaplan et al., 
2005). It was observed that the first cells to arrive in future metastases were not tumor cells, 
but actual BMDC. This suggested, at least in metastatic disease, that the environment in 
future metastatic sites is primed by cells from the bone marrow before tumors can begin to 
grow in these distant areas (Rafii & Lyden, 2008). This also supports the hypothesis by 
Stephen Paget over 100 years ago that the tumor microenvironment may play as important a 
role as the tumor cells themselves.  
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histological differences between low-grade and high-grade gliomas is a lack of 
neovascularization. Thus, activation of the angiogenic switch is a key element in the 
transformation of low-grade to high-grade glioma. Two elements are likely to contribute to 
this process. Genetic changes in tumor cells that occur during progression of disease activate 
pro-angiogenic factors. This has been observed in human tumor samples whereby genes 
involved in angiogenesis are upregulated in glioblastoma as compared to low grade 
astrocytoma (Godard et al., 2003). Kioi et al. also showed in their animal model that release 
of soluble factors by tumor cells or cells within the tumor microenvironment including 
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VEGF, FGF and EGF stimulates local angiogenesis (Kioi, 2010). Secondly, hypoxia is an 
additional critical event in triggering the switch (Kioi, 2010). As tumor size grows and 
metabolic demand exceeds local perfusion, hypoxic conditions occur. Release of hypoxia 
inducible factor-1 (HIF-1α) by tumor cells or cells within the hypoxic tumor environment, 
combined with stromal cell-derived factor-1 (SDF-1) and CXCR-4 receptor activation, 
mobilizes BMDCs to the tumor site and promotes vasculogenesis in gliomas (Du et al., 2008, 
Greenfield et al., 2010, Kioi, 2010). 
In an attempt to further understand these processes in gliomas, Du et al. utilized an 
orthotopic model of GBM in mice to demonstrate recruitment of BMDC in gliomas (Du et 
al., 2008). Based on their results they theorize that hypoxia and the subsequent release of 
HIF-1α is the key event in tumor progression. Elevation of VEGF, and subsequent SDF-1 
release and CXCR-4 receptor activation, mobilizes BMDC and recruits EPC and myeloid 
cells to the tumor. The net effect tips the balance to a pro-angiogenic state and 
neovascularization within the tumor bed. Kioi et al also further theorized that radiation 
treatment may exacerbate the vasculogenesis process and boost eventual tumor recurrence 
observed in current treatment regimens (Greenfield et al., 2010, Kioi, 2010). The endothelial-
mesenchymal transition and MSC have also been described in metastatic disease (Singh & 
Settleman). MSC exist within the brain and mobilize to the tumor site as well (Hata et al., 
Kang et al.). The exact roles of these particular BMDC remain elusive and require more 
study before they are fully delineated.  
In our laboratory, we have begun to investigate the correlation of BMDC mobilization and 
tumor grade in gliomas (unpublished data.) We used a PDGF-driven mouse model of GBM 
within which tumors develop slowly from low-grade to high-grade. Low-grade tumors 
have a clear absence of neovascularization and BMDC are not present within these lesions. 
In high-grade tumors, however, we have observed a profound increase in larger, irregularly 
shaped, hemorrhagic vessels and a significant population of BMDC exists that is not 
observed in low grade tumors. In addition, these cells are located near newly forming blood 
vessels in the perivascular niche. We have also observed that BMDC are mobilized in the 
bone marrow and are elevated in the peripheral blood of tumor bearing animals versus 
controls. In addition, a significant difference in this population of cells in the blood exists 
between low-grade and high-grade animals. While much work is yet to be done before this 
process is fully elucidated, it appears that the presence of BMDC correlates with tumor 
grade and the process of neovascularization. Thus, BMDC have a potential role in the 
angiogenic switch as tumors progress from low-grade to high-grade tumors. 
 
 
Fig. 2. Bone marrow-derived cells in human glioma. A, Immunofluorescence in grade II 
astrocytoma shows normal blood vessels (red, VE Cadherin) and a paucity of CD11b+ 
myeloid suppressor cells (Green). B, GBM shows abnormal vessel formation and an influx of 
CD11b+ cells (unpublished data.) 
 
Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma 
 
213 
Mobilization of BMDC in peripheral blood samples has similarly been observed in patients 
with astrocytomas. Circulating CD133+ and VEGFR2+ EPC were measured in patients with 
different grade gliomas. This population of cells was significantly elevated in brain tumor 
patients versus controls, correlated with tumor grade, and predicted survival. In one 
patient, this population also predicted recurrence prior to detection by serial radiographic 
study. Currently, patients are followed with serial imaging in order to diagnose recurrence 
or malignant progression. While advances in imaging technology show promise in earlier 
more accurate diagnosis, the critical event has already occurred and prognosis worsens 
considerably. Therefore, the identification of a potential surrogate biomarker that measures 
tumor angiogenicity and aggressiveness may potentially serve as an index for ongoing 
treatment effectiveness or recurrence.  
As histological and molecular differences between low-grade and high-grade gliomas are 
further defined and it becomes apparent that tumors cannot be loosely classified, specific 
treatments based on the particular characteristics of each individual tumor can potentially 
be designed. In addition, the presence of particular populations of BMDC in these tumors 
may also provide additional information on tumor behavior and serve as an additional 
treatment target along with tumor cells themselves. It has already been shown that the 
presence of BMDC in the blood correlates with tumor grade and initial animal studies 
suggest that BMDC are present in high-grade tumors only (Greenfield et al., 2009). In 
addition, TAM have been associated with poorer prognosis in metastatic lesions and other 
solid tumors (Wels et al., 2008). Thus histological stains aimed at identifying this population 
of cells may provide more accurate diagnosis and prognosis. Likewise, the molecular 
markers of this particular population of cells may offer an even more specific therapeutic 
target. Based on data collected in glioma patients, EPC can be identified by cell surface 
markers including CD133 and VEGFR2. Knocking down this population with specifically 
designed drug therapies has the potential for preventing recurrence by decreasing migration 
of these cells and reducing vasculogenesis within the tumor bed. Finally, one can also 
envision a role for advanced imaging technologies for improved diagnosis and treatment. 
For instance, PET has been used to specifically measure VEGF that has been labeled with 
copper in an orthotropic mouse model of GBM (Cai et al., 2006). If one could identify and 
label molecular targets that are specific to individual tumors subtypes and sensitive to new 
imaging techniques, this provides exciting non-invasive possibilities for tumor specific 
identification and treatment for each individual patient.  
9. Conclusions 
In summary, one of the primary factors predicting outcome in patients with low-grade 
glioma is malignant progression to high-grade tumor and it is evident that the angiogenic 
switch is an important event in this process. Initial management often entails surgical 
resection while adjuvant therapy for low-grade gliomas remains a controversial topic. 
Tumor grade is determined by histological analysis of tumor specimens, but the molecular 
fingerprint of these tumors is now being analyzed more thoroughly and holds promise for 
more exciting targeted treatment options. In addition, distinct, but as yet undefined, 
populations of cells are recruited to the tumor site and participate in neovascularization and 
promote tumor growth and invasiveness. Therefore, this population may represent an 
important therapeutic target in combating these tumors. Since survival is directly correlated 
with tumor grade, preventing tumor progression is imperative. While BMDC certainly are 
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Mobilization of BMDC in peripheral blood samples has similarly been observed in patients 
with astrocytomas. Circulating CD133+ and VEGFR2+ EPC were measured in patients with 
different grade gliomas. This population of cells was significantly elevated in brain tumor 
patients versus controls, correlated with tumor grade, and predicted survival. In one 
patient, this population also predicted recurrence prior to detection by serial radiographic 
study. Currently, patients are followed with serial imaging in order to diagnose recurrence 
or malignant progression. While advances in imaging technology show promise in earlier 
more accurate diagnosis, the critical event has already occurred and prognosis worsens 
considerably. Therefore, the identification of a potential surrogate biomarker that measures 
tumor angiogenicity and aggressiveness may potentially serve as an index for ongoing 
treatment effectiveness or recurrence.  
As histological and molecular differences between low-grade and high-grade gliomas are 
further defined and it becomes apparent that tumors cannot be loosely classified, specific 
treatments based on the particular characteristics of each individual tumor can potentially 
be designed. In addition, the presence of particular populations of BMDC in these tumors 
may also provide additional information on tumor behavior and serve as an additional 
treatment target along with tumor cells themselves. It has already been shown that the 
presence of BMDC in the blood correlates with tumor grade and initial animal studies 
suggest that BMDC are present in high-grade tumors only (Greenfield et al., 2009). In 
addition, TAM have been associated with poorer prognosis in metastatic lesions and other 
solid tumors (Wels et al., 2008). Thus histological stains aimed at identifying this population 
of cells may provide more accurate diagnosis and prognosis. Likewise, the molecular 
markers of this particular population of cells may offer an even more specific therapeutic 
target. Based on data collected in glioma patients, EPC can be identified by cell surface 
markers including CD133 and VEGFR2. Knocking down this population with specifically 
designed drug therapies has the potential for preventing recurrence by decreasing migration 
of these cells and reducing vasculogenesis within the tumor bed. Finally, one can also 
envision a role for advanced imaging technologies for improved diagnosis and treatment. 
For instance, PET has been used to specifically measure VEGF that has been labeled with 
copper in an orthotropic mouse model of GBM (Cai et al., 2006). If one could identify and 
label molecular targets that are specific to individual tumors subtypes and sensitive to new 
imaging techniques, this provides exciting non-invasive possibilities for tumor specific 
identification and treatment for each individual patient.  
9. Conclusions 
In summary, one of the primary factors predicting outcome in patients with low-grade 
glioma is malignant progression to high-grade tumor and it is evident that the angiogenic 
switch is an important event in this process. Initial management often entails surgical 
resection while adjuvant therapy for low-grade gliomas remains a controversial topic. 
Tumor grade is determined by histological analysis of tumor specimens, but the molecular 
fingerprint of these tumors is now being analyzed more thoroughly and holds promise for 
more exciting targeted treatment options. In addition, distinct, but as yet undefined, 
populations of cells are recruited to the tumor site and participate in neovascularization and 
promote tumor growth and invasiveness. Therefore, this population may represent an 
important therapeutic target in combating these tumors. Since survival is directly correlated 
with tumor grade, preventing tumor progression is imperative. While BMDC certainly are 
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not the only factor in progression of disease and neovascularization, blocking recruitment of 
these cells to tumors has been shown to reduce growth in animal models of other tumor 
types. Therefore, a greater understanding of this process may define a role for targeting this 
population of cells. In addition, BMDC exist in the periphery, and make for an easier 
therapeutic target than tumor cells within the blood brain barrier. Lastly, current 
management of tumor recurrence relies on serial imaging studies. Therefore, an effective 
and accurate biomarker capable of predicting progression of disease may allow for earlier 
detection and better treatment outcomes. This makes the case for monitoring BMDC in the 
periphery in addition to therapy aimed at this population of cells as potential adjuvant 
therapy in glioma. 
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1. Introduction 
Recent advances in molecular biology have led to new insights in the development, growth 
and infiltrative behaviors of primary brain tumors (Demuth and Berens, 2004; Huse and 
Holland, 2010; Johnson et al., 2009; Kanu et al., 2009). These tumors are derived from 
various brain cell lineages and have been historically classified on the basis of 
morphological and, more recently, immunohistochemical features with less emphasis on 
their underlying molecular pathogenesis (Huse and Holland, 2010). The detailed molecular 
characterization of brain tumors has laid the groundwork for augmentation of standard 
treatment with patient-specific designed targeted therapies (Johnson et al., 2009; Kanu et al., 
2009). Nevertheless, these tumors are extremely aggressive in their infiltration of brain tissue 
(Altman et al., 2007; Hensel et al., 1998; Yamahara et al., 2010), as well as in their metastasis 
outside of brain (Algra et al., 1992). Further, it now appears that the physiological conditions 
of the normal brain itself constitute a biological environment conducive to the uncontrolled 
dissemination of primary tumors (Bellail et al., 2004; Sontheimer, 2004). This review surveys 
the latest research on the invasive behavior of two major types of primary brain tumors: 
gliomas and medulloblastomas - the most common tumors diagnosed within adult and 
pediatric brain, respectively (Rickert and Paulus, 2001). The material has been divided into 
five sections: i) Characteristics of malignant brain tumors; ii) Mechanisms of tumor cell 
migration; iii) Models for the study of brain tumor invasion in vivo and ex vivo; iv) Models 
for the study of brain tumor invasion in vitro; and v) Future prospects of anti-invasive brain 
tumor therapy. 
2. Characteristics of malignant brain tumors 
Gliomas, commonly found in the anterior cerebral hemisphere, are a group of tumors 
derived from glial cells - the most abundant cells in the brain (Larjavaara et al., 2007; Lim et 
al., 2007; Louis et al., 2007). They are classified based on well-characterized histological 
features (Louis, 2006; Scheithauer, 2009; Trembath et al., 2008). The World Health 
Organization (WHO) defines gliomas by cell type, location and grade, and categorizes them 
into four classes (Lassman, 2004): i) Grade I tumors, or pilocytic astrocytomas; ii) Grade II 
tumors, also called low-grade astrocytomas; iii) Grade III tumors, or anaplastic 
astrocytomas; and iv) Grade IV tumors, also known as glioblastoma multiforme (GBM). 
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Grade I tumors typically do not invade surrounding brain and are often curable with 
surgery, while tumors of grades II to IV are diffuse and invade normal brain, with grade III 
and IV tumors being most aggressive. Grade III and IV tumors are called “high-grade” or 
“malignant” tumors although they almost never metastasize to other tissues of the body 
(Lassman, 2004).  
The etiological events causing glioma formation have not been clearly defined, but are 
thought to involve genetic alterations (Figure 1A). Such alterations disrupt cell cycle arrest 
pathways (Zhou et al., 2005; Zhou et al., 2010), and cause aberrant receptor tyrosine kinase 
activity in the brain cells (Dai et al., 2001). For instance, activation of receptors such as 
Hepatocyte Growth Factor Receptor (HGF) c-Met (Gentile et al., 2008), Platelet-Derived 
Growth Factor Receptor (PDGFR) (Cattaneo et al., 2006; Natarajan et al., 2006), and 
Epidermal Growth Factor Receptor (EGFR) (Chicoine and Silbergeld, 1997) is now well-
known to stimulate glioma motility. Additionally, marker specific glial progenitor 
populations, neural stem cells and cancer stem cells are being investigated for their roles as 
possible initiators of gliomagenesis (Briancon-Marjollet et al., 2010). 
 
 
Fig. 1. Origin of brain tumors: development gone wrong. (A) During normal brain 
development, neural stem cells give rise to three main adult cell types: neurons, 
oligodendrocytes and astrocytes. Genetic alterations occur within these differentiated cells 
that can lead to the rise of malignant tumors. Alternatively, immature stem cells may serve 
as cancer stem cells that confer both radio- and chemoresistance phenotypes to gliomas. (B) 
Medulloblastomas originate in the cerebellum, from granule neuron precursor cells 
(GNPCs), upon un-controlled activation of Sonic Hedgehog (Shh) signaling pathway. 
The current standard of care for gliomas is surgical removal of the tumor followed by post-
operative radio- and chemotherapy (Stupp and Weber, 2005). However, due to their 
diffusely invasive properties, gliomas are one of the most difficult tumors to isolate or treat 
(Burger et al., 1985). Furthermore, while cell migration is fundamental to normal brain 
development and homeostasis, unconstrained migration of pathological and diseased cells 
makes the complete resection of tumor lesions, often performed for other types of tumors, 
an ineffective clinical treatment in brain. Prior to the advance of high-throughput genetic 
screening techniques clinicians depended primarily on glioma recurrence for prognosis of 
patient survival. Later, the generation of models that combined gene expression and 
molecular markers made it possible to subcategorize gliomas, enabling the increase in 
 
Migration and Invasion of Brain Tumors 
 
227 
grade-specific predictability (Zhou et al., 2010). Recent findings suggest the possibility that 
the recurrent growth of glioma is derived from chemo- and radio-resistant cancer stem cell 
renewal and/or growth of diffusively invasive cells (Hadjipanayis and Van Meir, 2009). 
Evidence emerging over the past decade has suggested the existence of stem-like cells 
within brain tumors, which are currently examined as potential sources of tumor resistance 
and recurrence (Galli et al., 2004; Lenkiewicz et al., 2009; Singh and Dirks, 2007). The 
inability to remove high-grade gliomas in their entirety, or to prohibit their migration to 
other parts of the brain has led to low survival rates among brain cancer patients (Demuth 
and Berens, 2004).  Patients with GBM have a median survival of about 1 year, while 
patients with anaplastic gliomas can survive 2-3 years, and those with grade II gliomas often 
survive 10-15 years (Louis et al., 2007).  
Medulloblastomas (MBs) encompass a collection of clinically and molecularly diverse tumor 
subtypes, and are characterized by high tumor invasiveness to extraneural tissues and 
reoccurrence in the cerebellum after total resection (Dhall, 2009). Four different MB subtypes 
have been included in the current WHO classification (Louis et al., 2007): i) Classic MB; ii) 
Demoplastic/nodular MB; iii) MB with extensive nodularity;  and iv) Anaplastic or large cell 
MB. Two other variants, medullomyoblastoma and melanotic MB, are much more rare. MBs 
are overwhelmingly found in pediatric patients, but can rarely occur within adult brain, 
where the tumor characteristics become very atypical. Adult MB is arguably a biologically 
distinct challenge in that it exhibits a higher proportion of desmoplastic histological 
characteristics, shows more proclivity toward cerebellar hemispheric origin, possesses 
different proliferative and apoptotic indices, and demonstrates a notorious tendency for late 
relapse with respect to the pediatric variants (Chan et al., 2000; Sarkar et al., 2002). 
MBs are thought to arise within the cerebellum, with approximately 25% originating from 
granule neuron precursor cells (GNPCs) (Gibson et al., 2010) after aberrant activation of the 
Sonic Hedgehog (Shh) pathway (Figure 1B). A number of genetic alterations have been 
associated with MB (Biegel et al., 1997; Bigner et al., 1997; Herms et al., 2000; Yin et al., 2002). 
Studies of the receptors and intracellular signaling pathways that support proliferation and 
survival of GNPCs have shown a dysregulation of the Shh pathway, the canonical Wnt 
pathway, or the ERB-B pathway in both familiar and sporadic MBs (Gilbertson, 2004). A 
recent study showed that Wnt-subtype tumors infiltrate the dorsal brainstem, whereas Shh-
subtype tumors are located within the cerebellar hemispheres (Gibson et al., 2010). These 
results have profound implications for future research and treatment of this childhood 
cancer, because to date, few data link such genetic alterations to metastasis in MB.  
The treatment of patients with standard risk tumors, i.e. those who had tumors completely 
resected and with no evidence of dissemination to any other part of the body (Nishikawa, 
2010), has been partially successful with survival rates of up to 40% for gliomas over the last 
five years (Van Meir et al., 2010) and 78% for MBs (Gajjar et al., 2006). In contrast, the cure of 
metastatic disease has been limited until recently to single cases (Fruhwald and Plass, 2002). 
Even though promising, the current treatment options for high-risk brain tumors are 
associated with neural and neuroendocrine side effects, with a tremendous decline in 
quality of life among survivors (Edelstein et al., 2011; Palmer et al., 2001), as well as growth 
reoccurrence and aggressive brain infiltration (Farin et al., 2006).   
In the cases of both gliomas and MBs, the migration of cells from primary tumors to other 
locations, within brain or otherwise, has been one of the most clinically challenging and 
poorly understood processes that contributes to the poor life prognosis of patients. The 
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following sections will discuss the fundamental mechanisms of cellular migration, the 
common in vivo models used to examine tumor cell migration within brain, and current in 
vitro technologies used to characterize and better understand the migration of cells derived 
from gliomas and MBs. 
3. Mechanisms of tumor cell migration  
The migration of brain cancer cells is highly complex, involving interactions with 
extracellular matrix (ECM), and chemoattractants that either diffuse from blood vessels 
and/or are produced by neighboring cells (Condeelis and Segall, 2003; Sahai, 2005). As a 
consequence of such complexity, the molecular mechanisms of primary brain tumor 
migration and metastasis are poorly understood. Over the last several years, a group of 
critical growth factors has been the topic of research for their role as regulators of tumor 
biology and chemotaxis  (Hamel and Westphal, 2000). It is believed that over time secreted 
cytokines diffuse and generate concentration gradients that are sensed by glioma and MB-
derived cells, leading to the detachment and migration of these cells away from the primary 
tumor (Chicoine and Silbergeld, 1997; Piperi et al., 2005). Therefore, brain tumor invasion is 
believed to be induced by soluble cytokines that stimulate directional and/or random tumor 
cell motility (Brockmann et al., 2003). Alternatively, cancer cells may communicate with 
specific distant targets through secreted microvesicles that contain growth factors and 
receptors, functional mRNAs, and miRNAs (Cocucci et al., 2009; Skog et al., 2008; Valadi et 
al., 2007). Such microvesicles are shed by most cell types, including cancer cells, and have 
been found in sera from numerous cancer patients (Cocucci et al., 2009; Skog et al., 2008). 
While the effects of mitogens on the in vitro motility and invasion of glioma cells have been 
well documented using conventional assays, such as transwell chambers and spheroid 
models (discussed later in this chapter), the ability of soluble cytokines to drive various 
cellular functions (i.e. migration and/or proliferative growth) has been shown to depend 
upon several determinant factors. Some of these factors have been addressed in the 
literature, such as dosage-dependence (Gonzalez-Perez and Quinones-Hinojosa, 2010; Shih 
et al., 2004), contact inhibition (Weidner et al., 1990), as well as autocrine and paracrine 
signaling-driven tumor growth via extensive proliferation and aggressive recruitment of 
surrounding cells to the tumor (Betsholtz et al., 1984; Fomchenko and Holland, 2005; 
Hermansson et al., 1988; Rood et al., 2004). The diligent study of Central Nervous System 
tumor cell (CNSTC) invasion has identified four commonly overexpressed receptor tyrosine 
kinases as targets for anti-invasive therapies (EGFR, c-MET, PDGFR, and Vascular 
Epidermal Growth Factor Receptor (VEGFR)) (Abounader, 2009; Arora and Scholar, 2005; 
Huang et al., 2009; Zwick et al., 2001). 
Cancer cell locomotion is highly sensitive to stimuli from the ECM as well as from the 
surrounding media. Receptors on the plasma membrane can activate cellular signaling 
pathways that alter the mechanotransduction of a cell via reorganization of motility-related 
organelles and cellular compartments. As an example, tumor-derived cells are known to 
increase cell motility in response to protease inhibitors and adhesion inhibitors (Sahai, 2005). 
The modes of cancer cell migration vary according to whether the cells undergo single cell 
chain, or collective migration. Tumor-derived cells disseminate from the bulk tumor mass 
individually via mesenchymal or amoeboid movement. However, in many tumors both 
single cell and collective cell migration may be present depending on the molecular cues 
dictating migration (Friedl and Wolf, 2003). 
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During the mesenchymal-type migration often observed in gliomas, cells exhibit a highly 
polarized and fibroblastic morphology. Cells undergo the classical, overlapping processes 
generally exhibited during mammalian cell migration: cell polarization, protrusion of 
leading edge, traction at the trailing edge, and detachment (Lauffenburger and Horwitz, 
1996). First, cells become highly fibroblast-like, with bipolar opposites. Second, a growing 
number of actin filaments begin to push the cell membrane outwards on the leading edge 
via the formation of lamellipodia or filopodia. Actin polymerization then initiates signal 
transduction pathways along the leading edge. Next, cell integrins come into contact with 
ECM ligands and cluster to recruit intracellular signaling proteins that induce 
phosphorylation signaling, or so-called “outside in” signaling (Hynes, 2002; Miyamoto et al., 
1995) via focal adhesion kinases. Afterwards, surface proteases act to cleave ECM molecules 
via production of soluble matrix metalloproteases (MMPs) in order to degrade surrounding 
ECM. Finally, cell contraction occurs via myosin that leads to focal contact disassembly at 
the trailing edge and actin cleavage and filament turnover (Wear et al., 2000).  
Contrarily, during amoeboid movement, cells utilize a “fast gliding” mechanism driven by 
weak interactions with the substrate. As such, cells like neutrophils and lymphocytes exhibit 
a shape-driven migration with appreciable lack of focal adhesions that allows them to 
circumnavigate rather than degrade surrounding ECM during migration (Friedl et al., 2001). 
The result is an increased cell motility, as well as cell ability to undergo early detachment 
and metastatic spread from primary tumors. Cancer cells may undergo conversion from 
mesenchymal to amoeboid type migration in order to alter integrin distribution and actin 
cytoskeleton organization for increased dissemination (Wolf et al., 2003). 
Collective migration is a well-studied phenomenon that is characteristic of embryological 
development, such as during the migration of cell clusters or sheets in the ectoderm following 
closure of the neural tube (Davidson and Keller, 1999). In vitro studies (Friedl et al., 1995; 
Nabeshima et al., 1995) showed that cells can migrate as a functional unit, and that in contrast 
to single motile cells, cell-cell adhesion can lead to a particular form of cortical actin filament 
present along cell junctions. This enables formation of a larger, multicellular contractile body. 
Here, a select group of highly motile cells are designated as so-called “path-generating” cells 
that create migratory traction via pseudopod activity (Friedl et al., 1995; Hegerfeldt et al., 2002; 
Nabeshima et al., 1995). It is then believed that cells located in the inner and trailing regions 
are passively dragged behind during dissemination. In tumors, collective migration has been 
observed as protruding sheets that maintain contact with the primary site, or as cell clusters 
that detach from their origin and extend along paths of least resistance (Byers et al., 1995; 
Hashizume et al., 1996; Madhavan et al., 2001). Collective migration offers the advantage of 
protection from immunological response. Further, heterogeneous sets of cells that move as one 
functional unit can work together to promote the invasion of less motile, but potentially 
apoptosis-resistant, sub-populations that increase tumor survival. To complicate matters, cells 
may transition between collective and individual cell migration with dedifferentiated cells to 
increase dissemination and metastatic spread (Friedl and Wolf, 2003).  
4. Models for the study of brain tumor invasion in vivo and ex vivo 
Glioma and MB models have been largely developed by studying altered oncogene 
expression through retroviral transfection of murine neural tissue of genetically engineered 
mouse models (GEMMs) (Fisher et al., 1999; Hatton et al., 2008; Heyer et al., 2010; Huse and 
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observed as protruding sheets that maintain contact with the primary site, or as cell clusters 
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Hashizume et al., 1996; Madhavan et al., 2001). Collective migration offers the advantage of 
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functional unit can work together to promote the invasion of less motile, but potentially 
apoptosis-resistant, sub-populations that increase tumor survival. To complicate matters, cells 
may transition between collective and individual cell migration with dedifferentiated cells to 
increase dissemination and metastatic spread (Friedl and Wolf, 2003).  
4. Models for the study of brain tumor invasion in vivo and ex vivo 
Glioma and MB models have been largely developed by studying altered oncogene 
expression through retroviral transfection of murine neural tissue of genetically engineered 
mouse models (GEMMs) (Fisher et al., 1999; Hatton et al., 2008; Heyer et al., 2010; Huse and 
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Holland, 2010; Pazzaglia et al., 2002; Pazzaglia et al., 2006; Romer and Curran, 2004). Via this 
powerful methodology, diverse tumor types with distinct histological features have been 
generated dependent upon the specific genetic background of the cell of tumor origin and 
the disease location of interest (Furnari et al., 2007). In particular, the histological features of 
GEMM and implanted xenograph derived tumors have been shown to be similar to human 
brain tumors presented in identical CNS locations, and have shed light on the diverse nature 
of human gliomas found clinically (Candolfi et al., 2007).   
Historically, it has been suggested that glioma cell infiltration throughout the brain 
primarily utilizes mechanisms of migration innately patterned by neural progenitors during 
normal brain development (Cayre et al., 2009; Kakita and Goldman, 1999; Scherer, 1940). 
Confirmation of this similarity has been accomplished in vivo via implanted xenographs that 
result in spontaneous intracranial GBMs in six different animal model variations that show 
reproducible invasion of tumor cells into non-neoplastic brain regions (Figure 2) (Candolfi et 
al., 2007). More recently, several labs began utilizing GEMMs to specifically examine glial 
progenitor recruitment in vivo (Assanah et al., 2006; Masui et al., 2010). For instance, 
Assanah and colleagues have demonstrated via histological analysis of cortical sections from 
GEMMs that overexpression of tumor inducing proteins like PDGF can induce malignant 
glioma cells to invade across the corpus callosum into the contralateral hemisphere and 
overlying cortex (Assanah et al., 2006; Assanah et al., 2009). 
The diffusive invasion and increased recurrence of gliomas post-operatively have been 
attributed to the same therapies used to treat the disease. Narayana and colleagues reported 
clinical results of 61 high-grade GBM patients treated with an anti-angiogenesis drug, 
bevacizumab. Their results showed that 82% of the patients treated with bevacizumab suffer 
from tumor regrowth and 70% died from the disease within 19 months (Narayana et al., 
2009). Pàez-Ribes and colleagues reported similar results showing that although the use of 
angiogenesis inhibitors, such as Sunitinib and SU10944, extend that survival time of treated 
mice to an additional 7 weeks versus non-treated mice, the kinase inhibitors tend to also 
evoke an increase in glioma cell invasion as well as to promote tumor progression (Pàez-
Ribes et al., 2009). A closer examination using xenographs of human tumor spheroid 
implanted into rat brains, and further treated with the bevacizumab, led to a reduction in 
contrast enhancement in magnetic resonance imaging (MRI) analysis while enhancing 
glioma cell diffusion by 68% versus non-treated rats (Figure 3) (Keunen et al., 2011). 
Characterization of MB migration in vivo has yet to be analyzed at large, as most of the 
reports to-date focused on tumor growth and not its dissemination. Nevertheless, a select 
number of in vivo studies examined tumor cell migration and invasion. Hatton and 
colleagues illustrated in a GEMM for MB that 94% of the mice developed MB by 2 months of 
age, and that these tumors frequently exhibited leptomeningeal spread, a common feature of 
the human disease (Hatton et al., 2008). MacDonald and colleagues implanted human MB 
cells in the brain of nude mice, and thereafter followed them in vivo at single-cell level via 
fluorescence microscopy (MacDonald et al., 1998). These MB cells were shown to invade the 
brain and to form distant micro-metastases. In another study, MB cells were engineered to 
overexpress HGF and were implanted subcutaneously and intra-cranially (Li et al., 2005). 
The study reported activated c-Met that strongly increased MB xenograft growth and 
invasive characteristics with finger-like protrusions, metastatic growth, and leptomeningeal 
spread. Such findings illustrate that the HGF/c-Met pathway is one of the mediators of MB 
malignancy.  
 











Fig. 2. Neoplastic cellular infiltration into surrounding non-neoplastic brain tissue in 
syngeneic rat (CNS-1) and mouse (GL26) GBM models and human glioma xenografts in 
nude mice (U251 and U87). Paraffin sections (5 μm) from GBM were stained with 
hematoxylin and eosin for evaluating neoplastic invasion. The numbers in low-
magnification microphotographs depict areas magnified in the microphotographs on the 
right. Arrows indicate malignant cells, clusters of GBM cells, and tumoral blood vessels 
infiltrating surrounding brain parenchyma. The indistinct tumor borders and the malignant 
cells clearly entering the non-neoplastic brain tissue suggest an invasive phenotype. 
(Courtesy of Candolfi et al., 2007) 
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Fig. 3. Changes in blood vessel morphology and tumor cell invasion after bev treatment. 
Immunostaining for von Willebrand factor (vWF) (A and B) and quantification thereof (C), 
indicating a significant reduction in the density of medium and large blood vessels and in 
total vessel number after bev treatment. (Scale bar: 200 μm.) Nestin-stained composite 
images (D and E) reveal a more homogeneous appearance of the treated compared with 
untreated tumors, also reflected in corresponding T2-weighted MRI images (F). Large 
vessels (“V”) appear as dark tortuous lines in nestin and T2- weighted images and necrotic 
areas (“N”) as brighter spots. Quantification of the nestin-positive cells outside the tumor 
core (G and H) shows a 68% increase in cell invasion after treatment (I). mi.v: microvessels; 
in.v: intermediate-sized vessels; ma.v: macrovessels; Ctrl: controls; Tr: treated. (Scale bars: ± 
SE.) ***P < 0.001. (Courtesy of Keunen et al., 2011) 
The ability to visualize brain tumor invasion in direct response to specific genetic 
aberrations and alterations made to the immediate environment has been critical in 
understanding the characteristics of this process. An advance made in this direction was 
accomplished via the detection of specific biomarkers involved in the progression or 
migration of CNSTCs, such as Receptor Tyrosine Kinases (RTKs), using conjugated 
antibodies that enabled in vivo monitoring via MRI (Towner et al., 2008). Alternatively, to in 
vivo imaging procedures, ex vivo brain tumor invasion assays that enable the study of tissue 
outside of the living system have had a tremendous impact in the field. Brain slices from 
mice and rats have been used to quantify the invasion of human gliomas (Nakada et al., 
2004), and have demonstrated suppressed invasion on 2D surfaces, suggesting that the brain 
environment alone is capable of regulating protein function and, consequentially, the 
pattern and directionality of glioma migration (Beadle et al., 2008). Additionally, not only 
have ex vivo cell cultures been used to study the invasive properties of CNS tumors, but also 
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to characterize the expression molecular markers (Riffkin et al., 2001), and to evaluate the 
therapeutic potential of co-cultured T-cells for anti-tumor activity (Ahmed et al., 2007).    
By reducing the incidence of recurrent growth, clinicians envision the possibility of 
detecting and directly tracking migratory tumor cells in vivo, and therefore enabling 
operative procedures limited to a single total resection surgery. In order to accomplish this 
goal, there is a stringent need for development of enhanced imaging tools to allow 
visualization of migrating tumor cells. Meanwhile, the most successful quantitative 
assessment of CNSTCs migration has been accomplished outside of the brain itself, in 
engineered systems redesigned to mimic specific in vivo conditions. We will discuss these in 
vitro assays further, which have been utilized to evaluate a variety of cellular functions, from 
growth patterns and rates, to invasive motility of cells derived from highly malignant brain 
tumors. 
5. Models for the study of brain tumor invasion in vitro  
Tumor cells of the brain have been characterized as having a highly infiltrative phenotype 
for spreading into the healthy surrounding parenchyma. This malignant property is 
arguably the principle reason for tumor recurrence and high mortality rates (Lim et al., 
2007). The interaction of integrins, membrane anchored heterodimeric proteins, with various 
ECM proteins has been explored extensively, as it is one of the key events that occurs during 
the invasion of tumor cells within their local microenvironments (Teodorczyk and Martin-
Villalba, 2010). Another key process of tumor invasion is the cellular secretion/production 
of proteases that degrade ECM proteins in order to create pores through which the cells may 
migrate; such proteases include serine proteases, various MMPs, and cathepsins (Rao, 2003). 
In addition to stimulating tumor invasion via degradation of ECM protein components, it is 
assumed that MMPs are capable of enhancing tumor growth by indirectly triggering the 
release of growth factors trapped within the basement membrane itself (Mott and Werb, 
2004). Lastly, another key aspect of tumor dissemination is played by the activation of RTK 
signaling pathways. During the destruction of the basement membrane by MMPs, soluble 
growth factors are sequestered from the ECM and bind to their cognate cellular receptors to 
trigger a cascade of events that enhance cellular migration (Zucker et al., 2000).  
In vitro invasion assays are important tools for investigating the tumor-matrix interactions 
and the effects of extracellular macromolecules on these interactions. While not entirely 
identical to in vivo behavior, the study of tumor cell migration in vitro is advantageous due 
to the tightly-controlled experimental conditions, higher experimental throughput, and 
lower costs. The following section discusses the most commonly used in vitro assays, in the 
order of increased complexity.  
5.1 Culture dish assays 
Culture dish assays have the advantage of design simplicity and execution, while providing 
insightful information pertaining to cell-to-cell and cell-to-environment interactions. Coated 
culture dishes have been widely used to examine the roles played by specific ECM proteins, 
integrins, MMPs, and RTKs in stimulating the migration of brain tumor-derived cells, as 
detailed here.  
Integrins are membrane heterodimeric proteins that mediate cell-environment attachment 
(Hynes, 1987; Tucker, 2006). In addition to anchoring cells to their environment, integrins 
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have been shown to serve as signal mediators for ECM proteins that were found to stimulate 
tumor migration in vitro (Ohnishi et al., 1997; Tysnes et al., 1996). The most abundant ECM 
proteins found to interact with integrins in the brain are fibronectin, laminin, fibrinogen, 
tenascin-C, thrombodpondin, neuron-glia cell adhesion molecules (Ng-CAMs), and 
collagens IV and V (Rutka et al., 1988). Giese and colleagues evaluated astrocytoma 
migration as a function of integrin adhesiveness on various ECM proteins (collagen IV, 
fibronectin, laminin and vitronectin) (Giese et al., 1994). Based on the examination of eight 
different astrocytoma cell lines, the group concluded that the migration of glioma cells was 
subject to alteration depending on tumor expressed integrins and the availability of 
complementary matrix proteins. Furthermore, even though laminin frequently enabled 
tumor cells to adhere and migrate with increased adhesion, overall it was stated that there 
was no specific ECM protein that would always result in increased astrocytoma binding 
(Giese et al., 1994).  
Friedlander and colleagues examined the migration trends of twenty-four excised human 
astrocytomas, ten GBM cell lines, and three MB cell lines on nine different ECM protein 
coated culture dishes (Friedlander et al., 1996). The comparative migration of astrocytomas 
(grades I, II and III), GBMs and MBs demonstrated that most tumor cells, regardless of their 
grade, were capable of migrating on fibronectin and laminin at rates exceeding 30 μm over a 
16 hour period. A closer comparison between low-grade and high-grade tumor migration 
on all tested substrates revealed that, on average, high-grade tumors migrated 
approximately 14 μm more than low-grade tumor cells under similar conditions. 
Specifically, type IV collagen substrates induced a 4-fold increase in distances traveled by 
high-grade tumor cells over low-grade cells. Collagen IV coated substrates also stimulated 
approximately 100 μm migration over 16 hours of thirteen excised GBMs and eight well 
studied GBMs cell lines, with cell lines being more motile than the excised tumors 
(Friedlander et al., 1996). Finally, monoclonal antibodies specific for the v and 1 integrins 
were used to reduce the migration of four GBMs cell lines (U-373 MG, U-118 MG, U-251 MG 
and U-87 MG) on several migration enhancing ECM substrates, including collagen IV 
(Friedlander et al., 1996). These results illustrate that brain tumor-derived cells can migrate 
remarkably large distances within the brain, often to varied regions of the brain. However, 
tumor cell populations are very diverse, and such studies have not identified the lineage of 
motile cells, or whether certain sub-populations of cells could migrate farther than others 
within brain. 
MB samples revealed type I collagen present in the leptomeninges, and in the ECM 
surrounding blood vessels and tumor cells (Liang et al., 2008). Expression of both type I 
collagen and 1 integrin, a subunit of a known type I collagen receptor, localized to the same 
area of MB. The same study showed that the adherence of MB cells to type I collagen matrix 
in vitro depends on the presence of 1 integrin (Liang et al., 2008). 
A study by Corcoran and Del Maestro revealed that MB cell lines do not defer cell 
proliferation for migration across an uncoated surface or invasion of a type I collagen 
matrix, contrary to the “Go or Grow” hypothesis (Corcoran and Del Maestro, 2003). The “Go 
or Grow” hypothesis proposes that cell division and cell migration are temporally exclusive 
events, and that tumor cells defer cell division to migrate (Giese et al., 1996). Migrating and 
invading MBs continued to proliferate and migrate/invade, irrespective of the number of 
divisions that took place (Corcoran and Del Maestro, 2003). These findings emphasize the 
need to evaluate the effect of future therapies on both biological events and, if possible, to 
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identify intracellular signaling proteins that negatively regulate MB migration/invasion and 
proliferation. 
Matrix-degrading proteases are involved in the hydrolytic breakdown of ECM proteins and 
have been shown to regulate tumor cell progression and invasion (Levicar et al., 2003; Rao, 
2003; Rooprai and McCormick, 1997). Additionally, proteases have been well-studied and 
shown to display differential expression and activation patterns, correlated to their 
invasion-associated effects, i.e. angiogenesis (Forsyth et al., 1999; Thorns et al., 2003). These 
proteases are either located in the membrane of the cell or secreted into its surroundings, 
respectively denoted as MT-MMP and MMP. Diffusely invasive glioma cells express MMPs 
that enable them to catabolize ECM proteins that have been shown to prohibit the migration 
of other cells that lack these MMPs. For instance, specific membrane proteins expressed by 
CNS myelin have been shown to have anti-spreading functionality on neurite outgrowth, 
astrocytes and fibroblasts (Schwab and Caroni, 1988; Spillmann et al., 1998).  
The migration of glioma-, MB- and meningioma- cell lines on CNS myelin was found to be 
tumor grade-dependent and to involve active unspecified MMPs (Amberger et al., 1998). 
Culture dishes were coated with 15 g/dish rat spinal cord myelin, a concentration shown 
to reduce by 80% the fibroblast migration, followed by the seeding with various cell lines 
and the recording of cell ability to adhere and spread (Amberger et al., 1998). The results 
conclude that high grade GBMs, like U-251 MG, were able to strongly attach and spread, 
while low grade gliomas and MBs exhibited poor attachment and inhibited spreading 
(Amberger et al., 1998). Additionally, spreading of GBM and anaplastic astrocytomas cells 
on CNS myelin was strongly blocked when cells were treated with the MMP blocker O-
phenanthroline (Felber et al., 1962), and temporarily inhibited with carbobenzoxy-Phe-Ala-
Phe-Tyr-amide (Amberger et al., 1997) confirming the role played by MMPs in ECM 
modification as a precursory for migration.   
Belien and colleagues studied the role of MT1-MMP in enhanced spreading and migration 
of gliomas (Belien et al., 1999). As a substrate, they utilized myelin-coated culture dishes, 
since it was previously shown that invasion of gliomas predominantly occurs along the 
white matter of the CNS (Giese et al., 1996; Pedersen et al., 1995), which is heavily composed 
of myelin (Baumann and Pham-Dinh, 2001; McLaurin and Yong, 1995), to seed both gliomas 
and MT1-MMP-transfected fibroblasts. In this case, MT1-MMP was shown to be responsible 
for altering the cellular environment to enable migration of both gliomas and the transfected 
fibroblasts (Belien et al., 1999).  
When the invasiveness of five MB cell lines within a 3D in vitro collagen I or IV-based model 
was studied, the data showed that within hours of implantation, individual cells readily 
detached from the surface of the cell aggregates and invaded the collagen matrix, to 
distances of up to 1,200 µm and at rates of up to 300 µm per day (Ranger et al., 2010).  
Furthermore, MB invasiveness within this 3D model appears to depend upon a combination 
of metalloproteinase (MMP-1 and -2, TIMP-1 and -2) and cysteine protease activity (Ranger 
et al., 2010). 
The RTKs, like integrins, function as signal mediators of extracellular proteins yet in a 
different way. Integrins, as mentioned above, interact primarily with static, structural ECM 
proteins that are the composite materials of the cellular environment (Tucker, 2006). 
Meanwhile, RTKs interact with soluble macromolecules present in the environment, e.g. 
growth factors, that trigger a cascade of events in the cells, spanning from the extracellular 
surface of the plasma membrane to the nucleus, to elicit various cellular responses (Konopka 
and Bonni, 2003; Mueller et al., 2003; Teodorczyk and Martin-Villalba, 2010). Additionally, 
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identify intracellular signaling proteins that negatively regulate MB migration/invasion and 
proliferation. 
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proteases are either located in the membrane of the cell or secreted into its surroundings, 
respectively denoted as MT-MMP and MMP. Diffusely invasive glioma cells express MMPs 
that enable them to catabolize ECM proteins that have been shown to prohibit the migration 
of other cells that lack these MMPs. For instance, specific membrane proteins expressed by 
CNS myelin have been shown to have anti-spreading functionality on neurite outgrowth, 
astrocytes and fibroblasts (Schwab and Caroni, 1988; Spillmann et al., 1998).  
The migration of glioma-, MB- and meningioma- cell lines on CNS myelin was found to be 
tumor grade-dependent and to involve active unspecified MMPs (Amberger et al., 1998). 
Culture dishes were coated with 15 g/dish rat spinal cord myelin, a concentration shown 
to reduce by 80% the fibroblast migration, followed by the seeding with various cell lines 
and the recording of cell ability to adhere and spread (Amberger et al., 1998). The results 
conclude that high grade GBMs, like U-251 MG, were able to strongly attach and spread, 
while low grade gliomas and MBs exhibited poor attachment and inhibited spreading 
(Amberger et al., 1998). Additionally, spreading of GBM and anaplastic astrocytomas cells 
on CNS myelin was strongly blocked when cells were treated with the MMP blocker O-
phenanthroline (Felber et al., 1962), and temporarily inhibited with carbobenzoxy-Phe-Ala-
Phe-Tyr-amide (Amberger et al., 1997) confirming the role played by MMPs in ECM 
modification as a precursory for migration.   
Belien and colleagues studied the role of MT1-MMP in enhanced spreading and migration 
of gliomas (Belien et al., 1999). As a substrate, they utilized myelin-coated culture dishes, 
since it was previously shown that invasion of gliomas predominantly occurs along the 
white matter of the CNS (Giese et al., 1996; Pedersen et al., 1995), which is heavily composed 
of myelin (Baumann and Pham-Dinh, 2001; McLaurin and Yong, 1995), to seed both gliomas 
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The RTKs, like integrins, function as signal mediators of extracellular proteins yet in a 
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proteins that are the composite materials of the cellular environment (Tucker, 2006). 
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surface of the plasma membrane to the nucleus, to elicit various cellular responses (Konopka 
and Bonni, 2003; Mueller et al., 2003; Teodorczyk and Martin-Villalba, 2010). Additionally, 
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genetically modified and overexpressed RTKs are capable of eliciting cellular signals in the 
absence of ligand binding, thus bypassing the need for an extracellular trigger (Akbasak and 
Sunar-Akbasak, 1992; Dong et al., 2011; Strommer et al., 1990; Torp et al., 2007). Ding and 
colleagues employed U-87 MG cells grown on coated cultured dishes to demonstrate a 
strong adhesion to vitronectin, as opposed to collagen or laminin, which was mediated 
through the v3 and v5 integrins (Ding et al., 2003). Additionally, the group was able a to 
link the specific cooperative interaction between the RTK PDGFR and the v3 integrin to 
induce migration of U-87 MG cells into the wounded area in a scratch-wound assay after 
stimulation of the culture with PDGF (Ding et al., 2003). Therefore, these results suggest the 
direct correlation between the ability of RTKs to transmit extracellular signals into the cell 
and to convert these signals into direct and measurable cellular response.  
As an improvement upon the simple use of cell culture dishes for study of tumor cell 
migration, micropipette turning assays have been used to create gradients within culture 
dishes that enable changes in cell migration with micropipette position. Gradients, defined 
as fields where biochemical concentrations are varied along a specific distance, are 
generated via simple diffusion of biological molecules from the micropipette into the culture 
medium. Gradient formation and stability are functions of the molecular properties of the 
stimulant being used (i.e. diffusivity constant and molecular weight), as well as pipette 
mechanics (i.e. dimensions and flow rates) (Lohof et al., 1992), and for these reasons make 
gradient measurement difficult. Wyckoff and colleagues used the micropipette method to 
collect subpopulations of motile mammary carcinoma and macrophage cells into 
microneedles filled with Matrigel™ and a range of EGF concentrations from confluent 
culture dishes (Wyckoff et al., 2000). The Matrigel™ matrix is a solubilized basement 
membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma (Ohashi et 
al., 2006; Reed et al., 2009), commonly used in cell-matrix interaction studies. The contents of 
the microneedles were then emptied into new culture dishes and allowed to grow for at 
least 6 days before quantifying cell populations. A bell-shaped curve of normalized cell 
numbers was reported and had the maximal number of collected cells for 25 nM EGF, 8-fold 
greater than controls (Wyckoff et al., 2000). Such results illustrate that growth factor 
concentration gradients, or differences in concentrations along given distances, stimulate 
brain tumor cell migration. 
5.2 Spheroids 
A key question regarding cancer cell migration and invasion is based on determining the 
reason why tumor cells detach from the bulk tumor mass. Some studies have suggested that 
lack of contact-inhibition may be responsible for cell migration away from the bulk 
(Pedersen et al., 1995). While normal cells go into a quiescent state that allows apoptosis 
during nutrient depleted states, cancer cells do not rely on contact-dependent growth and 
therefore can detach and venture out to diffusely invade the parenchyma. The Spheroid 
Model utilizes the natural tendency of cancer cells to form colonies and to grow into 
localized spheres (Santini and Rainaldi, 1999; Zhang et al., 2005). This model mimics the 3D 
characteristics of cell migration, while culture dish experiments described in the previous 
subsection provide important data on 2D cell migration. As a result, the spheroid model has 
been used to study the directional migration of tumor cells from the bulk spheroid mass in 
response to specific motogens and chemotherapeutic agents, as well as to measure the 
penetration of various molecules into the tumor (Carlsson and Nederman, 1983; Nederman 
et al., 1983).  
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Spheroids grown from several different GBM cell lines were placed on uncoated 24-well 
dishes and treated with EGF, which triggered a strong stimulation of cellular invasion and 
increased growth (Lund-Johansen et al., 1990). Similarly, spheroids grown from several 
human glioma cell lines exhibited enhanced growth and directional migration when 
cultured in 10 ng/ml EGF or 10 ng/ml bFGF concentrations, compared to control and other 
growth factors, such as PDGFBB (Engebraaten et al., 1993). When MB cultures were induced 
to generate spheroids, gene expression of CD133 (a hallmark of the brain cancer stem cells 
and radioresistant tumors), MT1-MMP, and MMP-9 were induced and correlated with 
increased invasiveness of the spheroid cells (Annabi et al., 2008). Additionally, Corcoran 
and Del Maestro revealed that MB cells from an established cell line, UW228-13, could 
exhibit elevated levels of invasion into a 3D matrix of type 1 collagen compared to biopsied 
DAOY cells (Figure 4) (Corcoran and Del Maestro, 2003). 
 
 
Fig. 4. First and last images extracted from time-lapse videos of DAOY (A and B) and 
UW228-3 (C and D) spheroids invading Type I collagen matrices. Spheroids were recorded 
48 hours after implantation. The numbers identify cells that divided zero, one, or two times 
in 40 hours; parent cells are labeled in A and C and daughter cells in B and D. The number 
of hours elapsed from the start time of the videos (t) are indicated at the top right corner of 
images. Scale bars, 250 μm. (Courtesy of Corcoran and DelMaestro, 2003) 
Wild-Bode and colleagues grew glioma spheroids on agar base-coated culture flasks until 
they were ~200 m in diameter, followed by their transfer to 96-well plates. In order to 
examine the cause of glioma relapse in close proximity to the excised lesion, they measured 
the radial distance of migration as function of irradiation at 3 Gy. Irradiation led to 
increased migration of all cell lines, compared to non-irradiated cells, a phenomenon which 
was linked to increased expression and activation of MMP-2, MMP-9 and MT1-MMP (Wild-
Bode et al., 2001).  
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Just as the spheroid model employs a 3D environment in order to better mimic in vivo 
conditions, other in vitro technologies were developed to imitate the biochemical 
environment of the brain. In particular, transwell assays were developed in order to expose 
tumor-derived cells to different concentration gradients of cytokines present within brain. 
5.3 Transwell migration assays 
The transwell migration assay is a commonly-used test to study the migratory response of 
cells to inducers or inhibitors. This assay is also known as the Boyden or modified Boyden 
chamber assay, and was originally used to evaluate leukocyte chemotaxis (Boyden, 1962). In 
this assay, a chamber that is separated into two compartments by a polyethylene 
terephthalate filter (Figure 5A) and the cells placed into the upper compartment are allowed 
to settle, while the solution being tested for chemotactic activity is placed in the lower 
compartment. The membrane contains randomly distributed pores through which the cells 
migrate (Figure 5B), in response to the chemoattractant from the bottom compartment. 
Invasive cells migrated to the underside of the filter can be stained and quantified (Figure 
5C). 
Different ECM components can be used to coat the filter in order to mimic the basement 
membrane that cells must penetrate while invading in vivo, while exposing the cells to 
various chemicals for different time lengths. The main advantage of this assay is its 
detection sensitivity. Migration through the permeable membrane can be caused by very 
low levels of chemoattractants (Kreutzer et al., 1978). Prolonged studies are difficult, due to 
the fact that the chemoattractant concentration will quickly equalize between the 
compartment below the membrane and the compartment above the membrane. Another 
disadvantage is the relative difficulty in setting up the transwells. Despite these 
disadvantages, transwell assays are commonly the test of choice for migration and invasion 
studies in vitro. 
Over the last 50-years, several modifications have been implemented to this technology by 
various research groups in order to circumvent difficulties encountered with its use. For 
instance, upon crossing the membrane and reaching the lower surface of the chamber, cells 
may detach from the filter, thus resulting in an underestimate of transmigrated cells (Li and 
Zhu, 1999).  Albini and colleagues were among the first researchers to use filters coated with 
ECM. They used radiolabeled proteins to demonstrate an 8-10 hour gradient stabilization 
period within the Boyden chamber, and showed that cell invasion time was very much 
dependent on the volume of the coated matrix barrier (Albini et al., 1987). Li and Zhu 
pioneered the use of different cell populations to attract other cells, by growing a monolayer 
of bovine aortic endothelial cells on filters, and investigating the transendothelial migration 
of six cell lines of different human tumors (Li and Zhu, 1999). 
Chemotactic migration of GMB cells in response to several growth factors, predominately 
PDGF, EGF, and HGF, has been extensively studied (Hoelzinger et al., 2007). These studies 
have demonstrated dosage-dependent motogenic responses to various concentrations and 
combinations of these cytokines (Brockmann et al., 2003). For example, Moriyama and 
colleagues demonstrated, through a checkerboard analysis of various HGF concentrations, 
that a dose-dependent response to HGF induces both chemotaxis and chemokinesis of U-251 
MG cells (Moriyama et al., 1996). In this study the concept of an “optimal concentration” 
was introduced, and the authors reported a decline in the chemotactic activity of U-251 MG 
cells at concentrations exceeding the reported optimal concentration of 50 ng/ml (Moriyama 
et al., 1996). Similarly, Koochekpour and colleagues used transwell assays to show dose-
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dependent migration and invasion of five different human glioma cell lines toward various 
concentrations of HGF, in addition to reducing basal migration of these cells using an anti-
HGF neutralizing antibody (Koochekpour et al., 1997). Brockmann and colleagues reported 
increases in U-87 MG migration, as high as 33-fold greater than controls, in the presence of 
100 pM HGF concentrations. In the same study, 1 nM TGF and 50 nM FGF1 stimulated U-
87 MG migration 17- and 4-fold, respectively (Brockmann et al., 2003). Transwell assays 
were used to demonstrate the chemotaxis of metastatic breast adenocarcinomas toward 
bone and brain extracts, rather than extracts from liver or lung (Hujanen and Terranova, 
1985). Interestingly, it was found that C6-GFP rat glioma cells could extend their leading 
cytoplasmic processes through membrane pores, as a function of actin dynamics alone, but 
they required myosin IIA/B to generate additional cytoplasmic contractile forces to push the 
nucleus through pores having a smaller diameter (Beadle et al., 2008). 
 
 
Fig. 5. Boyden chamber assay. (A) Transwell migration assays are composed of a well insert 
with a porous filter bottom that temporarily separates the cell solution from the test 
solution. (B) The filter has randomly distributed microscale diameter pores as shown by 
arrows. (C) Invasive Daoy cells on the underside of the filter stained and imaged for 
migration analysis. Scale bar = 50 μm.  
A study that looked at the inhibitory effect of dietary-derived flavonols on the HGF receptor 
c-Met activity suggests that such an effect may contribute to the chemopreventive properties 
of these molecules (Labbe et al., 2009). The authors showed that the flavonols quercetin, 
kaempferol, and myricetin inhibited HGF/c-Met signaling in MB, preventing the formation 
of actin-rich membrane ruffles and resulting in the inhibition of c-Met-induced cell 
migration in Boyden chambers (Labbe et al., 2009). Furthermore, quercetin and kaempferol 
also strongly diminished HGF-mediated Akt activation (Labbe et al., 2009). 
While investigating the effect of ionizing irradiation on the invasiveness of glioma cells via 
transwell assays, Park and colleagues reported increased Matrigel™ invasion of PTEN null 
gliomas, U-251 MG and U-373 MG, as a result of elevated levels irradiation treatment, which 
the group suggested correlates with increases in MMP-2 secretion (Park et al., 2006). 
Similarly, Wild-Bode and colleagues found that the sublethal irradiation doses of 1, 3, and 6 
Gy increased the chemotactic migration and invasion of three different human glioma cell 
lines with increasing dosage (Wild-Bode et al., 2001). Similarly to glioma, radiation 
enhanced invasion and migration of 7 Gy irradiated MB compared to non-irradiated MB 
cells, as assessed via Boyden chamber assays (Nalla et al., 2010). Increased expression of 
urokinase-type plasminogen activator (uPA) and its receptor (uPAR), focal adhesion kinase 
(FAK), N-cadherin and integrin subunits (e.g., α3, α5 and β1) was detected in irradiated cells. 
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Conversely, down-regulation of uPAR reduced the radiation-induced adhesion, migration 
and invasion of the irradiated cells, primarily by inhibiting phosphorylation of FAK, Paxillin 
and Rac-1/Cdc42 (Nalla et al., 2010). 
Transwell assays were also used to study the activated RTK-dependent MB migration. 
These studies have shown that MB migration is dependent on estrogen-receptor (Belcher et 
al., 2009), c-Met (Guessous et al., 2010), and PDGFR-β activation (Yuan et al., 2010). Via a 
combination of wound-healing assays and modified Boyden chamber assays, two groups 
showed that PDGF-induced overexpression of Rac1, a Rho GTPase, is involved in MB cell 
migration and invasion, whereas knockdown of Rac1 expression dramatically inhibited 
migration and invasion of MBs (Chen et al., 2011; Yuan et al., 2010). These findings may 
promote the evaluation of Rac1 as a novel therapeutic agent impairing medulloblastoma 
PDGF-induced migration/invasion. Additional work has demonstrated that PDGFR-β 
activity may guide the migration of MB by transactivating EGFR (Abouantoun and 
MacDonald, 2009). These results are of particular interest, since EGFR is known to be 
expressed in GNPCs of the human cerebellum, participating in its normal development and 
function (Seroogy et al., 1995). Recently, the multifunctional signaling protein neurotrophin 
receptor p75NTR was shown to be a central regulator for GBM (Johnston et al., 2007) and MB 
spinal invasion while γ-secretase inhibitor, which blocks p75NTR proteolytic processing, 
significantly abrogates p75NTR induced MB migration and invasion in vitro and in vivo 
(Wang et al., 2010). 
The transwell assays, even though used commonly for cell migration experiments, often 
yield inconsistent results across research groups due to the experimental individual assay 
modifications made by each group. For example, the ECM component used for filter coating 
can serve as a chemoattractant via integrin signaling (triggered by the interaction with 
laminin contained in the matrix), or via the release of growth factors embedded in the 
matrix itself. Although a reduced-growth factor form of Matrigel™ is generally used (i.e. 
reduced amounts of the above mentioned molecules are present in the matrix), there are a 
plethora of ECM proteins and growth factors, reconstituted along with Matrigel™, whose 
concentrations may vary with each batch purchased, and cause variations in the results. Yet, 
perhaps the largest shortcoming of transwell assays with respect to quantifying migration is 
that the cytokine microenvironments they create are very complex to model mathematically. 
Diffusion gradients of molecules across the membrane pores are difficult to measure or 
predict analytically, with or without matrix coating. Among in vitro approaches, 
microfluidics has proven to be a powerful technology to study cell migration over the past 
few years, due to the ability to generate a precise cell microenvironment that can be both 
predicted by analytical models and validated experimentally (Kong et al., 2010), as 
summarized further on. 
5.4 Microdevices 
Advances in microfabrication have made microfluidics systems easier to design and 
manufacture. Currently, the majority of devices are constructed of polydimethylsiloxane 
(PDMS) via soft lithography pioneered by the Whitesides group (McDonald and Whitesides, 
2002). The polymer allows the construction of systems with high transparency and low 
thickness that are highly-compatible with biological microscopy. As dissemination of glioma 
or MB cells can often follow the path of white matter tracks or other heterogeneous 
structures, mechanical properties of the microenvironment play significant roles in tumor 
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cell locomotion (Guck et al., 2010). PDMS microsystems pre-define the cell migratory path 
within microsized channels that mimic in vivo conditions. As such, cell motility and 
directionality can be examined and measured via conventional time-lapse imaging. 
Pioneering applications of microdevices for cancer cell study utilized microchannels coated 
and filled with various extracellular matrixes in 2D and 3D (Schoen et al., 2010; Sung et al., 
2009) to illustrate the selectivity of cancer cell migration on distinct ECM, as well as to 
measure traction forces and leading edge protrusions of a variety of cancer cell types (Li et 
al., 2009). More recently, biomedical engineers have begun to develop systems that generate 
linear and non-linear cytokine gradients in order to more accurately investigate the 
chemotactic behavior of cells derived from primary tumors.  
Establishment of steady-state gradient profiles has been examined using flow-based 
gradient generators, diffusion-based gradient generators, as well as hybrid generators 
(mixture of convection and diffusion). One of the original microdesigns for migration study 
was developed by Li Jeon and colleagues, in a gradient mixer design initially used for 
neutrophil chemotaxis (Li Jeon et al., 2002). This device contains multiple inlets that enable 
the loading of different ligand solutions that are then mixed in channels perpendicular to 
the flow direction (Figure 6A). Subsequently, a variety of system designs have been 
developed to generate alterative gradient shapes for further chemotaxis study (Kim et al., 
2010). In such flow-based designs, two concentrations of biomolecules flow separately into a 
network of microchannels, where mixers are patterned to combine adjacent streams via 
convection in order to generate a chemical gradient. While flow-based devices are able to 
finely control the spatiotemporal resolution of the gradient, they require constant flow rates 
of reagents that remove molecules secreted from cells that are critical to regulation of tumor 
cell migration (Huang et al., 2011). 
 
 
Fig. 6. Schematics of microdevices currently used to generate concentration gradients  
(not to scale). The flow mixer device was first proposed by Li Jeon and colleagues to create 
highly controllable concentrations along specific distances via continuous convective flow.  
(A) Schematic representation of a premixing gradient generating device pioneered by Li 
Jeon and colleagues. (B) A hybrid microlane system uses interconnected reservoirs to create 
concentration gradients via both convection and diffusion. The microchannel approximately 
measures 13 mm in length, 90 μm in depth and 100 μm in width (averaged with the upper side 
of 95 μm and the lower side of 105 μm), as its semi-hemispherical cross-section shown in inset. 
(Courtesy of Kong et al., 2010) 
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cell locomotion (Guck et al., 2010). PDMS microsystems pre-define the cell migratory path 
within microsized channels that mimic in vivo conditions. As such, cell motility and 
directionality can be examined and measured via conventional time-lapse imaging. 
Pioneering applications of microdevices for cancer cell study utilized microchannels coated 
and filled with various extracellular matrixes in 2D and 3D (Schoen et al., 2010; Sung et al., 
2009) to illustrate the selectivity of cancer cell migration on distinct ECM, as well as to 
measure traction forces and leading edge protrusions of a variety of cancer cell types (Li et 
al., 2009). More recently, biomedical engineers have begun to develop systems that generate 
linear and non-linear cytokine gradients in order to more accurately investigate the 
chemotactic behavior of cells derived from primary tumors.  
Establishment of steady-state gradient profiles has been examined using flow-based 
gradient generators, diffusion-based gradient generators, as well as hybrid generators 
(mixture of convection and diffusion). One of the original microdesigns for migration study 
was developed by Li Jeon and colleagues, in a gradient mixer design initially used for 
neutrophil chemotaxis (Li Jeon et al., 2002). This device contains multiple inlets that enable 
the loading of different ligand solutions that are then mixed in channels perpendicular to 
the flow direction (Figure 6A). Subsequently, a variety of system designs have been 
developed to generate alterative gradient shapes for further chemotaxis study (Kim et al., 
2010). In such flow-based designs, two concentrations of biomolecules flow separately into a 
network of microchannels, where mixers are patterned to combine adjacent streams via 
convection in order to generate a chemical gradient. While flow-based devices are able to 
finely control the spatiotemporal resolution of the gradient, they require constant flow rates 
of reagents that remove molecules secreted from cells that are critical to regulation of tumor 
cell migration (Huang et al., 2011). 
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measures 13 mm in length, 90 μm in depth and 100 μm in width (averaged with the upper side 
of 95 μm and the lower side of 105 μm), as its semi-hemispherical cross-section shown in inset. 
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Subsequent microdevice designs now often generate soluble gradients by using passive 
diffusion. These systems can eliminate fluid flow near the surroundings of cells by using 3D 
hydrogels or high resistance channels so that transport occurs predominantly via diffusion 
(Beebe et al., 2002). In this configuration, two reservoirs are typically used to maintain given 
chemical concentration in a specified sink and source. Diffusion along adjoining 
microchannels then facilitates the formation of a concentration gradient between the 
reservoirs that enables cells to migrate along the defined gradient (Paguirigan and Beebe, 
2008). While these systems eliminate the flow stresses imposed upon cells in flow-based 
devices, they require several hours to generate desired gradients, and rapid adjustment to 
the gradient profile is often difficult if not impractical. As a result, hybrid microsystems 
have been developed to enable the use diffusion with a minute level of convection to bolster 
formation of a desired gradient. For example, our group was able to generate steady-state 
gradients that were stable for 2-3 days using a bridge design and by exploiting the ultra-low 
bulk velocities generated by density differences between the reagents used (Figure 6B) 
(Kong et al., 2010).  
The development of microfluidic platforms that incorporate real-time control of cell imaging 
and measurement of chemotactic concentration gradients is highly needed for 
understanding the dynamics of brain tumor interactions, an area which remains relatively 
unexplored when the majority of microfluidic studies focus on measurement of end-point 
cellular responses. 
6. Future prospects of anti-invasive brain tumor therapy 
The impetus for the development of anti-migratory therapeutic agents for brain tumors has 
been the desire to ease the manageability of the disease, by arresting tumor cells to their 
primary local environment. Such strategies can reduce the need to utilize the so-called 
“Search and Destroy” approach that is the currently suggested clinical necessity. Elucidation 
of possible mechanisms used by diffusely infiltrative glioma and MB cells will enable a 
better understanding of how to render these cells static, while providing targets for the 
development of pharmacological products capable of such a task.   
More recently it has been suggested that enhancing the recruitment of endogenous 
progenitors toward tumor masses will aid in restoring the brain regions that have been 
resected or lost via necrosis (Cayre et al., 2009). Neural stem cells (NSCs) have aroused 
attention in the field of neurooncology as delivery vehicles of therapeutic genes. In addition 
to their multipotential capabilities that allow them to differentiate into neurons, astrocytes 
and oligodendrocytes, NSCs are also characterized by their remarkable capability to migrate 
through the brain (Gage, 2000; Yandava et al., 1999). The ability of implanted NSCs to 
distribute themselves throughout the tumors and follow invasive glioma cells has raised the 
idea of their therapeutic potential in targeting invasive glioma cells in vivo (Aboody et al., 
2000; Staflin et al., 2009). Shimato and colleagues demonstrated in vitro that human NSCs 
exhibited extensive tropism for MB cells (Shimato et al., 2007). Using leptomeningeal 
dissemination mouse models, they confirmed in vivo that NSCs were able to distribute 
diffusely to MB cells that had spread throughout the entire spinal cord after implantation in 
the cisterna magna, and that genetically transformed NSCs functioned effectively in killing 
MB cells (Shimato et al., 2007). Similarly, genetically-modified NSCs were delivered intra-
cranially and shown to target MBs (Kim et al., 2006). Recently, it was shown that human 
 
Migration and Invasion of Brain Tumors 
 
243 
umbilical cord blood-derived stem cells can integrate into human MB after local delivery, 
and that MMP-2 expression by the tumor cells mediates this response through the 
SDF1/CXCR4 pathway (Bhoopathi et al., 2011). These results offer a new promising 
therapeutic modality that uses human stem cells for targeting intra-cranial as well as 
leptomeningeal dissemination of MBs. 
Although significant results are being generated from the stem cell community, brain tumor 
researchers have only recently begun to reflect on the specifics of glial progenitor 
recruitment as a form of treatment for the disease. Glial progenitor cells have shown 
increased healing potential after supplementing the cultures with exogenous concentrations 
of VEGF D when compared to controls (Kranich et al., 2009). Using transwell assays, a dose 
dependent invasive response of murine neural stem cells towards human glioma 
conditioned media (Heese et al., 2005) and bi-potential O-2A progenitors toward PDGF 
(Gallo et al., 1996) has been displayed. 
Ideally, as has been the case in previous years, the focus should be to target cytokines and 
their cognate receptors involved in glioma and MB chemotaxis signaling events.  Moving 
forward, the community is in great need of technologies and strategies that can both 
approximate the chemical microenvironment present in the in vivo brain, and replicate these 
environments in vitro. In so doing, migration strategies can be developed that examine how 
combinations of cytokine and/or pharmacological cocktails can be used to limit the 
diffusive migration of tumor-derived cells into healthy brain. 
7. Conclusion 
The migration of glioma and medulloblastoma tumor cells into healthy brain tissue is a 
critical, yet poorly-understood, component of the tumor invasion and metastasis that 
contributes to poor patient prognosis. Extensive in vivo studies of brain tumors have 
generated invaluable data to elucidate the molecular alterations and genetic backgrounds 
present in diseased cells, the signaling mechanisms cells use to communicate with their 
surrounding microenvironment, and the characteristic patterns of dissemination used by 
specific tumor cell types. Additionally, in vitro studies of brain tumor-derived cells have 
established the chemotactic potential of various cytokines and extracellular matrixes, 
evaluated the effectiveness of pharmaceutical cocktails on tumor growth, as well as enabled 
fundamental measurement of motility and directionality in tumor cell samples. While the 
majority of research efforts to date have focused on the origin and nature of tumorigenesis 
in glioma and medulloblastoma, the community is now beginning to examine the integrated 
role of cell migration in tumor growth and dissemination. Future research is needed to 
examine the existence and characteristics of tumor cell populations with highly motile 
phenotypes in order to establish cell migration as a viable therapeutic target, and start 
designing treatment regimens based on cell migratory behaviors.  
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1. Introduction 
Malignant gliomas are primary brain tumors, which are highly invasive but not known to 
metastasize outside the central nervous system (CNS). The median survival time of patients 
with glioma is only 6 months to 2 years depending on various patient, tumor and treatment 
parameters (Louis et al. 2007). The highly aggressive character of gliomas with glioblastoma 
multiforme (GBM) being the most aggressive subtype are characterized by their diffuse 
infiltration into the normal brain parenchyma and interaction with the extracellular matrix 
(ECM) components in the brain. Standard brain tumor therapies, which include surgery 
followed by chemotherapy and radiation are not effective in eradicating single glioma cells 
that migrated into the normal brain establishing new tumor foci. Glioma cells are locally 
invasive and when migrating through the ECM within several millimeters or centimeters 
from the main lesion they initiate recurrent tumors often distant to the primary lesion 
(Bolteus et al. 2001). The infiltrative path of glioma into the normal brain parenchyma 
involves the basement membrane of blood vessels and myelinated nerve fibers of white 
matter tracts (Rao 2003, Lefranc et al. 2005).  
The pattern of glioma cell invasion is related to the unique composition of the cerebral ECM 
microenvironment, which is remodeled during invasion by activated matrix 
metalloproteinases (MMPs) (reviewed by Rojiani et al. 2011). In addition, new ECM 
molecules are secreted and receptor adhesion molecules are expressed by glioma promoting 
the glioma cell-ECM interaction and signaling. Some of the secreted ECM molecules such as 
tenascin-C are known to be associated with cell motility and angiogenesis which are both 
essential for tumor development. Another important microenvironment component 
affecting glioma development was found to be mechanical force determined by ECM 
rigidity. More rigid ECM promotes glioma migration and proliferation and lower rigidity of 
ECM (similar to that of normal brain) would have an opposite effect (Ulrich et al. 2009). 
The recent sequencing data presented by the Cancer Genome Atlas Research Network 
(2008) revealed genomic abnormalities in GBM that relate to several signaling pathways 
such as Epidermal Growth Factor Receptor (EGFR) /Ras /PI3K known to be associated with 
ECM-related signaling (Ulrich et al. 2009). In addition, the recent integrated genomic 
analysis identified clinically relevant subtypes of GBM with its characteristic abnormalities 
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in platelet derived growth factor receptor A (PDGFRA), isocitrate dehydrogenase 1 (IDH1), 
neurofibromin 1 (NF1), and confirmed EGFR mutations across all newly defined subtypes of 
GBM such as classical, proneural, neural and mesenchymal (Verhaak et al. 2010). The most 
recent studies by Holland (2011) in PDGF-driven mouse models of proneural GBMs with a 
focus on the biology, therapeutic response and the complexity of the microenvironment 
showed that some of the genes found in mice are predictive of the survival of patients with 
this proneural subtype of GBM. Interestingly, many of these genes are rather expressed in 
the stroma of the tumor than by the tumor cells themselves.  
In this chapter, the most recent information pertaining to the glioma extracellular 
microenvironment and the possible biological targets within ECM for anti-glioma therapy 
will be reviewed.  
2. Extracellular matrix molecules in the normal brain  
In the central nervous system (CNS) approximately only 15-25% of the CNS volume is taken 
up by the extracellular space, while the majority of the CNS volume consists of cellular 
elements such as neurons, glia, astrocytic processes and blood vessels (Sykova 2002, 
Quirico-Santos et al. 2010). The components found within the extracellular space include 
various ions, metabolites, neurohormones, peptides and ECM molecules produced by 
neurons and glia. The ECM environment of the normal brain contains high levels of space-
filling carbohydrate molecules unbound to proteins such as the large glycosaminoglycan 
(GAG) hyaluronan (HA). HA binds to specific cell surface receptors such as cluster 
determinant 44 (CD44) adhesion molecule and receptor for hyaluronate mediated motility 
(RHAMM) regulating properties of ECM and tissue, e.g., proliferation, adhesion, motility 
etc. Protein-bound carbohydrate molecules, which are present in the normal brain at high 
levels, include sulfated proteoglycans such as chondroitin sulfate proteoglycans (CSPGs) 
and heparan sulfate proteoglycans (HSPGs). In addition, fibrous proteins associated with 
the basement membranes of the brain’s vasculature include collagens, fibronectin, and 
laminin (Wiranowska and Plaas 2008). The levels of these fibrous proteins in the normal 
brain are low compared to the connective tissue outside the central nervous system (Bellail 
et al. 2004, Quirico-Santos et al. 2010). However, the ECM microenvironment of glioma 
differs from the normal brain and varies depending on the grade of glioma, e.g., with the 
highly aggressive GBM producing collagen, fibronectin or laminin (Mahesparan et al. 2003). 
Several classes of ECM molecules play an important role in the normal CNS development 
but have altered functions in glioma are reviewed below. 
The main classes of ECM components in the normal brain are GAG hyaluronan (HA), also 
called hyaluronic acid, and proteoglycans (PGs), which consist of a core protein attached to 
GAG chain. HA plays multiple roles in providing an organization of the pericellular matrix. 
There is a high diversity of PGs due to various core proteins, and variations in GAG side 
chains. Two classes of transmembrane PGs, glypicans and syndecans, which contain 
heparan sulphate (HS) side chains called HSPGs are found at high levels in the CNS.  
An important class of PGs are chondroitin sulfate PGs (CSPGs), which are expressed at high 
levels in the regions of the developing fetal brain and later in mature brain in astrocytes and 
neurons (Rao 2003, Quirico-Santos et al. 2010). CSPGs, and especially the subclass of 
lecticans, are one of the major families of HA binding matrix glycoproteins in the CNS. A 
second family of PGs that bind HA in the CNS are HA- and proteoglycan-link proteins 
(HAPLNs) also called "link proteins”, which bind both HA and lecticans. The PGs called 
 
Extracellular Matrix Microenvironment in Glioma Progression 
 
259 
lecticans contain lectin and HA-binding domains and within that group there are molecules 
such as aggrecan, versican, neurocan, and brain enriched hyaluronic acid binding 
protein/brevican (BEHAB/brevican) that act as linkers to ECM components. They bind to 
HA as well as to cell-surface receptors regulating many processes within the CNS during 
development, e.g., cell motility, axonal navigation etc. (Sim et al. 2009). Some of these 
molecules such as versican are known to be produced by glial cells and neural stem cells 
(Abaskharoun et al. 2010). Another member of CSPGs is phosphocan, an astroglial 
proteoglycan that binds to neural cell adhesion molecules and tenascin-C. Neuroglial 
protein-2 (NG2), also a CSPG proteoglycan, which is known as a characteristic marker of 
oligodendrocyte progenitor cells and pericytes in developing vasculature, is expressed by 
many gliomas. The NG2 positive cells have been suggested to be the originating cells for 
glioma (Stallcup and Huang 2008).  
Tenascins (C and R), a family of glycoproteins exist in the ECM as assemblies of several 
subunits expressed in zones of proliferation, migration, and morphogenesis and are known 
to play an important role in the developing CNS. For example, tenascin-C was found highly 
expressed in the subventricular zone and essential for neural stem cell development 
(reviewed by Wiranowska and Plaas 2008). Galectins (Gal) , mannose- binding lectins, are 
glycan-binding proteins found inside and outside the cells. Gal-1 is highly represented in 
the CNS and takes part in the development of neural and non-neural networks and Gal-3 
interacts with other neural tissue derived glycoproteins and is expressed by astrocytes and 
endothelial cells (Quirico-Santos et al. 2010). The role of many ECM components of the 
normal brain described above, are altered dramatically in glioma.  
In the normal brain, the ECM complexes containing HA and PGs such as versican, brevican, 
neurocan, aggrecan, phosphacan and tenascin-C, tenascin-R, and link proteins form the 
ECM domains called perineuronal nets first described by Camillo Golgi in 1893. These 
perineuronal net aggregates enwrap the neuronal cell bodies and proximal dendrites of 
certain neurons and fill the space between neurons and glial processes. More recently, it was 
proposed that perineuronal nets within the brain are more heterogenous and include 
structures called “interstitial clefts” (Brightman 2002). As described by Brightman 
(Brightman 2002), interstitial clefts comprised of astrocytic walls, basal lamina and ECM 
molecules may vary in size , shape and content depending on the brain region. In addition, 
the size and the content of interstitial clefts was found to be different in the mature brain by 
being narrower with limited capacity for cell movement compared to that in the fetal brain. 
Here, in the fetal brain, the size and the content of interstitial clefts permit cell migration and 
outgrowth of neurites while in the mature brain cell migration in the interstitial clefts could 
only occur after enzymatic degradation of the ECM (Brightman 2002).  
2.1 Extracellular matrix in the brain as a cytokine and growth factor depot  
In the normal brain some regions are especially rich in ECM. These brain regions include 
subarachnoid space, supependymal packets, circumventricular organs (CVOs) supplied by 
fenestrated capillaries without blood-brain barrier (BBB), and perivascular space around 
arterioles and venules. These vessels are associated with stromal connective tissue space and 
lined by basal laminae containing heparan sulfate proteoglycans (HSPGs). HSPGs which are 
also components of ependymal, astroglial, and endothelial interfaces in the CNS (including 
interstitial clefts) have been suggested to serve as a storage site of growth factors and 
cytokines (Brightman and Kaya 2000). A large number of growth factors, for example, 
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insulin-like growth factor (IGF), transforming growth factor–beta (TGF-beta), hepatocyte 
growth factor (HGF) were found to bind to HSPG (Folkman 1998). A similar observation 
was made for certain cytokines (reviewed by Wiranowska and Plaas 2008). It was suggested 
by Mercier et al. (Mercier et al. 2003) that cytokines and growth factors secreted by cells of 
connective tissue may accumulate in the basal lamina, interact with ECM proteins and affect 
biological processes including cytogenesis of stem cells in the CNS.  
2.2 Extracellular matrix stem cell niche in the brain  
In the CNS, the ability of normal stem cells to self-renew and to differentiate into specific 
cell types is controlled by the microenvironment of a CNS area in which these cells reside 
and which is called niche. Similarly, in other tissues and organs, stem cells are found in the 
protective microenvironment of niches, which are composed of ECM molecules and various 
differentiated cell types that release regulatory factors and provide direct contact with stem 
cells maintaining their quiescence. The CNS microenvironment of the neural stem cells 
(NSC) niche is also called vascular niche, because stem cells concentrate near blood vessels. 
The NSC niche consists of several ECM components, and includes the basal lamina and 
endothelial cells of vasculature (Doetsch 2003). These mature, differentiated vascular 
endothelial cells have an intimate association with stem cells and play a regulatory role in 
the NSC niche through secreted soluble factors. These factors were shown to promote 
activation of Notch, a neural precursor receptor, resulting in self-renewal of neural stem 
cells (Shen et al. 2004). In addition, the basement membrane (also known as basal lamina) 
contributes to the microenvironment and provides a substrate for stem cells’ movement. The 
subventricular zone, a highly neurogenic area in the CNS, contains transmembrane HSPGs 
bound to the supependymal basal lamina located in proximity to the stem cells. As 
mentioned earlier (Section 2.1), HSPGs have the capacity to bind and to store a number of 
growth factors and cytokines thereby serving as a cytokine and growth factor depot. The 
growth factors and cytokines can diffuse quickly, and because of close proximity, they can 
reach high concentrations near the stem cells and regulate their development (Kearns et al. 
2003) . For example, EGF and basic fibroblast growth factor (bFGF) stored in the ECM of the 
subventricular zone can have a stimulatory effect on stem cells by enhancing their 
proliferation. The growth factors and cytokines can be stored in the ECM throughout life.  
As mentioned earlier, one of ECM molecules, tenascin-C, is highly expressed in the 
subventricular zone and essential for neural stem cell development (Wiranowska and Plaas 
2008). Tenascin-C plays a key role in the regulation of the developmental program of 
oligodendrocyte precursor cells (OPCs) and therefore confirming the importance of 
tenascin-C as an ECM component of the niche (Scadden 2006). Other ECM molecules, such 
as laminin and fibronectin, stimulate motility of stem/progenitor cells while CSPGs have an 
inhibitory effect (Kearns et al. 2003). It was also observed that upon activation of MMPs by 
proinflammatory cytokines, the neural progenitor cells were stimulated to migrate to the 
site of injury (Ben-Hur et al. 2006). In summary, many modulatory molecules were 
described within the ECM of the stem cell niche and, interestingly, many of them were 
found in glioma, but at higher levels than in the normal brain. In addition, not only the 
levels but also the functions of many of these molecules differ between the normal brain and 
glioma such as CSPGs, which are inhibitory for stem cells migration within the niche of the 
normal brain but stimulatory for glioma cell migration (Kearns et al. 2003, Sim et al. 2009). 
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3. Extracellular matrix in glioma 
3.1 Role of ECM and MMP molecules in vasculogenic mimicry in glioma: Historical 
perspective  
It was observed previously by Maniotis et al. (Maniotis et al. 1999) that blood vessels of 
highly aggressive tumors such as uveal melanoma originated from tumor cells, rather than 
from endothelial cells as it was originally expected. This phenomenon named vasculogenic 
mimicry (VM) was reported later also for other tumors including glioma (Yue and Chen 
2005). Although the mechanism of VM could not be explained at that time, many studies 
evaluated MMPs and ECM interactions in search for clues. It was suggested that several 
components of the tumor microenvironment may be contributing to the development of 
VM. For example, consideration was given to MMPs’ cleavage of laminin, VE-cadherin- 
promoted adherence of newly formed vascular channels to tumor cells, and 
dedifferentiation of tumor cells (Zhang et al. 2007). Three main factors were suspected to 
play a role in VM: 1) plasticity of malignant tumor cells, 2) remodeling of the ECM by MMPs 
secreted by tumor cells to obtain space for VM, and 3) the connection of newly formed VM 
channels with existing blood vessels to acquire blood from the host (Zhang et al. 2007). It 
was proposed by Maniotis et al. (Maniotis et al. 1999) that the level of the VM channel 
formation was directly proportional to the level of tumor aggressiveness and influenced by 
interstitial fluid pressure (IFP), a microenviromental factor known to affect angiogenesis. 
Tumors that proliferate rapidly have high IFP and compromised blood circulation. In 
addition, there is a limited blood supply from the host due to decreased endothelial cell 
sprouting and decreased formation of endothelium-lined blood vessels. Therefore, tumor 
cells that form VM channels obtain a sufficient blood supply to sustain tumor growth. It was 
observed that the blood vessels formed as a result of VM had a different structure than 
normal endothelial-lined blood vessels. VM channels were found to be lined by highly 
aggressive and poorly differentiated tumor cells that could degrade the base membrane of 
blood vessels by releasing proteases and migrate into the normal tissue. Recent data (Inoue 
et al. 2010) support this observation by showing that GBM cancer stem cells express MMP-
13 responsible for invasion and migration of these cells. 
Anti-vascular and anti-angiogenic therapies that used molecules such as angiostatin or 
endostatin that target endothelial cells, showed no effect on tumors with VM. To overcome 
the lack of understanding of the molecular mechanisms underlying VM, several in vitro 
studies were initiated in search of new therapeutic approaches based on the concept of ECM 
involvement in VM formation. For example, laminin was targeted in vitro showing that an 
anti-laminin antibody was able to inhibit VM channel formation by tumor cells (Sanz et al. 
2003). Other in vitro studies targeted and inhibited MMP-2 and MMP-9 involved in VM by 
using doxcyline (Zhang et al. 2007). Also, it was shown that the Cox-2 inhibitor, celecoxib, 
inhibited in vitro VM formation in a dose-dependent manner (Basu et al. 2005). Although, 
these results were only obtained in vitro, there may be a recent indirect in vivo confirmation. 
Interestingly, recent in vivo studies using a glioma mouse model, showed that non-steroidal 
anti-inflammatory drugs (NSAID) such as Cox-2 inhibitors suppress gliomagenesis (Fujita et 
al. 2011). Although the primary conclusion of this study was that gliomagenesis was 
suppressed due to inhibition of prostaglandin E2-dependent accumulation of myeloid 
derived suppressor cells in the tumor microenvironment, a secondary effect of Cox-2 
inhibitors on VM may be involved as addressed in section 6.2.2.  
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insulin-like growth factor (IGF), transforming growth factor–beta (TGF-beta), hepatocyte 
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by Mercier et al. (Mercier et al. 2003) that cytokines and growth factors secreted by cells of 
connective tissue may accumulate in the basal lamina, interact with ECM proteins and affect 
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the NSC niche through secreted soluble factors. These factors were shown to promote 
activation of Notch, a neural precursor receptor, resulting in self-renewal of neural stem 
cells (Shen et al. 2004). In addition, the basement membrane (also known as basal lamina) 
contributes to the microenvironment and provides a substrate for stem cells’ movement. The 
subventricular zone, a highly neurogenic area in the CNS, contains transmembrane HSPGs 
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2003) . For example, EGF and basic fibroblast growth factor (bFGF) stored in the ECM of the 
subventricular zone can have a stimulatory effect on stem cells by enhancing their 
proliferation. The growth factors and cytokines can be stored in the ECM throughout life.  
As mentioned earlier, one of ECM molecules, tenascin-C, is highly expressed in the 
subventricular zone and essential for neural stem cell development (Wiranowska and Plaas 
2008). Tenascin-C plays a key role in the regulation of the developmental program of 
oligodendrocyte precursor cells (OPCs) and therefore confirming the importance of 
tenascin-C as an ECM component of the niche (Scadden 2006). Other ECM molecules, such 
as laminin and fibronectin, stimulate motility of stem/progenitor cells while CSPGs have an 
inhibitory effect (Kearns et al. 2003). It was also observed that upon activation of MMPs by 
proinflammatory cytokines, the neural progenitor cells were stimulated to migrate to the 
site of injury (Ben-Hur et al. 2006). In summary, many modulatory molecules were 
described within the ECM of the stem cell niche and, interestingly, many of them were 
found in glioma, but at higher levels than in the normal brain. In addition, not only the 
levels but also the functions of many of these molecules differ between the normal brain and 
glioma such as CSPGs, which are inhibitory for stem cells migration within the niche of the 
normal brain but stimulatory for glioma cell migration (Kearns et al. 2003, Sim et al. 2009). 
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3. Extracellular matrix in glioma 
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cells that form VM channels obtain a sufficient blood supply to sustain tumor growth. It was 
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aggressive and poorly differentiated tumor cells that could degrade the base membrane of 
blood vessels by releasing proteases and migrate into the normal tissue. Recent data (Inoue 
et al. 2010) support this observation by showing that GBM cancer stem cells express MMP-
13 responsible for invasion and migration of these cells. 
Anti-vascular and anti-angiogenic therapies that used molecules such as angiostatin or 
endostatin that target endothelial cells, showed no effect on tumors with VM. To overcome 
the lack of understanding of the molecular mechanisms underlying VM, several in vitro 
studies were initiated in search of new therapeutic approaches based on the concept of ECM 
involvement in VM formation. For example, laminin was targeted in vitro showing that an 
anti-laminin antibody was able to inhibit VM channel formation by tumor cells (Sanz et al. 
2003). Other in vitro studies targeted and inhibited MMP-2 and MMP-9 involved in VM by 
using doxcyline (Zhang et al. 2007). Also, it was shown that the Cox-2 inhibitor, celecoxib, 
inhibited in vitro VM formation in a dose-dependent manner (Basu et al. 2005). Although, 
these results were only obtained in vitro, there may be a recent indirect in vivo confirmation. 
Interestingly, recent in vivo studies using a glioma mouse model, showed that non-steroidal 
anti-inflammatory drugs (NSAID) such as Cox-2 inhibitors suppress gliomagenesis (Fujita et 
al. 2011). Although the primary conclusion of this study was that gliomagenesis was 
suppressed due to inhibition of prostaglandin E2-dependent accumulation of myeloid 
derived suppressor cells in the tumor microenvironment, a secondary effect of Cox-2 
inhibitors on VM may be involved as addressed in section 6.2.2.  
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3.2 Microenvironment of glioma stem cell vascular niche: New theory of vascular 
mimicry  
Recently, a new concept of cancer progenitor cells, also known as cancer-initiating cells or 
cancer stem cells (CSCs), was proposed. These self-renewing, multipotent CSCs are highly 
tumorigenic and resistant to conventional therapies (Lakka and Rao 2008). Glioblastoma 
CSCs resemble the normal NSC and express the markers Nestin+/ CD133+ found in the 
neural stem cell population. Also, glioma CSCs, similar to NSCs, concentrate around blood 
vessels in the vascular niches with easy access to nutrients, signaling molecules, and the 
vasculature itself as a substrate for migration (Calabrese et al. 2007, Denysenko et al. 2010). 
However, CSCs differ from NSCs in their distribution in the brain and their capacity to 
proliferate. For example, the normal NSCs, which proliferate at a low rate are found only in 
specific CNS regions such as hippocampus and subventricular zone. In contrast, highly 
proliferative glioma CSCs can be found distributed across in all regions of cerebrum and 
cerebellum within the tumors. It was proposed that the main difference between the normal 
NSCs and glioma CSCs may be the way in which these cells are modulated by the 
microenvironment of the vasculature within the niche (Calabrese et al. 2007). The vascular 
niche in brain tumors is abnormal in such that it contributes to the propagation of CSCs 
thereby enhancing tumor growth. Furthermore, the endothelial cells from this abnormal 
vascular niche can interact with brain tumor CSCs, as shown in vitro, providing certain 
extracellular regulatory factors and maintaining the self-renewal capability and 
undifferentiated state of these cells (Calabrese et al. 2007). In that way the glioma 
vasculature establishes a microenvironment of the niche in which CSCs can transmit and 
receive signals from the ECM. For example, it was shown that upon stimulation of CSCs by 
ECM of the vascular niche, the CSCs can secrete vascular endothelial growth factor (VEGF) 
promoting angiogenesis and thereby enhancing tumor growth (Bao et al. 2006). In addition, 
the vascular niche was shown to interfere with radiation and chemotherapy by shielding the 
CSCs and contributing to the resistance to treatments (Denysenko et al. 2010). It was also 
suggested that the microenvironment of the niche may play a role in tumor initiation based 
on the observation that non-tumorigenic cell populations may become tumorigenic 
depending on a certain microenvironment (Rosen and Jordan 2009). Recent reports show 
that GBM stem cells have similar capabilities as the normal NSCs and undergo 
differentiation into endothelial cells forming the majority of new blood vessels in gliomas 
(El Hallani et al. 2010, Ricci-Vitiani et al. 2010, Wang et al. 2010). Blocking VEGF or silencing 
VEGF receptor 2 inhibits the maturation of tumor endothelial progenitors into endothelium 
but does not stop the differentiation of CSCs (CD133+ cells) into endothelial cells. However, 
silencing of Notch (neural precursor receptor as mentioned in section 2.2) blocks the 
transition of CSCs (CD133+ cells) into endothelial progenitors (Wang et al. 2010). Further 
studies of the microenvironmental components within the brain tumor vascular niche could 
lead to new therapeutic targets for treatments of glioma.  
3.3 Extracellular matrix and mechanical rigidity in glioma  
There are anatomic variations in stiffness in the normal brain parenchyma (Elkin et al. 2007) 
with basement membrane of blood vessels and the myelinated fiber tracts of white matter 
exhibiting a higher mechanical rigidity (Lefranc et al. 2005) and both serving as an 
infiltrative path for glioma invasion (Rao 2003, Ulrich et al. 2009, Kumar 2009). It was first 
observed in vitro that directed migration of fibroblasts occurs from soft to stiff areas of the 
ECM, a phenomenon named mechanotaxis (Lo et al. 2000). A similar observation was made 
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for glioblastoma where changes in ECM rigidity can both increase and decrease cell motility 
and the extent of the effect was cell–type dependent (Thomas and DiMilla 2000). It was 
found that high ECM stiffness enhanced the expression of contractility-mediating proteins 
such as Rho (Paszek et al. 2005). ECM components have been found to be the main 
regulators of cell motility in the brain. For example, previous studies showed a stimulatory 
effect of ECM proteins such as fibronectin, collagen, laminin and others on glioma cell 
migration (Mahesparan et al. 2003). Ulrich et al. (Ulrich et al. 2009) had shown that glioma 
cells cultured on fibronectin-coated polymeric ECM with varied but defined mechanical 
rigidity exhibited altered cell morphology and cytoskeletal organization. These authors 
showed that glioma cells cultured on softer substrates showed a decreased spreading area, 
disappearing stress fibers and focal adhesions. Interestingly, all evaluated glioma cell lines 
cultured on the softest substrates were rounded but viable with cortical rings of F-actin and 
punctuate vinculin-positive focal complexes, and with no indication of apoptosis (Ulrich et 
al. 2009). The rigidity of the soft substrates used in that study was comparable to the ECM 
rigidity of normal brain parenchyma while an increased stiffness was characteristic for 
glioma and its surrounding stroma.  
In addition, it was shown that increasing ECM rigidity resulted in increased cell spreading, 
motility and proliferation. It was suggested previously that glioma cells actively remodel 
their microenvironment changing it from normal brain ECM to rigid tumor-like ECM 
(Nakada et al. 2007). Therefore, it was suggested that glioma cells modify their ECM 
through proteolytic degradation of the normal brain matrix and secretion of new ECM 
components, thereby providing for a stiffer and more rigid microenvironment which in turn 
sends mechanobiological signals that support glioma cell invasion (Ulrich et al. 2009). This 
was observed previously also for invading breast cancer cells (Provenzano et al. 2008). By 
targeting either the signaling pathways for mechanotaxis or mechanical remodeling itself, 
new therapeutic approaches could be developed for the treatment of glioma which would 
affect glioma invasion and proliferation.  
3.4 Extracellular matrix molecules in glioma 
3.4.1 Glycosaminoglycan hyaluronan and CD44 adhesion molecule 
Glioma cells constitutively produce HA and its production is increased during cell 
proliferation (Wiranowska and Naidu 1994, Wiranowska et al. 2010) promoting glioma 
invasion (Park et al. 2008). HA is synthesized at the plasma membrane by HA-synthases and 
the synthesis can be enhanced by various growth factors, e.g., epidermal growth factor 
(Knudson and Knudson 1993) Interestingly, the content of HA in glioma resembles that of 
embryonic brain cells (Delpech et al. 1993). HA binds to the HA-binding proteins called 
hyaladherins which include the CD44 surface receptor. CD44 is a transmembrane 
glycoprotein expressed by many cell types and by glioma. CD44 serves as a surface receptor 
for ECM molecules such as HA and CSPGs (Ranuncolo et al. 2002).  
CD44 receptor is overexpressed in glioma cells in vitro (Wiranowska et al. 2000, Yu et al. 
2010) and found in vivo at the leading edge of glioma at the brain-tumor interface 
(Wiranowska et al. 2006). The HA-CD44 interaction and CD44 shedding from the cell 
surface were found to be associated with glioma cell motility, migration, and infiltration into 
the normal brain parenchyma (Annabi et al. 2005). These authors also described that CD44 
shedding was mediated by HA and accompanied by up-regulation of MT1-MMP 
expression.  
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cultured on the softest substrates were rounded but viable with cortical rings of F-actin and 
punctuate vinculin-positive focal complexes, and with no indication of apoptosis (Ulrich et 
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the synthesis can be enhanced by various growth factors, e.g., epidermal growth factor 
(Knudson and Knudson 1993) Interestingly, the content of HA in glioma resembles that of 
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After binding to the CD44 receptor, HA can be endocytosed, transported into lysosomes and 
degraded by hyaluronidases into small oligosaccharides shown to have glioma - stimulatory 
activity (Novak et al. 1999). It was previously reported that while small HA fragments were 
found in the tumor tissues, native HA of high molecular mass was found in the normal and 
benign tissue (Rooney et al. 1995). Both the high levels of full length polymeric HA and its 
low molecular weight degradation products, HA fragments, known as oligosaccharides 
support glioma growth (Novak et al. 1999). The HA oligosaccharides, e.g., hexamer 
oligoHA-6 (HA-6) or decamer oligoHA-10 (HA-10) are able to displace full length HA via 
competition for CD44 receptor binding. HA can be effectively displaced by HA 
decasaccharides, such as HA-10, but not by HA oligosaccharides that are shorter than  
10-mer (Tammi et al. 1998). It was observed that full length, large size HA had an anti-
angiogenic property, whereas smaller oligosaccharides after degradation (3-10 disaccharide 
units) were no longer anti-angiogenic (Deed et al. 1997). We found that small size 
oligosaccharide, decamer HA-10, exogenously added to the cell culture stimulated HA 
production by glioma cells (Wiranowska et al. 2010), as previously described for normal 
human fibroblasts (Luke and Prehm 1999). These authors found that displacement of 
nascent HA from the receptors by HA oligosaccharides led to stimulation of HA synthesis 
(Luke and Prehm 1999). Further studies of HA and the role of HA-CD44 interaction in 
glioma growth and invasiveness may provide new therapeutic targets for the treatment of 
glioma. Recent therapeutic approaches targeting HA-CD44 interaction are discussed in the 
Section 5.2.  
3.4.2 Chondroitin sulfate proteoglycans (CSPGs)  
CSPGs are expressed at elevated levels in the developing brain (as described in sections: 2 & 
2.2). In the normal brain, they are known for their inhibitory effect on stem cell migration 
(section 2.2). In glioma however, CSPGs are upregulated and stimulate glioma cell 
migration (Kearns et al. 2003, Sim et al. 2009). The two members of the CSPG subclass of 
lecticans (described in section 2) such as versican and BEHAB/brevican are expressed at a 
higher level in glioma than in the normal brain tissue. In addition, it was reported that the 
VO/VI versican isoform expressed by migratory glioma cells interacts with surface 
receptors e.g., EGFR activating the ERK signaling pathway involved in tumor promotion 
(Ricciardelli et al. 2009). In addition, versican and brevican can form complexes with 
mesenchymal matrix proteins found in the ECM of glioma, but not in the ECM of the 
normal brain (Sim et al. 2009). Gliomas of various grades, e.g., astrocytoma and GBM secrete 
high levels of BEHAB/brevican. The CSPG lectican has an N-terminal HA-binding domain 
that interacts with fibronectin, thereby further stimulating glioma progression (Viapiano 
and Matthews 2006). Several other ECM molecules such as HA, CD44, tenascin and 
transforming growth factor beta2 (TGFbeta2) also interact with versican and promote brain 
tumor cell invasion. Recently, the link proteins HAPLN4 and HAPLN2 were shown to be 
reduced in malignant gliomas and it was suggested that this reduction may be associated 
with matrix remodeling by glioma. Therefore, in contrast to the normal brain tissue where 
CSPGs lecticans associated to HAPLNs serve as inhibitors of cell motility, in glioma this 
stabilizing role of link proteins may be reduced or lost resulting in proinvasive activity of 
CSPGs in glioma (Sim et al. 2009).  
Another member of CSPGs family, neuroglial protein 2 (NG2), is also overexpressed in 
glioma (Schrappe et al. 1991, Wiranowska et al. 2006). NG2 was first found to be expressed 
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by oligodendrocyte progenitor cells (section 2). NG2 expressed by glioma cells has a strong 
association with ECM ligands such as collagen VI and cellular ligands such as CD44. It has 
been implicated in the invasive behavior of glioma and found to be expressed in vitro and in 
vivo by highly migratory glioma cells while not found in non migratory cells (Lin et al. 1996, 
Galli et al. 2004, Wiranowska et al. 2006, Stallcup and Huang 2008). NG2 is not only 
expressed by oligodendrocyte progenitor cells and glioma cells but also by pericytes, which 
are associated with microvasculature and may play a role in the development of glioma 
vasculature (Stallcup and Huang 2008). Therefore, NG2 may be considered as one of the 
main CSPGs involved in glioma progression.  
3.4.3 Vasculature-associated ECM molecules expressed by gliomas 
The basement membrane of the cerebral vasculature contains collagens (type IV and V), 
fibronectin, laminin, vitronectin and HSPGs such as glypicans and syndecans. Some HSPGs, 
e.g., syndecan-2 were reported to be increased in brain tumors (Theocharis et al. 2010). 
Laminin, collagen and fibronectin were also shown to be expressed by normal brain tissue 
bordering with glioma cells in spheroids (Knott et al. 1998). In addition, some of these 
molecules are also expressed by cells of highly aggressive gliomas. For example, it was 
found that fibronectin was expressed by GBM in vitro and in gliomesenchymal junctions in 
tumors and their blood vessels (Rao 2003). Another molecule, vitronectin, was found to be 
expressed in late stage GBM while it was absent in normal brain and early stage of glioma 
(Yamamoto et al. 1994). Laminins, which were found in blood vessels and in the glial 
limitants externa in glioma, were also shown to be expressed by human glioma cells positive 
for glial fibrillary astrocytic protein (GFAP) (Tysnes et al. 1999). An active site on laminin 
which was capable of binding to CD44 was identified (Hibino et al. 2004). In addition, 
Ljubimova et al. (Ljubimova et al. 2004) found that highly invasive GBMs overexpressed 
laminin-8, a member of the subset of laminins characterized by containing the alpha4 chain. 
Moreover, these authors also found that laminin-8 not only facilitated tumor invasion in 
vitro, but was involved in tumor regrowth after completion of a therapy. On the contrary, a 
different isoform, laminin-9, was found in lower grade gliomas, astrocytomas, and at low 
levels in benign brain tumors and in normal brain tissue. Therefore, many of these ECM 
molecules originally known to be associated with vasculature and now found at various 
levels expressed by glioma cells could be considered as biomarkers of glioma progression.  
Tenascin –C , a proteoglycan synthesized by glial and neural crest cells is highly expressed 
in the subventricular zone and essential for the development of neural stem cells (as 
described in sections 2 & 2.2 ). Tenascin-C, which is believed to be produced by endothelial 
cells, was found around blood vessels in astrocytoma and its expression correlated with 
angiogenesis and tumor progression from grade II to grade III (Zagzag et al. 1995, Quirico-
Santos et al. 2010). Tenascin-C was found overexpressed in invasive glioma both in vitro and 
in vivo (Mahesparan et al. 2003) thus confirming its significance as an ECM molecule in 
glioma pathology. Also, galectins are upregulated in glioma and shown to be involved in 
glioma cell migration and angiogenesis. While high levels of Gal-1 are correlated with 
aggressiveness of many tumors, the expression of Gal-3 by astrocytes and endothelial cells 
can be used diagnostically to differentiate GBM from other, less malignant types of glioma 
(Quirico-Santos et al. 2010). The schematic representation of ECM glioma microenvironment 
and the summary of representative ECM molecules and their functional significance are 
shown in Figure 1 and Table1. 
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Fig. 1. Schematic representation of the extracellular matrix (ECM) microenvironment of 
invasive glioma with necrotic centers and associated brain parenchyma. Hyaluronic acid 
(HA), a long space-filling molecule composed of a carbohydrate chain is shown either 
unbound or bound to proteoglycans (PGs) via link proteins (LPs) or bound to CD44 
receptor. Also shown are two glioma associated ECM molecules (both chondroitin sulfate 
proteoglycans): brain enriched hyaluronic acid binding protein/brevican 
(BEHAB/brevican) and neuroglial protein-2 (NG2) with the latter expressed by glioma cells 
and pericytes of blood vessels. In addition, glycoprotein tenascin-C, and matrix 
metalloproteinases (MMPs) are shown. Blood vessels (BV) shown in the glioma and the 
associated brain parenchyma contain fibrous proteins such as collagens, laminins etc. and 
heparan sulfate proteoglycans (HSPGs) associated with the BV basement membrane.  
4. Proteases, Matrix Metalloproteinases (MMPs), Their Inhibitors (TIMPS) and 
remodeling of ECM in glioma 
Matrix Metalloproteinases (MMPs) are a class of enzymes known to be involved in normal 
tissue remodeling, but also produced by glioma cells (Wiranowska et al. 2000) and involved 
in modification of glioma ECM. In the past, MMPs were considered a potential target for 
anti-cancer therapies. The result of ECM degradation by MMPs is the release and diffusion 
of cytokines and growth factors stored in the ECM with subsequent further activation of 
MMPs by these factors (Wiranowska and Plaas 2008). Since upregulation of MMPs was 
traditionally associated with inflammation and cancer progression, MMPs were considered 
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a logical target for anti-cancer therapy. Supporting evidence was generated using transgenic 
mouse models overexpressing MMPs (Ha et al. 2001). 
 
 
Table 1. ECM molecules and their functional significance 
4.1 Proteases in glioma 
The local infiltration of neoplastic cells into healthy CNS parenchyma is the hallmark of 
gliomas. In this context it is relevant to note that the brain extracellular matrix differs in its 
composition from other such matrices and that glioma cells have the ability to exploit this 
environment for invasion. Glioma cells aggressively disseminate as single cells through this 
unique ECM of the central nervous system. They infiltrate along the periphery of blood 
vessels or along the longitudinal white matter tracts utilizing different proteolytic enzymes, 
to achieve their goal of both invasion and metastasis. Serine, cysteine and 
metalloproteinases are employed to breakdown connective tissue barriers, induce 
angiogenesis and penetrate normal brain tissue thereby achieving the invasive phenotype 
(reviewed by Rao 2003). The urokinase plasminogen activator (uPA)/plasmin system of the 
serine protease family have been shown to be up-regulated in gliomas (Lakka and Rao 2008) 
and high uPA levels are associated with poor prognosis. Cathepsin B is a lysosomal cysteine 
protease shown to be secreted at increased levels in gliomas, with expression being 
significantly higher in glioblastoma than in low-grade glioma and normal brain (Rao 2003, 
Lakka and Rao 2008).  
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The third and the most widely studied protease system implicated in gliomas are the matrix 
metalloproteinases (MMPs). MMPs are a diverse family of endopeptidases that utilize zinc 
at their active site and encompass a broad spectrum of substrates. Common structural 
features of MMPs include a signal peptide, a catalytic domain which harbors the conserved 
zinc-binding site and a hemopexin-like domain. The proteolytic activity of MMPs affects 
diverse cellular functions such as cell proliferation, adhesion, migration, angiogenesis, bone 
development, wound healing and mammary involution, among others, by virtue of 
cleavage of ECM constituents, pro-growth factors, growth factor receptors and cell adhesion 
molecules. Within the tumor microenvironment, MMPs have been well documented to play 
a critical role in metastasis and angiogenesis (Kessenbrock et al. 2010). 
The family of Metzincin proteinases to which the MMPs belong also includes ADAM (a 
disintegrin and metalloproteinase) and ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs). The ADAMs are mostly cell associated, and responsible for 
cleavage of other proteins like amyloid precursor protein and Notch and hence are also 
called “sheddases”. On the other hand the ADAMTS are secreted (Murphy 2008). The role of 
ADAMs family members in nervous system development has been documented (Yang et al. 
2006).Though these two subfamilies have not been extensively studied in glioma, there is 
some documentation of their role in these tumors. In this context, it has been shown that 
ADAM 8 and 19 are overexpressed in glioma correlating with invasion. ADAMTS 4 and 5 
cleave brevican, a component of the ECM in the normal brain and have been shown to be 
upregulated in glioma cells (Rivera et al. 2010). 
4.2 MMPs and their inhibitors (TIMPs) in glioma 
MMPs span a wide range of subtypes within this family of endopeptidases that utilize zinc 
at their active site and interact with different targets. The proteolytic activity of MMPs 
affects diverse cellular functions as mentioned above, particularly impacting cell 
proliferation, adhesion, migration and angiogenesis. Thus they are important effectors of 
tissue remodeling, acting at various levels. The human MMP family comprises of over 23 
members and cleaves every component of the ECM. They are classified as follows: 
1. The archetypal MMPs: these include the collagenases i.e. MMP-1, MMP-8 and MMP-13; 
Stromelysins include MMP-3, MMP-10, MMP-11; Other archetypal MMPs e.g. the 
metalloelastase i.e MMP-12, also includes MMP-12, MMP-19, MMP-20 and MMP-27 
2. Matrilysins include MMP-7 and MMP-26 
3. Gelatinases include MMP-2 and MMP-9 
4. Membran-type (MT)-MMPs include MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 
and MMP-25 A subgroup of glycosylphosphatidylinositol (GPI) MT-MMP includes 
MMP-17 and MMP-25. 
5. Type II transmembrane MMPs include MMP-23A and MMP-23B-identical proteins 
encoded by distinct genes. 
The MT-MMPs are covalently linked to the cell surface, however secreted ones can also 
attach to the cell membrane by either binding to integrins or to CD44. MMPs are produced 
in cells as zymogens where cysteine from the pro-domain is bound to zinc at the catalytic 
site and require proteolytic cleavage for activation. Activation of MMPs often requires 
cleavage by other MMPs, or serine proteases outside the cell. However some, including the 
membrane-type MMPs, are activated intracellularly (Egeblad and Werb 2002). Besides 
activation of pro-enzymes, MMP activity is also regulated by gene expression, 
compartmentalization and inhibition of active enzymes by their specific tissue inhibitors. 
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Tissue inhibitors of metalloproteinases (TIMPs) are specific endogenous inhibitors of MMPs 
that have been correlated both positively and negatively in glioma invasion. 
4.2.1 MMPs in glioma 
MMP up-regulation has been implicated in several broad disease categories including 
inflammation, vascular pathologies, and cancer. Analysis of MMP expression in cancer 
patients show strong correlation between increased expression of many MMPs and tumor 
progression in a wide range of malignancies including gliomas. Within the tumor, MMPs 
are secreted by tumor cells, as well as by stromal cells of the tumor (Rojiani et al. 2010). It 
appears that tumor cells produce a potent factor called extracellular matrix 
metalloproteinase inducer (EMMPRIN) a cell surface glycoprotein of the immunoglobulin 
superfamily. EMMRPIN stimulates MMP expression in stromal cells and also in tumor cells 
(Jodele et al. 2006). 
Several studies have documented overexpression of MMPs in gliomas compared to normal 
brain tissue. However the MMPs involved in gliomas have almost exclusively been the 
gelatinases MMP-2 and MMP-9 (reviewed by Rao 2003).  
The glioma vasculature as well as infiltrating inflammatory cells, which form a portion of 
the glioma mass have been implicated in MMP expression (VanMeter et al. 2001). Strong 
gelatinase expression correlates with tumor grade (Forsyth et al. 1999, Wang et al. 2003). 
Intracranial implantation of glioblastoma cells in nude mice resulted in increased levels of 
MMP-9 during growth (Sawaya et al. 1998, Chintala et al. 1999). Raithatha et al. (Raithatha et 
al. 2000) carried out an RNA and protein localization study for gelatinases in a set of human 
gliomas with varied malignancy. They found that MMP-2 expression was most prominent 
in tumor cells whereas MMP-9 expression was seen in tumor cell but was more strongly 
expressed in the vasculature. Nakagawa et al. (Nakagawa et al. 1994) reported increased 
MMP-9 levels in blood vessels at proliferating margins. Recently Zhang et al. (Zhang et al. 
2009) showed that knockdown of Akt2 resulted in decreased MMP-9 expression with 
concomitant decrease in glioma invasion in vitro and in vivo. It should be pointed out that 
EMMPRIN levels have been shown to increase in glioma and correlate with tumor grade 
(Sameshima et al. 2000). EMMPRIN has also been shown to increase hyaluronan and co-
localizes with its receptor CD44 (Toole and Slomiany 2008). Given that Hyaluronan and 
CD44 are important players in the CNS and in gliomas (see section 3.4.1) EMMPRIN may 
play a significant role in glioma invasion. 
In vitro studies also manifest a strong correlation between the expression of gelatinases and 
glioma cell invasion (reviewed by Bellail et al. 2004). Using matrigel assay, it was shown that 
the most invasive GBM cell line produced the highest level of gelatinases (Uhm et al. 1996, 
Abe et al. 1994). Besides the gelatinases, there are a number of studies documenting the role 
of MT1-MMP as well as reports of other MMPs involved in gliomas. Lampert et al. (Lampert 
et al. 1998) found increased levels of gelatinases as well as MT1-MMP and MT2-MMP in 
brain tumors. Yamamoto et al. (Yamamoto et al. 1996) found that increased MT1-MMP 
expression is associated with the expression of activated form of MMP-2 which in turn 
correlated with malignant glioma progression in vivo. Overexpression of MT1-MMP in 
glioma cell lines leads to activation of pro-MMP-2 (Nakada et al. 2001, Deryugina et al. 
1997). Additionally, other studies show that MT1-MMP is increased in glioma-associated 
microglia and that glioma-released factors trigger this expression by microglia. The MT1-
MMP then activates glioma-derived proMMP-2 and promotes glioma expansion (Markovic 
et al. 2009). The known classical function of MT1-MMP is activation of proMMP-2 in 
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conjunction with TIMP-2. A complex of MT1-MMP and TIMP-2 interacts with proMMP-2 
thus resulting in cleavage of the pro-domain from MMP-2 (Murphy et al. 1999). Hence, it is 
not surprising that many studies on glioma define activation of proMMP-2. 
The gelatinases MMP-2 and MMP-9 as well as the membrane-type protease MT1-MMP have 
been well documented to play pivotal roles in invasion and angiogenesis (Handsley and 
Edwards 2005). Vascular basement membrane components are well recognized substrates of 
MMP-2 and MMP-9. MMP-9 is a known component of the angiogenic switch regulating the 
bioavailability of VEGF (Bergers et al. 2000). MMP-2 expression has been correlated with the 
degree of vascularization of tumor nodules (Fang et al. 2000). MT1-MMP deficient mice 
have provided convincing evidence for its role in angiogenesis (reviewed by Handsley and 
Edwards 2005). These same MMPs are found at the invasive front of the tumor. Invadopodia 
are actin-rich protrusions of tumor cells with proteolytic activity. The gelatinases and the 
MT1-MMP localize to or become activated at the invadopodia (Stylli et al. 2008). 
Within the realm of glioma angiogenesis, the gelatinases remain crucial. MMP-2 and MMP-9 
showed positive correlation with glioma invasion and angiogenesis (Wang et al. 2003). In a 
mouse model, glioma growth required host MMP-2 to support angiogenesis (Takahashi et 
al. 2002). Small interferring RNA (siRNA)-mediated targeting of MMP-9 inhibits glioma 
angiogenesis in in vitro and in vivo models (Lakka et al. 2005). Hypoxia-inducible factor-1 α 
(HIF1α) was shown to induce recruitment of CD45+ cells amongst other cellular 
components, in a murine glioblastoma model. MMP-9 activity of these bone marrow 
derived CD45+ cells was essential and sufficient to initiate angiogenesis by increasing VEGF 
bioavailability (Du et al. 2008). 
With regard to other MMPs, Lettau et al. (Lettau et al. 2010) have found that MMP-19 is 
strongly expressed in astroglial tumors and is also responsible for the invasion of glioma 
cells in vitro. In a study using the glioma cell line U251, Deng et al. (Deng et al. 2010) found 
that MMP-26 promoted cell invasion in vitro and in vivo. Stojic et al. (Stojic et al. 2008) have 
shown enhanced expression of MMP-1, MMP-11 and MMP-19 in glioblastoma multiforme 
in comparison to low grade astrocytomas and normal brain. Tenascin-C is an ECM protein 
of the brain parenchyma and its synthesis is known to be up-regulated in glioma. MMP-12 
was implicated in the invasion of glioma cell lines using tenascin-C in a three-dimensional 
matrix model (Sarkar et al. 2006).  
Hence, it appears that MMPs play a pivotal role in glioma aggressiveness which would 
appear to make them potential targets for therapy. However, it should be pointed out that 
MMPs, by virtue of their degradation capacity also generate endogenous angiogenesis 
inhibitors. Proteolytic cleavage of plasminogen by several MMPs generates angiostatin and 
endostatin is generated from the C-terminal fragment of collagen type XVIII. MMP-9 is 
involved in the release of Tumstatin, another inhibitor of angiogenesis. MMPs as potential 
targets are further discussed below. 
4.2.2 Tissue Inhibitors of Matrix Metalloproteinases (TIMPS) in glioma 
As mentioned above, MMP regulation occurs at four different levels i.e. transcription, 
zymogen activation, compartmentalization and natural endogenous inhibition. Inhibition by 
α2-macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) occurs in the liquid 
phase and in tissues, respectively (Nagase et al. 1999, Brew et al. 2000). Although TIMPs have 
been known for their primary function of inhibiting MMPs, it has now been widely recognized 
that TIMPs exhibit additional biological activities independent of their MMP inhibitory 
function. There are four TIMP members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4, all of which 
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inhibit MMP activity. TIMP-1, -2 and -4 are secreted, whereas TIMP-3 is associated with the 
extracellular matrix. They are differentially regulated i.e. TIMP-1 expression is inducible, 
whereas TIMP-2 expression is constitutive (Gomez et al. 1997, Nagase et al. 1999). 
The MMP-independent activity of TIMPs includes promotion of cell growth as exhibited by 
TIMP-1 and TIMP-2, apoptosis, angiogenesis as well as a role in cell signaling. These roles of 
TIMPs surfaced when overexpression of these molecules gave conflicting results. There are 
several earlier studies showing an inhibitory role of TIMPs in tumor growth and metastasis; 
however, a number of studies have also demonstrated a tumor-promoting function and 
serum levels of TIMP correlated with poor prognosis as well (reviewed by Rojiani et al. 
2010).  
This paradoxical tumor promoting and tumor inhibiting role of TIMPs extends to gliomas as 
well. In the normal murine brain TIMP-2, -3 and -4 are strongly expressed whereas there is 
very little TIMP-1 expression (reviewed by Crocker et al. 2004) . Studies demonstrating the 
classical role of TIMP show, for example, that adding TIMP-2 to cultured glioblastoma cells 
reduces their invasion (Rao et al. 1994). Likewise, use of recombinant TIMP-1 on glioma cells 
showed reduced glioma invasion (VanMeter et al. 2001). Also, TIMP-1 was shown to cause 
significant reduction in brain metastasis of implanted fibrosarcoma cells (Kruger et al. 1998) 
and a decrease in TIMP-2 levels in glioblastomas has been noted as well (Lampert et al. 
1998). TIMP-3 overexpression suppresses glioma cell infiltration (Baker et al. 1999). 
Interestingly, TIMP-3 gene is one of the most highly methylated genes found in brain 
tumors (Esteller et al. 2001) and has been referred to as a tumor suppressor. 
Nakada et al. (Nakada et al. 2001) found that TIMP-1 but not TIMP-2 levels were 
significantly higher in glioblastoma multiforme compared to other glioma grades when 
using sandwich enzyme immunoassays. The same study developed stable transfectants of 
MT1-MMP and found that invasion and gelatinase activity of these transfectants could be 
totally inhibited by recombinant TIMP-2 but not recombinant TIMP-1. Lampert et al. 
(Lampert et al. 1998) have demonstrated a significant increase in TIMP-1 levels in 
glioblastomas compared to low grade tumors. Pagenstecher et al. (Pagenstecher et al. 2001) 
investigated the expression profiles of 9 MMPs and all TIMPs in different gliomas and 
found that TIMP-1 expression was the highest in GBMs and grade I gliomas with expression 
being confined to walls of neovessels. Groft et al. (Groft et al. 2001) carried out an extensive 
study looking at the expression and localization of all four TIMPs in normal human brains 
and gliomas. A detailed analysis of the expression of mRNA and protein levels showed that 
TIMP-2 and TIMP-3 expression pattern did not alter with tumor grade. However TIMP-1 
levels correlated positively with glioma malignancy, whereas TIMP-4 correlated negatively. 
TIMP-1 transcript expression was localized to tumor cell and the surrounding tumor 
vasculature while TIMP-4 transcripts were found mainly in tumor cells with minor 
expression seen in vessels. These authors also showed that in an in vitro assay, recombinant 
TIMP-4 reduced invasion of U251 glioma cells through Matrigel. Thus, although TIMPs 
have clearly been shown to play a significant role in the invasive and growth aspects of 
glioma, their precise roles remain elusive. However, TIMPs deserve further consideration in 
the search for targeted therapies. 
5. Therapeutic targeting of ECM molecules in glioma 
5.1 Targeting metalloproteinases  
MMPs play a crucial role in tumor growth, metastasis and angiogenesis and therefore have 
been the targets of antitumor therapy. Due to highly pleiotropic activities of MMPs the 
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outcomes of the clinical studies targeting these molecules have been disappointing, resulting 
often in increased tumor growth (reviewed by Rojiani et al. 2011). The initial use of broad 
spectrum MMP inhibitors interfering with the function of many of these enzymes in clinical 
trials had unforeseen consequences and resulted in early termination of these studies 
(reviewed by Coussens et al. 2002). These disappointing results led to the realization that the 
experimental data had to be reevaluated. For example, in animal studies the inhibitors were 
administered in early or intermediate stages of cancer whereas in humans they were 
administered in advanced stages. Besides, it has now been well documented that a number 
of MMPs play a protective role and their elimination can have adverse consequences 
(Martin and Matrisian 2007).  
However, given their significant contribution to tumor progression, MMPs still remain 
strong potential target candidates for therapeutic interventions. Therefore, it is not 
surprising that there are a number of MMP inhibitors (MMPI) in clinical trials (reviewed by 
Roy et al. 2009). Their effectiveness has yet to be proven. Also, the timing of delivery has 
been reconsidered since drugs given at earlier stages of cancer appear to be more effective 
than when given in advanced stages (Roy et al. 2009). 
Despite the adaptation of clinical trials and because of the pleiotropic activities of MMPs, a 
prediction of outcome is still difficult. Therefore, attention is now also given to other ECM 
molecules in the glioma microenvironment. New classes of targets need to be identified, eg. 
ECM molecules found within the cancer stem cell niche. Examples of other ECM targets are 
discussed below (sections 5.2, 6.1 and 6.2).  
5.2 Targeting HA and CD44 adhesion molecule  
We showed previously that blocking CD44 and interfering with HA-CD44 ligand-receptor 
interaction resulted in inhibition of glioma cell invasion, decreased HA production and led 
to glioma cell apoptosis (Wiranowska et al. 1998, Wiranowska et al. 2010). In addition, recent 
data by Xu et al. (Xu et al. 2010) showed that CD44 attenuates activation of the Hippo 
signaling pathway and that knockdown of CD44 expression resulted in the inhibition of 
glioblastoma. It was suggested that CD44 is a prime therapeutic target for treatment of 
glioblastoma (Xu et al. 2010). Therefore, further studies of this promising biological target 
molecule in glioma are warranted. The soluble recombinant CD44-HA-binding domain 
(CD44-HABD) inhibited proliferation of endothelial cells in vitro , blocked angiogenesis in 
vivo and inhibited growth of various tumors (Pall et al. 2004) providing hope for a new 
therapeutic approach to glioma. In addition, HA was recently used in vivo as a delivery 
carrier for chemotherapeutic paclitaxel (HA-paclitaxel) targeting CD44 positive ovarian 
carcinoma (Auzenne et al. 2007). Also, recently cisplatin carrying HA nanoparticles were 
evaluated as potential treatment for cancer (Jeong et al. 2008).  
6. Future therapies of glioma 
6.1 ECM therapeutic targets: Hopes and disappointments 
Current therapies like surgery, radiotherapy and chemotherapy are aimed at debulking of 
the brain tumor mass as well as targeting and eradicating proliferating tumor cells. 
However, these therapies do not address the quiescent population of the cancer stem cells. 
These cells, which are nourished and protected from therapeutic interventions by the 
microenvironment of the CSCs vascular niche can repopulate and initiate new tumor foci in 
the brain (Denysenko et al. 2010) 
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The modulation of the ECM microenvironment of the stem cell niche may be a promising 
approach especially in light of the finding that many of the genes and their products 
prognostic for the faith of proneural GBM were identified in the stroma of the brain tumor 
but not in the brain tumor cells themselves (as mentioned in Section 1: Holland 2011). 
Therapies targeting solely the brain tumors and their CSCs population may not be 
successful due to the high complexity and heterogeneity of brain tumors as demonstrated 
by the existence of various subtypes of GBMs. In addition, the genetic instability in 
expressing markers for undifferentiated cells within these tumors makes it difficult to assign 
the correct differentiation status of the tumor cells (Denysenko et al. 2010). Therefore, other 
therapeutic options should be pursued including therapies targeting the ECM of the CSCs 
vascular niches which would disrupt the microenvironment protective and supportive of 
the CSCs’ self-renewal.  
One of the stimulatory pro-angiogenic molecules released within the CSCs niche which 
enhances the survival of neural stem cells is VEGF (section 3.2). It has been shown that 
targeting VEGF and disruption of the niches by anti-VEGF treatment in vivo resulted in 
CSCs depletion and tumor growth inhibition (Calabrese et al. 2007). Some other studies 
however, showed that blocking VEGF in vivo resulted in growth of satellite tumors 
(Rubenstein et al. 2000). The early data obtained from clinical trials of GBM patients using 
VEGF-specific inhibitors such as bevacizumab combined with chemotherapeutic drug CPT-
11, showed promising results (Calabrese et al. 2007). However, recent finding by Ricci-
Vitiani et al. (Ricci-Vitiani et al. 2010) and Wang et al. (Wang et al. 2010) showed that newly 
formed blood vessels originating from the GBM stem cells that differentiated into 
endothelial cells were not responsive to anti-VEGF therapy (section 3.2). Most recently, it 
has been shown (di Tomaso et al. 2011) that patients treated with anti-VEGF therapy still 
contained Nestin + cells, a characteristic marker of the CSCs, despite a decreased 
vascularization of the brain tumors. The phase II results from anti-VEGF therapy in 
combination with chemotherapeutic CPT-11 failed to show prolonged survival of the GBM 
patients (Lai et al. 2011). Similar results were obtained from phase III clinical studies with 
recurrent GBM patients treated with cediranib, an inhibitor of VEGF alone or in 
combination with chemotherapeutic lomustine (Batchelor, 2010). In addition, it was shown 
recently by Takano et al. (Takano et al. 2010) that failure of bevacizumab treatment was 
associated with the high incidence of infiltrative tumors and MMP activity in the samples of 
urine. Therefore, based on the current state of knowledge, other approaches targeting ECM 
molecules of the vascular niche of CSCs need to be developed. 
6.2 Glioma possible new prognostic factors and new targets 
6.2.1 ECM prognostic factors  
There is evidence that some ECM molecules could serve as prognostic markers of anti-
angiogenic therapy of glioma indicative of the fate of the therapy. For example, Takano et al. 
(Takano et al. 2010) found that failure of bevacizumab (anti-VEGF antibody) treatment was 
associated with the high incidence of infiltrative tumors and levels of MMP activity in urine. 
Therefore, early detection and measurement of urine MMPs activity in samples from 
patients could be indicative of progressive disease. The detection of this biomarker could 
allow for earlier therapeutic intervention or alteration of a given anti-glioma therapy. 
Another ECM prognostic factor of potential therapeutic value could be presence of soluble 
collagen IV in the blood. It was shown by Sorensen et al. (Sorensen et al. 2009) that in 
patients treated with anti-angiogenic therapy using cediranib (pan-VEGF receptor tyrosine 
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kinase inhibitor) increased levels of collagen IV were found. This increase in circulating 
collagen IV was explained as the result of “blood vessels normalization” involving thinning 
of the abnormally thick tumor associated basement membrane of blood vessels. Increased 
levels of circulating collagen IV were associated with progression-free and overall patient 
survival.  
6.2.2 New ECM targets 
Recent data by Inoue et al. (Inoue et al. 2010) showed that cancer stem-like cells of GBM 
express MMP-13 responsible for invasion and migration of these cells suggesting that, 
MMP-13 might be a potential new therapeutic target for glioblastomas. Blocking VEGF or 
silencing VEGF receptor 2 inhibits the maturation of tumor endothelial progenitors into 
endothelium but does not stop the differentiation of CSCs (CD133+ cells) into endothelial 
cells. However, silencing of Notch (neural precursor receptor as mentioned in section 2.2) 
blocks the transition of CSCs (CD133+ cells) into endothelial progenitors (Wang et al. 2010). 
Therefore, Notch may be another potential new target in the stem cell niche. Fujita et al. 
(Fujita et al. 2011) showed that non-steroidal anti-inflammatory drugs (NSAID) such as Cox-
2 inhibitors suppressed gliomagenesis via inhibition of prostaglandin E2 mediated 
accumulation of myeloid derived suppressor cells. In addition, as mentioned earlier (section 
3.1) the Cox-2 inhibitor, celecoxib, inhibited in vitro microvascular channel formation 
associated with VEGF down regulation (Basu et al. 2005). The effect was more pronounced 
and prostaglandin E2-independent in a highly invasive breast cancer cell line when 
compared to a less invasive cell line. Based on these findings, it could be hypothesized that 
the NSAID class may have potential application in highly invasive glioma by targeting of 
the inflammatory molecules and immune cells as well as VM channel formation in the ECM. 
7. Summary and conclusions 
Despite years of research, glioma therapy remains a challenge due to very limited 
therapeutic options and short survival of glioma patients (as described in section 1). Until 
recently the focus of research evaluating possible target molecules for treatment was mainly 
on the cancer cell itself and its genetic characterization. Therefore, routine anti-glioma 
therapies such as chemotherapy or radiation are solely focused on targeting proliferating 
glioma cells by interfering with their cell cycle and resulting in glioma cell death. Very little 
attention was given to evaluation and validation of therapeutic targets in the extracellular 
matrix in glioma, its vasculature and brain stroma outside the tumor. Recent clinical trials 
targeting glioma vasculature with anti-angiogenic molecules initially provided encouraging 
results but later failed to be effective in slowing glioma progression. On the contrary, some 
of the anti-angiogenic treatments despite achieving blood vessel “normalization” within the 
tumor later resulted in the development of new glioma foci in the brain parenchyma away 
from the main lesion. It became known recently that a population of glioma CSCs present 
within the tumors was capable of escaping this anti-angiogenic therapy giving rise to tumor 
endothelium which had no markers for anti-angiogenic therapy.  
Another attempt to stop glioma cell invasion into the normal brain parenchyma involved 
targeting various MMPs responsible for remodeling ECM during glioma progression. 
Although there were high expectations, the results of these studies were disappointing 
again. It was found that many of the targeted MMPs had anti-tumor as well as tumorigenic 
activities and blocking or eliminating their activity lead to glioma regrowth. Clearly, the 
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ECM and the surrounding stroma play an essential role in glioma progression but more 
studies need to be done in order to find proper targets within the ECM to slow or inhibit 
glioma growth. This is supported by most recent finding by Holland (Holland 2011) that 
genes expressed in the microenvironment of the stroma rather than in the glioma itself may 
be predictive of glioma patient survival. This chapter provides a review of recent 
information relating to ECM targets for anti-glioma therapy. Consideration was given to 
various ECM molecules within the normal brain, in glioma and in the vascular niche 
harboring glioma stem cells. Consideration was also given to ECM rigidity and its effect on 
glioma progression. In addition to discussing some pertinent ECM molecules in glioma 
progression, also new emerging ECM targets and new prognostic markers candidates were 
discussed. All in all, ECM molecules are of great importance in the development of new 
therapeutic strategies and the information compiled in this chapter summarizing their role 
should be suitable to give guidance for the search and the development of new ECM anti-
glioma targets.  
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1. Introduction 
Chemoattractant receptors are a superfamily of G-protein coupled seven transmembrane 
cell surface receptors (GPCRs), which transduce extracellular signals into intracellular 
effector pathways through the activation of heterotrimeric G proteins. This superfamily 
includes GPCRs for classical chemoattractants such as formyl peptides (fMLF) produced by 
Gram negative bacteria and host cell mitochondria, the complement cleavage components, 
leukotriene B4 (LTB4), and platelet activating factor (PAF) as well as GPCRs for chemokines 
(Le et al., 2002).  
Chemoattractant GPCRs have the ability to mediate directional migration of cells along a 
gradient of a chemoattractant. Initially, these receptors were identified mainly on 
leukocytes, where they play an important role in the trafficking of such cells to sites of 
inflammation and to lymphoid organs in immune responses (Le et al., 2004). However, 
during the past few years, both hematopoietic and nonhematopoietic cells have been found 
to express various chemoattractant GPCRs and are capable of migrating in response to 
agonists produced in tissue microenvironment. The interaction of chemoattractant GPCRs 
with their agonists participates in a variety of essential pathophysiological processes 
including immune responses, inflammation, host defense against microbial infection, 
hematopoiesis as well as cancer progression and metastasis (Huang et al., 2008).  
Chemoattractants and their GPCRs are widely expressed in the brain by neurons, glial and 
microglia cells. They are involved not only in cell migration during development and 
inflammation, but also act as regulators of neuronal survival, neurotransmission and cell-
cell communications (Ambrosini and Aloiso, 2004), as the third major transmitter system in 
the brain (Adler and Rogers, 2005). In addition, chemoattractants and their GPCRs are 
disregulated in neurodegenerative diseases, multiple sclerosis and brain tumors (Balkwill, 
2004; Ransohoff et al., 2007). A number of chemoattractant GPCRs have been detected in 
glioma cells including FPR1 and chemokine GPCRs (Table 1).  
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1. Introduction 
Chemoattractant receptors are a superfamily of G-protein coupled seven transmembrane 
cell surface receptors (GPCRs), which transduce extracellular signals into intracellular 
effector pathways through the activation of heterotrimeric G proteins. This superfamily 
includes GPCRs for classical chemoattractants such as formyl peptides (fMLF) produced by 
Gram negative bacteria and host cell mitochondria, the complement cleavage components, 
leukotriene B4 (LTB4), and platelet activating factor (PAF) as well as GPCRs for chemokines 
(Le et al., 2002).  
Chemoattractant GPCRs have the ability to mediate directional migration of cells along a 
gradient of a chemoattractant. Initially, these receptors were identified mainly on 
leukocytes, where they play an important role in the trafficking of such cells to sites of 
inflammation and to lymphoid organs in immune responses (Le et al., 2004). However, 
during the past few years, both hematopoietic and nonhematopoietic cells have been found 
to express various chemoattractant GPCRs and are capable of migrating in response to 
agonists produced in tissue microenvironment. The interaction of chemoattractant GPCRs 
with their agonists participates in a variety of essential pathophysiological processes 
including immune responses, inflammation, host defense against microbial infection, 
hematopoiesis as well as cancer progression and metastasis (Huang et al., 2008).  
Chemoattractants and their GPCRs are widely expressed in the brain by neurons, glial and 
microglia cells. They are involved not only in cell migration during development and 
inflammation, but also act as regulators of neuronal survival, neurotransmission and cell-
cell communications (Ambrosini and Aloiso, 2004), as the third major transmitter system in 
the brain (Adler and Rogers, 2005). In addition, chemoattractants and their GPCRs are 
disregulated in neurodegenerative diseases, multiple sclerosis and brain tumors (Balkwill, 
2004; Ransohoff et al., 2007). A number of chemoattractant GPCRs have been detected in 
glioma cells including FPR1 and chemokine GPCRs (Table 1).  
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Ligand (cell sources) Major effects on glioma References 





Zhou et al., 2005; 
Huang et al., 2007, 
2008, and 2010 
CXCR1  
(glioma cells) 




CXCL8 (glioma cells) Angiogenesis Brat DJ et al., 2005 
CXCR3  
(glioma cells) 
CXCL10 (glioma cells) ; 
CXCL9 (glioma cells) 
Proliferation; Growth Liu et al., 2010;  
Maru et al., 2008 
CXCR4  
(glioma cells) 
CXCL12 (glioma cells 
and stromal cells) 
Growth; Angiogenesis; 
Migration  
Ping et al., 2007 and 
2011 
CXCR5 
 (glioma cells) 
CXCL13 (glioma cells) Not clear Bajetto et al., 2006 
CXCR7  
(glioma cells) 
CXCL12 (glioma cells 
and stromal cells) 
Anti-apoptosis Hattermann et al., 2010 
CCR2A 
(glioma cells) 
CCL2 (glioma cells) Migration Liang Y et al., 2008 
CCR3 (glioma cells) CCL3L1 (glioma cells) Proliferation Kouno et al., 2004 
CCR4 (Treg cells) CCL22 (glioma cells) Treg infiltration Jacobs et al., 2010  
CCR5 (glioma cells) CCL3L1 (glioma cells) Proliferation Kouno et al., 2004 
CX3CR1 
(glioma cells and 
GIMs) 
CX3CL1 (glioma cells) Tumorigenesis; Pro-or 
anti-invasion based on 
whether CX3CL1 is  
soluble or membrane 
bound.  
Liu et al., 2008 
GIMs: glioma infiltrating macrophages; Treg: regulatory T cells.  
Table 1. The expression of chemoattractant GPCRs in glioma 
Glioma is the most common tumor type in human brain. Nearly two-thirds of human 
gliomas are highly malignant with rapid progression, high invasiveness, vigorous 
angiogenesis and resistance to chemotherapy and radiation treatment (Bar, 2011). 
Glioblastoma (GBM), the most aggressive form of malignant glioma, is characterized by 
extensive infiltration into the surrounding normal brain tissues and multifocal necrosis. 
Despite multiple therapeutic regimens (Jahraus and Friedman, 2010), the 2-year survival 
rate of patients with GBM is less than 30% and has not changed over the past two decades. 
Because of the increasing incidence of GBM and very poor prognosis, a better 
understanding of GBM initiation and progression is crucial for the development of more 
effective therapeutic approaches. GBM cells utilize the normal physiological functions of 
chemoattractant GPCRs to promote their growth by sensing cognate ligands produced in 
the microenvironment that enhance tumor cell proliferation, invasion and the production of 
angiogenic factors such as vascular endothelial cell growth factor (VEGF) and the 
chemokine CXCL8 (IL-8) (Yao et al., 2008; Ping et al., 2007). Recently, the chemoattractant 
GPCRs FPR1 and CXCR4 were also found to be expressed by glioma stem-like cells (GSLCs) 
and to mediate GSLC chemotaxis and the production of VEGF (Ping et al., 2007; Yao et al., 
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2008; Ping et al., 2011), suggesting the important role of these GPCRs in glioma initiation. In 
this article, we will review the contribution of chemoattractant GPCRs in glioma progression 
and discuss the potential for GPCRs as therapeutic targets in glioma.  
2. The role of the classical chemoattractant GPCR, FPR1, in the progression 
of GBM  
2.1 Identification of FPR1 in GBM 
Human FPR1 (originally named FPR) was detected in 1976 on the surface of human 
neutrophils, and was cloned in 1990 from a myeloid leukemia-cell line. FPR1 binds N-
formyl-methionyl-leucyl-phenylalanine (fMLF), a product of the Gram negative bacteria, as 
well as mitochondria formylated peptide, and elicits a cascade of signal transduction events 
mediated by pertussis toxin-sensitive G proteins of the Gi subtype and controlled by 
phospholipase C (PLC) and phosphoinositide (PI) 3 kinases (Pan et al., 2000). Human 
myeloid cells activated by FPR1 agonist peptides undergo rapid shape change, showing 
increased adhesion, chemotaxis, phagocytosis and release of bactericidal and 
proinflammatory mediators. These functions of FPR1 enable myeloid cells to have 
proinflammatory and antimicrobial activities. In fact, depletion of the human FPR1 
counterpart mFPR1 from mice decreased their resistance to infection by Listeria 
monocytogenes. Although FPR1 has been shown to be a GPCR that mediates host defense 
against bacterial infection by phagocytic leukocytes, we found that FPR1 was also selectively 
expressed by tumor cells in more highly malignant human glioma specimens (Zhou et al., 
2005). These findings prompted us to use established human glioma cell lines to investigate 
the relationship between FPR1 expression and the biological behavior of the tumor cells. For 
example, the human GBM cell line U87 expresses higher levels of FPR1 and forms more 
rapidly growing tumors in nude mice than glioma cell lines derived from low grade 
gliomas, which do not express FPR1 (Zhou et al., 2005). Therefore, observations with glioma 
cell lines lead us to hypothesize that FPR1 is selectively expressed by more highly malignant 
glioma cells and may play a role in promoting tumor growth.  
2.2 Function of FPR1 in GBM cells 
The function of FPR1 in GBM cells was extensively examined by using the prototype 
chemotactic agonist peptide, bacterial fMLF as a stimulator. In addition to inducing robust 
chemotaxis and calcium mobilization of GBM cells by fMLF, FPR1 exhibited several unique 
properties that are closely related to tumor progression. For instance, activation of FPR1 in 
GBM cells under suboptimal culture conditions (i.e. at low fetal calf serum (FCS) 
concentration) supports the survival of tumor cells in association with increased 
intracellular levels of the anti-apoptotic protein Bcl-2. In addition, FPR1 agonist peptide 
activated two important transcription factors, namely NF-κB and STAT3 in GBM cells. 
Increased NF-κB translocation has been observed as a consequence of FPR1 signaling 
pathway also in phagocytic leukocytes (Huang et al., 2001); FPR1 signaling in GBM cells 
stimulated the phosphorylation of STAT3 at Ser-727 and Tyr-105 residues, while only Ser-
727 was phosphorylated in human monocytes. Another transcription factor hypoxia 
inducible factor-1α (HIF-1α), which induces the adaptation to hypoxic microenvironment by 
regulating the gene transcription in several processes such as cell oxygen uptake, glucose 
metabolism, angiogenesis, cell survival and apoptosis, was also activated by FPR1 agonists 
in GBM cells (Zhou et al., 2005).  
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Since both STAT3 and HIF-1α are implicated in the transcriptional activation of the gene 
coding for VEGF, we investigated the effect of activating FPR1 on the production of VEGF 
by tumor cells. We found that supernatants from fMLF-stimulated GBM cells induced the 
migration and tubule formation of human vascular endothelial cells (EC) (Zhou et al., 2005). 
This property of the tumor cell supernatant was abolished by a neutralizing anti-human 
VEGF antibody (Zhou et al., 2005), suggesting VEGF was released by FPR1 agonist-
stimulated GBM cells. FPR1 in GBM cells was subsequently shown to promote the release of 
another angiogenic factor, the chemokine CXCL8 (IL-8) (Yao et al., 2008). The contribution of 
FPR1 to GBM progression was then tested in vivo in nude mice. Tumor cells containing 
small interference (si) RNA targeting FPR1 mRNA yielded tumors in nude mice with 
markedly reduced rate of growth as compared to control cells transfected with random 
siRNA (Zhou et al., 2005). Thus, the functional studies provide strong evidence for the 
involvement of FPR1 in supporting the rapid progression of GBM.  
Crosstalk between GPCRs and growth factor receptors plays an important role in orchestrating 
the interaction of intracellular signaling molecules implicated in tumor growth, angiogenesis 
and metastasis (Lappano and Maggiolini, 2011). The crosstalk between GPCRs and the 
receptor for epidermal growth factor (EGFR) has been shown to promote the progression of 
colon, lung, breast, ovarian, prostate, and head and neck carcinomas (Hart et al., 2005). Like 
many malignant tumors of human and mouse origin, human GBM cells express high levels of 
EGFR and stimulation with EGF increases tumor cell chemotaxis and proliferation with rapid 
phosphorylation of at least 4 tyrosine residues in the C-terminal domain of EGFR (Huang et 
al., 2007). When GBM cells were stimulated with the FPR1 agonist fMLF, EGFR was also 
rapidly phosphorylated but with restriction to a single tyrosine residue Tyr992. This 
transactivation of EGFR by FPR1 agonist peptide accounted for approximately 40% of the 
biological activity of FPR1 in GBM cells and was dependent on a Src kinase pathway (Huang 
et al., 2007). Moreover, GBM cells depleted of either FPR1 or EGFR grew more slowly as 
compared with parental cells and depletion of both receptors further reduced the 
tumorigenicity of the GBM cells (Huang et al., 2007). Thus, FPR1 aberrantly expressed in GBM 
cells is capable of exploiting the function of EGFR to exacerbate the malignant behavior of the 
tumor cells. Since interference with both receptors additionally reduced tumor growth, FPR1 
and EGFR also had non-redundant functions (Huang et al., 2008).  
2.3 The involvement of FPR1 in GBM cell invasion 
The ability of GBM cells to invade into surrounding brain tissue is a critical pathological 
event in the progression of GBM. In the human GBM cell line U87, there are FPR1+ and 
FPR1- subpopulations which could be isolated and cloned. FPR1+ cells showed a more 
“motile” phenotype in vitro as compared with cells lacking FPR1 expression (Huang et al., 
2010). Moreover, although both FPR1+ and FPR- GBM cells implanted subcutaneously into 
nude mice developed tumors, only tumors formed by FPR1+ cells invaded the surrounding 
connective tissues. In addition, FPR1- cells transfected with FPR1 showed enhanced 
mobility in vitro and the in vivo capacity to form more rapidly growing and invasive 
tumors in mice. Tumor invasion depends not only on tumor cell mobility, but also on the 
capacity of tumor cells to secrete metal matrimetalloproteases (MMPs) that degrade 
extracellular matrix (ECM) and facilitate the detachment of highly motive tumor cells. 
Stimulation of GBM cells with FPR1 agonist peptide up-regulates the expression of MMP2 
and MMP9 and increases the release of pro-MMP2. As reported in the literature, regulation 
of MMPs is controlled by AP1 transcription factor complex through MAP kinase pathways 
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and PKC, which are activated by FPR1 agonist in GBM cells. Thus stimulation of FPR1 
activates MMPs in GBM cells and increases proteolytic processes in the tumor 
microenvironment (Huang et al., 2010).   
2.4 Identification of endogenous FPR1 agonist released by necrotic GBM cells  
Despite extensive characterization of FPR1 function in GBM cells, whether host-derived 
agonists are present in the tumor microenvironment remains unknown. We tested GBM cell 
responses to the neutrophil granule protein cathepsin G, which is an endogenous agonist for 
FPR1 and induces the migration of myloid cells. We determinated that cathepsin G is 
capable of inducing the migration of GBM cells expressing FPR1 (Sun et al., 2004). However, 
cathepsin G is unlikely to be present in brain unless substantial tissue damage compromises 
the blood brain barrier and results in the release of this FPR1 agonist into the brain by 
neutrophils. We therefore examined other possible sources of potential FPR1 agonists that 
may act on GBM cells. Since mitochondrial peptides are also potential endogenous FPR1 
agonists and GBMs frequently contain necrotic foci in the rapidly growing tumor mass that 
may release mitochondrial components, we examined the presence of FPR1 agonists in 
supernatants of necrotic tumor cells. Indeed, supernatants of necrotic GBM cells and tumors 
formed by GBM cells in nude mice induced potent chemotaxis of live GBM cells as well as a 
rat basophil leukemia-cell line transfected to express human FPR1 (ETFR cells). The 
chemotactic activity released by necrotic GBM cells and tumor tissues was blocked by an 
anti-FPR1 antibody and by a FPR-specific antagonist tBoc-MLF (Zhou et al., 2005). The 
robust intracellular Ca2+ mobilization induced in GBM cells by necrotic GBM cell 
supernatant attenuated the subsequent cell response to fMLF, suggesting that agonist 
contained in the supernatants of necrotic tumor cells share a receptor with fMLF (Zhou et 
al., 2005). Further evidence to support the release of FPR1 agonists by necrotic GBM cells 
was provided by the observation that the tumor cell supernatant down-regulated FPR1 
expressed on the surface of human monocytes and FPR1 expressing ETFR cells. These 
observations confirm that FPR1 expressed on GBM cells is able to recognize agonist activity 
released in the tumor microenvironment in a paracrine and/or autocrine loop (Zhou et al., 
2005). Our recent effort to characterize the biochemical nature of the FPR1 agonist activity 
released by necrotic GBM cells revealed that the glucocorticoid binding protein annexin1 
(AnxA1), which has been reported to be an agonist for FPR1 and its variant receptor FPR2, 
can promote tumor cell invasion and angiogenesis. AnxA1 accounts for the majority of the 
FPR1 agonist activity released by necrotic GBM cells because depletion of AnxA1 from the 
necrotic tumor supernatant markedly reduced its capacity to stimulate FPR1 on viable GBM 
cells (Yang et al., unpublished observation). We therefore established a paradigm for the 
role of FPR1 in GBM progression in which FPR1 in GBM cells by responding to necrotic 
tumor cell-released agonist such as AnxA1 transactivates EGFR and the two receptors co-
operate to promote the growth, invasion, angiogenesis and progression of GBM (Fig 1A). 
3. The role of the chemokine GPCR CXCR4 in glioma progression 
3.1 CXCR4 and its ligand CXCL12  
CXCR4 selectively binds the CXC chemokine stromal cell-derived factor 1 (SDF-1), also 
known as CXCL12 (Furusato et al., 2010). CXCR4 is normally expressed in a wide variety of 
cells and tissues. The CXCR4 agonist CXCL12 was first cloned from a murine bone marrow 
stromal cell line, and was produced in high quantity by marrow stromal cells. In addition to 
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mediating cell chemotaxis in response to CXCL12, CXCR4 also acts as a co-receptor for CD4 
cell entry of T tropic HIV. In mouse models, deletion of CXCL12 or CXCR4 results in 
embryonic death with defects in the development of cardiac and central nervous systems as 
well as reduction in hematopoietic stem-cell homing (Zou et al., 1998). CXCR4 is up-
regulated in more than 20 different types of malignant tumors (Kryczek et al., 2007). Further 
studies show that CXCR4 regulates tumor progression by mediating tumor cell proliferation 
and metastasis as well as angiogenesis.  
3.2 The effect of CXCR4 on glioma invasion and metastasis 
CXCR4 expression was detected in primary human glioma specimens and the level of 
CXCR4 was correlated with the degree of malignancy of the tumors. In vitro, CXCR4+ 
malignant glioma cells secrete its ligand CXCL12, suggesting that two molecules may exert 
paracrine and autocrine regulation of glioma progression (Bajetto et al., 2006). Studies 
performed in human GBM specimens demonstrated that tumor cells infiltrating into 
surrounding brain tissues express higher levels of CXCR4, suggesting CXCR4 expression 
may define more highly invasive tumor cells. This is corroborated by in vitro experiments 
showing that invasive human glioma cells overexpress CXCR4 as compared with 
noninvasive tumor cells (Ehtesham et al., 2006). Invasive cells isolated from rat C6 glioma 
cell line express both CXCR4 and CXCL12 at high levels (Ehtesham et al., 2006). Moreover, 
application of CXCR4 antagonist or siRNA targeting CXCR4 in vivo inhibited the invasion 
of tumors formed by invasive C6 glioma cells.  
The invasion process of GBM requires the detachment of invading cells from tumor mass, 
attachment of tumor cells to ECM components, ECM degradation, and subsequent cell 
infiltration into surrounding brain tissues. Attachment of tumor cells to ECM components is 
an essential phase of invasion mediated by integrins that are overexpressed on both glioma 
cells and tumor vasculature. Recognition of CXCL12 by CXCR4 activates tumor-associated 
integrins, such as α2, α4, α5, and β1 to promote tumor dissemination (Hartman et al., 2004, 
and 2005). Inhibition of integrin function disrupts GBM cell migration. In vitro, interference 
of CXCR4 with the urokinase-receptor (uPAR) reduces the adhesion of CXCL12-mediated 
CXCR4+ GBM cells to collagen, the main component of ECM (Montuori et al., 2010).  
ECM degradation by MMPs enhances tumor invasion. In vitro, glioma cells with lower 
production of MMP-9 show diminished migration and invasion and such cells no longer 
form tumors following intracranial injection into nude mice. MMP-2 and -9 have been 
identified as MMPs in high grade gliomas and their level of expression directly correlates 
with the grade of glioma malignancy (Stojic et al., 2008). Similar to FPR1, CXCR4 mediated 
glioma invasion in vivo was also associated with its capacity to activate MMPs (Kryczek et 
al., 2007). It has been reported that CXCR4/ERK/NF-κ B signaling pathway induces the up-
regulation of MMPs in glioma cells. Activation of CXCR4 by its ligand CXCL12 also 
promotes tumor invasion by release of MMP-9. 
3.3 CXCR4 in glioma growth and angiogenesis  
3.3.1 Role of CXCR4/CXCL12 in malignant glioma growth and survival  
The CXCR4 ligand CXCL12 produced by tumor and stromal cells interacting with CXCR4 
on tumor cells results in the activation of several downstream pathways, including 
MAPK/ERK1/2, PI3k and Akt, as well as NF-κB. These pathways are known to participate 
in the regulation of cell proliferation and survival in normal or malignant glial cells. In vitro 
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activation of CXCR4 promotes the proliferation of GBM cell lines based on the activation of 
ERK1/2 and PI3K/Akt (Bian et al., 2007). In agreement with data obtained from GBM cell 
lines, 80% of clinical GBM samples express high levels of phosphorylated Akt 
(Hambardzumyan et al., 2008). CXCL12 induces the proliferation of primary GBM cells 
expressing CXCR4 by significantly increasing DNA synthesis in tumor cells (do Carmo et 
al., 2010). CXCR4-mediated tumor cell proliferation may also be amplified by EGFR 
signaling, since stimulation of CXCR4 has been reported to transactivate EGFR in many 
tumors of the epithelial lineage (Dolce et al., 2011). In fact, as discussed earlier, EGFR in 
GBM cells is transactivated by another chemoattractant GPCR FPR1, and the two receptors 
co-operate to promote the growth of GBM (Huang et al., 2007). The role of CXCR4 in 
promoting glioma growth was further supported by the use of a small molecule CXCR4 
antagonist, AMD3100, which significantly inhibited tumor cell proliferation in vitro and 
tumorigenicity in nude mice (do Carmo et al., 2010; and Dolce et al., 2011).  
Another important property of CXCR4 is to increase GBM cell resistance to apoptosis. 
Blockade of CXCR4 in glioma cells by the antagonist AMD3100 increased the rate of 
apoptosis, confirming the ability of CXCR4 to support tumor cell survival (do Carmo et al., 
2010). This anti-apoptotic effect is associated with the activation of PI3K/Akt (do Carmo et 
al., 2010), an observation consistent with results obtained from a variety of tumors in which 
CXCR4 actively contributes to the resistance of tumor cells to apoptosis. Stimulation of 
CXCR4 activates NF-κB, which in turn inhibits radiation-induced TNF-α production by 
glioma cells and increases tumor cell survival. In addition to directly protecting tumor cells 
from radiation-induced apoptosis, CXCR4 indirectly promotes cell survival by increasing 
their adherence. For example, stimulation of CXCR4 promotes the adhesion of glioma cells 
to vitronectin, a glioma-derived extracellular matrix protein, and prevents tumor cell death 
(do Carmo et al., 2010). Taken together, published results support the conclusion that 
CXCR4 plays an important role in promoting the proliferation and survival of glioma cells.  
3.3.2 CXCR4 promotes the production of angiogenic factors by glioma cells 
The requirement of CXCR4 and CXCL12 for angiogenesis was revealed by the prenatal 
lethal phenotype of both CXCR4 and CXCL12 knockout mice due to defects in the vascular 
development of gastrointestinal tract and cardiogenesis (Tachibana et al., 1998). In vitro, 
activation of CXCR4 in ECs stimulates the formation of capillary-like tubules (Salvatore et 
al., 2010). ECs in gliomas have been shown to be genetically and functionally distinct from 
normal ECs, and exhibit higher expression of CXCR4 and its ligand CXCL12. Proliferating 
ECs in GBM are positive for CXCR4 and its ligand CXCL12, while ECs that form a single 
layer in the capillaries of the anaplastic astrocytoma appeared to be negative for these two 
molecules. The lower levels of CXCR4/CXCL12 expression in anaplastic astrocytoma may 
contribute to the lower density of proliferating microvasculature. Consistent with these 
observations, CXCR4 and CXCL12 are detected in both malignant glioma cells and vascular 
ECs are associated with increased cell survival (Salmaggi et al., 2004). 
Interestingly, elevated CXCL12 levels by themselves in gliomas failed to induce significant 
vascularization. This was associated with the co-presence of low levels of VEGF, suggesting 
synergism of these angiogenic factors (Kryczek et al., 2005). In fact, although a major 
angiogenic factor in GBM, VEGF was detected only in a few cells or not at all in low-grade 
astrocytomas or in the normal brain tissue (Takano et al., 2010). Clinical and experimental 
evidence indicates that CXCR4 activation induces the production of VEGF in human glioma 
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mediating cell chemotaxis in response to CXCL12, CXCR4 also acts as a co-receptor for CD4 
cell entry of T tropic HIV. In mouse models, deletion of CXCL12 or CXCR4 results in 
embryonic death with defects in the development of cardiac and central nervous systems as 
well as reduction in hematopoietic stem-cell homing (Zou et al., 1998). CXCR4 is up-
regulated in more than 20 different types of malignant tumors (Kryczek et al., 2007). Further 
studies show that CXCR4 regulates tumor progression by mediating tumor cell proliferation 
and metastasis as well as angiogenesis.  
3.2 The effect of CXCR4 on glioma invasion and metastasis 
CXCR4 expression was detected in primary human glioma specimens and the level of 
CXCR4 was correlated with the degree of malignancy of the tumors. In vitro, CXCR4+ 
malignant glioma cells secrete its ligand CXCL12, suggesting that two molecules may exert 
paracrine and autocrine regulation of glioma progression (Bajetto et al., 2006). Studies 
performed in human GBM specimens demonstrated that tumor cells infiltrating into 
surrounding brain tissues express higher levels of CXCR4, suggesting CXCR4 expression 
may define more highly invasive tumor cells. This is corroborated by in vitro experiments 
showing that invasive human glioma cells overexpress CXCR4 as compared with 
noninvasive tumor cells (Ehtesham et al., 2006). Invasive cells isolated from rat C6 glioma 
cell line express both CXCR4 and CXCL12 at high levels (Ehtesham et al., 2006). Moreover, 
application of CXCR4 antagonist or siRNA targeting CXCR4 in vivo inhibited the invasion 
of tumors formed by invasive C6 glioma cells.  
The invasion process of GBM requires the detachment of invading cells from tumor mass, 
attachment of tumor cells to ECM components, ECM degradation, and subsequent cell 
infiltration into surrounding brain tissues. Attachment of tumor cells to ECM components is 
an essential phase of invasion mediated by integrins that are overexpressed on both glioma 
cells and tumor vasculature. Recognition of CXCL12 by CXCR4 activates tumor-associated 
integrins, such as α2, α4, α5, and β1 to promote tumor dissemination (Hartman et al., 2004, 
and 2005). Inhibition of integrin function disrupts GBM cell migration. In vitro, interference 
of CXCR4 with the urokinase-receptor (uPAR) reduces the adhesion of CXCL12-mediated 
CXCR4+ GBM cells to collagen, the main component of ECM (Montuori et al., 2010).  
ECM degradation by MMPs enhances tumor invasion. In vitro, glioma cells with lower 
production of MMP-9 show diminished migration and invasion and such cells no longer 
form tumors following intracranial injection into nude mice. MMP-2 and -9 have been 
identified as MMPs in high grade gliomas and their level of expression directly correlates 
with the grade of glioma malignancy (Stojic et al., 2008). Similar to FPR1, CXCR4 mediated 
glioma invasion in vivo was also associated with its capacity to activate MMPs (Kryczek et 
al., 2007). It has been reported that CXCR4/ERK/NF-κ B signaling pathway induces the up-
regulation of MMPs in glioma cells. Activation of CXCR4 by its ligand CXCL12 also 
promotes tumor invasion by release of MMP-9. 
3.3 CXCR4 in glioma growth and angiogenesis  
3.3.1 Role of CXCR4/CXCL12 in malignant glioma growth and survival  
The CXCR4 ligand CXCL12 produced by tumor and stromal cells interacting with CXCR4 
on tumor cells results in the activation of several downstream pathways, including 
MAPK/ERK1/2, PI3k and Akt, as well as NF-κB. These pathways are known to participate 
in the regulation of cell proliferation and survival in normal or malignant glial cells. In vitro 
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activation of CXCR4 promotes the proliferation of GBM cell lines based on the activation of 
ERK1/2 and PI3K/Akt (Bian et al., 2007). In agreement with data obtained from GBM cell 
lines, 80% of clinical GBM samples express high levels of phosphorylated Akt 
(Hambardzumyan et al., 2008). CXCL12 induces the proliferation of primary GBM cells 
expressing CXCR4 by significantly increasing DNA synthesis in tumor cells (do Carmo et 
al., 2010). CXCR4-mediated tumor cell proliferation may also be amplified by EGFR 
signaling, since stimulation of CXCR4 has been reported to transactivate EGFR in many 
tumors of the epithelial lineage (Dolce et al., 2011). In fact, as discussed earlier, EGFR in 
GBM cells is transactivated by another chemoattractant GPCR FPR1, and the two receptors 
co-operate to promote the growth of GBM (Huang et al., 2007). The role of CXCR4 in 
promoting glioma growth was further supported by the use of a small molecule CXCR4 
antagonist, AMD3100, which significantly inhibited tumor cell proliferation in vitro and 
tumorigenicity in nude mice (do Carmo et al., 2010; and Dolce et al., 2011).  
Another important property of CXCR4 is to increase GBM cell resistance to apoptosis. 
Blockade of CXCR4 in glioma cells by the antagonist AMD3100 increased the rate of 
apoptosis, confirming the ability of CXCR4 to support tumor cell survival (do Carmo et al., 
2010). This anti-apoptotic effect is associated with the activation of PI3K/Akt (do Carmo et 
al., 2010), an observation consistent with results obtained from a variety of tumors in which 
CXCR4 actively contributes to the resistance of tumor cells to apoptosis. Stimulation of 
CXCR4 activates NF-κB, which in turn inhibits radiation-induced TNF-α production by 
glioma cells and increases tumor cell survival. In addition to directly protecting tumor cells 
from radiation-induced apoptosis, CXCR4 indirectly promotes cell survival by increasing 
their adherence. For example, stimulation of CXCR4 promotes the adhesion of glioma cells 
to vitronectin, a glioma-derived extracellular matrix protein, and prevents tumor cell death 
(do Carmo et al., 2010). Taken together, published results support the conclusion that 
CXCR4 plays an important role in promoting the proliferation and survival of glioma cells.  
3.3.2 CXCR4 promotes the production of angiogenic factors by glioma cells 
The requirement of CXCR4 and CXCL12 for angiogenesis was revealed by the prenatal 
lethal phenotype of both CXCR4 and CXCL12 knockout mice due to defects in the vascular 
development of gastrointestinal tract and cardiogenesis (Tachibana et al., 1998). In vitro, 
activation of CXCR4 in ECs stimulates the formation of capillary-like tubules (Salvatore et 
al., 2010). ECs in gliomas have been shown to be genetically and functionally distinct from 
normal ECs, and exhibit higher expression of CXCR4 and its ligand CXCL12. Proliferating 
ECs in GBM are positive for CXCR4 and its ligand CXCL12, while ECs that form a single 
layer in the capillaries of the anaplastic astrocytoma appeared to be negative for these two 
molecules. The lower levels of CXCR4/CXCL12 expression in anaplastic astrocytoma may 
contribute to the lower density of proliferating microvasculature. Consistent with these 
observations, CXCR4 and CXCL12 are detected in both malignant glioma cells and vascular 
ECs are associated with increased cell survival (Salmaggi et al., 2004). 
Interestingly, elevated CXCL12 levels by themselves in gliomas failed to induce significant 
vascularization. This was associated with the co-presence of low levels of VEGF, suggesting 
synergism of these angiogenic factors (Kryczek et al., 2005). In fact, although a major 
angiogenic factor in GBM, VEGF was detected only in a few cells or not at all in low-grade 
astrocytomas or in the normal brain tissue (Takano et al., 2010). Clinical and experimental 
evidence indicates that CXCR4 activation induces the production of VEGF in human glioma 
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cells and glioma stem-like cells (Ping et al., 2007 and 2011). Therefore, CXCR4 may 
contribute to the production of VEGF by malignant glioma cells and the two pro-angiogenic 
factors synergistically promote angiogenesis in tumor. In addition to VEGF, the activation of 
CXCR4 in gliomas also is associated with increases the secretion of an angiogenic 
chemokine, CXCL8 (IL-8) (Ping et al., 2007). Interestingly, VEGF binds the receptors on ECs 
and leads to the up-regulation of the anti-apoptotic molecule Bcl-2 as well as the release of 
CXCL8 from ECs (Nör et al., 2001). CXCL8 then is capable of maintaining the angiogenic 
phenotype of ECs in an autocrine and paracrine manner (Nör et al., 2001; Heidemann et al., 
2003). In addition, the activation of CXCR4 also results in NF-κB translocation in glioma 
cells, which elicits the production of other angiogenic chemokines, such as CXCL1, CXCL2, 
and CXCL5 (Richmond et al., 2002). Therefore, glioma angiogenesis is the result of a well-
coordinated process participated in by multiple angiogenic factors among which CXCR4 
appears to be an upstream initiator.  
3.3.3 CXCR4/CXCL12 mediates vasculogenesis by mobilizing bone marrow derived 
progenitor cells  
In addition to tumor angiogenesis, which is thought to be established by the sprouting of 
blood vessels through the division of normal differentiated host ECs present in the tissue 
adjacent to tumor, another way to generate tumor vessels is through the process of 
vasculogenesis, which is formed by the recruitment of circulating EC precursor cells or bone 
marrow-derived cells (BMDCs) (Garcia-Barros et al., 2003). Circulating EC progenitor cells 
mobilized from the bone marrow are normally present in the peripheral blood of several 
species and participate in the neovascularization in tumor and in ischemic tissues (Spaeth et 
al., 2009). CXCR4 has been demonstrated to guide prime stem cells to the sites of rapid 
vascular expansion during embryonic organogenesis (Napoli et al., 2010). The pivotal role of 
CXCR4 and its ligand CXCL12 in vasculogenesis has been demonstrated in gene deletion 
mice as discussed earlier.  
Similar to the development of embryonic vessels, CXCR4 mediates tumor 
neovascularization by switching from angiogenesis in the recurrent malignant glioma to 
vasculogenesis. For instance, tumor growth supported mainly by angiogenesis from nearby 
normal vessels is abrogated by irradiation (Kioi et al., 2010). As a consequence, the growth 
of new tumor vasculature in irradiation animals will rely mainly on circulating blood EC 
progenitor cells from the bone marrow. Studies have demonstrated that CXCR4 is a key 
factor for the influx of BMDCs into the recurrent tumor after irradiation, since both the 
CXCR4 inhibitor AMD3100 and antibodies against CXCR4 are able to block the recruitment 
of BMDCs into tumor and prevent the restoration of the vasculature (Kioi et al., 2010). 
Hypoxia also mediates tumor vasculogenensis through CXCR4 in animal models. 
Irradiation results in a hypoxic microenvironment in the tumor resulting in the up-
regulation of the transcription factor HIF-1 (Ahn and Brown, 2008) and enhanced 
production of CXCL12 and VEGF. CXCL12 then induces the homing of CD11b+ BMDCs 
into the tumor site to initiate the formation of new vasculature (Kioi et al., 2010).  
4. CXCR7/CXCL12  
4.1 CXCR7 expression in glioma 
Although it was believed that CXCL12 uses CXCR4 as a sole receptor, recent studies have 
shown that CXCR7, a newly identified chemokine GPCR, acts as an alternate receptor for 
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CXCL12 and for another chemokine e.g. interferon-inducible T cell α chemoattractant (I-
TAC; also known as CXCL11). CXCR7 is expressed in several tumors and plays an 
important role in preventing tumor cell apoptosis and promoting tumor cell adhesion to 
ECs, a key step for the development of blood-borne metastasis (Burns et al., 2006). In glioma 
specimens, CXCR7 is widely distributed in tumor cells, microglia and ECs. In contrast, 
CXCR4 seems to be restricted to certain subsets of glioma cells and tumor stem-like cell 
populations. While the CXCR4 level is significantly higher in GBM than in lower grade 
gliomas, no distribution difference was detected for CXCR7 (Hattermann et al., 2010). One 
study reported that in eight glioma cell lines tested, only one expresses CXCR4. However, 
CXCR7 is highly expressed in all glioma cell lines (Hattermann et al., 2010). Interestingly, 
tumor stem-like cells derived from GBM cell line express CXCR4, but not CXCR7. In 
addition, differentiated glioma cells often are found to express CXCR7, but not CXCR4. 
These observations suggest that there is a difference between the role of CXCR4 and CXCR7 
in the function of glioma cells. In some tumors, CXCR7 and CXCL12 are co-localized and 
potentially cooperate in tumor progression (Hattermann et al., 2010). 
4.2 CXCR7 may mediate glioma progression  
Initially, CXCR7 was regarded as a decoy receptor that recognizes CXCL12 or a coreceptor 
that may form a heterodimeric complex with CXCR4 to enhance CXCL12 signaling in 
embryonic cells. Subsequently, CXCR7 was demonstrated to be functionally active in glioma 
cells. CXCR7 activation by CXCL12 stimulates a transient phosphorylation of ERK1/2 and 
inhibits the apoptosis of glioma cells induced by camptothecin and temozolomide, but did 
not increase tumor cell proliferation and migration (Hattermann et al., 2010). CXCR7 
activation also did not elicit calcium mobilization in tumor cells, but increases their adhesion 
(Burns et al., 2006). The absence of ligand-induced calcium influx and cell migration 
distinguishes the CXCR7 signaling pathway from CXCR4 and other typical chemokine 
GPCRs. In cells transiently transfected with human CXCR7 and rat cells expressing CXCR7, 
the signaling of CXCR7 is not mediated by Gαi protein, but by β-arrestins associated with 
the phosphorylation of MAP kinases (Rajagopal et al., 2010). Based on these properties of 
CXCR7, it is assumed that some of the previously reported effects of CXCL12 on glioma 
cells, such as phosphorylation of kinases and prevention of apoptosis might be partially 
mediated by CXCR7. Since ECs isolated from GBM express high levels of CXCR7 mRNA, it 
is postulated that CXCR7 may be involved in the formation of glioma vasculature (Takano 
et al., 2010). Indeed, in many CXCR7+ tumors, VEGF and CXCL8 (IL-8) are up-regulated. 
Therefore, CXCR7 is a novel chemokine GPCR that promotes glioma progression by 
supporting tumor cell survival, adhesion and possibly vessel formation. 
4.3 Potential interactions between CXCR7 and CXCR4 
Accumulating evidence suggests that CXCR7 and CXCR4 interact with each other in 
malignant tumors. In human rhabdomyosarcomas (Grymula et al., 2010), downregulation of 
CXCR7 expression by hypoxia was thought to increase CXCL12 signaling through CXCR4 
thus rendered rhabdomyosarcoma cells more motile and prone to detach from the primary 
tumor. Confocal microscopy shows that in glioma cell lines, CXCR7 is mainly localized in 
the space between the plasma membrane and endosomal compartment, whereas CXCR4 is 
mostly present on the cell surface of membrane (Calatozzolo et al., 2011). The biological 
significance of the distinct pattern of CXCR7 and CXCR4 expression in glioma cells is not 
clear. However, in somatic cells, CXCR7 facilitates CXCR4-mediated migration of 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
292 
cells and glioma stem-like cells (Ping et al., 2007 and 2011). Therefore, CXCR4 may 
contribute to the production of VEGF by malignant glioma cells and the two pro-angiogenic 
factors synergistically promote angiogenesis in tumor. In addition to VEGF, the activation of 
CXCR4 in gliomas also is associated with increases the secretion of an angiogenic 
chemokine, CXCL8 (IL-8) (Ping et al., 2007). Interestingly, VEGF binds the receptors on ECs 
and leads to the up-regulation of the anti-apoptotic molecule Bcl-2 as well as the release of 
CXCL8 from ECs (Nör et al., 2001). CXCL8 then is capable of maintaining the angiogenic 
phenotype of ECs in an autocrine and paracrine manner (Nör et al., 2001; Heidemann et al., 
2003). In addition, the activation of CXCR4 also results in NF-κB translocation in glioma 
cells, which elicits the production of other angiogenic chemokines, such as CXCL1, CXCL2, 
and CXCL5 (Richmond et al., 2002). Therefore, glioma angiogenesis is the result of a well-
coordinated process participated in by multiple angiogenic factors among which CXCR4 
appears to be an upstream initiator.  
3.3.3 CXCR4/CXCL12 mediates vasculogenesis by mobilizing bone marrow derived 
progenitor cells  
In addition to tumor angiogenesis, which is thought to be established by the sprouting of 
blood vessels through the division of normal differentiated host ECs present in the tissue 
adjacent to tumor, another way to generate tumor vessels is through the process of 
vasculogenesis, which is formed by the recruitment of circulating EC precursor cells or bone 
marrow-derived cells (BMDCs) (Garcia-Barros et al., 2003). Circulating EC progenitor cells 
mobilized from the bone marrow are normally present in the peripheral blood of several 
species and participate in the neovascularization in tumor and in ischemic tissues (Spaeth et 
al., 2009). CXCR4 has been demonstrated to guide prime stem cells to the sites of rapid 
vascular expansion during embryonic organogenesis (Napoli et al., 2010). The pivotal role of 
CXCR4 and its ligand CXCL12 in vasculogenesis has been demonstrated in gene deletion 
mice as discussed earlier.  
Similar to the development of embryonic vessels, CXCR4 mediates tumor 
neovascularization by switching from angiogenesis in the recurrent malignant glioma to 
vasculogenesis. For instance, tumor growth supported mainly by angiogenesis from nearby 
normal vessels is abrogated by irradiation (Kioi et al., 2010). As a consequence, the growth 
of new tumor vasculature in irradiation animals will rely mainly on circulating blood EC 
progenitor cells from the bone marrow. Studies have demonstrated that CXCR4 is a key 
factor for the influx of BMDCs into the recurrent tumor after irradiation, since both the 
CXCR4 inhibitor AMD3100 and antibodies against CXCR4 are able to block the recruitment 
of BMDCs into tumor and prevent the restoration of the vasculature (Kioi et al., 2010). 
Hypoxia also mediates tumor vasculogenensis through CXCR4 in animal models. 
Irradiation results in a hypoxic microenvironment in the tumor resulting in the up-
regulation of the transcription factor HIF-1 (Ahn and Brown, 2008) and enhanced 
production of CXCL12 and VEGF. CXCL12 then induces the homing of CD11b+ BMDCs 
into the tumor site to initiate the formation of new vasculature (Kioi et al., 2010).  
4. CXCR7/CXCL12  
4.1 CXCR7 expression in glioma 
Although it was believed that CXCL12 uses CXCR4 as a sole receptor, recent studies have 
shown that CXCR7, a newly identified chemokine GPCR, acts as an alternate receptor for 
 
The Role of Chemoattractant Receptors in the Progression of Glioma 
 
293 
CXCL12 and for another chemokine e.g. interferon-inducible T cell α chemoattractant (I-
TAC; also known as CXCL11). CXCR7 is expressed in several tumors and plays an 
important role in preventing tumor cell apoptosis and promoting tumor cell adhesion to 
ECs, a key step for the development of blood-borne metastasis (Burns et al., 2006). In glioma 
specimens, CXCR7 is widely distributed in tumor cells, microglia and ECs. In contrast, 
CXCR4 seems to be restricted to certain subsets of glioma cells and tumor stem-like cell 
populations. While the CXCR4 level is significantly higher in GBM than in lower grade 
gliomas, no distribution difference was detected for CXCR7 (Hattermann et al., 2010). One 
study reported that in eight glioma cell lines tested, only one expresses CXCR4. However, 
CXCR7 is highly expressed in all glioma cell lines (Hattermann et al., 2010). Interestingly, 
tumor stem-like cells derived from GBM cell line express CXCR4, but not CXCR7. In 
addition, differentiated glioma cells often are found to express CXCR7, but not CXCR4. 
These observations suggest that there is a difference between the role of CXCR4 and CXCR7 
in the function of glioma cells. In some tumors, CXCR7 and CXCL12 are co-localized and 
potentially cooperate in tumor progression (Hattermann et al., 2010). 
4.2 CXCR7 may mediate glioma progression  
Initially, CXCR7 was regarded as a decoy receptor that recognizes CXCL12 or a coreceptor 
that may form a heterodimeric complex with CXCR4 to enhance CXCL12 signaling in 
embryonic cells. Subsequently, CXCR7 was demonstrated to be functionally active in glioma 
cells. CXCR7 activation by CXCL12 stimulates a transient phosphorylation of ERK1/2 and 
inhibits the apoptosis of glioma cells induced by camptothecin and temozolomide, but did 
not increase tumor cell proliferation and migration (Hattermann et al., 2010). CXCR7 
activation also did not elicit calcium mobilization in tumor cells, but increases their adhesion 
(Burns et al., 2006). The absence of ligand-induced calcium influx and cell migration 
distinguishes the CXCR7 signaling pathway from CXCR4 and other typical chemokine 
GPCRs. In cells transiently transfected with human CXCR7 and rat cells expressing CXCR7, 
the signaling of CXCR7 is not mediated by Gαi protein, but by β-arrestins associated with 
the phosphorylation of MAP kinases (Rajagopal et al., 2010). Based on these properties of 
CXCR7, it is assumed that some of the previously reported effects of CXCL12 on glioma 
cells, such as phosphorylation of kinases and prevention of apoptosis might be partially 
mediated by CXCR7. Since ECs isolated from GBM express high levels of CXCR7 mRNA, it 
is postulated that CXCR7 may be involved in the formation of glioma vasculature (Takano 
et al., 2010). Indeed, in many CXCR7+ tumors, VEGF and CXCL8 (IL-8) are up-regulated. 
Therefore, CXCR7 is a novel chemokine GPCR that promotes glioma progression by 
supporting tumor cell survival, adhesion and possibly vessel formation. 
4.3 Potential interactions between CXCR7 and CXCR4 
Accumulating evidence suggests that CXCR7 and CXCR4 interact with each other in 
malignant tumors. In human rhabdomyosarcomas (Grymula et al., 2010), downregulation of 
CXCR7 expression by hypoxia was thought to increase CXCL12 signaling through CXCR4 
thus rendered rhabdomyosarcoma cells more motile and prone to detach from the primary 
tumor. Confocal microscopy shows that in glioma cell lines, CXCR7 is mainly localized in 
the space between the plasma membrane and endosomal compartment, whereas CXCR4 is 
mostly present on the cell surface of membrane (Calatozzolo et al., 2011). The biological 
significance of the distinct pattern of CXCR7 and CXCR4 expression in glioma cells is not 
clear. However, in somatic cells, CXCR7 facilitates CXCR4-mediated migration of 
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primordial germ cells by controlling the level of CXCL12 in the microenvironment to form a 
chemotactic gradient (Boldajipour et al., 2008). In HeLa cells, CXCR7 acts as a scavenger 
receptor for CXCL12, which results in the internalization of CXCL12 and the subsequent 
reduction of CXCR4 activity (Naumann et al., 2010). An alternative mechanism by which 
CXCR7 regulates CXCR4 activity may be its potential to form heterodimer with CXCR4. In 
fact, some studies have shown changes in CXCR4 signaling by heterodimerization with 
CXCR7. Although the precise mechanisms of interaction between CXCR7 and CXCR4 and 
the consequences in glioma progression remain to be determined, the available results 
suggest an important role for CXCR7 in regulating the activity of the more ubiquitously 
expressed CXCR4 in gliomas (Fig. 1B). 
5. CX3CR1/CX3CL1 in glioma progression 
Another chemoattractant GPCR CX3CR1 and its agonist CX3CL1 have also been reported to 
play a role in glioma progression. CX3CL1 is one of the most highly expressed chemokines 
in the brain (Bazan et al., 1997) and is a peculiar member of the chemokine family which can 
mediate both chemotaxis and adhesion of inflammatory cells via its highly selective receptor 
CX3CR1. CX3CR1 is overexpressed in gliomas at both mRNA and protein levels, regardless 
of tumor classification and clinical severity, while CX3CL1 expression is correlated with 
glioma grade and overall patient survival (Locatelli et al., 2010). CX3CL1 is more highly 
expressed in tumor area near sites of necrosis suggesting that necrosis may directly enhance 
CX3CL1 transcription in tumor cells, or indirectly via inflammatory cytokines released by 
necrotic cells, including TNFα, which is a potent stimulant of CX3CL1 transcription 
(Marchesi et al., 2010). The increased expression of CX3CL1 in higher grade gliomas implies 
the involvement of CX3CL1 and its receptor CX3CR1 in tumor progression. CX3CR1 and 
CX3CL1 contribute to glioma progression in two ways: (1) by affecting the host defense 
mediated by immune cells and (2) by directly promoting tumor cell proliferation.  
5.1 The role of CX3CR1 in immune cell activation in the brain 
In colorectal cancer patients, high expression of CX3CR1 in tumor tissue is correlated with 
increased density of tumor infiltrating lymphocytes, which is associated with more 
favorable prognosis (Dimberg et al., 2007). CX3CR1 deficient mice bearing B16 melanoma 
are reported to show increased lung tumor metastasis and cachexia as well as reduced 
recruitment of monocytes and NK cells into the tumor (Yu et al., 2007). Thus, CX3CR1 may 
promote the infiltration of immune cells with antitumor activity.  
Glioma-infiltrating microglia/macrophages (GIMs) are the major component in the stroma 
of glioma tumors and these cells express CX3CR1. In vitro, activation of CX3CR1 in GIMs 
isolated from human glioma specimens increases these cell adhesion and migration in 
response to CX3CL1 (Held-Feindt et al., 2010). Blocking CX3CR1 by a specific antibody 
reduced the migration of GIMs in response to the conditioned medium containing CX3CL1 
secreted by human GBM cell lines (Held-Feindt et al., 2010). However, GIMs in glioma 
stroma did not mediate antiglioma immune responses (Liu et al., 2008). In fact, GIMs are 
characterized by a phenotype that may potentially promote tumorigenesis, i.e., more likely 
functioning as type Ⅱ macrophages. Also, CX3CR1 activation increases the expression of 
MMP2, 9 and 14 in GIMs, which may not only favor the migration and adhesion of GIMs, 
but also the infiltration of normal brain tissue by tumor cells (Markovic et al., 2005).  
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Fig. 1. The role of chemoattractant GPCRs in glioma progression. A. FPR1 and EGFR 
cooperate to exacerbate the progression of GBM. FPR1 in GBM cells was activated by 
agonists released by necrotic tumor cells to promote GBM cell survival, invasion and 
angiogenesis. The FPR1 function in GBM cells is mediated in part by transactivation of 
EGFR through a Src kinase pathway. B. Interaction of CXCR4 with CXCL12 produced by 
glioma cells and stromal cells promotes the proliferation, invasion and angiogenesis of 
tumor. The activity of CXCL12 may be partially mediated by another CXCL12 receptor 
CXCR7. C. CX3CL1 secreted by glioma cells increases the infiltration of microglia 
/macrophages expressing CX3CR1 and promotes tumor progression. Interaction of CX3CR1 
with CX3CL1 produced by glioma cells increases cell-cell adhesion in tumor that inhibits the 
invasion of tumor cells. However tumor cells activated by CXCR4 ligand CXCL12 cleave 
CX3CL1 that increases the invasiveness of the individual tumor cells. 
CX3CL1 has been shown to inhibit glioma cell invasion in vitro (Sciumè et al., 2010). This 
activity of CX3CR1 may be attributed to the peculiar structure of the agonist CX3CL1 and 
may account for its ability to directly promote cell-cell adhesion when expressed as a 
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primordial germ cells by controlling the level of CXCL12 in the microenvironment to form a 
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reduced the migration of GIMs in response to the conditioned medium containing CX3CL1 
secreted by human GBM cell lines (Held-Feindt et al., 2010). However, GIMs in glioma 
stroma did not mediate antiglioma immune responses (Liu et al., 2008). In fact, GIMs are 
characterized by a phenotype that may potentially promote tumorigenesis, i.e., more likely 
functioning as type Ⅱ macrophages. Also, CX3CR1 activation increases the expression of 
MMP2, 9 and 14 in GIMs, which may not only favor the migration and adhesion of GIMs, 
but also the infiltration of normal brain tissue by tumor cells (Markovic et al., 2005).  
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transmembrane protein therefore impeding cell motility. The effect of this CX3CR1 and 
CX3CL1 interaction was reduced by TGF-β1 (Sciumè et al., 2010), which is also produced by 
glioma cells and downregulates CX3CL1 expression. The in vivo role of CX3CR1 in glioma 
growth is more complex. CXCL12 constitutively expressed in the central nervous system 
(CNS) activates CXCR4 in glioma cells to promote the cleavage of CX3CL1 into a soluble 
form that reduces the intercellular adhesion and results in the dissemination of glioma cells 
(Cook et al., 2010). Thus, it is postulated that CX3CR1 in the CNS may favor the invasion of 
glioma cells into neighboring tissues. In support of this assumption, CX3CR1 and CX3CL1 
have been reported to drive the neurotropic cancer cells to disseminate to peripheral nerves 
(Marchesi et al., 2010), a distinct but largely under appreciated route of metastasis, which 
has been shown in several tumors, including tumors of the brain, prostate, stomach, 
pancreas, bladder, and colorectum, as well as head and neck carcinoma. Thus, the balance 
between the transmembrane and soluble form plays an important role in the activity of 
CX3CL1 to either prevent or promote glioma progression (Fig. 1C).  
6. Involvement of chemoattractant GPCRs in infiltration of gliomas by 
regulatory T cells (Tregs) 
Tregs have been recognized as one of the major immune cell components that suppress host 
anti-tumor responses. Recruitment of Tregs into tumors contributes to tolerance by 
suppressing autoreactive T cells. It has been shown that Tregs infiltrate human brain tumors 
(Tran Tang et al., 2010) and preferentially accumulate in high grade malignant gliomas such 
as GBM. The importance of Tregs in the control of anti-tumor immune responses in 
experimental mouse glioma models is demonstrated by the observation that transient Treg 
depletion markedly augments the anti-tumor immunity (Tran Tang et al., 2010). Treg 
trafficking in vivo is facilitated by chemokine receptors. For instance, Treg accumulation in 
ovarian carcinoma is mediated by the chemokine receptor CCR4, which binds the ligand 
CCL22 produced in the tumor where specific T cell immunity is compromised (Curiel et al., 
2004). Analysis of lymphocyte subsets in GBM from patients shows that tumor infiltrating 
Tregs highly express CCR4 (Jacobs et al., 2010) and the ligand CCL22 is produced by GBM 
cells. But unlike ovarian carcinoma in which Treg accumulation clearly correlates with 
reduced patient survival, there is no correlation between Tregs and overall survival of GBM 
patients. Regardless, post-surgical immunotherapy has been proposed as a potentially valid 
method to eliminate residual GBM cells while preserving surrounding healthy brain cells.  
7. Chemoattractant GPCRs in gliomas as potential therapeutic targets  
Given the broad range of functions of chemoattractant GPCRs in malignant glioma 
development, progression, invasion and angiogenesis, blockage of these receptors is 
considered a novel therapeutic approach in conjunction with conventional surgical 
resection, irradiation and chemotherapy. Based on the association of CXCR4 with the 
malignant behavior of glioma, anti-CXCR4 monoclonal antibody and specific low-molecular 
weight antagonist for CXCR4 have been tested for their effects on tumor cell growth in vitro 
and in vivo. As predicted, anti-CXCR4 monoclonal antibody is able to attenuate the 
migration and proliferation of human GBM cells induced by CXCL12 (Cheng et al., 2009). In 
addition, administration of the CXCR4 antagonist AMD3100 suppressed the growth of 
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xenograft tumors formed by human GBM cells transplanted intracranially into mice, with 
increased apoptosis of the transplanted GBM cells (Rubin et al., 2003).  
Studies have also revealed the potential benefit of a combination of CXCR4 inhibitor with 
chemotherapy and radiotherapy in malignant glioma patients. In tests on a variety of GBM 
cell lines, a conventional cytotoxic chemotherapeutic agent, BCNU, in combination with the 
CXCR4 antagonist AMD3100 exhibits synergistic inhibition of tumor cell growth in vitro. In 
vivo in animal models, subtherapeutic doses of BCNU and AMD3100 also result in tumor 
regression, which is attributed to increased tumor cell apoptosis and decreased proliferation 
(Redjal et al., 2006). These effects of AMD3100 in conjunction with its capacity to reduce the 
recruitment of bone marrow EPCs to recurrent tumors post irradiation, suggest that 
targeting CXCR4 may not only directly inhibit tumor cell proliferation, but also indirectly 
abrogates neovascularization in GBMs (Kioi et al., 2010).  
Considering targeting CXCR4 as a means of inhibiting glioma, the ability of the CXCR4 
agonist CXCL12 to activate CXCR7 casts doubts about whether blockage of CXCR4 alone is 
sufficient without simultaneously inhibiting CXCR7. In fact, inhibition of CXCR4 only 
partially decreases the responsiveness of tumor cells to CXCL12 in several animal models. 
Studies have found that GSLCs express high levels of CXCR4 and low levels of CXCR7 
(Hattermann et al., 2010). In contrast, differentiation of GSLCs markedly decreased CXCR4 
expression but up-regulated CXCR7. It is therefore postulated that CXCR4 may mediate 
GSLC chemotaxis and survival, whereas differentiated glioma cells are protected from 
apoptosis by CXCR7 in response to CXCL12. It is therefore important to design strategies 
that target one or both CXCL12 receptors based on the stages of glioma cell differentiation.  
Small molecule natural compounds constitute another source of inhibition of 
chemoattractant GPCRs with therapeutic potential for gliomas (Ping et al., 2007). One of 
such compounds is Nordy, a chiral mimetic of a natural lipoxygenase inhibitor 
nordihydroguaiaretic acid. Nordy has been shown to exhibit a broad inhibitory activity on 
chemoattractant GPCRs such as CXCR4 and FPR1 on GBM cells by downregulating receptor 
expression, interfering with their signal transduction pathways and reducing tumor cell 
production of angiogenic factors VEGF and the chemokine CXCL8 (Ping et al., 2007; Chen et 
al., 2006 and 2007). In addition, Nordy has been found to inhibit GBM cell proliferation and 
to promote tumor cell differentiation into a lesser malignant phenotype. Recently, Nordy 
was found to inhibit the self-renewal of glioma stem cells and growth of xenografts 
generated by the stem cells (Wang et al., 2011). However, the effect of Nordy may not be 
specific by targeting only chemoattractant GPCRs on GBM cells. Further studies are 
required to identify more specific receptor targeting natural compounds with minimal side 
effects on key physiological cell processes.  
8. Conclusions 
There is now mounting evidence that chemoattractant GPCRs play multiple roles in the 
progression of malignant gliomas, by mediating the tumor cell growth, invasion and 
angiogenesis (Table 1). However, further molecular epidemiologic and genetic studies are 
required to obtain a better understanding of the mechanisms of the function of these 
receptors in glioma cells. It is especially important not to single out a given receptor to study 
glioma biology, but rather, studies should consider the complex host environment in which 
many factors may drive the aberrant expression of chemoattractant GPCRs and ligands. In 
addition, the interaction of chemoattractant GPCRs such as CXCR4 and FPR1 with other 
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transmembrane protein therefore impeding cell motility. The effect of this CX3CR1 and 
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growth is more complex. CXCL12 constitutively expressed in the central nervous system 
(CNS) activates CXCR4 in glioma cells to promote the cleavage of CX3CL1 into a soluble 
form that reduces the intercellular adhesion and results in the dissemination of glioma cells 
(Cook et al., 2010). Thus, it is postulated that CX3CR1 in the CNS may favor the invasion of 
glioma cells into neighboring tissues. In support of this assumption, CX3CR1 and CX3CL1 
have been reported to drive the neurotropic cancer cells to disseminate to peripheral nerves 
(Marchesi et al., 2010), a distinct but largely under appreciated route of metastasis, which 
has been shown in several tumors, including tumors of the brain, prostate, stomach, 
pancreas, bladder, and colorectum, as well as head and neck carcinoma. Thus, the balance 
between the transmembrane and soluble form plays an important role in the activity of 
CX3CL1 to either prevent or promote glioma progression (Fig. 1C).  
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Tregs have been recognized as one of the major immune cell components that suppress host 
anti-tumor responses. Recruitment of Tregs into tumors contributes to tolerance by 
suppressing autoreactive T cells. It has been shown that Tregs infiltrate human brain tumors 
(Tran Tang et al., 2010) and preferentially accumulate in high grade malignant gliomas such 
as GBM. The importance of Tregs in the control of anti-tumor immune responses in 
experimental mouse glioma models is demonstrated by the observation that transient Treg 
depletion markedly augments the anti-tumor immunity (Tran Tang et al., 2010). Treg 
trafficking in vivo is facilitated by chemokine receptors. For instance, Treg accumulation in 
ovarian carcinoma is mediated by the chemokine receptor CCR4, which binds the ligand 
CCL22 produced in the tumor where specific T cell immunity is compromised (Curiel et al., 
2004). Analysis of lymphocyte subsets in GBM from patients shows that tumor infiltrating 
Tregs highly express CCR4 (Jacobs et al., 2010) and the ligand CCL22 is produced by GBM 
cells. But unlike ovarian carcinoma in which Treg accumulation clearly correlates with 
reduced patient survival, there is no correlation between Tregs and overall survival of GBM 
patients. Regardless, post-surgical immunotherapy has been proposed as a potentially valid 
method to eliminate residual GBM cells while preserving surrounding healthy brain cells.  
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Given the broad range of functions of chemoattractant GPCRs in malignant glioma 
development, progression, invasion and angiogenesis, blockage of these receptors is 
considered a novel therapeutic approach in conjunction with conventional surgical 
resection, irradiation and chemotherapy. Based on the association of CXCR4 with the 
malignant behavior of glioma, anti-CXCR4 monoclonal antibody and specific low-molecular 
weight antagonist for CXCR4 have been tested for their effects on tumor cell growth in vitro 
and in vivo. As predicted, anti-CXCR4 monoclonal antibody is able to attenuate the 
migration and proliferation of human GBM cells induced by CXCL12 (Cheng et al., 2009). In 
addition, administration of the CXCR4 antagonist AMD3100 suppressed the growth of 
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xenograft tumors formed by human GBM cells transplanted intracranially into mice, with 
increased apoptosis of the transplanted GBM cells (Rubin et al., 2003).  
Studies have also revealed the potential benefit of a combination of CXCR4 inhibitor with 
chemotherapy and radiotherapy in malignant glioma patients. In tests on a variety of GBM 
cell lines, a conventional cytotoxic chemotherapeutic agent, BCNU, in combination with the 
CXCR4 antagonist AMD3100 exhibits synergistic inhibition of tumor cell growth in vitro. In 
vivo in animal models, subtherapeutic doses of BCNU and AMD3100 also result in tumor 
regression, which is attributed to increased tumor cell apoptosis and decreased proliferation 
(Redjal et al., 2006). These effects of AMD3100 in conjunction with its capacity to reduce the 
recruitment of bone marrow EPCs to recurrent tumors post irradiation, suggest that 
targeting CXCR4 may not only directly inhibit tumor cell proliferation, but also indirectly 
abrogates neovascularization in GBMs (Kioi et al., 2010).  
Considering targeting CXCR4 as a means of inhibiting glioma, the ability of the CXCR4 
agonist CXCL12 to activate CXCR7 casts doubts about whether blockage of CXCR4 alone is 
sufficient without simultaneously inhibiting CXCR7. In fact, inhibition of CXCR4 only 
partially decreases the responsiveness of tumor cells to CXCL12 in several animal models. 
Studies have found that GSLCs express high levels of CXCR4 and low levels of CXCR7 
(Hattermann et al., 2010). In contrast, differentiation of GSLCs markedly decreased CXCR4 
expression but up-regulated CXCR7. It is therefore postulated that CXCR4 may mediate 
GSLC chemotaxis and survival, whereas differentiated glioma cells are protected from 
apoptosis by CXCR7 in response to CXCL12. It is therefore important to design strategies 
that target one or both CXCL12 receptors based on the stages of glioma cell differentiation.  
Small molecule natural compounds constitute another source of inhibition of 
chemoattractant GPCRs with therapeutic potential for gliomas (Ping et al., 2007). One of 
such compounds is Nordy, a chiral mimetic of a natural lipoxygenase inhibitor 
nordihydroguaiaretic acid. Nordy has been shown to exhibit a broad inhibitory activity on 
chemoattractant GPCRs such as CXCR4 and FPR1 on GBM cells by downregulating receptor 
expression, interfering with their signal transduction pathways and reducing tumor cell 
production of angiogenic factors VEGF and the chemokine CXCL8 (Ping et al., 2007; Chen et 
al., 2006 and 2007). In addition, Nordy has been found to inhibit GBM cell proliferation and 
to promote tumor cell differentiation into a lesser malignant phenotype. Recently, Nordy 
was found to inhibit the self-renewal of glioma stem cells and growth of xenografts 
generated by the stem cells (Wang et al., 2011). However, the effect of Nordy may not be 
specific by targeting only chemoattractant GPCRs on GBM cells. Further studies are 
required to identify more specific receptor targeting natural compounds with minimal side 
effects on key physiological cell processes.  
8. Conclusions 
There is now mounting evidence that chemoattractant GPCRs play multiple roles in the 
progression of malignant gliomas, by mediating the tumor cell growth, invasion and 
angiogenesis (Table 1). However, further molecular epidemiologic and genetic studies are 
required to obtain a better understanding of the mechanisms of the function of these 
receptors in glioma cells. It is especially important not to single out a given receptor to study 
glioma biology, but rather, studies should consider the complex host environment in which 
many factors may drive the aberrant expression of chemoattractant GPCRs and ligands. In 
addition, the interaction of chemoattractant GPCRs such as CXCR4 and FPR1 with other 
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growth factor receptors has been reported and in fact different types of the receptors 
cooperate to exacerbate the progression of malignant glioma. In addition to their direct 
effect on glioma progression, chemoattractant GPCRs expressed on immune cells also 
mediate host response to tumors by promoting recruitment of “suppresive” leukocytes 
including myeloid suppressor cells, type II macrophages and Tregs into the tumor and 
peripheral lymphoid organ to compromise anti-tumor defense. Therefore, recognition of the 
multifaceted role of chemoattractant GPCRs in gliomas and other malignant tumors in 
general is fundamental to elucidating the mechanisms of tumor progression and the 
development of novel therapeutic agents.   
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1. Introduction 
After the hypothesis of ‘immune surveillance’ in tumor proposed in 1970, several 
investigations showed the evidences of its existence where immune system is able to 
recognize the defects due to tumor onset (MacFarlan Burnet, 1970). But how far this 
surveillance is effective in the compartmentalized brain in case of glioma still remains a big 
uncertainty. Glioma is one of the deadliest types of cancer for its rapid growth, invasiveness 
and short life expectancy of the victim. So, figuring out of the extent of host immune 
efficiency in glioma is crucial. As glioma is able to create a hostile environment for the 
immune cells by releasing different soluble factors, expressing death receptors and by 
receptor camouflaging etc, the working situation for the host immunity becomes more 
difficult. Therefore, proper assessment of the role of brain immune connection in glioma is 
crucial to explore the probable level of support that can be extended by the immune defense 
mechanism against glioma. This immune resistance is also vital to support the present 
therapeutic modalities including adjuvants used for treating glioma. 
2. Death of ‘Privilege’ myth: Immunocytes do not spare brain from their 
vigilance 
2.1 ‘Immune privilege’ of brain: A notion that prevailed more than 5 decades 
At the beginning of 20th Century, brain was thought to be a separate organ mostly 
abandoned by the immune system. The initial evidences of immune compromise of the 
brain compartment were observed from 1920s with the tumor tissue transplantation studies. 
Rat sarcoma, when transplanted in mouse brain parenchyma, was found to grow better in 
comparison to its subcutaneous and intramuscular (systemic) transplantations (Shirai, 1921). 
On contrary, when portions of recipient spleen were co-transferred with tumor in brain 
parenchyma, inhibition in tumor growth occurred (Murphy and Sturm, 1923). Thus a weak 
or less efficient immune intervention in brain was conceptualized and the term ‘immune 
privilege’ was proposed by Billingham and Boswell (Billingham & Boswell, 1953).  
With this, another set of observations in late 19th century and afterwards developed a 
concept of existence of a barrier between blood and CNS tissue. Basically, Paul Ehrlich’s 
observation with the intravenous administration of vital dye in experimental animals 
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showed infiltration of the dye in other organs except brain. That led him to propose a barrier 
between brain and blood stream (Ehrlich, 1885 & 1904). Goldmann’s study showed that 
tracers injected in blood do not enter into the parenchyma proper in brain, but accumulated 
in the choroid plexus, perivascular space or lymphatic clefts (Obersteiner, 1870; Goldmann, 
1913). The ‘no entry’ status of blood immunocytes was further fueled with the xeno- and 
allogenic tissue transplantation studies (Medawar, 1948; Barker & Billingham, 1977). In the 
following decades ultrastructural studies of the blood capillaries in brain showed the 
distinct cellular organization present in the interphase of blood and brain that prevent the 
flow of blood immunocytes and large molecular weight solvents into brain (Reese & 
Karnovsky, 1967; Engelhardt & Wolburg, 2002). Thus blood-brain-barrier (BBB) 
encapsulates the brain and seems to maintain the ‘immune privilege’ status. Till 1980s no 
direct lymphatic drainage from nervous system was detected. Negligible expression of 
MHC and undetected dendritic cells (DC) in brain indicated the inefficiency of antigen 
presentation in the organ (Sedgwick, 1995; Perry, 1998). 
2.2 Detection of secret routes connecting brain with systemic circulation 
But in last two decades a paradigm shift has occurred in this ‘immune privilege’ rank of 
brain. Basically, three obstacles that maintain the privilege are – i) lack of drainage of CNS 
antigens at least to cervical lymph node, ii) hindrance to easy access of T cells in the CNS 
parenchyma and iii) T cells require antigen presentation in the reaction site by the APCs 
which were thought to be scarce in brain. Initial experiments suggested that CNS antigens 
can drip outside passively by a different route along the olfactory nerves on to the 
cribriform plate which is connected to the lymphatics of nasal submucosa and finally to the 
cervical lymph node (Cserr & Knopf, 1992; Sedgwick, 1995). Tracer studies indicated CSF 
drainage to cervical lymph node (Boulton et al, 1999). CSF circulates from ventricles through 
subarachnoid spaces (a space between arachnoid and pial membrane filled with CSF and 
surround the brain and spinal cord) and it has access to Virchow-Robin space that 
surrounds blood vessels when they enter brain parenchyma [Figure – 1]. Ependymal lining 
of the ventricles lack ‘tight junctions’ and in other specialized perivascular spaces including 
Virchow-Robin’s that porosity is also present, which help in clearance of interstitial fluid 
from brain parenchyma (Ransohoff et al, 2003; Piccio et al, 2002). So the protein antigens 
have the probable, though slightly difficult than other organs, access to the lymphoid tissue 
through CSF. This generates opportunity for the passage of immunocytes.  
The afferent arm of CNS immune response is initiated with the antigen leakage from brain 
parenchyma to CSF; whereas the efferent arm is largely progressed with the migration of 
leukocytes to CNS into different routes. Ransohoff and colleagues identified three distinct 
routes which are – i) cells from blood extravasate through choroid plexus to the CSF, ii) 
leukocytes flowing through internal carotid artery cross the post capillary venules in the 
subarachnoid space and Virchow-Robin perivascular space and iii) finally leukocytes may 
cross the BBB deep into the brain to enter directly into the brain parenchyma (Ransohoff et 
al, 2003). Precisely speaking, BBB is a metaphor that describes the property of brain 
vasculatures restricting the entry of large molecules and cells (Bechmann et al, 2007). The 
perivascular spaces exist in the pre- and post-capillary segments in brain where a 
heterogeneous assembly of lymphocytic and monocytic cells are observed, more during 
inflammation. Both in the perivascular spaces and after entering into parenchyma they 
encounter antigen presenting cells (APCs) to continue the immune response in brain. 
 




Fig. 1. This figure represents routes of CNS antigen escape and immune cell connection from 
brain to peripheral circulation. T cells initially are primed by the CNS antigen leaked from 
brain to the cervical lymph node or olfactory bulb or nasal mucosa, become activated and 
reach to the blood vessel, subarachnoid area, Virchow-Robin space or perivascular space 
and CSF in brain. There also a repriming of the glioma antigen specific lymphocytes occurs 
by the APC circulating or residing at those spaces. Choroid plexus is also a very important 
route of this CNS antigen escape and site of antigen presentation to lymphocytes by the 
local APCs. These specific glioma antigen primed activated lymphocytes enter into the brain 
parenchyma and invade towards glioma. [The box has been elaborated in Figure – 4] 
2.3 Lymphocytes assess CNS antigen and enter into neuropil 
2.3.1 T cells can pass into neuropil and interact with brain APCs 
Early experiments showed that though graft rejection is comparatively slow in brain, once 
the graft is familiar to the immune system outside brain, the rejection occurs rapidly (Mason 
et al, 1986; Sedgwick, 1995). Simultaneously, Wekerle and colleagues demonstrated that 
activated or antigen primed T cell from the periphery can cross the BBB nonspecifically 
(Wekerle et al, 1986). Following experiments supported the fact when it was found that 
CD4+ T cell blasts of any specificity injected intravenous to experimental animals can pass 
into CNS tissue, although myelin antigen specific T cells are found to remain longer (Hickey 
et al, 1991). This delay of the myelin antigen specific T cells suggests some mechanism that 
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holds them to process and react in brain parenchyma. The answer is the cross-talk between 
them and microglia (or brain APC). Microglia is found ex-vivo to induce IFN-γ and TNF 
production from CD4 T cells as their effector activation, but do not support proliferation by 
IL-2 and induce apoptosis. Interestingly, perivascular macrophages show activation with IL-
2 mediated proliferation and survival of CD4+ T cells (Ford et al, 1996).  
 
 
Fig. 2. This section of brain parenchyma shows a blood capillary containing leukocytes. 
Many of them are at the margin of the capillary, tethering the endothelium and 
extravaseting at the perivascular spaces. Perivascular microglia/macrophage are visible. 
Few infiltrated leukocytes are found scattered in brain parenchyma. At least one rod shaped 
ramified microglia is detectable in the parenchyma. A simple H/E staining section of brain 
furnishes these visual evidences of neuro-immune connection. (Magnification 1000X, oil 
immersion in Olympus CH20i Microscope and photographed by Olympus DSC) 
The reverse is also visible in the GvHD affected CNS model where CD4+αβTCR+CD2+T cells 
infiltrat and scatter deep into neuropil or brain parenchyma. The microglial cells show 
activation with many fold increase in their CD11b/c, CD45 and MHC class II expression and 
cluster with intimate association with these T cells in situ that lead to microglial activation, 
proliferation and expansion (Sedgwick et al, 1998). Thus both microglia and infiltrated 
lymphocytes influence each other for their maturation and effector function in brain. 
With the citations of entry of lymphocytes in brain, the role of CNS APCs started to come 
into surface. They are subdivided as microglia and perivascular macrophages based on their 
position, morphology, immunophenotype and functional priority (Sedgwick et al, 1991; 
Bechmann et al, 2001). Therefore entry of lymphocytes into neuropil through pre- and post-
capillary vessels needs a two step process. Crossing the vessel endothelium, muscle layers 
and basement membranes lymphocytes and blood borne monocytes reside at the 
perivascular space encapsulated with glial limitans and pericytes. Next step is more 
restricted where the leukocytes cross the layer of glial limitans and step in to neuropil 
(Bechmann et al, 2007). To proceed for this step, brain APC associated with this limiting 
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layer is crucial (Tran et al, 1998; Greter et al, 2005) [Figure – 2]. Then the infiltrated 
lymphocytes may come across the APC present in the brain parenchyma or at the site of 
pathogenesis. The T cell-microglia interactions in CNS autoimmune encephalomyelitis 
(EAE) or brain tumor; T cell secretion of Th1 cytokines to mature microglia as functional 
APC and resulting restimulation of leukocytes by them; counter regulation of this 
inflammation by Th2 induction by microglia etc had been detailed mostly on the functional 
studies committed so far (Aloisi et al, 2000; Ghosh & Chaudhuri, 2010). 
2.3.2 Cell tracking experiments visualize leukocyte access in brain 
But a new generation of cell tracking experiments and lebelling methods now provide us 
more direct evidences of the events occurring beneath the skull. GFP-labelled unspecifically 
activated CD4 T lymphocytes when injected into cortex and ventricle of mice brain, there 
path through the cross-section of entire head-neck region was monitored. Irrespective of the 
sites, it was visualized that they pass through the cribroid plate, reach to nasal mucosa and 
accumulate in the cervical lymph node (Goldmann et al, 2006). Shifting the focus on CD8+ T 
cells, it was recently found that selective traffic of antigen specific CD8 T cells occurs in 
brain. Using immunofluroscence and confocal micrographs it was found that the process is 
dependent on luminal expression of MHC class I by cerebral endothelium in response to 
intracerebral antigen injection. Significantly, the process is quite independent of 
perivascular macrophages and different from CD4+ T cell entry (Galea et al, 2007). After 
visualizing the entry and exit of T cells from brain their activities in the brain needs a close 
watching. 
3. But glioma makes the immune system puzzled 
Despite the efforts of host immune system, which Burnet and Thomas described as ‘immune 
surveillance’, malignant glioma can evade and overcome this defense to grow. There are 
several generalized strategies for the tumor cells to bypass the immune resistance. They can 
be simply categorized as follows –  
a. Making the immune system ignorant about the tumor growth by lacking the tumor 
antigens in lymphoid organs, growing in immune privileged position, creating physical 
barriers by stoma, lacking adhesion molecules for cellular interactions etc. 
b. Actively impairing and suppressing the immune system by down-regulating the 
expression of MHC genes or imposing defects in antigen processing, secreting 
suppressive cytokines like TGF-β, IL-10 etc and other factors like prostaglandins.  
c. Inducing tolerance to immune system by minimizing costimulation that results into 
anergy and central tolerance to the tumor antigen as many of them produce self-
antigens or mimic them. Regulatory T cell mediated inhibition of DC maturation and T 
cell activation in the tumor environment plays a crucial role for dampening the immune 
resistance. 
d. Counter attacking the immune system by expressing different death receptor ligands 
like CD95L, decoy receptors, TRAIL family etc and expressing anti-apoptotic molecules 
for themselves.  
Glioma adapt most of these mechanisms successfully with their additional advantage to 
grow in a position which has been visited or monitored by the peripheral immune cells less 
frequently and less aggressively. 
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3.1 Glioma drastically reduces immune efficiency 
Different studies on a number of patients harboring glioma revealed that they suffered from 
impaired cell mediated immunity (Elliott et al, 1984). In vitro studies showed that peripheral 
blood lymphocytes (PBL) obtained from patients with gliomas proliferated poorly in 
response to mitogen and/or antigen stimulation in vitro and unresponsiveness to T-cell 
mitogens concanavalin A (ConA), phytohemagglutinin (PHA) and anti-CD3 mAb etc 
(McVicar et al, 1992). A number of potential mechanisms explaining the observed immune-
suppression including qualitative or quantitative alterations in cell surface marker 
expression on T-cells, elevated suppressor cell activity or T-cell lymphopenia were explored. 
T-cells obtained from glioma patients have intrinsic defects, which synthesize and secrete 
less than normal levels of interleuken-2 (IL-2) required for T-cell proliferation. IL-2 mRNA 
synthesis is impaired with less production of IL-2 receptor (IL-2R), and they also are unable 
to enter G1 phase of cell cycle (Elliott et al, 1990). Additionally, the numbers of CD4+ T-cells 
obtained from patients are reduced to a great extent than CD8+ T-cells, which predominately 
infiltrate glioma, but are deprived from CD4+ help. Based on their inability to produce and 
respond to IL-2 and lack of CD4+ help, T-cells obtained from glioma patients appear to be 
anergic (Elliott et al, 1990; Giometto et al, 1996).  
Wide level of T-cell signaling defects are observed in glioma patient derived T-cells. T-cells 
from glioma patients show reduced tyrosine phosphorylation compared to normal T cells, 
which is mostly reduced in PLCγ1. Additionally, both PLCγ1 and p56lck protein levels are 
found reduced dramatically and thus it causes the overall impairment of TCR/CD3-
mediated signaling. Reduced p56lck and associated signals also resists the cells to make 
sufficient contact with APCs, reduced their appropriate stimuli and movements (Marford et 
al, 1997, Dix et al, 1999). Severe T-cells lymphopenia i.e. rapid depletion of the cells is an 
important feature of glioma patients. As CD4+ T-cells are reduced in number and less 
responsive to mitogens and antigens, IL-2 and IFNγ production decreases further. Because 
both these cytokines are important for generation of LAK cells and CTL activity, they are 
responsible for impaired generation of antigen-stimulated, MHC-unrestricted cytotoxicity 
observed in glioma patients (Urbani et al, 1996; Dix et al, 1999). Even glioma condition 
facilitates to increase Th2 type IL-10 production and inhibit Th1 type IL-12 and TIL secrete 
predominantly Th2 type cytokines underscoring the Th1 effect. Glioma has been shown to 
synthesize and secrete multiple factors including TGFβ, PGE2, IL-10 and gangliosides (Zou 
et al, 1999, Huettner et al, 1997). Gliomas synthesize and secrete TGFβ1, 2, and 3 which down-
regulate monocyte surface marker expression, cytokine secretion, cytotoxicity and T-cell 
responsiveness. Gangliosides (GANGs) are components of human plasma with GM3 and GD3 
being major constituents, and can bind to both plasma proteins and lipoproteins. The 
highest concentrations of GANGs are found in brain and mainly include GM1, GD1a, GD1b and 
GI1b. These are highly immunosuppressive by inhibiting T-cell proliferation, CD4 
expression, generation of CTL and NK cell activity. In addition, GANGs may also suppress 
Ca2+ flux in T-cells (Ladisch et al, 1992; Zou et al, 1999; Dix et al, 1999). 
3.2 The mechanism behind glioma immune evasion 
Like any other tumors immune selective pressure on the glioma cells is also working to 
eradicate abnormal cells. Though the initial intensity is less and additional time is required 
to recognize and react, the precision is much higher against the neoplastic cells in brain 
(which will be discussed in the following sections). The genetic instability of glioma and 
 
Immune Connection in Glioma: Fiction, Fact and Option 
 
311 
their repeated exposure to immune selection act as the key to develop glioma cell variants 
with enhanced capacity to evade immune defense. 
Glioma cells are capable to secret copious factors that influence the immune system 
negatively. Cyclooxygenase enzyme COX-2 derived prostaglandin E2 (PGE2) bind with its 
receptor EPI-4 on glioma cells and encourage them to invade by increasing motility. PGE2 
downregulate Th1 cytokines like IL-2, IFNγ and TNFα, and upregulate Th2 cytokines like 
IL-4, IL-10 and IL-6 (Wang & Dubois, 2006). Glioma cells secrete IL-10 which inhibit IL-2 
induced T cell proliferation, DC and macrophage activation (Grutz, 2005). IL-10 is expressed 
by Treg cells present in glioma vicinity (Sakaguchi, 2005). TGFβ with its three isoform 
(TGFβ1,2,3) is involved in regulating inflammation, angiogenesis and proliferation 
(Govinden and Bhoola, 2003). TGFβ is the dominant isoform expressed by glioblastoma. 
They inhibit maturation of professional APCs, obstruct the synthesis of cytotoxic molecules 
including perforin, granzymes, FasL in activated CTL (Thomas and Massague, 2005). This 
cytokine may also efficiently recruit T reg cells in glioma. Glioma shows a considerable level 
of resistance against Fas induced apoptosis. Decoy receptor 3 (DcR3) is expressed in brain 
tumor and prevents Fas mediated apoptosis as well as decreases infiltration of CD4 and 
CD8 T cells (Roth et al, 2001). Apoptosis inhibitory proteins (IAPs) are active in glioma 
which inhibit caspase activity (Gomez & Kruse, 2006). Some of the glioma cells express FasL 
to counteract with the immunocytes (Husain et al, 1998). 
As cell to cell contact plays an important role to deliver the immune assault, glioma cells 
take the strategy to minimize or impair these adhesions. Cell adhesion interaction between 
glioma and immune cells was found to be prevented by a thick glycosaminoglycan coating 
and protect the neoplastic cells from CTL action (Dick et al, 1983). In glioma condition, 
ICAM-1/LFA-1 interaction is interrupted which inhibit target cell lysis by tumor specific T 
and NK cells (Schiltz et al, 2002; Fiore et al, 2002). The aberrant HLA class I expression in 
glioma helps them to evade T cell detection of transformed cells and subsequent cytotoxicity 
(Rosenberg et al, 2003). In glioma, B7-H1 (B7-homologue 1, a costimulatory molecule) 
inhibits allogenic T cell activation and associated cytokine secretion (Wilmotte et al, 2005).  
Some other factors like Indoleamine 2,3-dioxygenase (IDO) expression in glioma cells cause 
T cells to starve for tryptophan, cell cycle arrest and tolerance (Uyttenhove et al, 2003). 
Interestingly, IFNγ stimulate IDO production in glioma, create a local tryptophan shortage 
and T cell tolerance (Shirey et al, 2006). The activation of STAT-3 is another trick for glioma. 
STAT-3 regulates the anti-apoptotic proteins like Bcl-2, Bcl-XL, Mcl-1, cFLIP, surviving etc in 
glioma (Rahaman et al, 2005; Akasaki et al, 2006). Glioma uses various factors including 
chemokines and matrix degrading enzymes secreted from the brain macrophage/microglia 
population for their migration and spread in brain (these will be discussed later). 
4. Undaunted immune effort continues to resist transformed cells 
4.1 T cells mature to effector state after local interaction with APCs in CNS, even in 
brain tumor 
The experimental evidences furnished by Ford and his colleagues in 1996 revealed that the 
resident antigen presenting cell of brain i.e., microglia, interacts with the T cells to induce 
final effector function (Ford et al, 1996). Years’ later studies with GFP-labeled 
encephalitogenic T cells specific for MBP (TMBP-GFP cells) showed that, with the onset of the 
disease, huge number of CD4+ effector cells infiltrate in CNS with upregulated chemokine 
receptors. But these infiltrated TMBP-GFP cells when recovered after 24 hrs from brain 
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3.1 Glioma drastically reduces immune efficiency 
Different studies on a number of patients harboring glioma revealed that they suffered from 
impaired cell mediated immunity (Elliott et al, 1984). In vitro studies showed that peripheral 
blood lymphocytes (PBL) obtained from patients with gliomas proliferated poorly in 
response to mitogen and/or antigen stimulation in vitro and unresponsiveness to T-cell 
mitogens concanavalin A (ConA), phytohemagglutinin (PHA) and anti-CD3 mAb etc 
(McVicar et al, 1992). A number of potential mechanisms explaining the observed immune-
suppression including qualitative or quantitative alterations in cell surface marker 
expression on T-cells, elevated suppressor cell activity or T-cell lymphopenia were explored. 
T-cells obtained from glioma patients have intrinsic defects, which synthesize and secrete 
less than normal levels of interleuken-2 (IL-2) required for T-cell proliferation. IL-2 mRNA 
synthesis is impaired with less production of IL-2 receptor (IL-2R), and they also are unable 
to enter G1 phase of cell cycle (Elliott et al, 1990). Additionally, the numbers of CD4+ T-cells 
obtained from patients are reduced to a great extent than CD8+ T-cells, which predominately 
infiltrate glioma, but are deprived from CD4+ help. Based on their inability to produce and 
respond to IL-2 and lack of CD4+ help, T-cells obtained from glioma patients appear to be 
anergic (Elliott et al, 1990; Giometto et al, 1996).  
Wide level of T-cell signaling defects are observed in glioma patient derived T-cells. T-cells 
from glioma patients show reduced tyrosine phosphorylation compared to normal T cells, 
which is mostly reduced in PLCγ1. Additionally, both PLCγ1 and p56lck protein levels are 
found reduced dramatically and thus it causes the overall impairment of TCR/CD3-
mediated signaling. Reduced p56lck and associated signals also resists the cells to make 
sufficient contact with APCs, reduced their appropriate stimuli and movements (Marford et 
al, 1997, Dix et al, 1999). Severe T-cells lymphopenia i.e. rapid depletion of the cells is an 
important feature of glioma patients. As CD4+ T-cells are reduced in number and less 
responsive to mitogens and antigens, IL-2 and IFNγ production decreases further. Because 
both these cytokines are important for generation of LAK cells and CTL activity, they are 
responsible for impaired generation of antigen-stimulated, MHC-unrestricted cytotoxicity 
observed in glioma patients (Urbani et al, 1996; Dix et al, 1999). Even glioma condition 
facilitates to increase Th2 type IL-10 production and inhibit Th1 type IL-12 and TIL secrete 
predominantly Th2 type cytokines underscoring the Th1 effect. Glioma has been shown to 
synthesize and secrete multiple factors including TGFβ, PGE2, IL-10 and gangliosides (Zou 
et al, 1999, Huettner et al, 1997). Gliomas synthesize and secrete TGFβ1, 2, and 3 which down-
regulate monocyte surface marker expression, cytokine secretion, cytotoxicity and T-cell 
responsiveness. Gangliosides (GANGs) are components of human plasma with GM3 and GD3 
being major constituents, and can bind to both plasma proteins and lipoproteins. The 
highest concentrations of GANGs are found in brain and mainly include GM1, GD1a, GD1b and 
GI1b. These are highly immunosuppressive by inhibiting T-cell proliferation, CD4 
expression, generation of CTL and NK cell activity. In addition, GANGs may also suppress 
Ca2+ flux in T-cells (Ladisch et al, 1992; Zou et al, 1999; Dix et al, 1999). 
3.2 The mechanism behind glioma immune evasion 
Like any other tumors immune selective pressure on the glioma cells is also working to 
eradicate abnormal cells. Though the initial intensity is less and additional time is required 
to recognize and react, the precision is much higher against the neoplastic cells in brain 
(which will be discussed in the following sections). The genetic instability of glioma and 
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their repeated exposure to immune selection act as the key to develop glioma cell variants 
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glioma helps them to evade T cell detection of transformed cells and subsequent cytotoxicity 
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Some other factors like Indoleamine 2,3-dioxygenase (IDO) expression in glioma cells cause 
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Interestingly, IFNγ stimulate IDO production in glioma, create a local tryptophan shortage 
and T cell tolerance (Shirey et al, 2006). The activation of STAT-3 is another trick for glioma. 
STAT-3 regulates the anti-apoptotic proteins like Bcl-2, Bcl-XL, Mcl-1, cFLIP, surviving etc in 
glioma (Rahaman et al, 2005; Akasaki et al, 2006). Glioma uses various factors including 
chemokines and matrix degrading enzymes secreted from the brain macrophage/microglia 
population for their migration and spread in brain (these will be discussed later). 
4. Undaunted immune effort continues to resist transformed cells 
4.1 T cells mature to effector state after local interaction with APCs in CNS, even in 
brain tumor 
The experimental evidences furnished by Ford and his colleagues in 1996 revealed that the 
resident antigen presenting cell of brain i.e., microglia, interacts with the T cells to induce 
final effector function (Ford et al, 1996). Years’ later studies with GFP-labeled 
encephalitogenic T cells specific for MBP (TMBP-GFP cells) showed that, with the onset of the 
disease, huge number of CD4+ effector cells infiltrate in CNS with upregulated chemokine 
receptors. But these infiltrated TMBP-GFP cells when recovered after 24 hrs from brain 
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parenchyma or neuropil they showed fresh sign of reactivation with upregulation of OX-40 
and IL-2R, and upregulated expression of IFNγ, TNFα, TGFβ, IL-2, IL-10, CD3 mRNA 
expression (Flugel et al, 2001). These observations suggested the importance of brain APC at 
the site of proper functioning of the recruited cells.  
 
 
Fig. 3. The section shows that infiltrated lymphocytes in brain parenchyma interact with 
transformed oligodendroglial cells in a murine oligodendroglioma model and offer them the 
‘kiss of death’. One oligodendroglioma cell nucleus is protruded out of the cytoplasm and 
for the other cell, the lymphocyte is overlapping with it. One oligodendroglioma cell, one 
astrocyte and a free lymphocyte is visible in the field. (Magnification 1000X, oil immersion 
in Olympus CH20i Microscope and photographed by Olympus DSC) 
The function of APC is now becoming more substantial in CNS as some new experimental 
evidences indicate that they are important to reshape and retain Ag-specific CTLs in the site 
of neuropathogenesis. In a series of experiments Walker and team addressed the issue with 
precision. Whether CNS retention of tumor specific MHC class I restricted CD8+ T cells also 
require recognition of local APC cross-presenting tumor Ag was the problem under 
scrutiny. They used murine glioma transfected with cDNA encoding HLA-CW3 implanted 
in mice model. The observation was a massive expansion of H2Kd/CW3170-179-specific CTL 
using BV10TCR after immunization with CW3. In that animal model the endogenous 
presentation was tactically avoided and due to the absence of MHC class II on MT-CW3 
transfect, the CD4 arm is also avoided. Therefore any expansion of H2Kd restricted CW3-
specific CTL suggests the involvement of hosts APC at the tumor site. Detection of the 
localization of specific CTL, their cytotoxic efficacy and retention of effector functions in an 
antigen dependent manner speaks the importance of local APC within CNS (Calzascia et al, 
2003). They are activated macrophage/microglia and cells with DC phenotype found 
infiltrated heavily in tumor. In subsequent studies they also provide support for the fact that 
T cell homing at the specific CNS tumor site is defined by the cross-presentating APCs there 
and not predetermined in the lymph nodes where initial priming occurs (Calzascia et al, 
2005). In extended studies it was further found that Ag-experienced CD8+ T cells further 
differentiate at the intracerebral tumor site with enhanced IFNγ and Granzyme-B expression 
and induction of αEβ7 integrin that facilitate their retention in brain (Masson et al, 2007). 
Thus cytotoxic activity of lymphocytes on glioma is not rare [Figure – 3]. 
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4.2 Microglia, the local/resident APCs of brain accumulate in glioma 
Microglia is designated as local or resident antigen presenting cell throughout the brain 
parenchyma or neuropil and its margin. Most emphatic efforts of microglial research in the 
last two decades were invested to explore its functional relevance in the brain tissue. The 
striking feature of microglia is its versatile ability to respond according to the CNS 
microenvironment. Functionally speaking, microglia is a hybrid between white blood cells 
and glial cells, which is intended to protect and support the neuronal environment in brain. 
Microglia can respond against an extensive list of biochemical factors ranging as diverse as 
glycoconjugates, neurotransmitters or cytokines/chemokines (Nakamura, 2002).  
Nearly two decade of studies demonstrated the causative effects of chemokines in glioma 
microenvironment for macrophage/microglia infiltration. The C-C family chemokines, viz, 
monocyte chemotactic protein 1 (MCP-1) was first purified from glioma and Leung et al, 
1997 found that with increased MCP-1 the macrophage/microglia infiltrates in glioma. 
Astrocytoma cells were found capable of producing MCP-1, and complementary receptor 
CCR2 was present and expressed on activated microglia (Leung et al, 1997). In 2003, 
evidence showed that, MCP-1 promoted the microglial migration in glioma and microglia 
infested glioma grew rapidly (Platten et al, 2003). The involvement of PI-3K/Akt pathway 
was assumed in the secretion of microglia derived factors that mediate glioma invasiveness 
(Joy et al, 2003; Pu et al, 2004). CSF-1 (colony stimulating factor 1), which acted as 
chemotactic and mitogenic factors for myeloid lineage cells, and its receptor, were long been 
detected in glioma, whereas microglia also possessed the option of secreting and receiving 
the factor from self and neighboring cells. Eventually from glioma G-CSF/GM-CSF 
(granulocytes and granulocytes macrophage colony stimulating factor) were secreted and 
influenced the differentiation and maturation process of microglia like other myeloid 
lineage cells. Badie et al, 1999, in vitro demonstrated the specific microglia attracting capacity 
of glioma by the hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF signals the 
spectrum of mesenchymal cells for mitogenic stimulation, invasion and extravasation. 
Microglia possesses its receptor Met and can produce HGF/SF, whereas the glioma cells are 
capable of doing the same (Badie & Schartner, 2001). Thus, the balancing ratios of the factors 
in glioma microenvironment act as the determinant in the migration process of the cells. 
In 2002, the 15.3 KDa heparin-binding peptide Pleiotrophin (PTN) was found to appear in 
adult human glioma, normally a mitogenic/angiogenic factor in embryonic stage. Uniquely, 
PTN did not help to proliferate the glioma cells by its own, rather influenced microglial 
accumulation by acting as strong chemotactic and mitogenic agent. Its action thus passively 
helped glioma growth by targeting endothelial and microglial cells (Mentlein & Held-
Feindt, 2002). The question arose that what would be the interest of glioma to include 
microglia in its vicinity? In fact, the role of infiltrating macrophage/microglia in the process 
of angiogenesis in glioma was hinted previously when macrophage associated heme-
oxygenase-1 (HO-1) enzyme was found to be correlated with the vascular density of human 
glioma (Nishie et al 1999). Another enzyme cyclooxygenase (COX)-2 was found to be 
produced in higher amount in microglia isolated from intracranial glioma which increased 
the prostaglandin E2 (PGE2) production. The study suggested that glioma infiltrating 
microglia contributed in developing fatal cerebral edema in glioma through COX-2 
dependent pathway. It was reported that PGE2 increased the permeability of vascular 
endothelium by cytoskeletal rearrangement where TNFα acted as positive inducer. In that 
case, microglia was the source of both COX-2 and TNFα probably playing a role in its own 
migration, leukocyte trafficking and in parallel, glioma invasiveness (Badie et al, 2003).  
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evidences indicate that they are important to reshape and retain Ag-specific CTLs in the site 
of neuropathogenesis. In a series of experiments Walker and team addressed the issue with 
precision. Whether CNS retention of tumor specific MHC class I restricted CD8+ T cells also 
require recognition of local APC cross-presenting tumor Ag was the problem under 
scrutiny. They used murine glioma transfected with cDNA encoding HLA-CW3 implanted 
in mice model. The observation was a massive expansion of H2Kd/CW3170-179-specific CTL 
using BV10TCR after immunization with CW3. In that animal model the endogenous 
presentation was tactically avoided and due to the absence of MHC class II on MT-CW3 
transfect, the CD4 arm is also avoided. Therefore any expansion of H2Kd restricted CW3-
specific CTL suggests the involvement of hosts APC at the tumor site. Detection of the 
localization of specific CTL, their cytotoxic efficacy and retention of effector functions in an 
antigen dependent manner speaks the importance of local APC within CNS (Calzascia et al, 
2003). They are activated macrophage/microglia and cells with DC phenotype found 
infiltrated heavily in tumor. In subsequent studies they also provide support for the fact that 
T cell homing at the specific CNS tumor site is defined by the cross-presentating APCs there 
and not predetermined in the lymph nodes where initial priming occurs (Calzascia et al, 
2005). In extended studies it was further found that Ag-experienced CD8+ T cells further 
differentiate at the intracerebral tumor site with enhanced IFNγ and Granzyme-B expression 
and induction of αEβ7 integrin that facilitate their retention in brain (Masson et al, 2007). 
Thus cytotoxic activity of lymphocytes on glioma is not rare [Figure – 3]. 
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4.2 Microglia, the local/resident APCs of brain accumulate in glioma 
Microglia is designated as local or resident antigen presenting cell throughout the brain 
parenchyma or neuropil and its margin. Most emphatic efforts of microglial research in the 
last two decades were invested to explore its functional relevance in the brain tissue. The 
striking feature of microglia is its versatile ability to respond according to the CNS 
microenvironment. Functionally speaking, microglia is a hybrid between white blood cells 
and glial cells, which is intended to protect and support the neuronal environment in brain. 
Microglia can respond against an extensive list of biochemical factors ranging as diverse as 
glycoconjugates, neurotransmitters or cytokines/chemokines (Nakamura, 2002).  
Nearly two decade of studies demonstrated the causative effects of chemokines in glioma 
microenvironment for macrophage/microglia infiltration. The C-C family chemokines, viz, 
monocyte chemotactic protein 1 (MCP-1) was first purified from glioma and Leung et al, 
1997 found that with increased MCP-1 the macrophage/microglia infiltrates in glioma. 
Astrocytoma cells were found capable of producing MCP-1, and complementary receptor 
CCR2 was present and expressed on activated microglia (Leung et al, 1997). In 2003, 
evidence showed that, MCP-1 promoted the microglial migration in glioma and microglia 
infested glioma grew rapidly (Platten et al, 2003). The involvement of PI-3K/Akt pathway 
was assumed in the secretion of microglia derived factors that mediate glioma invasiveness 
(Joy et al, 2003; Pu et al, 2004). CSF-1 (colony stimulating factor 1), which acted as 
chemotactic and mitogenic factors for myeloid lineage cells, and its receptor, were long been 
detected in glioma, whereas microglia also possessed the option of secreting and receiving 
the factor from self and neighboring cells. Eventually from glioma G-CSF/GM-CSF 
(granulocytes and granulocytes macrophage colony stimulating factor) were secreted and 
influenced the differentiation and maturation process of microglia like other myeloid 
lineage cells. Badie et al, 1999, in vitro demonstrated the specific microglia attracting capacity 
of glioma by the hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF signals the 
spectrum of mesenchymal cells for mitogenic stimulation, invasion and extravasation. 
Microglia possesses its receptor Met and can produce HGF/SF, whereas the glioma cells are 
capable of doing the same (Badie & Schartner, 2001). Thus, the balancing ratios of the factors 
in glioma microenvironment act as the determinant in the migration process of the cells. 
In 2002, the 15.3 KDa heparin-binding peptide Pleiotrophin (PTN) was found to appear in 
adult human glioma, normally a mitogenic/angiogenic factor in embryonic stage. Uniquely, 
PTN did not help to proliferate the glioma cells by its own, rather influenced microglial 
accumulation by acting as strong chemotactic and mitogenic agent. Its action thus passively 
helped glioma growth by targeting endothelial and microglial cells (Mentlein & Held-
Feindt, 2002). The question arose that what would be the interest of glioma to include 
microglia in its vicinity? In fact, the role of infiltrating macrophage/microglia in the process 
of angiogenesis in glioma was hinted previously when macrophage associated heme-
oxygenase-1 (HO-1) enzyme was found to be correlated with the vascular density of human 
glioma (Nishie et al 1999). Another enzyme cyclooxygenase (COX)-2 was found to be 
produced in higher amount in microglia isolated from intracranial glioma which increased 
the prostaglandin E2 (PGE2) production. The study suggested that glioma infiltrating 
microglia contributed in developing fatal cerebral edema in glioma through COX-2 
dependent pathway. It was reported that PGE2 increased the permeability of vascular 
endothelium by cytoskeletal rearrangement where TNFα acted as positive inducer. In that 
case, microglia was the source of both COX-2 and TNFα probably playing a role in its own 
migration, leukocyte trafficking and in parallel, glioma invasiveness (Badie et al, 2003).  
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Contrary to the reports and assumptions, others demonstrated that TNF dependent action 
enhanced the macrophage/microglia recruitment in glioma where they form small cavities 
named microcysts and reduces the glioma growth (Villeneuve et al, 2005). A report stated 
that, the infiltrated macrophages (CD11b+CCR3-CD45high) caused TNF induced apoptosis in 
GL261 glioma cells where related microglial cells (CD11b+CCR3+CD45+) were negligible 
(Nakagawa et al, 2007). Actually the thin line of demarcation of cellular identity between 
macrophage and microglia could not exclude any of them from the function of TNF 
dependent glioma elimination. Opposing the recent believe of pro-tumoregenic role of 
macrophage population in different tumors, the reports raised question against application 
of anti-inflammatory drugs to suppress microglial action in glioma. To reestablish its role 
against glioma, the mechanism of their phagocytic recognition, killing machinery, and 
antigen presentation to CTL etc must have to be introspected more specifically. 
4.3 Microglia protects host brain as well as support glioma: A bi-edged sword 
Further findings showed that microglia helped glioma to invade by releasing matrix 
degrading enzymes. Even it was recently found that in rare Neurofibromatosis 1 (NF1), the 
heterozygote microglia had the role to promote glioma growth (Daginakatte & Gutmann, 
2007). In 2005, it was found that metalloprotease-2 (MMP-2) activity was increased in 
microglia by the soluble factors released from glioma cells (Markovic et al, 2005). Thus 
glioma in turn influenced microglia to invade and migrate, which was utilized by neoplastic 
cells itself to spread and grow. Previously, a separate study hinted the process when the 
motility of GL261 mouse glioma cells was assessed in presence of microglia. Even the 
microglia stimulated with GM-CSF or LPS enhanced this migration (Bettinger et al, 2002). 
Adenosine mediated anti-inflammatory effects on macrophage cell lines by modulating the 
cytokine balance was observed. Additionally, macrophage and microglia both the cells were 
found to present adenosine receptors. In 2006, Synowtz and his team found the effect of 
nucleoside Adenosine on microglial cell and glioma. Deficiency of A1 adenosine receptor 
(A1AR) on microglia helped to grow the GL261 glioblastoma cells and increased number of 
A1AR expressing microglia in the site inhibited this growth. The mentioned study also 
hinted that adenosine signaling through the receptor depleted glioma influenced microglial 
MMP-2 release, which in turn restricted glioma growth and invasion (Synowitz et al 2006). 
Again, Kettenmann and colleagues observed that Microglia express membrane type 1 
metalloprotease (MT1-MMP) in glioma condition, which helps to activate glioma released 
pro-MMP2 and thus promotes the spread of glioma in brain parenchyma (Markovic et al, 
2009). Their most recent finding is that the antibiotic minocycline attenuates microglial MT1-
MMP expression in glioma and as a result neoplastic cell expansion is reduced in glioma 
(Markovic et al, 2011). 
Plasticity, its migration to the site of injury or inflammation, response and then departure 
from the site required a plausible explanation mostly for its movement. Microglia was found 
to express α6β1 integrin, which was the receptor for laminin expressed on the extracellular 
matrix constituent projections of astrocytes. This particular adhesion was for migration and 
under strict control of cytokine milieu (Milner & Campbell, 2002). It was found recently that 
another integrin α5β1 expressed both on glioma and microglial cells were capable of 
inhibiting glioma growth when attenuated. Remarkably it was found that, the attenuation 
process and resulting depletion of glioma required the presence of microglial cells (Färber et 
al, 2008). It might be probable that microglia secreting products had control over this 
integrin-laminin adhesion and migration of cell itself and invasive migration of glioma cells. 
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Regarding the cytokine microenvironment, the role of TGF-β was hinted in migration 
(Milner & Campbell, 2002). The specific importance of the cytokine was demonstrated by 
RNAi mediated gene silencing of TGF-β in promoting growth and invasiveness of glioma by 
integrin family adhesion molecule (Wesolowska et al, 2008). Recently it was found that 
cyclosporin A (CsA), an inhibitor of calcineurin and immunosuppressive in effect, could 
inhibit microglia mediated glioma invasion and cause to change morphological structure of 
microglia via MAPK signaling (Silwa et al, 2007). 
In the present context, most of the studies demonstrated pro-tumerogenic action of microglia 
in glioma, which was facilitated by the secretary products, signaling molecules including 
cytokines, chemokines and receptors etc. In parallel, glioma cells favor microglial migration 
and encroachment in its vicinity. Though primarily macrophages/microglia are the cells to 
defend host tissue from faulty or malfunctioning cells or pathogens, their pro-glioma role 
leads to confusion. Remarkably, several findings also came with hopeful antagonistic results as 
already mentioned, where the roles of TNFα, TGFβ, A1AR dependent MMP-2 inhibition etc 
were focused (Villeneuve et al, 2005; Nakagawa et al, 2007; Synowitz et al 2006; Wesolowska et 
al, 2008). In 2007, Galarneau and team demonstrated that macrophage/microglia depletion 
helped in glioma growth (Galarneau et al, 2007). The study hinted for a separate anti-tumor 
potential of the cells. These contradicting results present microglia with a double agent stature.   
4.4 Glioma antigen presentation by microglia 
To determine the antigen presenting role of microglia their MHC class II expression along 
with the co-stimulatory molecule like B7.1 (CD80) and B7.2 (CD86) had been evaluated. 
Badie and his team found the lower level of expression of these essential surface molecule 
for APC function in microglia freshly isolated from glioma invasive cells and that suggested 
suppressive effect on glioma microenvironment in vivo (Badie & Schartner, 2001). In a 
comparative study of different rodent glioma model viz., C6, 9L and RG2, the expression 
profile was found to vary significantly depending on the immunogenicity of the model. The 
costimulatory B7 molecule expression could be favored when microglia were rejuvenated by 
cytokines GM-CSF and IFN-γ in vitro (Badie et al, 2002). At the same time, Graeber with his 
colleagues scanned 97 glioma samples of different WHO grades and found no such simple 
relations of the MHC expression of the cell with tumor grades, rather found downregulation 
of MHC class II in tissue areas where dense glioblastoma cells were infested. According to 
them microglia were functional in astrocytic tumors, though might be subjected to 
suppression with T cell clonal anergy in that glioma microenvironment (Tran et al, 1998). 
The stimulatory effect of the novel glycoprotein T11TS/SLFA-3 on microglial MHC class II 
expression was found. The dose-time dependent efficient MHC expression was found on 
microglia in rodent bearing experimental glioma when treated with T11TS (Begum et al, 
2004). Chaudhuri and her team also identified another important costimulatory molecule 
CD2 on microglia, which could also be regulated by the glycoprotein dose in glioma 
condition (Begum et al, 2004; Chaudhuri & Ghosh, 2006). A separate study by her team 
found simultaneous co-expression of MHC class II and CD2 on microglia in glioma where 
both expressed in low quantity (Sarkar et al, 2004). This observation with others supported 
the view of immunosuppressive milieu offered to microglia in glioma mostly by TGFβ, IL-
10, PGE2, gangliosides etc (Zou et al, 1999; Graeber et al, 2002), which could also 
simultaneously cripple the infiltrated lymphocytes (Dix et al, 1999). In this regard, the fact 
that microglia was the source of that IL-10 in glioma, had been finally established by 
Wagner and team (Wagner et al, 1999).  
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Contrary to the reports and assumptions, others demonstrated that TNF dependent action 
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Regarding the cytokine microenvironment, the role of TGF-β was hinted in migration 
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Fig. 4. This schematic diagram shows the activities of immune components in brain during 
glioma. After activated glioma antigen specific T cells enter into brain parenchyma they 
progressed towards glioma through parenchyma. Simultaneously, during glioma 
pathogenesis resident resting microglia get activated, upregulate their receptors, enhance 
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their local antigen presenting capacity and move towards glioma vicinity where astrocytic 
projections may assist this movement by providing the pavement for integrin-laminin 
interaction. At the glioma site, microglia locally represent antigens, produce cytokines and 
adhesion molecules to dialogue with lymphocytes which help them to mature and attain 
final effector function. At this point, a triangular complex interaction circuit become active 
between infiltrated lymphocytes, microglia and glioma cells when glioma tries to cripple the 
immune attack by applying many of its tricks (as discussed in the text). Overall cytokine, 
chemokine, growth factor and immunosuppressive factor become crucial to determine the 
success of immune defense or glioma. At the next step, cytotoxic T cells exert perforin, 
granzyme, FasL and other cytotoxic means to kill glioma and microglia uses its reactive 
oxygen and nitrogen intermediates to damage the abnormal or neoplastic cells. Target cells, 
intact, damaged or dead debris are scavenged by microglia. If the immune system manages 
to overcome the situation for a certain period they return to homeostasis. But aggressive 
glioma, after the initial arrest, overrules the immune defense by its rapid proliferation rate, 
immune evasion strategies and diverse modes for bypassing the attack. Gaining dominance 
during the triangular interaction phase marks the success of the party in the succeeding 
phases (Adopted from Chaudhuri & Ghosh, 2006, CNSAMC).  
Hemiberger and colleagues studied the myeloid lineage cells in post-operative tissue 
samples in human glioma. Accepting the cellular identity crisis, these workers found 
macrophage/microglia and dendritic cell populations within the tumor tissue. In their 
higher grade glioma samples microglial population though found to express MHC class II, 
lacked co-stimulatory CD80, CD86 and CD40, crucial for T cell functioning. Activation of 
microglia via Toll-like receptors (TLRs) were also insignificant to augment tumoricidal 
activity (Hussain et al, 2006a). Particularly, proinflammatory cytokines including IL-1β, IL-6, 
TNF α could not be sufficiently released to launch substantial innate immune function 
against glioma, however their phagocytic function was not impaired and also exhibited low 
level of non-specific cytotoxicity (Hussain et al, 2006b). In rodent glioma model lack of 
proinflammatory cytokines IFN γ, IL-12 and IL-6, and conversely cumulative dominance of 
IL-4 and IL-10 favoring the suppression of immune response was recently observed (Ghosh 
et al, 2010). Microglial activity stature was also reflected in their morphometry in scanning 
electron microscopy (SEM), where their filapodial extensions, sizes and shapes had shown 
noticeable alterations (Begum et al, 2003). 
4.5 Microglia can destroy glioma cells 
The cytotoxic effector function is an important part of CNS microglia/macrophage 
population which mainly dependents on its phagocytic mode of action. For the purpose 
super oxide anion production is the major function of phagocytic cells, however microglia 
generate sufficient endogenous NO in addition (Beyer et al, 2000). When microglial effector 
function in rat glioma model was studied, it was found that microglia mostly depends on 
NO production than ROS generation for exerting effector activity, whereas peripheral 
macrophages mainly depends on ROS for their normal phagocytic functions (Ghosh et al, 
2007). With tumoricidal actions NO plays certain role in complex signaling network of 
cytokine production, angiogenesis etc in brain microenvironment. Even microglia was 
found to release iNOS/NO from astrocytoma cells in contact. This was by IL-1β production 
of activated microglia and probably via p38 MAPK and NF-κB signaling pathway (Kim et al, 
2006).  
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Expression of Fas ligand on a cell may cause damage to adjoining cells or infiltrated 
activated lymphocytes in the tissue by triggering the death pathway. In glioma, FasL 
expression was thought to be a means of immune escape, whereas, investigations found 
FasL expression also on microglial cells in glioma (Badie et al, 2001). Hence, it could be 
thought that microglia would play role in local immune suppression by limiting the 
lymphocyte populations; or it might express FasL to damage glioma cells, which in turn 
restricted or crippled the lymphocytes infiltrated locally. Microglia prefers to phagocytose 
the damaged cells rather than intact ones (Bohatschek et al, 2001). A study showed that after 
adoptive transfer of alloreactive cytotoxic T cells in rat 9L gliosarcoma infested brain, the 
CTL damaged glioma cells were removed by phagocytic scavenging activities of microglia, 
whereas undamaged ones were spared (Kulprathipanja & Kruse, 2004). In this process of 
either Fas or oxidative stress mediated cell death, externalization of phosphatidylserine was 
found to be crucial in corpse clearance by microglia. Experimental evidences revealed 
increasing PS externalization in correlation with cytotoxic effector functions of microglia 
and infiltrated lymphocytes. Additionally, the investigation showed that microglia 
population was more steady than infiltrated lymphocytes as Bcl-2 aided the cells to maintain 
that steady turnover rate and low apoptosis in brain microenvironment (Kagan et al, 2002 & 
Ghosh et al, 2007). 
5. Conclusion: Future immuno-therapeutics must capitalize this resident and 
infiltrated immunocyte liaison to combat glioma 
Now it can be clearly stated that lymphocytes can enter into the brain parenchyma. During 
their entry, they are checked by the antigen presenting cells for their glioma antigen 
specificity. APCs try to ensure this glioma specific T cell entry by restimulating the 
candidates presenting the glioma antigens mostly in perivascular space and allied blood 
brain interface (Engelherdt, 2010). After entering they migrate to glioma and again interact 
with the local APCs which help them to gain maturation and final effector function. In this 
process peripheral APC in brain and ‘so called’ resident microglia as well as DCs also play 
very important role. The role of local APC in glioma immunity has been detailed by Ghosh 
and Chaudhuri with a new outlook to explain the contradiction of glioma promoting role of 
microglia (Ghosh and Chaudhuri, 2010).These myeloid cell populations have the potential 
to act as chief immunomodulator in brain by surveillance in the tissue environment, guiding 
the leukocytes in CNS and simultaneously exerting effector function to neoplastic cells. The 
damaging activities of the cell are probably their own misfired ‘goodness’ or their potential 
that is misled by glioma cells. Thus, both the lymphocytes and local APC (predominantly 
microglia) are capable of exerting the immune effector function against glioma in spite of the 
immune-compromise in the brain and glioma immune evasion strategies [Figure – 4]. 
Now the success of immunotherapeutic approaches against glioma, largely as adjuvant 
therapeutic strategy, depends on the proper usages of this delicate immune defense against 
this detrimental threat. The battle becomes more interesting and challenging because the 
opponent is extremely clever. So development of immunotherapeutic strategies against 
glioma needs detailed and critical interpretation of the work-plan of immunity in glioma 
and its careful application. Basic findings are increasing the repertoire of information about 
immune activity deep into the brain during glioma which in turn provide us newer tactics 
or facilitate the amendment of old ones for better effects (Dietrich et al, 2010; Vauleon et al, 
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2010). Even some of the approaches interestingly propose microglia as an effective vehicle 
for gene therapy and drug delivery by using its predifferentiated cellular status (Neumann, 
2006). Present immunotherapeutic advancements and limitations will be discussed in other 
chapters of this book and beyond the scope of this article. In this essay, the basic immune 
mechanisms, which are active in glioma, has been detailed. Further development of effective 
therapy needs this fundamental background knowledge for setting up a new 
immunotherapeutic intervention against glioma. 
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1. Introduction 
Dendritic cells (DCs) are well known for their capacity to induce adaptive antitumor 
immune response through their unique ability to uptake, processing and presenting 
antigens (Ags), and tumor-specific T cell activation. In addition, cytokines produced by 
dendritic cells are able to regulate the direction and strength of immune response, activate 
the cytotoxic cells (NK-, NKT-cells) and participate in the coordination of the humoral 
immune response (Melief, 2008; Banchereau et al., 2000). 
An increasing number of reports evidenced that besides this role, DCs may display 
additional antitumor effects. Indeed, DCs in vitro can inhibit proliferation and provide a 
direct cytotoxic effect on tumor cells. In this, human monocyte-derived DCs might exert 
antitumor activity through multiple TNF family members (i.e. TNF-α, lymphotoxin-α1β2, 
FasL, TRAIL), as well as perforin and/or granzyme (Wesa & Storkus, 2008; Chauvin & 
Josien, 2008). 
Direct tumor cell killing by DCs themselves appear to be highly important since involves 
immediate presentation of tumor-associated Ags in the context of MHC molecules for 
recognition by cognate T cells, inducing a specific immune response. Importantly, 
pleiotropy in DC mechanisms of cytotoxicity allows DCs to overcome the resistance of 
tumor cells that are heterogeneous with regard to their sensitivity to the various death 
pathways. A number of evidence suggests that the direct antitumor effect of DCs is not 
purely in vitro phenomenon, and is implemented in vivo. First, DCs are present in the 
tumors, and their higher content correlates with a more favorable prognosis (Becker 1999). 
Second, intra-tumoral injection of intact DC (not loaded with tumor antigen) has been 
shown to correlate with reduced tumor growth and even regression (Becker et al., 2001; 
Ehtesham et al., 2003). Finally, it is shown that the intra-tumoral introduction of DCs 
improves the effectiveness of chemotherapy, which may be due to synergistic effects of 
cytostatics and DCs (Vanderheyde et al., 2004). 
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Most studies on antitumor activity of DCs in humans were performed with myeloid DCs 
isolated from peripheral blood or generate in vitro from peripheral blood monocytes in the 
presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 
(IL-4). Cytotoxic activity of these DCs was found to be stronger after treatment with type I 
interferons (IFN) or IFNγ (Liu et al., 2001; Fanger et al., 1999). More recently, monocyte-
derived DCs generated in the presence of GM-CSF and IFNα instead of IL-4 were described. 
Is also known that IFNα-DCs are characterized by a higher expression of some molecules 
(TRAIL, FasL), which may mediate the cytotoxic/cytostatic activity of DCs (Chauvin & 
Josien, 2008). Indeed, we have demonstrated that LPS-activated IFNα-DCs inhibit the 
growth of tumor cell line HEp-2 more efficiently than IL4-DCs (Leplina et al., 2010). 
However, the antitumor potential of DCs generated in the presence of IFNα, remain 
virtually unexplored. 
Of great relevance is also an issue on safety of DC cytotoxic activity in cancer settings. 
Recently, we found that in patients with malignant gliomas IFNα-DCs generated in vitro are 
able to activate Th1 cells and induce an antitumor immune response (Leplina et al., 2007a). 
Nevertheless, these DCs exhibit several phenotypic and functional features, such as the 
moderate delay of differentiation/maturation and low capacity to induce the IFNγ-
producing T-cells in mixt lymphocyte culture (MLC) (Leplina et al., 2007b). Given the data 
on the development of immune insufficiency and monocyte dysfunctions in patients with 
malignant brain tumors (Khonina et al., 2002) the study of various functions of DCs in this 
pathology is important not only in terms of understanding pathogenesis of the disease, but 
also to rationale the therapy with dendritic cells. In this article we investigated the cytotoxic 
potential of human monocyte-derived DCs generated under replacement of IL-4 with IFNα, 
and compared cytostatic/cytotoxic activities of IFNα-induced DCs in healthy donors and 
patients with brain tumors. 
2. The text of the article 
2.1 Materials and methods 
2.1.1 Patients 
The study was held in 32 healthy volunteers and 37 patients with brain tumors (21 men and 
16 women; from 21 to 71 years; median age 37 years). Patients’ group included 20 patients 
with histologically verified gliblastoma (Grade IV), 8 - with astrocytoma (Grade III) and 9 - 
with angioreticuloma, fibrilyarno-protoplasmic astrocytoma or meningioma (Grade I-II). All 
studies were performed after receiving a written informed consent.  
2.1.2 In vitro differentiation and maturation of DCs 
Peripheral blood mononuclear cells (MNCs) were obtained by density gradient 
centrifugation (Ficoll-Paque, Sigma-Aldrich) of heparinized whole blood samples. Dendritic 
cells were generated by culturing of plastic-adherent MNC fraction in 6-well plates 
(Nunclon, Denmark) in RPMI-1640 medium (Sigma-Aldrich), supplemented with 0,3 
mg/ml L-glutamine, 5 mM HEPES buffer, 100 µg/ml gentamicin and 5% fetal calf serum 
(FCS, Sigma-Aldrich), in the presence of recombinant human (rh) GM-CSF (40 ng/ml, 
Sigma-Aldrich) and rhIFN-α (Roferon-A, 1000 U/ml, Roche, Switzerland) for 4 days (IFNα-
DCs) or with rhGM-CSF (40 ng/ml) and IL-4 (40 ng/ml, Sigma-Aldrich) for 5 days ( IL4-
DCs). The resulting immature DCs were further exposed with 10 µg/ml lipopolysaccharide 
(LPS E.colli 0114: B4, Sigma-Aldrich) into IFNα-DC and IL4-DC cultures for additional 24h 
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and 48h, respectively. For some experiments DC supernatans generated from LPS-activated 
IFNα-DCs were collected. The viability of obtained IFNα–DCs or IL4–DCs determined by 
Trypan blue exclusion was more than 93-95% in all cases. 
2.1.3 Cell lines 
Tumor cell lines used in this study included leukemia cell line Jurkat (T- lymphoblast cell 
leukemia) and solid tumor-derived cell lines: epithelial cells of human larynx carcinoma 
HEp-2 and glioblastoma U-87 were purchased from American Type Culture Collection 
(Manassas, VA). All cell lines were of human origin, mycoplasma free and were grown 
under standard cell culture conditions.  
2.1.4 Cytotoxicity assay 
Generated IFNα–DCs were tested for their cytotoxic activity against various tumor cell lines 
including Jurkat, HEp-2 and U-87. Before coculture, target cells were labeled with 
[3H]thymidine (1 µCi/well) for 18 h at 37°C, washed and placed at 104/well in 96-well tissue 
culture plates in RPMI-1640 medium containing 10% FCS. Cell-free supernatants from DC 
cultures (30%, v/v) or different numbers of effector cells (DCs) were added to tumor cells at 
effector:target (E:T) ratios of 10:1, 20:1 and 40:1. In some experiments DCs were pre-
incubated for 1 h with the following fusion proteins: rhTNFR1/TNFRSF1A Fc chimera (10 
μg/ml), rhFas/TNFRSF6/CD95 Fc chimera (10 μg/ml), and rhTRAIL R2/TNFRSF10B Fc 
chimera (10 μg/ml; all reagents from R & D Systems, USA). After 18 h of culture cells were 
harvested and thymidine incorporation was measured on a Liquid Scintillation beta-
Counter (Packard Instrument, Meriden, CT). Percentage of cytotoxicity was calculated by 
the formula:  
[1 - (cpm in cocultures of tumor and effector cells or DC supernatans/ cpm in tumor cell 
cultures)] x 100%. 
2.1.5 Cytostatic assay 
Cytostatic activity of DCs was evaluated by their ability to suppress the proliferation of 
tumor line cells (HEp-2 and U-87). For this, the target cells (103/well) were incubated for 48 
h in 96-well plates alone and in the presence of effector cells at E:T ratios about 10:1, 20:1 and 
40:1. Cell proliferation was measured by [3H]thymidine incorporation (1 μCi/well for last 24 
h). The percentage of cytostatic activity was calculated by the formula:  
[1 - (cpm in cultures with effector cells / cpm in control cultures)] x 100%. 
2.1.6 Apoptosis detection 
To determine the level of apoptosis, HEp-2 tumor cells were preliminary stained with vital 
dye CFSE (2 mM, Molecular probes, USA) for 15 min, then washed in RPMI-1640/10% FCS 
and incubated in 96-well tissue culture plates (104/well) in the presence of IFNα-DCs at a 
ratio 10:1 for 18 hours. The number of cell divisions was analyzed by flow cytometry (FACS 
Calibur, Becton Dickinson, USA) on channel FL1 (CFSE fluorescence) with the emission of 
517 nm. The level of apoptosis was detected by DNA intercalating dye 7-AAD (Calboichem, 
Israel). Results were expressed as a percentage of positive cells to the total cell number in the 
region studied. 
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2.1.7 TNFα production 
DC-free supernatants collected as deascribe above were measured for soluble TNFα by 
ELISA using a commercial kit (R & D Systems, USA) according to the manufacturer`s 
recommendations. 
2.1.8 Statistical analysis 
The data were expressed as mean ± SE. Statistica 6.0 software for Windows (StatSoft Inc. 
USA) was used for analysis of data. Statistical comparisons were performed using the 
nonparametric Mann-Whitney U test. P-values < 0,05 indicate significant differences. 
2.2 Results 
2.2.1 Cytotoxic activity of donor IFNα-DCs and DC supernatants against tumor cell 
lines  
First, we assessed whether in vitro generated mature IFNα-DCs could lyse tumor cell lines. 
IFNα-DCs in our study possessed significant dose-dependent cytotoxic activity against 
[3Н]thymidine-labeled tumor cell lines HЕp-2 and Jurkat. As illustrated in Fig.1A, Jurkat 
cells were lysed more efficiently at all E:T cell ratios. The most pronounced differences in 
cytotoxic activity of IFNα-DCs against Jurkat and HEp-2 were observed at a E:T ratio of 20:1 
(35,17 ± 5,6% and 16,44 ± 4,01 %, respectively; PU=0,027). High cytotoxic activity of IFNα-
DCs was also manifested when human glioblastoma U-87 cells were used as targets (Fig.1B). 
In this case, the cytotoxic potential of DCs at 20:1 was two-fold higher than with HEp-2 cells 
(38,6 ± 8,3%; PU=0,049). Taken together, these data indicate that i) mature IFNα-DCs 
mediated significant antitumor cytotoxic activity, effective at various E:T cell ratios, and ii) 
the cytotoxic activity of IFNα-DCs against tumor cell lines Jurkat and U-87 unlike HEp-2 




Fig. 1. Cytotoxic activity of donor IFNα-DCs against Jurkat, Hep-2, and U-87. A) The 
average values of IFNα-DC cytotoxic activity against tumor cell lines Jurkat and HEp-2 are 
presented. Effector cells (DCs) and [3H]thymidine-labeled target cells (Jurkat and HEp-2) 
were cultured for 18 h at ratios indicated. B) Cytotoxic activity of IFNα-DCs against Jurkat, 
HEp-2 and U-87 tumor cells at E:T ratio of 20:1. Results are shown as mean ± SE of triplicate 
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To examine the possible mechanisms underlying the cytotoxic activity of IFNα-DCs against 
tumor cells, we evaluated the cytotoxic activity associated with DC culture-conditioned 
medium. Contrary to DCs themselves, IFNα-DC culture-conditioned medium lacked 
cytotoxic activity or had a low ability to lyse tumor cells. Indeed, supernatants of DC 
cultures added to targets at 30% (v/v) were unable to lyse HEp-2 cells, and had some 
cytotoxic activity against Jurkat cell line (13,0 ± 1,7%) (Fig.2). These results showed that 
mediators of DC-associated antitumor activity are more likely cell membrane-bound 
molecules but not secreted proteins. 
2.2.2 Induction of apoptosis of tumor cell line HEp-2 by IFNα-DCs 
To investigate whether DC killer activity involved the induction of apoptosis, we next 
analyzed cell cycle in tumor cells HEp-2 pre-labeled with vital dye CFSE (Fig.3). Co-
culturing of CFSE-labeled HEp-2 cells with IFNα-DCs resulted in significant increase in the 
level of apoptosis detected in tumor cells. In addition, the cultivation of tumor cells with 
IFNα-DCs was accompanied by a decrease in number of cycling tumor cells (S + G2M 
phases of the cell cycle). These results showed that DCs in vitro can efficiently induce death 




















Fig. 2. Cytotoxic activity of DC culture-conditioned medium against Jurkat and HEp-2. The 
figure represents individual values of cytotoxic activity mediated by supernatants from 
cultures of healthy donor IFNα-DCs against tumor cell lines HEp-2 (n = 17) and Jurkat  
(n = 6). Jurkat cells and HEp-2 cells (104cells/well) were labeled with [3H]thymidine and 
incubated with DC culture-conditioned medium (30%, v/v) for 18 hours.  
2.2.3 Growth inhibition effect of IFNα-DCs on tumor cell lines HEp-2 and U-87 
These data result in the suggestion that the cytotoxic activity of IFNα-DCs is conditioned by 
induction of apoptosis in tumor cells and that, along with a cytotoxic effect, IFNα-DCs 
apparently could block cell cycle in tumor cells, thereby providing cytostatic effect. Indeed, 
analysis of IFNα-DCs impact on the proliferation of tumor cells (Fig. 4) revealed a 
pronounced antiproliferative effect exerted by donor DCs against the cell line HEp-2.  
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The data were expressed as mean ± SE. Statistica 6.0 software for Windows (StatSoft Inc. 
USA) was used for analysis of data. Statistical comparisons were performed using the 
nonparametric Mann-Whitney U test. P-values < 0,05 indicate significant differences. 
2.2 Results 
2.2.1 Cytotoxic activity of donor IFNα-DCs and DC supernatants against tumor cell 
lines  
First, we assessed whether in vitro generated mature IFNα-DCs could lyse tumor cell lines. 
IFNα-DCs in our study possessed significant dose-dependent cytotoxic activity against 
[3Н]thymidine-labeled tumor cell lines HЕp-2 and Jurkat. As illustrated in Fig.1A, Jurkat 
cells were lysed more efficiently at all E:T cell ratios. The most pronounced differences in 
cytotoxic activity of IFNα-DCs against Jurkat and HEp-2 were observed at a E:T ratio of 20:1 
(35,17 ± 5,6% and 16,44 ± 4,01 %, respectively; PU=0,027). High cytotoxic activity of IFNα-
DCs was also manifested when human glioblastoma U-87 cells were used as targets (Fig.1B). 
In this case, the cytotoxic potential of DCs at 20:1 was two-fold higher than with HEp-2 cells 
(38,6 ± 8,3%; PU=0,049). Taken together, these data indicate that i) mature IFNα-DCs 
mediated significant antitumor cytotoxic activity, effective at various E:T cell ratios, and ii) 
the cytotoxic activity of IFNα-DCs against tumor cell lines Jurkat and U-87 unlike HEp-2 




Fig. 1. Cytotoxic activity of donor IFNα-DCs against Jurkat, Hep-2, and U-87. A) The 
average values of IFNα-DC cytotoxic activity against tumor cell lines Jurkat and HEp-2 are 
presented. Effector cells (DCs) and [3H]thymidine-labeled target cells (Jurkat and HEp-2) 
were cultured for 18 h at ratios indicated. B) Cytotoxic activity of IFNα-DCs against Jurkat, 
HEp-2 and U-87 tumor cells at E:T ratio of 20:1. Results are shown as mean ± SE of triplicate 
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To examine the possible mechanisms underlying the cytotoxic activity of IFNα-DCs against 
tumor cells, we evaluated the cytotoxic activity associated with DC culture-conditioned 
medium. Contrary to DCs themselves, IFNα-DC culture-conditioned medium lacked 
cytotoxic activity or had a low ability to lyse tumor cells. Indeed, supernatants of DC 
cultures added to targets at 30% (v/v) were unable to lyse HEp-2 cells, and had some 
cytotoxic activity against Jurkat cell line (13,0 ± 1,7%) (Fig.2). These results showed that 
mediators of DC-associated antitumor activity are more likely cell membrane-bound 
molecules but not secreted proteins. 
2.2.2 Induction of apoptosis of tumor cell line HEp-2 by IFNα-DCs 
To investigate whether DC killer activity involved the induction of apoptosis, we next 
analyzed cell cycle in tumor cells HEp-2 pre-labeled with vital dye CFSE (Fig.3). Co-
culturing of CFSE-labeled HEp-2 cells with IFNα-DCs resulted in significant increase in the 
level of apoptosis detected in tumor cells. In addition, the cultivation of tumor cells with 
IFNα-DCs was accompanied by a decrease in number of cycling tumor cells (S + G2M 
phases of the cell cycle). These results showed that DCs in vitro can efficiently induce death 




















Fig. 2. Cytotoxic activity of DC culture-conditioned medium against Jurkat and HEp-2. The 
figure represents individual values of cytotoxic activity mediated by supernatants from 
cultures of healthy donor IFNα-DCs against tumor cell lines HEp-2 (n = 17) and Jurkat  
(n = 6). Jurkat cells and HEp-2 cells (104cells/well) were labeled with [3H]thymidine and 
incubated with DC culture-conditioned medium (30%, v/v) for 18 hours.  
2.2.3 Growth inhibition effect of IFNα-DCs on tumor cell lines HEp-2 and U-87 
These data result in the suggestion that the cytotoxic activity of IFNα-DCs is conditioned by 
induction of apoptosis in tumor cells and that, along with a cytotoxic effect, IFNα-DCs 
apparently could block cell cycle in tumor cells, thereby providing cytostatic effect. Indeed, 
analysis of IFNα-DCs impact on the proliferation of tumor cells (Fig. 4) revealed a 
pronounced antiproliferative effect exerted by donor DCs against the cell line HEp-2.  
 














Fig. 3. Effect of IFNα-DCs from healthy donors on the cell cycle in HEp-2. The figure shows 
the relative content (%) of CFSE-labeled HEp-2 cells in cell cycle phases in the absence of 
DCs (control; n= 4) and in co-cultures with IFNa-DCs (n= 4) for 18 hours at E:T ratio of 10:1. 
The data are presented as M ± SE (%). * - PU<0,01 (U - Wilcoxon's test, Mann-Whitney).  
 
 
Fig. 4. Tumor-inhibiting activity of IFNα-DCs from healthy donors against НЕр-2, Jurkat, 
and U-87. А) The graph shows the mean values (M ± SE) of cytostatic activity of IFNα-DCs 
against HEp-2 tumor cells (n = 8). Effector cells (DC) and target cells were cultured at ratios 
indicated for 24 hours, followed by the introduction of [3H]thymidine for 24 hours. B) 
Cytostatic activity rendered by IFNα-DCs against HEp-2 (n = 8), Jurkat (n = 7) and U-87  
(n = 5) in E:T ratio of 20:1. * - PU <0,05 - between the cytostatic activity of DCs vs HEp-2 and 
U-87 (U - Wilcoxon's test, Mann-Whitney). 
Importantly, DCs mediated potent inhibitory activity (45,4 ± 6,24%) even at a low E:T cell 
ratio (10:1). Moreover, IFNα-DCs also suppressed the proliferation of glioblastoma cell 
line U-87. However, in this case inhibition was almost two-fold lower, accounting for 27,4 
± 4,4% at E:T ratio of 20:1 vs 52,4 ± 4,4% in HEp-2 cultures (p <0,05). Thus, in our study 
IFNα-DCs were found to be cytostatic for tumor cell lines. Comparative analysis of 
cytotoxic and cytostatic activity mediated by IFNα-DCs showed no correlations between 
the level of DC cytotoxicity and their ability to inhibit the proliferation of HEp2 (rS = 0,21; 
p = 0,7), U-87 (rS = 0,5; p = 0,28) and Jurkat (rS = 0,33; p = 0,5) tumor cell line. The lack of 
such a relationship was also indicated by the fact that in cultures of U-87 dendritic cells 
displayed the highest cytotoxic effect while their cytostatic effects were only moderate. 












































Direct Antitumor Activity of Interferon-Induced 
Dendritic Cells of Healthy Donors and Patients with Primary Brain Tumors 
 
331 
2.2.4 Role of TNFα, FasL and TRAIL in cytotoxic activity of IFNα-DCs 
To get inside into the mechanism that could be responsible for DC tumoricidal activity, we 
have investigated the role of key molecules involved in the apoptosis pathway. Cytotoxic 
activity of DCs is attributed to the expression of some proapoptotic molecules such as 
TRAIL, FasL, perforin, granzymes A and B, TNF-α, lymphotoxin-α1, β2 (Chauvin & Josien, 
2008). To further characterized the molecular mechanisms by which HEp-2 cell death results 
from interaction with DCs, we studied the effect of some soluble receptors at the DC-
mediated cytotoxic activity. As evident from Fig. 5, pretreatment of IFNα-DCs with TNFR1: 
Fc resulted in almost complete neutralization of DC cytotoxic activity, whereas pretreatment 




Fig. 5. Neutralization of DC cytotoxic function by soluble forms of R:Fc, specific for TNF-
family ligands. [3H]thymidine-labeled tumor cells HEp-2 (104 cells/well) were incubated for 
18 hours with IFNα-DCs (at E:T ratio of 20:1) pre-treated for 1 h with TRAIL-R2: Fc fusion 
protein (10 μg/ml; n = 6), or TNFR1: Fc fusion protein (10 μg/ml; n = 6), or Fas: Fc fusion 
protein (10 μg/ml; n = 6). Data are presented as mean (M ± SE) of cytotoxic activity of IFNα-
DCs vs HEp-2. * - PU <0,01 - between intact DCs and DCs treated with TNFR1: Fc (U - 
Wilcoxon's test, Mann-Whitney). 
Thus, our data suggest that lysis of HEp-2 cells is not related with TRAIL- and FasL-mediated 
cytotoxicity but occurs with the involvement of TNFα molecules, since blocking of 
TNFα/TNFR1 binding leads to almost full suppression of DC killer activity. Apparently, the 
involvement only a single of three described mechanisms of DC cytotoxicity is due to 
resistance of tumor cells HEp-2 to TRAIL-and FasL-mediated apoptosis and determines 
relatively low cytotoxic activity of DCs against HEp-2 cells compared to Jurkat and U-87 which 
are sensitive to FasL-and TRAIL-mediated apoptosis (Röhn et al., 2001; Hoves et al., 2003). 
2.2.5 Cytotoxic activity of donor IL4-DCs in compared with IFNα-DCs 
Since we proposed IFNα-DCs may have a more pronounced antitumor activity than DCs 
generated with GM-CSF and IL-4, we then investigated whether cytotoxic and cytostatic 
activities of these two types of LPS-activated DC were distinct. As seen in Fig.6, IFNα-DCs 
possessed the higher ability to lyse leukemia cells Jurkat (Fig. 6A) and comparable cytotoxic 
activity in HEp-2 cultures (Fig.6B). However, IFNα-DCs were found to be more effective in 
suppressing the growth of tumor cell line HEp-2 than IL4-DCs (45 ± 6% vs 29 ± 7%, 
respectively, at E:T ratio of 10:1, PU <0,05). 
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Fig. 6. Cytotoxic activity of IFNα-DCs and IL4-DCs of healthy donors against tumor lines 
Jurkat (A) and HEp-2 (B). Data are presented as mean (M ± SE) of cytotoxic activity. Effector 
cells (donor IFNα-DCs and IL4-DCs) were incubated with target cells ([3H]thymidine-
labeled tumor cell lines Jurkat and HEp-2) at ratios indicated for 18 h. *- РU<0,05 – between 
IFNα-DCs and IL4-DCs against Jurkat (U - Wilcoxon's test, Mann-Whitney).  
2.2.6 Cytotoxic activity of patient IFNα-DCs vs HEp-2  
While donor DCs were found to be tumoricidal, evaluation of the cytotoxic activity of DCs 
generated in vitro from peripheral blood of brain glioma patients revealed they were 
significantly less cytotoxic against HEp-2 cells (Fig.7A). The decrease of cytotoxic activity 
was manifested at all E:T ratios which were analyzed. At the same time assessment of 
patient DC killer activity at E:T ratio of 20:1 (n=37) allowed to reveal significant 
heterogeneity for DC cytotoxic potential in patients with brain tumors (Fig.7B). Indeed, in 25 
patients (67%) cytotoxic activity was completely absent, whereas remained relatively 
unaltered in another 12 patients (32%). 
 
 
Fig. 7. Cytotoxic activity of IFNα-DCs of patients with brain tumors against HEp-2. A) Effector 
cells (donor and patient IFNα-DCs) were cultured with [3H]thymidine-labeled target cells 
(HEp-2) for 18 h at ratios indicated. Results are shown as the mean ± SE of DC cytotoxic 
activity. *- PU <0,01 - between donor and patient DCs (U - Wilcoxon's test, Mann-Whitney) at 
E:T ratio of 40:1 and 20:1. B) Individual values of cytotoxic activity mediated by IFNα-DCs of 
healthy donors and brain tumor patients against HEp-2 are presented. Effector cells (DC) were 
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Analysis of patients according to the degree of tumor malignancy demonstrated that the 
decrease in cytotoxic activity of DCs was typical for patients with high grade (III-IV) 
gliomas while patients with low grade (I-II) intracerebral gliomas were characterized by 
unaltered cytotoxic activity (Table 1). 
 
E:T ratio = 20:1 Donors (n=22) Patients with brain tumors 
Grade I-II (n=9) Grade III-IV (n=28) 
M ± S.E 21,5 ± 2,6 22,56 ± 5,64  4,75 ± 1,95  
Median 17,0 20,0 0 
LQ-UQ 10,3- 32,0 13,0- 29,0 0- 4,0 
Table 1. Cytotoxic activity of IFNα-DCs in patients with low and high grade glioma 
Effector cells (IFNα-DCs) were generated from peripheral blood of healthy donors and 
patients with low grade (I-II) and high grade (III-IV) gliomas and cultured with 
[3H]thymidine-labeled target cells (HEp-2) for 18 h at E:T ratio of 20:1. The average values 
(M ± SE), Median and interquartile range (from low to upper quartile, LQ-UQ) of cytotoxic 
activity are presented. 
Figure 8 shows the individual examples of cytotoxic activity of IFNα-DCs of patients with 
Grade I-II (n=3) and III-IV (n=3) brain tumors. 
2.2.7 Survival rates of patients with intact and reduced levels of IFNα-DC cytotoxic 
activity vs HEp-2 cells 
Considering that the degree of malignancy is predictive factor of patient survival, we further 
questioned about the survival rates of patients with intact and reduced levels of DC 
cytotoxic activity against HEp-2 cells (Fig. 9). The criterion for division into such groups was 
the lower quartile range of cytotoxic activity mediated by donor IFNα-DCs against HEp-2 
cells (LQ=10,3%).  
Patients with decreased cytotoxic activity of IFNα-DCs (< 10,3%, 1 patient with Grade II and 
15 patients with Grade III-IV) differed by a lower survival rate compared with patients of 
the opposite group. For example, a median of survival in patients with low DC cytotoxic 
activity was about 13 months, and in the group with unchanged cytotoxic activity of DCs all 
patients (5 patients with Grade I-II and 4 patients with Grade III) were followed alive. 
2.2.8 Growth inhibition effect of patient IFNα-DCs on tumor cell line HEp-2  
Next, we investigated whether DCs of patients with brain tumors could inhibit the growth 
of HEp-2 cells (Table 2). While donor DCs possessed the marked cytostatic activity, IFNα-
DCs of patients with intracerebral gliomas were found to be incapable of suppressing the 
proliferation of HEp-2. Moreover, the addition of DCs led to 3-fold increased tumor cell 
proliferation. The index of DC impact ranged from 0,5 to 7,2, averaging about 3,06± 0,4. It 
should be noted that such a stimulatory effect of DCs on HEp-2 cell growth was detected 
both in patients with high grade III-IV (3,08 ± 0,65; n = 19) and low grade I-II (3,37 ± 1,49;  
n = 8) tumors, and unlike cytotoxic activity, was independent on the degree of malignancy. 
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Analysis of patients according to the degree of tumor malignancy demonstrated that the 
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gliomas while patients with low grade (I-II) intracerebral gliomas were characterized by 
unaltered cytotoxic activity (Table 1). 
 
E:T ratio = 20:1 Donors (n=22) Patients with brain tumors 
Grade I-II (n=9) Grade III-IV (n=28) 
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patients with low grade (I-II) and high grade (III-IV) gliomas and cultured with 
[3H]thymidine-labeled target cells (HEp-2) for 18 h at E:T ratio of 20:1. The average values 
(M ± SE), Median and interquartile range (from low to upper quartile, LQ-UQ) of cytotoxic 
activity are presented. 
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Grade I-II (n=3) and III-IV (n=3) brain tumors. 
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activity vs HEp-2 cells 
Considering that the degree of malignancy is predictive factor of patient survival, we further 
questioned about the survival rates of patients with intact and reduced levels of DC 
cytotoxic activity against HEp-2 cells (Fig. 9). The criterion for division into such groups was 
the lower quartile range of cytotoxic activity mediated by donor IFNα-DCs against HEp-2 
cells (LQ=10,3%).  
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the opposite group. For example, a median of survival in patients with low DC cytotoxic 
activity was about 13 months, and in the group with unchanged cytotoxic activity of DCs all 
patients (5 patients with Grade I-II and 4 patients with Grade III) were followed alive. 
2.2.8 Growth inhibition effect of patient IFNα-DCs on tumor cell line HEp-2  
Next, we investigated whether DCs of patients with brain tumors could inhibit the growth 
of HEp-2 cells (Table 2). While donor DCs possessed the marked cytostatic activity, IFNα-
DCs of patients with intracerebral gliomas were found to be incapable of suppressing the 
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n = 8) tumors, and unlike cytotoxic activity, was independent on the degree of malignancy. 
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Fig. 8. Cytotoxic activity of IFNα-DCs of individual patients. Figure represents the 
individual values of cytotoxic activity of IFNα-DCs generated in vitro from peripheral blood 
of tumor patients against HEp-2. Effector cells (DCs) and [3H]thymidine-labeled HEp-2 cells 
were co-cultured for 18 h at ratios indicated. Percentage of cytotoxicity was calculated as 
follows: [1 - (cpm in cultures with target and effector cells / cpm in control cultures without 


















Fig. 9. Survival rates of patients with brain tumors based on the level of DC cytotoxic 
activity. Dotted line: cytotoxic activity of DCs of patients is below (<10,3%) donor lower 
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The table represents the individual values of indexes of IFNα-DC impact on proliferation of 
tumor cell line HEp-2. For this, effector cells (DCs) and targets were cultured at 20:1 for 24 
hours, followed by the introduction of [3H]thymidine for the next 24 hours. The index of DC 
impact was calculated by the formula: cpm in cultures with target and effector cells / cpm in 
control cultures without effector cells. * - PU <0,01 between donors and patients (U - 
Wilcoxon's test, Mann-Whitney). 
 
Patients Diagnosis DC cytostatic activity 
(Indexes of DC impact) 
P 1, female, 60 years Grade 1 5,6 
Р 2, female, 71 years  Grade 1 6,2 
Р 3, male, 53 years  Grade 1 0,9 
P 4, female, 35 years  Grade 2 7,2 
Р 5, male, 42 years  Grade 2 3,4 
P 6, female, 38 years  Grade 2 0,8 
P 7, female, 36 years Grade 2 0,5 
P 8, female, 35 years  Grade 2 0,5 
M±SE (n=8)  3,37 ± 1,49 
Р 9, male, 56 years  Grade 3 5,0 
Р 10, male, 25 years  Grade 3 3,5 
Р 11, male, 46 years  Grade 3 0,5 
Р 12, male, 29 years  Grade 3 2,3 
P 13, female, 24 years  Grade 3 3,2 
Р 14, male, 32 years  Grade 4 3,1 
P 15, female, 54 years  Grade 4 5,2 
Р 16, male, 48 years  Grade 4 3,2 
Р 17, male, 53 years  Grade 4 2,4 
Р 18, male,41 years  Grade 4 2,4 
Р 19, male, 34 years  Grade 4 1,8 
Р 20, male, 24 years  Grade 4 1,4 
Р 21, male, 38 years  Grade 4 0,8 
Р 22, male,47 years  Grade 4 2,3 
P 23, female, 45 years  Grade 4 6,9 
P 24, female, 58 years  Grade 4 6,5 
P 25, female, 60 years  Grade 4 6,9 
P 26, female, 71 years  Grade 4 0,8 
P 27,female, 57 years  Grade 4 2,0 
 M±SE (n=19)  3,08 ± 0,645 
Patients (n=27)   3,06 ± 0,4* 
Healthy donors (n=14)   0,4 ± 0,04 
Table 2. Effect of IFNα-DCs of patients with brain tumors on the proliferation of HEp-2 cells 
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Fig. 8. Cytotoxic activity of IFNα-DCs of individual patients. Figure represents the 
individual values of cytotoxic activity of IFNα-DCs generated in vitro from peripheral blood 
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Р 10, male, 25 years  Grade 3 3,5 
Р 11, male, 46 years  Grade 3 0,5 
Р 12, male, 29 years  Grade 3 2,3 
P 13, female, 24 years  Grade 3 3,2 
Р 14, male, 32 years  Grade 4 3,1 
P 15, female, 54 years  Grade 4 5,2 
Р 16, male, 48 years  Grade 4 3,2 
Р 17, male, 53 years  Grade 4 2,4 
Р 18, male,41 years  Grade 4 2,4 
Р 19, male, 34 years  Grade 4 1,8 
Р 20, male, 24 years  Grade 4 1,4 
Р 21, male, 38 years  Grade 4 0,8 
Р 22, male,47 years  Grade 4 2,3 
P 23, female, 45 years  Grade 4 6,9 
P 24, female, 58 years  Grade 4 6,5 
P 25, female, 60 years  Grade 4 6,9 
P 26, female, 71 years  Grade 4 0,8 
P 27,female, 57 years  Grade 4 2,0 
 M±SE (n=19)  3,08 ± 0,645 
Patients (n=27)   3,06 ± 0,4* 
Healthy donors (n=14)   0,4 ± 0,04 
Table 2. Effect of IFNα-DCs of patients with brain tumors on the proliferation of HEp-2 cells 
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2.2.9 Cytotoxic activity of patient IFNα-DCs vs U-87 
In the next experiments, we investigated cytotoxic potential of patient IFNα-DCs towards 
TRAIL-sensitive tumor line U-87. Interestingly, we found no decrease in killer activity of 
patient DCs in this case. Furthermore, IFNα-DCs of patients with malignant tumors (Grade 
III-IV), unable to lyse HEp-2 cells, were highly cytotoxic against U-87 cells compared with 
healthy donors (Table 3). Further experiments demonstrated the ability of patient DCs to 
inhibit the proliferation of U-87 cell line which is also more expressed in patients than in 
donors (46,6 ± 7,5 and 27,4 ± 4,4%, respectively; РU< 0,01). In this, we found a strong positive 
correlation between cytotoxic and cytostatic activities (rS = 0,89; p = 0,001). Thus, 
impairment of cytotoxic and cytostatic activity of patient DCs was only revealed against 
HEp-2 cells. 
 




Р 1, male, 36 years Grade 4 76 54 
Р 2, male, 24 years Grade 4 55 28 
P 3, female,69 years Grade 4 39 40 
P 4, female, 42 years Grade 3 60 44 
P 5, female, 71 years Grade 3 57 40 
P 6, female, 54 years Grade 4 60 43 
P 7, female, 46 years Grade 4 56 12 
Р 8, male, 48 years Grade 4 80 89 
Р 9, male, 24 years Grade 3 69 69 
Patients (n=9)  61,3 ± 4,1* 46,6 ± 7,5* 
Healthy donors (n=5)  38,6 ± 8,3 27,4 ± 4,4 
Table 3. Cytotoxic/cytostatic activity of DCs in patients with brain tumors against U-87. The 
table represents the individual and average values (M ± SE) of cytotoxic and cytostatic 
activities of patient and donor DCs. Cytotoxicity was measured by coculturing of DCs and 
[3H]thymidine-labeled U-87 cells for 18 h at 20:1. For cytostatic activity evaluation, DCs and 
U-87 cells were cultured at 20:1 for 24 hours, followed by the introduction of [3H]thymidine 
for 24 hours. * - РU <0,01 between donors and patients (U - Wilcoxon's test, Mann-Whitney). 
2.2.10 TNFα production by donor and patient IFNα-DCs 
Since the cytotoxic activity of DCs against HEp-2 cells was related with TNF-mediated 
apoptosis, we further compared the ability of DCs of patients with malignant gliomas 
(Grade III-IV) and donors to produce TNFα. The concentration of TNFα was evaluated in 4-
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day cultures of LPS-activated IFNα-DCs. As follows from Table 4, supernatants from patient 
DC cultures differed little from healthy donor culture-conditioned medium by the level of 
TNFα production. A slight decrease in production of TNFα was a tendency, which had no 
statistical significance. 
 
Patients Diagnosis TNFa (pg/ml) 
P 1, male, 39 years  Grade 4 856 
P 2, female, 46 years Grade 3 767 
P 3, male, 35 years Grade 3 800 
P 4, male, 46 years  Grade 3 914 
P 5, male, 24 years Grade 4 918 
P 6, female, 43 years  Grade 4 693 
P 7, female, 38 years Grade 2 256 
P 8, male, 52 years Grade 4 486 
P 9, male, 68years  Grade 3 710 
Patients  
 (n=9)                  M ± SE   711 ± 82 
Healthy donors 
 (n=11)                M ± SE   824 ± 59 
Table 4. TNFα concentrations in cultures of donor and glioma patient IFNα-DCs. The table 
represents the individual and average values (M ± SE) of TNFα concentrations in culture 
supernatants of IFNα-DCs generated in vitro from peripheral blood of patients with 
malignant gliomas and healthy donors. 
2.3 Discussion 
The ability of DCs generated in vitro to inhibit the growth of human tumor cell lines and 
lyse tumor cells was first demonstrated by Chapoval (Chapoval et al., 2000). Thereafter, 
spontaneous cytotoxicity mediated by DCs without any stimulation was also described by 
other authors (Vanderheyde et al. 2004; Yang et al., 2001; Manna & Mohanakumar, 2002; Joo 
et al., 2002 ; Janjic et al., 2002), which revealed that the tumoricidal potential of DCs 
generated in the presence of GM-CSF and IL-4 was mediated by effector molecules such as 
FasL (Yang et al., 2001), TNF (Manna & Mohanakumar, 2002; Joo et al., 2002), lymphotoxin- 
α1, β2 (Lu et al., 2002) or TRAIL (Liu et al., 2001). The cytolytic properties of cultured human 
monocyte-derived DCs are enhanced by certain activation stimuli, such as LPS (Chapoval et 
al., 2000; Manna & Mohanakumar, 2002). While myeloid DCs being treated with IFN- 
exhibited upregulation of intracellular TRAIL and increased cytotoxic potential (Liu et al., 
2001), study of antitumor activity of DCs generated in the presence of IFNα were not 
performed previously. In this study, we reported the novel data on cytostatic/cytotoxic 
activities of LPS-activated IFNα-DCs generated in vitro from peripheral blood monocytes of 
healthy donors and patients with brain tumors. 
We report here that LPS-activated IFNα-DCs can lyse both NK-sensitive (Jurkat lymphoma 
cells) and NK-resistant (HEp-2, U-87) tumor cell lines. Such a cytotoxic effect requires cell 
contact, since the supernatants of IFNα-DCs either lack or possess the poor cytotoxic 
activity. Using HEp-2 tumor cells as targets, we revealed that DCs appear to promote the 
apoptosis and suppress cell cycle in tumor cells, thus having a cytostatic effect. Cytostatic 
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U-87 cells were cultured at 20:1 for 24 hours, followed by the introduction of [3H]thymidine 
for 24 hours. * - РU <0,01 between donors and patients (U - Wilcoxon's test, Mann-Whitney). 
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day cultures of LPS-activated IFNα-DCs. As follows from Table 4, supernatants from patient 
DC cultures differed little from healthy donor culture-conditioned medium by the level of 
TNFα production. A slight decrease in production of TNFα was a tendency, which had no 
statistical significance. 
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P 1, male, 39 years  Grade 4 856 
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P 3, male, 35 years Grade 3 800 
P 4, male, 46 years  Grade 3 914 
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P 8, male, 52 years Grade 4 486 
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 (n=9)                  M ± SE   711 ± 82 
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 (n=11)                M ± SE   824 ± 59 
Table 4. TNFα concentrations in cultures of donor and glioma patient IFNα-DCs. The table 
represents the individual and average values (M ± SE) of TNFα concentrations in culture 
supernatants of IFNα-DCs generated in vitro from peripheral blood of patients with 
malignant gliomas and healthy donors. 
2.3 Discussion 
The ability of DCs generated in vitro to inhibit the growth of human tumor cell lines and 
lyse tumor cells was first demonstrated by Chapoval (Chapoval et al., 2000). Thereafter, 
spontaneous cytotoxicity mediated by DCs without any stimulation was also described by 
other authors (Vanderheyde et al. 2004; Yang et al., 2001; Manna & Mohanakumar, 2002; Joo 
et al., 2002 ; Janjic et al., 2002), which revealed that the tumoricidal potential of DCs 
generated in the presence of GM-CSF and IL-4 was mediated by effector molecules such as 
FasL (Yang et al., 2001), TNF (Manna & Mohanakumar, 2002; Joo et al., 2002), lymphotoxin- 
α1, β2 (Lu et al., 2002) or TRAIL (Liu et al., 2001). The cytolytic properties of cultured human 
monocyte-derived DCs are enhanced by certain activation stimuli, such as LPS (Chapoval et 
al., 2000; Manna & Mohanakumar, 2002). While myeloid DCs being treated with IFN- 
exhibited upregulation of intracellular TRAIL and increased cytotoxic potential (Liu et al., 
2001), study of antitumor activity of DCs generated in the presence of IFNα were not 
performed previously. In this study, we reported the novel data on cytostatic/cytotoxic 
activities of LPS-activated IFNα-DCs generated in vitro from peripheral blood monocytes of 
healthy donors and patients with brain tumors. 
We report here that LPS-activated IFNα-DCs can lyse both NK-sensitive (Jurkat lymphoma 
cells) and NK-resistant (HEp-2, U-87) tumor cell lines. Such a cytotoxic effect requires cell 
contact, since the supernatants of IFNα-DCs either lack or possess the poor cytotoxic 
activity. Using HEp-2 tumor cells as targets, we revealed that DCs appear to promote the 
apoptosis and suppress cell cycle in tumor cells, thus having a cytostatic effect. Cytostatic 
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activity was also confirmed by the tumor growth/proliferation inhibiting capacity realized 
by IFNα-DCs. When compare the cytotoxicity of IFNα-DCs and IL4-DCs, we revealed that 
IFNα-DCs expressed the higher ability to kill Jurkat tumor cells as well as comparable with 
IL4-DCs cytotoxic activity in HEp-2 cultures.  
Since the highest cytotoxic activity of IFNα-DCs was manifested in U-87 and Jurkat tumor 
cell cultures, which are reported to be sensitive to TRAIL-induced apoptosis (Lee et al., 2003; 
Panner et al., 2005; Siegelin et al., 2009), it is reasonable to assume that this cytotoxicity could 
be due to the stimulative effect of IFNα on TRAIL expression (Riboldi et al., 2009). Indeed, 
as a further corroboration of the suggested cytotoxic capacity, our data demonstrated that 
LPS-activated IFNα-DCs were found to contain significantly higher amounts of cells 
expressing membrane-bound TRAIL compared with IL4-DCs (data not shown). Apparently, 
these data could also explain a higher cytotoxic activity of IFNα-DCs on Jurkat tumor cells. 
There are a very few data on sensitivity of HEp-2 cells to the cytotoxic effect of DCs 
mediated by TNF family molecules. The tumoricidal activity was not mediated by FasL/Fas 
or TRAIL/TRAILR2 systems, whereas TNFα/TNFR1 blocking completely abolished the 
ability of DCs to lyse HEp-2 cells. Thus, tumor cell line HEp-2 cells can be considered as 
resistant to FasL- and TRAIL-induced apoptosis, but sensitive to cytotoxicity triggered by 
TNFα/TNFR1 pathway. At that, the fact that anti–TNFα antibody almost completely 
decreased cytotoxicity, while DC culture-conditioned medium containing quite high 
concentrations of TNFα lacked lytic activity (Leplina et al., 2007b), further implies that 
membrane-bound, not the soluble form, of TNFα partially contributes to the effect. 
Our results are consistent with the reported data on TNFα expression by HEp-2 cells 
(Paland et al., 2008), as well as the resistance of this tumor cell line to FasL-induced 
apoptosis (Morton & Blaho, 2007). The lack of sensitivity HEp-2 cells to TRAIL/TRAILRII-
induced death explains the absence of distinction in the cytotoxic activity of IFNα-DCs and 
IL4-DCs against HEp-2 cells. 
Since we revealed no correlations between cytotoxic and cytostatic effects of IFNα-DCs on 
HEp-2 cells, then one can believe that cytotoxicity and cytostasis could be mediated by 
distinct mechanisms. Similar tendency was observed for IL4-DCs (Vanderheyde et al., 2004), 
where the authors have shown that LPS-stimulated IL4-DCs possess TNFα-associated 
cytostatic activity unrelated with cytotoxicity. Indeed, IL4-DCs inhibited the growth of 
modified Jurkat cells deficient in caspase-8 or overexpressing Bcl-2. On the other hand, 
supernatants of IL4-DCs suppressed the proliferation of non-modified Jurkat cells, but 
showed no cytotoxic activity. Evidently, cytostatic and cytotoxic activities of IFNα-DCs are 
also implemented through independent mechanisms. This hypothesis could be confirmed 
by the fact that a higher cytotoxic activity of IFNα-DCs against U-87 and Jurkat cells was 
associated with less pronounced DC cytostatic activity on these lines compared with HEp-2. 
Investigation of the effector functions of IFNα-DCs in patients with intracerebral gliomas 
revealed impaired ability of these cells to lyse HEp-2 tumor cells. Importantly, such an 
impairment of DC cytotoxicity was identified mainly in patients with high grade (III-IV) 
brain tumors, while in low grade (I-II) tumors DCs were quite effective killers. Furthermore, 
patients with intact DC cytotoxic activity had a higher survival rate than patients with 
reduced killer activity. In addition, patient DCs regardless of tumor histology showed no 
cytotoxic activity against HEp-2 cells, whereas both cytotoxic and cytostatic activities of DCs 
against U-87 cells were found to be enhanced. 
According to the data, glioblastoma cells U-87 are resistant to cytotoxicity mediated by 
TNFα (Sawada et al., 2004), and sensitive to TRAIL- (Knight et al., 2001) and Fas-induced 
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apoptosis (Choi et al., 2004). As we have found, DC cytotoxicity on HEp-2 cells likely 
engaged TNF/TNFR1 pathway than TRAIL or FasL effects. Given these facts, the high 
cytotoxic activity of patient DCs against U-87 cells and dramatic decline of such activity 
against HEp-2 tumor cells could indicate a defect in TNFα-related mechanism of DC 
cytotoxicity in patients with malignant gliomas. 
Our facts seemed to be important in several aspects. First, the defect in cytotoxic activity of 
DCs may be of interest in diagnosis and prognosis, since the expression of cytotoxic activity 
is associated with tumor malignancy and survival rates. Second, this phenomenon is of 
interest from the pathogenetic point of view. Malignant brain tumors induce a weak 
antigen-specific response due to tumor-induced immunosuppression, as well as localization 
of the tumor in the immunologically privileged brain tissues (Parney et al., 2000). We have 
previously shown that patient IFNα-DCs are characterized by intact antigen-presenting 
function, capable of activating T cells to produce Th1 cytokines and induce proliferation of T 
lymphocytes to antigens of tumor cell lysates (Chernykh et al., 2009). Then impairment of 
DC effector functions may inhibit the early induction of antigen-specific immune response 
being yet another reason for infringement of anti-tumor protection in patients with 
malignant brain tumors.  
We can also assume that if tumoricidal potential of DCs is disturbed, cytoreductive therapy 
(radio-chemotherapy) becomes especially important, both in regard of direct elimination of 
tumor cells and release of tumor antigens required to start specific immune response.  
However, whether IFNα-DCs could effectively destroy primary glioma cells and does this 
ability is disrupted in patients with malignant gliomas remains to find. Most of glioblastoma 
cell lines and primary cells gliomas are absolutely resistant to cytotoxic effect of certain 
proapoptogenic molecules, such as TRAIL (Eramo et al., 2005) and TNF. At that, the 
effective destruction of tumor lines by DCs requires the interaction of separate molecules. 
Besides, it is shown that some proapoptogenic molecules could induce the expression of 
receptors for another mediators of apoptosis. Such as, TNFα can induce the expression of 
Fas and sensitize glioma cells to FasL/Fas-mediated apoptosis (Weller et al., 1994). 
The further elucidation of the DC cytotoxic/static activity mechanisms and the possible role 
of the defect of DC cytotoxic properties in patients with gliomas as weel as the studies on 
correlation between the antitumor activity of IFNα-DCs and clinical outcomes could 
probably explain the different sensitivity of cancer patients to the treatment, and justify new 
immunotherapeutic approaches to the treatment of malignant brain gliomas. 
3. Conclusion 
The capacity of IFNα-DCs to lyse tumor cell lines and inhibit their proliferation has been 
investigated. LPS-activated IFNα-DCs of healthy donors were shown to have dose-
dependent cytotoxic and cytostatic activity against various tumor lines through the 
induction of apoptosis and arrest of cell cycle. DCs lysed both TRAIL-sensitive (Jurkat cells) 
and TRAIL-resistant (HEp-2) cells, and cytotoxic activity against HEp-2 line was mediated 
through the TNF-TNFR1 pathway. In contrast to healthy donors, DCs of patients with 
malignant glioma failed to inhibit growth, but stimulated proliferation of HEp-2 cells. In 
addition, patient DCs had significantly reduced cytotoxic activity against HEp-2 cells. 
Patients with decreased cytotoxic activity were characterized by significantly lower survival 
since defect of cytotoxic activity was associated with high-grade glioma. The defective 
cytotoxic activity of DCs noted against HEp-2 cells was not revealed against glioblastoma U-
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activity was also confirmed by the tumor growth/proliferation inhibiting capacity realized 
by IFNα-DCs. When compare the cytotoxicity of IFNα-DCs and IL4-DCs, we revealed that 
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impairment of DC cytotoxicity was identified mainly in patients with high grade (III-IV) 
brain tumors, while in low grade (I-II) tumors DCs were quite effective killers. Furthermore, 
patients with intact DC cytotoxic activity had a higher survival rate than patients with 
reduced killer activity. In addition, patient DCs regardless of tumor histology showed no 
cytotoxic activity against HEp-2 cells, whereas both cytotoxic and cytostatic activities of DCs 
against U-87 cells were found to be enhanced. 
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apoptosis (Choi et al., 2004). As we have found, DC cytotoxicity on HEp-2 cells likely 
engaged TNF/TNFR1 pathway than TRAIL or FasL effects. Given these facts, the high 
cytotoxic activity of patient DCs against U-87 cells and dramatic decline of such activity 
against HEp-2 tumor cells could indicate a defect in TNFα-related mechanism of DC 
cytotoxicity in patients with malignant gliomas. 
Our facts seemed to be important in several aspects. First, the defect in cytotoxic activity of 
DCs may be of interest in diagnosis and prognosis, since the expression of cytotoxic activity 
is associated with tumor malignancy and survival rates. Second, this phenomenon is of 
interest from the pathogenetic point of view. Malignant brain tumors induce a weak 
antigen-specific response due to tumor-induced immunosuppression, as well as localization 
of the tumor in the immunologically privileged brain tissues (Parney et al., 2000). We have 
previously shown that patient IFNα-DCs are characterized by intact antigen-presenting 
function, capable of activating T cells to produce Th1 cytokines and induce proliferation of T 
lymphocytes to antigens of tumor cell lysates (Chernykh et al., 2009). Then impairment of 
DC effector functions may inhibit the early induction of antigen-specific immune response 
being yet another reason for infringement of anti-tumor protection in patients with 
malignant brain tumors.  
We can also assume that if tumoricidal potential of DCs is disturbed, cytoreductive therapy 
(radio-chemotherapy) becomes especially important, both in regard of direct elimination of 
tumor cells and release of tumor antigens required to start specific immune response.  
However, whether IFNα-DCs could effectively destroy primary glioma cells and does this 
ability is disrupted in patients with malignant gliomas remains to find. Most of glioblastoma 
cell lines and primary cells gliomas are absolutely resistant to cytotoxic effect of certain 
proapoptogenic molecules, such as TRAIL (Eramo et al., 2005) and TNF. At that, the 
effective destruction of tumor lines by DCs requires the interaction of separate molecules. 
Besides, it is shown that some proapoptogenic molecules could induce the expression of 
receptors for another mediators of apoptosis. Such as, TNFα can induce the expression of 
Fas and sensitize glioma cells to FasL/Fas-mediated apoptosis (Weller et al., 1994). 
The further elucidation of the DC cytotoxic/static activity mechanisms and the possible role 
of the defect of DC cytotoxic properties in patients with gliomas as weel as the studies on 
correlation between the antitumor activity of IFNα-DCs and clinical outcomes could 
probably explain the different sensitivity of cancer patients to the treatment, and justify new 
immunotherapeutic approaches to the treatment of malignant brain gliomas. 
3. Conclusion 
The capacity of IFNα-DCs to lyse tumor cell lines and inhibit their proliferation has been 
investigated. LPS-activated IFNα-DCs of healthy donors were shown to have dose-
dependent cytotoxic and cytostatic activity against various tumor lines through the 
induction of apoptosis and arrest of cell cycle. DCs lysed both TRAIL-sensitive (Jurkat cells) 
and TRAIL-resistant (HEp-2) cells, and cytotoxic activity against HEp-2 line was mediated 
through the TNF-TNFR1 pathway. In contrast to healthy donors, DCs of patients with 
malignant glioma failed to inhibit growth, but stimulated proliferation of HEp-2 cells. In 
addition, patient DCs had significantly reduced cytotoxic activity against HEp-2 cells. 
Patients with decreased cytotoxic activity were characterized by significantly lower survival 
since defect of cytotoxic activity was associated with high-grade glioma. The defective 
cytotoxic activity of DCs noted against HEp-2 cells was not revealed against glioblastoma U-
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87 line. The data obtained suggest that defect of antitumor activity of patient DCs may have 
diagnostic and prognostic significance. However, whether IFNα-DCs could effectively 
destroy primary glioma cells and does this ability play role in pathogenesis of brain glioma 
remains to be clarified. 
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87 line. The data obtained suggest that defect of antitumor activity of patient DCs may have 
diagnostic and prognostic significance. However, whether IFNα-DCs could effectively 
destroy primary glioma cells and does this ability play role in pathogenesis of brain glioma 
remains to be clarified. 
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1. Introduction 
Gliomas are the most common primary tumors that arise from glial cells and their 
precursors in the central nervous system. Animal models always are important tool in the 
study of tumorigenesis, various therapy or preclinical trials for gliomas. It has been known 
since the 1970's that repetitive intravenous administration of nitrosourea compounds such 
as methynitrosourea (MNU) and N-ethyl-N-nitrosourea (ENU) produces glial-type 
neoplasms in immunocompetent rats. However, the long time required to induce 
neoplasms, and inconsistency of tumor development, led to a shift towards implantation of 
neoplastic cells propagated in vitro. Implantation of rodent glioma cells has proven an 
excellent intracranial brain tumor model due to their efficient tumorigenesis, reproducible 
and fast growth rates and accurate knowledge of the tumor location. Over the past few 
decades, several mouse glioma models have been generated based on human genetic 
abnormalities and the induced gliomas exhibit histological similarities to their human 
counterparts. More accurate animal models are required for research on the molecular and 
genetic bases of this disease. Here we expand on the existing animal models for gliomas 
with different strategies.  
2. Classification 
While there exist a multitude of methods for introducing glial-type neoplasms into the 
rodent central nervous system (CNS), which histologically mimic human primary tumors, 
these methods can be described as belonging to one of two groups: 1) Tumors created by 
methods which do not target a specific gene, and 2) Tumors created by targeted mutation of 
genes known to be mutated in human tumors.  
2.1 Traditional animal models of glioma 
While the majority of these models involve the use of rodent glioma cells injected in 
syngeneic hosts, it is also possible to use human glioma cells in vivo via their implantation 
in athymic mice. We will describe both of the two classes of glioma animal models, and 
eight commonly used rat brain tumor models and their application for the development of 
novel therapeutic and diagnostic modalities.  
The rat has been one of the most widely used experimental animals, and rat brain tumor 
models have been used extensively since the mid 1970s. Here we will focus on rat brain 
tumor models and their utility in evaluating the efficacy of various therapeutic modalities. 
Until recently, murine models (Fomchenko & Holland, 2006) were used less frequently than 
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rat models, but the ability to produce genetically engineered cell lines (Lampson, 2001) has 
increased the use of murine models over the past five years. The relative advantages of rat 
and murine tumor models are summarized in Table 1. Feline and canine models have been 
used less frequently (Kimmelman & Nalbantoglu, 2007), but nevertheless, still provide an 
intermediate between rodent models and humans.  
2.1.1 Rat brain tumor models  
It was first reported in the early 1970s that CNS tumors could be induced reproducibly and 
selectively in adult rats that had been given repeated, weekly intravenous injections of 
MNU or a single dose of ENU. These studies led to the development of a number of rat 
brain tumor models that were highly reproducible and did not require the toxic application 
of a chemical carcinogen to the brain (Candolfi et al, 2007).  
 
Advantages  Disadvantages 
1. Larger size of the rat brain (compared to 
the mouse brain ~1200 mg vs ~ 400 mg) 
permits more precise stereotactic 
implantation than in mice, a longer 
interval of time until death and a thicker 
skull essentially eliminates osseous 
invasion and s.c. growth. 
Rat brain tumor models cannot be as easily 
genetically engineered and manipulated as 
mouse models in order to elucidate the 
importance of genetic factors, signaling 
pathways, cell types and stroma in tumor 
growth and invasion. 
2. Larger tumor size prior to death permits 
better in vivo localization and imaging 
by a variety of diagnostic modalities in 
the rat. 
The potential to produce genetically 
engineered tumor cell lines is less in the rat 
than in the mouse. 
3. Larger tumor size prior to death permits 
the administration of larger amounts of 
various therapeutic agents, especially if 
administered i.c. by CED and more 
critical evaluation of their effectiveness.
There are a smaller number of mAbs 
directed against rat surface antigens and 
chemokines compared to the mouse. 
4. More extensive literature on in vitro and 
in vivo studies of rat brain tumors 
compared to mouse tumors. 
Rats are more expensive to purchase and 
maintain than mice. 
Table 1. Advantages and disadvantages of rat brain tumor models compared to mouse 
models.  
The cellular signaling pathways important for the genesis of brain tumor are multiple, with 
feedback mechanisms that can dramatically affect the efficacy of molecularly targeted 
therapeutic strategies. The heterogeneous composition of human high grade gliomas, which 
consists of tumor stem cells and differentiated tumor cells with varying characteristics, 
further complicates their susceptibility to treatment. Brain tumors also can evolve within 
their microenvironment, adapting to changes that produce epigenetic effects thereby 
altering their biology, but concomitantly providing additional targets for therapeutic 
intervention. Finally, genetic variations between individuals can dictate how tumors initiate, 
progress, and respond to treatment. Rat brain tumor models have provided a wealth of 
information on the in vitro and in vivo responses to various therapeutic modalities. The 
larger rat brain (~1200 mg) compared to that of the mouse (~400 mg) allows for more precise 
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tumor cell implantation, and relatively larger volumes (~20 μl) that can be injected versus 
mice (5 μl; Table 1). Mouse models, on the other hand, have allowed researchers to 
rigorously test hypotheses developed from examining human tumors by genetically 
manipulating them and controlling specific variables such as environmental influences, in 
order to better understand the roles of different pathways, cell types, stromal factors and 
genetic variation (Reilly et al, 2008). Mouse tumor models (Table 1) also have allowed 
researchers to test hypotheses derived from examining human tumors, in a controlled 
environment with specific genetic alterations and controlled environmental influences 
(Reilly et al, 2008). There is a general consensus that valid brain tumor models should fulfill 
the following criteria: (1) they should be derived from glial cells; (2) it should be possible to 
grow and clone them in vitro as continuous cell lines and propagate them in vivo by serial 
transplantation; (3) tumor growth rates should be predictable and reproducible; (4) the 
tumors should have glioma-like growth characteristics within the brain including 
neovascularization, alteration of the bloodbrain barrier (BBB), an invasive pattern of growth, 
and lack of encapsulation; (5) host survival time following i.c. tumor implantation should be 
of sufficient duration to permit therapy and determination of efficacy; (6) for therapy 
studies, the tumors should be either non or weakly immunogenic in syngeneic hosts; (7) 
they should not grow into the epidural space or extend beyond the brain and finally (8) their 
response or lack thereof to conventional treatment should be predictive of the response in 
human brain tumors.  
In studies carried out prior to the 1970s, either cells or tumor fragments were injected i.c. 
using a free hand approach, which generally lacked reproducibility and precision. A 
stereotactic implantation procedure using suspensions of tissue-culture-derived brain tumor 
cells was more successful (Barker et al, 1973). This procedure was further improved by the 
use of concentrated cell suspensions in small volumes, improved injection needles, better 
stereotactic localization to structures deeper in the white matter such as the caudate nucleus, 
the use of slower injection rates (Landen et al, 2004), 0.5–1.0% low gelling agarose to prevent 
backflow of tumor cells through the injection track (Kobayashi et al, 1980) and cleansing of 
the operative field with a solution of Betadine. Finally, rinsing the surface of the brain with 
sterile water destroys extravasated tumor cells by osmosis prior to closure of the skull with 
bone wax has also been recommended. This implantation procedure resulted in high success 
rates of i.c. tumor growth with the elimination of spinal and extracranial dissemination. The 
implantation of plastic (Kobayashi et al, 1980)or metallic screws (Lal et al, 2000) with an 
entry port, which are permanently implanted in the skull to inject tumor cells, have been 
very useful (Saini et al, 2004). Such devices can be left in place either at the time of or after 
tumor cell implantation in order to facilitate future administration of therapeutic agents at 
the same location without further stereotactic surgery. These are well tolerated and non-
irritating in rats, but they cannot be as easily used in mice due to the thinness of their skulls. 
Keeping these general principles of tumor cell implantation in mind, we will now discuss 
the currently available rat glioma models that have been used in immunocompetent 
animals. 
The C6 glioma was produced by Benda et al. (Benda et al, 1968)and Schmidek et al. 
(Schmidek et al, 1971), in Sweet’s laboratory at the Massachusetts General Hospital (MGH) 
by repetitively administering MNU to outbred Wistar rats over a period of approximately 8 
months. When animals developed neurological signs, they were euthanized, and the tumors 
were excised and explanted into tissue culture. Among these was a tumor designated as 
“#6”, which was subsequently cloned by Benda et al. and was shown to produce S-100 
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rat models, but the ability to produce genetically engineered cell lines (Lampson, 2001) has 
increased the use of murine models over the past five years. The relative advantages of rat 
and murine tumor models are summarized in Table 1. Feline and canine models have been 
used less frequently (Kimmelman & Nalbantoglu, 2007), but nevertheless, still provide an 
intermediate between rodent models and humans.  
2.1.1 Rat brain tumor models  
It was first reported in the early 1970s that CNS tumors could be induced reproducibly and 
selectively in adult rats that had been given repeated, weekly intravenous injections of 
MNU or a single dose of ENU. These studies led to the development of a number of rat 
brain tumor models that were highly reproducible and did not require the toxic application 
of a chemical carcinogen to the brain (Candolfi et al, 2007).  
 
Advantages  Disadvantages 
1. Larger size of the rat brain (compared to 
the mouse brain ~1200 mg vs ~ 400 mg) 
permits more precise stereotactic 
implantation than in mice, a longer 
interval of time until death and a thicker 
skull essentially eliminates osseous 
invasion and s.c. growth. 
Rat brain tumor models cannot be as easily 
genetically engineered and manipulated as 
mouse models in order to elucidate the 
importance of genetic factors, signaling 
pathways, cell types and stroma in tumor 
growth and invasion. 
2. Larger tumor size prior to death permits 
better in vivo localization and imaging 
by a variety of diagnostic modalities in 
the rat. 
The potential to produce genetically 
engineered tumor cell lines is less in the rat 
than in the mouse. 
3. Larger tumor size prior to death permits 
the administration of larger amounts of 
various therapeutic agents, especially if 
administered i.c. by CED and more 
critical evaluation of their effectiveness.
There are a smaller number of mAbs 
directed against rat surface antigens and 
chemokines compared to the mouse. 
4. More extensive literature on in vitro and 
in vivo studies of rat brain tumors 
compared to mouse tumors. 
Rats are more expensive to purchase and 
maintain than mice. 
Table 1. Advantages and disadvantages of rat brain tumor models compared to mouse 
models.  
The cellular signaling pathways important for the genesis of brain tumor are multiple, with 
feedback mechanisms that can dramatically affect the efficacy of molecularly targeted 
therapeutic strategies. The heterogeneous composition of human high grade gliomas, which 
consists of tumor stem cells and differentiated tumor cells with varying characteristics, 
further complicates their susceptibility to treatment. Brain tumors also can evolve within 
their microenvironment, adapting to changes that produce epigenetic effects thereby 
altering their biology, but concomitantly providing additional targets for therapeutic 
intervention. Finally, genetic variations between individuals can dictate how tumors initiate, 
progress, and respond to treatment. Rat brain tumor models have provided a wealth of 
information on the in vitro and in vivo responses to various therapeutic modalities. The 
larger rat brain (~1200 mg) compared to that of the mouse (~400 mg) allows for more precise 
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tumor cell implantation, and relatively larger volumes (~20 μl) that can be injected versus 
mice (5 μl; Table 1). Mouse models, on the other hand, have allowed researchers to 
rigorously test hypotheses developed from examining human tumors by genetically 
manipulating them and controlling specific variables such as environmental influences, in 
order to better understand the roles of different pathways, cell types, stromal factors and 
genetic variation (Reilly et al, 2008). Mouse tumor models (Table 1) also have allowed 
researchers to test hypotheses derived from examining human tumors, in a controlled 
environment with specific genetic alterations and controlled environmental influences 
(Reilly et al, 2008). There is a general consensus that valid brain tumor models should fulfill 
the following criteria: (1) they should be derived from glial cells; (2) it should be possible to 
grow and clone them in vitro as continuous cell lines and propagate them in vivo by serial 
transplantation; (3) tumor growth rates should be predictable and reproducible; (4) the 
tumors should have glioma-like growth characteristics within the brain including 
neovascularization, alteration of the bloodbrain barrier (BBB), an invasive pattern of growth, 
and lack of encapsulation; (5) host survival time following i.c. tumor implantation should be 
of sufficient duration to permit therapy and determination of efficacy; (6) for therapy 
studies, the tumors should be either non or weakly immunogenic in syngeneic hosts; (7) 
they should not grow into the epidural space or extend beyond the brain and finally (8) their 
response or lack thereof to conventional treatment should be predictive of the response in 
human brain tumors.  
In studies carried out prior to the 1970s, either cells or tumor fragments were injected i.c. 
using a free hand approach, which generally lacked reproducibility and precision. A 
stereotactic implantation procedure using suspensions of tissue-culture-derived brain tumor 
cells was more successful (Barker et al, 1973). This procedure was further improved by the 
use of concentrated cell suspensions in small volumes, improved injection needles, better 
stereotactic localization to structures deeper in the white matter such as the caudate nucleus, 
the use of slower injection rates (Landen et al, 2004), 0.5–1.0% low gelling agarose to prevent 
backflow of tumor cells through the injection track (Kobayashi et al, 1980) and cleansing of 
the operative field with a solution of Betadine. Finally, rinsing the surface of the brain with 
sterile water destroys extravasated tumor cells by osmosis prior to closure of the skull with 
bone wax has also been recommended. This implantation procedure resulted in high success 
rates of i.c. tumor growth with the elimination of spinal and extracranial dissemination. The 
implantation of plastic (Kobayashi et al, 1980)or metallic screws (Lal et al, 2000) with an 
entry port, which are permanently implanted in the skull to inject tumor cells, have been 
very useful (Saini et al, 2004). Such devices can be left in place either at the time of or after 
tumor cell implantation in order to facilitate future administration of therapeutic agents at 
the same location without further stereotactic surgery. These are well tolerated and non-
irritating in rats, but they cannot be as easily used in mice due to the thinness of their skulls. 
Keeping these general principles of tumor cell implantation in mind, we will now discuss 
the currently available rat glioma models that have been used in immunocompetent 
animals. 
The C6 glioma was produced by Benda et al. (Benda et al, 1968)and Schmidek et al. 
(Schmidek et al, 1971), in Sweet’s laboratory at the Massachusetts General Hospital (MGH) 
by repetitively administering MNU to outbred Wistar rats over a period of approximately 8 
months. When animals developed neurological signs, they were euthanized, and the tumors 
were excised and explanted into tissue culture. Among these was a tumor designated as 
“#6”, which was subsequently cloned by Benda et al. and was shown to produce S-100 
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protein. Following cloning, it was redesignated “C6” (Pfeiffer et al, 1970). The C6 glioma is 
composed of a pleomorphic population of cells with variably shaped nuclei. There is focal 
invasion into contiguous normal brain (Fig. 1a). Initially, the tumor was histopathologically 
classified as an astrocytoma, and eventually it was designated as a glial tumor following 
accession by the American Type Culture Collection, Rockville, MD (ATCC# CCL-107). The 
cells have been reported to have a mutant p16/Cdkn2a/ Ink4a locus (Schlegel et al, 1999) 
with no expression of p16 and p19ARF mRNAs, and a wildtype p53 (Asai et al, 1994). More 
recent molecular characterization, which compared changes in gene expression between the 
C6 glioma and rat stem cell-derived astrocytes, revealed that the changes in gene expression 
observed in the C6 cell line were the most similar to those reported in human brain tumors 
(Sibenaller et al, 2005). Compared to astrocytes, they also had increased expression of the 
PDGFβ, IGF-1, EGFR and Erb3/Her3 genes, which are frequently overexpressed in human 
gliomas (Guo et al, 2003; Heimberger et al,2005). In a recent study, the significance of PDGF 
in gliomagenesis in adult rats was established by infecting white matter with a retrovirus 
encoding for PDGF and GFP. Within 2 weeks 100% of the animals had tumors derived from 
both infected and uninfected glial progenitors, thereby implicating PDGF in both autocrine 
and paracrine stimulation of glial progenitor cells (Assanah et al, 2006). Although, IGF-1 
was overexpressed in C6 glioma cells, there was reduced expression of IGF-2, FGF-9 and 
FGF-10 relative to astrocytes. Similar to the increased activity of the Ras pathway observed 
in human gliomas (Nakada et al, 2005), C6 cells also had an increase in both Ras expression 
and Ras guanine triphosphate activator protein (Sibenaller et al, 2005). However, contrary to 
what has been reported for human GBM, there was an increase in expression of Rb in these 
cells (Sibenaller et al, 2005). A subclone of C6 cells, stably expressing β-galactosidase, 
subsequently was described (Lampson et al, 1993) and this has permitted in vivo 
immunohistochemical analysis of these tumors in the brain. This clone is available through 
the ATCC (# CRL-2303). However, it must be noted that the β-galactosidase marker protein 
itself can serve as a tumor antigen, and immunization of rats against the reporter gene 
protected the animals against tumor growth. 
The C6 rat glioma model has been widely used in experimental neuro-oncology to evaluate 
the therapeutic efficacy of a variety of modalities, including chemotherapy (Doblas et al, 
2008), antiangiogenic therapy (Solly F et al, 2008), proteosome inhibitors (Ahmed et al, 2008), 
treatment with toxins (Zhao et al, 2008), radiation therapy (Sheehan et al, 2008), 
photodynamic therapy (Mannino et al, 2008), oncolytic viral therapy (Yang et al, 2004) and 
gene therapy (Tanriover et al, 2008). Since this tumor arose in an outbred Wistar rat, 
however, there is no syngeneic host in which it can be propagated. This is a very serious 
limitation that diminishes its usefulness for survival studies since the tumor is 
immunogenic, even in Wistar rats. The C6 glioma has been demonstrated to be 
immunogenic in Wistar and BDX rats (Parsa et al, 2000), and it therefore is not useful for 
evaluating the efficacy of immunotherapy. This problem is exemplified by prior studies in 
which C6 glioma cells were transfected with an antisense cDNA expression vector that 
downregulated the constitutive production of IGF-1 (Trojan et al, 1993). Not recognizing 
that the tumor was of Wistar origin, the authors unfortunately used BD IX rats, which they 
thought was the strain of origin, due to some ambiguity in the literature. Subsequently, it 
was reported that BD IX rats, which had been immunized with the C6 anti-sense IGF-1 
transfected cells, were resistant to both s.c. and i.c. challenge of the C6 glioma. Similarly, 
Wistar rats, bearing C6 gliomas (s.c. or i.c.), developed potent humoral and cellular immune  
 




Fig. 1. Histopathologic features of the C6, 9L, RG2, F98, CNS-1, and BT4C brain tumors. A The 
C6 glioma is composed of a pleomorphic population of cells with nuclei ranging from round to 
oblong. A herring-bone pattern of growth is seen in some areas and there is focal invasion of 
contiguous normal brain. There are scattered foci of necrosis with pseudo-palisading of tumor 
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protein. Following cloning, it was redesignated “C6” (Pfeiffer et al, 1970). The C6 glioma is 
composed of a pleomorphic population of cells with variably shaped nuclei. There is focal 
invasion into contiguous normal brain (Fig. 1a). Initially, the tumor was histopathologically 
classified as an astrocytoma, and eventually it was designated as a glial tumor following 
accession by the American Type Culture Collection, Rockville, MD (ATCC# CCL-107). The 
cells have been reported to have a mutant p16/Cdkn2a/ Ink4a locus (Schlegel et al, 1999) 
with no expression of p16 and p19ARF mRNAs, and a wildtype p53 (Asai et al, 1994). More 
recent molecular characterization, which compared changes in gene expression between the 
C6 glioma and rat stem cell-derived astrocytes, revealed that the changes in gene expression 
observed in the C6 cell line were the most similar to those reported in human brain tumors 
(Sibenaller et al, 2005). Compared to astrocytes, they also had increased expression of the 
PDGFβ, IGF-1, EGFR and Erb3/Her3 genes, which are frequently overexpressed in human 
gliomas (Guo et al, 2003; Heimberger et al,2005). In a recent study, the significance of PDGF 
in gliomagenesis in adult rats was established by infecting white matter with a retrovirus 
encoding for PDGF and GFP. Within 2 weeks 100% of the animals had tumors derived from 
both infected and uninfected glial progenitors, thereby implicating PDGF in both autocrine 
and paracrine stimulation of glial progenitor cells (Assanah et al, 2006). Although, IGF-1 
was overexpressed in C6 glioma cells, there was reduced expression of IGF-2, FGF-9 and 
FGF-10 relative to astrocytes. Similar to the increased activity of the Ras pathway observed 
in human gliomas (Nakada et al, 2005), C6 cells also had an increase in both Ras expression 
and Ras guanine triphosphate activator protein (Sibenaller et al, 2005). However, contrary to 
what has been reported for human GBM, there was an increase in expression of Rb in these 
cells (Sibenaller et al, 2005). A subclone of C6 cells, stably expressing β-galactosidase, 
subsequently was described (Lampson et al, 1993) and this has permitted in vivo 
immunohistochemical analysis of these tumors in the brain. This clone is available through 
the ATCC (# CRL-2303). However, it must be noted that the β-galactosidase marker protein 
itself can serve as a tumor antigen, and immunization of rats against the reporter gene 
protected the animals against tumor growth. 
The C6 rat glioma model has been widely used in experimental neuro-oncology to evaluate 
the therapeutic efficacy of a variety of modalities, including chemotherapy (Doblas et al, 
2008), antiangiogenic therapy (Solly F et al, 2008), proteosome inhibitors (Ahmed et al, 2008), 
treatment with toxins (Zhao et al, 2008), radiation therapy (Sheehan et al, 2008), 
photodynamic therapy (Mannino et al, 2008), oncolytic viral therapy (Yang et al, 2004) and 
gene therapy (Tanriover et al, 2008). Since this tumor arose in an outbred Wistar rat, 
however, there is no syngeneic host in which it can be propagated. This is a very serious 
limitation that diminishes its usefulness for survival studies since the tumor is 
immunogenic, even in Wistar rats. The C6 glioma has been demonstrated to be 
immunogenic in Wistar and BDX rats (Parsa et al, 2000), and it therefore is not useful for 
evaluating the efficacy of immunotherapy. This problem is exemplified by prior studies in 
which C6 glioma cells were transfected with an antisense cDNA expression vector that 
downregulated the constitutive production of IGF-1 (Trojan et al, 1993). Not recognizing 
that the tumor was of Wistar origin, the authors unfortunately used BD IX rats, which they 
thought was the strain of origin, due to some ambiguity in the literature. Subsequently, it 
was reported that BD IX rats, which had been immunized with the C6 anti-sense IGF-1 
transfected cells, were resistant to both s.c. and i.c. challenge of the C6 glioma. Similarly, 
Wistar rats, bearing C6 gliomas (s.c. or i.c.), developed potent humoral and cellular immune  
 




Fig. 1. Histopathologic features of the C6, 9L, RG2, F98, CNS-1, and BT4C brain tumors. A The 
C6 glioma is composed of a pleomorphic population of cells with nuclei ranging from round to 
oblong. A herring-bone pattern of growth is seen in some areas and there is focal invasion of 
contiguous normal brain. There are scattered foci of necrosis with pseudo-palisading of tumor 
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cells at the periphery. B The 9L gliosarcoma is composed of spindle-shaped cells with a 
sarcomatoid appearance. A whorled pattern of growth is seen with sharp delineation of the 
margins of the tumor with little invasion of contiguous normal brain. C The RG2 glioma is 
very similar in appearance to the F98 glioma and also has a highly invasive pattern of growth. 
D The F98 glioma is composed of a mixed population of spindle-shaped cells with fusiform 
nuclei, frequently forming a whorled pattern of growth, and a smaller subpopulation of 
polygonal cells with round to oval nuclei. There is extensive invasion of contiguous normal 
brain with islands of tumor cells at varying distances from the main tumor mass, which form 
perivascular clusters. Usually, there is a central area of necrosis filled with tumor cell ghosts. E 
The CNS-1 glioma is composed of a pleomorphic population of cells that show great variation 
in size and shape. There is extensive invasion of contiguous normal brain with dense infiltrates 
in some areas and in others, more circumscribed clusters of tumor cells. Small foci of 
hemorrhage are scattered through the tumor. F The BT4C glioma is composed of a 
pleomorphic population of tumor cells with a sarcomatous pattern of growth. Scattered tumor 
giant cells are seen and mitotic figures are frequent. The tumor grows expansively and invades 
the surrounding normal brain along perivascular tracts and occasional tumor cell nests are 
seen in the surrounding normal brain. There is neo-vascularization, especially in the tumor 
periphery, where microhemorrhages are frequent. Central necrosis is usually not present but 
occasionally scattered areas of necrosis may be seen in larger tumors. All photomicrographs 
are at a magnification of 200×, except for F 
responses to the tumor, and rats challenged simultaneously with s.c. and i.c. tumors, had a 
survival rate of 100% (Parsa et al, 2000). Since C6 glioma cells are allogeneic in all inbred 
strains, this should provide a strong cautionary note for studies employing this tumor 
model and they should not be used for immunotherapy studies. Despite this limitation, the 
C6 glioma model continues to be used for a variety of studies related to brain tumor biology 
(Karmakar et al, 2007). These have included studies on tumor growth, invasion, migration, 
BBB disruption, neovascularization, growth factor regulation and production, and 
biochemical studies (Assadian et al, 2008). Finally, single-cell clonal analysis has revealed 
that C6 cells also have cancer stem cell-like characteristics, including self-renewal, the 
potential for multi-lineage differentiation in vitro and tumor formation in vivo (Shen et al, 
2008). 
The 9L gliosarcoma has been the most widely used experimental rat brain tumor model. It 
was produced in Fisher 344 rats by the intravenous injection of 5 mg/kg of MNU for 26 
weeks (Benda et al, 1971). The original tumor was designated as tumor #9, which 
subsequently was cloned at the Brain Tumor Research Center, University of California, San 
Francisco, and then was designated “9L”. These tumor cells could be propagated in vitro, 
which made them very useful for in vivo studies to investigate the effects of various 
therapeutic modalities on brain tumors. 9L cells can be implanted i.c. into syngeneic Fischer 
rats, following which they give rise to rapidly growing tumors. These are composed of 
spindle-shaped cells with a sarcomatoid appearance. The tumor margins are sharply 
delineated with little obvious invasion into the contiguous normal brain (Fig. 1b). The 9L 
gliosarcoma has a mutant p53 gene (Asai et al, 1994), but there is normal expression of p16 
and p19ARF mRNAs, indicating that there is a wild type p16/Cdkn2a/INK4α locus 
(Schlegel et al, 1999). Molecular characterization of the 9L relative to rat stem cell derived 
astrocytes revealed an increased expression of the genes encoding TGFα and its receptor, 
EGFR (Sibenaller et al, 2005). Interestingly, decreased expression of FGF-2, FGF-9, and 
FGFR-1 and PDGFRβ also was noted (Sibenaller et al, 2005). Recently, cancer stem-like cells 
 
Animal Models of Glioma 
 
351 
(CSLCs) have been demonstrated in the 9L cell line. These CSLCs grow as neurospheres in 
chemically defined medium and express the neural stem cell markers Nestin and Sox2. They 
are self-renewable and differentiate in vitro into neuron- and glial-like cells (Ghods et al, 
2007). The neurospheres have a lower proliferation rate and express several anti-apoptotic 
and drug related genes. Furthermore, these cells form tumors that are more aggressive than 
the parental 9L tumor (Ghods et al, 2007), which could be an important property in future 
studies. The 9L gliosarcoma model has been used extensively to investigate mechanisms 
and development of drug resistance (Barcellos-Hoff et al, 2006), transport of drugs across 
the blood-brain and bloodtumor barrier (Black et al, 2008), imaging of brain tumors 
including radiological techniques such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET) and imaging to evaluate tumor hypoxia and metabolism 
(Bansal et al, 2008), pharmacokinetic studies of nitrosourea (Warnke et al, 1987), 
mechanisms and effects of anti-angiogenic drugs (Yang et al, 2007), effects of radiation 
(Regnard et al, 2008), chemotherapy (Bencokova et al, 2008), gene therapy (Kumar et al, 
2008), cancer stem cells (Ghods et al, 2007), immunotoxin treatment, immunotherapy and 
cytokine therapy (Liu et al, 2007) and oncolytic viral therapy (Madara et al, 2005). A number 
of these studies have yielded impressive therapeutic results, including apparent cures of 
tumor bearing animals. However, it must be emphasized that this tumor has been shown to 
be highly immunogenic. Animals immunized with X-irradiated 9L cells were resistant to 
both subcutaneous (s.c.) as well as i.c. tumor challenge, compared to 100% tumor takes in 
immunologically naïve animals (Blume et al, 1974). This report was first published in the 
proceedings of a meeting, which did not receive wide circulation, but subsequent studies 
have confirmed the immunogenicity of this model (Morantz et al, 1979). Expression of the s-
Myc gene under the control of a CMV promotor resulted in complete suppression of 9L 
tumor growth, as well as rejection of subsequent challenges of tumor cells. Histological 
examination of the tumors after s-Myc therapy revealed massive mononuclear cell 
infiltration with CD8 + T lymphocytes, which accounted for >70% of these infiltrating cells. 
These observations suggested that tumor rejection was due to a potent T-cell mediated, anti-
tumor immune response. This, and several more recent studies, have underscored the 
significance of the anti-tumor immune response following gene therapy induced tumor 
eradication observed with 9L model. It is now recognized that in vivo bystander cell killing 
(Chen et al, 1995), which has been observed with the 9L gliosarcoma following delivery of 
the Herpes simplex virus thymidine kinase gene (hsv-tk), (Moolten et al, 1986) followed by 
treatment with ganciclovir, was due in part to an anti-tumor immune response. The 
immunogenicity of the 9L glioma must be kept in mind when utilizing this model to 
evaluate the efficacy of novel therapeutic agents. Early studies employing radiation or 
chemotherapy alone were largely unsuccessful in curing the 9L tumor. However, the success 
obtained by boron neutron capture therapy and gene therapy highlights the importance of 
utilizing anti-tumor treatments that can destroy individual cancer cells and simultaneously 
spare host immune effector cells that can eradicate residual tumor cells (Moriuchi et al, 
2002).  
Despite the fact that the 9L arose in a Fischer rat, 9L gliosarcoma cells also can form i.c. 
tumors in allogeneic Wistar rats (Stojiljkovic et al, 2003). Histopathological evaluation 
revealed that these tumors formed circumscribed masses that were not infiltrative and did 
not spread into the subarachnoid space or ventricles. Immunostaining of the tumors 
revealed the presence of glial fibrillary acidic protein (GFAP)-positive, infiltrating astrocytic 
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cells at the periphery. B The 9L gliosarcoma is composed of spindle-shaped cells with a 
sarcomatoid appearance. A whorled pattern of growth is seen with sharp delineation of the 
margins of the tumor with little invasion of contiguous normal brain. C The RG2 glioma is 
very similar in appearance to the F98 glioma and also has a highly invasive pattern of growth. 
D The F98 glioma is composed of a mixed population of spindle-shaped cells with fusiform 
nuclei, frequently forming a whorled pattern of growth, and a smaller subpopulation of 
polygonal cells with round to oval nuclei. There is extensive invasion of contiguous normal 
brain with islands of tumor cells at varying distances from the main tumor mass, which form 
perivascular clusters. Usually, there is a central area of necrosis filled with tumor cell ghosts. E 
The CNS-1 glioma is composed of a pleomorphic population of cells that show great variation 
in size and shape. There is extensive invasion of contiguous normal brain with dense infiltrates 
in some areas and in others, more circumscribed clusters of tumor cells. Small foci of 
hemorrhage are scattered through the tumor. F The BT4C glioma is composed of a 
pleomorphic population of tumor cells with a sarcomatous pattern of growth. Scattered tumor 
giant cells are seen and mitotic figures are frequent. The tumor grows expansively and invades 
the surrounding normal brain along perivascular tracts and occasional tumor cell nests are 
seen in the surrounding normal brain. There is neo-vascularization, especially in the tumor 
periphery, where microhemorrhages are frequent. Central necrosis is usually not present but 
occasionally scattered areas of necrosis may be seen in larger tumors. All photomicrographs 
are at a magnification of 200×, except for F 
responses to the tumor, and rats challenged simultaneously with s.c. and i.c. tumors, had a 
survival rate of 100% (Parsa et al, 2000). Since C6 glioma cells are allogeneic in all inbred 
strains, this should provide a strong cautionary note for studies employing this tumor 
model and they should not be used for immunotherapy studies. Despite this limitation, the 
C6 glioma model continues to be used for a variety of studies related to brain tumor biology 
(Karmakar et al, 2007). These have included studies on tumor growth, invasion, migration, 
BBB disruption, neovascularization, growth factor regulation and production, and 
biochemical studies (Assadian et al, 2008). Finally, single-cell clonal analysis has revealed 
that C6 cells also have cancer stem cell-like characteristics, including self-renewal, the 
potential for multi-lineage differentiation in vitro and tumor formation in vivo (Shen et al, 
2008). 
The 9L gliosarcoma has been the most widely used experimental rat brain tumor model. It 
was produced in Fisher 344 rats by the intravenous injection of 5 mg/kg of MNU for 26 
weeks (Benda et al, 1971). The original tumor was designated as tumor #9, which 
subsequently was cloned at the Brain Tumor Research Center, University of California, San 
Francisco, and then was designated “9L”. These tumor cells could be propagated in vitro, 
which made them very useful for in vivo studies to investigate the effects of various 
therapeutic modalities on brain tumors. 9L cells can be implanted i.c. into syngeneic Fischer 
rats, following which they give rise to rapidly growing tumors. These are composed of 
spindle-shaped cells with a sarcomatoid appearance. The tumor margins are sharply 
delineated with little obvious invasion into the contiguous normal brain (Fig. 1b). The 9L 
gliosarcoma has a mutant p53 gene (Asai et al, 1994), but there is normal expression of p16 
and p19ARF mRNAs, indicating that there is a wild type p16/Cdkn2a/INK4α locus 
(Schlegel et al, 1999). Molecular characterization of the 9L relative to rat stem cell derived 
astrocytes revealed an increased expression of the genes encoding TGFα and its receptor, 
EGFR (Sibenaller et al, 2005). Interestingly, decreased expression of FGF-2, FGF-9, and 
FGFR-1 and PDGFRβ also was noted (Sibenaller et al, 2005). Recently, cancer stem-like cells 
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(CSLCs) have been demonstrated in the 9L cell line. These CSLCs grow as neurospheres in 
chemically defined medium and express the neural stem cell markers Nestin and Sox2. They 
are self-renewable and differentiate in vitro into neuron- and glial-like cells (Ghods et al, 
2007). The neurospheres have a lower proliferation rate and express several anti-apoptotic 
and drug related genes. Furthermore, these cells form tumors that are more aggressive than 
the parental 9L tumor (Ghods et al, 2007), which could be an important property in future 
studies. The 9L gliosarcoma model has been used extensively to investigate mechanisms 
and development of drug resistance (Barcellos-Hoff et al, 2006), transport of drugs across 
the blood-brain and bloodtumor barrier (Black et al, 2008), imaging of brain tumors 
including radiological techniques such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET) and imaging to evaluate tumor hypoxia and metabolism 
(Bansal et al, 2008), pharmacokinetic studies of nitrosourea (Warnke et al, 1987), 
mechanisms and effects of anti-angiogenic drugs (Yang et al, 2007), effects of radiation 
(Regnard et al, 2008), chemotherapy (Bencokova et al, 2008), gene therapy (Kumar et al, 
2008), cancer stem cells (Ghods et al, 2007), immunotoxin treatment, immunotherapy and 
cytokine therapy (Liu et al, 2007) and oncolytic viral therapy (Madara et al, 2005). A number 
of these studies have yielded impressive therapeutic results, including apparent cures of 
tumor bearing animals. However, it must be emphasized that this tumor has been shown to 
be highly immunogenic. Animals immunized with X-irradiated 9L cells were resistant to 
both subcutaneous (s.c.) as well as i.c. tumor challenge, compared to 100% tumor takes in 
immunologically naïve animals (Blume et al, 1974). This report was first published in the 
proceedings of a meeting, which did not receive wide circulation, but subsequent studies 
have confirmed the immunogenicity of this model (Morantz et al, 1979). Expression of the s-
Myc gene under the control of a CMV promotor resulted in complete suppression of 9L 
tumor growth, as well as rejection of subsequent challenges of tumor cells. Histological 
examination of the tumors after s-Myc therapy revealed massive mononuclear cell 
infiltration with CD8 + T lymphocytes, which accounted for >70% of these infiltrating cells. 
These observations suggested that tumor rejection was due to a potent T-cell mediated, anti-
tumor immune response. This, and several more recent studies, have underscored the 
significance of the anti-tumor immune response following gene therapy induced tumor 
eradication observed with 9L model. It is now recognized that in vivo bystander cell killing 
(Chen et al, 1995), which has been observed with the 9L gliosarcoma following delivery of 
the Herpes simplex virus thymidine kinase gene (hsv-tk), (Moolten et al, 1986) followed by 
treatment with ganciclovir, was due in part to an anti-tumor immune response. The 
immunogenicity of the 9L glioma must be kept in mind when utilizing this model to 
evaluate the efficacy of novel therapeutic agents. Early studies employing radiation or 
chemotherapy alone were largely unsuccessful in curing the 9L tumor. However, the success 
obtained by boron neutron capture therapy and gene therapy highlights the importance of 
utilizing anti-tumor treatments that can destroy individual cancer cells and simultaneously 
spare host immune effector cells that can eradicate residual tumor cells (Moriuchi et al, 
2002).  
Despite the fact that the 9L arose in a Fischer rat, 9L gliosarcoma cells also can form i.c. 
tumors in allogeneic Wistar rats (Stojiljkovic et al, 2003). Histopathological evaluation 
revealed that these tumors formed circumscribed masses that were not infiltrative and did 
not spread into the subarachnoid space or ventricles. Immunostaining of the tumors 
revealed the presence of glial fibrillary acidic protein (GFAP)-positive, infiltrating astrocytic 
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cells, and activated ED1 positive macrophages/ microglia. Higher numbers of K(ATP) and 
K(Ca) channels have been observed in 9L tumors grown in allogeneic Wistar rats compared 
to those grown in syngeneic Fischer rats. Furthermore, the allogeneic tumors showed a 
greater increase in brain tumor permeability upon treatment with potassium channel 
agonists, compared to those grown in syngeneic hosts. The 9L tumor model also has been 
used following treatment to study the effect of BBB disruption, implantation of devices for 
repeated intratumoral delivery and imaging (Bhattacharya et al, 2007). 
The 9L gliosarcoma model also has been used to develop a model for brainstem tumors 
(Jallo et al, 2006). Progression to hemiparesis with the onset of symptoms occurred 17 days 
postimplantation into the brainstem. This model has been used to evaluate the efficacy of 
convection enhanced delivery (CED) of carboplatin to the brainstem, and to study the 
response of recurrent, chemo-resistant gliomas. Two bis-chloroethyl nitrosourea (BCNU) 
resistant cell lines were derived from 9L cells by treating them with BCNU in vitro or in 
vivo. Both of these cell lines formed tumors in a 100% of the animals following i.c. 
implantation, and were much more invasive than the parental 9L cells (Saito et al, 2004). The 
9L gliosarcoma also has been used as a model to evaluate drug-resistant and invasive 
recurrent gliomas (Schepkin et al, 2006), but as previously indicated, caution must be used 
in evaluating results obtained with such a highly immunogenic tumor. 
Although not fully appreciated, the T9 glioma was at one time, and still may be the same as 
the 9L gliosarcoma. The original stock of T9 cells was obtained from Sweet’s laboratory at 
the MGH by Denlinger, and Koestner, and it was renamed T9 by them. Similar to the 
immunogenicity of the 9L gliosarcoma, the T9 glioma also was found to be highly 
immunogenic. Kida et al. found that rats immunized with irradiated T9 cells or T9 cells 
mixed with C. parvum rejected subsequent s.c. implants of T9 glioma cells (Kida et al, 1983). 
However, in order to immunize against intracranial tumors, rats initially had to reject 
intradermal T9 cells. As might have been predicted, these results indicated that, similar to 
the 9L gliosarcoma, the T9 glioma also was immunogenic. The T9 cell line subsequently has 
been shared among numerous investigators and has been used for many studies, including 
the evaluation of antiangiogenic (Jeffes et al, 2005), and chemotherapeutic agents 
(Pietronigro et al, 2003), immunotherapy (Shibuya et al, 1984), and gene therapy with 
interferon-β(Harada et al, 1995). Although tumor specific or tumor associated antigens have 
yet to be identified, for the 9L gliosarcoma and T9 glioma, it is only a matter of time before 
they are identified. 
The RG2 glioma (ATCC #CRL-2433) was produced in Koestner’s laboratory at The Ohio 
State University by the i.v. administration of ENU (50 mg/kg body weight) to a pregnant 
Fischer 344 rat on the 20th day of gestation. Subsequently, the in vitro growth and 
morphology of the F98 glioma was described in detail (Ko et al, 1980), and based on its 
histopathology it was classified as an anaplastic or undifferentiated glioma. The progeny of 
ENU-injected rats subsequently developed tumors, and following cloning by Wechsler in 
Germany, one of these clones was designated as “RG2” (rat glioma 2). The same clone was 
called the “D74-RG2” or “D74” in Koestner’s laboratory at The Ohio State University. The 
RG2 glioma (Fig. 1c) is similar in microscopic appearance to the F98 glioma (Fig. 1d), and 
also has a highly invasive pattern of growth, which has made it a good representative model 
for GBM (Weizsacker et al, 1982). Gene expression profiling of these cells established that 
they had increased gene expression of PDGFβ, IGF-1, Ras, Erb3/HER3 precursor mRNA 
and cyclin D2. They express a wildtype p53 and a concurrent loss in the expression of the 
p16/Cdkn2a/Ink4 gene locus. It has been used for a variety of preclinical studies to evaluate 
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changes in vascular permeability (Ferrier et al, 2007), disruption of the BBB (Ningaraj et al, 
2002), anti-angiogenic therapy (Zagorac et al, 2008), gene therapy, chemotherapy 
(Miknyoczki et al, 2007) and radionuclide therapy (Shen et al, 2004). 
The RG2 glioma is non-immunogenic in syngeneic Fischer rats and has low levels of MHC-1 
expression compared to the C6 and 9L gliomas (Oshiro et al, 2001). However, in vitro 
treatment with IFN-γ upregulated MHC class I antigen expression and also resulted in a 
significant in vivo anti-tumor immune response with increased survival of treated animals. 
More recently, the RG2 glioma has been stably transfected with human Herpes virus Entry 
Mediator C (HveC) to facilitate HSV infection and has been used to study the therapeutic 
effects of oncolytic Herpes simplex virus-1 treatment (Kurozumi et al, 2007). The transfected 
cells retained their tumorigenicity following i.c. implantation in Fischer rats, and 
transfection of the HveC gene did not affect i.c. tumor growth (Wakimoto et al, 2004). 
However, it has not been determined if HveC can cause these cells to become immunogenic, 
and therefore, this must be taken into account when using the RG2 for immunotherapy 
studies.  
The F98 glioma (ATCC # CRL-2397) was produced by Wechsler in Koestner’s laboratory at 
the same time as the RG2 glioma. It is composed of a mixed population of spindle-shaped 
cells, the majority of which have fusiform nuclei, and a smaller number of polygonal cells 
with round to oval nuclei. There is extensive invasion of contiguous normal brain with 
islands of tumor cells at varying distances from the tumor mass, many of which form 
perivascular clusters (Fig. 1d). Similar to human GBM, these cells overexpress PDGFβ, and 
Ras along with an increase in EGFR, cyclin D1 and cyclin D2 expression relative to rat 
astrocytes (Sibenaller et al, 2005). Like the C6 glioma, they also have increased expression of 
Rb relative to rat astrocytes. Immunofluorescence studies of F98 cells also revealed low 
expression of BRCA1, and a lack of radiation and cisplatin induced BRCA1 foci in these cells 
(Bencokova et al, 2008). Usually, there is a necrotic core, scattered mitotic cells and non-
glomeruloid neovascular proliferation. The tumor is GFAP and vimentin positive with 
negligible staining for CD3 + T cells (Mathieu et al, 2007). Since it simulates the behavior of 
human GBMs in a number of important ways, such as its highly invasive pattern of growth 
and low immunogenicity, it has been used to evaluate the efficacy of a variety of 
experimental therapeutic agents. It is refractory to a number of therapeutic modalities, 
including systemic chemotherapy with paclitaxel, and carboplatin (von Eckardstein et al, 
2005), and it is poorly responsive to photon-irradiation alone, which in part may be related 
to its functionally impaired BRCA1 status that can favor genomic instability and impaired 
DNA repair. Recently, it has been shown to be responsive to a combination of synchrotron 
radiation with cisplatin (Biston et al, 2004), and to convection enhanced delivery (CED) of 
carboplatin in combination with 6 MV photon-irradiation in rats bearing i.c. tumors 
(Rousseau et al, 2008). This model has been used extensively by Barth et al. to evaluate the 
efficacy of boron neutron capture therapy (BNCT) (Yang et al, 2008). Elleaume and her 
coworkers have evaluated cisplatin, carboplatin and iodine enhanced synchrotron 
stereotactic radiotherapy (Cho et al, 2002) in F98 glioma bearing rats (Adam et al, 2005). It 
has also been used to evaluate non-invasive MRI to visualize tumor growth, diffusion tensor 
imaging (Zhang et al, 2007), tumor angiogenesis and the tumor tropism of mesenchymal 
stem cells (Wu et al, 2008). 
The F98 glioma is very weakly immunogenic (Tzeng et al, 1991) and transfection with the 
gene encoding B7.1 co-stimulatory molecule (Paul et al, 2000), or syngeneic cellular 
vaccination combined with GMCSF, did not enhance its immunogenicity (Clavreul et al, 
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changes in vascular permeability (Ferrier et al, 2007), disruption of the BBB (Ningaraj et al, 
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(Miknyoczki et al, 2007) and radionuclide therapy (Shen et al, 2004). 
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2006). This makes it a very attractive model to investigate the mechanisms underlying 
glioma resistance to immunotherapy. It has also been used to study the molecular genetic 
alterations in GBMs (Hanissian et al, 2005), effects of infusion rates on drug distribution in 
i.c. tumors, and for suicide gene therapy with Herpes simplex virus-1 thymidine kinase 
(HSV-TK) (von Eckardstein et al, 2001). Like the 9L gliosarcoma, F98 cells also have been 
injected into the pontine tegmentum of the brainstem of Fischer rats to produce a model for 
brainstem tumors. The histopathological and radiobiological characteristics of these tumors 
were comparable to aggressive, primary human brainstem tumors, which could facilitate 
preclinical testing of therapeutics to treat these lethal tumors.  
F98 cells have been stably transfected with expression vectors encoding for wildtype EGFR 
and EGFRvIII, and the resulting cell lines have been designated F98EGFR (ATCC# CRL-
2948) and F98npEGFRvIII (ATCC# CRL-2949). They each express ~105 non-functional (i.e. 
nonphosphorylatable) receptor sites per cell. This is below the threshold number of 106 sites 
per cell that can evoke a xeno-immune response against human EGFR in rats. These cell 
lines have been used in Fischer rats for studies on molecular targeting (Yang et al, 2005) to 
evaluate the therapeutic efficacy of boronated mAbs and EGF for neutron capture therapy 
(NCT) (Wu et al, 2007). The boronated mAbs, L8A4, which is specific for EGFRvIII, and 
cetuximab, which recognizes wild type EGFR, specifically targeted their respective receptor 
positive i.c. tumors after CED and they were therapeutically effective following NCT.  
A bioluminescent F98 cell line recently was constructed by stably transfecting F98 cells with 
the luciferase gene. When implanted i.c. into the brains of Fischer rats, tumor size could be 
monitored by measuring luminescence. This model should permit rapid, non-invasive 
imaging of i.c. tumor growth to evaluate novel therapeutic modalities (Bryant et al, 2008). 
Finally, F98 cells also are capable of growing as i.c. xenografts in cats (Ernestus et al, 1992), 
but since these cells can evoke a xenoimmune response, this model is of limited usefulness. 
It is important to note that, what may be therapeutically effective in the rat, may not be in 
the human. However, it probably is safe to say that if a particular therapeutic approach is 
ineffective in a rat model, it is even more unlikely to be so in humans. 
The CNS-1 glioma was derived from an inbred Lewis rat that had received weekly i.v. 
injections of MNU for 6 months (Kruse et al, 1994). Following i.c. implantation into Lewis 
rats, it demonstrated an infiltrative pattern of growth with leptomeningeal, perivascular, 
and periventricular spread and extension of the tumor into the choroid plexus. 
Histologically, these tumors exhibited hypercellularity, nuclear atypia and pleomorphism, 
and had necrotic foci. These were surrounded by glioma cells arranged in a 
pseudopalisading pattern (Fig. 1e), although to a lesser extent than that seen in human 
GBM. These tumors are weakly immunogenic. Like human GBMs, these also were 
infiltrated with macrophages and T-cells, but did not have extensive glomeruloid 
endothelial/microvascular proliferation. Kielian et al. identified the constitutive expression 
of monocyte chemotactic factor 1 (MCP-1) by CNS-1 cells (Kielian et al, 2002). In vivo, CNS-1 
tumors also showed extensive infiltration by macrophages, which might confer a growth 
advantage (Platten et al, 2003). This model has been useful to study glioma invasion (Owens 
et al, 1998), changes in the biology of glioma cells and their extracellular matrix (Lapointe et 
al, 2004), and gene therapy (Biglari et al, 2004). It also has been used to study the efficacy of 
immunotherapy as a potential treatment for human GBM (Ali et al, 2004) although its 
immunogenicity has not been studied in great detail. 
The BT4C glioma was derived by giving a single transplacental administration of N-ethyl-
Nnitrosourea (ENU) to pregnant BD IX rats. Dissociated brain tumor cells from one of these 
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animals were propagated in vitro and after 200 days in culture they became tumorigenic. 
The cells subsequently were implanted s.c. into BD IX rats and the resulting tumors 
contained a mixture of multipolar glia-like cells and flattened cells with fewer and shorter 
cytoplasmic processes and occasional giant cells (Laerum et al, 1977). BT4C glioma-derived 
tumors show high cellularity and have pleomorphic nuclei and numerous mitotic figures 
and the tumor blood vessels are irregular, dilated and show areas of proliferation (Fig. 1f) 
(Stuhr et al, 2007). At the molecular level, BT4C cells express VEGF, tPA, uPA and MVD in 
the periphery of the growing tumor and are S100 positive by immunohistochemistry (M. 
Johansson, Personal communication). This model has been useful to test novel 
chemotherapeutic targeting strategies (Pulkkinen et al, 2008), antitumor effects of gene 
therapy (Raty JK et al, 2004), anti-angiogenic agents alone (Huszthy et al, 2006) and in 
combination with radiation and temozolomide (Sandstrom et al, 2008). BT4C gliomas also 
have been used to investigate the impact of hyperoxia on tumor bearing rats. This resulted 
in slower growth accompanied by increased apoptosis of tumor cells and reduced 
microvessel density (MVD). Apart from studies to evaluate therapeutic efficacy, the BT4C 
glioma model also has been used to study the molecular and biological changes induced by 
chemotherapy (Vallbo et al, 2002), radiation therapy (Andersson et al, 2002) and suicide 
gene therapy (Griffin et al, 2003). BT4C cells, stably transfected with cDNA encoding β- 
galactosidase, have been used to evaluate the migration of single migrating tumor cell 
glioma spheroids and fetal brain aggregate coculture systems in vitro and in rat brains in 
vivo (Garcia-Cabrera et al, 1996;). 
Avian sarcoma virus induced and RT-2 glioma. The induction of experimental brain 
tumors by the injection of Rous sarcoma virus has been described in canines, rats, and 
monkeys. Tumors were induced by inoculating neonatal Fischer rats i.c. with purified avian 
sarcoma virus (ASV) suspensions (Copeland et al, 1976). All of the animals developed 
tumors within 2 weeks following ASV injection, 94% of which were anaplastic astrocytomas, 
and the remainder were low grade gliomas or sarcomas (Prabhu et al, 2000). This model has 
been used to study the effects of chemo- and radiotherapy, BBB disruption, tumor 
permeability, and if de novo tumor induction is an important requirement. The response to 
immunotherapy indicated that these tumors were immunogenic, and expressed a variety of 
virally encoded tumor specific antigens. A continuous cell line, designated “RT-2”, was 
derived from an ASV-induced Fischer rat tumor, and this has been used to study tumor 
growth, photochemotherapy, cytotoxic gene therapy (Valerie et al, 2001) and radio-
sensitization (Valerie et al, 2000). The RT2 tumor appears to be immunogenic, as evidenced 
by its ability to evoke a CD8 + T cell-mediated anti-tumor immune response (Shah et al, 
2003), and this must be taken into account if it is used for immunotherapy studies. RT-2 cells 
expressing GFP have been used for quantitative assessment of glioma invasion in the rat 
brain (Mourad et al, 2003). The RT-2 glioma model also has been used to evaluate the 
therapeutic efficacy of oncolytic adenoviruses. Although they can be efficiently infected they 
do not permit efficient replication of E1- attenuated adenoviruses. These cells also have been 
transfected with cDNA encoding heat shock protein 72 (HSP72), which was thought to be 
necessary for replication of E1 deleted adenoviruses. These transfectants have been found to 
be permissive for replication of E1- deleted, conditionally replication-competent 
adenoviruses. The inherent immunogenicity of the RT-2 glioma may limit its usefulness for 
survival studies, but nevertheless it still may be a useful model for other types of studies. 
Rat brain tumor models have provided a wealth of information on the biology, 
biochemistry, imaging and experimental therapeutics of brain tumors in experimental 
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neuro-oncology, and there is every reason to believe that they will continue to do so. 
However, it is essential to recognize the limitations of each of the models that have been 
described, and depending on the nature of the study to be conducted, it is important that the 
appropriate model be selected. It now has become clear that immunogenic tumors such as 
the C6, 9L and T9 are not good choices for studies in immunocompetent rats, if the endpoint 
is prolongation of survival time or cure of the tumor. Destruction of tumor cells in these 
models, which have tumor infiltrating host immune effector cells within the tumor, can lead 
to significant amplification of an antitumor response. This may be the single most important 
in vivo contributor to the bystander effect that has been observed with gene therapy of the 
C6 and 9L gliomas following transfection with the HSV-tK gene and the lack of such 
immune amplification with the weakly immunogenic RG2 glioma. Anti-tumor immune 
response following transfection with suicide genes such as HSV-tK initially was 
unanticipated, but it is an important effect associated with both gene therapy and boron 
neutron capture therapy, but not with conventional chemo- and radiotherapy of the 9L 
gliosarcoma. Since human high grade brain tumors generally are regarded as being either 
non- or weakly immunogenic, therapeutic exploitation of this using modalities that spare 
tumor infiltrating host immune effector cells could have important therapeutic implications. 
Undoubtedly other rat brain tumor models will be developed, especially cell lines derived 
from genetically engineered rats that will expand the types of studies that can be carried out 
in this very important laboratory animal. 
2.1.2 Human glioma xenografts implanted in immunocompromised mice 
Xenograft models of malignant astrocytoma have been extensively used to assess the function 
of various signaling molecules or matrix proteins in glioma growth and invasion (Hingtgen et 
al, 2008). Xenograft models that transplant human malignant astrocytoma/glioma cells into 
the brains of immunocompromised mice (athymic nude or SCID) have the advantage of being 
relatively rapid models with which to assess the role of a particular molecule in positively or 
negatively regulating proliferation and/or regulating invasion in vivo. Also, these models are 
very useful for the initial evaluation of novel imaging techniques as well as new therapies for 
GBM, including antiangiogenic therapy chemotherapy, radiotherapy, targeted toxins, 
cytotoxic or conditionally replicative oncolytic viruses. One disadvantage of human xenograft 
models is that most human glioma cell lines are not invasive when propagated in vivo (Curtin 
et al, 2008). Another disadvantage is that the propagation of human malignant 
astrocytoma/glioma cell lines in culture can result in their loss of key genetic alterations, such 
as expression of the mutant EGFR (Tsurushima et al, 2007), that are the most likely to be 
important in gliomagenesis. This limitation has been overcome by propagating primary 
human GBM tumors in the nude mouse (either subcutaneously or intracerebrally) instead of in 
culture; when these tumors are propagated in vivo, the genetic alterations found in the 
patients biopsy are retained (Ozawa et al, 2005). For xenograft models it is also important to 
propagate the tumors for experimental analysis in an orthotopic environment (the brain) 
because the microenvironment in the brain (i.e., the extracellular matrix, growth factors, and 
stromal cells) is different from that found in the subcutaneous tissue. 
2.2 Gene trgeted animal models 
Recently, transgenic technology has allowed investigators to alter the function of specific 
genes of interest and thus exploit defined genetic lesions to produce more biologically 
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correct models of CNS cancers that result from activation and/or inactivation of 
endogenous genes in rodent genomes. 
 p53,  
 INK4a/ARF,  
 Phosphatase and Tensin Homolog (PTEN),  
 Epidermal Growth Factor Receptor (EGF-R),  
 Platelet Derived Growth Factor (PDGF) 
These models support the concept that the genetic alterations in human tumors, such as p53 
loss and loss of PTEN function, are probably important in the development of astrocytomas 
(Grades II and III). Rodent models of GBM tumors are also available. In a somatic gene-
transfer model, simultaneous retroviral expression of constitutively active Ras and Akt gives 
rise to the formation of high-grade gliomas that are morphologically similar to human GBM 
tumors (Holland et al, 2000). Although Ras mutations are uncommon in GBM tumors, one 
study (Sharma et al, 2005) suggests that Ras activity is increased in human GBM biopsies 
due to a point mutation. In mice, the combination of EGFR amplification and either loss of 
p53 plus CDK4 overexpression or loss of INK4a-ARF is sufficient to induce glioma tumor 
formation that resembles that of human GBM tumors (Zhu et al, 2009). In an EGFR 
transgenic mouse model, LOH of p16INK4a, p19ARF, and PTEN cooperates with the 
amplification of EGFR to induce a highly infiltrative GBM tumor. Also, simultaneous 
deletion of p53 and PTEN in the mouse central nervous system generates an acute-onset, 
high-grade malignant glioma tumor that is histologically similar to human GBM tumors 
(Zheng et al, 2008). A new model of GBM tumor has been created by retroviral expression of 
PDGF-B in adult rat neural progenitor cells (Assanah et al, 2006). In this model, intracranial 
injection of retrovirus containing PDGF-B alone or in combination with PDGFRα results in 
the development of GBM-like tumors. To date, individual disruption or LOH of a single 
gene regulating the cell cycle, such as p53, INK4a, or ARF, has been insufficient to initiate 
gliomagenesis in vivo (Holland et al, 2001). Taken together, these studies suggest that 
alterations in neural progenitor cells probably give rise to at least some high-grade gliomas. 
There are limitations in the use of the above-discussed models. These include the facts that 
the tumor cells are not of human origin and that the rodents can in some instances require 
several months to reliably develop glioma tumors. 
Over the past two decades, scientists have developed a greater understanding of the 
molecular and genetic basis of brain tumorigenesis (Zhu et al, 2002). Evidence of the 
downregulation of tumor suppressor genes such as p53 and PTEN as well as elevated 
expression of growth factors, and their cognate tyrosine kinase receptors, such as PDGF and 
EGFR are found in a high percentage of human GBM tumors (Schwartzbaum et al, 2006). 
Researchers have exploited the role of these molecular pathways in brain tumor 
development to induce endogenous brain tumors in rodents. Thus, genetic engineering of 
mouse genes or intracranial delivery of oncogenic transgenes in adult mice and rats have 
been attempted in order to trigger the development of endogenous brain tumor in rodents. 
Germline deletion of the tumor suppressor genes p53 and NF1 increased the susceptibility 
of mice to develop astrocytomas (Reilly KM, 2009). These mice exhibit a wide range of 
astrocytoma stages, with tumor growth detected in 50-70% of the mice and median survival 
times of 6-8 months. This model is a valuable tool to study the development of secondary 
glioblastoma upon loss of p53. Germline deletion of other tumor suppressor genes, such as 
PTEN and Rb has also been attempted (Begemann et al, 2002). However, deletion of certain 
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genes can lead to embryonic lethality or to the generation of tumors in other organs, limiting 
the utility of these models. 
Tissue specific overexpression of putative oncogenes of interest, using methods which link 
the gene of interest to a glial specific promoter such as GFAP, S100β, or Nestin, provides an 
appealing approach towards the creation of spontaneously occurring brain tumors in 
animals seen in many germline knockout animals. Tissue targeted models involving 
deletion of tumor suppressor genes is more difficult. Conditional knockout models 
represent a promising new attempt to eliminate tumor suppressor function in a cell specific 
manner. These techniques have recently been utilized to create of variety of transgenic brain 
tumor models using targeted conditional knockouts of p53, PTEN, Ptc, and Rb. Frequently, 
conditional knockouts used in combination with oncogenes overexpressed on tissue specific 
promoters or introduced using viral vectors can create a localized tumor genetically similar 
to human cancer in an immune competent animal.  
Transgenic mice that display cell type-specific overexpression of oncogenes have been 
employed to study genetic abnormalities in astrocytes and neural progenitors. This has 
proven useful to establish the role of oncogenes in the tumorgenesis and progression of 
GBM (Ding et al, 2001). Overexpression of the transcription factor E2F1 under the 
transcriptional control of the GFAP promoter led to the formation of astrocytomas in p53 
KO mice, suggesting a role for E2F1 as an oncogene in the formation of brain tumors (Olson 
et al, 2007). Considering that cell typespecific expression of certain genes is lethal during 
early development, oncogene overexpression has also been approached by delivery of gene 
therapy vectors into the brain of pre-natal or adult rodents, leading to the formation of 
endogenous brain tumors. These tumors harbor the genetic abnormalities found in human 
GBM, as well as the histopathological hallmarks of human GBM, including the aggressive 
invasive behavior. The use of viral or plasmid based vectors to introduce genetic aberrations 
permits the tight anatomical restriction of tumor-forming genetic events to specific areas of 
the brain. Furthermore, viral and plasmid vectors allow for the delivery of multiple 
tumorigenic genes in any combination, thereby reducing the amount of time required to 
generate germline transgenic mouse models. Thus, endogenous rodent GBM models 
constitute a very promising and stringent animal model of GBM which recapitulates the 
most salient histopathological features, molecular attributes, and heterogeneity of human 
GBM in a syngeneic rodent background. However, the applicability of the endogenous brain 
tumor models to assess the pre-clinical efficacy of experimental therapeutics is still limited 
due to the long latency and the variable reproducibility of these models. 
Extensive evidence from across this developing field suggests that formation of endogenous 
brain tumors using viral vectors or plasmid systems to deliver oncogenes is somewhat 
variable. The degree of penetrance, tumor latency, and histopathological characteristics are 
dependant on the species and age of animals, the identity of specific genetic alterations and the 
vector system used to deliver them, and the anatomical location of genetic alterations. 
Retroviral- mediated delivery of PDGF into the adult rat white matter leads to formation of 
brain tumors with histopathological features that resemble human GBM; 100% of the animals 
succumb due to tumor burden 14-20 days after injection (Assanah et al, 2006). However, when 
retro-PDGF is delivered into the brain of newborn mice brain tumor formation only occurred 
in ~40% of the animals within 14-29 weeks. The incidence and grade of brain tumor formation 
in mice has been suggested to be dependant on the levels of expression of PDGF. Newborn 
mice were administered with retroviral vectors encoding a PDGF gene that lacks its regulatory 
sequences, which leads to higher levels of PDGF expression. Within 4-12 weeks, 100% of these 
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mice developed invasive glioblastoma that exhibited neo-vascularization and tumor cell 
infiltration throughout the brain parenchyma (Shih et al, 2004). 
In order to mimic the multiple genetic lesions encountered in human GBM, retroviral 
vectors that encode growth factors and a cycline-dependent kinase (cdk) were injected in the 
brain of neo-natal mice harboring additional mutations in tumor suppressor genes. Delivery 
of a constitutively active form of epidermal growth factor receptor gene (EGFR) in 
combination with basic fibroblast growth factor (bFGF) or ckd4 into the brain of neo-natal 
mice that are deficient in INK4a–ARF or p53 tumor suppressor genes led to formation of 
GBM in ~50% of the animals, while single mutations were unable of generating tumors 
(Holland et al, 1998). These findings support the notion that combination of genetic lesions 
is required for the induction of endogenous GBM in mice. Additionally, combined genetic 
aberrations can be targeted to specific cell populations by the development of transgenic 
mice that express the retroviral receptor under the control of cell-type specific promoters, 
such as the progenitor nestin promoter or the astrocyte GFAP promoter (Dai et al, 2001). 
This system is very functional because it allows cell-type-specific transfer of oncogenes 
expressed within retroviral vectors under any type of promoter.  
Lentiviral vectors have recently been employed to deliver oncogenes into the mouse brain. 
Considering that lentiviral vectors can transduce both dividing and non-dividing cells, these 
vectors constitute an attractive vehicle to deliver oncogenes to the brain of adult rodents 
(Singer O, Verma IM, 2008). In order to recapitulate the initiation of GBM, which is thought to 
arise upon genetic mutations in a few cells, oncogenic transgenes were delivered in a small 
population of cells in adult mouse brain by region-specific injection of lentiviral vectors 
encoding H-Ras or AKT. To target astrocytes the Cre-LoxP-controlled lentiviruses were 
injected in the cortex, hippocampus and subventricular zone of GFAP-Cre mice. Again, 
administration of single oncogenes did not induce formation of tumors for up to 10 months. 
However, when Ras and AKT were delivered together in the hippocampal area ~30% of mice 
exhibited brain tumors that exhibit a high degree of invasiveness within 3-5 months post 
injection. Only one mouse developed a tumor following transduction in the sub-ventricular 
zone, and no animals had tumors following transduction into the cortex. Combined delivery of 
H-Ras and AKT into p53 KO mice greatly increased the tumorigenesis of these vectors leading 
to 75 and 100% of the mice injected in the subventricular zone and hippocampus, respectively. 
These tumors also exhibited a much shorter tumor latency with many histopathological 
characteristics found in human GBM (Marumoto et al, 2009). These findings indicate that 
lentiviral vectors are useful tools to induce endogenous GBM in adult mice when several 
genetical abnormalities are induced in combination in the appropriate area of the brain. 
Another recent approach to induce endogenous GBM in mice is the use of the Sleeping 
Beauty (SB) transposable element to achieve integration of oncogenes in the genome of brain 
cells of neo-natal immune competent mice (Ohlfest et al, 2005). SB is a synthetic transposable 
element composed of a transposon DNA substrate and a transposase enzyme. SB 
transposase mediates excision and insertion of transposon DNA into the host genome, 
leading to long term expression (Ohlfest et al, 2004). Spontaneous brain tumors were 
induced by injecting SB-dependent plasmid harboring up to three genetic alterations (AKT, 
N-RAS, EGRFvIII, and/or shRNA specific for p53) into the lateral cerebral ventricle of 
neonatal mice of three different strains (Wiesner et al, 2009). The histological characteristics 
of the tumors were dependant of the combination of genetic lesions introduced to the mice, 
although most resembled human astrocytoma or GBM. In some mice, multifocal tumors, 
another hallmark of human GBM, was observed. The combination of N-RAs, EGFRvIII, and 
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p53 silencing was the most robust combination of genes with a 100% penetrance and a 
median survival of 83 days. These tumors were highly invasive and immunoreactive for 
nestin and GFAP indicating heterogeneity in the tumor mass. The SB is a very attractive and 
versatile system to induce endogenous brain tumors, allowing integration of large 
transposons (<10 kb) into the genome of many strains of mice. 
In summary, endogenous rodent brain tumor models that recapitulate the genetic 
aberrations found in human GBM are very useful for the study of gliomagenesis; however, 
their variable tumor formation rate and long latency limits their use for testing preclinical 
treatments. Nevertheless, the use of imaging techniques to confirm tumor formation before 
the treatment would allow rigorous evaluation of novel therapies in these models, which 
resemble hystologically and genetically the human disease. 
2.3 Other models 
Dogs bearing spontaneous GBM constitute a valuable tool in preclinical brain cancer 
research. GBM is the most common primary brain tumor in dogs, and brachycephalic breeds 
such as Boston terriers and Boxers (Heidner et al, 1991) are predisposed to develop 
spontaneous GBM (Stoica et al, 2004). Dog GBM exhibits the same histopathological 
characteristics of the human disease, including necrosis with pseudopalizading, 
neovascularization and endothelial proliferation. The presence of pseudopalisading 
necroses and endothelial proliferation that closely resemble those found in human GBMs 
suggest the presence of a hypoxic environment in dog GBM, as described in human patients 
(Rong et al, 2006). Importantly, canine GBM is highly invasive and exhibits the classical 
patterns of human GBM invasion, which makes it a very valuable tool to test not only the 
efficacy of novel therapies, but also their toxicity to the normal brain. The large size of the 
dog brain would be useful for preclinical assessment of doses and volumes in order to 
optimize treatment protocols before the translation into the clinic. Also, the detection of 
therapy-induced toxicity and side effects, as well as behavioral abnormalities are technically 
very well developed in dogs and constitutes a routine assessment in clinical veterinary 
practice. Moreover, the individual variability of outbreed dogs could help to better predict 
the clinical outcomes in human patients. Clinical signs and prognosis of dogs with 
spontaneous GBM are very similar to those in human, and there is a high correlation of 
neuro-imaging features seen with MRI in canine and human GBM, which is also used as a 
diagnostic tool for canine GBM (Lipsitz et al, 2003). The standard care of treatment in dogs 
with GBM is very similar to that used in human patients, consisting of surgical resection 
followed by radiation therapy and chemotherapy which leads to a median survival of 8.5-10 
months. This allows performing preclinical trials that will mimic more closely the clinical 
scenario, in which new therapies are applied in patients that simultaneously undergo 
traditional treatment. Candolfi and others have previously demonstrated the feasibility of 
delivering therapeutic transgenes to dog GBM cells in vitro and dog brain cells in vivo upon 
intracranial injection of gene therapy vectors, such as type 5 adenoviral vectors (Candolfi et 
al, 2007), adeno-associated viral vectors (Ciron et al, 2006), plasmid DNA/polyethylenimine 
(PEI) complexes (Oh et al, 2007), which suggests that dogs bearing spontaneous GBM would 
be a suitable model to test novel gene therapy approaches. Importantly, the availability of 
canine GBM J3T (Rainov et al, 2000) and W&W (Garcia-Escudero et al, 2008) cell lines allows 
in vitro screening of novel therapeutic agents before moving to preclinical trials in dogs 
bearing spontaneous GBM. Also, the characterization of cancer stem cells from a GBM in a 
Boxer has been recently reported (Stoica et al, 2009). These cells exhibit cancer stem markers 
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and have highly proliferative rate, and ability of self-renewal and differentiation. In vitro 
they form neurospheres and in vivo they growth intracranially in the brain of nude mice, 
forming GBMs that exhibit histopathological features of dog GBM. 
In summary, canine GBM emerges as an attractive animal model for testing novel therapies 
in a spontaneous tumor in the context of a large brain. The features of dog GBM make it a 
unique large animal model for preclinical cancer research with therapeutic outcomes which 
could better predict their efficacy in human trials. In spite of these attractive features, dogs 
are very expensive to treat and scarce, therefore the routine testing on novel therapeutics in 
these animals would be unfeasible. 
3. Application and future projection  
As a prelude to the implementation of gene therapy clinical trials for glioblastoma 
multiforme, it is critical to test potential novel therapies in relevant animal models of this 
disease. The ideal brain tumor model should exhibit predictable and reproducible 
intracranial growth patterns, have histopathological and biochemical resemblance to human 
GBMs and be nonimmunogenic. There are several models available in which it is feasible to 
study the efficacy and toxicity of different therapeutic approaches for this disease, i.e., anti-
angiogenic agents, proapoptotic molecules, immunotherapy, etc. these glioma models help 
unravel the biology of tumorigenesis and etiology of human central nervous system tumors. 
These mouse-modeling experiments may identify essential targets for therapy and provide 
test animals for preclinical trials of mechanistically designed therapeutics. 
4. Conclusion 
Main glioma animal models are murine implantation models traditionally, in this chapter, 9 
rat models are described in detail. The most widely used model C6 rat glioma arose in an 
outbred Wistar rat, is non-syngeneic. Since the tumor is immunogenic, even in Wistar rats, 
the C6 glioma is not suitable for study of immunotherapy. Syngeneic murine models, i.e. 
CNS-1 cells in Lewis rats, F98 and RG-2 cells in Fisher rats, GL26 cells in C57BL6 mice, 
SMA-560 cells in VMDK mice, are non-immunogenic, constituting an excellent tool. Human 
glioma xenografts implanted in immunocompromised mice have been extensively 
employed in preclinical brain cancer research. Although their xenogeneic nature impairs the 
study of immune-mediated anti-tumor strategies, they allow assessing the efficacy of 
therapeutic approaches in human GBM cells in the context of normal brain tissue. In fact, 
human xenografts exhibit histopatological features that resemble the human GBM and 
retain gene amplifications detected in the in situ tumors.  
Recently, transgenic technique and gene knock-out technique rapidly developed, new 
animal models of gliomas were created. Central nervous system–specific inactivation of the 
genes encoding the tumor suppressors p53 and Nf1 leads to the spontaneous onset of Grade 
II and III astrocytoma tumors, as well as to GBM tumors in mice. This gliomagenesis can be 
accelerated by haploinsufficiency of the PTEN gene, and in neural progenitor cells 
conditional inactivation of p53 coordinates with a haploinsufficiency of PTEN and Nf1 to 
induce tumor formation. p53, INK4a/ARF, PTEN, EGFR, PDGF are the most popular genes 
in glioma research. Viral vectors or plasmid systems are used to deliver oncogenes. By 
means of linking the gene of interest to a glial specific promoter such as GFAP, S100β, or 
Nestin, transgenic mice that display cell type-specific overexpression of oncogenes. When 
large animal models are necessary, dog glioma models are available for alternative.  
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 Tumorigenesis Method Technique Tumor Animal 
Implantation 9 L Gliosarcoma Syngeneic Graft GS Rat 
C6 Syngeneic Graft  GBM Rat 
T9 Syngeneic Graft  GS Rat 
RG2 Syngeneic Graft  GBM Rat 
F98 Syngeneic Graft  GBM Rat 
RT-2 Syngeneic Graft  GBM  Rat 
CNS-1 Syngeneic Graft  GBM  Rat 
GL261 Syngeneic Graft  GBM  Mouse 
Human Tumor Cells (U87, 
U251)  
Xenograft GBM Mouse 
Genetic p53 +/-, NF-1 +/-  Germline mutations Astro Mouse  
GFAP- p53 +/-, NF-1 +/- Conditional KO Astr o Mouse 
GFAP- p53 +/-, NF-1 +/-, 
PTEN-/-  
Conditional KO Astro  Mouse  
GFAP- p53 +/-, PTEN-/- Conditional KO Astro  Mouse 
INK4a/ARF -/-, PDGF 
Overexpression  
Germline mutation, RCAS Astro  Mouse  
INK4a/ARF -/-, EGF-R 
overexpression 
Germline mutation, RCAS Astro  Mouse 
INK4a/ARF -/-, Ras, Akt 
overexpression 
Germline mutation, RCAS Astro Mouse 
Ras, Akt overexpression RCAS Astro Mouse 
Ras, Akt overexpression, 
PTEN -/- 
RCAS, Conditional KO Astro Mouse 
GFAP-V12 Ras, EGFRvIII Astrocyte targeted mutation, Adenovirus Astro Mouse 
GFAP-V12 Ras, PTEN -/- 
 
Astrocyte targeted mutation,  
Germline mutation 
Astro Mouse 
RAS, EGF-R targeted 
overexpression 
Astrocyte targeted mutations Astro Mouse 
PDGF-B overexpression MMLV retrovirus  ODG Mouse 
PDGF-B overexpression RCAS ODG Mouse 
Rb inactivation, PTEN -/- GFAP-Cre targeted conditional KO ODG  
INK4a/ARF -/-, PDGF 
 overexp., PTEN -/- 
Germline mutation, RCAS,  
Conditional KO 
ODG Mouse 
P53 +/-, S100β promoter  
driven-v-erbB  
Germline mutation,  
Oligodendrocyte mutation 
ODG Mouse 
INK4a-ARF +/-, S100β  
promoter v-erbB 
Germline mutation,  
Oligodendrocyte mutation 
ODG Mouse 
p53 +/-, EGF-R  
overexpression 
Germline mutation,  
Oligodendrocyte mutation  
ODG Mouse 
Ptc +/- Germline mutation or Conditional KO  MB Mouse 
Ptc +/-, p53 -/- Germline mutations MB Mouse 
Shh, n-Myc RCAS  MB Mouse 
Rb +/-, p53 +/- GFAP-conditional KO  MB Mouse 
BRCA2 -/-, p53 +/- Nestin-conditional KO  MB Mouse 
Xrcc4 -/-, p53 -/- Nestin-conditional KO  MB Mouse 
SmoM2 GFAP-conditional KO MB   Mouse 
Abbreviations (GS-Gliosarcoma, GBM-glioblastoma multiforme, Astro-astrocytoma, ODG-
oligodendroglioma, MB-Medulloblastoma, KO-knockout) 
Table 2. A summary of existing animal models of brain tumors 
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1. Introduction 
In the field of glioma research, in vitro models are widely used to investigate tumor biology 
as well as tumor response to chemotherapy and radiation. There is an increasing need to 
improve these in vitro models in order to meet the new challenges arising in drug discovery. 
It is thus important that development of new drugs is based on the latest knowledge about 
glioma biology such as for example the recent discovery of tumor stem cells (Reya et al., 
2001). When investigating glioblastomas in vitro – and especially the supposed tumor stem 
cells – three dimensional multicellular spheroid models have recently come into focus.  
The aim of this chapter is to review the development as well as the most recent aspects of 
the three-dimensional glioma in vitro models focusing on glioma spheroids. The 
implementation of these models in current and in future in vitro glioma research will be 
discussed putting emphasis on the themes described below. 
Cell lines cultured as monolayers have been the in vitro model of choice for many years 
(Ponten & Macintyre, 1968). However, the three-dimensional aspect came into focus in the 
1970’s, where scientists started to grow tumor cells from cell lines as multicellular spheroids 
(Yuhas et al., 1977). Over the years the spheroid model has been improved by deriving 
spheroids from cells obtained from dissociated primary glioblastoma tissue (Mackillop et al., 
1985) as well as by using organotypic primary spheroids derived from small tumor 
fragments (Bjerkvig et al., 1990).  
In general, most in vitro studies are performed with cells cultured in conventional serum-
containing medium. Recently – as the tumor stem cell theory has evolved – the culturing 
medium has come into focus. It has thus been demonstrated that the use of serum-free 
medium for culturing of cell line-derived spheroids preserved the in vivo-like features as 
well as the tumor stem cell-like phenotype suggesting crucial importance of the use of 
serum-free medium in tumor stem cell research (Lee et al., 2006).  
Identification of the glioma stem cells is still a matter of discussion. The most used marker in 
the field has been the cell surface marker CD133. Expression of this putative tumor stem cell 
marker in gliomas has been studied in several papers demonstrating clusters or niches of 
CD133 positive tumor cells as well as CD133 positive single cells dispersed in the tumor 
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CD133 positive tumor cells as well as CD133 positive single cells dispersed in the tumor 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
374 
(Christensen et al., 2008; Hermansen et al., 2011). These important tumor stem cell niches are 
preserved in primary glioma spheroids in contrast to cell line spheroids (Christensen et al., 
2010).  
Another important aspect in culturing of glioma stem cells is hypoxia, since several studies 
have shown that hypoxia influences radiation resistance. This may be explained by effects of 
hypoxia in vitro on proliferation of the tumor cells, spheroid formation and expression of 
stem cell markers, suggesting that also this aspect should be taken into consideration 
(Heddleston et al., 2009; Kolenda et al., 2010; McCord et al., 2009; Soeda et al., 2009). 
Several studies have used the different types of spheroids mentioned above for investigating 
the effects of chemotherapy and radiation on the tumor cells and in particular on the tumor 
stem-like cells (Bao et al., 2006; Bauman et al., 1999; Fehlauer et al., 2005; Fehlauer et al., 
2006; Fehlauer et al., 2007; Genc et al., 2004; Gliemroth et al., 2003; Haas-Kogan et al., 1996; 
Johannessen et al., 2009; Kaaijk et al., 1997; Khaitan et al., 2009; Sunayama et al., 2010; Terzis 
et al., 1997; Terzis et al., 1998; Wakimoto et al., 2009; Wang et al., 2010). After such 
treatments cell viability and cell proliferation assays as well as secondary spheroid 
formation assays have been used to evaluate induced effects. Moreover, expression of 
apoptosis and proliferation markers and for example stem cell markers have been 
investigated immunohistochemically in paraffin embedded spheroids (Christensen et al., 
2010). The advantages using this panel of methods will be an important part of this chapter. 
High grade gliomas are known to be highly invasive and new knowledge concerning tumor 
cell invasion also incorporating the tumor stem cell aspect is urgently needed. In our 
laboratory we have worked to improve in vitro models when investigating the invasive 
features of gliomas. This led to establishment of an in vivo-like model of invasion, where 
spheroids are implanted into organotypic brain slice cultures. 
Taken together the three-dimensional multicellular spheroid model is the three dimensional 
model of choice for in vivo-like glioma in vitro studies. However, at the same time this 
model is under ongoing development to become an even more in vivo-like model in order 
to meet the new challenges of glioma research and drug development. The use of spheroids 
in especially tumor stem cell research has been fast increasing in recent years making 
spheroids an important tool also in future glioma research. 
2. Establishment and development of the spheroid model 
In the field of cancer research it is important to continuously develop in vitro models 
mimicking in vivo conditions as much as possible. By isolating cells from tumor tissue, 
tumor cell lines can be established from almost any kind of tumor including brain tumors 
such as glioblastomas. Glioblastoma cell lines are traditionally cultured as adherent 
monolayers but can also be cultured as single cell suspensions or spheroids. One of the most 
used cell lines in glioblastoma research is the cell line U87MG established by Pontén and 
Macintyre in 1968 (Ponten & Macintyre, 1968). This cell line was established from an 
astrocytic tumor with necrosis, which corresponds to this tumor being a glioblastoma 
multiforme according to WHO (World Health Organization) guidelines 2007 (Louis et al. 
2007). U87MG was originally established in a traditional serum containing medium and the 
cells were described as large, extremely bizarre and very slowly growing. Today U87MG 
can be described as having only limited pleomorphism as well as being fast growing, clearly 
indicating that such cell lines change over time. U87MG has been used in a variety of glioma 
studies and is still used. Since the cell line has been cultured in different laboratories for 
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over 40 years new genomic mutations have arisen capable of giving rise to different 
phenotypic subpopulations in different laboratories. It is also well known that the 
phenotypic characteristics and genetic aberrations found within in vitro cells passaged 
repeatedly for about 10 times in serum containing medium often show only little 
resemblance with the original primary tumor (Lee et al., 2006). It is therefore not surprising 
that the U87MG cell line is known to have a highly aberrant genomic structure as visualized 
by karyotyping (Galli et al., 2004). Galli et al. (Galli et al., 2004) demonstrated loss of 
chromosome 1, 9, 10, 11, 12, 13, 14, 16, 19, 20, 22 and X. Furthermore, 11 unidentified 
abnormal chromosomes were found, whereas no gains of chromosomes were seen. In 
addition to this, Clark et al (Clark et al., 2010) have sequenced the genome of U87MG in 
order to further characterize it. They identified 35 interchromosomal translocation events, 
1,315 structural variations (>100 bp), 191,743 small (< 21 bp) insertions and deletions as well 
as 2,384,470 single nucleotide variations. Protein coding sequences were disrupted 
predominantly by small insertions and deletions as well as larger deletions and 
translocations and 512 genes were homozygously mutated. Surprisingly, the study by Clark 
et al. also indicated that although this U87MG cell line has been cultured for more than 40 
years, the cell line has now been relatively stable for years and is not rapidly changing 
anymore. This relative stability could be an advantage when using the U87MG cell line. In 
addition, the use of this cell line for four decades has resulted in a very well characterized 
cell line. 
In general, there are many advantages when using cell lines. When first established, they are 
easy to handle in the laboratory and a large number of cells can be obtained in a short 
period of time, making it feasible to conduct large scale studies. In addition, cell lines are 
relatively easy to manipulate genetically by transfection and knock-down etc. establishing 
subpopulations with specific gene expression. These cell lines are important tools in the field 
of basic research investigating cellular pathways involved in tumor biology and response to 
different drugs. In addition to the obvious advantages, there will always be challenges when 
working with cell lines. As mentioned above, tumor cell lines are very likely to acquire new 
mutations and chromosome damage when undergoing cell division, because of the unstable 
genome in the tumor cells. The longer cultures are maintained and passaged the more 
changes accumulate (Lee et al., 2006) leading to changes in tumor cell behaviour. This is one 
of the main problems by culturing cell lines for many years. There will always be a 
possibility that the cells further mutate and several subpopulations will arise. This is 
important to keep in mind, when comparing results obtained with the same commercial cell 
line but in different laboratories at different time points.  
Another obstacle to overcome when using cell lines is the heterogeneity seen in tumors like 
glioblastomas. It is not possible to maintain the high degree of heterogeneity in long term 
cell cultures. In order to improve models using cell lines, short term cultures prepared from 
fresh tumor biopsies can be an alternative (Kolenda et al., 2010; Potter et al., 2009). The use 
of short term cultures may reduce differences between the tumor of origin and the cultured 
cells. In a study by Potter et al. (Potter et al., 2009) short term cultures from 6 pediatric 
pilocytic astrocytomas and 3 adult glioblastomas were established and cultured in 
conventional medium containing fetal calf serum. Gene expression profiles of the derived 
short term cell cultures harvested below passage 8 and their respective original biopsies 
were performed. They demonstrated that although short term cultures more resemble in 
situ gliomas than homogenous long term cultures, significant changes in gene expression 
were found between the biopsies and the derived short term cultures. The most significant 
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functions differing for the glioblastomas were associated with cell structure, shape, motility, 
proliferation, cellular development, cell death, cellular assembly and organization, cell-to-
cell signaling and interaction, as well as cell cycle. 
As our knowledge of tumor cells expands, there is a need to establish more advanced 
models to mimic the tumor in situ. One of the main problems is the fact, that the cells are 
removed from their natural environment, dissociated and cultured as single cells. It may 
therefore be important to prevent this in order to be able to mimic the natural environment 
as much as possible. Moreover in the recent years, the use of serum containing cell culturing 
medium has come into focus. The composition of serum has not been fully understood for 
many years, but it is known that it supplies the cells with nutrients, vitamins, hormones, 
and growth-, differentiation-, and attachment-factors. These factors may affect the cells in 
ways we are not fully aware of. It is also well known that there are differences between 
batches of serum (Fisher & Wieser, 1983). Another important issue is the fact that only a 
small fraction of cells in the organism is in direct contact with serum. This may be a problem 
in glioma research, since the brain and brain tumor tissues are not among these cells. In this 
context, it is also worth highlighting that neural stem cells should be cultured under serum-
free conditions similar to what has been found for the so called glioblastoma tumor stem 
cells.  
The three-dimensional glioma spheroid model came into focus in the 1970’s, where scientists 
started to grow tumor cells as multicellular spheroids using tumor cells from conventional 
monolayer cultures (Yuhas et al., 1977). Such spheroids are usually formed by aggregation 
of cells growing into the larger three-dimensional spheroids. They are believed to be a better 
model than monolayer cultures due to a three-dimensional structure with more in vivo-like 
intercellular contacts. This model was later on further improved by deriving spheroids from 
single cells obtained from dissociated primary glioblastoma tissue (Mackillop et al., 1985). In 
order to obtain an even more in vivo-like model the primary organotypic spheroids were 
introduced (Bjerkvig et al., 1990). Organotypic means that the properties characteristic of the 
tissue of origin is maintained. These spheroids are derived from freshly removed glioma 
tissue and have been shown to be a valid tumor model providing a biological system that 
mimics the original glioma in vivo.  
When deriving primary spheroids from glioma biopsies, it is important to process the tumor 
tissue as soon as it is removed. As we have published earlier (Christensen et al., 2010) the 
glioma tissue should be collected directly in the operation theatre, where the tissue is placed 
in a tube with Hanks’ Balanced Salt Solution supplemented with 0.9 % glucose and 
transported to the laboratory. The tumor tissue can then be processed according to the study 
by Bjerkvig et al. (Bjerkvig et al., 1990), where small tumor fragments of approximately 200-
400 µm in diameter are obtained after sectioning the tumor tissue manually using scalpels. 
These fragments are then transferred to 0.75% agar-coated culture flasks of 75 cm2 with pre-
warmed medium. The cultures should be kept in a standard tissue culture incubator (95% 
humidity, 95% air, and 5% CO2) and the following day the culturing medium should be 
changed in order to remove dead blood cells and cellular debris. The tumor fragments 
should then be examined under a light microscope every day, until they round up to form 
spheroids within 5-15 days.  
The main advantages by primary organotypic spheroids are the preservation of the original 
intercellular contacts and the tumor heterogeneity. However, because of this heterogeneity it 
is important to include a larger number of spheroids in in vitro studies using primary 
spheroids in order to obtain reproducible results. In a study by Bjerkvig et al., (Bjerkvig et 
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al., 1990) it was shown that when culturing small tumor fragments from astrocytic brain 
tumors of increasing grade, small primary spheroids were formed for the majority of the 
tumors within 3-5 days. The spheroids were analyzed by light microscopy as well as 
transmission- and scanning electron microscopy (TEM and SEM, respectively) after 3 and 10 
weeks of culture, showing the unique preservation of cell- to cell interaction, blood vessels, 
extracellular matrix, and macrophages. It was moreover demonstrated that the primary 
spheroids could be cultured for 70 days with preservation of the histology of the spheroids. 
In a similar study in our laboratory, glioma tissue was collected from 11 patients. The tissue 
pieces from 7 of these patients formed vital spheroids within a week. Thereafter, the 
spheroids were fixed, paraffin embedded and investigated immunohistochemically as 
described later in this chapter. Areas of necrosis were seen in some of the spheroids, 
whereas blood vessels were present in the majority of the glioma-derived spheroids.  
 
 
Fig. 1. Adherent monolayer cells and free floating spheroids. U87MG grows as an adherent 
monolayer when the cells are cultured in serum containing medium (A). However, in 
serum-free medium U87MG grows as spheroids (B). Tissue derived from freshly removed 
glioblastoma (C) and cells from a glioblastoma short term culture (D) also grow as spheroids 
when cultured in a serum-free medium. The organotypic spheroids (C) can be grown in 
serum containing medium as well and preserves in both media some of the characteristics 
found in the primary tumor such as tumor necrosis and blood vessels, whereas the short 
term culture spheroid in (D) has lost these characteristics.  
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term culture spheroid in (D) has lost these characteristics.  
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1. Collect tissue and transport the freshly removed tumor tissue in Hanks’ Balanced Salt 
Solution supplemented with 0.9% glucose  
2. Place the tissue in a sterile petri dish  
3. Section the tumor tissue manually using two scalpels until tumor fragments  
of 50-400 µm in diameter are obtained 
4. Culture fragments in 0.75% agar coated culture flasks containing 20 ml medium 
5. Incubate the cultures in 36°C humidified air containing 5% CO2 and 95% atmospheric 
air  
6. Change the medium the next day 
7. Change the medium twice a week in 10-15 days until the fragments round up and 
form spheroids 
Box 1. Preparation of organotypic primary spheroids 
3. The tumor stem cell paradigm and the spheroid model 
The tumor stem cell paradigm proposes that only a small subset of cells – the so-called 
tumor stem cells - within the tumor cell population is able to initiate and sustain tumor 
growth (Ward & Dirks, 2007). These tumor stem cells have been found in a variety of 
different cancers such as leukaemia (Bonnet & Dick, 1997), colon cancer (Daidone et al., 
2004), breast cancer (Al-Hajj et al., 2003) and brain cancer (Singh et al., 2004). With the 
discovery of the neural stem cells (Reynolds & Weiss, 1992) it also became plausible that 
brain tumors could be derived from the transformation of neural stem cells or progenitor 
cells (Singh et al., 2004). The neural stem cells were first isolated by Reynolds and Weiss in 
1992 (Reynolds & Weiss, 1992). They found a small population of cells isolated from the 
adult striatum in mouse brain that were able to proliferate and differentiate. They cultured 
these cells in a serum-free environment supplemented with the growth factors EGF 
(epidermal growth factor) and bFGF (basic fibroblast growth factor), and the cells grew as 
neurospheres. When dissociating the neurospheres and re-plating them as single cells new 
neurospheres developed. Under these serum-free conditions most differentiating and 
differentiated cells died, whereas the neural stem cells responded to the growth factors and 
proliferated to form neurospheres (Vescovi et al., 2006). By applying the same conditions to 
human glioblastoma cells, it was possible to isolate a population of cells that formed 
tumorspheres. These cells were capable of differentiation and self-renewal (Galli et al., 2004; 
Ignatova et al., 2002; Lee et al., 2006; Singh et al., 2003). Furthermore, the cells from the 
tumorspheres gave rise to tumors resembling the primary tumor when injected into the 
brains of immunodeficient mice, suggesting that a population of the cells isolated were brain 
tumor-initiating stem-like cells. 
When culturing putative tumor stem cells, spheroid models are often used. Especially the 
clonogenic neurosphere assay is used for preserving tumor stem-like cells in serum-free 
medium (Lee et al., 2006). In this assay, primary human brain tumor tissue form spheroids 
after repeated dissociation into single cells. However, cell-to-cell interactions are interrupted 
and this might affect experimental results obtained with the tumor stem cell line-derived 
spheroids. This could be particularly important in tumor stem cell research, since the 
suggested close relationship between brain tumor stem cells and adjacent endothelial cells 
(Bao et al., 2006; Calabrese et al., 2007) is lost in these spheroids. In addition, the culturing 
medium has come into focus when performing studies focusing on tumor stem cells. As 
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mentioned earlier, normal neural stem cells are cultured under serum-free conditions, since 
it is well known that serum causes irreversible differentiation of neural stem cells (Gage et 
al., 1995). Lee et al. (Lee et al., 2006) cultured glioblastoma short term cultures in a serum-
free medium similar to the medium used for culturing neural stem cells in order to preserve 
and select for tumor stem-like cells. This serum-free medium consisted of neurobasal 
medium supplemented with EGF and bFGF, because EGF and bFGF earlier seemed to select 
for tumor stem-like cells by inducing proliferation of multipotent, self-renewing, and 
expandable tumor stem cells (Galli et al., 2004; Ignatova et al., 2002; Lee et al., 2006). In the 
study by Lee et al., (Lee et al., 2006) dissociated glioblastoma cells, cultured as short term 
cultures, formed spheroids expressing putative tumor stem cell markers but when culturing 
the selected cells in serum containing medium, they irreversibly differentiated into neural 
and glial cell lineages. Interestingly, this is in line with the irreversible differentiation of 
neural stem cells under the same conditions (Gage et al., 1995).  
In the search for improvement of in vitro models we performed a study in our laboratory 
(Christensen et al., 2010), where organotypic primary spheroids were cultured in serum-free 
medium. In terms of the tumor stem cell concept, culturing of these organotypic primary 
spheroids in serum-free conditions may be closer to the in vivo situation than using tumor 
stem cell line-derived spheroids, especially regarding studies of radiation and chemo-
sensitivity. We investigated the influence of serum-containing medium and serum-free 
medium on the phenotype of primary glioma spheroids. The aim was to elucidate whether 
serum-free medium also favors the presence of tumor cells expressing stem cell markers in 
these spheroids, when investigated immunohistochemically. The results based on seven 
malignant astrocytomas WHO Grade III–IV, supported the hypothesis that putative brain 
tumor stem cells are better preserved in serum-free culture medium with EGF and bFGF. 
When comparing spheroids from both media, we found increased CD133 expression when 
culturing primary glioma spheroids in serum-free medium compared to serum-containing 
medium, which is in line with the study by Lee et al. (Lee et al., 2006) using short term 
cultures. In contrast to Lee, who found a drastic decrease in Sox2, Bmi-1, and Nestin when 
culturing short term cultures in serum, we only found a slightly decreased expression of 
Sox2, whereas Bmi-1 and Nestin were equally expressed in both media. This better 
preservation of stem cell marker expression in serum-containing medium in primary glioma 
spheroids (Christensen et al., 2010) may be explained by primary spheroids preserving an 
intact microenvironment, whereas Lee et al. (Lee et al., 2006) repeatedly dissociated the 
spheroids. Another interesting observation was that primary glioma spheroids cultured in 
serum-free medium contained more blood vessels than in serum-containing medium, and 
furthermore, many blood vessels were hyperplastic. The immunohistochemical comparison 
showed more CD34 and VWF, but less CD31 in serum-free medium compared to serum-
containing medium. This increase was accompanied with more CD133 positive cells, thus 
suggesting that the close relationship between blood vessels and tumor stem-like cells may 
be better preserved in serum-free medium. 
As it is clear from the tumor stem cell research field, markers specific for tumor stem cells 
are of crucial importance. This has resulted in the development of a great number of 
antibodies against tumor stem cell-related proteins. Some of the most important markers in 
the field of brain tumors have been (table 1) CD133 (Bandopadhyay et al. 2010; Bidlingmaier 
et al., 2008; Christensen et al., 2008; Dell'albani, 2008; Fargeas et al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et al., 2008; Pfenninger et al., 2007; Wang et al., 2008; Zeppernick et 
al., 2008), A2B5 (Balik et al., 2009; Merzak et al., 1994; Ogden et al., 2008; Piepmeier et al., 
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mentioned earlier, normal neural stem cells are cultured under serum-free conditions, since 
it is well known that serum causes irreversible differentiation of neural stem cells (Gage et 
al., 1995). Lee et al. (Lee et al., 2006) cultured glioblastoma short term cultures in a serum-
free medium similar to the medium used for culturing neural stem cells in order to preserve 
and select for tumor stem-like cells. This serum-free medium consisted of neurobasal 
medium supplemented with EGF and bFGF, because EGF and bFGF earlier seemed to select 
for tumor stem-like cells by inducing proliferation of multipotent, self-renewing, and 
expandable tumor stem cells (Galli et al., 2004; Ignatova et al., 2002; Lee et al., 2006). In the 
study by Lee et al., (Lee et al., 2006) dissociated glioblastoma cells, cultured as short term 
cultures, formed spheroids expressing putative tumor stem cell markers but when culturing 
the selected cells in serum containing medium, they irreversibly differentiated into neural 
and glial cell lineages. Interestingly, this is in line with the irreversible differentiation of 
neural stem cells under the same conditions (Gage et al., 1995).  
In the search for improvement of in vitro models we performed a study in our laboratory 
(Christensen et al., 2010), where organotypic primary spheroids were cultured in serum-free 
medium. In terms of the tumor stem cell concept, culturing of these organotypic primary 
spheroids in serum-free conditions may be closer to the in vivo situation than using tumor 
stem cell line-derived spheroids, especially regarding studies of radiation and chemo-
sensitivity. We investigated the influence of serum-containing medium and serum-free 
medium on the phenotype of primary glioma spheroids. The aim was to elucidate whether 
serum-free medium also favors the presence of tumor cells expressing stem cell markers in 
these spheroids, when investigated immunohistochemically. The results based on seven 
malignant astrocytomas WHO Grade III–IV, supported the hypothesis that putative brain 
tumor stem cells are better preserved in serum-free culture medium with EGF and bFGF. 
When comparing spheroids from both media, we found increased CD133 expression when 
culturing primary glioma spheroids in serum-free medium compared to serum-containing 
medium, which is in line with the study by Lee et al. (Lee et al., 2006) using short term 
cultures. In contrast to Lee, who found a drastic decrease in Sox2, Bmi-1, and Nestin when 
culturing short term cultures in serum, we only found a slightly decreased expression of 
Sox2, whereas Bmi-1 and Nestin were equally expressed in both media. This better 
preservation of stem cell marker expression in serum-containing medium in primary glioma 
spheroids (Christensen et al., 2010) may be explained by primary spheroids preserving an 
intact microenvironment, whereas Lee et al. (Lee et al., 2006) repeatedly dissociated the 
spheroids. Another interesting observation was that primary glioma spheroids cultured in 
serum-free medium contained more blood vessels than in serum-containing medium, and 
furthermore, many blood vessels were hyperplastic. The immunohistochemical comparison 
showed more CD34 and VWF, but less CD31 in serum-free medium compared to serum-
containing medium. This increase was accompanied with more CD133 positive cells, thus 
suggesting that the close relationship between blood vessels and tumor stem-like cells may 
be better preserved in serum-free medium. 
As it is clear from the tumor stem cell research field, markers specific for tumor stem cells 
are of crucial importance. This has resulted in the development of a great number of 
antibodies against tumor stem cell-related proteins. Some of the most important markers in 
the field of brain tumors have been (table 1) CD133 (Bandopadhyay et al. 2010; Bidlingmaier 
et al., 2008; Christensen et al., 2008; Dell'albani, 2008; Fargeas et al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et al., 2008; Pfenninger et al., 2007; Wang et al., 2008; Zeppernick et 
al., 2008), A2B5 (Balik et al., 2009; Merzak et al., 1994; Ogden et al., 2008; Piepmeier et al., 
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1993; Tchoghandjian et al., 2009), Podoplanin (Goodman et al. 2009; Grau et al., 2008; 
Mishima et al., 2006; Nakamura et al., 2006; Ogasawara et al., 2008; Ordonez, 2006; 
Shibahara et al., 2006), Nestin (Dahlstrand et al., 1992a; Dahlstrand et al., 1992b; Dell'albani, 
2008; Ehrmann et al., 2005; Ma et al., 2008; Maderna et al., 2007; Strojnik et al., 2007; Wan et 
al., 2011), Mushashi-1 (Kanemura et al., 2001; Ma et al., 2008; Okano et al., 2005; Sakakibara 
& Okano, 1997; Thon et al., 2010; Toda et al., 2001), Bmi-1 (Bruggeman et al., 2007; Hayry et 
al., 2008; Park et al., 2004; Zencak et al., 2005) and Sox2 (Gangemi et al., 2009; Ma et al., 2008; 
Phi et al., 2008) and new upcoming markers such as ID1 (Kamalian et al., 2008; Maw et al., 
2009; Nam & Benezra, 2009; Schindl et al., 2001; Schindl et al., 2003; Schoppmann et al., 2003; 
Tang et al., 2009), NG2 (Brekke et al., 2006; Chekenya et al., 1999; Chekenya et al., 2002a; 
Chekenya et al., 2002b; Chekenya et al., 2008; Chekenya & Immervoll, 2007; Chekenya & 
Pilkington, 2002; Joo et al., 2008; Petrovici et al., 2010; Stallcup & Huang, 2008) and CD15 
(Capela & Temple, 2002; Capela & Temple, 2006; Read et al., 2009; Ward et al., 2009). Until 
now, the most widely used marker in brain tumors has been CD133 (Bidlingmaier et al., 
2008; Christensen et al., 2008; Dell'albani, 2008; Fargeas et al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et al., 2008; Pfenninger et al., 2007; Wang et al., 2008; Zeppernick et 
al., 2008).  
 
Markers Short introduction  References 
CD133 CD133 is a cell membrane glycoprotein with 
five transmembrane domains. CD133 has been 
found in a variety of non-pathogen human 
tissues including the brain. However, the 
function remains unknown. It was identified 
as a marker of hematopoietic stem cells in 1997 
and later as a marker of human neural stem 
cells. Since 2004, CD133 has been widely used 
for identifying tumor stem cells in brain 
tumors. However, some results suggest that 
CD133 is not specific for tumor stem cells. 
Downregulation of CD133 in glioma cell lines 
has been suggested to influence migration, 
spheroid formation and resistance to 
chemotherapeutics. 
Bandopadhyay et al. 2010; 
Bidlingmaier et al., 2008; 
Christensen et al., 2008; 
Dell'albani, 2008; Fargeas et 
al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et 
al., 2008; Pfenninger et al., 
2007; Wang et al., 2008; 
Zeppernick et al., 2008 
A2B5 A2B5 is a cell surface ganglioside found on 
white matter progenitors of the 
oligodendrocyte lineage. A2B5 has been found 
in gliomas in a population of cells, which are 
distinct from the CD133+ population but have 
the capacity to initiate tumors. A2B5 might be 
involved in glioma cell invasion in vitro, 
probably because of adhesion of the molecule 
to basement membrane components. 
Balik et al., 2009; Merzak et 
al., 1994; Ogden et al., 2008; 
Piepmeier et al., 1993; 
Tchoghandjian et al., 2009 
Podoplanin Podoplanin is a mucin-type transmembrane 
glycoprotein found in several normal tissues 
but not in mature astrocytes, oligodendrocytes 
Goodman et al. 2009; Grau et 
al., 2008; Mishima et al., 
2006; Nakamura et al., 2006; 
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Markers Short introduction  References 
or neurons. A high expression of Podoplanin 
has been found in high grade astrocytomas. 
However, no protein has been detected in 
diffuse astrocytomas or in normal brain tissue. 
Podoplanin has been suggested to be 
expressed in human glioma stem cells. This 
podoplanin positive cell population formed 
neurospheres in vitro and tumors in vivo. 
Moreover, these cells showed increased 
resistance to radiation.  
Ogasawara et al., 2008; 
Ordonez, 2006; Shibahara et 
al., 2006 
Nestin Nestin is a protein belonging to the class VI of 
intermediate filaments and it appears after 
neurulation in the CNS stem cells. In the 
normal adult brain, nestin is only expressed in 
the neural stem cells lining the ventricular wall 
and the central canal. It is believed to be a 
marker of proliferating and migrating cells. 
Nestin has been found in several tumor types 
including gliomas. The expression of nestin 
may be related to a dedifferentiated tumor 
stem cell status, enhanced cell motility, 
invasive potential and increased malignancy.  
Dahlstrand et al., 1992a; 
Dahlstrand et al., 1992b; 
Dell'albani, 2008; Ehrmann et 
al., 2005; Ma et al., 2008; 
Maderna et al., 2007; Strojnik 
et al., 2007; Wan et al., 2011 
Musashi-1 Musashi-1 belongs to a family of evolutionary 
well conserved neural RNA-binding proteins. 
Musashi-1 is found in neural stem cells and 
progenitor cells in the adult human brain and 
plays important roles in cell fate decision, 
including the maintenance of the stem cell 
state, differentiation, and tumorigenesis. 
Musashi-1 has been found in a variety of 
tumors including gliomas.  
Kanemura et al., 2001; Ma et 
al., 2008; Okano et al., 2005; 
Sakakibara & Okano, 1997; 
Thon et al., 2010; Toda et al., 
2001 
Bmi-1 Bmi-1 (B lymphoma Mo-MLV insertion region) 
is a Polycomb group transcription repressor, 
thought to be essential for self-renewal of 
neural stem cells and maintenance of the stem 
cell population by preventing premature 
senescence. Bmi-1 is found mainly around the 
ventricles in the subventricular zone and in 
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Bidlingmaier et al., 2008; 
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Dell'albani, 2008; Fargeas et 
al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et 
al., 2008; Pfenninger et al., 
2007; Wang et al., 2008; 
Zeppernick et al., 2008 
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oligodendrocyte lineage. A2B5 has been found 
in gliomas in a population of cells, which are 
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Balik et al., 2009; Merzak et 
al., 1994; Ogden et al., 2008; 
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Tchoghandjian et al., 2009 
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al., 2005; Ma et al., 2008; 
Maderna et al., 2007; Strojnik 
et al., 2007; Wan et al., 2011 
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al., 2008; Okano et al., 2005; 
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Markers Short introduction  References 
neuronal stem cell fate. It is found in the 
ventricular and sub-ventricular zone in fetal 
brains, but only in the ependymal cells in the 
human adult brain. It has been found to be 
highly expressed in glioblastoma cells 
compared to normal human brain and is 
believed to be involved in proliferation and 
tumorigenesis. 
ID1 ID1 (inhibitor of DNA binding 1) belongs to a 
class of transcription factors known as helix-
loop-helix (HLH) proteins. The Id gene family 
is involved in regulation of cell-cycle status 
and differentiation during embryogenesis and 
has been found in a rare type of neural stem 
cells, the B1 type, where it is necessary for self-
renewal. Expression of Id proteins has been 
demonstrated in a variety of human tumors 
including gliomas and has been investigated as 
a potential proto-oncogene. Overexpression of 
Id1 in human tumor cells induces cell 
proliferation and invasion, and also protects 
cells against drug-induced apoptosis. 
Kamalian et al., 2008; Maw et 
al., 2009; Nam & Benezra, 
2009; Schindl et al., 2001; 
Schindl et al., 2003; 
Schoppmann et al., 2003; 
Tang et al., 2009 
NG2 NG2 is a transmembrane proteoglycan that 
interacts with the ECM to mediate cell 
adhesion and proliferation. It is expressed on 
oligodendrocyte precursor cells in the adult 
CNS. It has been found in human acute 
myeloid leukemia and in gliomas, where it in 
the latter seems to increase tumor cell 
proliferation in vitro and promote 
angiogenesis in vivo.  
Brekke et al., 2006; Chekenya 
et al., 1999; Chekenya et al., 
2002a; Chekenya et al., 
2002b; Chekenya et al., 2008; 
Chekenya & Immervoll, 
2007; Chekenya & 
Pilkington, 2002; Joo et al., 
2008; Petrovici et al., 2010; 
Stallcup & Huang, 2008 
CD15 CD15 (leukocyte cluster of differentiation 15) 
also known as LeX or stage-specific embryonic 
antigen 1, SSEA-1, is an extracellular matrix-
associated carbohydrate. CD15 is secreted by 
neural progenitor cells including stem cells 
into the stem cell niche, where it binds factors 
such as WNT-1 that are important for 
progenitor proliferation and self-renewal. It is 
highly expressed on pluripotent stem cells and 
has been found in CNS germinal zones. It has 
been found in various normal tissues but also 
in different cancers including gliomas. 
Capela & Temple, 2002; 
Capela & Temple, 2006; Read 
et al., 2009; Ward et al., 2009 
Table 1. Some of the most used stem cell markers in the field of brain tumors.  
 




Fig. 2. Spheroids derived from a glioblastoma short term culture were stained 
immunohistochemically with a panel of stem cell markers. After culturing, the spheroids 
were formalin fixed, paraffin embedded and sectioned in 3 µm thin sections followed by 
immunohistochemical staining. The section in (A) was stained with hematoxylin and eosin 
(HE) which is widely used in histology to identify cell nucleus and cytoplasm. Moreover, 
sections were immunohistochemically stained with the stem or tumor stem cell markers 
CD133 (B), Podoplanin (C), Nestin (D), Bmi-1 (E) and Sox2 (F).  
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CD133 was initially identified as a marker of hematopoietic stem cells in 1997 (Miraglia et 
al., 1997; Yin et al., 1997) and later as a marker of human neural stem cells (Uchida et al., 
2000). In 2003 a CD133+ subpopulation of cells with stem cell properties were isolated from 
medulloblastomas and pilocytic astrocytomas by flow cytometry (Singh et al., 2003). The 
isolated CD133+ cells formed primary neurospheres in vitro, whereas the CD133- cells did 
not. As previously mentioned, the sphere forming capability is believed to be a stem cell 
hallmark. In 2004 the same group isolated CD133+ subpopulations from medulloblastomas 
and glioblastomas and showed that they also exhibited stem cell properties in vivo. The 
CD133+ population could initiate phenotypically similar tumors, when injected 
intracranially into NOD/SCID mice in numbers as few as 100 CD133+ cells. This was not the 
case for CD133- cells, where up to 100,000 cells could not initiate new tumor formation 
(Singh et al., 2004). Although these results had a great impact on the field of glioma 
research, it should be mentioned that today controversies exist in this area. An important 
paper contributing to this controversy was a paper showing that also CD133- cells were 
tumorigenic and could give rise to CD133+ cells (Wang et al., 2008).  
In accordance with the general idea of neural stem cells residing in discrete stem cell niches 
in the adult subventricular zone (Riquelme et al., 2008; Zhu et al., 2005), we have found 
CD133+ cells in this particular zone (Hermansen et al., 2011). In line with this, 
immunohistochemical studies performed by different groups (Calabrese et al., 2007; Thon et 
al., 2010; Zeppernick et al., 2008) including our group (Christensen et al., 2008; Hermansen 
et al., 2011) have shown that CD133 is located in clusters or niches in brain tumors, some of 
which are perivascular. The size of the niches varies from large positive areas to small 
perivascular niches comprising only a few cells. Several studies, including studies from our 
group (Christensen et al., 2008; Hermansen et al., 2011; Immervoll et al., 2008) have, 
however, also reported a widespread CD133 expression pattern in areas of various normal 
tissues, which is not normally associated with stem cells. This suggests that CD133 is not 
specific for stem cells and should be used in combination with other stem or progenitor cell 
markers to isolate tumor stem cells. 
4. Hypoxia and tumor stem cells 
Several studies associate tumor hypoxia with poor patient outcome and resistance to 
therapies (Bar, 2011; Li et al., 2009; Mashiko et al., 2011). In line with this, one of the 
hallmarks of glioblastomas is the presence of necrosis, occurring as a consequence of poor 
oxygenation and nutrition because of rapid tumor growth and formation of vessel 
thrombosis (Hulleman & Helin, 2005; Louis et al., 2007; Preusser et al., 2006). The hypoxia-
inducible factors (HIFs) are transcription factors upregulated at low oxygen levels. These 
factors mediate the cellular hypoxia response influencing angiogenesis, cell survival, 
chemotherapy and radiation resistance, invasion and metastasis (Bar, 2011).  
Usually culturing of cells is performed at 21 % O2, but with the knowledge that the 
physiological oxygen concentration in the healthy brain ranges between 2.5 % and 12.5 % O2 
and in glioblastomas is even lower (Bar, 2011), it is worth considering culturing cells at 
lower oxygen concentrations. Spheroids of large sizes become hypoxic even if cultured in 
normoxia because of a diffusion gradient. However, a study by Glicklis et al. (Glicklis et al., 
2004) has described that hepatocyte spheroids with diameters up to 100 μm have a good 
oxygenation status. Other studies by Fehlauer et al. (Fehlauer et al., 2005; Fehlauer et al., 
2006; Fehlauer et al., 2007) have reported that by using glioma spheroids with diameters of 
200-250 μm, there are only few hypoxic cells and no central necrosis present. 
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Low oxygen levels in different tumor types are believed to increase the population of tumor 
stem cells and to promote a stem-like state (Bar et al., 2010; Heddleston et al., 2009; Saigusa 
et al., 2011; Soeda et al., 2009; Wang et al., 2011; Xing et al., 2011; Yeung et al., 2011). This is 
similar to results obtained for embryonic stem cells showing that low oxygen levels promote 
maintenance of pluripotent potential, and maintenance of the cells in an undifferentiated 
stem cell state (Ezashi et al., 2005; Heddleston et al., 2009). The existence of tumor stem cells 
has been suggested to be restricted to perivascular niches and hypoxic areas within the 
tumor (Heddleston et al., 2009) explaining the poor outcome and therapeutic resistance seen 
in these hypoxic tumors. In addition to obtaining a more in vivo like metabolic milieu when 
culturing cells in hypoxic conditions, hypoxia also seems to promote the existence and 
propagation of tumor stem cells (Heddleston et al., 2009; McCord et al., 2009; Seno et al., 
2009; Soeda et al., 2009). Several studies thus reported an increase in spheroid diameter, cell 
proliferation and number of spheroids (Heddleston et al., 2009; McCord et al., 2009; Soeda et 
al., 2009) when culturing spheroids in hypoxic compared to normoxic conditions. In a study 
from our group (Kolenda et al., 2010), spheroids obtained from a glioblastoma short term 
culture and the commercial glioblastoma cell line U87MG were cultured in both normoxia 
and hypoxia. Interestingly, a significant increase in the expression of the proposed stem cell 
markers CD133, Podoplanin and Bmi-1 was found in both types of spheroids when cultured 
in hypoxia. Furthermore, a study by Heddelston et al. (Heddleston et al., 2009) proposed 
that a phenotypic shift from non-stem to stem-like cells was obtained when culturing tumor 
cells in hypoxia. On the more mechanistic level, the spheroid formation in hypoxia has been 
shown to be affected by the hypoxia inducible factors as shown in studies by Li et al. (Li et 
al., 2009) and Méndez et al. (Mendez et al., 2010). Knockdown of HIF altered spheroid 
formation in glioma spheroids, resulting in smaller and fewer spheroids. Overall these 
findings suggest that culturing of cells in hypoxia as spheroids provides important in vivo-
like conditions that are optimal when studying the stem cell biology of brain tumors. 
5. Primary spheroids and radiotherapy 
In the last three decades radiotherapy has been the standard treatment or part of the 
standard treatment for newly diagnosed glioblastoma patients (Stupp et al., 2009) providing 
a significant survival benefit (Laperriere et al., 2002). However, due to resistance to the 
current treatment of a subset of cells, it remains palliative. Primary spheroids obtained from 
glioma tissue have for years been reported to be a useful model for investigating in vitro 
radiobiology due to the preserved cellular organization. Features existing in these spheroids 
such as cell-cell contact, variation in the cell cycle distribution, diffusion effects, altered 
metabolism and hypoxia may influence the outcome of treatment, contributing to a better 
resemblance of the in vivo situation than obtained with a monolayer model (Olive & 
Durand, 1994; Sutherland & Durand, 1972). One feature of particular importance in these 
spheroids is possibly the low oxygen status being partly responsible for the increased 
radioresistance of the spheroid tumor cells (Blazek et al., 2007; Hsieh et al., 2010; Sutherland, 
1998). Ionising radiation causes the formation of reactive oxygen species (ROS) (Brahme & 
Lind, 2010; 2008) and oxygen has therefore long been known to be a potent radiosensitizer 
(Vlashi et al., 2009). ROS causes damage to cellular components including DNA damage 
(Nishikawa, 2008) and are critical for irradiation-induced killing of tumor cells (Diehn et al., 
2009). However, there have also been reports of no evident correlation between hypoxia and 
radioresistance (Buffa et al., 2001; Gorlach & Acker, 1994; Sminia et al., 2003) A study by 
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Sminia et al. (Sminia et al., 2003) found that both hypoxic and well-oxygenated organotypic 
multicellular spheroids derived from glioblastoma specimens showed high resistance to 
irradiation.  
A study by Kaaijk et al. (Kaaijk et al., 1997) described the observation of only minor 
histological changes including a few shrunken nuclei, but no major histological damage in 
normoxic organotypic multicellular glioblastoma spheroids after a single dose of 50 Gy. This 
is in line with a study by Bauman et al. (Bauman et al., 1999), where C6 astrocytoma 
spheroids were implanted into a collagen type I gel. Following irradiation with 12 and 25 
Gy, neither the hypoxic core nor the rim of the spheroids experienced a significant increase 
in the fraction of apoptotic cells. Similar to this, U87MG monolayer cultures irradiated with 
8 and 20 Gy showed no considerable apoptosis five days after treatment and remained 
viable ten weeks after a 40 Gy dose was administered. However, in fact Kaaijk et al. 
reported that proliferation in three investigated organotypic multicellular spheroids was 
decreased 7-20 fold relative to untreated controls one week after hypofractionated radiation 
with a total of 40 Gy. Moreover, Fehlauer et al. (Fehlauer et al., 2005; Fehlauer et al., 2006) 
described in two studies a decrease in the percentage of MIB-1 positive proliferative cells in 
organotypic multicellular spheroids following irradiation with 20 Gy.  
It has also been suggested that tumor stem cells might show increased radioresistance 
compared to more differentiated cells (Bao et al., 2006; Phillips et al., 2006; Rich, 2007). Bao et 
al. (Bao et al., 2006) thus showed that CD133+ cells survived ionizing radiation better than 
CD133- cells and that the fraction of CD133+ cells was enriched in gliomas after radio-
therapy, suggesting that the CD133+ cellular population of gliomas is contributing to glioma 
radioresistance and could be the source of tumor repopulation after radiation. Liu et al. (Liu 
et al., 2006) investigated mRNA levels of various markers including BCRP1 (breast cancer 
resistance protein), MGMT (O-6-methylguanine-DNA methyltransferase), anti-apoptosis 
proteins and inhibitors of apoptosis protein families in CD133+ cells isolated by FACS. 
These markers are involved in treatment resistance and elevated mRNA levels were shown 
in CD133+ cells compared to CD133- cells. A significant degree of resistance towards 
chemotherapeutics such as temozolomide, carboplatin, paclitaxel and etoposide were 
demonstrated in the CD133+ cells (Liu et al., 2006). In line with these results Liu et al. 
showed enrichment of CD133+ cells in five recurrent gliomas when compared to the 
respective newly diagnosed tumors. Furthermore, results obtained in our laboratory have 
shown a much more pronounced reduction in the secondary spheroid formation capacity of 
irradiated spheroids derived from recently established glioma spheroids with stem cell 
characteristics compared to U87MG derived spheroids without these characteristics 
(Jakobsen et al. 2011). 
6. Spheroids and chemotherapy 
Besides irradiation and surgery, the treatment of glioblastomas consists of chemotherapy. 
Although the introduction of temozolomide as standard chemotherapeutic in 2005 (Stupp et 
al., 2005) has increased the overall patient survival, new and more efficient 
chemotherapeutics or targeted therapies are urgently needed. Here spheroids also have an 
important role to play. 
Investigations of the specific effects of chemotherapeutics and other drugs on glioma 
spheroids are often done by investigating the size and number of spheroids as well as the 
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viability and the proliferation of cells in the spheroids, including the ability of the cells to 
form secondary spheroid.  
Frequently used assays for measuring the viability of the cells after treatment is tetrazolium-
based cell proliferation assays. Several variations of this assay exists (XTT, MTT, MTS or 
WST-1) (Berridge et al., 2005), but all utilize the conversion of tetrazolium salts by active 
mitochondria into dark red formazan that can be monitored by absorbance measurements 
(Berridge et al., 2005). Usually these assays are used on adherent monolayer cultures, which 
consist of uniform cell populations. However, these assays have also been used on spheroids 
consisting of more heterogenous cell populations. In one study (Johannessen et al., 2009) the 
doxorubicin sensitivity was determined in high and low passage spheroids by a MTS-assay. 
This was done by placing one spheroid per well in a 96 well plate, measuring viability 
relative to size after incubation with doxorubicin for 96 hours. After the viability 
measurements, the spheroids were allowed to adhere to the bottom of the plastic plates 
resulting in cell migration from the spheroids. Immunostaining of the migratory cells were 
performed using the neural stem cell markers Nestin, Vimentin and Musashi-1. 
Another widely used assay is the lactate dehydrogenase assay (LDH-assay), measuring cell 
death. The LDH-assay indirectly measures plasma membrane damage, which is related to 
cell death. Due to membrane damage, LDH leaks to the culture medium, where it 
participates in the conversion of tetrazolium salts to formazan. The amount of formazan 
produced is directly proportional to the amount of LDH in the culture medium, which in 
turn is directly proportional to the number of dead or damaged cells (Korzeniewski & 
Callewaert, 1983). 
The size of spheroids after drug treatment has also been used as a measure of cell viability 
(Fehlauer et al., 2007; Johannessen et al., 2009; Khaitan et al., 2009; Yamaguchi et al., 2010). 
Khaitan et al. (Khaitan et al., 2009) investigated the effect of the glycolytic inhibitor 2-deoxy-
D-glucose on spheroids derived from a human glioma cell line by measuring the size of the 
spheroids after drug exposure. In a stem cell context, number and size of primary and 
secondary spheroids have also been widely used as measures of the self-renewal potential, 
which is one of the hallmarks of stem cells. Especially the traits that are attributable to tumor 
stem cells are of interest, as the tumor stem cell hypothesis states that the tumor stem cells 
need to be targeted specifically in order to improve cancer treatment. In the so called 
spheroid formation assays or clonogenic assays, the ability of the cells to form spheroids is 
investigated. In many studies (Sunayama et al., 2010; Wakimoto et al., 2009; Wang et al., 
2010; Zhu et al., 2010) this is primarily done after treatment of the cells, thereby 
investigating the effect of a given drug on the ability of the cells to self-renew. Different 
experimental setups have been employed using different cell densities, probably resulting in 
two different assays - one assay with high cell densities for evaluation of proliferation and 
another assay with small so-called clonal cell densities for evaluation of self-renewal or 
clonogenic capabilities of the cells. High cell densities often result in cell and spheroid fusion 
due to a high motility of the spheroids (Singec et al., 2006) and it is therefore not possible to 
investigate the self-renewal mechanism in this assay. A plating density of 20 cells/µl has 
been considered as clonal conditions in terms of neurosphere formation (Singec et al., 2006). 
In glioma studies cell densities ranging between 0.15 cells/µl to 300 cells/µl have been used 
(Kolenda et al., 2010; Sunayama et al., 2010; Wakimoto et al., 2009; Wang et al., 2010; Zhu et 
al., 2010) when studying spheroid formation.  
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7. An in vivo-like in vitro model of glioma invasion 
Gliomas are known to be highly invasive and new knowledge concerning tumor cell invasion 
also incorporating the tumor stem cell aspect is urgently needed. In our laboratory we have 
worked to improve in vitro models when investigating the invasive features of glioblastoma 
cells. This led to establishment of an in vivo-like model of invasion, where spheroids are 
implanted into organotypic brain slice cultures.  
The organotypic brain slice cultures became very popular research tools especially with the 
development of the roller-tube technique by Gähwiler in 1981 (Gahwiler, 1981) and the 
inter-face culturing method developed by Stoppini in 1991 (Stoppini et al., 1991). These 
cultures preserve many of the basic structural and connective tissue structures present in the 
tissue, when it is localized in the brain (Gahwiler, 1988). By implanting the organotypic 
spheroids into the organotypic brain slice cultures, it is possible to establish an organotypic 
spheroid-based slice-culture invasion assay, suitable for following tumor cell invasion into 
the brain tissue in vitro.  
The investigation of glioma invasion has been performed since the 1980’s but the models 
used have improved during the years. Different assays have been used to address the 
invasive capacities of the tumor cells. A frequently used migration assay allows spheroids to 
adhere to the bottom of coated plastic plates, and after a period of time the distance of 
migrating cells from the spheroid can be measured (Gliemroth et al., 2003; Narla et al., 1998; 
Terzis et al., 1997; Terzis et al., 1998). Another extensively used invasion assay is the Boyden 
or Boyden-like chamber-based assays. The Boyden chamber was first introduced by Boyden 
in order to investigate the chemotactic effect of mixtures of antibody and antigen on 
leukocytes (Boyden, 1962). The principle in the Boyden chambers is cell migration into a 
microporous membrane, often made of matrigel (Deryugina et al., 1997; Paulus & Tonn, 
1994; Schichor et al., 2005). The membrane is placed in between two medium-filled 
compartments; the upper compartment containing cells whereas the lower compartment 
may contain a chemotactic agent. After an incubation period, the cells migrating through the 
microporous membrane can be stained and counted (Chen, 2005). In a variation of the 
Boyden Chamber assay, slices of porcine white and gray matter were placed on top of a 
filter between the two compartments facilitating the cells to migrate through the porcine 
brain slice, making this assay a combination of the Boyden Chamber and the organotypic co-
culture system (Schichor et al., 2005).  
In the first real invasion studies, tissue aggregates from rat brain or chick heart were (Lund-
Johansen et al., 1990) placed next to the tumor tissue, but first with the development of the 
organotypic brain slice culture, it was possible to preserve the brain architecture and 
organization in an optimal way, thereby creating the conditions necessary for a more in 
vivo-like model of glioma invasion. Several groups have been using this model to 
investigate the invasion of glioma cell into organotypic brain slice cultures (Aaberg-Jessen et 
al. 2011; Caspani et al., 2006; De et al., 2002; Eyupoglu et al., 2005; Guillamo et al., 2009; 
Jensen et al. 2010; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004; Stoppini et 
al., 1991). In one study using this model, invasion was shown to be associated with the 
histological type and grade of the tumor (Palfi et al., 2004) and in another study invasion 
and tumor-induced neurotoxicity was shown to be associated (Eyupoglu et al., 2005). Most 
interestingly, quantitative analysis of invasion has also been performed (De et al., 2002) 
using confocal laser scanning microscopy and a three-dimensional visualization after having 
followed invasion over several weeks (Matsumura et al., 2000). 
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Besides investigating tumor invasion into the brain tissue, the model offers several other 
applications. Guillamo et al. (Guillamo et al., 2009) investigated the invasion, proliferation 
and angiogenesis of six human malignant glioma spheroids implanted into organotypic 
brain slice cultures, when these co-cultures were treated with gefinitib. Some of the tumors 
implanted had EGFR amplifications resulting in more pronounced invasion than tumors 
without EGFR amplification. Upon treatment with gefinitib only tumor cell invasion from 
tumors with EGFR amplification was inhibited, whereas vascular density was decreased in 
all tumors. In another study, Caspani et al. (Caspani et al., 2006) used the co-culture model 
to investigate the re-organization of the cytoskeleton in migrating glioblastoma cells. Cells 
transfected with green fluorescent protein were introduced into collagen gels, brain slice 
cultures and in vivo into mice brains and the re-organization and motility of the 
glioblastoma cells in the different models were monitored by confocal microscopy.  
Organotypic brain slice cultures from rodents have been used in a variety of different 
studies using tissue obtained from different areas in the brain. The organotypic brain slice 
cultures used in the invasion studies varied from explants from spinal cord (Caspani et al., 
2006), brain slices cut in the sagittal plane (Caspani et al., 2006) and the coronal plane (De et 
al., 2002; Guillamo et al., 2009; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004) 
as well as entorhinohippocampal slice cultures (Eyupoglu et al., 2005). Since glioblastomas 
are often located in the subcortical white matter of the cerebral hemisphere and tumor 
infiltration often extends into the adjacent cortex and through corpus callosum (Louis et al., 
2007) we have used organotypic corticostriatal brain slice cultures with cortex, striatum and 
corpus callosum for our studies of the invasive features of the glioblastoma cells. Such 
corticostriatal slice cultures should be cultured by the interface method placing the brain 
slices at the interface between air and culturing medium on a porous, transparent and low-
protein binding membrane. This allows the cultures to be oxygenated on one site, while 
receiving nutrients from the other site. In the following text our approach is described in 
details.  
The corticostriatal slice cultures are prepared from newborn Wistar rat pups by a method 
slightly modified from Kristensen et al. (Kristensen et al., 1999). The brain is aseptically 
removed from the pup and placed in a petri dish under a stereomicroscope, where the 
meninges are carefully removed. Hereafter the brain is sectioned coronally in 400 μm slices 
on a McIIwain tissue Chopper and the slices are transferred to a petri dish containing 
Hanks’ Balanced Salt Solution supplemented with 0.9% glucose. The brain slices are 
separated from each other and the sections containing cortex and striatum are divided into 
the two hemispheric parts resulting in the final brain slices. These slices are randomly 
moved to the insert membranes with four cultures on each membrane. Finally, the 
membrane inserts are placed in a 6-well plate in 1 ml preheated medium, and incubated in 
36°C humidified air containing 5% CO2 and 95% atmospheric air.  
Cell line spheroids or organotypic primary spheroids are implanted into organotypic 
brain slice cultures in the corpus callosum area between cortex and striatum, whereby a 
co-culture is established. In order to identify and follow tumor cells when they invade the 
slice, the spheroids can be labeled with the fluorescent dye, DiI (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) for 24 h before implantation, enabling confocal 
microscopy. The labeled spheroids are prepared by adding a DiI solution to the medium 
with spheroids, achieving a concentration of 25 μg/ml. Before implantation the spheroids 
are washed in medium to avoid bringing excess dye onto the brain slice cultures. 
Spheroids around 200-400 μm in diameter are captured using a denudation pipette and 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
388 
7. An in vivo-like in vitro model of glioma invasion 
Gliomas are known to be highly invasive and new knowledge concerning tumor cell invasion 
also incorporating the tumor stem cell aspect is urgently needed. In our laboratory we have 
worked to improve in vitro models when investigating the invasive features of glioblastoma 
cells. This led to establishment of an in vivo-like model of invasion, where spheroids are 
implanted into organotypic brain slice cultures.  
The organotypic brain slice cultures became very popular research tools especially with the 
development of the roller-tube technique by Gähwiler in 1981 (Gahwiler, 1981) and the 
inter-face culturing method developed by Stoppini in 1991 (Stoppini et al., 1991). These 
cultures preserve many of the basic structural and connective tissue structures present in the 
tissue, when it is localized in the brain (Gahwiler, 1988). By implanting the organotypic 
spheroids into the organotypic brain slice cultures, it is possible to establish an organotypic 
spheroid-based slice-culture invasion assay, suitable for following tumor cell invasion into 
the brain tissue in vitro.  
The investigation of glioma invasion has been performed since the 1980’s but the models 
used have improved during the years. Different assays have been used to address the 
invasive capacities of the tumor cells. A frequently used migration assay allows spheroids to 
adhere to the bottom of coated plastic plates, and after a period of time the distance of 
migrating cells from the spheroid can be measured (Gliemroth et al., 2003; Narla et al., 1998; 
Terzis et al., 1997; Terzis et al., 1998). Another extensively used invasion assay is the Boyden 
or Boyden-like chamber-based assays. The Boyden chamber was first introduced by Boyden 
in order to investigate the chemotactic effect of mixtures of antibody and antigen on 
leukocytes (Boyden, 1962). The principle in the Boyden chambers is cell migration into a 
microporous membrane, often made of matrigel (Deryugina et al., 1997; Paulus & Tonn, 
1994; Schichor et al., 2005). The membrane is placed in between two medium-filled 
compartments; the upper compartment containing cells whereas the lower compartment 
may contain a chemotactic agent. After an incubation period, the cells migrating through the 
microporous membrane can be stained and counted (Chen, 2005). In a variation of the 
Boyden Chamber assay, slices of porcine white and gray matter were placed on top of a 
filter between the two compartments facilitating the cells to migrate through the porcine 
brain slice, making this assay a combination of the Boyden Chamber and the organotypic co-
culture system (Schichor et al., 2005).  
In the first real invasion studies, tissue aggregates from rat brain or chick heart were (Lund-
Johansen et al., 1990) placed next to the tumor tissue, but first with the development of the 
organotypic brain slice culture, it was possible to preserve the brain architecture and 
organization in an optimal way, thereby creating the conditions necessary for a more in 
vivo-like model of glioma invasion. Several groups have been using this model to 
investigate the invasion of glioma cell into organotypic brain slice cultures (Aaberg-Jessen et 
al. 2011; Caspani et al., 2006; De et al., 2002; Eyupoglu et al., 2005; Guillamo et al., 2009; 
Jensen et al. 2010; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004; Stoppini et 
al., 1991). In one study using this model, invasion was shown to be associated with the 
histological type and grade of the tumor (Palfi et al., 2004) and in another study invasion 
and tumor-induced neurotoxicity was shown to be associated (Eyupoglu et al., 2005). Most 
interestingly, quantitative analysis of invasion has also been performed (De et al., 2002) 
using confocal laser scanning microscopy and a three-dimensional visualization after having 
followed invasion over several weeks (Matsumura et al., 2000). 
 
Three-Dimensional In Vitro Models in Glioma Research – Focus on Spheroids 
 
389 
Besides investigating tumor invasion into the brain tissue, the model offers several other 
applications. Guillamo et al. (Guillamo et al., 2009) investigated the invasion, proliferation 
and angiogenesis of six human malignant glioma spheroids implanted into organotypic 
brain slice cultures, when these co-cultures were treated with gefinitib. Some of the tumors 
implanted had EGFR amplifications resulting in more pronounced invasion than tumors 
without EGFR amplification. Upon treatment with gefinitib only tumor cell invasion from 
tumors with EGFR amplification was inhibited, whereas vascular density was decreased in 
all tumors. In another study, Caspani et al. (Caspani et al., 2006) used the co-culture model 
to investigate the re-organization of the cytoskeleton in migrating glioblastoma cells. Cells 
transfected with green fluorescent protein were introduced into collagen gels, brain slice 
cultures and in vivo into mice brains and the re-organization and motility of the 
glioblastoma cells in the different models were monitored by confocal microscopy.  
Organotypic brain slice cultures from rodents have been used in a variety of different 
studies using tissue obtained from different areas in the brain. The organotypic brain slice 
cultures used in the invasion studies varied from explants from spinal cord (Caspani et al., 
2006), brain slices cut in the sagittal plane (Caspani et al., 2006) and the coronal plane (De et 
al., 2002; Guillamo et al., 2009; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004) 
as well as entorhinohippocampal slice cultures (Eyupoglu et al., 2005). Since glioblastomas 
are often located in the subcortical white matter of the cerebral hemisphere and tumor 
infiltration often extends into the adjacent cortex and through corpus callosum (Louis et al., 
2007) we have used organotypic corticostriatal brain slice cultures with cortex, striatum and 
corpus callosum for our studies of the invasive features of the glioblastoma cells. Such 
corticostriatal slice cultures should be cultured by the interface method placing the brain 
slices at the interface between air and culturing medium on a porous, transparent and low-
protein binding membrane. This allows the cultures to be oxygenated on one site, while 
receiving nutrients from the other site. In the following text our approach is described in 
details.  
The corticostriatal slice cultures are prepared from newborn Wistar rat pups by a method 
slightly modified from Kristensen et al. (Kristensen et al., 1999). The brain is aseptically 
removed from the pup and placed in a petri dish under a stereomicroscope, where the 
meninges are carefully removed. Hereafter the brain is sectioned coronally in 400 μm slices 
on a McIIwain tissue Chopper and the slices are transferred to a petri dish containing 
Hanks’ Balanced Salt Solution supplemented with 0.9% glucose. The brain slices are 
separated from each other and the sections containing cortex and striatum are divided into 
the two hemispheric parts resulting in the final brain slices. These slices are randomly 
moved to the insert membranes with four cultures on each membrane. Finally, the 
membrane inserts are placed in a 6-well plate in 1 ml preheated medium, and incubated in 
36°C humidified air containing 5% CO2 and 95% atmospheric air.  
Cell line spheroids or organotypic primary spheroids are implanted into organotypic 
brain slice cultures in the corpus callosum area between cortex and striatum, whereby a 
co-culture is established. In order to identify and follow tumor cells when they invade the 
slice, the spheroids can be labeled with the fluorescent dye, DiI (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) for 24 h before implantation, enabling confocal 
microscopy. The labeled spheroids are prepared by adding a DiI solution to the medium 
with spheroids, achieving a concentration of 25 μg/ml. Before implantation the spheroids 
are washed in medium to avoid bringing excess dye onto the brain slice cultures. 
Spheroids around 200-400 μm in diameter are captured using a denudation pipette and 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
390 
thereafter carefully placed next to corpus callosum between cortex and striatum in the 
brain slice cultures. The culturing plates are placed in the incubator in 36°C humidified air 
containing 5% CO2 and 95% atmospheric air, whereafter the medium is changed twice a 
week. By monitoring the co-culture with confocal time-lapse microscopy, tumor cell 
invasion into the surrounding rat brain tissue can be visualized. Using a confocal 
microscope, a z-stack can be made consisting of thin sections at different levels of the 
culture. This makes it possible to follow invasion from all parts of the spheroid in 
different layers of the brain slice culture, whereby a three-dimentional movie and image 
can be constructed or alternatively an accumulated two-dimensional image based on 







1. Decapitate a newborn rat pup 
2. Aseptically remove the brain  
3. Remove the meninges 
4. Section the brain coronally in 400 µm slices on a McIIwain tissue Chopper 
5. Separate the brain slices and choose the slices containing cortex and striatum 
6. Divide these slices into the two identical halves for obtaining the final brain slice 
cultures 
7. Move slices randomly to a transparent insert membrane  
8. Place the insert membranes in a 6-well culturing plate with 1 ml preheated medium 
9. Incubate the cultures in 36°C humidified air containing 5% CO2 and 95% atmospheric 
air 
10. Change the medium twice a week 
11. Label organotypic spheroids or spheroids derived from short term cultures with 
25µg/ml DiI for 24 h before implantation 
12. Wash the spheroids 3 times with medium before implantation  
13. Use spheroids in the size range from 200-400 µm 
14. Place the spheroids in the area between cortex and striatum next to corpus callosum 
by a denudation pipette 
15. Incubate the co-cultures in 36°C humidified air containing 5% CO2 and 95% 
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Box 2. Preparation of organotypic corticostriatal brain slice cultures and implantation of 
spheroids. 
 




Fig. 3. Schematic overview of the implantation of glioma spheroids into organotypic rat 
corticostriatal brain slice cultures. Glioma tissue is obtained from patients and collected in 
the operation theatre. Thereafter, it is processed and cultured in the laboratory until 
spheroids are formed. Alternatively, spheroids from established short term cultures or cell 
lines can be used. Simultaneously, brain slice cultures from newborn rats are prepared and 
cultured by the interface method. The spheroids are labeled with the fluorescent dye DiI and 
implanted into the brain slice cultures in the corpus callosum area between cortex and 
striatum, here illustrated by a phase contrast image of a spheroid immediately after 
implantation and after 14 days of culturing. Note the less marked edge of the spheroid as 
the cells migrate into the surrounding brain tissue (Cx- cortex and Str-striatum). 
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different layers of the brain slice culture, whereby a three-dimentional movie and image 
can be constructed or alternatively an accumulated two-dimensional image based on 
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Fig. 4. Confocal images of an invasive DiI-labeled glioma spheroid implanted into an 
organotypic rat brain slice culture. The spheroid is followed by confocal timelapse 
microscopy for a period of 72 hours. The images are accumulated images based on overlay 
of all the images from one z-stack. A z-stack consists of several images obtained at different 
levels of the co-culture.  
8. Conclusion 
We conclude that the three-dimensional spheroid models offers advantages in glioma 
research taking tumor biology and microenvironment into account. Especially, when using 
the organotypic models, where the structure and organization of the tissue is preserved, 
features close to the in vivo situation are supposed to be obtained. In tumor stem cell 
research, the spheroids are a necessary tool as this culture method seems to promote the 
existence of these cells. This is especially the case when culturing the spheroids in a hypoxic 
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environment. As discussed in the chapter, spheroids have been used in a wide range of 
experiments investigating radiation responses, effects of chemotherapy and effects of 
different types of experimental drugs as well as in migration and invasion studies. The 
experimental setups may be somewhat more difficult than by using monolayer cultures, but 
since the spheroid models are supposed to be closer to the in vivo situation, the results and 
answers obtained are also supposed to be closer to what it true for the corresponding 
tumors in the human brain. However, efforts should be made to develop these three-
dimensional models to become even more in vivo-like, in order to meet new challenges in 
glioma research and drug development. The use of spheroids in especially tumor stem cell 
research has been fast increasing in recent years making spheroids an important tool also in 
future glioma research.  
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Glioblastomas (GBM) are the most malignant solid tumours (grade IV) of CNS. They are glial 
lineage neoplasias with a high proliferative and invasive capacity, reaching to occupy an entire 
lobe of the brain (Kleihues et al., 2007). According with their genesis, they can be differentiated 
between primary and secondary glioblastoma. The primary is the most common glioblastoma. 
This is a new generated tumour after a brief medical history (three months), with no evidence 
of a less malignant lesion. On the other hand, secondary glioblastoma develops from diffuse 
astrocytoma, anaplastic astrocytoma or oligodendroglioma and malignant progression. Its 
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Glioblastomas (GBM) are the most malignant solid tumours (grade IV) of CNS. They are glial 
lineage neoplasias with a high proliferative and invasive capacity, reaching to occupy an entire 
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development time is about five years. It is thought that both types of glioblastomas may be 
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addition, these cancer stem cells called “glioma stem cells” (GSCs) may be the responsible for 
glioma recurrences due to chemo-and radio resistance (Bao et al., 2006; Rich, 2007). Glioma 
stem cells (GSCs) are a subpopulation of neoplastic cells identified in glioma sharing 
properties with neural stem cells (self-renewal, high proliferation rate, undifferentiating, and 
neurospheres conformation) and the capacity for leading the tumourigenesis and tumour 
malignancy. The proliferation and the invasion into adjacent normal parenchyma have been 
attributed to glioma stem cells as well. Indeed, they were related to the angiogenesis process 
needed for the growth and survival of the neoplasia.  
 The microvascular network in gliomas has to get adapt to metabolic tissue requirements 
(Folkman, 2000). When the vascular network cannot satisfy cell requirements (Oxygen 
pressure of 5-10 mm Hg) tissue hypoxia occurs. This situation triggers the synthesis of pro-
angiogenic factors as matrix metalloprotease (MMP-2), angiopoietin-1, phosphoglycerate 
kinase (PGK), erythropoietin (EPO), and vascular endothelial growth factor (VEGF)-A 
(Fong, 2008).  
Vascular endothelial growth factor (VEGF) is a major regulator of tumour angiogenesis 
(Bulnes & Lafuente, 2007; Lafuente et al., 1999; Machein & Plate, 2004; Marti et al., 2000). 
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VEGF acts as mitogen, survival, antiapoptotic and vascular permeability factor (VPF) for the 
endothelial cells (Dvorak, 2006). The increase of this pro-angiogenic factor, secreted either 
by neoplastic cells or by cells of the tumour microenvironment, induces the start of 
angiogenesis, the called “angiogenic switch” (Bergers & Benjamin, 2003). This event results 
in the transition from avascularised hyperplasia to outgrowing vascularised tumour and 
eventually to malignant progression. It has been shown in human glioma biopsies that 
VEGF overexpression correlates directly to proliferation, vascularization and degree of 
malignancy, and therefore inversely to prognosis (Ke et al., 2000; Lafuente et al., 1999; Plate, 
1999). The synthesis of VEGF is mediated by the Hypoxia-Inducible Factor (HIF-1), a critical 
step for the formation of new blood vessels and for the adaptation of microenvironment to 
the growth of gliomas (Jin et al., 2000; Marti et al., 2000; Semenza, 2003). Recent researches 
have reported that glioma stem cells play a pivotal role inducing the angiogenesis via HIF-
1/VEGF (Bao et al., 2006). By the other hand, hypoxia has been related to clones selection of 
tumour cells. These clones adapted to the tumour microenvironment have acquired the 
phenotype of tumour stem cell with increased proliferative and infiltrative capacity 
(Heddleston et al., 2009; Li et al., 2009). Invasion of adjacent normal parenchyma has been 
attributed to glioma stem cells as well.  
Due to these evidences, GSCs are currently being considered as a potential therapeutic 
target of the tumours. Recent studies have been focused on the identification of GSCs. In 
human glioblastomas they have been identified using CD133 marker (Ignatova et al., 2002). 
However, little is known about their genesis during glioma progression, especially during 
the early stages.  
Some authors have previously reported the induction of glial tumour in rats by 
transplacentary administration of the carcinogen ethylnitrosourea (ENU) as a suitable 
method for studying the natural development of glioma (Bulnes-Sesma et al., 2006; Zook et 
al., 2000). In addition to this, it has been reported that ENU glioma model is a representative 
model for human glioma due to its location and also to its similar cellular, molecular and 
genetic alterations (Kokkinakis et al., 2004). Our experience with this model has proven to be 
useful to study many aspects of tumourigenesis and neoangiogenesis. In previous 
researches we reported the progression of tumour malignancy associated with vascular 
structural alterations and blood brain barrier (BBB) disturbances (Bulnes & Lafuente, 2007; 
Bulnes et al., 2009). ENU induced glioma permitted us to identify tumour development 
stages following microvascular changes. In addition, it was possible to study the 
angiogenesis process. Recently, we have used this model to study the relationship between 
glioma stem cells and angiogenesis process during the neoplasia development. 
Many evidences corroborate the hypothesis that “glioma stem cells” have a close 
relationship with angiogenesis process, intratumour hypoxia and neoplastic microvascular 
network. In this chapter we centred to show this relationship from early to advanced stages 
of glioma using ENU-model.  
2. Endogenous glioma model 
Over the years, different methods have been employed to induce experimental tumours in 
the Central Nervous System of animals. Exposure to radiation, inoculation of carcinogenic 
virus, xenografts of tumour cell lines or tumour fragments in nude rats or mice, 
administration of chemical substances (Bulnes-Sesma et al., 2006) and genetically engineered 
mouse models have been used to replicate CNS tumours. The administration of chemical 
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substances as nitroso compounds is one of the most commonly-used methods to induce 
experimental CNS neoplasm. There is strong experimental data showing that nitrosamides 
(R1NNO-COR2), a type of N-nitroso compounds (NOC), are potent neuro-carcinogens 
when administered transplacentally. N-nitrosoureas MNU and ENU (a class of 
nitrosamides) have been demonstrated to be carcinogenic in animals, and particularly 
related to the development of CNS tumours. N-ethyl-N-nitrosourea (ENU) acts alkylating 
the O6 in the guanine (G:C---T:A transition) and the O2 in the thymine (T:A---A:T 
transversion). The accumulation of these successive DNA mutations seems to be responsible 
of the neurooncogenic effect of ENU (Bulnes-Sesma et al., 2006; O'Neill, 2000). Recently it 
has been reported that ENU exposure affects primitive neuroepithelial cells of the 
subventricular plate (SVZ) and germinative zone (VZ). ENU prenatal exposure affects the 
differentiation of these cells generating glial lineage tumours (Burger, 1988; Vaquero et al., 
1994; Yoshimura et al., 1998) and its exposure in adult affects the neurogenesis of the SVZ 
(Capilla-Gonzalez et al., 2010). In previous studies we found that gliomas induced in 
offspring were similar to the human gliomas (Kokkinakis et al., 2004). Therefore, ENU brain 
induced tumours have allowed the study of several aspects of glioma behaviour, for 
example, microvascular organization (Schlageter et al., 1999; Yoshimura et al., 1998); 
neoplastic cell dedifferentiation (Jang et al., 2004); gene mutations (Bielas & Heddle, 2000; 
O'Neil, 2000); microcirculation and angiogenesis process (Bulnes & Lafuente, 2007; Bulnes et 
al., 2009) or experimental therapeutic agents (Kish et al., 2001). 
In our model, the glioma induction was performed by prenatal exposure of Sprague Dawley 
rats to ENU. Briefly, pregnancy rats, on the 15th day of gestation, were given a single i.p. 
injection of 80 mg of ENU/kg body weight (Bulnes et al., 2009; Bulnes et al., 2010). Offspring 
rats exposed to ENU were reared in standard laboratory conditions and the study was 
performed from 5 months to one year of age. The identification of ENU-Gliomas was 
performed by T2-w and postcontrast T1-weighted NMR images and by histopathology 
diagnosis from H&E staining and immunophenotypic study as previously described (Bulnes 
& Lafuente 2007) (Figure 1, 2). Following our results, ENU-glioma starts from the fifth 
month of offspring rat age and becomes GBM at 10 months of age (Bulnes-Sesma et al., 
2006). ENU-glioma starts as cellular proliferation growing near ventricles in association with 
subcortical white matter. Over 6 months of extrauterine life, this tumour proliferation 
become nodular and rats display neurological signs (Figure 1). Around one year they grow 
as a GBM toward the contralateral hemisphere (Figure 2). Following our findings, we have 
identified three stages of ENU-glioma development: initial, intermediate and advanced. The 
advanced stage corresponds to anaplastic oligodendroglioma or glioblastoma (GBM) similar 
to the human. ENU-GBM may reach to infiltrate whole cerebral hemisphere, showing 
malignant histopathological features such as: high tissue heterogeneity, aberrant 
angioarchitecture, macro-haemorrhages, macrocysts or palisade necrosis (Klehiues et al., 
2007). Thanks to this model we could isolate early glioma stages, which is impossible to 
carry out in human brain. 
3. Stem cells and cancer stem cells 
Stem cells are functionally defined as self-renewing and multipotent cells that exhibit 
multilineage differentiation (Till & McCulloch, 2011). Nowadays they have been proposed 
to be an important tool in regenerative therapy being used to regenerate tissue in many 
diseases like heart stroke, neurodegenerative diseases, etc (Nadig, 2009). However, in 
oncology and especially in cerebral gliomas, the presence of the stem cells has been related 
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to a poor prognosis. Recent investigations in glioblastomas have reported that these cancer 
stem cells called glioma stem cells (GSCs) have tumourigenic capacities like tumour 
malignant process, peripheral tissue infiltration and angiogenesis induction (Hadjipanayis 
& Van Meir, 2009; Rich, 2007). 
 
 
Fig. 1. Coronal sections of rat brains displaying ENU-glioma showed by MRI on T2-w and 
T1-w after injection of gadolinium. a, b) Small neoplastic mass growing on the cerebral 
cortex with an homogeneous hyperintense signal on T2-w images. These neoplastic masses 
correspond to initial stage of ENU-glioma. e, f) Both masses display an isointense signal on 
T1-w. c, d) ENU-glioma tumour with nodular shape showed on T2-w hyperintense signal 
that represents intermediate stage. g, h) At this stage there is a gadolinium contrast 
enhancement observed as homogeneous soft hyperintense signal on T1-w image.  
 
 
Fig. 2. Coronal sections of rat brains with ENU-glioma of advanced stage showed by MRI on 
T2-w and T1-w after injection of gadolinium. All of these anaplastic gliomas display 
heterogeneous hyperintense signal on T2 (a-d) and on T1-w (e-h). This heterogeneity is due 
to the presence of histopathology features of malignity. c-d) ENU-GBMs high-proliferative 
covering a whole cerebral hemisphere. The T2-w images reveal an intratumour hyperintense 
signal corresponding with intratumour oedema or macrocysts. g-h). Gadolinium 
enhancement of this T1-w image adopts a rim shape bordering the neoplastic mass. This rim 
represents the microvascular proliferation with dysfunction of Blood Brain Barrier.  
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In the middle of the 60s, Altman and Das reported the first evidences about stem cells in 
adult brain. They observed stem cells in the hippocampus and olfactory bulb of rats, and it 
supposed the first sign of division of stem cells. Later on they were called Neural Stem Cells 
(NSCs). NSCs were considered the unique population of Central Nervous System cells 
characterized by self-renewal and multilineage differentiation properties (Muller et al., 
2006). They can form neurospheres (Reynolds & Weiss, 1992) and differentiate in vitro into 
the three neuroectodermal lineages astrocytes, oligodendrocytes and neurons (Alvarez-
Buylla & Garcia-Verdugo, 2002). Furthermore, when they are transplanted in vivo in the 
cerebellum, they can generate neurons and glial cells (Lee et al., 2005). Also, after 
transplantation into nude mice they can differentiate into neuroblasts (Tamaki et al., 2002). 
NSCs reside in the germinal layers of the developing brain, initially in the early 
neuroepithelium, later in the ventricular (VZ) and subventricular zone (SVZ) during 
embryogenesis (Götz & Huttner, 2005). In adult brain, three areas are supposed to harbour 
neural stem cells: dentate gyrus of hippocampus, SVZ (Doetsch et al., 1999; Eriksson et al., 
1998) and the fibbers connecting olfactory bulb to lateral ventricle (Lois & Alvarez-Buylla, 
1994; Whitman & Greer, 2009). In recent times, they were also isolated in the subcortical 
white matter (Nunes et al., 2003). 
In the 1960s, evidence emerged supporting the presence of stem cells in tumours. Bergsagel 
and Valeriote (1968) showed that only certain cells within a tumour had the capacity to 
generate a new tumour; they termed these cells “tumour stem cells”. After this, tumour stem 
cells were identified in breast tumour (Al-Hajj et al., 2003), pancreatic tumour (Esposito et 
al., 2002) etc. 
The first concept of cancer stem cell, later on also called tumour initiating cells, appeared in 
the beginning of the 90s. Bonnet and Dick (1977) describe how some cells, isolated from 
leukaemia patient´s blood, had proliferation and differentiation capacities in vivo. Fan et al. 
(2007) described cancer stem cells as the cellular subpopulation capable of tumour 
regeneration within a permissive environment. Rich and collaborators reported that cancer 
stem cells have tumourigenic, infiltration and angiogenesis properties as well as 
radio/chemo-resistance (Rich, 2007; Hadjipanayis & Van Meir, 2009).  
The relation between stem cells and cancer stem cells was studied. The results explained 
that both cellular types share the previously mentioned characteristics, as well as many cell 
signalling pathways as oncogene bcl-2, Sonic hedgehog (Shh) and Wnt signalling cascade 
(Reya et al., 2001). Both types of stem cells also share common markers like CD133, Nestin 
(Dahlstrand et al., 1992) and transcription factor Sox2 (Gangemi et al., 2009). However, there 
are differences between stem cells and cancer stem cells, such as expression of different 
markers, chromosomal alterations and tumourigenic capacity. Holland et al. (2000) 
published that cancer stem cells could develop from modified neural stem cells. They have 
been described many pathways that can lead to cancer stem cell formation like Notch 
(Takebe & Ivy 2010), Akt (Germano et al., 2010) activation or p53 pathway alteration. 
3.1 Glioma stem cells (GSCs) 
Dahlstrand et al. (1992) identified a cancer stem cells subtype inside glial lineage brain 
tumours which were called Glioma Stem Cells (GSCs). These GSCs may be responsible for 
maintenance of the entire tumour and also they have the potential, when injected in 
immunodeficient mice, to generate gliomas similar to the original tumours (Heddleston et 
al., 2009).  
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to a poor prognosis. Recent investigations in glioblastomas have reported that these cancer 
stem cells called glioma stem cells (GSCs) have tumourigenic capacities like tumour 
malignant process, peripheral tissue infiltration and angiogenesis induction (Hadjipanayis 
& Van Meir, 2009; Rich, 2007). 
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Fig. 2. Coronal sections of rat brains with ENU-glioma of advanced stage showed by MRI on 
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In the middle of the 60s, Altman and Das reported the first evidences about stem cells in 
adult brain. They observed stem cells in the hippocampus and olfactory bulb of rats, and it 
supposed the first sign of division of stem cells. Later on they were called Neural Stem Cells 
(NSCs). NSCs were considered the unique population of Central Nervous System cells 
characterized by self-renewal and multilineage differentiation properties (Muller et al., 
2006). They can form neurospheres (Reynolds & Weiss, 1992) and differentiate in vitro into 
the three neuroectodermal lineages astrocytes, oligodendrocytes and neurons (Alvarez-
Buylla & Garcia-Verdugo, 2002). Furthermore, when they are transplanted in vivo in the 
cerebellum, they can generate neurons and glial cells (Lee et al., 2005). Also, after 
transplantation into nude mice they can differentiate into neuroblasts (Tamaki et al., 2002). 
NSCs reside in the germinal layers of the developing brain, initially in the early 
neuroepithelium, later in the ventricular (VZ) and subventricular zone (SVZ) during 
embryogenesis (Götz & Huttner, 2005). In adult brain, three areas are supposed to harbour 
neural stem cells: dentate gyrus of hippocampus, SVZ (Doetsch et al., 1999; Eriksson et al., 
1998) and the fibbers connecting olfactory bulb to lateral ventricle (Lois & Alvarez-Buylla, 
1994; Whitman & Greer, 2009). In recent times, they were also isolated in the subcortical 
white matter (Nunes et al., 2003). 
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cells were identified in breast tumour (Al-Hajj et al., 2003), pancreatic tumour (Esposito et 
al., 2002) etc. 
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the beginning of the 90s. Bonnet and Dick (1977) describe how some cells, isolated from 
leukaemia patient´s blood, had proliferation and differentiation capacities in vivo. Fan et al. 
(2007) described cancer stem cells as the cellular subpopulation capable of tumour 
regeneration within a permissive environment. Rich and collaborators reported that cancer 
stem cells have tumourigenic, infiltration and angiogenesis properties as well as 
radio/chemo-resistance (Rich, 2007; Hadjipanayis & Van Meir, 2009).  
The relation between stem cells and cancer stem cells was studied. The results explained 
that both cellular types share the previously mentioned characteristics, as well as many cell 
signalling pathways as oncogene bcl-2, Sonic hedgehog (Shh) and Wnt signalling cascade 
(Reya et al., 2001). Both types of stem cells also share common markers like CD133, Nestin 
(Dahlstrand et al., 1992) and transcription factor Sox2 (Gangemi et al., 2009). However, there 
are differences between stem cells and cancer stem cells, such as expression of different 
markers, chromosomal alterations and tumourigenic capacity. Holland et al. (2000) 
published that cancer stem cells could develop from modified neural stem cells. They have 
been described many pathways that can lead to cancer stem cell formation like Notch 
(Takebe & Ivy 2010), Akt (Germano et al., 2010) activation or p53 pathway alteration. 
3.1 Glioma stem cells (GSCs) 
Dahlstrand et al. (1992) identified a cancer stem cells subtype inside glial lineage brain 
tumours which were called Glioma Stem Cells (GSCs). These GSCs may be responsible for 
maintenance of the entire tumour and also they have the potential, when injected in 
immunodeficient mice, to generate gliomas similar to the original tumours (Heddleston et 
al., 2009).  
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GSCs indeed of share properties of somatic or embryonic stem cells (high proliferation rate, 
undifferentiating, formation of neurospheres) are chemo-and radio resistant (Bao et al., 2006, 
Rich, 2007). Their radiotherapy resistance may be thanks to a more efficient DNA reparation 
mechanism and protein kinases phosphorilation Chk1 and Chk2 (Bao et al., 2006). The 
resistance to chemotherapeutic drugs is through membrane transporters that bomb the 
drugs outside the cell (Donnenberg & Donnenberg, 2005).  
The first GSCs identification was found in the tumour advanced stage corresponding with 
human-GBM (Ignatova et al., 2000). However, the first moment of GSCs expression remains 
unknown, as well as their role in early stages of tumour development. It is very important to 
identify and explain GSCs apparition in early glioma stages to research about future tumour 
therapy.  
The discovery of GSCs in gliomas involved the creation of a new glioma-genesis hypothesis 
called “hierarchical hypothesis”. Before GSCs discovery, glioma development was 
explained by the “stochastic theory”. Stochastic theory is based on all neoplastic cells are 
clones from a single undifferentiated cell and they have the same genetic alterations 
(Hadjipanayis & Van Meir, 2009). Nowadays the “hierarchical theory” explains that only a 
few neoplastic cells can adapt to the tumour environment and are able to start the 
tumourigenic process. Even though the low proliferation of GSCs, they guide the tumour 
growth giving raise to more mature cells with limited proliferation capacity (Shen et al., 
2008).  
After the glioma stem cells finding, the research about glioma development has been 
centred in the identification of them. So far markers as CD133/Promonin-1, presents in 
glioma stem cells (Dell'Albani, 2008), Nestin, a protein found in neural stem cells in SVZ and 
other markers of neuroepithelial stem cells (Jang et al., 2004) including Musashi-1, Sox-2, 
GFAP, Map-2, Neural-tubulin, Neurofilament O4 and Noggin were used in order to identify 
tumour stem cells. But the lack of a specific marker makes it very difficult to identify 
(Hadjipanayis & Van Meir, 2009; Li et al., 2009).  
Nestin is an intermediate filament protein typical for neural precursor cells. It has been 
extensively used as a marker for neural stem cells. It is expressed in primitive 
neuroepithelial cells of all regions of CNS during the development. In adult its expression is 
restricted to the ventricular wall (SVZ) and the central canal. In pathological conditions like 
brain trauma, CNS ischemia, neurotoxicity, neoplastic transformation and in response to 
cellular stress, the nestin over-expression was showed (Holmin et al., 1997, Jang et al., 2004). 
In primary malignant tumours of CNS high amounts of cells positive for Nestin have been 
reported. Nestin has been described as a marker of GSCs in astroglial tumours (Singh et al., 
2003), indicating undifferentiating and malignance degree (Schiffer et al., 2010), but it is not 
specific for glioma stem cells (Hadjipanayis & Van Meir, 2009). Indeed, Nestin expression 
has been described to appear since the first stages in glioma models (Jang et al., 2004).  
CD133 (prominin-1) was the first identified member of the prominin family of pentaspan 
membrane proteins which acts as a marker of hematopoietic progenitor cells. It is a cell 
surface marker used for the identification and isolation of stem/progenitor cells in several 
tissues, for instance, endothelium, brain, bone narrow, liver, prostate, pancreas and foreskin 
(Mizrak et al., 2008). CD133 was originally described as an hematopoietic stem cell marker 
and was subsequently related to number of progenitor cells including neuroepithelium 
(Corbeil et al., 2000) as well as cancer stem cells in various tumours such as prostate and 
Endogenous Experimental Glioma Model, 
Links Between Glioma Stem Cells and Angiogenesis 
 
411 
colon cancer (Cheng et al., 2009; Collins et al., 2005; O'Brien et al., 2007). In human 
glioblastoma, CD133 expression has been associated to GSCs and bad prognosis of the 
tumour (Germano et al., 2010).  
4. Tumour angiogenesis 
Gliomas proliferate in the brain, a privileged organ from the point of view of blood supply. 
The exchange of metabolites between blood and cerebral tissue occurs essentially in the brain 
capillaries. The diameter of brain capillaries in the adult human is between 5 and 7 microns. 
These microvessels feed to the cells that are 10-20 microns away. Although the distance 
between cells and microvessels is lesser than 20 µm, the growth and survival of the gliomas 
depend on vascular remodelling and angiogenesis (Folkman, 2006). Along the early stages of 
small gliomas the metabolic demand is supplied by the vast microvascular network but when 
the metabolic supply has been exceeded, new formation of vessels becomes necessary 
(Carmeliet & Jain, 2000; Yancopoulos et al., 2000). The genesis of the new vessels from pre-
existing ones is called angiogenesis in opposite to vasculogenesis refereed to the formation of 
vessels from hemopoietic niches (Carmeliet, 2003; Risau & Falmme 1995; Risau, 1997). 
Angiogenesis is a complex process that requires proteolytic and mitogenic activity of 
endothelial cells and interaction of these with the extracellular matrix molecules and cells of 
peri-endothelial support cells (pericytes and smooth muscle cells). Many molecules and 
pathways are involved in this process, such as VEGF, its receptors VEGFR-1 and VEGFR-2, 
the endothelial receptor tyrosine kinase tie-1 and tie-2 and the angiopoietin ligands 1 and 2. 
Many other molecules as PDGF and TGF-β, integrin receptors, are very important (Millauer 
et al., 1993; Neufeld et al., 1999). 
Angiogenesis requires some angiogenic stimulus, such as hypoxia, new metabolic 
requirements or tumour growth to start. Intratumour hypoxia occurs at the time when there is 
an imbalance between supply and demand oxygen due to the irregular and chaotic blood flow 
(Jensen, 2006). The relative tissue hypoxia triggers the production of hypoxia inducible factor-
1α, upregulating the expression of VEGF. In addition to this, it was reported that hypoxia 
plays a fundamental role in the induction of cell phenotype neoplastic to the undifferentiated 
state of GSCs. According to recent research, hypoxia selects tumour cell clones that have 
adapted to the tumour microenvironment and have acquired the phenotype tumour stem cell, 
with its capabilities of proliferation and infiltration (Heddleston et al., 2009; Li et al., 2009). 
Heddleston et al. (2009) observed how in cultures of human glioma neoplastic cells exposed 
to hypoxia reverted to a state of tumour stem cells. Griguer et al. (2008) related the 
appearance of CD133 + cells with oxygen stress in gliomas. On the other hand, it was 
observed a decrease in the expression of CD133 when reverted to conditions of normoxia. 
Furthermore, studies of human GBM have described the relationship between the gradient 
of intratumour oxygen and the appearance of the phenotype tumour stem cell (Pistollato et 
al., 2010). As above, only a cluster of neoplastic cells resists to the conditions of hypoxia and 
intratumoural ischemia. This group of cells may be stem cell precursors, and after adapting 
to the new microenvironment, are transformed to GSCs.  
4.1 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis in 
development (Bengoetxea et al., 2008; Ferrara et al., 2003; Ment et al., 1997) and pathological 
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colon cancer (Cheng et al., 2009; Collins et al., 2005; O'Brien et al., 2007). In human 
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tumour (Germano et al., 2010).  
4. Tumour angiogenesis 
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capillaries. The diameter of brain capillaries in the adult human is between 5 and 7 microns. 
These microvessels feed to the cells that are 10-20 microns away. Although the distance 
between cells and microvessels is lesser than 20 µm, the growth and survival of the gliomas 
depend on vascular remodelling and angiogenesis (Folkman, 2006). Along the early stages of 
small gliomas the metabolic demand is supplied by the vast microvascular network but when 
the metabolic supply has been exceeded, new formation of vessels becomes necessary 
(Carmeliet & Jain, 2000; Yancopoulos et al., 2000). The genesis of the new vessels from pre-
existing ones is called angiogenesis in opposite to vasculogenesis refereed to the formation of 
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the endothelial receptor tyrosine kinase tie-1 and tie-2 and the angiopoietin ligands 1 and 2. 
Many other molecules as PDGF and TGF-β, integrin receptors, are very important (Millauer 
et al., 1993; Neufeld et al., 1999). 
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requirements or tumour growth to start. Intratumour hypoxia occurs at the time when there is 
an imbalance between supply and demand oxygen due to the irregular and chaotic blood flow 
(Jensen, 2006). The relative tissue hypoxia triggers the production of hypoxia inducible factor-
1α, upregulating the expression of VEGF. In addition to this, it was reported that hypoxia 
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state of GSCs. According to recent research, hypoxia selects tumour cell clones that have 
adapted to the tumour microenvironment and have acquired the phenotype tumour stem cell, 
with its capabilities of proliferation and infiltration (Heddleston et al., 2009; Li et al., 2009). 
Heddleston et al. (2009) observed how in cultures of human glioma neoplastic cells exposed 
to hypoxia reverted to a state of tumour stem cells. Griguer et al. (2008) related the 
appearance of CD133 + cells with oxygen stress in gliomas. On the other hand, it was 
observed a decrease in the expression of CD133 when reverted to conditions of normoxia. 
Furthermore, studies of human GBM have described the relationship between the gradient 
of intratumour oxygen and the appearance of the phenotype tumour stem cell (Pistollato et 
al., 2010). As above, only a cluster of neoplastic cells resists to the conditions of hypoxia and 
intratumoural ischemia. This group of cells may be stem cell precursors, and after adapting 
to the new microenvironment, are transformed to GSCs.  
4.1 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis in 
development (Bengoetxea et al., 2008; Ferrara et al., 2003; Ment et al., 1997) and pathological 
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disease (Bulnes & Lafuente, 2007; Lafuente et al., 1999; Marti et al., 2000; Plate, 1992). 
However, the role of VEGF in nervous tissue is even more extensive. Previous studies 
showed that VEGF also has strong neuroprotective, neurotrophic and neurogenic properties 
(Jin et al., 2002; Ortuzar et al., 2011; Rosenstein & Krum, 2004; Storkebaum et al., 2004).  
Although the synthesis of this proangiogenic cytokine is associated to tumour cells and 
endothelial cells, it has been described in others, such as: neurons, astrocytes, pericytes, 
smooth muscle cells, macrophages, lymphoid cells, platelets and fibroblasts (Zagzag et al., 
2000). The VEGF family consists of five different homologous factors, VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and placental growth factor (PIGF) (Ferrara et al., 2003). VEGF-A (VEGF) 
is the predominant form and is a hypoxia-inducible 45 KDa homodimeric glycoprotein. 
VEGF-A acts as mitogen, survival and antiapoptotic factor for the endothelial cells from 
arteries, veins and lymphatics. Faced with increased secretion of VEGF and its binding to 
receptors on the surface of endothelial cells, VEGF is a signal transduction leading to 
production of molecules including enzymes for the degradation of extracellular matrix and 
increase of vascular permeability. This will facilitate cell proliferation, survival and 
migration of endothelial cells. It is also known as the vascular permeability factor (VPF) 
(Dvorak, 2006) on the basis of its ability to induce leakage through the blood brain barrier in 
some pathological situations (Ferrara, 2001; Lafuente et al., 1999; Lafuente et al., 2002). 
Helmlinger et al. (2000) stated that in the vasodilatation process the VEGF induced the 
elongation of endothelial cells but not their proliferation. In the angiogenesis process, VEGF 
works in line with other factors such as angiopoietin and ephrins (Tonini et al., 2003). It has 
been shown in human biopsies that VEGF overexpression in gliomas correlates directly to 
proliferation, vascularization and degree of malignancy, and therefore inversely to 
prognosis (Ke et al., 2000; Lafuente et al., 1999; Plate, 1999).  
5. ENU glioma microvascular adaptation 
Along the glioma progression, there is a transition from the homogeneous capillary network 
to an anarchic angioarchitecture. Microvessels have to adapt in order to maintain blood 
perfusion and metabolic support in adverse conditions, constituting a peculiar tissular 
microenvironment in response to hypoxia (Blouw et al., 2003). Glioma microvascular 
remodelling consists in a process of vascular aberration along the neoplasia development. 
Vascular development process led to microvascular proliferations that are a 
histopathological hallmark of glioblastoma (Kleihues et al., 2007). Some authors consider the 
core of a high-grade glioma as an avascular zone, since it has scarce capillaries with wide 
lumen and a fragmented basal membrane, being rather inefficient for metabolic exchange 
(Vajkoczy & Menger, 2004).  
Tumour blood vessels have multiple abnormalities that result in a heterogeneous 
environment. They are disorganized, tortuous, sinusoidal, branchy and leaky, the diameter 
is irregular and the walls are thinner than those found in healthy brain tissue (Bigner et al., 
1998). Following our results obtained by LEA and Butyrylcholinesterase (BChE) 
histochemistry (Bulnes et al., 2009) we showed a transition from the homogeneous capillary 
network of early stages to an anarchic angioarchitecture of advanced ENU-glioma stages 
(Figure 3). It was found that the vessel density decreased and the vascular size increased in 
order to glioma malignity (Bulnes et al., 2009). The initial stage of ENU-glioma was 
constituted by microvessels similar to the brain capillaries, the intermediate stage by 
tortuous, disorganized and dilated vessels and the advanced stage by anarchic and aberrant 
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vessels such as: multilayered “glomeruloid tuft”; “garland” of proliferated vessels and huge 
dilated vessels (Klehues et al., 2007).  
One result to take in consideration was the gradient from the well-oxygenated tumour 
periphery to the central hypoxic core of ENU-glioblastoma. Dilated intratumour vessels, 
expressing VEGF (Lafuente et al., 1999) increase their lumen on account of endothelial 
elongation but not of cell proliferation (Helmlinger et al., 2000). The intratumour area displays 
irregularly branching vessels, variable intravascular spaces and large avascular areas. It is also 
worth mentioning that perivascular cells of aberrant vessels of ENU-GBM often displayed a 
high activity for BChE, depicted by a strong brown staining (Bulnes et al., 2009). BChE activity 
is strongly related to neurogenesis and cellular proliferation (Mack & Robitzki, 2000), having a 
great role in tumourigenesis. These findings have led us to postulate that these perivascular 
cells might be stem cells proliferating around intratumour vessels (Anderson et al., 2005; Brat 
et al., 2004) and migrating through the vascular extracellular matrix (Ruoslahti, 2002). This 
could corroborate the hypothesis that stem cells adapted to hypoxic stress use the vascular 
extracellular matrix for migration and invasion. In addition to this, in previous work we have 
shown that these cells co-expressed Ki-67 and VEGF (Bulnes & Lafuente, 2007).  
 
 
Fig. 3. Angioarchitecture study of gliomas shown by butyrylcholinesterase histochemistry. 
a) Angioarchitecture of the cerebral cortex of the rat brain. b) Periventricular small 
neoplastic mass (initial stage) showing some strongly-positive vessels for BChE. c) 
Intermediate ENU-glioma stage displaying a network of numerous tortuous capillaries of 
anarchic distribution. d) Malignant infiltrating macrotumour, with dilated vessels of the 
intratumour area with strongly BChE positive cells. (Scale bar of 50µm). 
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disease (Bulnes & Lafuente, 2007; Lafuente et al., 1999; Marti et al., 2000; Plate, 1992). 
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Glioma malignancy process is mediated by the vascular remodelling and the angiogenesis 
process where the blood brain barrier (BBB) function is implicated. The BBB is the set of 
mechanisms (physical and metabolic) that regulate the passage of elements from the blood 
plasma to neural tissue. This especial barrier is necessary for the cerebral homeostasis and it 
is associated with the hydrostatic and osmotic pressure gradients across the capillary 
(Hatashita & Hoff, 1986).  
In pathological conditions, the increase of vascular permeability could be due to the blood 
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2000; Bian et al., 2006). Microvascular adaptations in early development stages are based on 
vasodilatation, endothelium elongation and permeability increase mediated by VEGF-A 
without BBB dysfunction. On the other hand, in malignant gliomas the microvascular 
adaptations vary according to blood flow perfusion. Permeability increase in intratumour 
vessels is not enough to supply the metabolic demand, and triggering of the angiogenesis 
process on the tumour border is necessary. When the blood flow inside and around the 
tumour becomes irregular and chaotic, partly due to the aberrant microvessels, the relative 
tissue hypoxia triggers the production of hypoxia inducible factor-1α (Chen et al., 2009; Jain 
et al., 2007), upregulating the expression of VEGF-A and endothelial nitric oxide synthase 
(eNOS). VEGF-A induces the synthesis of NO by phosphorylation of endothelial NO 
synthase via PI-3K/Akt kinase (Osuka et al., 2004, Ziche & Morbidelli, 2009), thus 
promoting BBB breakdown and increasing permeability. Although, the role of eNOS and 
VEGF-A in tumour induced brain oedema is still a matter of debate. Our previous studies 
demonstrates that eNOS overexpression in the microvasculature of intermediate and 
advanced ENU-gliomas correlates with the loss of immunostaining for primary BBB 
markers GluT-1 and EBA (Bulnes et al., 2010) (Figure 4). 
Following the finding showed in human tissues, in ENU-malignant glioma astrocytic 
processes and pericytes were loosely attached to endothelial cells of tumour vessels without 
forming a continuous layer (Baluk et al., 2005) (result not published). In addition to this, 
defective tight junctions (TJs) without occludin protein expression, also lead to oedema 
associated with ENU induced brain tumours. We showed an intratumoural glioma oedema 
instead of peritumoural one by gadolinium contrast enhancement and intravital dyes 
extravasation (Bulnes et al., 2009, 2010). 
6. Glioma stem cells and angiogenesis in ENU model 
The moment named “angiogenenic switch”, when the angiogenesis starts, is showed at 
ENU-glioma intermediate stage due to the presence of overexpression of VEGF and eNOS 
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(Bulnes et al., 2010). Because stem cells have been associated with the synthesis of VEGF 
(Bao et al., 2006), we focused on the identification of GSC using antibodies against the 
antigens CD133 and Nestin. We showed three distribution patterns of these cells (Figure 5): 
1- isolated in the tumour periphery areas; 2- numerous small cells forming intratumour 




Fig. 4. Vascular endothelial growth factor and endothelial nitric oxide synthase expression 
during ENU-glioma development. Confocal microphotographs showing VEGF165 (a-c, red) 
and eNOS (d-f, red) in different stages of glioma. Vascular network is showed by 
immunofluorescence for tomato lectin LEA (green). (a, d) Initial stages of gliomas display 
basal stain of VEGF165 (a) and overexpression of eNOS only in dilated vessels (d, white 
arrow). (b, e) Anaplastic ENU-glioma corresponding with the intermediate tumour stage 
shows overexpression of VEGF165 in the neoangiogenic tumour border (b) and 
overexpression of eNOS (e, yellow) in dilated and tortuous vessels from intratumour area. 
(c, f) ENU-induced glioblastomas show an heterogeneous pattern of expression for both 
markers. VEGF distribution is mainly showed in the peritumour neoangiogenic area (c) 
while eNOS overexpress as patching in vascular sections of intratumour aberrant 
microvessels (f). (Bar scale of 200 µm). 
According to human astrocitomas, in ENU-glioma the number of positive cells for CD133 
and Nestin antibodies increases with malignant grades of the tumour (Ma et al., 2008). 
Nestin+ cells were found in every stage of tumour development. It corroborated that the 
expression of Nestin is linked to the glioma grade, as stated in previous researches 
(Ehrmann et al., 2005).  
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Fig. 5. Immunoexpression of Nestin antigen in 4 μm paraffin sections showed by DAB 
staining (Brown). a-b) Intratumour area of ENU-Glioma showing two kinds of isolated cells 
marked by Nestin antibody. a) Cells of big cytoplasm and nucleon distributed 
predominantly near the periphery of the tumour. They display an astrocyte shape and 
GFAP positivity. b) Small cells with scarce cytoplasm and prolongations. c-d) Two 
distribution of stem cells: Intratumour niches (c) and around the vascular endothelium of 
neoplastic microvessels (d). (Bar scale of 10µm). 
By the other hand, CD133+ cells were only present since intermediate stages corresponding 
with “angiogenenic switch”. The distribution of CD133+ cells corresponds mainly to 
overexpression of VEGF in neoangiogenic border and intratumour hypoxic areas of 
neoplasia (Bulnes & Lafuente, 2007). It has been reported that tumour stem cells over-
express VEGF factor, so this cell population could be involved in the process of 
angiogenesis. Our results agree with the staining of CD133 described in the advanced and 
medium stage of human gliomas. Therefore, CD133 expression has been related to poor 
prognosis (Zeppernick et al., 2008).  
We showed that some cells coexpress the antibodies Nestin, CD133 and VEGF165. They were 
forming niches around microvessels or into hypoxic areas (Figure 6). Only cells distributed 
in the periphery of neoplasia were stained for GFAP and displayed astrocyte morphology.  
The relationship between CD133+ cells and vessels wall was shown around the glomeruloid 
vessels, distributed in the neoangiogenic border of ENU-GBM, and delimiting huge dilated 
intratumour vessels (Figure 7). The presence of CD133+ cells near these aberrant vessels 
which display BBB disturbance may corroborate the pivotal role of stem cells in the 
Endogenous Experimental Glioma Model, 
Links Between Glioma Stem Cells and Angiogenesis 
 
417 
neoplasia proliferation and invasion. These cells may be use extracellular matrix of vessel 
wall to migrate and infiltrate the brain parenchyma (Borovski et al., 2009).  
 
 
Fig. 6. Relationship between stem cell markers and proangiogenic factor VEGF in 
intratumour niches of advanced ENU-glioma stage. Study performed by double 
immunofluorescence, all tumours are counterstained with Hoechst. a-c) Microphotographs 
of Nestin+ cells (a, in green) and VEGF+ cells (b, in red) and colocalization (yellow, c). 
VEGF+ cells predominate over Nestin+ cells. Some cells with big cytoplasm are Nestin-
VEGF+. Small Nestin+ cells form a cluster and lack the staining of VEGF (at the top). d-f) 
Colocalization (yellow) of glial fibrillary acidic protein (GFAP, green) and VEGF (red). All 
VEGF+ cells in this intratumour area are stained for GFAP and display the astrocyte shape. 
g-i) Relationship between the two markers of stem cells: Nestin (green) and CD133 (reed). 
This niche shows higher density of nestin+ cells (g) than CD133+ cells (h). Almost all of the 
CD133+ cells coexpress nestin antibody (i, yellow). j-l) Coexpression of GFAP (green) and 
CD133 (red). Some cells coexpress both antibodies (l, yellow). (x400 Amplification) 
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Fig. 7. Immunofluorescence confocal images of CD133 antibody (red) in ENU-glioblastoma. 
All sections are counterstained with Hoechst (blue). a) Intratumour niche displaying some 
CD133+ cells. b) Tortuous vessel of the periphery of the neoplasia with CD133+ structures 
attached to the vascular endothelium. c) Aberrant vessels sections demarcated by 
CD133+cells. d) Vessels with huge lumen display CD133+ cells around some vascular 
sections. (Scale bar of 20µm).  
Although some authors proposed that CD133+ cells were selected cells with tumorigenic 
capacity (Schiffer et al., 2010), others postulated that a fraction of CD133+ cells might be 
related to the endothelial differentiation and could generate tumour vessels (Wang et al., 
2010). Recently, Soda et al. (2011) reported that part of the vasculature of GBM was 
originated from tumour cells. Therefore, some researchers as Wang et al. (2010) and Ricci-
Vitiani et al. (2010) were centred to describe the proportion of the stem cells that contributed 
to blood vessels in glioblastoma. After their results they postulated that glioblastoma 
microvessels were originated from tumour stem like cells. 
Endogenous Experimental Glioma Model, 




Following evidences reported in the literature and our findings, the distribution of “glioma 
stem cells” close to microvascular wall during the glioma malignancy process suggests a 
synergistic role of both structures. Indeed, based on our results we corroborate the 
hypothesis that glioma stem cells may induce angiogenesis via VEGF synthesis or 
endothelial differentiation. 
This knowledge will contribute to the generation of new antitumour therapy treatment 
against glioma stem cells. ENU experimental model would be considered as an useful 
option to check a design of treatment strategies against these cells. 
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1. Introduction 
Established tumor-derived cell lines are widely and routinely used as in vitro cancer models 
for various kinds of biomedical research. The easy management of these cell cultures, in 
contrast to the inherent difficulty in establishing and mantaining primary tumoral cultures, 
has contributed to the wide use of these inmortalized cell lines in order to characterize the 
biological significance of specific genomic aberrations identified in primary tumors. 
Therefore, it has been assumed that the genomic and expression aberrations of long-term 
established cell lines resemble, and are representative, of the primary tumor from which the 
cell line was derived. Indeed, the cell line-based research has been performed, not only for 
the definition of the molecular biology of several cancer models, but also for the 
investigation of new targeted therapeutic agents in a prior step to clinical practice. The use 
of tumor-derived cell lines has been highly relevant for the testing and development of new 
therapeutical agents, with several cancer cell-line panels having been developed for drug 
sensitivity screening and new agents’ discovery (Sharma et al, 2010).  
Controversial concerning the ability of tumor-derived cell lines to accurately reflect the 
phenotype and genotype of the parental histology has been documented. A previous report 
of Greshock and coworkers using array-based Comparative Genomic Hybridization (aCGH) 
data of seven diagnosis-specific matched tumors and cell lines showed that, on average, cell 
lines preserve in vitro the genetic aberrations that are unique to the parent histology from 
which they were derived, while acquiring additional locus-specific alterations in long-term 
cultures (Greshock et al, 2007). In contrast, a study on breast cancer cell lines and primary 
tumors highlight that cell lines do not always represent the genotypes of parental tumor 
tissues (Tsuji et al, 2010). Furthermore, a parallel genomic and expression study on glioma 
cell lines and primary tumors states that in this specific cancer type, cell lines are poor 
representative of the primary tumors (Li et al, 2008). Given the importance of the use of cell 
lines as models for the study of the biology and development of tumors, and for the testing 
of the mode of action of new therapeutical agents, the knowledge of which genomic 
alterations are tumor-specific or which are necessary for the maintenance of the cell line in 
culture, becomes essential. 
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Sometimes cell line studies are interpreted in the context of artifacts introduced by selection 
and establishment of cell lines in vitro, given the prevalence of documented cell line-specific 
cytogenetic changes acquired with multiple growth passages which is associated with random 
genomic instability. Therefore, the ability of glioma cell-line models to accurately reflect the 
phenotype and genotype of the parental glioma tumors remains unstudied. The aim of this 
study is to compare the genomic aberrations of the most commonly used glioma cell lines for 
in vitro analysis with those alterations more prevalent in primary glioma tumors.  
2. Copy number alterations in glioma cell lines 
2.1 High-level DNA copy number alterations in glioma cell lines 
2.1.1 Amplifications 
Genomic high-level DNA copy number gains (regions of amplification, or amplicons, i.e. 
chromosome regions that show more than 5- to 10-fold copy number increases) were 
detected at 4q, 10q and 19q in two of the cell lines: SW1783 (4q12) and SF767 (10q21.2-q23.1 
and 19p12) (table 1, figure 1). The MLPA analysis confirmed some of the genomic alterations 
observed by aCGH, such as the amplification of PDGFRA (4q12) which was observed in 
SW1783 cell line (see below table 3). 
 
CHROMOSOME GENES CELL LINE (RegionSize Mb)
4q12
CHIC2, GSH2, PDGFRA, KIT, KDR, SRD5A2L, TMEM165, CLOCK, PDCL2, 




COL13A1, H2AFY2, AIFM2, TYSND1, SAR1A, PPA1, NPFFR1, LRRC20, 
EIF4EBP2, NODAL, PRF1, ADAMTS14, SGPL1, PCBD1, UNC5B, SLC29A3, 
CDH23, PSAP, CHST3, SPOCK2, ASCC1, DNAJB12, CBARA1, CCDC109A, 
OIT3, PLA2G12B, P4HA1, NUDT13, ECD, DNAJC9, MRPS16, TTC18, 
ANXA7, ZMYND17, PPP3CB,  , USP54, MYOZ1, SYNPO2L, SEC24C, FUT11, 
NDST2, CAMK2G, PLAU, VCL, AP3M1, ADK, MYST4, DUSP13, SAMD8, 
VDAC2, KCNMA1, DLG5, NAG13, POLR3A, RPS24, ZMIZ1, PPIF, SFTPD, 
ANXA11, MAT1A, DYDC1, DYDC2, TSPAN14, NRG3
SF767 (13.37)
19p12 ZNF43,SINE-R ,ZNF208,ZNF257 SF767 (0.28)
 
Table 1. Summary of high-level gains (amplifications) detected by aCGH 
Amplification of the EGFR gene, located on chromosome 7, and subsequent over-expression 
of EGFR protein, is the most common genetic alteration found in primary glioblastoma 
(GBM), the most aggressive high-grade glioma. This amplification is detected in about 40% 
of these tumors, and is present as double-minute extrachromosomal elements (Louis et al, 
2007). Amplification of the EGFR gene is often associated with structural rearrangements, 
resulting in tumors expressing both wild-type EGFR as well as the mutated EGFR. The most 
common truncated EGFR variant is the EGFRvIII one, consisting of 801-bp in-frame deletion 
comprising exons 2-7 of the gene.  
Among the cell lines analyzed in this study, some of them derived from primary GBMs, 
none of them carried either amplification of the EGFR gene, nor the EGFRvIII mutant form 
of the receptor (Figure 2). Besides, EGFR sequence analysis of exons 18-21, coding for the 
tyrosine kinase domain, revealed not a mutation in this region, unlike what is found in non-
small lung cancer tumors. 
 














Fig. 1. aCGH results of chromosomes 4 (a) and 10 (b) in SW1783 and SF767 cell lines, 
respectively. Moving average of log2-genomic ratios over five neighbouring genes are 
plotted. 
 
Fig. 2. RT-PCR analysis for the detection of EGFR wild-type (EGFRwt) and EGFRvIII mutant 
receptor. The inset shows control gene GAPDH results. Line 1: GOS3, 2: A172, 3: U118, 4: 
SF767, 5: T98, 6: wt EGFR control, 7: EGFRvIII control; M: molecular marker. 
2.1.2 Homozygous deletions 
Analysis of the high-level copy number changes detected by aCGH in the eleven glioma cell 
lines revealed higher frequency of genomic losses than gains. A stringent filter was applied 
in order to detect homozygous deletions. 
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Genomic homozygous losses were detected at 1p, 1q, 2q, 3p, 4q, 5q, 6q, 7p, 9p, 10p, 10q and 
21p (Table 2).  
Homozygous losses affecting two or more cell lines were detected at 1p33, 9p21.3-21.1, 
10q23.2-23.3 and 21p11.1 (Table 2). Main target genes of these regions were: CDKN2C 
(p18INK4c) on chromosome 1, CDKN2A (p16INK4a) and CDKN2B (p15INK4b) on chromosome 9, 
and PTEN on chromosome 10. The most frequent homozygous gene loss was the loss of 
CDKN2A (p16INK4a) and CDKN2B (p15INK4b), affecting nine (82%) and eight (73%) of 11 
glioma cell lines, respectively.  
2.1.2.1 Loss of CDKN2C 
The Cancer Cell Line project (CCL) database from the Genome Cancer Project of the Sanger 
Institute (http://www.sanger.ac.uk/genetics/CGP/CellLines/) was used to confirm these 
alterations when possible. Homozygous deletion of CDKN2C (1p33) was described in this 
project for T98 and U87 cell lines. Homozygous deletion of CDKN2C on U373 cell line was 
not reported in this project. By contrast, this deletion was not reported in the study of Li and 
coworkers for T98 and U87 cell lines (Li et al, 2008). 
2.1.2.2 Loss of CDKN2A and CDKN2B 
CDKN2A (9p21.3) loss of cell lines A172, H4, SW1088, T98, U118 and U87 was reported by 
the CCL project. Similarly, this gene was described as not mutated in SW1783, therefore 
confirming our results. Data from GOS3, LN18 and U373 were not provided in this 
database. Deletion of the 9p21 region was also reported in A172 and U87 cell lines by Li and 
coworkers, again validating our findings. Strikingly, T98 cell line was not deleted in that 
study (Li et al, 2008). Furthermore, the MLPA analyses performed on the cell lines 
confirmed the homozygous deletions observed by aCGH (Table 2). Therefore homozygous 
deletion of the CDKN2A gene was present in 9 of the 11 glioma cell lines (Table 2, Figure 3).  
Remarkably, there were two cell lines that lack any alteration at the CDNK2A locus, either 
by homozygous or hemizygous loss of the region. 
2.1.2.3 Loss of PTEN 
The aCGH analysis revealed homozygous deletion of PTEN in SW1088 and H4 cell lines 
(Table 2), which was confirmed by the MLPA assay (Figure 4). In addition, homozygous 
deletion of PTEN in these cell lines was also reported by the CCL project. PTEN hemizygous 
deletion was detected in SF767 and GOS3 cell lines by aCGH and MLPA. Surprisingly, A172 
cell line had homozygous deletion of all the PTEN probes of the MLPA assay except those of 
exons 1 and 2. This loss could not be detected by the aCGH analysis, probably because only 
two of the three probes included in the microarray were in the deleted part of PTEN 
(homozygous losses were considered as present when three consecutive clones were under 
the threshold 1.0) (Figure 4).  
Further analyses of PTEN sequence were performed attending to PTEN expression (see 
Table 5 in section 3). Western-blot analysis showed PTEN expression in T98, LN18, GOS3 
and SF767 (the two latter carring hemizygous deletion of the gene). Lack of protein 
expression was found in 7 of the eleven cell lines, three of them having homozygous 
deletion of PTEN. Therefore, we carried out exon-sequencing analysis of the other four 
PTEN deficient cell lines (U118, U87, U373 and SW1783) in order to detect putative 
mutations of the genomic sequence that could explain the observed suppression of protein 
expression. U118 and U87 presented a substitution mutation (G>T) in the splicing site of 
exons 8 (c.1026+1G>T) and 3 (c.209+1G>T), respectively; U373 showed an homozygous TT 
insertion in exon 7 causing a shift in the reading frame (c.723_724insTT); and SW1783 
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showed a substitution in exon 7 (c.691C>T) which results in a stop codon (CGA>TGA). The 
latter mutation was confirmed with the database from the Cancer Genome Project (CGP, 
Sanger Institute). The CGP report the same mutation that we found in cell line U373, for the 
U251 glioma cell line, which is derived from the same tumour as U373, and thus contains 
the same TT insertion mutation in PTEN. 
 
CHROMOSOME GENES CELL LINE (Mb lost)
1p33 FAF1, CDKN2C U87 (0.17), T98 (0.07), U373 (0.23)
1p31.1 LRRC44, FPGT, TNNI3K, CRYZ, TYW3 U118
1q42.2 DISC1,SIPA1L2,PCNXL2 GOS3 (1.33)
2q42.2 BAZ2B GOS3 (0.12)
3p24.3 TBC1D5,SATB1,KCNH8,EFHB,RAB5A, SGOL1, PCAF H4 (4.63)
3p24.1 TGFBR2 SF767 (0.23)
3p12.2-p11.2 IGSF4D,VGLL3,CHMP2B,POU1F1,HTR1F, CGGBP1 LN18 (6.32)
4q34.1 FBXO8,HPGD,GLRA3 U118 (0.40)
5q14.1 THBS4, SERINC5 SF767 (0.13)
6q22.2 ROS1,DCBLD1 U118 (0.17)
7p21.2-p21.1
ETV1, DGKB, MEOX2, OSTDC1, 
ANKMY2, BZW2, TSPAN13, 
AGR2, BCMP11, AHR, SNX13, 
HDAC9
SF767 (5.09)
9p22.1-p21.1 SLC24A2 LN18 (6.37)
MLLT3, IFNB1 U118 (10.86), U87 (3.52), LN18
IFNW1 U118, U87,LN18, H4 (1.22)
KLHL9,IFNA2,IFNA8 U118, U87,LN18, H4, SW1088 (7.22)
IFNE1,MTAP U118, U87,LN18, H4, SW1088,A172 (0.71)
9p21.3-p21.1 CDKN2A U118,U87,LN18,H4,SW1088,T98,U373,A172,GOS3 (0.18)
CDKN2B U118, U87,LN18, H4, SW1088, U373, A172, GOS3
ELAVL2 U118, LN18, SW1088
hel-N1 U118, LN18
PLAA, IFT74,  LNG01784, TEK, 
MOBKL2B, LRRN6C U118, SW1088
LINGO2 U118
10p11.21 PARD3 T98 (0.11)
MINPP1 H4 (0.73)
10q23.2 - q23.31 PAPSS2,ATAD1,PTEN H4,SW1088
LIPF,ANKRD22,STAMBPL1, 
ACTA2, FAS,CH25H,LIPA SW1088 (1.50)
10q25.2 TCF7L2 T98 (0.16)
12q21.2 PAWR GOS3 (0.14)
21p11.1 BAGE4,BAGE5,BAGE3,BAGE2, BAGE H4 A172, U118, GOS3 (0.04)
 
 
Table 2. Homozygous losses detected in glioma cell lines by aCGH 
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Fig. 3. Homozygous loss detected on chromosome 9 (including CDKN2Alocus) in two 
representative cell lines: U118 (a) and LN18 (b). Upper panel: aCGH plot (moving average of 
log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
 



















































Fig. 3. Homozygous loss detected on chromosome 9 (including CDKN2Alocus) in two 
representative cell lines: U118 (a) and LN18 (b). Upper panel: aCGH plot (moving average of 
log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
 






































Fig. 4. Homozygous loss detected on chromosome 10 (including PTEN) in two 
representative cell lines: SW1088 (a) and H4 (b). Upper panel: aCGH plot (moving average 
of log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
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2.2 Low-level DNA copy number alterations in glioma cell lines 
Analyses of the DNA copy number changes in 11 of the most commonly used glioma cell 
lines revealed higher frecquency of genomic losses than gains. While 22.15% of the analyzed 
probes were lost, only 12.35% of them presented gains. Chromosomes containing frequently 
gained probes among all the cell lines included chromosomes 7, 16, 17, 19 and 20. Similarly, 
chromosomes containing frequently lost probes included chromosomes 4, 6, 10, 13, 14 and 
18 (Figure 5). Surprisingly, chromosome 9, presenting loss of the CDKN2A/CDKN2B locus 
in most of the cell lines (9 out of 11 cell lines) presented a similar percentage of gained and 
loss probes. This result may be explained due to this loss is relatively small in most of the 
cell lines, and to the low-level DNA copy number gain of most of chromosome 9 in SF767 






































































Fig. 5. Percentage of low-level DNA copy number gains (black) and losses (grey) relative to 
the analyzed probes in the microarray per chromosome. 
Chromosome 7 was one of the most gained chromosomes, with complete or almost 
complete chromosome 7 gain in SW1088 and GOS3 cell lines, or with relative wide regions 
of gain in H4, U373, U118 or A172 cell lines. Gain of the EGFR gene (located at 7p12) was 
evaluated by MLPA assays, showing EGFR low-level copy number gain in 8 out of the 11 
cell lines (table 3).  
Other gains detected by MLPA analysis were PI3KCA, BRAF and BIRC5. Three of the cell 
lines presented a PI3KCA gain (3q). PIK3CA is one of the three genes encoding components 
of PI3K which is involved in activation of AKT signaling. Amplification of PIK3CA has been 
observed in various types of cancer, including gliomas (Karakas, 2006; Kita, 2007; Vogt, 
2006). BRAF oncogene (7q34) was gained in five of the cell lines. BRAF is a serine/threonine 
kinase that is frequently activated in many types of cancer by a specific mutation (V600E). In 
pilocytic astrocytomas, BRAF is frequently activated by tandem duplication and 
rearrangement of part of the gene, resulting in fusion proteins containing the kinase domain 
(exons 9-18). Activation of BRAF through these mechanisms of duplication or fusion is 
infrequent in diffusely infiltrating astrocytic gliomas (Bar et al, 2008; Riemenscheneider et al, 
2010). All the cell lines analyzed in this study were obtained from adult patients with high 




















































Fig. 4. Homozygous loss detected on chromosome 10 (including PTEN) in two 
representative cell lines: SW1088 (a) and H4 (b). Upper panel: aCGH plot (moving average 
of log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
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2.2 Low-level DNA copy number alterations in glioma cell lines 
Analyses of the DNA copy number changes in 11 of the most commonly used glioma cell 
lines revealed higher frecquency of genomic losses than gains. While 22.15% of the analyzed 
probes were lost, only 12.35% of them presented gains. Chromosomes containing frequently 
gained probes among all the cell lines included chromosomes 7, 16, 17, 19 and 20. Similarly, 
chromosomes containing frequently lost probes included chromosomes 4, 6, 10, 13, 14 and 
18 (Figure 5). Surprisingly, chromosome 9, presenting loss of the CDKN2A/CDKN2B locus 
in most of the cell lines (9 out of 11 cell lines) presented a similar percentage of gained and 
loss probes. This result may be explained due to this loss is relatively small in most of the 
cell lines, and to the low-level DNA copy number gain of most of chromosome 9 in SF767 






































































Fig. 5. Percentage of low-level DNA copy number gains (black) and losses (grey) relative to 
the analyzed probes in the microarray per chromosome. 
Chromosome 7 was one of the most gained chromosomes, with complete or almost 
complete chromosome 7 gain in SW1088 and GOS3 cell lines, or with relative wide regions 
of gain in H4, U373, U118 or A172 cell lines. Gain of the EGFR gene (located at 7p12) was 
evaluated by MLPA assays, showing EGFR low-level copy number gain in 8 out of the 11 
cell lines (table 3).  
Other gains detected by MLPA analysis were PI3KCA, BRAF and BIRC5. Three of the cell 
lines presented a PI3KCA gain (3q). PIK3CA is one of the three genes encoding components 
of PI3K which is involved in activation of AKT signaling. Amplification of PIK3CA has been 
observed in various types of cancer, including gliomas (Karakas, 2006; Kita, 2007; Vogt, 
2006). BRAF oncogene (7q34) was gained in five of the cell lines. BRAF is a serine/threonine 
kinase that is frequently activated in many types of cancer by a specific mutation (V600E). In 
pilocytic astrocytomas, BRAF is frequently activated by tandem duplication and 
rearrangement of part of the gene, resulting in fusion proteins containing the kinase domain 
(exons 9-18). Activation of BRAF through these mechanisms of duplication or fusion is 
infrequent in diffusely infiltrating astrocytic gliomas (Bar et al, 2008; Riemenscheneider et al, 
2010). All the cell lines analyzed in this study were obtained from adult patients with high 
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BIRC5 or survivin (17q) was gained in five of the cell lines. Survivin, which promotes cell 
proliferation, angiogenes and inhibits apoptosis, is frequently overexpressed in proliferating 
tissues and tumors (Zhen et al, 2005). In gliomas, survivin overexpression is significantly 
associated with tumorigenesis and progression, and with a worse prognosis of patients 
(Shirai et al, 2009). Previous studies revealed, as well, BIRC5 gain and overexpression in 
oligodendroglial tumors (Blesa et al, 2009). High expression of BIRC5 in nervous system 
tumors have been already reported (Das, 2002; Hogdson, 2009; Sasaki, 2002).  
As a summary, at the gene-level, the most represented gains and losses in the 11 analyzed 
cell lines are shown in table 4. 
 
 CHROMOSOME GENE NAME CELL LINE 
HOM 
LOSS 
9p21 CDKN2A U373, U118, SW1088, GOS3, A172, H4, T98, U87, LN18
10q23 PTEN A172, SW1088, H4
HEMI 
LOSS 
1p13.2 NRAS A172, H4





3q26.3 PIK3CA A172, SW1783, H4
7p12 EGFR U373, U118, SW1088, GOS3, A172, H4, T98, SF767
7q34 BRAF U87, U373, SW1088, GOS3, T98
17p11.2 TOM1L2 LN18
17q25 BIRC5 H4, LN18, T98, U373, SW1783
21q22.3 RUNX1 H4, A172, T98
A 4q11 PDGFRA SW1783
Table 3. Summary of gene-specific MLPA-validated copy number alterations (HOM LOSS: 
homozygous loss; HEMI LOSS: one copy loss; GAIN: low-level copy number gains; A: 
amplifications). 
 
GAIN HOMOZYGOUS DELETION 
Gene (location) Total Gene (location) Total 
EGFR (7p12) 8 CDKN2A (9p21) 9 
BRAF (7q34) 5 CDKN2B (9p21) 8 
BIRC5 (17q25) 5 MTAP (& others; 9p21) 6 
PI3KCA (3q26.3) 3 BAGE (21p11.1) 4 
 PTEN (10q23) 3 
CDKN2C (1p33) 3 
Table 4. Summary of the alterations most represented on the eleven glioma cell lines 
studied. (Total: number of cell lines presenting the alteration described) 
 




































CDKN2A EGFR ERRB2 PTEN P53




Fig. 6. Genomic analysis of A172 (a, b) and SW1088 cell lines (c, d). a) MLPA analysis (each 
bar represents a probe of the MLPA assay) showing EGFR gain, CDKN2A homozygous 
deletion, and PTEN homozygous deletions except for exons 1 and 2. b) aCGH analysis 
(moving average of log2-genomic ratios over five neighbouring genes) of chromosomes 7, 9 
and 10. c) MLPA analysis showing EGFR gain, and homozygous deletions of CDKN2A and 
PTEN d) aCGH analysis of chromosomes 7, 9 and 10. Observe that no PTEN deletions 
(10q23.2) were detected in A172 cell line compared to SW1088. 
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Fig. 6. Genomic analysis of A172 (a, b) and SW1088 cell lines (c, d). a) MLPA analysis (each 
bar represents a probe of the MLPA assay) showing EGFR gain, CDKN2A homozygous 
deletion, and PTEN homozygous deletions except for exons 1 and 2. b) aCGH analysis 
(moving average of log2-genomic ratios over five neighbouring genes) of chromosomes 7, 9 
and 10. c) MLPA analysis showing EGFR gain, and homozygous deletions of CDKN2A and 
PTEN d) aCGH analysis of chromosomes 7, 9 and 10. Observe that no PTEN deletions 
(10q23.2) were detected in A172 cell line compared to SW1088. 
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3. Comparison between copy number alterations in glioma cell lines and 
primary tumors 
Gliomas are the most frequent primary brain tumors, and include a variety of different 
histological tumor types and malignancy grades. High-grade gliomas are those graded as III 
or IV according to the criteria of the World Health Organization (WHO) classification 
system (Louis et al, 2007), including anaplasic astrocytoma (WHO grade III) and GBM 
(WHO grade IV). High-grade gliomas may arise from diffuse astrocytoma WHO grade II or 
III, or de novo, i.e. without evidence of a less malignant precursor lesion. GBM is the most 
frequent primary brain tumor. Primary GBM manifest rapidly de novo, while secondary 
GBM develops slowly from diffuse or anaplastic astrocytomas. 
It is important to note that most of the cell lines used in this study derived from astrocytoma 
tumors of high-grade (8 cell lines: T98, LN18, U373, SW1088, H4, SW1783, U118, and A172), 
with the exception of GOS3 cell line that was derived from a high-grade mixed tumor with 
oligodendroglial component. 
From a genetic point of view, progression to malignancy in gliomas is a multistep process, 
driven by the sequential acquisition and accumulation of genetic alterations. Distinctions 
between the genetic alterations identified in primary and secondary GBM have been made, 
with TP53 mutations occurring more commonly in secondary GBMs and EGFR 
amplifications, and PTEN mutations occurring more frequently in primary GBMs. However, 
none of these alterations sufficiently distinguishes between primary and secondary GBM.  
Recently, a comprehensive sequencing and genomic copy number analysis of GBM tumors 
showed that the majority of the tumors analyzed had alterations in genes encoding 
components of each of the TP53, RB1, and PI3K pathways, previously known to be altered in 
GBMs (Parsons et al, 2008). In these tumors, all but one of the cancers with mutations in 
members of a pathway did not have alterations in other members of the same family, 
suggesting that such alterations are functionally equivalent in tumorigenesis. Opposite to 
what is found in primary and secondary GBMs, glioma cell lines usually harbor functional 
alterations of the three pathways simultaneously (e.g. SW1088, SW1783 or U118, table 5). 
Alteration mutations of the tumor suppressor gene TP53 (located at 17p13.1) and loss of 
heterozygosity on chromosome arm 17p are frequent in secondary GBM. While TP53 copy 
number analysis showed nor gains or losses in the cell lines tested, neither by CGH nor by 
MLPA, point mutations have been reported by the Sanger database in some of the analyzed 
cell lines (Table 5). 
Primary GBM, on another hand, characterises by EGFR amplification or overexpression, 
PTEN mutation, trisomy of chromosome 7, monosomy of 10 and genomic gains of 12p, 19q 
and 20q (Riemenschneider et al, 2010).  
Regarding alterations of PTEN gen (PI3K pathway), loss of chromosome 10 is one of the 
most frequent alteration in primary GBM tumors (60-80% of cases). While many tumors 
show loss of one entire copy of chromosome 10, loss of heterozygosity (LOH) studies have 
reported the involvement of several regions of LOH, suggesting several potential tumor 
suppressor genes in addition to PTEN. The cell lines analyzed in our study frequently 
presented alteration of PTEN gene (nine out of 11 cell lines), either by mutation or genomic 
loss. Absence of PTEN protein expression in these cell lines was confirmed in seven of these 
cell lines by western blot (data not shown). 
Concerning amplifications, EGFR high-level copy number gain is the most frequent 
alteration found in primary GBM. As mentioned before, this alteration is present as double-
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minutes, i.e. small and circular fragments of extrachromosomal DNA that are replicated in 
the nucleus of the cell during cell division but that, unlike actual chromosomes, lack 
centromere or telomere. This EGFR amplification has not been detected in any of the 
analyzed glioma cell lines, probably due to the difficulty in maintaining a highly unstable 
extrachromosomal fragment that lacks centromere, in long-term cultures. A recent report, 
however, describes another type of EGFR gain in which extra copies (in small numbers) of 
EGFR are inserted in different loci of chromosome 7 (Lopez-Gines et al, 2010). The presence 
of this type of gain in glioma cell lines remains to be studied. 
 
RB  pathway
CDKN2A PTEN PTEN seq EGFR EGFRvIII Tp53 p53 mut
T98G del HOMO N - G No N p.M237I
LN18 del HOMO N - N No N* nd
SF767 N del HEMI - G No N* nd
U373 del HOMO N* c.723_724insTT G No N nd
U87MG del HOMO N* c.209+1G>T N No N* nd
SW1088 del HOMO del HOMO* - G No N p.R273C
H4 del HOMO del HOMO* - G No N* nd
SW1783 N N* c.691C>T N No N p.R273C
U118 del HOMO N* c.1026+1G>T G No N p.R213Q
GOS3 del HOMO del HEMI - G No N nd
A172 del HOMO del HOMO*,# - G No N* nd
PI3K  pathway TP53  pathway
 
*Protein expression not detected (Western-blot or Immunohistochemistry, data not shown) #deletion 
except for exons 1 and 2. del HOMO: homozygous deletion; del Hemi: hemizygous deletion; G: Gain; N: 
No copy number change; No: EGFRvIII mutation not detected; p53 mut: data from the Sanger database; 
nd: no data from available. 
Table 5. Alterations of the RB, TP53 and PI3K pathways. 
Thus, at least for what concerns to the EGFR amplification, glioma cell lines seem not to 
resemble primary tumors. This result contrast to what is found in breast cancer cell lines, 
where amplification of ERBB2 (17q12) is detected indeed more frequently in cell lines that in 
primary tumors (Tsuji et al, 2010). Of note, amplification of ERBB2 takes place within 
homogeneously staining regions, where the extra copies of the gene are integrated within 
the chromosome, thus allowing its maintenance in established cell lines. 
Similarly, other amplifications reported in primary GBM tumors have not been found in 
these cell lines, such as those of 1q (MDM4, PIK3C2B), 7q (MET, PEX1, CDK6), 12p (CCDN2) 
12q (MDM2, GLI, CDK4) or 13q (Rao et al, 2010; Ruano et al, 2006). The only common 
amplification detected in glioma cell lines and tumors was that of 4q (PDGFRA) which was 
detected in SW1783 cell line. PDGFRA encodes for a cell surface tyrosine kinase receptor of 
the members of the platelet-derived growth factor family. These growth factors are mitogens 
for cells of mesenchymal origin and activate intracellular signaling through the MAPK, PI3K 
and PKCgamma pathways with roles in the regulation of many biological processes 
including embryonic development, angiogenesis, cell proliferation and differentiation. On 
the other hand, to our knowledge, amplifications of 10q and 19p detected in SF767 cell line 
have not been reported before in glioma tumors.  
Digital karyotyping for eight tumor-derived cultured samples and one bulk tumor was used 
by Rao and coworkers (2010) to describe genomic alterations in GBM. This group described 
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3. Comparison between copy number alterations in glioma cell lines and 
primary tumors 
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driven by the sequential acquisition and accumulation of genetic alterations. Distinctions 
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alterations of the three pathways simultaneously (e.g. SW1088, SW1783 or U118, table 5). 
Alteration mutations of the tumor suppressor gene TP53 (located at 17p13.1) and loss of 
heterozygosity on chromosome arm 17p are frequent in secondary GBM. While TP53 copy 
number analysis showed nor gains or losses in the cell lines tested, neither by CGH nor by 
MLPA, point mutations have been reported by the Sanger database in some of the analyzed 
cell lines (Table 5). 
Primary GBM, on another hand, characterises by EGFR amplification or overexpression, 
PTEN mutation, trisomy of chromosome 7, monosomy of 10 and genomic gains of 12p, 19q 
and 20q (Riemenschneider et al, 2010).  
Regarding alterations of PTEN gen (PI3K pathway), loss of chromosome 10 is one of the 
most frequent alteration in primary GBM tumors (60-80% of cases). While many tumors 
show loss of one entire copy of chromosome 10, loss of heterozygosity (LOH) studies have 
reported the involvement of several regions of LOH, suggesting several potential tumor 
suppressor genes in addition to PTEN. The cell lines analyzed in our study frequently 
presented alteration of PTEN gene (nine out of 11 cell lines), either by mutation or genomic 
loss. Absence of PTEN protein expression in these cell lines was confirmed in seven of these 
cell lines by western blot (data not shown). 
Concerning amplifications, EGFR high-level copy number gain is the most frequent 
alteration found in primary GBM. As mentioned before, this alteration is present as double-
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minutes, i.e. small and circular fragments of extrachromosomal DNA that are replicated in 
the nucleus of the cell during cell division but that, unlike actual chromosomes, lack 
centromere or telomere. This EGFR amplification has not been detected in any of the 
analyzed glioma cell lines, probably due to the difficulty in maintaining a highly unstable 
extrachromosomal fragment that lacks centromere, in long-term cultures. A recent report, 
however, describes another type of EGFR gain in which extra copies (in small numbers) of 
EGFR are inserted in different loci of chromosome 7 (Lopez-Gines et al, 2010). The presence 
of this type of gain in glioma cell lines remains to be studied. 
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*Protein expression not detected (Western-blot or Immunohistochemistry, data not shown) #deletion 
except for exons 1 and 2. del HOMO: homozygous deletion; del Hemi: hemizygous deletion; G: Gain; N: 
No copy number change; No: EGFRvIII mutation not detected; p53 mut: data from the Sanger database; 
nd: no data from available. 
Table 5. Alterations of the RB, TP53 and PI3K pathways. 
Thus, at least for what concerns to the EGFR amplification, glioma cell lines seem not to 
resemble primary tumors. This result contrast to what is found in breast cancer cell lines, 
where amplification of ERBB2 (17q12) is detected indeed more frequently in cell lines that in 
primary tumors (Tsuji et al, 2010). Of note, amplification of ERBB2 takes place within 
homogeneously staining regions, where the extra copies of the gene are integrated within 
the chromosome, thus allowing its maintenance in established cell lines. 
Similarly, other amplifications reported in primary GBM tumors have not been found in 
these cell lines, such as those of 1q (MDM4, PIK3C2B), 7q (MET, PEX1, CDK6), 12p (CCDN2) 
12q (MDM2, GLI, CDK4) or 13q (Rao et al, 2010; Ruano et al, 2006). The only common 
amplification detected in glioma cell lines and tumors was that of 4q (PDGFRA) which was 
detected in SW1783 cell line. PDGFRA encodes for a cell surface tyrosine kinase receptor of 
the members of the platelet-derived growth factor family. These growth factors are mitogens 
for cells of mesenchymal origin and activate intracellular signaling through the MAPK, PI3K 
and PKCgamma pathways with roles in the regulation of many biological processes 
including embryonic development, angiogenesis, cell proliferation and differentiation. On 
the other hand, to our knowledge, amplifications of 10q and 19p detected in SF767 cell line 
have not been reported before in glioma tumors.  
Digital karyotyping for eight tumor-derived cultured samples and one bulk tumor was used 
by Rao and coworkers (2010) to describe genomic alterations in GBM. This group described 
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amplifications in 1q, 7p, 8q and 12q, and homozygous deletions in 1p, 9p and 9q. However 
7p11.2-12.1 (EGFR), 8q24.21 (MYC) and 12q15 (MDM2) amplifications were found just in 
case of the tumor sample, consistent with previous observations that adherent GBM cells 
tend to lose EGFR amplification during culturing. The most frequent amplifications found 
by this group was 12q13.3-q14.1, which targeted GLI1 and CDK4 oncogenes, affecting 3 
samples. Two of the samples showed amplification of PI3KC2B and MDM4 in 1q32.1. Table 
6 shows comparison of our results with those published by Rao and coworkers (2010). Low-
level copy number gains (e.g. PI3KC2B: A172 cell lines; EGFR: 8/11 cell lines) but not 
amplifications were detected in the cell lines. 
The p16ink4a/CDK4/RB1 pathway is important for the control of progression through G1 
into the S phase of the cell cycle. In GBM tumors, alterations affecting this pathway are 
found at an overall frequency of 40-50% (Louis et al, 2007). Homozygous deletions affecting 
CDKN2A locus (9p21) were described by digital karyotyping in 44% of cultured samples 
(four out of nine) (Rao et al, 2010). Our study reveals 82% (9/11) and 73% (8/11) of cell lines 
carrying homozygous deletions for CDKN2A and CDKN2B genes, respectively (Table 6).  
 
Chromosome band Target oncogene Rao % 
(n=9) 











7p11.2-12.1 EGFR 11 73 (G) 
8q24.21 MYC 11 45 (G) 
12q13.3-q14.1 GLI1,CD4 33 18 (G) 
12q14.1 Unknown 22 9 (G) 
12q15 MDM2 11 0 
Homozygous deletions 
1p36.31-p36.23 TP73, LRRC47, DFFB 33 18 
9p21.3-22.3 CDKN2A, CDKN2B 44 82, 73 
9q34.3 CACNA1B 44 0 
Table 6. Comparison of results obtained by Digital Karyotyping (Rao et al, 2010) with aCGH 
alterations observed in glioma cell lines. Only amplification data from Rao´s study was 
available.  
Finally, regarding the number of DNA copy number alterations in cell lines, the lost probes 
almost doubled the gained ones, with an average of losses and gains per cell line of 9,908 
and 5,072 probes, respectively. This result contrast to what is observed in primary GBM 
tumors, having similar numbers of gains and losses (Ruano et al, 2006). Accordingly, similar 
results were obtained in tumor-derived cell lines from other histologies (Greshock et al, 
2007) and specifically in breast cancer cell lines (Tsuji et al, 2010; Naylor et al, 2005), with 
more alterations found in cell lines than in tissue specimens, as a general trend. In fact, 
genomic losses in breast cancer cell lines almost doubled the gains (Tsuji et al, 2010). These 
observations may suggest the accumulation of genomic alterations in long-term cultures 
that are not present in primary tissues. 
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4. Cell culture specific aberrations 
Several of the frequent genomic alterations detected in glioma cell lines are not found in 
primary tumors, suggesting that some of the commonly seen alterations in vitro could be 
artifacts secondary to the selection pressure for optimal cell growth in vitro following years 
of passage. This observation has been reported previously in gliomas (Li et al, 2008), but the 
presence of acquired locus-specific alterations in culture has also been recognized in tumors 
and cell lines of other histologies (Greshock et al, 2007). For example, genome-specific copy 
number alterations of chromosomes 5 (gained), 8, 11 and 18 (lost) in glioma cell lines have 
been attributed exclusively to the phenotype of established cell lines. Furthermore, other 
copy number alterations not commonly found in cell lines, such as those of specific areas of 
chromosomes 2, 3, 6 and 8 have been rarely observed in primary tumors. 
Our findings (Figure 5) have identified areas of low-level gain on chromosomes 5, 16 and 17 
affecting between 5 and 7 cell lines, which do not feature GBM tumors. In addition, areas of 
loss of chromosomes 6, 8, 11, and, most importantly, loss of chromosome 18 have been 
identified in most of cell lines. These alterations seem to be culture-associated changes 
present in cell lines and suggest a genomic instability phenotype in established cell lines that 
is not present in primary tumor tissues. 
Absence of chromosome 13 deletions in glioma cell lines, which were commonly found in 
primary GBMs, was reported by Li and coworkers (2008) as a striking discrepancy between 
cell lines and tumors. Our study, however, did detected chromosome 13 losses (Figure 5). In 
the present study, complete loss of chromosome 13 was identified by aCGH in H4, LN18, 
U373, SW1088 and U118 cell lines, while partial loss was detected in U87, SF767, SW1783 
and A172 cell lines. No loss was observed in T98 and GOS3 cell lines. Curiously, cell lines 
analyzed in common by our study and that of Li, had partial chromosome 13 loss in our 
study and partial chromosome 13 LOH in the study of Li and coworkers (U87 and A172), or 
no chosmosome 13 loss in both studies (T98). 
5. Material and methods  
5.1 Cell lines and cell culture  
The human glioma cell lines GOS3, U87MG (U87), A172, SW1783, U118 MG (U118), T98G 
(T98), SW1088, H4, LN18, U373MG (U373) and SF767WL (SF767) were kindly provided by 
Dr. Velasco (Complutense University of Madrid, Spain) or Dr. Setién (Catalan Institute of 
Oncology, Spain). These cell lines were maintained in RPMI medium containing 10% FBS 
(Gibco, Grand Island, NY) in standard culture conditions. Total DNA and RNA were 
extracted from cell cultures according to standard phenol-chloroform and Trizol (Invitrogen, 
Carlsbad, CA) techniques, respectively. Nucleic acids obtained were quantified using 
NanoDrop-1000 (NanoDrop Technologies, Inc., Wilmington, DE). 
5.2 Comparative genomic hybridization  
Copy number analyses of the 11 glioma cell lines were screened by array-based 
Comparative Genomic Hybridization (aCGH) in the Microarrays Analysis Service of the 
CIPF (Centro de Investigación Principe Felipe, Valencia). “Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis” protocol Version 4.0 (Agilent Technologies, Palo 
Alto, California USA. p/n G4410-90010) was followed to obtain labeled DNA. 2000 ng of 
DNA from samples and reference DNA (pool of sex-matched normal brain DNA) was 
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amplifications in 1q, 7p, 8q and 12q, and homozygous deletions in 1p, 9p and 9q. However 
7p11.2-12.1 (EGFR), 8q24.21 (MYC) and 12q15 (MDM2) amplifications were found just in 
case of the tumor sample, consistent with previous observations that adherent GBM cells 
tend to lose EGFR amplification during culturing. The most frequent amplifications found 
by this group was 12q13.3-q14.1, which targeted GLI1 and CDK4 oncogenes, affecting 3 
samples. Two of the samples showed amplification of PI3KC2B and MDM4 in 1q32.1. Table 
6 shows comparison of our results with those published by Rao and coworkers (2010). Low-
level copy number gains (e.g. PI3KC2B: A172 cell lines; EGFR: 8/11 cell lines) but not 
amplifications were detected in the cell lines. 
The p16ink4a/CDK4/RB1 pathway is important for the control of progression through G1 
into the S phase of the cell cycle. In GBM tumors, alterations affecting this pathway are 
found at an overall frequency of 40-50% (Louis et al, 2007). Homozygous deletions affecting 
CDKN2A locus (9p21) were described by digital karyotyping in 44% of cultured samples 
(four out of nine) (Rao et al, 2010). Our study reveals 82% (9/11) and 73% (8/11) of cell lines 
carrying homozygous deletions for CDKN2A and CDKN2B genes, respectively (Table 6).  
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7p11.2-12.1 EGFR 11 73 (G) 
8q24.21 MYC 11 45 (G) 
12q13.3-q14.1 GLI1,CD4 33 18 (G) 
12q14.1 Unknown 22 9 (G) 
12q15 MDM2 11 0 
Homozygous deletions 
1p36.31-p36.23 TP73, LRRC47, DFFB 33 18 
9p21.3-22.3 CDKN2A, CDKN2B 44 82, 73 
9q34.3 CACNA1B 44 0 
Table 6. Comparison of results obtained by Digital Karyotyping (Rao et al, 2010) with aCGH 
alterations observed in glioma cell lines. Only amplification data from Rao´s study was 
available.  
Finally, regarding the number of DNA copy number alterations in cell lines, the lost probes 
almost doubled the gained ones, with an average of losses and gains per cell line of 9,908 
and 5,072 probes, respectively. This result contrast to what is observed in primary GBM 
tumors, having similar numbers of gains and losses (Ruano et al, 2006). Accordingly, similar 
results were obtained in tumor-derived cell lines from other histologies (Greshock et al, 
2007) and specifically in breast cancer cell lines (Tsuji et al, 2010; Naylor et al, 2005), with 
more alterations found in cell lines than in tissue specimens, as a general trend. In fact, 
genomic losses in breast cancer cell lines almost doubled the gains (Tsuji et al, 2010). These 
observations may suggest the accumulation of genomic alterations in long-term cultures 
that are not present in primary tissues. 
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4. Cell culture specific aberrations 
Several of the frequent genomic alterations detected in glioma cell lines are not found in 
primary tumors, suggesting that some of the commonly seen alterations in vitro could be 
artifacts secondary to the selection pressure for optimal cell growth in vitro following years 
of passage. This observation has been reported previously in gliomas (Li et al, 2008), but the 
presence of acquired locus-specific alterations in culture has also been recognized in tumors 
and cell lines of other histologies (Greshock et al, 2007). For example, genome-specific copy 
number alterations of chromosomes 5 (gained), 8, 11 and 18 (lost) in glioma cell lines have 
been attributed exclusively to the phenotype of established cell lines. Furthermore, other 
copy number alterations not commonly found in cell lines, such as those of specific areas of 
chromosomes 2, 3, 6 and 8 have been rarely observed in primary tumors. 
Our findings (Figure 5) have identified areas of low-level gain on chromosomes 5, 16 and 17 
affecting between 5 and 7 cell lines, which do not feature GBM tumors. In addition, areas of 
loss of chromosomes 6, 8, 11, and, most importantly, loss of chromosome 18 have been 
identified in most of cell lines. These alterations seem to be culture-associated changes 
present in cell lines and suggest a genomic instability phenotype in established cell lines that 
is not present in primary tumor tissues. 
Absence of chromosome 13 deletions in glioma cell lines, which were commonly found in 
primary GBMs, was reported by Li and coworkers (2008) as a striking discrepancy between 
cell lines and tumors. Our study, however, did detected chromosome 13 losses (Figure 5). In 
the present study, complete loss of chromosome 13 was identified by aCGH in H4, LN18, 
U373, SW1088 and U118 cell lines, while partial loss was detected in U87, SF767, SW1783 
and A172 cell lines. No loss was observed in T98 and GOS3 cell lines. Curiously, cell lines 
analyzed in common by our study and that of Li, had partial chromosome 13 loss in our 
study and partial chromosome 13 LOH in the study of Li and coworkers (U87 and A172), or 
no chosmosome 13 loss in both studies (T98). 
5. Material and methods  
5.1 Cell lines and cell culture  
The human glioma cell lines GOS3, U87MG (U87), A172, SW1783, U118 MG (U118), T98G 
(T98), SW1088, H4, LN18, U373MG (U373) and SF767WL (SF767) were kindly provided by 
Dr. Velasco (Complutense University of Madrid, Spain) or Dr. Setién (Catalan Institute of 
Oncology, Spain). These cell lines were maintained in RPMI medium containing 10% FBS 
(Gibco, Grand Island, NY) in standard culture conditions. Total DNA and RNA were 
extracted from cell cultures according to standard phenol-chloroform and Trizol (Invitrogen, 
Carlsbad, CA) techniques, respectively. Nucleic acids obtained were quantified using 
NanoDrop-1000 (NanoDrop Technologies, Inc., Wilmington, DE). 
5.2 Comparative genomic hybridization  
Copy number analyses of the 11 glioma cell lines were screened by array-based 
Comparative Genomic Hybridization (aCGH) in the Microarrays Analysis Service of the 
CIPF (Centro de Investigación Principe Felipe, Valencia). “Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis” protocol Version 4.0 (Agilent Technologies, Palo 
Alto, California USA. p/n G4410-90010) was followed to obtain labeled DNA. 2000 ng of 
DNA from samples and reference DNA (pool of sex-matched normal brain DNA) was 
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fragmented and labeled (Cyanine 3-dUTP for the cell lines DNA and cyanine 5-dUTP for the 
reference DNA) according to the “Agilent Genomic DNA labeling kit plus” protocol. 
Labeled DNA was hybridized with Human Genome CGH Microarray 44 k (Agilent p/n 
G4426B-014950) containing 45,214 probes with 42,494 distinct biological features. Arrays 
were scanned in an Agilent Microarray Scanner (Agilent G2565BA). Data was analyzed 
using DNA Analytics 4.0 CGH Module (Agilent Technologies). Genomic alterations were 
detected using an ADM-2 algorithm with two different filters: one, used to detect low level 
alterations, , detects those alterations affecting to three consecutive probes with a ratio above 
or below to 0.25; the other, used to obtain amplifications or homozygous deletion, included 
in 2.1 section, detects only three consecutive probes above or below a ratio of 1.0.  
5.3 MLPA analysis 
Specific gene alterations were validated by Multiple ligation probe assay experiments 
(MLPA®, Mrc-Holland, The Netherlands) with SALSA MLPA kit P105 Glioma-2 for EGFR, 
PTEN, CDKN2A and p53. Besides, SALSA® MLPA® kit P173 was used to detect copy 
number alteration of several genes which are frequently altered in several tumors, such as: 
BCL2L11, BIRC5, BRAF, ERBB4, JAK2, NRAS, PDGFRA, PIK3C2B, PIK3CA. MLPA assays 
were carried in total DNA from the eleven cell lines, obtained by standard methods, 
following manufacturers’ conditions. Polymerase chain reaction products were separated 
and quantified on an ABI PRISM 310 DNA sequencer (Applied Biosystems), and 
electropherograms were analyzed using GeneMapper v.3.7 software (Applied Biosystems). 
Three nontumor reference samples were included in each run. 
5.4 EGFRvIII analysis 
Presence of EGFR vIII variant was determined by RT-PCR from total RNA of the cell 
cultures. cDNA was obtained from lµg of total RNA using the Superscript System (Gibco®). 
Primers and PCR conditions used were previously described (Lee et al, 2006). 
Amplifications products were visualized in bromure ethydium 2% agarose gel. 
5.5 EGFR and PTEN sequence analysis  
Mutations in exons 1 to 9 of PTEN gene and 18 to 21 of the EGFR gene were screened by 
direct sequencing in an ABI PRISM 310 DNA Analyser (Applied Biosystems) according to 
the manufacturer’s instructions. PCR primers and conditions for EGFR amplification were 
previously described (Hsieh et al, 2006). 
 
Exon Upstream primer 5'-3' Downstream primer 5'-3' Annealing T (°C)
1 TCCTCCTTTTTCTTCAGCCAC GAAAGGTAAAGAGGAGCAGCC 56
2 GCTGCATATTTCAATCAAACTAA ACATCAATATTTGAAATAGAAAATC 54
3 TGTTAATGGTGGCTTTTTG GCAAGCATACAAATAAGAAAAC 56
4 TTCCTAAGTGCAAAAGATAAC TACAGTCTATCGGGTTTAAGT 56
5 TTTTTTTTTCTTATTCTGAGGTTAT GAAGAGGAAAGGAAAAACATC 51
6 AGTGAAATAACTATAATGGAACA GAAGGATGAGAATTTCAAGC 54
7 AATACTGGTATGTATTTAACCAT TCTCCCAATGAAAGTAAAGTA 56
8 TTTTTAGGACAAAATGTTTCAC CCCACAAAATGTTTAATTTAAC 54
9 GTTTTCATTTTAAATTTTCTTTC TGGTGTTTTATCCCTCTTG 54  
Table 7. PTEN sequence and annealing temperature used for PCR reactions of nine exon 
primers 
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6. Conclusion  
High-level copy number alterations have been observed in cell lines of different sources 
such as breast, melanoma or lung tumors. Some authors suggest that some of the commonly 
seen alterations in the glioma cell lines can be due to the in vitro cell growth process 
following long term passage cultures. These observations are based on (i) the comparison of 
the genomic alterations of glioma and other non glioma cancer cell lines: some of these 
alterations are common between established cancer cell lines from different origin and 
uncommon in glioma tumors (Li et al, 2008). ii) Differential expression analyses suggest that 
established cancer cell lines share an underlying molecular similarity more closely related to 
their in vitro culture conditions than to their original tumor type of origin. Although some 
functional signalling pathways are up-regulated both in glioma tumors and glioma cell lines 
(epidermal growth factor receptor, vascular endothelial growth factor receptor, p53, PI3K 
pathway), there are some others gene expression sets whose up-regulation is just seen in 
cancer cell lines (cell cycle, proteasome activity, purine metabolism, mitochondrial activity). 
Our findings show that established glioma cell lines and glioma tumours have differences in 
genomic alterations, concluding that glioma cell lines may not be such an accurate 
representation or model system for primary gliomas as would be desirable. As opposed to 
primary tumors, glioma cell lines did not present either EGFR amplification, or presence of 
EGFRvIII variant, events that are frequent in high-grade gliomas. Homozygous CDKN2A 
deletion was frequently observed in glioma cell lines, as occur in cell lines derived from 
other histologies and in glioma tumors. Chromosome 7 gain and PTEN deletions represent 
the most specific glioma alterations present in these cell lines. 
The easy of management of glioma cell lines make these cell lines as good candidate models 
for exploring basic glioma biology and for the use and discovery of therapeutic agents in 
preclinical screens. However, it is of interest that cell clycle-related alterations of gene 
expression are importantly affected in these cell lines, and that most drugs have been tested 
for cytotoxicity against rapidly dividing cells. Therefore, selection bias toward the 
identification of therapeutic agents involved in molecular functions more related to the long 
term culture than to glioma biology could occur. 
On the other hand, many efforts are being done to create adequate culture conditions that 
allow the maintenance of the genomic profiles of the original tumor, such as glioma stem-
like cell cultures, which may be more representative of their parent tumors. Several reports 
have demonstrated that glioma cultures under serum free conditions and stimulated with 
mitogens, epidermal growth factor and fibroblast growth factor, grow as neurospheres and 
maintain a phenotype and genotype closer to that typical of primary tumours compared to 
traditional serum-derived cell lines and culture techniques (Fael Al-Mayhani et al, 2009; 
Ernst et al, 2009). Perhaps, the standardization of this culture method could enhance and 
improve the research with cell lines in brain tumors.  
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Exon Upstream primer 5'-3' Downstream primer 5'-3' Annealing T (°C)
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Oxidative Stress and Glutamate 
Release in Glioma  
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1. Introduction  
Glioma are a family of glial cell tumours of the central nervous system (CNS) well-
characterized as aggressive cancers with dismally limited treatment options. The relatively 
recent discoveries of mechanisms surrounding glioma cell antioxidant protection and 
neuronal and glial cell destruction have opened the gates to a new therapeutic avenue 
whose implications to the field of cancer biology extend far beyond the treatment of glioma 
alone. Stemming from the discovery of significant glutamate release and glutathione 
production by glioma cells, the mechanisms through which glioma mediate oxidative stress 
and influence their extracellular microenvironment are now being unravelled.  
This chapter will discuss the upregulation of the cystine/glutamate antiporter, system xc-, in 
glioma and the far ranging consequences that stem from this compensatory action. 
Specifically, a characteristic shift of cancer cell metabolism away from the tricarboxylic acid 
(TCA) cycle and towards increased rates of glycolysis, a process termed the Warburg effect, 
produces a high amount of reactive oxygen species (ROS) that would prove cytotoxic 
without adequate cellular antioxidant defences. In response to this metabolic abnormality, 
glioma have demonstrated increased synthesis of the primary cellular antioxidant 
glutathione and an increased circulation of the cystine/cysteine redox cycle. These 
antioxidant increases are driven by an upregulation of system xc-, which supplies the cell 
with the rate limiting substrate for glutathione synthesis, cysteine, and acts as one half of the 
transport machinery for the cystine/cysteine cycle. The increased tolerance to oxidative 
stress that is conferred by these mechanisms allows glioma survival and growth advantages 
and mediate chemo- and radiation-resistance to treatment. The corollary effect of cystine 
import via system xc- is the export of the neurotransmitter and ubiquitous cell-signalling 
molecule, glutamate. This release has destructive consequences for the peritumoral brain. 
Glutamate induces neuronal and glial excitotoxic cell death, and acts in an autocrine and 
paracrine signalling manner to stimulate glioma cell growth and migration. Treatments 
based on these mechanisms are currently under development and some have progressed as 
far as clinical trials. Glutamate receptor antagonists and system xc- inhibitors are as of yet the 
primary avenues of investigation. The potential treatment benefits of targeting these 
pathways are great, and the discovery of system xc- prevalence in other cancers beyond 
glioma suggests that study of this pathway may produce wide-ranging cancer treatment 
options. 
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2. Glioma metabolism and oxidative stress 
Cancer cells exist under self-induced conditions of abnormally elevated oxidative stress 
resulting from a characteristic shift in glucose metabolism away from the TCA cycle and 
towards a high rate of aerobic glycolysis (Kroemer & Pouyssegur, 2008). This metabolic shift 
results in less efficient ATP production from glucose by the cell, but serves to confer unique 
benefits upon the cancer cell allowing survival in conditions of high proliferation, high 
oxidative stress, and varying access to blood vasculature. One adaptive characteristic of 
cancer cells is the upregulation of antioxidant defence mechanisms, necessary for protection 
from the high level of ROS generated by escalated glycolysis.  
2.1 Cancer cell metabolism 
In normal cells, the metabolism of glucose generates ATP through glycolysis followed by a 
high rate of pyruvate metabolism through the TCA cycle. The final electron acceptor in the 
TCA cycle is oxygen, without which, the cycle ceases to function, and pyruvate is converted 
to lactate via anaerobic glycolysis (Kim & Dang, 2006). Anaerobic glycolysis is prevalent in 
hypoxic environments when the TCA cycle has no access to oxygen, however, glycolysis is 
also predominant in cancer cells even during aerobic conditions (Kim & Dang, 2006). This 
phenomenon of cancer cell metabolism was first described in the 1920s by Nobel laureate 
Otto Warburg and is to this day termed the Warburg effect, or aerobic glycolysis (Warburg 
et al., 1927). Most cancer cells, limited with regards to energy production by their shift away 
from the efficiency of the TCA cycle, rely upon an increased rate of glucose uptake for 
glycolytic ATP production. This allows the cell a number of advantages including the use of 
glycolytic intermediates for anabolic reactions, without which, rapidly proliferating cells in 
conditions of fluctuating oxygen availability could not survive (See review by Kroemer & 
Pouyssegur, 2008). All aerobic respiration generates ROS which induces oxidative damage 
within the cell (Balendiran et al., 2004). The enhanced metabolic activity of cancer cells raises 
ROS production to a level that demands adaptation by the cell to survive and proliferate 
despite the resulting high level of oxidative stress (Halliwell, 2007). The Warburg effect has 
been identified as a key factor in the increased oxidative stress that cancer cells face, and has 
also been directly implicated in the activation of oncogenes and the loss of tumour 
suppressor genes (Le et al., 2010). 
2.2 Glutathione synthesis response 
Glutathione (GSH) is a tripeptide thiol synthesized intracellularly from the amino acids 
glutamate, cysteine and glycine. In the cell it performs a number of functions, one of which 
is as the predominant cellular antioxidant in the body (Meister, 1995). GSH fulfils this role 
by acting as a substrate for several antioxidant enzymes as well as by acting directly upon 
free radicals in its reduced form, GSH, or in its oxidized form, glutathione disulfide 
(Meister, 1995). The rate-limiting step in GSH biosynthesis is the availability of cysteine, 
which in glioma cannot be synthesized intracellularly (Ishii et al., 1992). In glioma, increased 
oxidation of intracellular GSH and elevated oxidative stress induce the upregulation of 
cystine transport into the cell, allowing the dual processes of increased GSH biosynthesis, 
and increased cycling of the cystine/cysteine redox cycle, both of which counter the effects 
of ROS mediated damage (Banjac et al., 2008; Chung et al., 2005).  
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3. The System xc- antiporter and glioma 
In several cancers including glioma, cysteine must be obtained through the import of cystine 
from the extracellular environment. Cystine is imported into the cell via the system xc- 
cystine/glutamate antiporter; a transporter that is a feature of many cancer cell lines and 
endogenous to many tissues in the body. Cystine is the oxidized form of the amino acid, 
comprised of two cysteine molecules joined by a covalent double bond, and more prevalent 
in the oxidizing extracellular space. In the reducing environment of the cell, imported 
cystine is rapidly reduced to cysteine which is then incorporated as a substrate in GSH 
biosynthesis or serves to propel the cystine/cysteine redox cycle that plays a large role in 
maintaining extracellular redox balance (Ishii et al., 1992). The exported glutamate can have 
a number of deleterious effects upon the surrounding host tissue, many of which favour 
cancer cell survival and progression (Ishii et al., 1992).  
3.1 System xc- 
System xc- is the name given to the Na+ independent electroneutral exchanger of cystine and 
glutamate first described in human fibroblasts by Bannai & Kitamura (1980), and later 
named by Makowske & Christensen (1982). It is classified within the family of heteromeric 
amino acid transporters, all of which are comprised of a single heavy polypeptide subunit 
(SLC3 family) and a single light subunit (SLC7 family) coupled via a disulfide bridge 
(Chillarón et al., 2001). These transporters are essential for the import of amino acids to the 
cell that cannot be intracellularly synthesized. In system xc- the heavy subunit is 4F2hc 
(SLC3A2), a type II membrane glycoprotein common to many amino acid transporters 
(Verrey et al., 2004). It plays a regulatory role, functioning to traffic and adhere the 
transporter complex to the cell membrane. It features one transmembrane domain, and has a 
molecular weight of ~85 kDa (Lim & Donaldson, 2010). 4F2hc is not essential to the 
transport action of system xc- , and can be supplanted with another heavy chain polypeptide 
with similar transport and adherence capabilities, (ex. rBAT) without losing antiporter 
function (Wang et al., 2003). The light subunit of system xc- is xCT (SLC7A11), which is 
entirely responsible for the amino acid exchange function of the transporter and unique to 
system xc-. It features 12 transmembrane domains, and has a molecular weight of ~55 kDa 
(Lim & Donaldson, 2010). Cystine and glutamate are exchanged with a 1:1 stoichiometry 
that does not require an ionic gradient, rather it is thought that glutamate, which must be 
eliminated from the cytosol to prevent toxicity, provides the concentration gradient 
necessary for transporter function (Bannai & Ishii, 1988).  
3.1.1 System xc- in glia 
System xc- is expressed endogenously in a number of tissues in the body. In the human 
brain, it is a feature of both neurons and glial cells. Specifically, xCT was found to be 
expressed in neurons of the cerebral cortex, GFAP positive glial cells, vascular endothelial 
cells and the leptomeninges (Burdo et al., 2006). The prominence of system xc- in the brain is 
thought to be related to the organ’s relatively high rate of glucose metabolism and the need 
for antioxidants to protect highly sensitive neurons from the resulting ROS production 
(Conrad & Sato, 2011). The expression of xCT fluctuates greatly, and can be readily induced 
under a number of stimuli including low levels of extracellular cystine (Bannai & Kitamura, 
1982), and oxidative stress (Bannai et al., 1991). In astrocytes, the induced upregulation of 
xCT increased GSH synthesis and release and conferred antioxidant protection on immature 
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neurons in an in vitro co-culture model (Shih et al., 2006). Due to its critical role in 
maintaining antioxidant and glutamate balance, the misregulation of system xc- has the 
potential for great damage, and the transporter has been implicated in a number of CNS 
pathologies, including some characteristic features of morbidity in glioma.  
3.1.2 System xc- in glioma 
The ability of xCT to be readily induced upon exposure to oxidative stress or cysteine deficit 
is thought to be responsible for the presence of system xc- as a cell-culture induced artifact in 
some cell lines. In glioma cell lines this is not the case; system xc- has not only been 
demonstrated in established cell lines (Chung et al., 2005), but also in normal glia (Burdo et 
al., 2006), and in glioma tumour samples from patients (Lyons et al., 2007). 
In glioma, glucose metabolism is significantly escalated, as is characteristic of cancer cell 
metabolism. The resulting increase in the production of ROS from aerobic glycolysis induces 
the upregulation of xCT expression (Kim et al., 2001). With 4F2hc present in abundance, this 
xCT increase is sufficient to initiate an upregulation of system xc- characteristic of glioma 
(Sontheimer, 2008). The consequences of this system xc- upregulation are immensely 
detrimental to the patient as a result of both of the substrate actions of the antiporter. The 
greater import of cystine by system xc- allows the cell to survive and proliferate in conditions 
of oxidative stress that would be lethal to other cells. This increased resistance has a 
destructive outcome for the patient, allowing the glioma to survive and progress to a greater 
extent, and endowing the cell with resistance to cancer treatments, many of which attack 
cancer cells through increased oxidative stress. The simultaneous export of high levels of 
glutamate into the microenvironment of glutamate-sensitive brain tissues induces neuron 
and glial cell death and promotes the growth and migration of the tumour. These uniquely 
destructive outcomes from the action of system xc- ultimately aid the progression of the 
cancer. (See Fig. 1 concept model). 
4. System xc- and oxidative stress in glioma  
The upregulation of xCT readily occurs in response to oxidative stress. To mediate 
oxidative damage, the system xc- antiporter acts in two cystine-dependent manners to 
provide antioxidant capabilities to the cell and surrounding microenvironment. By 
increasing the availability of intracellular cysteine, this rate-limiting substrate is provided 
for both the synthesis of GSH, and for the completion of one half of the cystine/cysteine 
redox cycle. 
4.1 System xc- drives glutathione synthesis 
Within the cell, the tripeptide GSH is synthesized from its constituent amino acids, glycine, 
glutamate and cysteine via the enzymes -glutamylcysteine synthetase, adding glutamate; 
and glutathione synthetase, adding glycine in two steps (See Fig. 2). Oxidized GSH can be 
reduced back to its active form via glutathione reductase (Conrad & Sato, 2011). The rate-
limiting factor in this pathway is the availability of intracellular cysteine (Ishii et al., 1987). 
Most mammalian cells have the ability to directly import cysteine with a number of 
transporters (Lo et al., 2008), however cysteine is not prevalent in the extracellular space to 
the degree of cystine. Upon export from the cell, cysteine, the reduced and more prominent 
intracellular form of the amino acid, is rapidly oxidized to cystine, which is vastly more 
 
 




Fig. 1. Summary concept model demonstrating the impact of altered cancer cell metabolism 
and cytotoxic treatments on cellular ROS, the upregulation of system xc-, and the consequent 
import of cystine and export of glutamate. Cystine import allows the synthesis of GSH and 
the cycling of the cystine/cysteine redox cycle. The export of glutamate has cytotoxic effects 
on brain cells within the tumour microenvironment, and autocrine and paracrine effects on 
the glioma initiating growth and increased migration.  
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Fig. 2. Glutathione biosynthesis and the cystine/cysteine redox cycle as driven by amino 
acid transporters in glioma. Glutamate is secreted by system xc- which requires both 
substrates to function. 
common in circulation (Bannai & Ishii, 1988). Not all cells possess the molecular machinery 
to import cystine, however, many brain cells and consequently, glioma with their high 
expression of system xc- and abundance of intracellular glutamate have both the mechanisms 
and the gradient to drive cystine transport. Once inside the cell, cystine is reduced to 
cysteine where it can be incorporated into polypeptide synthesis including the synthesis of 
GSH (Savaskan & Eyüpoglu, 2010). System xc- is one of many cystine transporters in the 
CNS, however it has been identified as the only cystine transporter expressed in glioma 
(Chung et al., 2005). Many cancers including glioma have demonstrated increased basal 
levels of intracellular GSH (Louw et al., 1997). Pharmacological inhibition of system xc-, and 
therefore limitation or elimination of available intracellular cysteine is able to deplete 
intracellular GSH almost entirely in a dose and time-dependent manner in glioma cell lines 
(Chung et al., 2005; Chung & Sontheimer, 2009; Pham et al., 2010). The negative effects of 
this GSH limitation on cell growth can be rescued entirely by the introduction of membrane 
permeable exogenous GSH, suggesting that cysteine availability for GSH production is 
critical for glioma cell growth (Chung & Sontheimer, 2009). 
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4.2 System xc- drives the cystine/cysteine redox cycle 
As cysteine is rate-limiting in GSH synthesis, it is well expected that increased availability of 
the amino acid from system xc- upregulation would have the observed positive impact on 
GSH levels. Increased cystine import in glioma has also been demonstrated to drive the 
cystine/cysteine redox cycle across the cell membrane, which acts independently of GSH to 
counter ROS. To cycle the amino acid , cystine is imported by system xc-, where it is 
promptly reduced in the cytoplasm, likely by GSH, and conversely cysteine is exported by 
the amino acid transporters system-L or system ASC to the extracellular environment where 
it is promptly oxidized (Conrad & Sato, 2011). It was discovered in xCT induced lymphoma 
cells that the cystine/cysteine cycle raised concentrations of extracellular cysteine and acted 
as an effective antioxidant even in cases of GSH depletion (Banjac et al., 2008). A subsequent 
study found that in cells negative for γ-glutamylcysteine synthetase and therefore unable to 
produce GSH, the cystine/cysteine cycle was sufficient to maintain oxidative stress 
protection (Mandal et al., 2010). This suggests that alternative redox systems can 
compensate for each other to the point of redundancy, and in this case, both cycles are 
driven by the import of cystine (Mandal et al., 2010). Both this redox cycle and GSH 
synthesis are enabled by the actions of system xc- and in glioma, both confer protection from 
oxidative stress to the cell.  
4.3 Consequences of ROS resistance 
The upregulation of antioxidant defences in glioma cells confers proliferation and survival 
benefits to glioma above those of normal cells without which, glioma could not thrive in their 
self-induced oxidative environment. The ability of glioma to upregulate antioxidant 
production in the face of ROS has long been suspected to contribute to the chemotherapy and 
radiation-resistance that is devastatingly common in the treatment of glioma, a condition 
already characterized by poor prognoses (Sontheimer, 2008). A large scale microarray to 
coordinate transporter gene expression in 60 cancer cell lines with the activity of 1400 
anticancer drugs revealed 39 drugs that positively correlate with SLC7a11 (xCT) expression 
and 296 that negatively correlate (Huang & Sadée, 2006). An example of a positively 
correlating drug is L-alanosine, an amino acid analogue whose uptake is mediated by system 
xc-. The authors demonstrated that pharmacologic system xc- inhibition reduced the efficacy of 
L-alanosine by impeding its system xc- mediated uptake. A negatively correlating drug is 
geldanamycin, an antibiotic that targets heat shock protein 90 (Hsp90). System xc- inhibition 
increased the efficacy of geldanamycin through a reduction of intracellular GSH which 
reduced cellular resistance to the drug’s cytotoxicity (Huang et al., 2005). Celastrol is another 
Hsp90 targeting drug that has demonstrated antitumoral properties specifically in glioma, and 
is also very negatively correlated with SLC7a11 expression (Huang et al., 2008). Inhibition of 
system xc- in celastrol-resistant glioma cells reduced chemoresistance to celastrol treatment, as 
did other negative modulators of GSH synthesis, indicating that celastrol resistance in glioma 
is at least in part mediated through the availability of GSH (Pham et al., 2010). 
5. System xc- and glutamate  
The corollary effect of system xc- mediated cystine uptake is the necessary secretion of 
glutamate into the extracellular space, without which system xc- cannot function. It has been 
demonstrated that glioma cells secrete amounts of glutamate via this mechanism that are 
significant enough to mediate excitotoxic cell death in the brain (Sontheimer, 2003; Takano 
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et al., 2001; Ye & Sontheimer, 1999). The amino acid glutamate is most well known as the 
primary excitatory neurotransmitter in the CNS, however it also functions as a growth 
factor and motogen to different cell types in the brain (de Groot & Sontheimer, 2010), and 
mediates critical cell signalling in many non-neuronal tissues (Hinoi et al., 2004).  
5.1 Glutamate release 
The normal brain usually does not harbour extracellular glutamate in excess of 1-3µM, likely 
due to the glutamate reuptake mechanisms of glia (de Groot & Sontheimer, 2010). In vitro, 
astrocyte cultures demonstrate the ability to reduce extracellular glutamate concentrations 
to near 1µM from 92µM within 3 hours, while conversely several glioma cell lines raised 
extracellular glutamate to 400-500µM in a 12-hour period (Ye & Sontheimer, 1999). When 
neurons were grown in co-culture or treated with media from independent glioma cultures, 
neurons died from glutamate-mediated excitotoxicity (Ye & Sontheimer, 1999). In normal 
brain, glutamate released into the extracellular space is rapidly removed, either back into the 
presynaptic nerve terminal, or, more commonly, by glial cells via one of the excitatory amino 
acid transporters (EAAT1 or EAAT2) (Danbolt, 2001). Glutamate reuptake is a key feature of 
normal glial cells that surround the synaptic cleft, a mechanism that contributes to neuron 
protection and signal consistency (de Groot & Sontheimer, 2010). It has been demonstrated 
by microarray that EAAT2 expression in glioma is negatively correlated with tumour 
progression, and that induction of glioma with EAAT2 expression dose-dependently limits 
cell growth, suggesting that the loss of EAAT function in glioma cells may play a role in the 
accumulation of extracellular glutamate (de Groot et al., 2005). Glutamate release from 
glioma was confirmed in vivo through glioma cells implanted into rat brain. Glutamate was 
measured to be highest in peritumoral regions, significantly higher than in the normal brain 
and the tumour itself (Behrens et al., 2000; Takano et al., 2001). Cells of the same type cloned 
as to not release glutamate grew significantly smaller tumours than their glutamate-
releasing counterparts (Takano et al., 2001). In glioma patients, despite conflicting reports, it 
appears that glutamate concentrations are significantly elevated in glioma in both the 
tumour (Behrens et al., 2000) and the peritumoural region (Roslin et al., 2003).  
5.2 Consequences of glutamate release 
Glutamate release into the peritumoral environment has a number of cytotoxic and cell 
signalling effects whose results are advantageous to glioma and seriously deleterious to the 
host. It has been suggested that glutamate release confers an adaptive advantage upon 
glioma (Sontheimer, 2003), but it is also possible that the release in great quantities of such a 
ubiquitous signalling molecule into a tissue that is highly sensitive to such molecules exerts 
a disruptive influence simply as a side-effect. This has also been demonstrated as a feature 
of glutamate-releasing cancers metastasized to bone, a tissue where glutamate is an 
important intercellular communication molecule (Seidlitz et al., 2010).  
Glioma exist in an environment physically constrained to the cavity of the cranium, a space 
consumed by 85% tissue and 15% cerebrospinal fluid (CSF). To grow, glioma must create 
space to occupy, as compression cannot occur in a vessel filled with fluid. Glutamate-
induced excitotoxic cell death is thought to be principally responsible for the clearance of 
brain cells along the tumour borders that allows glioma progression. Indicating the 
succeptability of brain tissues to glutamatergic disruption is that no cell type in the brain is 
without receptors for glutamate. The inhibition of system xc- in glioma significantly reduces 
extracellular glutamate levels, as well as neurodegeneration and cellular edema both in vitro 
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and in vivo, indicating the role of system xc- in the induction of these morbidities (Savaskan 
et al., 2008). Excitotoxicity is thought to be initiated as a result of excessive activation of 
glutamate receptors resulting in the uncontrolled increase of intracellular Ca2+ which 
stimulates the activation of cytotoxic enzymes (Choi, 1988). Neurons possess both the 
ionotropic α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid (AMPA) glutamate 
receptors, and N-methyl-D-aspartate (NMDA) glutamate receptors for excitatory glutamate 
signal transmission. Neurons in coculture and in vivo were shown to be highly sensitive to 
excitotoxic cell death when exposed to glutamate release from glioma (Takano et al., 2001). 
Treatment with the NMDA receptor antagonist MK801 reduced but did not entirely 
eliminate this excitotoxicity (Takano et al., 2001).  
Normal glial cells are also highly receptive to glutamate. Oligodendrocytes demonstrate a 
similar low tolerance to glutamate exposure as neurons, while astrocytes can tolerate much 
higher concentrations (Oka et al., 1993). Astrocytes normally function to remove glutamate 
from the extracellular space, so their tolerance to high glutamate concentrations is not 
surprising; however they too are eventually killed by an expanding glioma. Whether this 
cell death is also mediated by exposure to glutamate is not yet understood (de Groot & 
Sontheimer, 2010). 
It has also been reported that glutamate may have an autocrine or paracrine signalling effect 
on glioma cells. AMPA, NMDA, Kainate, and the metabotropic glutamate receptors mGluR3 
and mGLuR5 have all been identified in glioma, and growth-effects have been 
demonstrated through manipulation of both AMPA and NMDA receptors. Most glioma 
express AMPA receptors that are permeable to Ca2+ upon activation by glutamate (Ishiuchi 
et al., 2007). Induced expression of the GluR2 receptor subunit which renders AMPA 
receptors Ca2+ impermeable sensitized glioma cells to apoptosis and reduced tumour 
growth in vivo, suggesting the ability of glioma-derived glutamate signalling through 
AMPA receptors to act in an autocrine/paracrine manner to stimulate cell growth (Ishiuchi 
et al., 2007). 
Exogenous glutamate has a stimulatory effect on growth when applied to glioma cells, and 
conversely, antiproliferative effects on glioma have been demonstrated individually with 
several AMPA receptor antagonists and several NMDA receptor antagonists (Rzeski et al., 
2001). Inhibition of mGlu2/3 receptors with the antagonist LY341495 in glioma cells positive 
for both receptors also was able to reduce glioma cell growth both in vitro and in vivo 
(Arcella et al., 2005). Taken together, these results obtained through the blockade of nearly 
all glutamate receptors expressed in glioma suggest a significant autocrine/paracrine effect 
on growth of glioma-derived glutamate. 
6. Experimental therapeutics 
The myriad consequences originating from the upregulation of xCT in glioma have 
uncovered several novel possibilities for treatment of glioma. Any therapeutic targeting of 
the mechanisms of antioxidant production and glutamate release could prove to be critical 
in the treatment of glioma, as current therapies are limited in efficacy and often become 
redundant through acquired cell-resistance (Sontheimer, 2008). Symptom management may 
also arise from treating glutamate release, as it is hypothesized that frequent seizures, a 
morbidity that affects over 80% of glioma sufferers could be related to glutamate-induced 
hyperexcitability in the CNS, possibly in advance of neuron excitotoxic death and possibly 
an early indication of the cancer (de Groot & Sontheimer, 2010). 
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6.1 Targeting glutamate receptors 
AMPA receptor targeting has emerged as the most prolific avenue of interest for treatment 
from glioma glutamate-release work. An AMPA antagonist called talampanel is currently 
the most likely candidate for glioma treatment in this manner in large part because it does 
not exhibit the side-effects of most glutamate receptor antagonists in the CNS, and it has 
been shown to increase the lifespan of mice xenografted with human glioma (Goudar et al., 
2004). Two clinical trials have developed from these findings. The first, begun in 2009, was a 
phase II trial designed to examine the efficacy of talampanel in conjunction with standard 
radiation and temozolomide treatments in improving survival in adults with newly 
diagnosed glioblastoma (Grossman et al., 2009). This trial concluded that patients treated 
with talampanel demonstrated significantly longer survival than those who received 
standard care alone (Grossman et al., 2010). While this is promising and certainly demands 
further investigation, this study alone cannot be deemed conclusive. The second trial, a 
smaller phase II trial, examined the effects of talampanel alone on 6-month survival of 
patients with recurrent malignant glioma (Iwamoto et al., 2010). This trial determined that 
talampanel alone conferred no obvious advantage on patient survival, but the drug was 
tolerated well with no severe side-effects (Iwamoto et al., 2010). 
Inhibitors of other glutamate receptors have not yet been clinically evaluated, however the 
preliminary success of animal models of glioma treatment as mentioned above will certainly 
lead to trials of other glutamate receptor antagonists in the near future. Significant promise 
is held by these inhibitors as both candidate adjuvant therapies capable of supplementing 
treatment cytotoxicity or of mediating the effects of glutamate on the brain.  
6.2 System xc- Inhibition 
While the above-mentioned therapies for mediating the excess glutamate released by glioma 
are promising, certainly the most attractive potential therapies to arise from these studies 
are those that involve the inhibition of system xc-. Rather than mediate the consequences of 
destructive glutamate release and treatment-resistance, system xc- inhibition could eliminate 
the function of the transporter responsible for the excess glutamate, and consequently limit 
the multiple morbidities of glutamate release rather than manage its downstream effects. In 
addition, system xc- inhibition would limit cysteine availability to the glioma cell and 
therefore inhibit its antioxidative capabilities by way of both limiting glutathione synthesis 
and halting the drive of the cystine/cysteine redox cycle. There are many chemical 
inhibitors of system xc-; of these, the cyclic glutamate analogue S-(4)-carboxyphenylglycine 
has emerged as the most potent inhibitor (Patel et al., 2004), and the FDA approved anti-
inflammatory drug sulfasalazine has garnered the most clinical interest. Sulfasalazine has 
been demonstrated in animal models to effectively slow the growth of glioma and reduce 
levels of both intracellular GSH and extracellular glutamate (Chung et al., 2005; Chung & 
Sontheimer, 2009). A phase I clinical trial of sulfasalazine to evaluate drug safety and effects 
on tumour growth in the treatment of grade 3 glioma in a small number of patients was 
prematurely terminated due to several adverse effects during treatment (Robe et al., 2009; 
2006). This study was initiated on the basis on sulfasalazine acting as an inhibitor of NFkB, 
however treatment did not differ from that required for system xc- inhibition. Although the 
poor outcomes from this trial are unfortunate, they do little to dampen the potential of 
sulfasalazine for glioma treatment or system xc- as a therapeutic target. Another phase I 
clinical trial has just recently been initiated with the intent to examine the effects of 
sulfasalazine on glutamate release in the brain, and on seizures in low-grade, newly-
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diagnosed glioma patients (de Groot & Sontheimer, 2010). The upcoming results of this trial 
will be the first clinical evidence of treatments directed at system xc- inhibition, and will 
contribute greatly to the establishment of the role of this critical transporter in glioma 
morbidity and treatment. 
7. Conclusion 
Glioma exist in conditions of high oxidative stress as a result of the metabolic shift away 
from the TCA cycle and towards increased rates of glycolysis. This metabolic shift, the 
Warburg effect, is characteristic of cancer cells and confers unique benefits to the cell which 
allow survival and proliferation in conditions of rapid growth, division and variable access 
to blood vasculature. However, a result of this reliance on glycolysis is the increased 
prevalence of ROS in the cancer cell. To survive these conditions, cancer cells must possess 
upregulated mechanisms of antioxidation. Glioma exhibit an oxidative stress-mediated 
upregulation of the xCT coding gene SLC7a11, which, along with the membrane-anchoring 
protein 4F2hc comprise the two subunits of the Na+ independent electroneutral 
cystine/glutamate antiporter called system xc-. This antiporter drives the molecular turnover 
that is ultimately responsible for several of the features of morbidity in glioma, as well as its 
characteristic chemo- and radiation-resistance. The import of cystine into the cell increases 
the availability of cysteine for the GSH synthesis pathway and for the cystine/cysteine 
redox cycle. These two antioxidant pathways function to relieve the glioma cell of 
significant oxidative stress, allowing increased proliferation and survival of the cancer cells. 
This also allows resistance of glioma to oxidative stress-inducing radiation and 
chemotherapies. Conversely, the export of glutamate results in the neurotoxic death of 
neurons and glial cells in the vicinity of the tumour, and acts in an autocrine/paracrine 
manner to stimulate glioma proliferation and migration. Therapies are currently under 
development with these mechanisms in mind. Glutamate receptor antagonists have been 
demonstrated to limit brain cell death and to inhibit tumour growth in vitro and in xenograft 
animal models of glioma. System xc- inhibitors that prevent the import of cystine for 
antioxidant purposes and also prevent the release of glutamate into the extracellular 
environment have also demonstrated success in vitro and in vivo, and a clinical trial is 
currently underway with the inhibitor sulfasalazine. This work opens new pathways for 
investigation in a condition well known for poor prognoses and limited treatment options. 
The evidence of system xc- in other cancers in addition to glioma suggests that this 
mechanism may soon become of great importance to cancer treatment. 
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1. Introduction 
The problem of cancer embraces a lot of unresolved issues, among which there dominates 
the problem of ascertainment of the mechanisms of uncontrolled growth and cellular spill of 
tumor neoplasm, composed of dividing cancer cells and cancer stem cells (Schatton & Frank 
MH, 2009; Schatton et al., 2009; Frank NY et al., 2010). It is impossible to answer the 
question about a complete removal of the tumor tissue and simultaneous minimizing 
the adverse effects of surgical and other manipulations while removing the tumor without 
solving this problem. This is a particularly relevant goal for physicians who are engaged in 
treatment of brain tumors. The destruction of nerve tissue nonaffected by tumor growth has 
a negative impact on the integrative brain activity and at least on the central control of all 
bodily functions and homeostasis maintenance. How is it possible to reduce by-effects of 
major therapeutic technologies in neurooncology (surgical, radiological, chemotherapeutic), 
having preserved or enhanced their selective tumor damaging action? 
Since you choose chemotherapy as one of the ways to impact on tumor tissue, it is 
impossible not to mention the commonly known toxic effect of chemotherapeutic agents on 
all body tissues. Destroying the tumor cells, cytotoxic agents kill healthy cells and tissues. 
Thus, local or systemic applying the chemotherapy leads inevitably to the destruction 
of healthy brain cells in case of the tumor localization within the cranial cavity and the 
spinal canal. Thus, one of the objectives of this work was to develop methodic of leveling 
the general toxic effects of chemotherapy while strengthening their local destructive 
effect on tumor tissue. What ways have been chosen to solve this problem? 
Tumors of the brain and spinal cord have extremely variety (set) of histological forms which 
are accounted for their origin from the elements of various tissues and for peculiarity of 
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genesis not solved up to the end in respect to especially neuroepithelial tumors (Hirose & 
Yoshida, 2006; Nicholas et al., 2011; Van den Eynde et al., 2011). The nervous system tumors 
account for almost 10% of all human neoplasms, and up to 20% for children (Alomar, 2010; 
Davis et al., 2010; Myung et al., 2010). Neoplasms of brain and spinal cord are the most 
common solid tumors in childhood. They take the second place in frequency after leukemia 
of all child malignancies. In childhood (under 14 years) the vast majority of cases occur in 
neuroepithelial tumors. Of these, about 80% are of six histological forms: medulloblastoma, 
juvenile pilocytic astrocytoma, diffuse astrocytoma, ependymoma, craniopharyngioma, and 
neuroblastoma. 
Among the tumors of neuroepithelial tissues 9 sub-groups are selected out: astrocytic, 
oligodendroglial, ependymal, oligoastrocytic tumors (mixed gliomas), tumors 
of vascular plexus, and other neuroepithelial tumors (glial tumors of unspecified origin), 
neuronal and neuronal-glial, pineal, and embryonal tumors. In most cases glial tumors 
(gliomas) such as astrocytic, oligodendroglial, and ependymal glioma ones are detected. 
Histological diagnosis was based on identifying the predominant cell type.  
Combined treatment of the brain cancer (children including), which supposes surgery 
interference together with chemo- and radiotherapy, does not so far reach the desired 
impact. According to statistics concerning only medulloblastoma, the average disease-
free and overall survival during 2-7 years for patients up to 4 years old is respectively 
46% and 54%. So, tiny comforting is aggravated by data that uniquely ascertain the growth 
of intracerebral cancer. Thus, in the U.S. during 30 years from 1973 to 2003 it increased from 
4.1 to 5.2 for women and from 5.9 to 7.0 for men per 100 000 population (Alomar, 2010). 
Similar dynamics were recorded by The Child Cancer Registry of the Belarusian Republic. 
The percentage of brain tumors rose from 2.5 to 3.3 per 100 000 children living in Belarus 
from 1989 to 2005. 
A number of intractable causes is due to a low curability of brain tumors. The 
most productive radical method of removal of cancer neoplasm is often limited by the fact 
of their location near vital centers. Courses of medical and radiation treatment in 
accordance with approved protocols HIT`91, PO/02-PO/04 (Dunkel et al., 2010; Rosenfeld 
et al., 2010) along with known positive ones embrace recognizable negative aspects. To the 
negative ones there pertain as follows: i) a low permeability of the blood-brain barrier being 
created by tight contacts of micro vessel intracerebral network, which became completed 
with a set of proteins (Claudine 1,5, Occludin and others), which are impermeable to 
hydrophilic low soluble compounds exceeding a diameter of 18 Å and a molecular weight of 
180 Da. The vast majority of cytotoxic drugs pertain to them (Erdlenbruch et al., 2000; 
Kemper et al., 2004; Xie et al., 2005); ii) a weak selectivity of the concentration of cytostatic in 
the place of neoplasm (Cragnolini & Friedman, 2008); iii) an insufficiently studied 
mechanism of the action of traditional and new pharmacological agents, as well as their 
clearance, which hinders a reasonable estimation of the amount of molecules that come in 
direct contact with tumor cells (Gerstner & Fine, 2007; Ta et al., 2009); iv) a lack of unified 
schemes of medical product application, taking into account the morphological structure of 
complex heterogeneous neoplasias, stages of their malignancy, and individual sensitivity of 
the tumor cells to them and patient age (Alomar, 2010; Myung, et al., 2010); v) a 
symptomatic toxic side effect, reduced to a violation of general tissue metabolism and 
endocrine function, to immunity suppression, involvement in a destructive reaction of 
abnormal elements along with intact (healthy) cell ones, as well as the development of 
complications (acute arachnoiditis, meningo encephalopathy, renal failure, passing 
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deviation from the motor areas, speech, vision, hearing, stop of growth, and cognitive 
deficits with reduced intelligence), what in totality leads to disability (Kemper et al., 2004; 
Vega et al., 2003); vi) a limited range of available medications. 
The postulates set forward underline the actuality of further improving of existing strategies 
and creating new ones for earlier diagnosis, prognosis and a more successful fight against 
cancer. One of the ways to the aim is a broad involvement in oncology of a very 
representative class of multifunctional endogenous biological regulators of peptide nature, 
generally called as growth factors. In own structure they number a series of families, among 
which are neurotrophins (Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor 
(BDNF), Neurotrophins 3, 4, 5 (NT), Transforming Growth Factor (TGF), Fibroblast Growth 
Factor ( FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), 
Insulin-Like Growth factor (IGF), and others, rating more than 50 different variants 
(Antonelli et al., 2007; Beebe et al., 2003). The key role belongs to growth factors in the 
capacity of epigenetic "directive" signals in the control of such fundamental morphogenetic 
processes in ontogenesis as growth, survival, proliferation, differentiation (i.e., the selection 
of the terminal tract of specialization by stem and progenitor cells), guided migration and 
elongation processes, synaptogenesis, regulation of cell homeostasis by apoptosis, 
regeneration, as well as maintaining a normal cyto-biochemical status of mature cells and 
their resistance to damaging factors (Alam et al., 2010; Charles et al., 2011; Vinores & Perez-
Polo, 1983; Xie et al., 2005). 
The interest to determine the significance of these compounds in tumor formation and in 
their reverse transforming potential has just relatively recently emerged, when it became 
vivid that virtually all types of neoplasias are synthesized not only by growth factors but 
actively expressize their receptors (Antonelli et al., 2007; Barnes et al., 2009; Blum & 
Konnerth, 2005; Brossard et al., 2009; Evangelopoulos et al, 2004; Krűttgen et al., 2006; 
Nakagawara, 2001). At the same time we point out a startling fact: NGF was purified for the 
first time from sarcoma secretions S180, and protooncogenes sites, which take it, were 
purified from high-affinity TrkA and low relational P75 from biopsies of colon carcinoma 
(intestinum crassum) and human melanoma. It is much more interesting that bio testing of 
growth factors on its activity is performed on rat pheochromocytoma PC12 (Krűttgen et al., 
2006). 
The experiments proved that in vitro the cell lines of neuroblastoma (IMR-32, SY-5Y, SK-N-
SH, NB-GR) and medullary pheochromocytoma cease to divide in the presence of NGF and 
are transformed into neuron-like elements at braking formation of DNA, at the 
intensification of including labeled amino acids, at the appearance of sprouts, at the growth 
of size, substrate adhesion together with the formation of pseudoganglies and at the 
occurrence in membrane of electrical excitability (Krűttgen et al., 2006; Poluha et al., 
1995). On the other hand, the ability of NGF in vivo to reduce the number of induced 
nitrosourea by neurinomas was revealed, as well as the speed of their development, and the 
ability to reduce the volume and to prolong animal survival after subcutaneous injection or 
intracerebral implantation of anaplastic glioma cell F98, T9, and neurinomas (Yaeger et al., 
1992). The predictive value of identification of perceiving Neurotrophins receptors is 
overviewed. So thus the over expression of TrkA and C (for NT-3) in neuro-, medulla and 
glioblastomas promises a favorable outcome, due to a spontaneous regression (through 
differentiation), the inclusion of suicide programs or autophagy (Blum & Konnerth, 2005; 
Collins, 2004; Krűttgen et al., 2006; Yamaguchi et al., 2007). Patients with low or no 
detectable levels of these receptors in medulloblastoma exhibit 5-fold risk of death than with 
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a high level (Krűttgen et al., 2006). Per contra, the enhanced expression of TrkB (ligand 
BDNF), which takes place in aggressive tumors, where isoforms often truncated and lacked 
of intracellular domain, goes with the pessimistic ending. 
In this light the aim of the research was to study individual and combined effects of some of 
cytostatic and growth factors (Liu et al., 2010), which are in circulation, on the survival of 
primary culture of cells. Alongside an attempt of the combined action of cytostatic, that is 
the factor of Nerve Growth and Dendrimers (or Heterocyclic Compounds) on primary 
culture cells of neuroepithelial tumors was undertaken. Dendrimers are the extended three-
dimensional molecules which contain a large number of active functional groups on the 
outer surface (Morgan et al., 2006; Waite & Roth, 2009). We focused on one of the most 
common types of Dendrimers – Polyamidoamine, (PAMAM), containing ethylenediamine 
core and branching of methyl acrylate and ethylenediamine (Kang et al., 2010). We aimed at 
verifying the hypothesis about the possibility of dose reducing of cytostatic at combined 
application of chemotherapy with growth factors and nanoparticles, in particular 
Dendrimers in these experiments. The fifth generation of Dendrimer (PAMAM G5) was 
used. The effect of combinations of cytostatic, Nerve Growth Factor and Dendrimers or the 
cytostatic agent, Nerve Growth Factor and Heterocyclic Compounds was studied in 
separate series of experiments. Heterocycles of isoxazole series (Isoxazole) and isothiazolyl 
(Isothiazole) (typical representatives of 1,2-azoles) are structural fragments of a wide range 
molecules of active physiologically substances, what causes a growing interest in the 
research of the synthesis and in the study of the biological properties of these compounds. 
Isoxazole heterocycle is a compound part of molecules of the cytotoxic, antitubercular 
agents, anticonvulsants, and pesticides.  
The compounds to be perspective for the treatment of Alzheimer's disease and 
inflammatory, antithrombosis and anticonvulsive drugs were identified among the 
derivatives of isothiazolyl. It was recently found that some isothiazolyls were inhibitors of 
kinases and could be used in the treatment of tumors. For example, isothiazolyl with urea 
function in position 3 is an inhibitor of tyrosine kinases and now it is under studying as an 
anticancer drug CP-547, 632 (Beebe et al., 2003). The fellow-colleagues of Institute of 
Physical Organic Chemistry NAS of Belarus developed methods for the synthesis of new 5-
substituted 1,2-thiazol-3-ilcarbamids and their heteroanalogs – 1,2-oxazole-3-ilcarbamids – 
isosteres known as inhibitors of tyrosine kinases, which are of some interest for testing in 
our planned experiments. The goal of these experiments was to find ways of reducing the 
dose of cytotoxic drugs, under condition of preserving or increasing the toxic effects of 
chemotherapy on tumor tissue. 
2. Methodic 
The biopsy material was taken from 67 children aged from 1 to 15 years old who were 
treated at the children's neurosurgical department of Municipal Clinical Emergency 
Hospital in Minsk from November 2008 to December 2010. 
2.1 The research protocol  
The biopsy material taken during the fine-needle stereotactic or neurosurgical operation was 
transported in an hour to the Pathology Laboratory to determine the histology forms of the 
tumor and degrees of its malignancy, and was simultaneously delivered to the Laboratory 
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of Cell Monitoring to assess individual sensitivity of tumor cells to chemotherapeutic drugs 
in vitro. After the mentioned period 0.5 ml of chemotherapy was added in doses approved 
by instructions and converted either to a square cup (10.0 cm2) or to β-subunit of 
recombinant human NGF (Sigma-Aldrich, USA, 1.0 μg / ml) or to Dendrimers (PAMAM 
0.1, 1.0, 10.0 μg / ml, Sigma-Aldrich, USA), or to heterocyclic compounds (0.1, 1.0, 10.0 μg / 
ml), or to these or others in various combinations. Each series of observations in vitro 
consisted of 30 applications (n = 30). Assessment of the viability of tumor cells was 
estimated in 24 hours after putting test compounds into the environment for their ability to 
incorporate trypan blue. For this matter the cell suspension was mixed with 2% dye solution 
in saline buffer pH = 7.2 at a ratio of 1:10 and transferred into Goryaev’s chamber, where the 
number of dead (paint over) and living (light) elements was counted at a percentage. The 
obtained data were reported to neurosurgeons who together with other specialists 
developed the tactics of post-operative treatment and determined prognosis. 
2.2 Cytoscopic study  
Cytoscopic study of surgical specimens was carried out after using the methods of frozen 
sections, or the crushed drop. The final conclusion of the histological form of the tumor and 
its malignancy degree was made after alcohol treatment, filling material in paraffin, 
sectioning and staining by the following methodic: a method of staining with hematoxylin 
and eosin; histochemical methods for the detection of glial filaments, collagen and reticulin 
fibers; immunohistochemical studies for detection of acidic glial fibrillary protein, 
neurofilaments, synaptophysin, and neuron-specific enolase; a definition of PCNA, Ki-67, 
cyclins in order to clarify the nature of proliferative activity. The conducted cytoscopic 
research allowed to identify indications of malignancy and was a guide to neurosurgeons in 
case of choosing the treatment tactics. 
2.3 Cultural studies  
Pieces of biopsy material were washed from the blood and mechanically comminuted in 
Hank’s solution (Sigma-Aldrich, USA) with Gentamicin sulfate added, and then for 30 min 
they were put in a mixture of 0.25% trypsin solution in Ethylenediaminetetraacetic acid 
(EDTA) (2 ml) at a ratio of 1:3. The effect of the enzyme was inhibited by adding 3 ml Fetal 
Calf Serum – FCS (Sigma-Aldrich, USA) for a period of 3-5 minutes. The material treated in 
such a way was crushed under a microscope with a sterile blade up to pasty consistency and 
then was taken to a sterile Petri dish with medium Dulbecco's Modified Eagle's Medium 
(DMEM) (Sigma-Aldrich, USA), with adding ETS at a ratio of 1:10 and 4% sulfate 
solution Gentamicin (10-4 g / l). The cells obtained from the substrate were grown in a 
medium of this composition for 2-7 days at 37ºC, 95% humidity and 5% partial pressure of 
CO2 (Chekan et al., 2009). Stay duration of the cells in vitro was dictated by the speed of the 
attachment to the substrate. 
2.4 Clinical, laboratory and instrumental methods 
Clinical, laboratory and instrumental methods of the study included a list of routine clinical 
examination methods and laboratory diagnostics, as well as computed tomography and 
nuclear magnetic resonance. The credibility of differences between the average values was 
set by a Mann-Whitney test for nonparametric samples using the computer program 
StatPlus 2005. Differences were estimated to be significant at P <0.05. 
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The following types of cancer were included according to the histological conclusions based 
on classification of brain tumors (WHO, 2007) into the observations: astrocytic, embryonic, 
and compiled under the title "other types" of neoplasm. In the group of cancers of astrocytic 
origin were present: pilocytic, pilomixoidnic, protoplasmic, pleomorphic, anaplastic 
neoplasm. Medulloblastoma, atypical teratoidnic/rabdoidnic tumor of posterior fossa, and 
malignant neuroectodermal tumor of the left temporal lobe were in the category of 
embryonic tumors. The category of "the other options" of neoplasm included: anaplastic 
oligodendrogliomas, oligoastrocytomas of a cerebellar vermis, ependymoma, 
gangliogliomas of a mixed neuroglial type, immature teratoma of a pineal region, which 
was attributable to germinocell tumors, glioma of an optic chiasm, and a gemangioblastoma 
to be regarded as an intramedullary tumor of a cervical spinal cord.  
It was revealed in the experiments in vitro that Cisplatin (Merck, USA, 1.0 μg / ml) took 
priority in the samples of pilocytic astrocytoma, medulloblastoma, and malignant 
neuroectodermal tumors of the temporal lobe, where the percentage of dead cells reached 
respectively 61.9 ± 12.9, 40.9 ± 11.4, 41.6 ± 8.5, 68.6 ± 7.8 reliably exceeding the one in those 
experiments where the cells of a primary culture of neuroepithelial tissue devolved out of 
contact with chemotherapy (14.3 ± 5.0%). A similar position was taken by Carboplatin 
(Merck, USA, 4.0 μg / ml) in biopsies from pleyomorfic xanthoastrocytoma, anaplastic 
oligodendroglioma (Fig. 1), optic chiasm glioma and atypical teratoid / rhabdoid tumors 
(Fig. 2) with lethality according to the order of enumeration 57.9 ± 5.9, 68.4 ± 10.6, 78.9 ± 4.1 
and 79.5 ± 1.0%.  
 
 
Fig. 1. Anaplastic oligodendroglioma 
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Fig. 2. Atypical teratoid / rhabdoid tumor 
The same can be said about Etoposide (Ebewe Artsnaym., Austria, 1.0 μg / ml) in relation to 
the protoplasmic astrocytoma cells (61.0 ± 4.7%), oligoastrocytoma (55.1 ± 8.5%) (Fig. 3 a, b) 
and especially about hemangioblastoma (74.7 ± 3.9%). 
 
    
a     b     c 
Fig. 3. Oligoastrocytoma cell survival in a day after the application of Etoposide (b) and β-
NGF (c) in comparison with intact cells of primary culture of the tumor (a). The 
magnification is x 312.5. 
Cytarabine (Belmedpreparaty, Belarus, 1.0 μg / ml) effectively suppressed the cell vitality in 
cultures of anaplastic astrocytoma (51.4 ± 5.9%) and immature teratoma (90.6 ± 5.0%). Other 
substances – Methotrexate (Ebewe Artsnaym., Austria, 50.0 μg / ml) and Gemcitabine (Wee-
Em-Gee Pharmaceuticals Pvt. Ltd., India, 2.0 μg / ml) though were not included in the list of 
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Fig. 2. Atypical teratoid / rhabdoid tumor 
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Fig. 3. Oligoastrocytoma cell survival in a day after the application of Etoposide (b) and β-
NGF (c) in comparison with intact cells of primary culture of the tumor (a). The 
magnification is x 312.5. 
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leading substances, often successfully shared with them the second or third 
position. However, in a case of anaplastic oligodendroglioma the latter was not 
effective. Moreover, in its presence the cells of pleomorphic xanthoastrocytoma like 
Etoposide ones demonstrated a paradoxical reaction – a statistically significant increase of 
survival potential. The same is with carboplatin. Maximum susceptibility to it is shown by 
document in the samples of four neoplasm, and first of all of atypical teratoid / rabdoid 
tumor and optic chiasm glioma to have lost 79.5 ± 1.0 and 78.9 ± 4.1% viable units. These 
compounds are followed by Etoposide, which predominant efficacy was also recorded in 
three types of tumor cells, especially in glioblastoma.  
 
 
Fig. 4. Glioblastoma with marked vascular proliferation and the formation 
of glomerular structures. 
It is right to note the following fact: culture objects manifested almost the same (competitive) 
sensitivity to two or more agents in virtually all cases, if one takes into consideration the 
closeness of a number of infected cells, differences of which were not included in the 
validation category. As for β-NGF, its superiority (although not statistically significant) over 
the cytostatic regarding a number of perished in vitro units occurred in biopsies of 
pilomixoid astrocytoma (47.6 ± 1.3% vs. 40.9 ± 11.4% of Cisplatin), medulloblastoma (Fig. 5) 
(44.9 ± 2.9 vs. 41.6 ± 8.5% from the same preparation), oligoastrocytoma (78.3 ± 0.9 vs. 55.1 ± 
8.5% of Etoposide) (Fig. 3 a, b, c) and ependymoma (62.4 ± 6.0 vs. 58.6 ± 4.4% of 
Carboplatin). 
The efficiency of β-NGF (68.2 ± 0.5%) almost coincided with that of Cytarabine (68.9 ± 
11.9%), and under the contact with the cells of anaplastic astrocytomas (Fig. 6) (38.2 ± 2.3%) 
reached the 2nd position after for Cytarabine (54.4 ± 5.9%), pushing on the third place 
Carboplatin (35.9 ± 1.8%) when glioblastoma was applied to the cells the primary culture. In 
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the contrast, the derivatives of pleomorphic xanthoastrocytoma responded to β-NGF by a 
significant increase in its resistance to the toxin (an increase of vitality). Their death was 13.6 
± 2.9% in relation to the fixed one in the tumor cells which were not subjected to any 




Fig. 5. Undifferentiated medulloblastoma 
 
 
Fig. 6. Anaplastic astrocytoma. Moderate cellularity. Nuclear polymorphism 
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The access to the analysis of a destructive influence of combined test compounds 
application, while keeping in mind the possibility of potentiation of their individual effects 
was the logical corollary from an analysis of the brought materials. It turned out that in most 
combinations (excluding β-NGF + Methotrexate in the case of pilocytic astrocytoma), a 
marked tendency of a destructive cellular reactions increase in comparison with those 
described in the isolated introduction of preparation) was observed. A combination of 
Cisplatin + Etoposide (89.5 ± 0.8%), Carboplatin + Cytarabine (81.4 ± 2.0%), Carboplatin + 
Etoposide (69.2 ± 3.0%) and Cisplatin + Carboplatin (68.8 ± 7.3%) for cells oligoastrocytoma, 
and Cisplatin + Carboplatin (78.1 ± 1.9%) and β-NGF + Cisplatin (55.5 ± 3.2%) shown with 
an example of cells of ganglioglioma was especially attractive in vitro conditions. In these 
cases, the combined effect of cytotoxic drugs significantly exceeded observed ones under 
individual applications of each component from every pair of drugs. It’s worth noting that 
β-NGF, despite the decline of its performance in a variant of samples from 
oligoastrocytoma, tends as a rule to significantly increasing toxic effects on the tumor cells 
survival in a combination with cytotoxic drugs. This raises a question of reasonableness of 
the further research in terms of the simultaneous application of these agents. For the sake of 
fairness it should be emphasized that in any case of their combination one failed to reveal 
signs of synergy, where the reaction to the combination would have excelled the arithmetic 
sum of the personal effects, included as components in its structure. This can be conditioned 
by complex polymorphism of brain tumors, including dividing tumor cells and stem tumor 
cells at that. The survival of an even single cancer stem cell could lead to a recurrence of 
tumor metastasis and uncontrolled process in other parts of the central nervous system. 
It is important to point out that varying selective affinity touched not only biopsy samples 
belonging to different types of tumors, but also tumors taken away from an absolutely 
analogous composition accordingly to histological compounds and a measure of tumor 
progression. For example, the maximum destruction of cultured cells was recorded against a 
background application Cytarabine (68.3 ± 6.9%, P <0.05), and to a lesser extent Cisplatin 
(49.4 ± 5.4%, P <0.05), and Methotrexate (39.7 ± 7.2%, P <0.05) in three patients with 
medulloblastoma of the IV stage. The other chemotherapy drugs effect on cells of tumor had 
actually no difference in growth of cell culture without the application of cytostatic. This 
circumstance makes relevant carrying out a preliminary rapid assessment of individual 
susceptibility of patients to chemotherapeutic drugs with involvement of cultural systems. 
Moreover, it was possible to show by a document a certain correlation between the 
effectiveness of test compounds and the degree of malignancy at the same astrocytic nature 
of the tumors. Let us demonstrate this by the following examples. Thus Cisplatin (61.9 ± 
12.9%), Carboplatin (53.8 ± 7.9%) and Methotrexate (47.0 ± 7.2%) came into the triad of 
superior according to induction of cell lethality at the Ist stage. At the IInd stage Carboplatin 
(57.9 ± 5.9%), Methotrexate (51.1 ± 4.0%) and Cytarabine (50.2 ± 9.4%) occupied the 
dominant position. On the IIId – Cytarabine (54.4 ± 5.9%), Carboplatin (35.9 ± 1.8%) and 
Etoposide (34.5 ± 4.4%), and at the IVth – Cytarabine (68.9 ± 11.9%), Etoposide (63.1 ± 0.4%) 
and Gemcitabine (61.5 ± 1.7%). As a matter of fact the mentioned graduation should be 
viewed with a certain degree of conditionality, since statistically significant differences 
between the members of each triad could not be established. It’s noteworthy, however, that 
β-NGF, occupying a relatively modest position in the first phase of malignancy acquired a 
tough competition (68.2 ± 0.5%) leading to the IVth stage of Cytarabine (68.9 ± 11.9%) and 
bunched over (38.2 ± 2.3%) from the 2nd stage (35.9 ± 1.8%) of Carboplatin (please, bear in 
mind: at isolated applications of β-NGF).  
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The dependence of the destructive action of cytostatic and β-NGF also correlated with the 
age of the patients. Differences in digital indicators which characterize the percentage of cell 
loss of primary tumor culture in vitro gave evidence of the complex mechanisms of 
interaction between tumor cells with cytotoxic drugs coming in the triad of the most active 
compounds. So, at the child age under 3 years old the tumor generating effect was observed 
in Carboplatin (59.7 ± 4.1%), Cisplatin (51.4 ± 4.5%) and Cytarabine (48.3 ± 2.4%), and at the 
age from 4 to 6 years old β-NGF (63.2 ± 4.8%), Cisplatin (62.3 ± 7.6%) and Methotrexate (49.4 
± 5.8%) were in the lead. At the age from 7 to 10 years old the toxic substances rating looked 
like follows: Carboplatin (38.1 ± 8.8), β-NGF (27.1 ± 6.1%) and Methotrexate (26.2 ± 3.1%). At 
the age from 11 to 15 years old Methotrexate moved to the first position (56.0 ± 3.8%), 
slightly ahead of Carboplatin (54.4 ± 2.9%) and Cisplatin (53.6 ± 3.7%). β-NGF, taking the 
first place in terms of suppression of cell survival in the intermediate age groups, showed in 
the fourth (most mature) group an inverted effect, which increased cell survival significantly 
(13.3 ± 2.9%) compared with control (32.9 ± 3.0%). 
Experiments conducted in vitro demonstrated once again the well-known position of the 
highest individual sensitivity of glioma to cytostatics. No one has ever managed to fix the 
same sequence in the effectiveness of tumor destroying the action by the protocol approved 
cytostatic at absolutely identical histological diagnoses. Registered dependence of 
differences of effects from sex and age did not permit to explain the inner workings of such 
a high individual sensitivity of glioma to chemotherapy. It is obvious that one of 
explanations for this phenomenon can be a different degree of presence of stem tumor cells 
in tumor tissue. The high stability of stem tumor cells to damaging agents is well known. 
We are therefore got interested in the effect of enhancing the anticancer effect of cytostatics 
and NGF presence. As a hypothesis we can suggest that a strengthening of an anticancer 
effect of a combination of chemotherapeutic drugs and NGF is determined by an influence 
of drugs not only on dividing tumor cells but also on stem tumor cells. If it is so, then it is 
advisable to try to test different combinations of chemotherapy with cytotoxic substances of 
a new generation. In particular, we talk about the heterocyclic compounds, many of which 
are capable of inhibiting the intracellular tyrosine kinas path and, thus, to initiate the 
mechanisms of apoptosis in tumor tissue. The use of nanoparticles, in particular, Fullerenes 
or Dendrimers seems making a promise for these tasks. More details will be discussed 
below. There are many more challenges in oncology on the way to more effective cancer 
therapy. The well known high toxicity of chemotherapeutic drugs for all organs and systems 
of a living organism stimulates scientists and oncologists to find ways of reducing the 
general toxic action of cytostatic, and maintaining their anti-tumor effect. The result in these 
experiments on primary culture oligoastrocytoma cerebellar vermis can be given as an 
example of such a design. The data are presented in Table 1. 
The following fact draws attention at analyzing the data. In comparison with the natural 
death of cells the addition of Carboplatin, Methotrexate or Cisplatin was accompanied by an 
increase in the percentage of dead cells in a Petri dish from 35% to 47 % in the control (when 
cells of primary culture of oligoastrocytoma cerebellar vermis were developing in the 
culture medium without any contact with the chemotherapy). The combination of one of 
these three chemotherapy drugs with Nerve Growth Factor under decreasing doses of the 
cytostatic factor led in 10 times to the preservation or even an increase of the cytostatic effect 
(Table 1). The effect of two cytostatics - Carboplatin and Methotrexate increased especially 
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demonstratively. If you are not going to speculate on possible mechanisms of this 
phenomenon, then one is competent to conclude that the concentration of cytostatic can be 
significantly reduced in situations of combined use of chemotherapy with NGF. This 
reduction of dosage will be accompanied by a decline in general toxic action of 
chemotherapy drugs (which is critical for every cancer patient) and a persistence of the 
cytostatic action in relation to tumor cells (what is critical for a patient and a physician). A 
similar cytotoxic effect was observed earlier while applying diamond-like structures 
(Chekan et al., 2009). Experiments in vitro decreased survival of rat C6 glioma cells in the 
presence of implants made of titanium alloy VT-16. Putting diamond-like carbon coatings 
on the alloy VT-16 was accompanied with an increase in the percentage of cell death on the 
fifth day of cultivation, compared with the control: 39.9 ± 2.1% and 5.4 ± 0.3%, respectively. 
A more significant decrease in mitotic activity and cell viability was observed when C6 
glioma cells contacted with diamond-like carbon coating, comprising silver 
nanoparticles. The number of cell destruction of glioma C6 at contact with the diamond-like 
carbon covering, including up to 3.5 % Silver nanoparticles, made 53.7 ± 2.1%, and at doping 
up to 6.7 % Silver the cell destruction reached 66.7 ± 3.2% (P <0.05) in comparison with the 
control. Hence, the maximum toxic effect in regard to C6 glioma was detected in samples 
coated with diamond-like film, including silver nanoparticles. Similar results were obtained 
in the application of diamond coatings on the primary culture of human gliomas. If the 
surface of titanium samples with a diamond-like coatings included additional silver 
nanoparticles, the cytotoxic effect on the second day after exposure of cells of 
oligodendrogliomas with the surface of the samples would be disastrous for the viability of 
these cells. As it is shown in Fig. 7 A, processes of proliferation are continuing in tumor cells 
outside the titanium samples, while at the site location on a Petri dish of titanium sample 
almost all cells died (Fig. 7 B). 
 
 
Title Series Cell death, % 
Control 12.5 ± 4.2 
Carboplatin 4.0 μg / ml 35.3 ± 0.9* 
Carboplatin 0.4 μg / ml + β NGF 0.1 μg / ml 57.1 ± 12.5* 
Methotrexate 50.0 μg / ml 43.7 ± 8.6* 
Methotrexate 5.0 μg / ml + β NGF 0.1 μg / ml 72.4 ± 2.5* 
Cisplatin 1.0 μg / ml 47.4 ± 3.0* 
Cisplatin 0.1 μg / ml + β NGF 0.1 μg / ml 50.0 ± 8.1* 
 
Table 1. Percentage of cell death oligoastrocytoma cerebellar vermis at a combination of 
different doses of cytostatics with Nerve Growth Factor (NGF). (The asterisk * denotes the 
reliability of P <0.05) 
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Fig. 7. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
titanium sample with diamond-like coating containing silver nanoparticles (A), and at 1 mm 
from the edge of the sample (B) 
It was established that if the titanium samples were coated with titanium dioxide (TiO2), a 
cytotoxic effect of these samples (Fig. 8 A and B) would not differ from a cytotoxic effect of 
those which coating consisted of silver nanoparticles. 
 
Fig. 8. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
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almost all cells died (Fig. 7 B). 
 
 
Title Series Cell death, % 
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Carboplatin 0.4 μg / ml + β NGF 0.1 μg / ml 57.1 ± 12.5* 
Methotrexate 50.0 μg / ml 43.7 ± 8.6* 
Methotrexate 5.0 μg / ml + β NGF 0.1 μg / ml 72.4 ± 2.5* 
Cisplatin 1.0 μg / ml 47.4 ± 3.0* 
Cisplatin 0.1 μg / ml + β NGF 0.1 μg / ml 50.0 ± 8.1* 
 
Table 1. Percentage of cell death oligoastrocytoma cerebellar vermis at a combination of 
different doses of cytostatics with Nerve Growth Factor (NGF). (The asterisk * denotes the 
reliability of P <0.05) 
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Fig. 7. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
titanium sample with diamond-like coating containing silver nanoparticles (A), and at 1 mm 
from the edge of the sample (B) 
It was established that if the titanium samples were coated with titanium dioxide (TiO2), a 
cytotoxic effect of these samples (Fig. 8 A and B) would not differ from a cytotoxic effect of 
those which coating consisted of silver nanoparticles. 
 
Fig. 8. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
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The highest potentiating effect of the combination of chemotherapy and nanoparticles was 
obtained by the application of Dendrimers. Series of experiments of a Cisplatin combination 
with PAMAM on the primary culture of medulloblastoma are in Table 2. 
 
Title Series Cell death, % 
Control 20.7 ± 3.3 
Cisplatin 1.0 μg / ml 67.6 ± 7.4* 
Cisplatin 1.0 μg / ml + β NGF 0.1 μg / ml 49.2 ± 6.8* 
PAMAM 30 mM (10.0 μl ) 45.5 ± 6.7* 
Cisplatin 1.0 μg / ml + PAMAM 30 mM 
(10.0 μl ) 
92.7 ± 4.9* 
Cisplatin 0.1 μg / ml + PAMAM 30 mM 
(10.0 μl ) 
98.4 ± 1.5* 
Table 2. Percentage of cell death medulloblastoma IV at a combination of different doses of 
Cisplatin with Polyamidoamine (PAMAM) Dendrimer (the asterisk * denotes the reliability 
of P <0.05) 
As it is seen in Table 2, the percentage of cell death of malignant medulloblastoma increased 
significantly in primary culture under the action of Cisplatin and paradoxically reduced by 
a combination of Cisplatin with NGF. This fact does illustrate once again the high specificity 
of each particular tumor in each patient, what determines the choice of individual treatment 
strategy in each case. This choice should be guided by research data and the sensitivity of 
cells in primary culture in vitro.  
Application of PAMAM 30 mM (10.0 μl) in a Petri dish was accompanied by increased cell 
death in comparison with control ones. In principle, the anticancer effect of Dendrimer is 
described in literature but has not been studied in detail (Bei et al., 2010). At this stage we 
have only stated such an action of PAMAM. Surprisingly a stable toxic effect of a 
combination Cisplatin with PAMAM was demonstrated at using two different 
concentrations of chemotherapeutic drugs (Table 2). The anticancer effect of this drug 
combination ranged from 92% to 98% (Fig. 9, and Fig. 10). Therefore it is very 
important to find such a combination chemotherapy with growth factors and nanoparticles, 
which would reduce the dose of cytostatics, when we tried to determine the sensitivity of 
individual tumor in vitro to cytostatic in the next phase of the research. At the same 
cytotoxic effect of substances used must be maintained at maximum levels. Dendrimers 
belong to a class of polymeric compounds whose molecules have a large number of 
branches. At their acquisition a number of branches of the molecule increase with every 
elementary act of growth. As a result, the shape and rigidity of the molecules change with 
increasing molecular weight of these compounds, what is usually accompanied with 
changes in physical and chemical properties of Dendrimers. Inside Dendrimers cavities are 
formed which can be filled in with a variety of substances, such as cytostatic. This ability of 
Dendrimers was one of the factors to determine the decision to use them for enhancement of 
their anticancer effect of chemotherapy. 
The paper drew attention also to other compounds that might be effective against tumor 
growth. The input material for the synthesis of heterocyclic compounds was 1,2-azole-3-
carboxylic acids, which were consistently converted into azides or carbamide. Implemented 
computer modeling of ligand-protein complexes of carbamide was carried out in the 
framework of the methods of molecular mechanics using the program Dock 6.4 and USF 
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Chimera. Evaluation of energy characteristics of the van der Waals and electrostatic 
interaction suggests the possibility of efficient binding of 1,2-azole ligand protein. These 
studies helped to choose the best version of heterocyclic compounds (Carbamide), which 
application in a combination with cytostatic agents and Nerve Growth Factor allowed 
reducing the dose of the cytostatic factor in 10 times at maintaining in vitro the tumor 




Fig. 9. Atypical teratoid / rhabdoid tumor cells remaining in a day after the application of 
Cisplatin (1.0 μg / ml), β-NGF (0.1 μg / ml), Polyamidoamine Dendrimer (30 mM, 10.0 μl) 
 
 
Fig. 10. Atypical teratoid / rhabdoid tumor cells remaining in a day after the application of 
Cisplatin (0.1 μg / ml), β-NGF (0.1 μg / ml), Polyamidoamine Dendrimer (30 mM, 10.0 μl) 
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Anticancer effects of heterocyclic compounds in one more series of experiments were 
approved (Figs. 11-13). The Fig. 11 shows the primary tumor cells of pilocytic astrocytoma in 
two days after passage. Figure 12 shows primary tumor cells pilocytic astrocytoma in two 
days after the addition of Azide at a concentration of 1.0 mg / ml. Figure 13 shows primary 
tumor cells pilocytic astrocytoma in two days after the addition of Carbamide at a 
concentration of 1.0 mg / ml. Toxic properties of Azides and Carbamide can be explained by 
their ability to inhibit the tyrosine kinase pathway. This mechanism can be implemented in 
the subsequent initiation of apoptosis in tumor cells. 
 
 
Fig. 11. Pilocytic astrocytoma cells in a day after passage 
 
 
Fig. 12. Pilocytic astrocytoma cells in a day after application of Azide at a concentration of 
1.0 mg / ml 
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Fig. 13. Pilocytic astrocytoma cells in a day after application of Carbamide at a concentration 
of 1.0 mg / ml 
4. Conclusion 
The data obtained are the basis to discuss several aspects of increasing the chemotherapy 
effectiveness problem. Being general toxic poisons in the action by their nature, 
chemotherapy drugs come out as an essential attribute of anticancer therapy in accordance 
with the majority of the approved treatment protocols. There are no alternatives to their use 
considering the presence of appropriate evidence. In such a case, how can one reduce the 
general antineoplastic action of cytostatics and keep their strong anticancer effect? The 
anticancer effect is under discussion in respect of not only dividing tumor cells, but also 
stem tumor cells. The advantage of a mutual use of cytostatics and NGF compared with 
their individual use was confirmed in the work. It puts on the agenda the top-priority 
intensively developing problem, that is of improving the permeability of the blood-brain 
barrier at systemic application of chemotherapy and the search for "circuitous" ways to the 
desired delivery of biologically active compounds to tumor tissues (Alam et al., 2010; Chen 
et al., 2011; Gerstner & Fine, 2007). In order to implement the first plan several directions are 
supposed. One of them is to attract hyperosmotic solutions containing histamine, 
bradykinin, mannitol and so on, which will contribute to achieving the cytostatic targets in 
the brain at their systematic putting into operation (Kemper et al., 2004; Xie et al., 2005). But 
the transient opening by them of the entrance gate provides at the same time an opportunity 
of entering via them for the neurotoxic substance what is especially dangerous in case of a 
more complex operative procedure of an intracarotid infusion of chemotherapeutic agents. 
This may be accompanied by disorders of speech, movement, visual perception. 
One more trend is based on creation of conjugates of an active commencement with 
proteins, which are able to recognize the integral components of cerebrovascular structures, 
such as antibodies to the receptor ferritin in relation to the NGF. This ensures its 
effectiveness in a rank of low concentrations. The simultaneous application of anticancer 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
480 
Anticancer effects of heterocyclic compounds in one more series of experiments were 
approved (Figs. 11-13). The Fig. 11 shows the primary tumor cells of pilocytic astrocytoma in 
two days after passage. Figure 12 shows primary tumor cells pilocytic astrocytoma in two 
days after the addition of Azide at a concentration of 1.0 mg / ml. Figure 13 shows primary 
tumor cells pilocytic astrocytoma in two days after the addition of Carbamide at a 
concentration of 1.0 mg / ml. Toxic properties of Azides and Carbamide can be explained by 
their ability to inhibit the tyrosine kinase pathway. This mechanism can be implemented in 
the subsequent initiation of apoptosis in tumor cells. 
 
 
Fig. 11. Pilocytic astrocytoma cells in a day after passage 
 
 
Fig. 12. Pilocytic astrocytoma cells in a day after application of Azide at a concentration of 
1.0 mg / ml 
Improving the Efficiency of 




Fig. 13. Pilocytic astrocytoma cells in a day after application of Carbamide at a concentration 
of 1.0 mg / ml 
4. Conclusion 
The data obtained are the basis to discuss several aspects of increasing the chemotherapy 
effectiveness problem. Being general toxic poisons in the action by their nature, 
chemotherapy drugs come out as an essential attribute of anticancer therapy in accordance 
with the majority of the approved treatment protocols. There are no alternatives to their use 
considering the presence of appropriate evidence. In such a case, how can one reduce the 
general antineoplastic action of cytostatics and keep their strong anticancer effect? The 
anticancer effect is under discussion in respect of not only dividing tumor cells, but also 
stem tumor cells. The advantage of a mutual use of cytostatics and NGF compared with 
their individual use was confirmed in the work. It puts on the agenda the top-priority 
intensively developing problem, that is of improving the permeability of the blood-brain 
barrier at systemic application of chemotherapy and the search for "circuitous" ways to the 
desired delivery of biologically active compounds to tumor tissues (Alam et al., 2010; Chen 
et al., 2011; Gerstner & Fine, 2007). In order to implement the first plan several directions are 
supposed. One of them is to attract hyperosmotic solutions containing histamine, 
bradykinin, mannitol and so on, which will contribute to achieving the cytostatic targets in 
the brain at their systematic putting into operation (Kemper et al., 2004; Xie et al., 2005). But 
the transient opening by them of the entrance gate provides at the same time an opportunity 
of entering via them for the neurotoxic substance what is especially dangerous in case of a 
more complex operative procedure of an intracarotid infusion of chemotherapeutic agents. 
This may be accompanied by disorders of speech, movement, visual perception. 
One more trend is based on creation of conjugates of an active commencement with 
proteins, which are able to recognize the integral components of cerebrovascular structures, 
such as antibodies to the receptor ferritin in relation to the NGF. This ensures its 
effectiveness in a rank of low concentrations. The simultaneous application of anticancer 
 
Glioma – Exploring Its Biology and Practical Relevance 
 
482 
drugs with inhibitors of a large glycoprotein P, which prevents the movement of cytotoxic 
drugs through the blood-brain barrier (Gerstner & Fine, 2007; Kemper et al., 2004) is 
promising. Preclinical trials with Paclitaxel have confirmed the perspectives of such a 
method, making reasonable transition to clinical trials.  
Attempts of a different kind are being made, namely the involvement of the bradykinin 
analog BMP-7, endowed with a more extended half-life period and with selectivity in 
respect to the receptor B2 in comparison with the being endogenously synthesized 
compound (Kemper et al., 2004; Ta et al., 2009; Xie et al., 2005). Being associated with them, 
BMP-7 leads to the opening of calcium channels in cells, an increase in their level of free 
cations. That leads to a reaction of endothelial cells and to weakening of intercellular 
contacts. The vascular permeability increases in addition. The recorded concentrations of 
growth factors were achieved in 30 minutes with the highest representation in the striatum, 
hippocampus, cerebral cortex and relatively low concentrations in the olfactory bulb, 
cerebellum and brainstem at joint custody of NGF and BMP-7 into stabilized liposomes, 
which are smaller than 100 nm. There was a good agreement between the permeability 
coefficient of the drug and its targeted action (Xie et al., 2005) at that. Under intracarotid 
administration of BMP-7 with Carboplatin in rat models of gliomas such a combination has 
significantly reduced the number of cytostatic normally used in humans. Phase II in clinical 
trials conducted on 87 patients with recurrence of malignant gliomas recorded a noticeable 
advantage of processing BMP-7 + Carboplatin before individually using only Carboplatin. 
The advances in molecular biology and genetic engineering, which ensured the 
implementation of experimental and clinical use of low molecular weight peptides, proteins, 
oligonucleotides, monoclonal antibodies, etc. (Kruttgen et al., 2006; Xie et al., 2005) 
contributed to considerable progress in the development of a "roundabout" ways of delivery 
of drugs. In total they have created a fertile ground not only for in-depth understanding the 
basic mechanisms of carcinogenesis, but also simultaneously for widening the means of 
early diagnosis, the front of anticancer attack and optimization of medical schemes. 
In a series of widely exploited methods there is a stereotactic implantation in the bed, 
formed after excision of tumor, indifferent biodegradable polymer substrates, impregnated 
in that or another way with an active principle. In this case, the cytostatic penetrates in 
measured doses into the surrounding tissue during a long period of time and destroy the 
remaining infected cells (Kemper et al., 2004; Ta et al., 2009). The concentration of drugs, 
developed in this case, can exceed observed ones with intravenous injection from 4 to 1200 
times. In one of the clinical trial performed on 222 adult patients with recurrent gliomas 
mortality of persons who were within 6 months receiving such a method Cisplatin was 44% 
versus 67% among patients treated with placebo (P < 0.02). 
The use of polymer capsules can also supply the brain with cells (transfected with viral 
vectors) which express a particular desired target gene which products act targeteous on the 
relevant parts of oncogenesis. The primary fibroblasts, astrocytes, ependimocytes, stem or 
progenitor cells serve as usual objects. For example, subclones Cyclin-Dependent Kinase 2 
Interacting Protein (CINP) releasing in vitro NGF at 2 ng/ h/10-5 cells over 10 weeks was 
isolated from conventionally immortalized progenitor neuroblasts of the central nervous 
system of rat embryos with embedded DNA of growth factors. Being introduced into the 
brain such cells survived well, migrated at a distance of 15 mm from the implant site and 
integrated with the host tissue without any signs of growth or tumor formation. 
Thus, we can conclude: 
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i. Sensitivity of glioma cells to chemotherapeutic agents, Nerve Growth Factor, and 
Dendrimers, Diamond like coated samples, heterocyclic compaunds in vitro depends on 
the origin, histological type tumors, the degree of malignancy, age and individual 
characteristics of patients; 
ii. Combined application of Nerve Growth Factor and chemotherapy increases the 
percentage of dying in a culture of cellular elements; 
iii. A complementary effect of Nerve Growth Factor appears to enhance cytotoxic effects of 
chemotherapy. This addictiveness reduces the effective dose of cytotoxic drugs in more 
than 10 times; 
iv. The presence of growth factor and/or Dendrimers, heterocyclic compounds do reduce 
the toxic dose of the chemotherapeutic drugs simultaneously maintaining a high 
cytostatic effect; 
v. Detection in vitro of high individual sensitivity of brain tumors to cytostatics confirms 
the hypothesis concerning polymorphism in mechanisms of carcinogenesis; 
vi. It is appropriate to take into account the results of experiments in order to determine 
the sensitivity of tumor cells of primary culture to cytostatic drugs in the development 
of new specialized treatment protocols for brain tumors (mono- or polychemotherapy).  
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